<SEC-DOCUMENT>0001628280-25-024664.txt : 20250512
<SEC-HEADER>0001628280-25-024664.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512160729
ACCESSION NUMBER:		0001628280-25-024664
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		102
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38599
		FILM NUMBER:		25934805

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>aqst-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7fd918af-7463-495d-a5aa-7a090fe24bee,g:404d0fa2-95d9-41b4-b7eb-3a9cfeb5fb76,d:bc17e35e18524b0cae1e0a983b1038de-->
<html xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:aqst="http://aquestive.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>aqst-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001398733</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-26">December 31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">False</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-100">http://fasb.org/us-gaap/2024#ManufacturedProductOtherMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-101">http://fasb.org/us-gaap/2024#ManufacturedProductOtherMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="aqst-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="product"><xbrli:measure>aqst:product</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>aqst:segment</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>aqst:lease</xbrli:measure></xbrli:unit><xbrli:unit id="payment"><xbrli:measure>aqst:payment</xbrli:measure></xbrli:unit><xbrli:unit id="pricing_period"><xbrli:measure>aqst:pricing_period</xbrli:measure></xbrli:unit><xbrli:unit id="pending_case"><xbrli:measure>aqst:pending_case</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-03</xbrli:startDate><xbrli:endDate>2024-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-23</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:LincolnParkAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-12</xbrli:startDate><xbrli:endDate>2022-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-22</xbrli:startDate><xbrli:endDate>2024-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AnaphylmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AnaphylmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AQST108Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AQST108Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LibervantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LibervantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:PersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:PersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:ManufactureAndSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:ManufactureAndSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LicenseAndRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LicenseAndRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:CoDevelopmentAndResearchFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:CoDevelopmentAndResearchFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:OtherReceivablesAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:OtherReceivablesAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:HyperaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:HyperaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:HyperaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:CommercialExploitationAgreementWithIndiviorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:CommercialExploitationAgreementWithIndiviorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-02</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LicenseAndRoyaltyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:MarathonPangolinRoyaltyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-03</xbrli:startDate><xbrli:endDate>2020-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:MarathonPangolinRoyaltyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-03</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:MarathonPangolinRoyaltyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-03</xbrli:startDate><xbrli:endDate>2020-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:AtnahsPharmaUKLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-26</xbrli:startDate><xbrli:endDate>2022-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:LicenseSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:AtnahsPharmaUKLimitedAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aqst:AssertioHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:ExistingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:NewWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:DebtCovenantRedemptionScenarioAxis">aqst:RedemptionScenario1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:DebtCovenantRedemptionScenarioAxis">aqst:RedemptionScenario2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:ABLFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:ABLFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aqst:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:InitialWarrantOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-14</xbrli:startDate><xbrli:endDate>2023-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:Warrants0.96ExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:Warrants4.25ExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:Warrants5.38ExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-03</xbrli:startDate><xbrli:endDate>2020-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">aqst:ManufacturingAndSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">aqst:ManufacturingAndSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:MarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:MarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:NeurelisIncVAquestiveTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:NeurelisIncVAquestiveTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:SuboxoneProduceLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:SuboxoneProduceLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:SuboxoneProduceLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-15</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibc17e35e18524b0cae1e0a983b1038de_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:34.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:472.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2025</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:34.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:472.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _____</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">to _____</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38599</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Aquestive Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">30 Technology Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Warren</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">NJ</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">07059</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-12">82-3827296</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of Incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(&#160;<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">908</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">941-1900</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address, Zip Code and Telephone Number of Registrant&#8217;s Principal Executive Offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">AQST</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Market</ix:nonNumeric></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#9746; <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160; &#9744; No</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#9746; <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160; &#9744; No</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Securities Exchange Act of 1934.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#9744;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; &#9744; Yes&#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric> No</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value of $0.001 per share (the "Common Stock"), as of the close of business on May&#160;8, 2025 was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">99,327,928</ix:nonFraction>.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I &#8211; FINANCIAL INFORMATION</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_19">Condensed Balance Sheets as of March 31, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_22">Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_25">Condensed Statements of Changes in Stockholders&#8217; Deficit for the three months ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_31">Condensed Statements of Cash Flows for the three months ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_34">Notes to Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_34">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_103">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_139">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_139">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_142">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_142">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II &#8211; OTHER INFORMATION</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_148">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_148">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_151">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_151">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_154">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_154">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_157">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_157">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_160">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_160">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_163">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_163">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_169">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_169">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_172">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc17e35e18524b0cae1e0a983b1038de_172">49</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GLOSSARY OF TERMS, ABBREVIATIONS AND ACRONYMS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following terms, abbreviations and acronyms are used to identify frequently used terms and phrases that may be used in this report (dollar amounts in thousands):</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:20.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TERM</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFINITION</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5% Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5% Senior Secured Notes redeemed on November 1, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5% Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5% Senior Secured Notes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACAAI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American College of Allergy Asthma and Immunology</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABL facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-based borrowing facility</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADHD</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention deficit hyperactivity disorder </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrenaverse&#8482; </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epinephrine prodrug platform currently comprised of Anaphylm&#8482; and AQST-108</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amyotrophic lateral sclerosis</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANVISA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazilian Health Regulatory Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">API</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Active Pharmaceutical Ingredients</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aquestive</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aquestive Therapeutics, Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AQST</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq ticker symbol for Aquestive Therapeutics, Inc.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting Standards Codification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assertio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assertio Holdings, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assertio Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License Agreement between Aquestive and Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute Repetitive Seizures</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting Standards Updates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATM facility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At-The-Market facility for the purchase of AQST Common Stock, then in effect</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CODM</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Decision Maker</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share, of the Company </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants issued with private placement of up to $100,000 aggregate principal of 12.5% Notes originally due 2025</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aquestive Therapeutics, Inc.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug Enforcement Administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EOP2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End-of-phase 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange Act</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Exchange Act of 1934</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Existing Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Purchase Warrants with the holder of the remaining 5,000,000 warrants</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FASB</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First amendment to the Sunovion License Agreement</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally Accepted Accounting Principles </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haisco</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haisco Pharmaceutical Group Co., Ltd.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Haisco Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">License, Development and Supply Agreement with Haisco, a Chinese limited company listed on the Shenzhen Stock Exchange</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hypera</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hypera Pharma, CosMed Industria De Cosmeticos E Medicamentos S.A</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigational New Drug</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement governing the 13.5% Senior Secured Notes</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indivior</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indivior Inc. (formerly, Reckitt Benckiser Pharmaceuticals Inc)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indivior Amendment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 11 to the Indivior License Agreement</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:20.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indivior License Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Exploitation Agreement with Reckitt Benckiser Pharmaceuticals, Inc. (with subsequent amendments collectively)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Park</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Park Capital Fund, LLC</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Park Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase Agreement with Lincoln Park Capital Fund, LLC</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marathon</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marathon Asset Management</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monetization Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase and Sale Agreement between Aquestive and Sunovion </span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPA or Mitsubishi</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mitsubishi Tanabe Pharma America, Inc. (formerly, Mitsubishi Tanabe Pharma Holdings America, Inc.)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not Meaningful, used in percentage changes</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Nasdaq Stock Market</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NDA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Drug Application</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase 2,750,000 shares of Common Stock </span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ODE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan Drug Exclusivity </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$45,000 aggregate principal amount of 13.5% Notes due November 1, 2028.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PD</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacodynamics</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmanovia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atnahs Pharma UK Limited, a company registered in England and Wales</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmanovia Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and Supply Agreement with Atnahs Pharma UK Limited,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmanovia Amendment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended License and Supply Agreement with Atnahs Pharma UK Limited as of March 27, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PK</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacokinetic</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Patent and Trademark Office</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDUFA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Drug User Fee Act</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-IND</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-Investigational New Drug</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the Royalty Rights Agreements</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Rights Agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Rights Agreements, component of 13.5% Senior Secured Notes</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Unit</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEC</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities and Exchange Commission</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Purchase Agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Purchase Agreements with certain purchasers entered into on June 6, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunovion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunovion Pharmaceuticals Inc</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunovion License Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYNMOBI Commercialization Agreement</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Territory</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain countries of the European Union, the United Kingdom, Switzerland, Norway and the Middle East and North Africa under the Pharmanovia Agreement</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TGA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian Government Department of Health&#8217;s Therapeutics Goods Administration</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underwritten Public Offering</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital raise of gross proceeds of $77,519, including partial exercise of the underwriters' option for $2,519 on April 22, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zambon</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zambon S.p.A.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zevra</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zevra Therapeutics, Inc. (formerly KemPharm, Inc.)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:70.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">68,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">71,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:TradeAndOtherReceivablesNet" format="ixt:num-dot-decimal" scale="3" id="f-32">10,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:TradeAndOtherReceivablesNet" format="ixt:num-dot-decimal" scale="3" id="f-33">7,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-34">7,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-35">6,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">89,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">88,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">3,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-41">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">5,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-43">5,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">4,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">102,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-47">101,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">12,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">10,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">3,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">5,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-52">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-53">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:RoyaltyObligationsLiabilityCurrent" scale="3" id="f-58">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:RoyaltyObligationsLiabilityCurrent" scale="3" id="f-59">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LoansPayableCurrent" scale="3" id="f-60">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LoansPayableCurrent" scale="3" id="f-61">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">18,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">18,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">33,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:RoyaltyObligationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">21,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:RoyaltyObligationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">20,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">62,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">62,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">4,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">4,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">19,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">20,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">2,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">2,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-76">163,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-77">161,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingencies (Note 20)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-78"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-79"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-81">0.001</ix:nonFraction></ix:nonFraction> par value. Authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">250,000,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-85">99,317,153</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-87">91,413,742</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-88">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-89">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-90">325,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-91">302,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-92">386,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">363,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">60,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">60,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">102,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">101,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-98">8,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-99">12,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-100"><span style="-sec-ix-hidden:f-101">Manufacture and supply</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-102">3,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-103">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">5,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">5,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">19,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">10,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-108">28,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-109">21,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-110">19,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-111">8,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income/(expenses):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-112">2,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-113">2,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to royalty obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">1,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">1,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to the sale of future revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="aqst:InterestExpenseSaleOfFutureRevenues" scale="3" id="f-116">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="aqst:InterestExpenseSaleOfFutureRevenues" scale="3" id="f-117">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="aqst:InterestAndOtherIncomeNet" scale="3" id="f-118">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="aqst:InterestAndOtherIncomeNet" scale="3" id="f-119">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-120">22,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-121">12,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">22,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">12,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-124">22,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-125">12,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share attributable to common stockholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted (in dollars per share)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-126"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-127">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-128"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-129">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted (in shares)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-130"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-131">95,497,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-132"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-133">73,614,710</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Statements of Changes in Stockholders&#8217; Deficit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended March&#160;31, 2025 and March&#160;31, 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.358%"/><td style="width:0.1%"/></tr><tr style="height:19pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deficit</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-134">91,413,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-135">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">302,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-137">363,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">60,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock issued under public equity offering-ATM</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-139">7,457,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-140">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-141">21,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-142">22,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of common stock issued under public equity offering-ATM</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-143">729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-144">729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-145">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-146">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested restricted stock units, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-147">445,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="f-148">702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="f-149">702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">22,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-151">22,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">99,317,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-153">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">325,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">386,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">60,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div id="ibc17e35e18524b0cae1e0a983b1038de_28"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.358%"/><td style="width:0.1%"/></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deficit</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157">68,533,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-158">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">212,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">319,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">106,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock issued under public equity offering-ATM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-162">4,557,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-163">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-164">12,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-165">12,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of common stock issued under public equity offering-ATM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-166">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-167">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock issued under public equity offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-168">16,666,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-169">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-170">74,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-171">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of common stock issued under public equity offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-172">5,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-173">5,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-174">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-175">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested restricted stock units, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-176">490,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="f-177">893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="f-178">893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-179">231,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-180">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-181">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">12,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">12,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-184">90,478,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-185">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">295,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">331,905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">36,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">22,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">12,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used for operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation, amortization, and impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-191">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-192">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-193">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-194">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs and discounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-195">2,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-196">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-197">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-198">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-199">3,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="f-200">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-201">1,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-202">965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-203">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-204">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-205">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-206">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-207">2,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-208">1,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="f-209">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="f-210">388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-211">23,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-212">10,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-213">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-214">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-215">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-216">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock issued under public equity offering-ATM, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-217">21,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-218">11,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock issued under public equity offering, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-220">70,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-222">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt principal including lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-223">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-224">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for royalty obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="aqst:PaymentsForRoyaltyObligationsFinancingObligations" scale="3" id="f-225">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="aqst:PaymentsForRoyaltyObligationsFinancingObligations" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for taxes on share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-227">703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-228">893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-229">20,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">81,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-231">2,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-232">71,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-233">71,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-234">23,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-235">68,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-236">95,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-237">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-238">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with public equity offering in Accounts Payable</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="aqst:CostsAssociatedWithPublicEquityOfferingInAccountsPayable" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="aqst:CostsAssociatedWithPublicEquityOfferingInAccountsPayable" scale="3" id="f-240">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with public equity offering-ATM in Accounts Payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="aqst:CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" scale="3" id="f-241">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="aqst:CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited, in thousands, except share and per share information)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_40"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-243" continuedAt="f-243-1" escape="true">Company Overview and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-243-1" continuedAt="f-243-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(A) Company Overview</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aquestive Therapeutics, Inc. is a pharmaceutical company advancing medicines to bring meaningful improvement to patients&#8217; lives through innovative science and delivery technologies. The Company is developing pharmaceutical products to deliver complex molecules through alternative administrations to invasive and inconvenient standard of care therapies. The Company is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis, under the Anaphylm&#8482; trade name, and its Adrenaverse&#8482; epinephrine prodrug pipeline platform. The Company has <ix:nonFraction unitRef="product" contextRef="c-1" decimals="INF" name="aqst:RevenueFromContractWithCustomerNumberOfCommercializedProducts" format="ixt-sec:numwordsen" scale="0" id="f-244">four</ix:nonFraction> licensed commercialized products which are marketed by its licensees in the U.S. and around the world. The Company is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm&#174;, and has proven drug development and commercialization capabilities. The Company&#8217;s production facilities are located in Portage, Indiana, and its corporate headquarters and primary research laboratory facilities are based in Warren, New Jersey.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B)&#160;Equity Transactions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Offering of Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established its first ATM facility in September 2019, and since inception to March&#160;31, 2025, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-35" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-245">27,315,145</ix:nonFraction> shares of Common Stock under its ATM Facility which has generated net cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-246">81,829</ix:nonFraction>, net of commissions and other transactions costs of $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-247">3,814</ix:nonFraction>. On April 3, 2024, the Company filed a new shelf registration statement on Form S-3, the 2024 Registration Statement, which was declared effective by the SEC on April 23, 2024. Included as part of the 2024 Registration Statement are (i) a base prospectus registering the offer, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="aqst:SaleOfStockMaximumTransactionAmount" format="ixt:num-dot-decimal" scale="0" id="f-248">250,000</ix:nonFraction> worth of Common Stock, preferred stock, debt securities, warrants, rights and units and (ii) a $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="aqst:SaleOfStockAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="3" id="f-249">100,000</ix:nonFraction> ATM facility prospectus. During the three months ended March 31, 2025, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-250">7,457,627</ix:nonFraction> shares of Common Stock pursuant to the ATM prospectus and the Amended Equity Distribution Agreement with Piper Sandler &amp; Co. (successor to Piper Jaffray &amp; Co.), which provided net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-251">21,306</ix:nonFraction> after deducting commissions and other transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-252">694</ix:nonFraction> of which $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="aqst:SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" scale="3" id="f-253">89</ix:nonFraction> remains unpaid as of March 31, 2025. For the three months ended March 31, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-254">4,557,220</ix:nonFraction> shares under the ATM facility which provided net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-255">12,012</ix:nonFraction> after deducting commissions and other transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-256">373</ix:nonFraction>. The remaining authorized balance of the ATM facility was $<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="3" id="f-257">78,000</ix:nonFraction> as of March&#160;31, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2022, the Company entered into the Lincoln Park Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth in the Lincoln Park Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="aqst:RightToSellCommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-258">40,000</ix:nonFraction> worth of shares of Common Stock from time to time over the <ix:nonNumeric contextRef="c-41" name="aqst:AgreementTerm" format="ixt-sec:durwordsen" id="f-259">36-month</ix:nonNumeric> term of the Lincoln Park Purchase Agreement. The Lincoln Park Purchase Agreement contains an ownership limitation such that the Company will not issue, and Lincoln Park will not purchase, shares of Common Stock if it would result in Lincoln Park&#8217;s beneficial ownership exceeding <ix:nonFraction unitRef="number" contextRef="c-42" decimals="4" name="aqst:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" scale="-2" id="f-260">9.99</ix:nonFraction>% of the Company&#8217;s then outstanding Common Stock. Lincoln Park has covenanted under the Lincoln Park Purchase Agreement not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company&#8217;s Common Stock. The Company did <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-261">not</ix:nonFraction> sell shares in connection with the Lincoln Park Purchase Agreement during the three months ended March 31, 2025 or in 2024. The Lincoln Park Purchase agreement expired on May 1, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2024, the Company completed the underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-262">16,666,667</ix:nonFraction> shares of its Common Stock at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-263">4.50</ix:nonFraction> per share. At closing, Aquestive received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-264">70,500</ix:nonFraction> after deducting underwriting discounts of $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="aqst:SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-265">4,500</ix:nonFraction>. In addition to the underwriting discounts related to this offering, the Company incurred professional fees and other costs totaling $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-266">687</ix:nonFraction> as of March 31, 2024. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the partial exercise of the underwriters' option, on April 22, 2024, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-267">559,801</ix:nonFraction> shares of Common Stock, for additional net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-268">2,368</ix:nonFraction>, after deducting underwriting discounts of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="aqst:SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" scale="3" id="f-269">151</ix:nonFraction>. In addition to the underwriting discounts related to the partial exercise of the underwriters' option, the Company incurred professional fees and other costs totaling $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-270">207</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Basis of Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-271" continuedAt="f-271-1" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed financial statements were prepared in conformity with U.S. GAAP and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-271-1"><ix:continuation id="f-243-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and related notes for the fiscal year ended December&#160;31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;5, 2025 (the &#8220;2024 Annual Report on Form 10-K&#8221;). As included herein, the Condensed Balance Sheet as of December&#160;31, 2024 is derived from the audited financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of interim periods have been included. The accompanying condensed financial statements reflect certain reclassifications from previously issued financial statements to conform to the current presentation. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying condensed financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in the Notes to applicable guidance refers to the authoritative U.S. GAAP as found in the ASC and ASU of FASB.</span></div></ix:continuation></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_43"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-272" continuedAt="f-272-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-272-1" continuedAt="f-272-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-273" continuedAt="f-273-1" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted as of March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company adopted the new disclosure requirements as of December 31, 2024. Refer to Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the required disclosure.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Accounting Standards Update was issued to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Among other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. More specifically, the ASU reduces the number of models that may be used to account for convertible instruments from five to three, amends diluted EPS calculations for convertible instruments, modifies the requirements for a contract that may be settled in an entity&#8217;s own shares to be classified in equity and requires expanded disclosures intended to increase transparency. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Accounting Standards Update was issued to clarify the guidance in Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, and to introduce new disclosure requirements for such equity securities. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the Statements of Operations, and Comprehensive Loss as well as qualitatively describe the remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company&#8217;s definition of selling expenses. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact from the adoption of ASU 2024-03 on disclosures to its financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#8212;Improvements to Income Tax Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Accounting Standards Update was issued to enhance the transparency and decision usefulness of income tax </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-273-1"><ix:continuation id="f-272-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures. The ASU requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). It further requires disclosure on an annual basis of the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). Additionally, it requires the following information disclosure: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The ASU eliminates certain current disclosure requirements. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2025, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2023-09 on disclosures to its financial statements.</span></div></ix:continuation></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="f-274" continuedAt="f-274-1" escape="true">Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="f-274-1" continuedAt="f-274-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company&#8217;s cash requirements for the remainder of 2025 and beyond include expenses related to continuing development and clinical evaluation of its products, manufacture and supply costs, costs of regulatory filings, patent prosecution expenses and litigation expenses, expenses related to commercialization of its products, as well as costs to comply with the requirements of being a public company operating in a highly regulated industry. As of March&#160;31, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-275">68,657</ix:nonFraction> of cash and cash equivalents.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has experienced a history of net losses. The Company&#8217;s accumulated deficits totaled $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-276">386,144</ix:nonFraction> as of March&#160;31, 2025. The net losses and accumulated deficits were partially offset by gross margins from sales of commercialized licensed and proprietary products, license fees, milestone and royalty payments from commercial licensees and co-development parties. The Company&#8217;s funding requirements have been met by its cash and cash equivalents, as well as its equity and debt offerings, including the <ix:nonFraction unitRef="number" contextRef="c-48" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-277">13.5</ix:nonFraction>% Senior Secured Notes as further discussed in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ATM facility and other equity offerings, including the underwritten public offering as discussed in Note 1, Part B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Transactions.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-274-2">While the Company&#8217;s ability to execute its business objectives and achieve profitability over the longer term cannot be assured, the Company&#8217;s on-going business, existing cash and cash equivalents, expense management activities, including, but not limited to the ceasing of R&amp;D activities, as well as access to the equity capital markets through its ATM facility, provide near term liquidity for the Company to fund its operating needs for at least the next twelve months as it continues to execute its business strategy.</ix:continuation> </span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_1326"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.         </span><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-278" continuedAt="f-278-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></ix:nonNumeric></div><div><span><br/></span></div><ix:continuation id="f-278-1" continuedAt="f-278-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate discrete financial information is available for evaluation by the CODM in deciding how to allocate resources and in assessing performance. For the three months ended March 31, 2025 and 2024, the Company has identified <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-279"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-280">one</ix:nonFraction></ix:nonFraction> operating and reportable segment. The Company defines its operating segment based on internally reported financial information that is regularly reviewed by the CODM to analyze financial performance, make decisions, and allocate resources. The Company's Chief Executive Officer (&#8220;CEO&#8221;) is the CODM. The Company manages its operations as a single segment for purposes of assessing performance and making operating decisions. This segment encompasses the development and advancement of a product pipeline for the treatment of severe allergic reactions, including anaphylaxis, and the Adrenaverse epinephrine prodrug pipeline platform. Additionally, the Company serves as the exclusive manufacturer for its proprietary product, Libervant, and four licensed commercialized products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM reviews the segment's profit or loss based on net loss reported on the Condensed Statements of Operations and Comprehensive Loss. The CODM also considers forecast-to-actual variances on a monthly basis for expenses deemed significant. Furthermore, the CODM reviews the segment's assets based on total assets reported on the Condensed Balance Sheets. All long-lived assets are held in the United States. While the Company generated $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-281">8,720</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-282">12,053</ix:nonFraction> in revenues for the three months ended March 31, 2025 and 2024, respectively, management expects the Company to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials, ultimately seeking regulatory approval. The CODM uses cash forecast models to guide investment decisions and assess entity-wide operating results and performance. Net loss is used to monitor budget and rolling forecasts versus actual results. The CODM views specific categories within research and development expenses, selling expenses, and general and administrative expenses as significant due to their direct correlation with cash burn and profitability.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-283" escape="true"><ix:continuation id="f-278-2"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles reported revenues to net loss under the significant expense principle for the three months ended March 31, 2025 and 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-284">8,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-285">12,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Manufacture and Supply Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-286">3,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-287">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D Project expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anaphylm project expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-288">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-289">3,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AQST-108 project expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-290">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-291">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libervant project expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-293">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D other expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-294">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-295">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-296">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-297">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Research and Development Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-298">5,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-299">5,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selling expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:SellingExpense" scale="3" id="f-300">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:SellingExpense" scale="3" id="f-301">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:SellingExpense" format="ixt:num-dot-decimal" scale="3" id="f-302">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:SellingExpense" scale="3" id="f-303">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Selling expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:SellingExpense" format="ixt:num-dot-decimal" scale="3" id="f-304">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:SellingExpense" format="ixt:num-dot-decimal" scale="3" id="f-305">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General &amp; Administrative expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-306">4,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-307">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-308">11,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-309">4,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total General and Administrative Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-310">16,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-311">9,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Selling, General and Administrative Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-312">19,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-313">10,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-314">28,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-315">21,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-316">19,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-317">8,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-318">3,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-319">3,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-320">22,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-321">12,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-322">22,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">12,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-324">22,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-325">12,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.952%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - R&amp;D Personnel costs include payroll expenses,  share-based compensation expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - Selling Personnel costs include payroll expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - Other Selling expenses include commercialization and other related expenses</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - G&amp;A Personnel costs include payroll expenses,  share-based compensation expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs</span></div></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="ibc17e35e18524b0cae1e0a983b1038de_49"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-326" continuedAt="f-326-1" escape="true">Revenues and Trade Receivables, Net</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-327" continuedAt="f-327-1" escape="true"><ix:continuation id="f-326-1" continuedAt="f-326-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues include (i) sales of manufactured products pursuant to contracts with commercialization licensees, (ii) license and royalty revenues, (iii) co-development and research fees generally in the form of milestone payments, </span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-327-1" continuedAt="f-327-2"><ix:continuation id="f-326-2" continuedAt="f-326-3"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (iv) sales of its proprietary CNS product, Libervant, for patients between two to five years of age while Libervant had U.S. market access. The Company recognizes revenue to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve this core principle, a five-step model is applied that includes (1) identifying the contract with a customer, (2) identifying the performance obligation in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the current revenue recognition standard.&#160;A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a distinct good.&#160;When identifying performance obligations, the Company considers all goods or services promised in a contract regardless of whether explicitly stated in the contract or implied by customary business practice. The Company&#8217;s performance obligations consist mainly of transferring goods and services identified in the contracts, purchase orders, invoices or statements of work.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacture and supply revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; this revenue is derived from products manufactured exclusively for specific customers according to their strictly-defined specifications, subject only to specified quality control inspections. Accordingly, at the point in time when quality control requirements are satisfied, revenue net of related discounts is recorded.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Revenu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e &#8211; license revenues are determined based on an assessment of whether the license is distinct from any other performance obligations that may be included in the underlying licensing arrangement. If the customer is able to benefit from the license without provision of any other performance obligations by the Company and the license is thereby viewed as a distinct or functional license, the Company then determines whether the customer has acquired a right to use the license or a right to access the license. For functional licenses that do not require further development or other ongoing activities by the Company, the customer is viewed as acquiring the right to use the license as, and when, transferred and revenues are generally recorded at a point in time, subject to contingencies or constraints. For symbolic licenses providing substantial value only in conjunction with other performance obligations to be provided by the Company, revenues are generally recorded over the term of the license agreement. Such other obligations provided by the Company generally include manufactured products, additional development services or other deliverables that are contracted to be provided during the license term. Payments received in excess of amounts ratably or otherwise earned are deferred and recognized over the term of the license or as contingencies or other performance obligations are met.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is estimated and recognized when sales under supply agreements with commercial licensees are recorded, absent any contractual constraints or collectability uncertainties. Royalties based on sales of licensed products have been recorded in this manner.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition arising from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., an NDA filing or obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales occur or the performance obligation to which the sales relate to has been satisfied.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-development and Research Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development defined within a contractual development or feasibility study agreement with a customer. The nature of these performance obligations, broadly referred to as milestones or deliverables, are usually dependent on the scope and structure of the project as contracted, as well as the complexity of the product and the specific regulatory approval path necessary for that product. Accordingly, the duration of the Company&#8217;s research and development projects may range from several months to approximately <ix:nonNumeric contextRef="c-61" name="aqst:ResearchAndDevelopmentProjectDuration" format="ixt-sec:durwordsen" id="f-328">three years</ix:nonNumeric>. Although each contractual arrangement is unique, common milestones included in these arrangements include those for the performance of efficacy and other tests, reports of findings, formulation of initial prototypes, production of stability clinical and/or scale-up batches, and stability testing of those batches. Additional milestones may be established and linked to clinical results of the product submission and/or approval of the product by the FDA and the commercial launch of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary product revenue, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - this net revenue is recognized when product is shipped and title passes to the customer, typically at time of delivery. At the time of sale, estimates for various revenue allowances are recorded based on historical trends and judgmental estimates. For sales of Libervant for patients between two to five years of age, returns allowances and prompt pay discounts are estimated based on contract terms and historical return rates, if available, and these estimates are recorded as a reduction of receivables. Similarly determined estimates are recorded relating to wholesaler service fees, co-pay support redemptions, and other rebates, and these estimates are reflected as a component of accrued liabilities. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-326-3" continuedAt="f-326-4"><ix:continuation id="f-327-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once all related variable considerations are resolved and uncertainties as to collectable amounts are eliminated, estimates are adjusted to actual allowance amounts. Provisions for these estimated amounts are reviewed and adjusted on no less than a quarterly basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, customer contractual payment terms provide for invoicing in arrears. Accordingly, some, or all performance obligations may be completely satisfied before the customer may be invoiced under such agreements.&#160;In these situations, billing occurs after revenue recognition, which results in a contract asset supported by the estimated value of the completed portion of the performance obligation. These contract assets are reflected as a component of other receivables within Trade and other receivables within the Condensed Balance Sheets. As of March&#160;31, 2025, and December&#160;31, 2024, such contract assets were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="f-329">718</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="f-330">578</ix:nonFraction>, respectively, consisting primarily of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, customer contractual payment terms are structured to permit invoicing in advance of delivery of a good or service. In such instances, the customer&#8217;s cash payment may be received before satisfaction of some, or any, performance obligations that are specified. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. These contract liabilities are reflected as deferred revenue within the Condensed Balance Sheets. As remaining performance obligations are satisfied, an appropriate portion of the deferred revenue balance is credited to earnings. As of March&#160;31, 2025 and December&#160;31, 2024, such contract liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-331">20,792</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-332">21,053</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, the Company may incur incremental costs of obtaining a contract with a customer. These costs, if expected to be recovered, are recognized as an asset and reflected as other assets within the Condensed Balance Sheets. The asset is amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. As of March&#160;31, 2025 and December&#160;31, 2024, such costs to obtain contracts were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CapitalizedContractCostNet" scale="3" id="f-333">472</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CapitalizedContractCostNet" scale="3" id="f-334">480</ix:nonFraction>, respectively.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-335" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues were comprised of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-336">7,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-337">10,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-338">790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-339">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-development and research fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-340">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-341">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-342">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-344">8,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-345">12,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-346" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides disaggregated net revenue by geographic area: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-347">5,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-348">10,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-349">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-350">1,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-351">8,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-352">12,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025, United States revenues were derived primarily from Indivior (manufacture and supply revenue, and co-development and research fees), and Assertio (manufacture and supply revenue, license and royalty revenue and co-development and research fees). Ex-United States revenues were derived primarily from Indivior (manufacture and supply revenue, license and royalty revenue and co-development and research fees), and Hypera (manufacture and supply revenue, and license and royalty revenue) for revenue markets outside of the United States. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024, United States revenues were derived primarily from Indivior (manufacture and supply revenue, and co-development and research fees), and Assertio (manufacture and supply revenue, license and royalty revenue, and co-development and research fees). Ex-United States revenues were derived primarily from Indivior (manufacture and supply revenue, license and royalty revenue and co-development and research fees), Zambon (manufacture and supply revenue, license and royalty revenue and co-development and research fees), and Pharmanovia (co-development and research fees). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-326-4" continuedAt="f-326-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-353" continuedAt="f-353-1" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-354">8,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-355">4,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-356">2,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-357">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sales-related allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-358">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-359">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:TradeAndOtherReceivablesNet" format="ixt:num-dot-decimal" scale="3" id="f-360">10,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:TradeAndOtherReceivablesNet" format="ixt:num-dot-decimal" scale="3" id="f-361">7,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract and other receivables totaled $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-362">2,213</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-363">2,473</ix:nonFraction> as of March&#160;31, 2025 and December&#160;31, 2024, respectively, consisting primarily of contract assets and other receivables. Contract assets consist of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties. Other receivables include the current portion related to the Monetization royalty receivable and other receivables. Sales-related allowances as of March&#160;31, 2025 were estimated in relation to revenues recognized for sales of Libervant for patients between two to five years of age.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses on accounts receivable, which is recorded as a reduction to accounts receivable. Changes in the allowance are classified as Selling, general and administrative expenses in the Statements of Operations and Comprehensive Loss. The Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when it identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status. It also considers customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. On an ongoing basis, management evaluates the adequacy of these reserves. The allowance for credit losses was $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="f-364"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" id="f-365">0</ix:nonFraction></ix:nonFraction> as of March 31, 2025 and December 31, 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" id="f-366" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the allowance for credit losses:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-368">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance reduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-370">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_55"></div><ix:continuation id="f-326-5" continuedAt="f-326-6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-Related Allowances</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of prompt payment discounts, wholesaler service fees, returns allowances, chargebacks, rebates and co-pay support redemptions. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.</span></div><ix:continuation id="f-353-1" continuedAt="f-353-2"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provides a summary of activity with respect to sales-related allowances:</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="f-353-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-373">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-375">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-376">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="3" id="f-377">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="3" id="f-378">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-379">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-380">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for returns allowances and prompt pay discounts are reflected as a direct reduction of trade receivables and accruals for wholesaler service fees, co-pay support redemptions and other rebates are reflected as current liabilities. The accrued balances relative to these provisions included in Trade and other receivables, net and accrued expenses were $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-381">77</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-382">609</ix:nonFraction>, respectively, as of March&#160;31, 2025, and $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-383">48</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-384">665</ix:nonFraction>, respectively, as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-326-6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Major Customers</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers are considered major customers when net revenue exceeds 10% of total revenue for the period or outstanding receivable balances exceed 10% of total receivables. For the three months ended March 31, 2025, Indivior and Hypera, represented approximately <ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-385">67</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-386">17</ix:nonFraction>%, of total revenue, respectively. As of March&#160;31, 2025, Indivior and Hypera exceeded the 10% threshold for outstanding receivable balances and represented approximately <ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-387">56</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-388">14</ix:nonFraction>% of total trade and other receivables, respectively. For the three months ended March&#160;31, 2024, Indivior exceeded the 10% threshold for revenue and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-389">84</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total revenue. As of December&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Indivior and Hypera exceeded the 10% threshold for outstanding receivable balances and represented <ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-390">41</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-94" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-391">16</ix:nonFraction>% of total trade and other receivables, respectively.</span></div></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-392" continuedAt="f-392-1" escape="true">Material Agreements</ix:nonNumeric></span></div><ix:continuation id="f-392-1" continuedAt="f-392-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Exploitation Agreement with Indivior</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2008, the Company entered into the Indivior License Agreement (with subsequent amendments) with Reckitt Benckiser Pharmaceuticals, Inc. who was later succeeded to in interest by Indivior.&#160;Pursuant to the Indivior License Agreement, the Company agreed to manufacture and supply Indivior&#8217;s requirements for Suboxone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a sublingual film formulation, both inside and outside the United States on an exclusive basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Indivior License Agreement, the Company is required to manufacture Suboxone in accordance with current Good Manufacturing Practice standards and according to the specifications and processes set forth in the related quality agreements the Company entered into with Indivior. Additionally, the Company is required to obtain API&#160;for the manufacture of Suboxone directly from Indivior. The Indivior License Agreement specifies a minimum annual threshold quantity of Suboxone that the Company is obligated to fill and requires Indivior to provide the Company with a forecast of its requirements at various specified times throughout the year. The Indivior License Agreement provides for payment by Indivior of an agreed upon purchase price per unit until January 1, 2025 and, thereafter, that is subject to annual adjustments based on changes in an agreed upon price index. In addition to the purchase price for the Suboxone supplied, Indivior is required to make certain single digit percentage royalty payments tied to net sales value (as provided for in the Indivior License Agreement) outside of the U.S., subject to annual maximum amounts and limited to the life of the related patents. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indivior License Agreement contains customary contractual termination provisions, including with respect to a filing for bankruptcy or corporate dissolution, an invalidation of the intellectual property surrounding Suboxone, and commission of a material breach of the Indivior License Agreement by either party. Additionally, Indivior may terminate the Indivior License Agreement if the FDA or other applicable regulatory authority declares the Company&#8217;s manufacturing site to no longer be suitable for the manufacture of Suboxone or Suboxone is no longer suitable to be manufactured due to health or safety reasons. The initial term of the Indivior License Agreement was <ix:nonNumeric contextRef="c-95" name="aqst:LicenseAgreementTerm" format="ixt-sec:durwordsen" id="f-393">seven years</ix:nonNumeric> from the commencement date. Thereafter, the Indivior License Agreement automatically renewed for successive <ix:nonNumeric contextRef="c-95" name="aqst:AutomaticRenewalPeriodOfAgreement" format="ixt-sec:durwordsen" id="f-394">one-year</ix:nonNumeric> periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of March 2, 2023, the Company and Indivior entered into the Indivior Amendment to the Indivior License Agreement. The Indivior Amendment was entered into for the primary purpose of amending the Agreement as follows: (i) extending the term of the Agreement until August 16, 2026 and thereafter providing for automatic renewal terms of successive <ix:nonNumeric contextRef="c-96" name="aqst:AutomaticRenewalPeriodOfAgreement" format="ixt-sec:durwordsen" id="f-395">one-year</ix:nonNumeric> periods unless Indivior delivers notice to the Company, at least twelve months prior to the expiration of the then current term, of Indivior&#8217;s intent not to renew, subject to the earlier termination rights of the parties under the Agreement, and providing that the Agreement will not automatically renew for any renewal term beginning after the expiration of the last to expire of the product patents covered under the Indivior License Agreement; and (ii) agreeing to transfer pricing and payment terms for supplied product under the Indivior License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Sunovion Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2016, the Company entered into a license agreement with Cynapsus Therapeutics Inc. (which was later succeeded to in interest by Sunovion), referred to as the Sunovion License Agreement, pursuant to which Sunovion obtained an exclusive, worldwide license (with the right to sub-license) to certain intellectual property, including existing and future patents and patent applications, covering all oral films containing apomorphine for the treatment of off episodes in Parkinson&#8217;s disease patients. Sunovion used this intellectual property to develop its apomorphine product KYNMOBI, which was approved by the FDA on May 21, 2020. This approval triggered Sunovion&#8217;s obligation to remit a payment of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-396">4,000</ix:nonFraction>, due on the earlier of: (a) the first day of product availability at a pharmacy in the United States; or (b) within six months of FDA approval of the product. This amount was received as of September 30, 2020 and was included in License and royalty revenues for the twelve months ended December 31, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective March 16, 2020, the Company entered into the First Amendment. The First Amendment was entered into for the primary purpose of amending the Sunovion License Agreement as follows: (i) including the United Kingdom and any other country currently in the EU which later withdraws as a member country in the EU for purpose of determining the satisfaction of the condition triggering the obligation to pay the third milestone due under the Sunovion License Agreement, (ii) extending the date after which Sunovion has the right to terminate the Sunovion License Agreement for convenience from December 31, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-392-2" continuedAt="f-392-3"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 to March 31, 2028, (iii) modifying the effective inception date of the first minimum annual royalty due from Sunovion to the Company form January 1, 2020 to April 1, 2020, and (iv) modifying the termination provision to reflect the Company&#8217;s waiver of the right to terminate the Sunovion License Agreement in the event that KYNMOBI was not commercialized by January 1, 2020. This Sunovion License Agreement will continue until terminated by Sunovion in accordance with the termination provisions of the First Amendment. The Sunovion License Agreement continues (on a country-by-country basis) until the expiration of all applicable licensed patents unless earlier terminated under the termination provisions contained therein. Upon termination of the Sunovion License Agreement, all rights to intellectual property granted to Sunovion to develop and commercialize apomorphine-based products will revert to the Company. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company amended the Sunovion License Agreement to clarify the parties' agreement with respect to certain provisions in the Sunovion License Agreement, specifically the date after which Sunovion has the right to terminate the Sunovion License Agreement and the rights and obligations of the parties regarding the prosecution and maintenance of the Company&#8217;s patents covered under the Sunovion License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the rights granted to Sunovion under the Sunovion License Agreement, the Company received aggregate payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-397">22,000</ix:nonFraction> to date. In addition to the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-398">5,000</ix:nonFraction>, the Company has also earned an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-399">17,000</ix:nonFraction> in connection with specified regulatory and development milestones in the United States and Europe (the &#8220;Initial Milestone Payments&#8221;), all of which have been received to date. With the Monetization Agreement (defined below) entered into on November 3, 2020 relating to KYNMOBI as described in the paragraph below, the Company is no longer entitled to receive any payments under the Sunovion License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase and Sale Agreement with an affiliate of Marathon</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2020, the Company entered into the Monetization Agreement with Marathon. Under the terms of the Monetization Agreement, the Company sold to Marathon all of its contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#8217;s apomorphine product, KYNMOBI. In exchange for the sale of these rights, the Company received an upfront payment from Marathon of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-400">40,000</ix:nonFraction> and an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-401">10,000</ix:nonFraction> through the achievement of the first milestone. The Company has received an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-402">50,000</ix:nonFraction> through March&#160;31, 2025 under the Monetization Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Monetization Agreement, additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:ContingentMonetizationAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="3" id="f-403">75,000</ix:nonFraction> may be due to the Company upon the achievement of worldwide royalty and other commercial targets within a specified timeframe, which could result in total potential proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-404">125,000</ix:nonFraction>. In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets; therefore, the Company likely will not receive any of the additional contingent payments under the Monetization agreement. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the accounting for the Monetization Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement to Terminate CLA with Zevra Therapeutics, Inc. (formerly KemPharm)</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2012, the Company entered into an agreement with Zevra to terminate a Collaboration and License Agreement entered into by the Company and Zevra in April 2011. Under this termination arrangement, the Company has the right to participate in any and all value that Zevra may derive from the commercialization or any other monetization of KP-415 and KP-484 compounds or their derivatives. Among these monetization transactions are those related to any business combinations involving Zevra and collaborations, royalty arrangements, or other transactions from which Zevra may realize value from these compounds, including the product Azstarys</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Supply Agreement with Haisco for Exservan&#8482; (Riluzole Oral Film) for ALS Treatment in China</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Haisco Agreement with Haisco, a Chinese limited company listed on the Shenzhen Stock Exchange, effective as of March 3, 2022, pursuant to which Aquestive granted Haisco an exclusive license to develop and commercialize Exservan&#8482; (riluzole oral film) for the treatment of ALS in China. Under the terms of the Haisco Agreement, Aquestive was the exclusive sole manufacturer and supplier for Exservan in China. Under the Haisco Agreement, as amended, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-405">7,000</ix:nonFraction> upfront cash payment in September 2022 and was entitled to receive regulatory milestone payments and double-digit royalties on net sales of Exservan in China and earn manufacturing revenue upon the sale of Exservan in China. In June 2024, the Haisco Agreement was terminated, and the Company will not receive any contingent payments under the Haisco Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Supply Agreement with Atnahs Pharma UK Limited </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Pharmanovia Agreement, effective as of September 26, 2022, pursuant to which the Company granted Pharmanovia an exclusive license to certain of the Company&#8217;s intellectual property to develop and commercialize Libervant&#8482; (diazepam) Buccal Film for the treatment of prolonged or acute, convulsive seizures in all ages in the Territory during the term of the Pharmanovia Agreement. Under the Pharmanovia Agreement, Pharmanovia will lead the regulatory and commercialization activities for Libervant in the Territory and the Company will serve as the exclusive sole </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-392-3"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer and supplier of Libervant in the Territory. Pursuant to the Pharmanovia Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-406">3,500</ix:nonFraction> upon agreement execution and, upon the occurrence of certain conditions set forth in the Pharmanovia Agreement, will receive additional milestone payments and profit shares, as well as manufacturing fees and royalty fees through the expiration of the Pharmanovia Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective March 27, 2023, the Company amended the Pharmanovia Agreement to expand the scope of territory for the license of Libervant to cover the rest of the world, excluding the U.S., Canada and China. Under the Pharmanovia Amendment, Pharmanovia will be responsible for seeking applicable regulatory approval in the expanded territories, which include Latin America, Africa and Asia Pacific. Pursuant to the terms of the Pharmanovia Amendment, the Company received a non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-407">2,000</ix:nonFraction> from Pharmanovia in connection with the execution of the Pharmanovia Amendment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreement with Assertio Holdings, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of October 26, 2022, the Company entered into the Assertio Agreement to license Sympazan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox&#8208;Gastaut syndrome in patients aged two years of age and older. Under the terms of the Assertio Agreement, the Company granted to Assertio an exclusive, worldwide license of its intellectual property for Sympazan to Assertio during the term of the Assertio License Agreement for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="3" id="f-408">9,000</ix:nonFraction>. In addition, Aquestive received a $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-409">6,000</ix:nonFraction> milestone payment subsequent to Aquestive&#8217;s receipt of a notice of allowance from the PTO of the Company&#8217;s patent application U.S. Serial No. 16/561,573, and payment by the Company of the related allowance fee. The Company received the notice of allowance from the PTO and paid the related allowance fee on October 27, 2022. Further, under the Assertio Agreement, the Company will receive royalties from Assertio for the sale of the product through the expiration of the Assertio Agreement. The Company also entered into a long-term supply agreement with Assertio for Sympazan pursuant to which the Company is the exclusive sole worldwide manufacturer and supplier of the product and will receive manufacturing fees from Assertio for the product through the expiration of such supply agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreement with Mitsubishi Tanabe Pharma America, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that Aquestive granted an exclusive license to MTPA for the commercialization of Exservan in the United States. MTPA is a multinational pharmaceutical company with a focus on patients with ALS. The product was launched by MTPA in June 2021. Under the terms of the MTPA license agreement, Aquestive was the exclusive manufacturer and supplier of Exservan for MTPA in the United States. In June 2024, under the Second Amendment to the License and Supply Agreement, MTPA and the Company mutually agreed to terminate the agreement. As of June 30, 2024 and as part of the termination, the parties were released from any existing or ongoing obligations (except for certain limited non-material post-termination obligations).</span></div></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-410" continuedAt="f-410-1" escape="true">Financial Instruments &#8211; Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-410-1" continuedAt="f-410-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&#160;Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 1 &#8212; Observable quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 2 &#8212; Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity, such as pricing models, discounted cash flow&#160;methodologies and similar techniques.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the Condensed Balance Sheets for Trade and other receivables, prepaid and other current assets, accounts payable and accrued expenses, and deferred revenue approximate their fair values based on the short-term maturity of these assets and liabilities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted warrants to certain noteholders in connection with its debt repayment and debt refinancing of the <ix:nonFraction unitRef="number" contextRef="c-108" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-411">12.5</ix:nonFraction>% Notes during 2020 and 2019, respectively. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation. See Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on these warrants.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company issued pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="0" name="aqst:SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" format="ixt:num-dot-decimal" scale="0" id="f-412">4,000,000</ix:nonFraction> shares of Common Stock and Common Stock Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="0" name="aqst:SharesOfCommonStockToBePurchasedByCommonStockWarrants" format="ixt:num-dot-decimal" scale="0" id="f-413">8,850,000</ix:nonFraction> shares of Common Stock in connection with its Securities Purchase Agreements with certain purchasers. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-410-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide. See Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on these warrants.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, the Company entered into the Letter Agreement with the Exercising Holder of the remaining warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-414">5,000,000</ix:nonFraction> of the shares of Common Stock. Pursuant to the Letter Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise all of its Existing Warrants for shares of Common Stock underlying the Existing Warrants at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-415">0.96</ix:nonFraction> per share of Common Stock, the current exercise price of the Existing Warrants. Under the Letter Agreement, in consideration of the Exercising Holder exercising the Existing Warrants, the Company issued to the Exercising Holder new warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-416">2,750,000</ix:nonFraction> shares of new warrants at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-417">2.60</ix:nonFraction> per share. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide. See Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on these warrants.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, in connection with the issuance of the <ix:nonFraction unitRef="number" contextRef="c-112" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-418">13.5</ix:nonFraction>% Notes, the Company and the Note Holders entered into the Royalty Right Agreements dated as of November 1, 2023, which provides the Note Holders:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">a tiered royalty between <ix:nonFraction unitRef="number" contextRef="c-113" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-419">1.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-420">2.0</ix:nonFraction>% of annual worldwide net sales of Anaphylm&#8482; (epinephrine) Sublingual Film for a period of <ix:nonNumeric contextRef="c-115" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm" format="ixt-sec:durwordsen" id="f-421">eight years</ix:nonNumeric> from the first sale of Anaphylm on a global basis, and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">a tiered royalty between <ix:nonFraction unitRef="number" contextRef="c-113" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-422">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-423">2.0</ix:nonFraction>% of annual worldwide net sales of Libervant&#174; (diazepam) Buccal Film until the earlier of (1) the first sale of Anaphylm and (2) <ix:nonNumeric contextRef="c-115" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm" format="ixt-sec:durwordsen" id="f-424">eight years</ix:nonNumeric> from the first sale of Libervant. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those Royalty Agreements were valued based on Level 3 inputs and their&#160;fair value was based primarily on internal management estimates developed based on third-party data and reflect management&#8217;s judgements, current market conditions, and forecasts. The initial fair value measurement of the Royalty Right Agreements was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and the estimated amount of future sales of Anaphylm and Libervant. See Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion.</span></div></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_64"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-425" continuedAt="f-425-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-426" escape="true"><ix:continuation id="f-425-1"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Inventory are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw material</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-427">2,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-428">3,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Packaging material</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:InventoryPackingMaterialGross" format="ixt:num-dot-decimal" scale="3" id="f-429">2,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:InventoryPackingMaterialGross" format="ixt:num-dot-decimal" scale="3" id="f-430">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-431">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="f-432">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-433">7,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-434">6,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ibc17e35e18524b0cae1e0a983b1038de_67"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-435" continuedAt="f-435-1" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-435-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-436" escape="true"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful<br/>Lives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-116" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-437">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-117" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-438">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-439">20,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-440">20,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-120" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-441">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-121" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-442">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-443">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-444">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-445">21,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-446">21,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer, network equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-126" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-447">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-127" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-448">7</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-449">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-450">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-451">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-452">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-453">47,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-454">47,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-455">43,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-456">43,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-457">3,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-458">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation, amortization, and impairment related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-459">139</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-460">168</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-461" continuedAt="f-461-1" escape="true">Right-of-Use Assets and Lease Obligations</ix:nonNumeric></span></div><ix:continuation id="f-461-1"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases all realty used at its production and warehouse facilities, corporate headquarters, commercialization operations center and research and laboratory facilities. None of these <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="aqst:NumberOfOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="f-462">three</ix:nonFraction> leases include the characteristics specified in ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which require classification as financing leases and, accordingly, these leases are accounted for as operating leases. These leases, as amended, provide remaining terms between <ix:nonNumeric contextRef="c-132" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-463">3.0</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-133" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-464">8.5</ix:nonNumeric> years, including renewal options expected to be exercised to extend the lease periods. Commitments under finance leases are not significant, and are included in Property and equipment, net, and Notes Payable, net on the Condensed Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize a right-to-use asset and lease liability for short-term leases, which have terms of 12 months or less on its Condensed Balance Sheets. For longer-term lease arrangements that are recognized on the Company&#8217;s Condensed Balance Sheets, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company&#8217;s short-term leases, as well as variable costs relating to the Company&#8217;s lease arrangements, are not material to the Company&#8217;s financial results.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implicit interest rates of the Company&#8217;s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. Measurement of the operating lease liability reflects a range of an estimated discount rate of <ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-465">14.8</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-133" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-466">15.6</ix:nonFraction>% applied to minimum lease payments, including expected renewals, based on the incremental borrowing rate experienced in the Company&#8217;s collateralized debt refinancing. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease costs are recorded in manufacture and supply, research and development and selling, general and administrative expenses in its Condensed Statements of Operations and Comprehensive Loss. For the three months ended March&#160;31, 2025, total operating lease expenses totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-467">427</ix:nonFraction>, including variable lease expenses such as common area maintenance and operating costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-468">93</ix:nonFraction>. For the three months ended March&#160;31, 2024, total operating lease expenses totaled $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-469">444</ix:nonFraction>, including variable lease expenses such as common area maintenance and operating costs of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-470">115</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-471" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s payments due under its operating leases are as follows: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-472">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-473">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-474">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-475">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" format="ixt:num-dot-decimal" scale="3" id="f-476">3,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-477">8,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-478">3,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-479">5,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_73"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-481" escape="true"><ix:continuation id="f-480-1" continuedAt="f-480-2"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of identifiable intangible assets, all of which are finite lived:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased intangible</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-482">3,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-483">3,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased patent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-484">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-485">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-486">4,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-487">4,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-488">4,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-489">4,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-480-2">There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-492">no</ix:nonFraction> amortization expense incurred during the three months ended March&#160;31, 2025. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-493">39</ix:nonFraction> for the three months ended March&#160;31, 2024. In June 2024, in connection with a termination of an agreement, the Company recorded an adjustment to the remaining balance of $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="3" id="f-494">1,200</ix:nonFraction> of the intangible asset</ix:continuation>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherAssetsDisclosureTextBlock" id="f-495" continuedAt="f-495-1" escape="true">Other Non-current Assets</ix:nonNumeric></span></div><ix:continuation id="f-495-1" continuedAt="f-495-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="f-496" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of other non-current assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:CumulativeRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="f-497">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:CumulativeRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="f-498">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-499">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-500">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other non-current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-501">4,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-502">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, under the Sunovion License Agreement, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-503">8,000</ix:nonFraction> of royalty revenue and corresponding royalty receivable, related to the <ix:nonFraction unitRef="payment" contextRef="c-140" decimals="INF" name="aqst:NumberOfGuaranteedRoyaltyPayments" format="ixt-sec:numwordsen" scale="0" id="f-504">eight</ix:nonFraction> $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="aqst:MinimumAnnualRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="f-505">1,000</ix:nonFraction> annual minimum guaranteed royalty payments that are due to the Company. In connection with the Monetization Agreement, the Company performed an assessment under ASC 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfer and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to determine whether the existing receivable was transferred to Marathon and concluded it was not transferred. As of March&#160;31, 2025 and December&#160;31, 2024, Royalty receivable consists of <ix:nonFraction unitRef="payment" contextRef="c-142" decimals="INF" name="aqst:NumberOfAnnualRoyaltyPaymentsReceivable" format="ixt-sec:numwordsen" scale="0" id="f-506"><ix:nonFraction unitRef="payment" contextRef="c-143" decimals="INF" name="aqst:NumberOfAnnualRoyaltyPaymentsReceivable" format="ixt-sec:numwordsen" scale="0" id="f-507">four</ix:nonFraction></ix:nonFraction> annual minimum payments due from Sunovion, the last of which is due in March 2028. The current portion of the royalty receivable is included in Trade and other receivables, net. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on how this receivable relates to the Monetization Agreement transaction.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><ix:continuation id="f-495-2" continuedAt="f-495-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of costs to obtain contracts capitalized under ASC 340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs, </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-495-3">is recorded within Other non-current assets on the  Condensed Balance Sheets as of March 31, 2025 and December 31, 2024.</ix:continuation> </span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_79"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-508" continuedAt="f-508-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="f-508-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-509" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-510">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-511">4,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate and personal property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="f-512">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="f-513">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued distribution expenses and sales returns provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-514">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-515">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-516">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-517">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-518">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-519">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-520">3,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-521">5,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reduction in Accrued compensation is mostly related to payments of accrued bonuses during the three months ended March 31, 2025, partially offset by the current year accrual of bonuses. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued distribution expenses and sales returns provision mostly represent estimated liabilities for wholesaler service fees, co-pay support redemptions and other rebates related to the proprietary product Libervant and returns and other expenses related to the proprietary product Sympazan (prior to outlicensing to Assertio in October 2022).</span></div></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_82"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-522" continuedAt="f-522-1" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="f-522-1" continuedAt="f-522-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-523">13.5</ix:nonFraction>% Senior Secured Notes</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, the Company entered into an Indenture Agreement with certain institutional investors (the &#8220;Note Holders&#8221;) and issued $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-524">45,000</ix:nonFraction> aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-525">13.5</ix:nonFraction>% Notes due 2028. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-526">4,326</ix:nonFraction> from this transaction after the repayment of the <ix:nonFraction unitRef="number" contextRef="c-108" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-527">12.5</ix:nonFraction>% Notes and deduction of debt discount, and debt issuance costs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-528">13.5</ix:nonFraction>% Notes are senior secured obligations of the Company and mature on November 1, 2028. The <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-529">13.5</ix:nonFraction>% Notes bear interest at a fixed rate of <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-530">13.5</ix:nonFraction>% per year, payable quarterly commencing on December 30, 2023. On each payment date commencing on June 30, 2026, the Company will pay an installment of principal of the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-531">13.5</ix:nonFraction>% Notes pursuant to a fixed amortization schedule, along with the applicable Exit Fee. The Exit Fee totals $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="3" id="f-532">2,000</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, at its option, redeem the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-533">13.5</ix:nonFraction>% Notes in full or in part:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">if such redemption occurs prior to November 1, 2025, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-534">100</ix:nonFraction>% of the principal amount plus accrued and unpaid interest, plus the applicable Exit Fee, plus an Applicable Premium which is the greater of </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt"><ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="f-535">1.0</ix:nonFraction>% of the principal redeemed; and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-522-2" continuedAt="f-522-3"><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">the amount, if any, by which the present value of the principal to be redeemed on November 1, 2025, plus all required interest due on such date, computed using a discount rate equal to the Treasury Rate, plus <ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="aqst:DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" scale="-4" id="f-536">100</ix:nonFraction> basis points, exceeds the amount of principal to be redeemed; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">if such redemption occurs after November 1, 2025, the redemption price is equal to <ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-537">108.5</ix:nonFraction>% of the principal amount plus accrued and unpaid interest, plus the applicable Exit Fee. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a change of control, the Note Holders may require the Company to repurchase for cash all or any portion of the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-538">13.5</ix:nonFraction>% Notes at a change of control repurchase price equal at <ix:nonFraction unitRef="number" contextRef="c-145" decimals="3" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-539">108.5</ix:nonFraction>% plus the Exit Fee of the remaining principal, plus accrued interest at the election of the Note Holders. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture permits the Company, upon the continuing satisfaction of certain conditions, including that the Company has at least $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="aqst:LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" format="ixt:num-dot-decimal" scale="0" id="f-540">100,000</ix:nonFraction> of net revenues for the most recently completed twelve calendar month period, to enter into an ABL facility not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="aqst:LineOfCreditFacilityAccordionFeatureIncreaseLimit" format="ixt:num-dot-decimal" scale="0" id="f-541">10,000</ix:nonFraction>. The ABL Facility may be collateralized only by assets of the Company constituting inventory, accounts receivable, and the proceeds thereof. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-542">13.5</ix:nonFraction>% Notes, the Company and the Note Holders entered into the Royalty Right Agreements dated as of November 1, 2023, which provides Note Holders:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">a tiered royalty between <ix:nonFraction unitRef="number" contextRef="c-113" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-543">1.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-544">2.0</ix:nonFraction>% of annual worldwide net sales of Anaphylm&#8482; (epinephrine) Sublingual Film for a period of <ix:nonNumeric contextRef="c-115" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm" format="ixt-sec:durwordsen" id="f-545">eight years</ix:nonNumeric> from the first sale of Anaphylm on a global basis, and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">a tiered royalty between <ix:nonFraction unitRef="number" contextRef="c-113" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-546">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentage" scale="-2" id="f-547">2.0</ix:nonFraction>% of annual worldwide net sales of Libervant&#174; (diazepam) Buccal Film until the earlier of (1) the first sale of Anaphylm and (2) <ix:nonNumeric contextRef="c-115" name="aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm" format="ixt-sec:durwordsen" id="f-548">eight years</ix:nonNumeric> from the first sale of Libervant. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-549">13.5</ix:nonFraction>% Notes and Royalty Right Agreements, represent freestanding instruments which were issued in conjunction with each other. They are classified as debt within the scope of ASC 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and are subsequently measured on an amortized cost basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial fair value measurement of the Royalty Right Agreements was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and the estimated amount of future sales of Anaphylm and Libervant. These inputs are derived using internal management estimates developed based on third-party data and reflect management&#8217;s judgements, current market conditions, and forecasts.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Royalty Right Agreements&#8217; fair value is estimated by applying probability-weighted cash flows for future sales, which are then discounted to present value. Changes to fair value of the Royalty Rights Agreements can result from changes to one or a number of the aforementioned inputs. A significant change in unobservable inputs could result in a material increase or decrease to the effective interest rate of the Royalty Right Agreements liability.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-550" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant unobservable inputs used in the fair value measurement of the Royalty Right Agreements:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Methodology</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Input</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average (range, if applicable)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="us-gaap:LongTermDebtMeasurementInput" scale="-2" id="f-551">15</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Right Agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted<br/>income approach</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Success</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="us-gaap:LongTermDebtMeasurementInput" scale="-2" id="f-552">75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Years of Payments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has updated the projected years of payments to 2034 and the effective interest rate by <ix:nonFraction unitRef="number" contextRef="c-152" decimals="4" name="aqst:DebtInstrumentInterestRateChangeInEffectivePercentage" scale="-2" id="f-553">0.56</ix:nonFraction>% as of December&#160;31, 2024. The Company periodically re-assesses the projections and, to the extent the future projections are greater or less than its previous estimates or the estimated timing of such payments is materially different than its previous estimates, the Company will adjust the effective interest calculation. As of March&#160;31, 2025, there were no material changes to the significant unobservable inputs used to recognize the Royalty Right Agreements liability.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Royalty Right Agreements were issued in connection with the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-554">13.5</ix:nonFraction>% Notes, the Company allocated the proceeds to the two instruments based on their relative fair values. The Company allocated approximately $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-555">13,856</ix:nonFraction> to the Royalty Right Agreements. The Company determined the allocated fair value by calculating the present value of estimated future royalties to be paid to Note Holders over the life of the arrangement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of future estimated royalty payments of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-556">56,926</ix:nonFraction> over the $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-557">13,856</ix:nonFraction> of allocated fair value is recognized as a discount related to the Royalty Right Agreements and is amortized as interest expense using the effective interest method.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-522-3"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocated amounts of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-558">13,856</ix:nonFraction> when combined with the Exit Fee of $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="aqst:DebtInstrumentExitFee" format="ixt:num-dot-decimal" scale="3" id="f-559">2,000</ix:nonFraction>, original issue discount of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:num-dot-decimal" scale="3" id="f-560">1,125</ix:nonFraction> and debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-561">3,517</ix:nonFraction>, resulted in a debt discount of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-562">20,498</ix:nonFraction>. The debt discount is being amortized over the term of <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-563">13.5</ix:nonFraction>% Notes using the effective interest method.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense arising from the discounts related to the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-564">13.5</ix:nonFraction>% Notes for the three months ended March&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-565">1,254</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-566">1,257</ix:nonFraction>, respectively. Amortization expense arising from the discounts related to the Royalty Right Agreements for the three months ended March&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-567">1,437</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-568">1,358</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized discounts totaled $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-569">11,392</ix:nonFraction> for the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-570">13.5</ix:nonFraction>% Notes and $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-571">35,269</ix:nonFraction> for the Royalty obligations as of March&#160;31, 2025. Unamortized discounts totaled $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-572">12,646</ix:nonFraction> for the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-573">13.5</ix:nonFraction>% Notes and $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-574">36,706</ix:nonFraction> for the Royalty obligations as of December&#160;31, 2024, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-575" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term notes and unamortized debt discount balances are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-576">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-577">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount, including Exit Fee</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-578">11,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-579">12,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, long-term</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-580">33,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-581">32,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease, long-term</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-582">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-583">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-584">33,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-585">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-586">56,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-587">56,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-588">35,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-589">36,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-590">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-591">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-592">21,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-593">20,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-594" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled principal payments on the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-595">13.5</ix:nonFraction>% Notes as of March&#160;31, 2025 are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="f-596">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-597">9,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-598">14,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-599">20,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-600">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="aqst:WarrantsDisclosureTextBlock" id="f-601" continuedAt="f-601-1" escape="true">Warrants</ix:nonNumeric></span></div><ix:continuation id="f-601-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants Issued to <ix:nonFraction unitRef="number" contextRef="c-163" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-602">12.5</ix:nonFraction>% Senior Secured Noteholders </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants that were issued in conjunction with the Initial Notes (the &#8220;Initial Warrants&#8221;) and Additional Notes (the &#8220;Additional Warrants&#8221;) expire on June 30, 2025 and entitled the noteholders to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-603">2,143,000</ix:nonFraction> shares of Common Stock and included specified registration rights. Management estimated the fair value of the Initial Warrants to be $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-604">6,800</ix:nonFraction> and the Additional Warrants to be $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="f-605">735</ix:nonFraction>, each based on an assessment by an independent third-party appraiser. The fair value of the respective warrants was treated as a debt discount, amortizable over the term of the respective warrants, with the unamortized <ix:nonFraction unitRef="number" contextRef="c-163" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-606">12.5</ix:nonFraction>% Notes portion applied to reduce the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="c-163" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-607">12.5</ix:nonFraction>% Notes. The <ix:nonFraction unitRef="number" contextRef="c-163" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-608">12.5</ix:nonFraction>% Notes were refinanced with the <ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-609">13.5</ix:nonFraction>% Notes on November 1, 2023. Additionally, since the Initial Warrants and Additional Warrants issued do not provide warrant redemption or put rights within the control of the holders that could require the Company to make a payment of cash or other assets to satisfy the obligations under the warrants, except in the case of a &#8220;cash change in control&#8221;, the fair value attributed to the warrants is presented in Additional Paid-in Capital in the Company&#8217;s Condensed Balance Sheets. There were <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="aqst:ClassOfWarrantOrRightWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-610"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="aqst:ClassOfWarrantOrRightWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-611">no</ix:nonFraction></ix:nonFraction> warrants exercised as it relates to the Initial Warrants and the Additional Warrants during the three months ended March&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-612">1,683,784</ix:nonFraction> shares of Common Stock with exercise prices of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-613">4.25</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-614">5.38</ix:nonFraction> for <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-615">1,571,429</ix:nonFraction> warrants and <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-616">112,355</ix:nonFraction> warrants, respectively, remain outstanding as of March&#160;31, 2025 and December&#160;31, 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants Issued Under Securities Purchase Agreements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company issued pre-funded warrants and Common Stock warrants to certain purchasers in connection with the Securities Purchase Agreements. The pre-funded warrants entitled purchasers to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-617">4,000,000</ix:nonFraction> shares of Common Stock and were exercised in full during the year ended December 31, 2022. The Common Stock warrants expire on June 8, 2027 and entitled the purchasers to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-618">8,850,000</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-619">0.96</ix:nonFraction> per share. Management estimated the fair value of the pre-funded warrants and Common Stock warrants to be $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-620">5,874</ix:nonFraction> based on an assessment by an independent third-party appraiser. The fair value of the pre-funded and Common Stock warrants is treated as equity and presented in Additional Paid-in Capital in the Company&#8217;s Condensed Balance Sheets. On June 14, 2023, <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="0" name="aqst:ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="f-621">3,689,452</ix:nonFraction> Common Stock warrants issued pursuant to the Securities Purchase Agreements were exercised with proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="f-622">3,542</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, the Company entered into the Letter Agreement with the Exercising Holder of <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-623">5,000,000</ix:nonFraction> of the remaining Common Stock Warrants. Pursuant to the Letter Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise all of its Existing Warrants for shares of Common Stock underlying the Existing Warrants at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-624">0.96</ix:nonFraction> per share of Common Stock, the current exercise price of the Existing Warrants. Under the Letter Agreement, in consideration of the Exercising Holder exercising the Existing Warrants, the Company issued to the Exercising Holder New Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-625"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-626">2,750,000</ix:nonFraction></ix:nonFraction> shares of Common Stock. The New Warrants became exercisable after February 2, 2024, expire on February 2, 2029 and are issuable only for cash, subject to exception if the shares of Common Stock underlying the New Warrants are not registered in accordance with the terms of the Letter Agreement, in which case the New Warrants may also be exercised, in whole or in part, at such time by means of a "cashless exercise". The New Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-627">2.60</ix:nonFraction> per share. Management estimated the fair value of the warrants to be $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-628">4,671</ix:nonFraction> based on an assessment by an independent third-party appraiser. The fair value of the New Warrants is treated as equity and is presented in Additional Paid-in Capital in the Company&#8217;s Condensed Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="aqst:ClassOfWarrantOrRightWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-629"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="aqst:ClassOfWarrantOrRightWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-630">no</ix:nonFraction></ix:nonFraction> warrants issued or exercised as it relates to the Warrants Issued Under Securities Purchase Agreements during the three months ended March&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-631">2,750,000</ix:nonFraction> shares of Common Stock described above, there remain outstanding warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-632">160,548</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-633">0.96</ix:nonFraction> and warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-634">1,683,784</ix:nonFraction> shares of Common Stock outstanding related to the original issuance of the <ix:nonFraction unitRef="number" contextRef="c-175" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-635">12.5</ix:nonFraction>% Notes prior to the debt refinancing referenced in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with exercise prices of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-636">4.25</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-637">5.38</ix:nonFraction> for <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-638">1,571,429</ix:nonFraction> warrants and <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-639">112,355</ix:nonFraction> warrants, respectively.</span></div></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_88"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="aqst:SaleOfFutureRevenueTextBlock" id="f-640" continuedAt="f-640-1" escape="true">Sale of Future Revenue</ix:nonNumeric></span></div><ix:continuation id="f-640-1" continuedAt="f-640-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2020, the Company entered into the Monetization Agreement with Marathon. Under the terms of the Monetization Agreement, the Company sold all of its contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#8217;s apomorphine product, KYNMOBI, an apomorphine film therapy for the treatment of off episodes in Parkinson&#8217;s disease patients, which received approval from the FDA on May 21, 2020. In exchange for the sale of these rights, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-641">40,000</ix:nonFraction> and an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-642">10,000</ix:nonFraction> through </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-640-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the achievement of the first milestone. The Company has received an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-643">50,000</ix:nonFraction> through March&#160;31, 2025 under the Monetization Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Monetization Agreement, additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:ContingentMonetizationAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="3" id="f-644">75,000</ix:nonFraction> may be due to the Company upon the achievement of worldwide royalty and other commercial targets within a specified timeframe, which could result in total potential proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-645">125,000</ix:nonFraction>. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the upfront proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-646">40,000</ix:nonFraction> and subsequent first milestone of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-647">10,000</ix:nonFraction>, reduced by $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-648">2,909</ix:nonFraction> of transaction costs, as a liability related to the sale of future revenue that will be amortized using the effective interest method over the life of the Monetization Agreement. As future contingent payments are received, they will increase the balance of the liability related to the sale of future revenue. Although the Company sold all of its rights to receive royalties and milestones, as a result of ongoing obligations related to the generation of these royalties, the Company will account for these royalties as revenue. Its ongoing obligations include the maintenance and defense of the intellectual property and to provide assistance to Marathon in executing a new license agreement for KYNMOBI in the event Sunovion terminates the Sunovion License Agreement in one or more jurisdictions of the licensed territory under the Sunovion License Agreement. The accounting liabilities, as adjusted over time, resulting from this transaction and any non-cash interest expenses associated with those liabilities do not and will not represent any obligation to pay or any potential future use of cash.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, under the Sunovion License Agreement, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-649">8,000</ix:nonFraction> of royalty revenue and corresponding royalty receivable, related to the $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="aqst:MinimumAnnualRoyaltyReceivable" format="ixt:num-dot-decimal" scale="3" id="f-650">1,000</ix:nonFraction> annual minimum guaranteed royalty that is due. In connection with the Monetization Agreement, the Company performed an assessment under ASC 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfer and Servicing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to determine whether the existing receivable was transferred to Marathon and concluded that the receivable was not transferred. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As royalties are remitted to Marathon from Sunovion, the collection of the royalty receivable and balance of the liability related to the sale of future revenue will be effectively repaid over the life of the agreement. In order to determine the amortization of the liability related to the sale of future revenue, the Company is required to estimate the total amount of future royalty and milestone payments to Marathon over the life of the Monetization Agreement and contingent milestone payments from Marathon to the Company. The sum of future royalty payments less the $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="aqst:ProceedsFromSaleOfFutureRevenuesNet" format="ixt:num-dot-decimal" scale="3" id="f-651">50,000</ix:nonFraction> in proceeds received and future contingent payments has been recorded as interest expense over the life of the Monetization Agreement. At execution, the estimate of this total interest expense resulted in an effective annual interest rate of approximately <ix:nonFraction unitRef="number" contextRef="c-179" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-652">24.9</ix:nonFraction>%. This estimate contained significant assumptions that impact both the amount recorded at execution and the interest expense that will be recognized over the life of the Monetization Agreement. The Company assesses the estimated royalty and milestone payments to Marathon from Sunovion and contingent milestone payments from Marathon to the Company. To the extent the amount or timing of such payments is materially different from the original estimates, an adjustment will be recorded prospectively to increase or decrease interest expense. There are a number of factors that could materially affect the amount and timing of royalty and milestone payments to Marathon from Sunovion and, correspondingly, the amount of interest expense recorded by the Company, most of which are not under the Company&#8217;s control. Such factors include, but are not limited to, changing standards of care, the initiation of competing products, manufacturing or other delays, generic competition, intellectual property matters, adverse events that result in government health authority imposed restrictions on the use of products, significant changes in foreign exchange rates as the royalties remitted to Marathon are made in U.S. dollars (USD) while a portion of the underlying sales of KYNMOBI will be made in currencies other than USD, and other events or circumstances that are not currently foreseen. Changes to any of these factors could result in increases or decreases to both royalty revenue and interest expense related to the sale of future revenue. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets. Therefore, the Company likely will not receive any of the additional contingent payments under the Monetization agreement. Further, the Company discontinued recording interest expense related to the sale of future revenue during the fourth quarter of 2022.</span></div><ix:nonNumeric contextRef="c-1" name="aqst:RoyaltyObligationActivityTableTextBlock" id="f-653" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity of the liability related to the sale of future revenue:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net at beginning of the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-654">63,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-655">64,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties related to the sale of future revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-657">1,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-658">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-659">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net at end of the period (includes current portion of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-660">1,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-661">1,000</ix:nonFraction>, respectively)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-662">63,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="aqst:LiabilitiesSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-663">63,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-664" continuedAt="f-664-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-664-1"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-665" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted EPS is adjusted by the effect of dilutive securities, including options and awards under the Company&#8217;s equity compensation plans, warrants and ESPP. As a result of the Company&#8217;s net loss incurred for the three months ended March&#160;31, 2025 and 2024, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations.&#160;Therefore, basic and diluted net loss per share are the same for the three months ended March&#160;31, 2025 and 2024 as reflected below.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-666">22,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-667">12,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares &#8211; basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-668"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-669">95,497,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-670"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-671">73,614,710</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per common share &#8211; basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-672"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-673">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-674"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-675">0.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">For the three months ended March&#160;31, 2025 and 2024, outstanding stock options of <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-676">6,977,367</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-677">6,169,489</ix:nonFraction> to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the three months ended March&#160;31, 2025 and 2024, outstanding restricted stock units of <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-678">5,167,351</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-679">3,918,451</ix:nonFraction> to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">For the three months ended March&#160;31, 2025 and 2024, outstanding warrants of <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-680">4,594,332</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-188" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-681">4,624,977</ix:nonFraction> to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div></ix:nonNumeric></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_94"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-682" continuedAt="f-682-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-683" escape="true"><ix:continuation id="f-682-1" continuedAt="f-682-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation in its Condensed Statements of Operations and Comprehensive Loss during the three month periods ended March&#160;31, 2025 and 2024 as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-684">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-685">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-686">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-687">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-688">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-689">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-690">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-691">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-692">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-693">933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-694">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-695">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-696">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-697">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-682-2" continuedAt="f-682-3"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Equity Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-698" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information about the Company&#8217;s restricted stock unit and stock option activity during the three month period ended March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s awards of service-based and market conditions vesting-based restricted stock units for the three month period ended March&#160;31, 2025:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Restricted Stock Unit Awards (RSUs) - Service-based:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-699">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-700">3.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-195" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-701">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-702">2.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-195" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-703">713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-704">3.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-195" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-705">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-706">3.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-707">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-708">3.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="-3" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" format="ixt:num-dot-decimal" scale="3" id="f-709">3,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" scale="0" id="f-710">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="f-711">8,369</ix:nonFraction> of total unrecognized compensation expenses related to unvested service-based restricted stock units are expected to be recognized over a remaining weighted average period of <ix:nonNumeric contextRef="c-195" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-712">2.14</ix:nonNumeric> years. The service-based restricted stock units granted to employees are subject to a <ix:nonNumeric contextRef="c-195" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-713">three-year</ix:nonNumeric> graduated vesting schedule and are not subject to performance-based criteria other than continued employment.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-714" escape="true"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Restricted Stock Unit Awards (RSUs) - Market conditions vesting-based:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-715">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-201" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-716">2.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-202" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-717">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-718">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-202" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-202" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-723">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-724">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="-3" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" format="ixt:num-dot-decimal" scale="3" id="f-725">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" scale="0" id="f-726">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="f-727">2,798</ix:nonFraction> of unrecognized compensation expense related to unvested market condition vesting- based restricted stock units are expected to be recognized over a remaining weighted average period of <ix:nonNumeric contextRef="c-205" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-728">1.87</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 market conditions vesting-based restricted stock units vest based on a Performance Price measured as the <ix:nonNumeric contextRef="c-206" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" format="ixt-sec:durwordsen" id="f-729">30-day</ix:nonNumeric> average of the closing prices of the Company&#8217;s common stock as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the <ix:nonNumeric contextRef="c-207" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-730">three-year</ix:nonNumeric> performance period (which ends on the third anniversary of the grant date). To the extent the Performance Price is less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-208" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-731">1.75</ix:nonFraction>, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-209" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="f-732">zero</ix:nonFraction>. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-210" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-733">1.75</ix:nonFraction>, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-211" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-734">50</ix:nonFraction>%. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-212" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-735">1.76</ix:nonFraction> or greater, but less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-213" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-736">2.50</ix:nonFraction>, the Vesting Percentage will be a prorated amount between <ix:nonFraction unitRef="number" contextRef="c-214" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-737">50.01</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-215" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-738">99.99</ix:nonFraction>%, based on straight-line interpolation. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-739">2.50</ix:nonFraction>, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-217" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-740">100</ix:nonFraction>%. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-218" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-741">2.51</ix:nonFraction> or greater, but less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-742">3.25</ix:nonFraction>, the Vesting Percentage will be a prorated amount between <ix:nonFraction unitRef="number" contextRef="c-220" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-743">100.01</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-221" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-744">149.99</ix:nonFraction>%, based on straight-line interpolation. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-222" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-745">3.25</ix:nonFraction> or greater, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-223" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-746">150</ix:nonFraction>%. In no event will the Vesting Percentage exceed <ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-747">150</ix:nonFraction>%.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 market conditions vesting-based restricted stock units were measured over a <ix:nonNumeric contextRef="c-225" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-748">three-year</ix:nonNumeric> performance period. The performance period is split into <ix:nonFraction unitRef="pricing_period" contextRef="c-225" decimals="INF" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" format="ixt-sec:numwordsen" scale="0" id="f-749">two</ix:nonFraction> pricing periods. The first pricing period commences on the grant date and ends on the calendar day immediately proceeding the second anniversary of the grant date. The second pricing period commences on the second anniversary of the grant date and ends on the third anniversary of the grant date, The performance price for the first pricing period is calculated based on the <ix:nonNumeric contextRef="c-226" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" format="ixt-sec:durwordsen" id="f-750">30-day</ix:nonNumeric> average price observed for the last <ix:nonNumeric contextRef="c-226" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" format="ixt-sec:durday" id="f-751">30</ix:nonNumeric> days of the first pricing period. The performance price for the second pricing period is calculated based on the highest <ix:nonNumeric contextRef="c-226" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" format="ixt-sec:durwordsen" id="f-752">30-day</ix:nonNumeric> average for any <ix:nonNumeric contextRef="c-226" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" format="ixt-sec:durwordsen" id="f-753">30-day</ix:nonNumeric> period </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-682-3"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">throughout the second pricing period. To the extent the Performance Price is less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-227" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-754">6.00</ix:nonFraction>, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-228" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="f-755">zero</ix:nonFraction>. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-229" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-756">6.00</ix:nonFraction>, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-230" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-757">50</ix:nonFraction>%. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-758">6.01</ix:nonFraction> or greater, but less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-232" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-759">7.00</ix:nonFraction>, the Vesting Percentage will be a prorated amount between <ix:nonFraction unitRef="number" contextRef="c-233" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-760">50.01</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-234" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-761">99.99</ix:nonFraction>%, based on straight-line interpolation. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-235" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-762">7.00</ix:nonFraction>, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-236" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-763">100</ix:nonFraction>%. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-764">7.01</ix:nonFraction> or greater, but less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-238" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-765">8.00</ix:nonFraction>, the Vesting Percentage will be a prorated amount between <ix:nonFraction unitRef="number" contextRef="c-239" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-766">100.01</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-240" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-767">149.99</ix:nonFraction>%, based on straight-line interpolation. To the extent the Performance Price is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-241" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" scale="0" id="f-768">8.00</ix:nonFraction> or greater, the Vesting Percentage will be <ix:nonFraction unitRef="number" contextRef="c-242" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-769">150</ix:nonFraction>%. In no event will the Vesting Percentage exceed <ix:nonFraction unitRef="number" contextRef="c-243" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-770">150</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="aqst:ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" id="f-771" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimates of the fair value of the 2025 market conditions vesting-based awards at their grant or valuation dates were based on a Monte Carlo simulation and considered various variables and the following assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.515%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-772">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-773">91.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-774">3.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price at grant date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-775">2.65</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Inducement Equity Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Nasdaq Listing Rule 5635(c)(4), the Company adopted the 2022 Equity Inducement Plan approved by the Compensation Committee of the Board of Directors of the Company effective as of July 29, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-776" escape="true"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Stock Option Awards:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-244" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-777">6,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-778">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-779">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-780">2.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-197" decimals="-3" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" scale="3" id="f-783">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-784">5.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-245" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-785">6,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-245" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-786">5.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-245" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-787">6,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-245" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-788">5.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-245" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-789">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-245" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-790">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of stock options granted were estimated using the Black-Scholes pricing model based on the following assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.906%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-791">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-792">100</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-246" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-793">6.1</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-246" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-794">4.2</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock options granted during the three months ended March&#160;31, 2025 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-795">2.15</ix:nonFraction>. During the three months ended March&#160;31, 2025, stock options were granted with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-796">2.65</ix:nonFraction> and accordingly, given the Company&#8217;s share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-797">2.90</ix:nonFraction> at March&#160;31, 2025, the intrinsic value provided by certain shares granted during this period was de minimis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-798">3,849</ix:nonFraction> of unrecognized compensation expense related to non-vested stock options is expected to be recognized over a remaining weighted average period of <ix:nonNumeric contextRef="c-197" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-799">1.97</ix:nonNumeric> years.</span></div></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_97"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-800" continuedAt="f-800-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-800-1" continuedAt="f-800-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as net operating loss carryforwards and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-800-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax asset will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items. For the three months ended March&#160;31, 2025, the effective income tax rate was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-801">0</ix:nonFraction>%, and the Company recorded <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-802">no</ix:nonFraction> income tax expense from its pretax losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-803">22,930</ix:nonFraction>. For the three months ended March&#160;31, 2024, the effective income tax rate was <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-804">0</ix:nonFraction>%, and the Company recorded <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-805">no</ix:nonFraction> income tax expense from its pretax losses of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-806">12,828</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary factors impacting the effective tax rate for three months ended March&#160;31, 2025 is the anticipated full year pre-tax book loss and a full valuation allowance against any associated net deferred tax assets.</span></div></ix:continuation><div id="ibc17e35e18524b0cae1e0a983b1038de_100"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-807" continuedAt="f-807-1" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-807-1" continuedAt="f-807-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has been and may again become involved in legal proceedings arising in the course of its business, including product liability, intellectual property, securities, civil tort, and commercial litigation, and environmental or other regulatory matters.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kentucky Litigation - Humana</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Humana Inc. v. Indivior Inc, Indivior Solutions Inc., Indivior PLC, Reckitt Benckiser Group plc, Reckitt Benckiser Healthcare (UK) Ltd., and Aquestive Therapeutics, Inc. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2021, Humana filed a complaint in state court in Kentucky, alleging conspiracy to violate the RICO Act, fraud under state law, unfair and deceptive trade practices under state law, insurance fraud, and unjust enrichment against the Company relating to Indivior&#8217;s launch of Suboxone Sublingual Film in 2010. The Humana action was stayed pending related litigation, and the stay was lifted on October 30, 2023. The parties to this case reached a settlement in November 2024, the terms of which are confidential. Aquestive had no obligation, cost or liability in the settlement as all were assumed by Indivior.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Litigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Neurelis, Inc. v. Aquestive Therapeutics, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2019, Neurelis, Inc. ("Neurelis") filed a lawsuit against the Company in the Superior Court of California, County of San Diego alleging the following <ix:nonFraction unitRef="pending_case" contextRef="c-247" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-808">three</ix:nonFraction> causes of action: (1) Unfair Competition under California Business and Professional Code &#167; 17200 (&#8220;UCL&#8221;); (2) Defamation; and (3) Malicious Prosecution. Neurelis filed a First Amended Complaint on December 9, 2019, alleging the same <ix:nonFraction unitRef="pending_case" contextRef="c-247" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-809">three</ix:nonFraction> causes of action. The Company filed a Motion to Strike Neurelis&#8217;s Complaint under California&#8217;s anti-SLAPP (&#8220;strategic lawsuit against public participation&#8221;) statute on January 31, 2020, which Neurelis opposed. On August 6, 2020, the Court issued an order granting in part and denying in part the Company&#8217;s anti-SLAPP motion. The parties cross-appealed the ruling to the California Court of Appeal. The appeals court held oral argument on the appeal on October 14, 2021, and issued its ruling on November 17, 2021. Under the ruling, the court struck the entirety of the malicious prosecution claim and struck portions of the UCL and defamation claims. On April 12, 2022, Neurelis filed a Second Amended Complaint in response to the Court of Appeal&#8217;s decision. The Second Amended Complaint also added a cause of action for Trade Libel. On May 3, 2022, the Company filed a "demurrer" challenge to the sufficiency of the allegations of the Second Amended Complaint. Oral argument on the Company&#8217;s motion for attorney fees related to the anti-SLAPP motion and on the Second Amended Complaint and demurer challenge was held on June 17, 2022. The Court entered an order granting the Company&#8217;s motion for attorney fees, awarding $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="3" id="f-810">156</ix:nonFraction> and ordering Neurelis to pay the fees within <ix:nonNumeric contextRef="c-248" name="aqst:LitigationSettlementAmountAwardPeriodDue" format="ixt-sec:durday" id="f-811">60</ix:nonNumeric> days of June 17, 2022. The Court denied the Company&#8217;s demurrer and the parties proceeded with discovery on the claims in the Second Amended Complaint. The plaintiff filed a motion to file a third amended complaint, which the Court granted on November 17, 2023. The Third Amended Complaint alleges additional facts but includes the same claims as the Second Amended Complaint. Hearings on motions for summary judgement are scheduled for May 16, 2025. The trial in this matter is scheduled for July 18, 2025. The Company is not able to determine or predict the ultimate outcome of this proceeding or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurelis FDA Lawsuit</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Neurelis v. Califf, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, U.S. District court for the District of Columbia</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, Neurelis filed a complaint in the U.S. District Court for the District of Columbia against the U.S. Food and Drug Administration, the U.S. Department of Health and Human Services, and certain government officials. The complaint in this matter alleges that the defendants violated the Administrative Procedure Act by approving the Company's NDA for Libervant for ARS patients aged between two and five years, and asked the Court to vacate that approval and enjoin the defendants from approving Libervant for this pediatric patient population until January 10, 2027, the scheduled date for the expiration of the U.S. orphan drug market exclusivity granted by the FDA to the Valtoco nasal spray product of Neurelis. The Company intervened in this litigation to defend the approval of Libervant for this ARS pediatric patient population and, on June </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><ix:continuation id="f-807-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25, 2024, the Court entered a scheduling order governing further proceedings in the case. Pursuant to that order, Neurelis filed a motion for summary judgment on August 19, 2024; the Company and the federal defendants each filed their own cross-motions for summary judgment and opposed Neurelis&#8217;s motion for summary judgment on September 18, 2024. Neurelis filed its combined reply brief in support of its motion for summary judgment and in opposition to the defendants&#8217; cross-motions on October 9, 2024, and the Company and the federal defendants filed their closing briefs on October 30, 2024. Following the FDA's award of ODE to Libervant for ARS patients between two and five years of age, Neurelis filed a motion for preliminary injunction requesting an expedited order to vacate FDA's approval and enjoining the sale of Libervant. On February 14, 2025, the Court ruled in favor of Neurelis, granting its summary judgment motion, and against the FDA's and the Company's cross-motions for summary judgment. In an accompanying opinion, the Court directed the FDA to vacate the approval of Libervant. Because the Court entered a final appealable judgment in favor of Neurelis, Neurelis' motion for an expedited preliminary injunction was denied as moot by the Court. On February 18, 2025, the Company filed an appeal of the District Court's decision with the U.S. Circuit Court of Appeals for the District of Columbia (the "DC Appellate Court") and, on the same day, filed an emergency motion with the District Court to stay its order pending a decision on the appeal with the DC Appellate Court. The District Court denied the motion for a stay. On March 27, 2025, the DC Appellate Court denied the Company's emergency motion for stay. The FDA filed an appeal of the District Court's decision to the DC Appellate Court and the Company withdrew its appeal. As a result of the District Court's ruling, the FDA converted the approval of Libervant to a "tentative approval" and the Company has ceased marketing activities in the United States. The Company is communicating with the FDA on a path forward for approval of Libervant for ARS patients aged between two and five years but the Company has not yet received any decision from the FDA on market access for these Libervant pediatric patients. No dates have been set for arguments on the appeal proceedings at the DC Appellate Court. The Company is not able to determine or predict the ultimate outcome of these proceedings or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter or whether the FDA will grant U.S. market access to Libervant for ARS patients aged between two and five years in advance of the ODE expiration period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Suboxone Product Liability Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was named as a defendant in a multitude of product liability lawsuits, along with Indivior and several other named defendants, in which the individual plaintiffs in those cases allege that their use of Suboxone&#174; Sublingual Film, a prescription drug product for opioid use disorder, caused them dental injuries. On February 2, 2024, this litigation became a Multidistrict Litigation (&#8220;MDL") consolidated in the U.S District Court for the Northern District of Ohio. <ix:nonFraction unitRef="pending_case" contextRef="c-249" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-812">One</ix:nonFraction> case alleging the same allegations as contained in the MDL has been filed in a state court in the State of New Jersey. The parties to the MDL have agreed to a tolling of unfiled claimants in several states. Indivior has agreed to defend the Company in these litigation matters. Discovery is underway and no trial date has been set in the MDL matter. The Company's motion to dismiss the MDL matter was granted as to all claims by plaintiffs except design defect claims. The Company is not able to determine or predict the ultimate outcome of this litigation or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was named as a defendant in <ix:nonFraction unitRef="pending_case" contextRef="c-250" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-813">three</ix:nonFraction> proposed class action lawsuits filed in Canada, along with Indivior and several other named defendants, in which the individual plaintiffs in those cases allege that their use of Suboxone&#174; products caused them dental injuries. <ix:nonFraction unitRef="pending_case" contextRef="c-251" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-814">Two</ix:nonFraction> of these cases have been filed in British Columbia, and the plaintiffs in those cases are seeking assignment of a case management judge. The anticipated next step in British Columbia will involve applications by the plaintiffs to determine which of the <ix:nonFraction unitRef="pending_case" contextRef="c-251" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-815">two</ix:nonFraction> cases will proceed towards a certification hearing and which will be stayed. The third case has been filed in Quebec and is proceeding towards an authorization hearing, the date of which has not yet been set. The authorization and certification hearings will determine whether the Courts will allow the cases to proceed as class actions. Pre-discovery and case management proceedings are underway and no trial date has yet been set. Given the early stages of these proceedings, the Company is not able to determine or predict the ultimate outcome of this litigation or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this litigation.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read this section in conjunction with our condensed interim financial statements and related notes included in Part I Item 1 of this Quarterly Report on Form 10-Q and our audited financial statements and related notes thereto and management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s discussion and analysis of financial condition and results of operations for the years ended December&#160;31, 2024 and 2023 included in our 2024 Annual Report on Form 10-K. All dollar amounts are stated in thousands except for share data. </span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_106"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and certain other communications made by us include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions are intended to identify forward-looking statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm&#8482; (epinephrine) Sublingual Film through clinical development and approval by the FDA, including the acceptance of the NDA for Anaphylm with the FDA, and the following launch of Anaphylm, if approved by the FDA; the results of the Company&#8217;s clinical studies for Anaphylm and the ability of such results to support submission of the NDA for approval of Anaphylm to the FDA; Anaphylm's potential to be the first and only oral administration of epinephrine and to be accepted as an alternative to existing standards of care, if approved by the FDA; the expected growth of the U.S. epinephrine market including in value and the opportunity such growth presents to the Company should Anaphylm be approved by the FDA; the advancement, growth and related timing of our Adrenaverse&#8482; pipeline epinephrine prodrug product candidates, including AQST-108 (epinephrine) Topical Gel, through clinical development and FDA regulatory approval process, including design and timing of clinical studies including those necessary to support the targeted indication of alopecia areata for AQST-108 and the following launch of AQST-108, if approved by the FDA; the potential sale or outlicensing of Anaphylm, Libervant or other product candidates; the advancement and related timing of our product candidate Libervant&#174; (diazepam) Buccal Film for the indicated epilepsy patient population aged between 6 and 11 years through clinical development and FDA regulatory approval and the following launch of Libervant for this patient population if approved by the FDA; the approval for U.S. market access of Libervant and overcoming the orphan drug market exclusivity of an FDA approved nasal spray product of another company extending to January 2027; the commercial opportunity of Libervant, Anaphylm, AQST-108 and our other product candidates, including potential revenues (including projected peak annual sales) generated from commercialization of these products, should these product candidates be approved by the FDA; the focus on continuing to manufacture Suboxone&#174;, Emylif&#174;, Sympazan&#174;, Ondif&#174; and other licensed products; the potential growth of our patent portfolio including the extension of patent protection for Anaphylm should the pending patents be approved by the U.S. Patent and Trademark Office (PTO); the potential benefits our products and product candidates could bring to patients; the achievement of clinical and commercial milestones, product orders and fulfillment; our cash requirements, cash funding and cash burn; short-term and longer term liquidity and the ability to fund our business operations; our growth and future financial and operating results and financial position, including with respect to our 2025 financial outlook; and business strategies, market opportunities, and other statements that are not historical facts.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm (including for pediatric patients), AQST-108, and our other product candidates; risk of delays in advancement of the regulatory approval process through the FDA of our product candidates, including the filing and acceptance of the respective NDAs, for Anaphylm, AQST-108, Libervant for patients aged between 6 and 11 and other product candidates, or failure to receive FDA approval at all of any of these product candidates; risk of whether the Company&#8217;s clinical data is sufficient for approval of our product candidates, including with respect to our PK/PD comparability submission for FDA approval of Anaphylm; risks associated our ability to address the FDA&#8217;s comments on our future clinical trials and other concerns identified in the FDA Type C meeting minutes for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risks associated with the success of any competing products, including generics; risk that we may not overcome the seven year orphan drug market exclusivity granted by the FDA for the approved nasal spray product of another company in the U.S. in order for Libervant to be granted U.S. market access for patients prior to expiration of the orphan drug market exclusivity period of the nasal spray product, which is due to occur in January 2027, or for other reasons; risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of development of a sales and marketing capability for commercialization of our product candidates, including Anaphylm and AQST-108; risks associated with the potential impact on the value of the Company of the sale or outlicensing of our product and product candidates, including Libervant and Anaphylm and other product candidates; risk of insufficient capital and cash resources, including insufficient access to available debt and equity financing, including under our ATM facility, and revenues from operations, to satisfy all of our short-term and longer-term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to commence principal payments on our 13.5% Notes in 2026 and to fund future clinical development and commercial activities for our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product candidates, including Anaphylm, AQST-108 and Libervant for patients aged between 6 and 11, should these product candidates be approved by the FDA, and for Libervant upon expiration of the orphan drug marketing exclusivity period of the nasal spray product; risk that our manufacturing capabilities will be insufficient to support demand for Libervant should Libervant receive U.S. market access, and for demand for our licensed products in the U.S. and abroad; risk of eroding market share for Suboxone&#174; as a sunsetting product, which accounts for a substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risks associated with the rate and degree of market acceptance in the U.S. and abroad of Libervant for epilepsy patients if approved for U.S. market access and after the expiration of the orphan drug market exclusivity period in January 2027; risk of the rate and degree of market acceptance in the U.S. and abroad of Anaphylm, AQST-108 and our other product candidates, should these product candidates be approved by the FDA, and for our licensed products in the U.S. and abroad; risk associated with the size and growth of our product markets; risk associated with our compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to our products; risk that our patent applications for our product candidates, including for Anaphylm, will not be timely issued, or issued at all, by the PTO; risk of unexpected patent developments; risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and product candidates and product pricing, reimbursement or access therefor; risk of loss of significant customers; risks related to claims and legal proceedings against us including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; risk of product recalls and withdrawals; risks related to any disruptions in our information technology networks and systems, including the impact of cybersecurity attacks; risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; risk of adverse developments affecting the financial services industry; risks related to inflation and changing interest rates; risks related to the impact of pandemic diseases on our business; risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items, including a potential recession; risks related to uncertainty about U.S. government initiatives and their impact on our business, including imposition of tariffs and other trade restrictions; and other uncertainties affecting us including those described in the "Risk Factors" section and in other sections included in this Quarterly Report on Form 10-Q. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the risk factors of the Company&#8217;s 2024 Annual Report on Form 10&#8209;K and our other Quarterly Reports on Form 10&#8209;Q and in our Current Reports on Form 8-K and our other filings with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. We assume no obligation to update forward-looking statements, or outlook or guidance after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise, except as may be required by applicable law. Readers should not rely on the forward-looking statements included in this Quarterly Report on Form 10-Q as representing our views as of any date after the date of the filing of this Quarterly Report on Form&#160;10&#8209;Q.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to &#8220;Aquestive,&#8221; the "Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Aquestive Therapeutics, Inc.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_109"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. We are advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis, under the "Anaphylm&#8482;" trade name, and our Adrenaverse&#8482; epinephrine prodrug pipeline platform. We have four licensed commercialized products which are marketed by our licensees in the U.S. and around the world. We are the exclusive manufacturer of these licensed products. Aquestive also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm, and has proven drug development and commercialization capabilities. Our production facilities are located in Portage, Indiana, and our corporate headquarters and primary research laboratory facilities are based in Warren, New Jersey. </span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture licensed products at our facilities and anticipate that our current manufacturing capacity is sufficient for commercial quantities of our licensed products, proprietary product and product candidates currently in development. Our facilities have been inspected by the FDA, TGA, and DEA, and are subject to inspection by all applicable health agencies, including ANVISA and EMA. Not all collaborative or licensed products of the Company that may be commercially launched in the future will necessarily be manufactured by us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Complex Molecule Portfolio</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a proprietary pipeline of complex molecule-based product candidates as alternatives to invasively administered standard of care therapeutics addressing large market opportunities. The active programs in our complex molecule pipeline portfolio are:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Anaphylm&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (epinephrine) Sublingual Film &#8211; the first and only non-device based, orally delivered epinephrine product candidate in development that has shown clinical results comparable to auto-injectors (such as EpiPen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Auvi-Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the emergency treatment of allergic reactions, including anaphylaxis. Epinephrine is the standard of care in the treatment of anaphylaxis and is typically administered via intramuscular injection (IM), including manual auto-injectors such as EpiPen and Auvi-Q, which require patients or their caregivers to inject epinephrine into the patient&#8217;s thigh during an emergency allergic reaction. As a result of this route of administration, many patients and their caregivers are reluctant to use injectable products. In August 2024, a nasal spray device was approved by the FDA for the treatment of severe allergic reactions, including anaphylaxis. However, Anaphylm would, if approved by the FDA, allow a patient to simply place a dissolvable strip, approximately the size and weight of a postage stamp, under the tongue, providing an appropriate medication where it is needed and when it is needed.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conditionally accepted the proprietary name Anaphylm&#8482; (pronounced &#8220;ana-film&#8221;) as the proposed brand name for Anaphylm. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of Anaphylm, if any.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, following a Phase 1 clinical study conducted by the Company outside of the U.S., the FDA cleared our IND for Anaphylm, allowing for clinical investigation of Anaphylm in the U.S. The FDA confirmed that the 505(b)(2) regulatory approval pathway is acceptable for the development of Anaphylm. The FDA granted Fast Track designation of Anaphylm in March 2022.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2022 and 2023, we reported positive topline data from several clinical studies evaluating multiple oral film formulations and dosage strengths of Anaphylm in healthy adult subjects, including cross over studies comparing the PK and PD of epinephrine delivered via Anaphylm compared to current standards of care, EpiPen and IM injectors. These studies demonstrated that treatment with Anaphylm was well tolerated, with no serious adverse events, significant medical events, or treatment-related severe adverse events reported. The data from these clinical studies formed the basis for the EOP2 meeting with the FDA in December of 2022, which provided clarity as to the FDA&#8217;s expectations regarding key clinical program areas for design of revised dosing instructions expected for use in our pivotal clinical trial.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we received comments from the FDA on the protocol for our pivotal clinical study for Anaphylm, which comments indicated that our proposed endpoints, sample size, and statistical analysis for the proposed pivotal clinical study were reasonable and provided clarity on PK sustainability with repeat-dose requirements. We incorporated the FDA&#8217;s feedback into the pivotal clinical study design, which study commenced in in the fourth quarter of 2023.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we completed a Type C meeting with the FDA in which the FDA found that we had adequately addressed the FDA&#8217;s previous concerns noted in the EOP2 meeting, including addressing (1) the impact of any product hold time, (2) the potential for emesis (vomiting), and (3) the impact of potential mouth conditions such as angioedema (swelling), by removing product hold time from the administration instructions and providing additional information on how to characterize emesis in our NDA submission with the FDA. Regarding mouth conditions, the FDA recommended administering Anaphylm after oral exposure to a known allergen and assessing PK performance thereunder. This study replaced our previously planned angioedema study. In those comments, the FDA did not outline any new clinical development requirements for the Anaphylm program. The FDA reserved judgement on the sufficiency of the Anaphylm clinical development program until completion of ongoing and planned studies, the results of which were presented at a pre-NDA interaction with the FDA on November 22, 2024.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we released topline data from our pivotal clinical study for Anaphylm. The two-part, Phase 3, single-center, open-label, randomized study was designed to compare the PK and PD of single and repeat doses of Anaphylm versus single and repeat doses of the IM injection and epinephrine autoinjectors (EpiPen&#174; and Auvi-Q&#174;) in healthy adult subjects. The results of this study demonstrated that the primary endpoint, epinephrine PK biocomparability of the single administration of Anaphylm to the single administration of Adrenalin (epinephrine IM injection) and epinephrine autoinjectors in healthy adult subjects was met. The study also met its secondary endpoints, which included evaluating the PK sustainability of Anaphylm following repeat administration, as well as its safety and tolerability of Anaphylm following single and repeat administrations versus epinephrine IM injection and epinephrine autoinjectors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n June 2024, we reported positive topline PK data from the Company's temperature / pH study of Anaphylm. The single-dose, five-period, randomized crossover study was designed to compare the PK and PD of Anaphylm just after consuming normal water at different temperatures (hot, cold, and room temperature) as well as water of different pHs (acidic- lemon water, and basic- baking soda water). The most consumed beverages, such as soda, milk, coffee, and juice, have acidity between lemon water and normal water. The primary PK parameters were the maximum amount of epinephrine measured in plasma (Cmax) and exposure, or the area under the curve (AUC), at predefined time points after dosing, in 30 healthy adult subjects. Topline PK and PD data from the study showed no statistically significant difference in PK and PD results between the different groups based on temperature and pH variability in the mouth.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we reported positive topline data from the self-administration PK study of Anaphylm. The single-dose, three-period, randomized crossover study was designed to compare the PK and PD of Anaphylm self-administered, Anaphylm healthcare provider (HCP)-administered, and Adrenalin IM injection HCP- administered. The primary PK parameters were the Cmax and the AUC exposures, at predefined time points after dosing in 36 healthy adult subjects. The median time to maximum concentration (Tmax) was 15 minutes for both the Anaphylm self-administered and HCP-administered arms, while the median Tmax for the Adrenalin IM injection HCP-administered arm was 50 minutes post-administration. Also, there was no statistical difference between the Anaphylm self-administered and HCP- administered arms of the study based on a comparison of epinephrine exposures across the first 60 minutes post-administration. Topline PD data from the study showed no difference in the median increase in systolic blood pressure, diastolic blood pressure, and heart rate whether Anaphylm was self-administered or HCP-administered.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we reported positive topline data from an oral allergy syndrome challenge study (now referred to as the "OASIS" study), meeting both primary and secondary endpoints. The two-part study demonstrated that Anaphylm's PK and PD profile during allergen-induced oral physiological changes was consistent with its profile without an allergen challenge. In addition, following allergen exposure where 94% of subjects exhibited moderate to severe symptoms per the predefined oral severity score, rapid symptom resolution was observed beginning as early as 2 minutes post-administration. The median time to complete symptom resolution was 12 minutes compared to 74 minutes at screening baseline, with 50% of all symptoms across all subjects resolving by 5 minutes. The mean time of symptom resolution for edema, which affected approximately 25% of subjects, was 5 minutes after Anaphylm administration. The PK profile remained consistent, with median Tmax maintained at 12 minutes and comparable Cmax values between allergen-exposed and non-exposed cohorts. The safety profile was favorable, with all adverse events classified as mild to moderate and resolving without medical intervention. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in October 2024, at the ACAAI 2024 Annual Meeting in Boston, we presented results from a subsequent analysis of our pivotal study data demonstrating Anaphylm's consistent PK and PD profile regardless of variable placement or intraoral movement. The analysis showed that 87.5% of subjects maintained consistent film placement during disintegration. In the 12.5% of subjects where movement was noted, there were no significant differences in Cmax and Tmax. These findings further demonstrate that initial placement or subsequent movement of the sublingual film had no impact on epinephrine PK or PD comparability to epinephrine autoinjectors.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2024, we received positive pre-NDA written response feedback from the FDA prior to our planned NDA submission in the first quarter of 2025. The FDA did not indicate in those responses that any additional adult clinical trials would be necessary for submitting the NDA for Anaphylm. In addition, the FDA agreed with our planned NDA content and format for the submission, planned safety evaluation, and planned pediatric trial. The FDA also provided further guidance on additional data views to be included in the planned NDA submission and continued to emphasize its focus on PK sustainability for a single dose. In addition, the FDA requested minor modifications to the pediatric trial protocol which requested modifications were incorporated in the final pediatric trial protocol. Finally, the FDA noted that due to the new route of administration and the data supporting this route of administration, an advisory committee meeting may be necessary prior to FDA approval and we are preparing for this potential request from the FDA.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the NDA submission to the FDA in the first quarter of 2025. The pediatric study in subjects from the ages of 7 to 17 (weight greater than or equal to 30 kgs) was completed with positive topline data reported on April 1, 2025. A total of thirty-two patients completed the study. The PK results were consistent with previous adult studies. Anaphylm was shown to be safe and well-tolerated with no serious adverse events reported. We are planning on initiating a product launch of Anaphylm, if approved by the FDA, in the first quarter of 2026. This anticipated timing is based on acceptance of the NDA submission by the FDA in the second quarter of 2025.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">AQST-108 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epinephrine) Topical Gel &#8211; Our product candidate, AQST&#8209;108 is composed of the prodrug dipivefrin which is enzymatically cleaved into epinephrine after administration. AQST&#8209;108, is a topically delivered adrenergic agonist prodrug, which we believe has the potential to support the re-establishment of immune privilege in the hair follicle and we are pursuing its development for the treatment of alopecia areata, which is an autoimmune disease leading to hair loss on the scalp, face and, in more severe cases, other body areas. We completed the first human </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial for AQST-108. The two-part trial was designed to assess the safety and local tolerability of AQST-108. Part 1 was designed as a single ascending dose escalation study to assess the safety and PK of five different dose levels. The 1.0% dose of AQST-108 was chosen based on the down selection from the highest dose to move into the Part 2 study of the development program. In Part 2, three formulations based on excipient variations were evaluated in twelve healthy subjects. In Parts 1 and 2, no serious adverse events or topical adverse events were observed. In Part 2, the calculated percentage of AQST-108 observed in the skin remained consistent across all studied formulations and zero post-dose AQST-108 concentrations in plasma were observed. We received pre-IND FDA feedback in the fourth quarter of 2024 to align on the Phase 2a clinical trial design. We are continuing pre-clinical development studies in advance of plans to open an IND in the fourth quarter of 2025 and initiate the Phase 2a clinical trial in the first half of 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary CNS Product</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the application of our proprietary PharmFilm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology is particularly valuable and relevant to patients suffering from certain CNS disorders to meet patients&#8217; unmet medical needs and to solve patients&#8217; therapeutic problems. Our most advanced asset within our proprietary CNS portfolio, focused in epilepsy, is as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Libervant&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; a buccally, or inside of the cheek, administered soluble film formulation of diazepam, Libervant was developed as an alternative to device-dependent rescue therapies currently available to patients with refractory epilepsy, which are a rectal gel and nasal sprays. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2024, the FDA approved Libervant for U.S. market access for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, seizure clusters, ARS) that are distinct from a patient&#8217;s usual seizure pattern in patients with epilepsy between two to five years of age. Libervant is the first and only orally administered rescue product for the treatment of seizure cluster in patients between ages two to five. The only other current FDA approved products for these ARS patients between two to five years of age is a diazepam rectal gel and a diazepam nasal spray. In October 2024, Libervant 5mg, 7.5mg, 10mg, 12.5mg and 15 mg for ARS patients between two and five years of age became available through multiple retail distribution channels.  In the fourth quarter of 2024 the FDA granted seven years of ODE to Libervant&#174; (diazepam) Buccal Film for ARS patients between two to five years of age. Libervant was originally granted Orphan Drug Designation on November 10, 2016. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2025, in a lawsuit brought by Neurelis, Inc. ("Neurelis") against the FDA (Neurelis, Inc. v. Califf, for which the Company joined as a Defendant Intervenor) challenging the FDA's approval of Libervant for ARS patients aged between two and five years, the U.S. District for the District of Columbia issued a final appealable order entering a judgment in favor of Neurelis's motion for summary judgement and vacating the FDA&#8217;s approval of Libervant. The District Court's ruling was not based on grounds of safety or efficacy of Libervant, but rather on the grounds that the law granting ODE to the FDA approved nasal spray Valtoco for patients aged six years and older should be interpreted to extend to children aged two to five years, despite that Valtoco was not approved by the FDA to treat these younger patients at the time the FDA approved Libervant for this pediatric age group. The FDA is appealing this ruling. As a result of the District Court ruling, the FDA converted the approval of Libervant for patients aged between two and five years to a "tentative approval" and Aquestive has ceased marketing activities for Libervant in the United States.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2025, Aquestive filed a request with the FDA that the FDA also confirms approval of Libervant for ARS patients aged between two and five years on the FDA regulatory grounds of clinical superiority over the other currently existing FDA approved ARS drugs. FDA&#8217;s orphan drug regulations define a &#8220;clinically superior&#8221; drug as &#8220;a drug shown to provide a significant therapeutic advantage over and above that provided by an approved orphan drug (that is otherwise the same drug)&#8221; in one of three ways: the basis of greater efficacy or safety, or providing a major contribution to patient care.  The FDA has taken this request under advisement and has not yet provided a response to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the FDA approval of Libervant for ARS patients between two to five years, the FDA granted tentative approval in August 2022 for Libervant for the same indication in patients with epilepsy 12 years of age and older, finding that Libervant had met all required quality, safety, and efficacy standards for approval. However, due to the existing FDA regulatory grant of ODE for Valtoco for use in ARS patients 6 years of age and older, the FDA determined that Libervant was not yet eligible for marketing in the United States for this patient population of 12 years of age and older. We expect to file for FDA approval for use of Libervant for these ARS patients aged between 6 and 11 years prior to the expiration of the ODE for Valtoco. However, as a result of the ODE granted by the FDA to Valtoco and the District Court's ruling, the FDA cannot give final approval for U.S. market access for Libervant for any age group until the expiration of the ODE or a determination by the FDA of inapplicability of the ODE for Libervant, unless the District Court's ruling vacating the FDA approval of Libervant for ARS patients aged between two and five years is overturned on appeal.  In the event that the District Court's ruling is reversed without further right of appeal, and the tentative approval of Libervant for ARS patients aged between two and five is converted to a final </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval by the FDA, the Company would only be able to market Libervant for ARS patients aged between two and five years and would continue to be restricted from market access of Libervant for older ARS patients until the expiration of the ODE for Valtoco. However, overcoming the orphan drug marketing exclusivity determination is difficult to establish, with limited precedent, and there can be no assurance that the FDA will agree with our position seeking to overcome such market exclusivity and approve Libervant for U.S. market access for any age group earlier than January 2027, the scheduled date for expiration of ODE for Valtoco. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensed Commercial Products, Product Candidates and Other Products &#8211; Libervant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for a discussion of the licensing arrangement for Libervant.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensed Commercial Products, Product Candidates and Other Products</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio also includes other products and product candidates that we have licensed, or will seek to license, or for which we have licensed our intellectual property for commercialization. In the three months ended March&#160;31, 2025 and 2024, our licensed product portfolio generated $8,720 and $12,053 in revenue to Aquestive, respectively. Those products include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Suboxone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; a sublingual film formulation of buprenorphine and naloxone, respectively an opioid agonist and antagonist, that is marketed in the United States and internationally for the treatment of opioid dependence. Suboxone was launched by our licensee, Indivior, in 2010. Suboxone is the most prescribed branded product in its category and was the first sublingual film product for the treatment of opioid dependence. We are the sole and exclusive supplier and manufacturer of Suboxone and have produced over 2.8 billion doses of Suboxone since its launch in 2010. As of March&#160;31, 2025, Suboxone branded products retain approximately 27% film market share as generic film-based products have penetrated this market. We have filed patent infringement lawsuits against certain companies relating to generic film-based products for buprenorphine-naloxone. More details regarding these lawsuits are described in the accompanying condensed financial statements, Note 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contained herein. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Emylif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; an oral film formulation of riluzole, has been developed by Aquestive for the treatment of ALS. We believe that Emylif can bring meaningful assistance to patients who are diagnosed with ALS and face difficulties swallowing traditional forms of medication. This product was originally approved and marketed in the U.S. under the name Exservan. Exservan was approved by the FDA on November 22, 2019. We submitted a request for voluntary withdrawal of the NDA as the product is no longer marketed in the U.S. and the NDA was officially withdrawn on February 14, 2025. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2019, we announced the grant of a license to Zambon for the development and commercialization of Exservan in the EU for the treatment of ALS which it markets as Emylif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Zambon is a multinational pharmaceutical company with a focus on the CNS therapeutic area. Under the terms of the license agreement with Zambon, an upfront payment was paid to Aquestive for the development and commercialization rights of Emylif in the EU, and Aquestive will be paid development and sales milestone payments and low double-digit royalties on net sales of the product in the EU. Zambon is responsible for the regulatory approval and marketing of Emylif in the countries where Zambon seeks to market the product and Aquestive is responsible for the development and manufacture of the product. During the second quarter of 2023, Aquestive received a $0.5 million milestone payment in connection with the first commercial sale in the first country in the licensed territory for Emylif pursuant to the terms of the license agreement with Zambon.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced that we granted an exclusive license to MTPA for the commercialization in the United States of Exservan. MTPA is a multinational pharmaceutical company with a focus on patients with ALS. The product was launched by MTPA in June 2021. Under the terms of the MTPA license agreement, Aquestive was the exclusive manufacturer and supplier of Exservan for MTPA in the United States. In June 2024, the Company and MTPA mutually agreed to terminate the MTPA Licensing Agreement.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced the grant of an exclusive license to Haisco for Haisco to develop and commercialize Exservan for the treatment of ALS in China. Haisco is a China-based public pharmaceutical company. Haisco lead the regulatory and commercialization activities for Exservan in China. Aquestive was the exclusive sole manufacturer and supplier for Exservan in China. Under the terms of the license agreement with Haisco, as amended, Aquestive received a $7.0 million upfront payment in September 2022, and was to receive regulatory milestone payments, double-digit royalties on net sales of Exservan in China, and earn manufacturing revenue upon the sale of Exservan in China. In June 2024, Aquestive and Haisco mutually agreed to terminate the Haisco Agreement. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:line-through">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ondif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; an oral soluble film formulation of ondansetron, a 5-HT antagonist, was developed for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Ondansetron is available as branded and generic products as intravenous injections, intramuscular injections, orally dissolving tablets, oral solution tablets, and film. We licensed commercial rights for this product to Hypera in Brazil (which Hypera markets as Ondif). Hypera received approval to market Ondif in Brazil from ANVISA on February 21, 2022. Aquestive manufactures and supplies Ondif to Hypera. This product was originally approved and marketed in the U.S. under the name Zuplenz&#174;. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted a request for voluntary withdrawal of the NDA for Zuplenz, as the product is no longer marketed in the U.S. In November 2024, the request for FDA withdrawal of the NDA for Zuplenz was completed.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Libervant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into the Pharmanovia Agreement with Pharmanovia, effective as of September 26, 2022, pursuant to which we granted Pharmanovia an exclusive license to certain of our intellectual property to develop and commercialize Libervant for the treatment of prolonged or acute, convulsive seizures in all ages in certain countries of the Territory, as defined in the Pharmanovia Agreement, during the term of the Pharmanovia Agreement. Under the Pharmanovia Agreement, Pharmanovia will lead the regulatory and commercialization activities for Libervant in the Territory and Aquestive will serve as the exclusive sole manufacturer and supplier of Libervant in the Territory. We received $3.5 million upon agreement execution. Effective March 27, 2023, we amended the Pharmanovia Agreement to expand the scope of the licensed territory for Libervant to cover the rest of the world, excluding the U.S., Canada and China. Pharmanovia will be responsible for seeking appropriate regulatory approval in the expanded territories. Pursuant to the terms of the Pharmanovia Amendment, we received a non-refundable payment of $2.0 million from Pharmanovia on execution of the Pharmanovia Amendment.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sympazan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome, or LGS, in patients aged two years of age or older, was approved by the FDA on November 1, 2018. We commercially launched Sympazan in December 2018. On October 26, 2022, we entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc., pursuant to which we granted an exclusive, worldwide license of its intellectual property for Sympazan to Assertio during the term of that agreement for an upfront payment of $9.0 million. Additionally, we subsequently received from Assertio a $6.0 million milestone payment upon its receipt of a notice of allowance from the United States Patent and Trademark Office of its patent application U.S. Serial No. 16/561,573, and payment of the related allowance fee. Aquestive is the exclusive sole manufacturer and supplier of Sympazan for Assertio and will receive manufacturing fees from Assertio for the product through the expiration of such License Agreement.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">KYNMOBI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; a sublingual film formulation of apomorphine, which is a dopamine agonist, was developed to treat episodic off-periods in Parkinson&#8217;s disease. We licensed our intellectual property to Cynapsus Therapeutics, Inc., a company that was acquired by Sunovion for the commercialization of KYNMOBI under the Sunovion License Agreement. KYNMOBI was approved by the FDA on May 21, 2020 and commercially launched by Sunovion in September 2020. On November 3, 2020, we entered into the Monetization Agreement. Under the terms of the Monetization Agreement, we sold all of our contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#8217;s apomorphine product, KYNMOBI. In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Azstarys</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an FDA-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. AZSTARYS consists of serdexmethylphenidate, a prodrug of d-methylphenidate (d-MPH), co-formulated with immediate release d-MPH. In March 2012, we entered into an agreement with Zevra (formerly KemPharm, Inc.) to terminate a Collaboration and License Agreement entered into by the Company and Zevra in April 2011. Under this termination arrangement, we have the right to participate in any and all value that Zevra may derive from the commercialization or any other monetization of KP-415 and KP-484 compounds or their derivatives. Among these monetization transactions are those related to any business combinations involving Zevra and collaborations, royalty arrangements, or other transactions from which Zevra may realize value from these compounds, including the product Azstarys. On March 2, 2021, Zevra announced FDA approval of Azstarys for the treatment of ADHD. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the March 2012 agreement with Zevra, we began to receive </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone and royalty revenues for Azstarys.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_112"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                  Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and use of estimates as previously disclosed in our 2024 Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act and Smaller Reporting Company</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain a &#8220;smaller reporting company&#8221;, meaning we are not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent company that is not a "smaller reporting company" which allows us to take advantage of many of the same exemptions from disclosure requirements including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and certain reduced financial disclosures in our periodic reports. In addition, we are eligible to remain a smaller reporting company, for so long as we have a public float (based on our Common Stock equity) of less than $250 million measured as of the last business day of our most recently completed second fiscal quarter or a public float (based on our Common Stock equity) of less than $700 million as of such date and annual revenues of less than $100 million during the most recently completed fiscal year. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive as a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result of these disclosure exemptions, there may be a less active trading market for our Common Stock and our stock price may be more volatile.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_115"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues to date have been earned from our manufactured products made to order for licensees, as well as revenue from our self-developed, self-commercialized proprietary product, Libervant.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evenues are also earned from our product development services provided under contracts with customers, and from the licensing of our intellectual property. We generate revenues in four primary categories: manufacture and supply revenue, license and royalty revenue, co-development and research fees, and proprietary product revenue, net.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacture and Supply Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture based on receipt of purchase orders from our licensees, and our licensees have an obligation to accept these orders once quality assurance validates the quality of the manufactured product with agreed upon technical specifications. In most cases, our licensees are responsible for all other aspects of commercialization of these products, and we have no role, either direct or indirect, in our customers&#8217; commercialization activities, including those related to marketing, pricing, sales, payor access and regulatory operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect future manufacture and supply revenue from licensed products to be based on volume demand for existing licensed products, and for manufacturing and supply rights under license and supply agreements for existing or new agreements for successful product development collaborations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We realize revenue from licenses of our intellectual property. For licenses that do not require further development or other ongoing activities by us, our licensee has acquired the right to use the licensed intellectual property for self-development of their product candidate, for manufacturing, commercialization or other specified purposes, upon the effective transfer of those rights, and related revenues are generally recorded at a point in time, subject to contingencies or constraints, if any. For licenses that may provide substantial value only in conjunction with other performance obligations to be provided by us, such as development services or the manufacture of specific products, revenues are generally recorded over the term of the license agreement. We also earn royalties based on our licensees&#8217; sales of products that use our intellectual property that are marketed and sold in the countries where we have patented technology rights.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-development and Research Fees</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development defined within a contractual development or feasibility study agreement with a customer. The nature of these performance obligations, broadly referred to as milestones or deliverables, are usually dependent on the scope and structure of the project as contracted, as well as the complexity of the product and the specific regulatory approval path necessary for that product. Accordingly, the duration of our research and development projects may range from several months to as long as three years. Although each contractual arrangement is unique, common milestones contained in these arrangements include those for the performance of efficacy and other tests, reports of findings, formulation of initial prototypes, production of stability clinical and/or scale-up batches, and stability testing of those batches. Additional milestones may be established and linked to clinical results of the product submission and/or approval of the product by the FDA and the commercial launch of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary product revenue, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This net revenue is recognized when product is shipped and title passes to the customer, typically at time of delivery. At the time of sale, estimates for various revenue allowances are recorded based on historical trends and judgmental estimates. For sales of Libervant for patients between two to five years of age, returns allowances and prompt pay discounts are estimated based on contract terms and historical return rates, if available, and these estimates are recorded as a reduction of receivables. Similarly determined estimates are recorded relating to wholesaler service fees, co-pay support redemptions, and other rebates, and these estimates are reflected as a component of accrued liabilities. Once all related variable considerations are resolved and uncertainties as to collectable amounts are eliminated, estimates are adjusted to actual allowance amounts. Provisions for these estimated amounts are reviewed and adjusted on no less than a quarterly basis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our costs and expenses are primarily the result of the following activities: generation of manufacture and supply revenues; development of our pipeline of proprietary product candidates; and selling, general and administrative expenses, including pre-launch and post-launch commercialization efforts, intellectual property procurement, protection, prosecution and litigation expenses, corporate management functions, medical and clinical affairs administration; public company costs, share-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based compensation expenses and interest on our corporate borrowings. We primarily record our costs and expenses in the following categories:</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacture and Supply Costs and Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacture and supply costs and expenses are primarily incurred from the manufacture of our commercialized licensed pharmaceutical products, including raw materials, direct labor and overhead costs principally in our Portage, Indiana facilities. Our material costs include the costs of raw materials used in the production of our proprietary dissolving film and primary packaging materials. Direct labor costs consist of payroll costs (including taxes and benefits) of employees engaged in production activities. Overhead costs principally consist of indirect payroll, facilities rent, utilities and depreciation for leasehold improvements and production machinery and equipment. These costs can increase, or decrease, based on the costs of materials, purchased at market pricing, and the amount of direct labor required to produce a product, along with the allocation of fixed overhead, which is dependent on production volume.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacture and supply costs and expenses are impacted by our customers&#8217; supply requirements. Costs of production reflect the costs of raw materials that are purchased at market prices and production efficiency (measured by the cost of a salable unit). These costs can increase or decrease based on the amount of direct labor and materials required to produce a product and the allocation of fixed overhead, which is dependent on the levels of production.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our proprietary products coming online, we may add licensee products which may need additional resources to manufacture. If such growth should occur for higher volume product opportunities such as Suboxone and Ondif, we would incur increased costs associated with hiring additional personnel to support the increased manufacturing and supply costs arising from higher manufactured volumes from proprietary and licensed products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused significant resources on our research and development activities. Research and development expenses primarily consist of:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including compensation, benefits, share-based compensation and travel expense;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under arrangements with third parties, such as CROs, investigational sites and consultants;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of acquiring, developing and manufacturing clinical study materials; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with preclinical and clinical activities and regulatory operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to continue to be significant over the next several years as we continue to develop existing product candidates such as Anaphylm, AQST-108 and others, and as we identify and develop or acquire additional product candidates and technologies. We may hire or engage additional skilled colleagues or third parties to perform these activities, conduct clinical trials and ultimately seek regulatory approvals for any product candidate that successfully completes those clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, General and Administrative expenses consist primarily of salaries, benefits, share-based compensation, other related costs for executive, finance, and operational personnel. Other costs include facility and related costs not otherwise included in research and development expenses such as: professional fees for patent-related and other legal expenses, regulatory fees, consulting, tax and accounting services; insurance; market research; advisory board and key opinion leaders; depreciation; and general corporate expenses, inclusive of IT systems related costs. In addition, these expenses also include warehousing, distribution, selling and business development, and other costs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative costs include costs related to accounting, audit, legal regulatory, and tax-related services required to maintain compliance with exchange listing and SEC regulations, director and officer insurance costs, and investor and public relations costs. We continue to incur significant costs in seeking to protect our intellectual property rights, including significant litigation costs in connection with seeking to enforce our rights concerning third parties&#8217; at-risk launch of generic products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to manage business costs to prepare for a potential future decline in Suboxone revenue and other external factors affecting our business. We continue to focus on our core business and regulatory and pre-commercial launch activities for Anaphylm.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of interest costs on the outstanding balances of our 13.5% Notes at a fixed rate of 13.5%, payable quarterly, as well as amortization of issuance costs and debt discounts. The issuance of 13.5% Notes is discussed in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our Condensed Financial Statements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for further detail on our 13.5% Notes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense related to Royalty Obligations</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 13.5% Notes, we entered into the Royalty Rights Agreements with each of the Note Holders granting the Note Holders a tiered royalty between 1.0% and 2.0% of annual worldwide net sales of Anaphylm (epinephrine) Sublingual Film for a period of eight years from the first sale of Anaphylm on a global basis. The Note Holders are also entitled to a tiered royalty between 1.0% to 2.0% of annual worldwide net sales of Libervant (diazepam) Buccal Film until the earlier of (1) the first sale of Anaphylm and (2) eight years from the first sale of Libervant. These royalty agreements are classified as debt, and the value of the $45,000 13.5% Notes has been allocated between debt and the Royalty Obligations based on their relative fair market values. The excess of future estimated royalty payments of $56,828 over the $13,758 of the allocated fair value is recognized as a discount related to the Royalty Right Agreements and is amortized as interest expense using the effective interest method. The 13.5% Notes are discussed in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense related to the Sale of Future Revenue</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2020, we entered into the Monetization Agreement with Marathon. Under the terms of the Monetization Agreement, we sold to Marathon all of our contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#8217;s apomorphine product, KYNMOBI, an apomorphine film therapy for the treatment of off episodes in Parkinson&#8217;s disease patients, which received approval from the FDA on May 21, 2020. In exchange for the sale of these rights, we received an upfront payment from Marathon of $40,000 and an additional payment of $10,000 through the achievement of the first milestone. We have received an aggregate amount of $50,000 through March&#160;31, 2025 under the Monetization Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Monetization Agreement, additional contingent payments of up to $75,000 may be due to us upon the achievement of worldwide royalty and other commercial targets within a specified timeframe, which could result in total potential proceeds of $125,000. In June 2023, Sunovion announced that it has voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets, therefore, we likely will not receive any of the additional contingent payments under the Monetization agreement. We discontinued recording interest expense related to the sale of future revenue under the Monetization agreement in the fourth quarter of 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, under the Sunovion License Agreement, we recognized $8,000 of royalty revenue and corresponding royalty receivable, related to the $1,000 annual minimum guaranteed royalty that is due in each of the subsequent eight years. In connection with the Monetization Agreement, we performed an assessment under ASC 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfer and Servicing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to determine whether the existing receivable was transferred to Marathon and concluded that the receivable was not transferred. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our Condensed Financial Statements for further detail.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and other income, net</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income, net consists of earnings derived from an interest-bearing account, investments in money market Treasury mutual funds and other miscellaneous income and expense items.&#160;The interest-bearing account and money market Treasury mutual funds have no minimum amounts to be maintained in the accounts nor any fixed length of period for which interest and dividends are earned.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_118"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2025 and 2024</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our revenue data for the periods indicated.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.507%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except %)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,325)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-development and research fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,333)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025, total revenues decreased 28%, or $3,333 compared to the same period in the prior year primarily due to decreases in manufacture and supply revenue and license and royalty revenue , partially offset by increases in proprietary product revenue, net.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacture and supply revenue decreased approximately 32%, or $3,325 for the three months ended March&#160;31, 2025 compared to the same period in the prior year. This decrease was primarily due to a $4,463 decrease in Suboxone revenues, partially offset by a $1,471 increase in Ondif revenues due to timing of orders.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License and royalty revenue decreased 30%, or $342 for the three months ended March&#160;31, 2025 compared to the same period in the prior year. This decrease was primarily due to lower Aztarys royalty revenues and lower license revenues associated with the termination of a licensing and supply agreement in the prior year.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-development and research fees for the three months ended March&#160;31, 2025 remained relatively consistent compared to the same period in the prior year.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary product revenue, net increased by $319 for the three months ended March&#160;31, 2025 compared to the same period in the prior year.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_124"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses, Interest Income and Other Income:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our expenses and income for the periods indicated.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.090%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months<br/>Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except %)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to royalty obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to the sale of future revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacture and supply costs and expenses decreased 17% or $737 for the three months ended March&#160;31, 2025 compared to the same period in the prior year. The decrease was largely due to lower volume of strips sold and changes in product mix.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased 10% or $571 for the three months ended March&#160;31, 2025 compared to the same period in the prior year. The decrease in Research and development expenses is primarily due to lower clinical trial costs associated with the continued advancement of the Anaphylm program, partially offset by increases in product research and preclinical expenses, higher personnel costs and higher share-based compensation. The tables below provide a breakdown of the major costs included in total Research and development expenses and project costs by type of expense for each of the main clinical development projects in which we are engaged for each period presented:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months<br/>Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,477)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Research Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Project Expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,683&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D personnel costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation/amortization</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other R&amp;D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The details of the project expenses are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>&#160;inc /<br/>dec</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anaphylm</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>&#160;inc /<br/>dec</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AQST-108</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br/>&#160;inc /<br/>dec</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libervant</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;inc /</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">dec</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Trials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and Manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product Research Expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Project Expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,683&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)%</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/M</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total project expenses for Anaphylm decreased 21%, or $659 over the comparable period in 2024. Anaphylm clinical trial expenses and development and manufacturing expenses decreased $1,053 and $119, respectively, over the comparable period in 2024, partially offset by increases in product research expenses of $513. During the three months ended March 31, 2025 and 2024, clinical trial expenses for Anaphylm of $1,922 and $2,975, respectively, were primarily due to clinical trial costs associated with the continued advancement of the Anaphylm program. Product research expenses for Anaphylm increased by $513, primarily related to expenses incurred for the preparation of the NDA filing. Total project expenses for AQST-108 decreased 75%, or $594, over the comparable period in 2024. AQST-108 clinical trial expenses and product research expenses decreased $407 and $188, respectively over the comparable period in 2024 due the clinical study and feasibility work for AQST-108 performed in the prior year period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D personnel costs increased by 17%, or $268 over the comparable period in 2024, due to additional headcount. R&amp;D share-based compensation increased by $160, or 94% primarily related to the effect of  RSU grants to R&amp;D personnel. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other R&amp;D expenses include rent, utilities, maintenance and other expenses and fees.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased 78% or $8,383 for the three months ended March&#160;31, 2025 as compared to the same period in the prior year. The increase primarily represents regulatory fees related to the Anaphylm PDUFA fee of approximately $4,310, higher legal fees of $2,250, higher commercial spending of approximately $2,130, higher regulatory and licensing fees of approximately $505 related to the regulatory fee for Libervant, higher personnel costs of approximately $440, and higher share-based compensation expenses of $310, partially offset by decreases in severance costs of approximately 1,100 and lower insurance expenses of $240.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $2,782 and $2,784  for the three months ended March&#160;31, 2025 and 2024, respectively. These amounts represent interest incurred on the outstanding 13.5% Notes, and amortization of the debt discount and capitalized debt issuance costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to amortization of the discount on the royalty obligations was $1,437 and $1,358 for the three months ended March&#160;31, 2025 and 2024, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts are due to the accounting associated with the royalty obligations as part of the 13.5% Notes issuance. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the sale of future revenue was $59 and $58 for the three months ended March&#160;31, 2025 and March&#160;31, 2024, respectively, and represents amortization of the issuance costs. These amounts are due to the accounting associated with the sale of future revenue related to KYNMOBI royalties sold to Marathon on November 3, 2020 and do not represent or imply a monetary obligation or cash outflow at any time during the life of the transaction. In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets. Therefore, the Company likely will not receive any of the additional contingent payments under the Monetization agreement. As a result, the Company discontinued recording interest expense related to the sale of future revenue in the fourth quarter of 2022. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our Condensed Financial Statements for details. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income, net was $713 and $329 for the three months ended March&#160;31, 2025 and 2024, respectively. The increase primarily represents higher investment income due to higher cash balances over a greater number of days invested in interest-bearing and dividend-earning money market accounts compared to the prior year period.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_130"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $68,657 in cash and cash equivalents as of March&#160;31, 2025. While our ability to execute our business objectives and achieve profitability over the longer term cannot be assured, our on-going business, existing cash and cash equivalents, expense management activities, potential asset sales or product outlicensing as well as access to the equity capital markets, including through the ATM facility, provide near term liquidity for us to fund our operating needs for at least the next twelve months as we continue to execute our business strategy.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We established our first ATM facility in September 2019, and since inception to March&#160;31, 2025, we have sold 27,315,145 shares of Common Stock which has generated net cash proceeds of approximately $81,829, net of commissions and other transactions costs of $3,814. On April 3, 2024, we filed a new shelf registration statement on Form S-3 to register the offer and sale of up to $250,000 worth of shares of Common Stock, preferred stock, debt securities, warrants, rights and units ("Registration Statement No. 333-278498" or the "2024 Registration Statement"), that was declared effective by the SEC on April 23, 2024. Included as part of the 2024 Registration Statement was a $100,000 ATM facility, prospectus covering the offering, issuance and sale of Common Stock pursuant to the Amended Equity Distribution Agreement with Piper Sandler &amp; Co.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company sold 7,457,627 shares of Common Stock under the ATM facility which provided net proceeds of approximately $21,306 after deducting commissions and other transaction costs of $694 of which $89 remains unpaid as of March 31, 2025. During the three months ended March 31, 2024, we sold 4,557,220 shares of Common Stock under the ATM facility which provided net proceeds of approximately $12,012 after deducting commissions and other transaction costs of $373.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2022, we entered into the Lincoln Park Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations under the Lincoln Park Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $40,000 worth of shares of our Common Stock from time to time over the 36-month term of the Lincoln Park Purchase Agreement. The Lincoln Park Purchase Agreement contains an ownership limitation such that we will not issue, and Lincoln Park will not purchase, shares of Common Stock if it would result in their beneficial ownership exceeding 9.99%. Lincoln Park has covenanted under the Lincoln Park Purchase Agreement not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our Common Stock. We did not sell shares in connection with the Lincoln Park Purchase Agreement during the three months ended March 31, 2025 or in 2024. The Lincoln Park Purchase agreement expired on May 1, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, we entered into the Securities Purchase Agreements with certain purchasers. The Securities Purchase Agreements provide for the sale and issuance by us of an aggregate of: (i) 4,850,000 shares of Common Stock, (ii) pre-funded warrants to purchase up to 4,000,000 shares of Common Stock and (iii) Common Stock warrants to purchase up to 8,850,000 shares of Common Stock. The pre-funded warrants were fully exercised in 2022. In June 2023, 3,689,452 Common Stock warrants issued pursuant to the Securities Purchase Agreements were exercised with proceeds of approximately $3,542. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into the Letter Agreement with the Exercising Holder of 5,000,000 of the remaining Common Stock Warrants. Pursuant to the Letter Agreement, the Exercising Holder and Aquestive agreed that the Exercising Holder would exercise all of its Existing Warrants at the then current exercise price of the Existing Warrants. The Exercising Holder subsequently exercised the Existing Warrants, with Aquestive receiving gross proceeds of $4,800. We also issued to the Exercising Holder New Warrants to purchase up to an aggregate of 2,750,000 shares of Common Stock. The New Warrants are exercisable after February 2, 2024, expire on February 2, 2029 and are exercisable only for cash, unless the shares of Common </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock underlying the New Warrants are not registered in accordance with the terms of the Letter Agreement, in which case the New Warrants may also be exercised by means of a "cashless exercise". The New Warrants have an exercise price of $2.60 per share. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, we issued $45,000 aggregate principal amount of its 13.5% Notes due November 1, 2028. A portion of the net proceeds from that offering was used to repay all of the outstanding 12.5% Notes and to pay expenses relating to that offering, with the balance of the proceeds to be used for general corporate purposes. Interest on the 13.5% Notes accrues at a rate of 13.5% per annum and is payable quarterly in arrears on March 30, June 30, September 30 and December 30 of each year commencing on December 30, 2023. The 13.5% Notes are interest-only until June 30, 2026, whereupon on such date and each payment date thereafter we will also pay an installment of principal of the 13.5% Notes pursuant to a fixed amortization schedule, along with a portion of an Exit Fee determined as of the applicable date of prepayment, payment, acceleration, repurchase or redemption, as the case may be.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2024, we completed the underwritten public offering of 16,666,667 shares of its Common Stock at the public offering price of $4.50 per share. At closing, we received net proceeds of $70,500 after deducting underwriting discounts of $4,500. In addition to the underwriting discounts related to this offering, we incurred professional fees and other costs totaling $687 as of March 31, 2024. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, pursuant to the partial exercise of the underwriters' option, on April 22, 2024, we sold an additional 559,801 shares of Common Stock resulting in net proceeds of $2,368, after deducting underwriting discounts of $151. In addition to the underwriting discounts related to the partial exercise of the underwriters' option, we incurred professional fees and other costs totaling $207.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_133"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March 31, 2025 and 2024</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for operating activities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,384)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,889)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used for operating activities</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used for operating activities for the three months ended March&#160;31, 2025 increased by $13,016 compared to the same period in the prior year.&#160;The increase in cash used for operating activities was primarily related to the change in net loss of $10,102, increases in trade and other receivables of $3,276, and net changes in other liabilities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash used for investing activities</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used for investing activities for the three months ended March&#160;31, 2025 increased by $106 compared to the same period in the prior year. The use of cash was related to capital expenditures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by financing activities</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2025 decreased by $61,095 compared to the same period in the prior year. The decrease was primarily related to no proceeds received from the underwritten public offering as compared to net proceeds of $70,126 received in the same period in the prior year, partially offset by higher ATM proceeds of $9,386 due to higher volumes and Common Stock prices as compared to the three months ended March&#160;31, 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our on-going business, existing cash and equivalents, expense management activities as well as access to the equity capital markets, including through our ATM facility, and potential asset sales or product outlicensing potentially provide near term funding opportunities for Aquestive, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. On November 1, 2023, we issued $45,000 in aggregate principal amount of the 13.5% Notes due November 1, 2028. A portion of the net proceeds from the Offering were used to redeem all of the outstanding 12.5% Notes and to pay expenses relating to the Offering, with the balance of the proceeds to be used for general corporate purposes. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2024, the Company completed the underwritten public offering of 16,666,667 shares of its Common Stock at the public offering price of $4.50 per share. At closing, Aquestive received net proceeds of $70,500 after deducting underwriting discounts of $4,500. In addition to the underwriting discounts related to this offering, the Company&#8217;s incurred professional fees and other costs totaling $687 as of March 31, 2024. In addition, pursuant to the partial exercise of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">underwriters' option, on April 22, 2024, the Company sold an additional 559,801 shares of Common Stock, for additional gross proceeds of $2,519.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have used and intend to continue to use our existing cash and cash equivalents, primarily to advance the development and commercialization of our product pipeline,  including Anaphylm&#8482; (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and the commercial expansion of Libervant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(diazepam) Buccal Film for the treatment of ARS patients aged between two and five years until its U.S. market access was denied upon conversion by the FDA of its approval of Libervant for this patient population to a tentative approval, and for working capital, capital expenditures and general corporate purposes. We can provide no assurance that any of these sources of funding, either individually or in combination, will be available on reasonable terms, if at all, or sufficient to fund our business objectives. In addition, we may be required to utilize available financial resources sooner than expected. We have based our expectation on assumptions that could change or prove to be inaccurate, due to unrelated factors including factors arising in the capital markets, asset monetization markets, regulatory approval process, and regulatory oversight and other factors. Key factors and assumptions inherent in our planned continued operations and anticipated growth include, without limitation, those related to the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued ability of our customers to pay, in a timely manner, for presently contracted and future anticipated orders for our manufactured products, including effects of generics and other competitive pressures as currently envisioned;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued ability of our customers to pay, in a timely manner, for presently contracted and future anticipated orders for provided co-development and feasibility services, as well as regulatory support services for recently licensed products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">access to debt or equity markets if, and at the time, needed for any necessary future funding, including our ability to access funding through our ATM facility, should we choose to access this facility;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continuing review and appropriate adjustment of our cost structure consistent with our anticipated revenues and funding;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued growth and market penetration of Sympazan, including anticipated patient and physician acceptance and our licensee&#8217;s ability to obtain adequate reimbursement and payment support from government agencies and other private medical insurers;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">infrastructure and administrative costs at expected levels to support operations as an FDA and highly regulated public company;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a manageable level of costs for ongoing efforts to protect our intellectual property rights and litigation matters in which we are involved;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued compliance with all covenants under our 13.5% Notes, including our ability to comply with our debt service obligations as required thereunder; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">absence of significant unforeseen cash requirements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to manage business costs to appropriately reflect the anticipated general decline in Suboxone revenue, and other external resources or factors affecting our business including, if available, future equity financing, other future access to the capital markets or other potential available sources of liquidity. In doing so, we plan to continue to focus on the core drivers of value for our stockholders, including, more importantly, continued investments in our ongoing product development activities in support of Anaphylm and AQST-108. Until profitability is achieved, if at all, additional capital and/or other financing or funding will be required, which could be material, to develop and commercialize Anaphylm and AQST-108, if approved by the FDA, and to meet our other cash requirements, including debt service, specifically our 13.5% Notes. Even as such, we expect to incur losses and negative cash flows for the foreseeable future and, therefore, we expect to be dependent upon external financing and funding to achieve our operating plan.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sufficiency of our short-term and longer-term liquidity is directly impacted by our level of operating revenues and our ability to achieve our operating plan for revenues, regulatory approval in the time period planned for our product candidates and our ability to monetize other royalty streams or other licensed rights within planned timeframes, and there can be no assurance that we will be successful in any monetization transaction. Our operating revenues have fluctuated in the past and can be expected to fluctuate in the future. We expect to incur significant operating losses and negative operating cash flows for the foreseeable future, and we have a significant level of debt on which we have substantial ongoing interest payments, have principal repayments related to our 13.5% Notes starting in June 2026 through the debt maturity date and royalty obligation payments projected to be made from the fourth quarter of 2024 to 2034, which are further discussed in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our Condensed Financial Statements. A substantial portion of our current and past revenues has been dependent upon </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our licensing, manufacturing and sales with one customer, Indivior, which is expected to continue, and it could take significantly longer than planned to achieve anticipated levels of cash flows to help fund our operations and cash needs. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional funds by issuance of equity securities, our stockholders would experience further dilution, and the terms of these securities could include liquidation or other preferences (if and to the extent permitted under the Indenture) that would adversely affect our stockholders&#8217; rights. Our ability to secure additional equity financing could be significantly impacted by numerous factors including our operating performance and prospects, positive or negative developments in the regulatory approval process for our product candidates, our existing level of debt which is secured by substantially all of our assets under the Indenture, and general financial market conditions, and there can be no assurance that we will continue to be successful in raising capital or that any such needed financing will be available on favorable or acceptable terms, if at all.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available for our short-term or longer-term liquidity needs and cash requirements as and when needed, we would be required to engage in expense management activities such as reducing staff, delaying, significantly scaling back, or even discontinuing some or all of our current or planned launch activities and research and development programs and clinical and other product development activities, and otherwise significantly reducing our other spending and adjusting our operating plan, and we would need to seek to take other steps intended to improve our liquidity. We also may seek outlicensing opportunities for our proprietary products and product candidate programs that we currently plan to self-commercialize, including for Libervant and Anaphylm, or explore other potential liquidity options or strategic opportunities. Such strategic opportunities could include asset sales, outlicensing or other monetization opportunities of our proprietary products and product candidates, including Libervant and Anaphylm, although we cannot assure that any of these actions or opportunities would be available or available on acceptable terms. While an outlicensing of our proprietary products and product candidates, if approved by the FDA, could limit our exposure to the costs of commercialization of the product and provide a potential source of royalty and milestone revenues, the benefit from the potential of additional future value that could result from our independent commercialization of these products and product candidates, assuming a successful launch of our proprietary products and product candidates, if approved by the FDA, would likely be limited. In addition, in the event of any such asset sales or outlicensing transactions, the future growth of the Company would be dependent on continued successful development of our early stage product candidates and/or asset acquisitions or other strategic transactions for the Company.  There is no assurance that any such outlicensing or other strategic opportunities will be available or available on reasonable terms. </span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_136"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period presented, we did not have any material off-balance sheet arrangements, nor do we have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_139"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company&#8221; as defined by Item 10 of Regulation S-K promulgated by the SEC under the U.S. Securities Act of 1933, as amended, we are not required to provide the information required by this Item 3.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_142"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (2) accumulated and communicated to our management, including to our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(b) and 13a-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.&#160;Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of March&#160;31, 2025, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act), identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_148"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on Legal Proceedings, see Part I Item I. Financial Statements (Unaudited), Note 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_151"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this report, you should carefully review and consider the information regarding certain risks and uncertainties facing the Company that could have a material adverse effect on our business prospects, financial condition, results of operations, liquidity and available capital resources set forth in Part I, Item 1A of Aquestive&#8217;s 2024 Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks associated with tariffs and other trade restrictions, which could have a material adverse impact on our results of operations and financial condition.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Company faces risks associated with tariffs and other trade protection measures (including tariffs that have been or may in the future be imposed by the United States or other countries), import or export licensing requirements, trade embargoes, sanctions (including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury), other trade barriers (including further legislation or actions taken by the United States or other countries that restrict trade), and protectionist or retaliatory measures taken by the United States or other countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2025, the new administration in the United States began to increase tariff rates on numerous products from a range of nations. On April 2, 2025, the United States announced a 10% baseline reciprocal tariff on imports from all countries, plus an additional country-specific tariff on imports from select trading partners. Other countries have announced retaliatory actions or plans for retaliatory actions. On April 9, 2025, the United States implemented a 90-day pause on the country-specific tariffs for all countries except China, while maintaining the 10% baseline tariff. While pharmaceutical products are currently excluded from the baseline and "reciprocal" tariffs imposed by the United States, such tariffs still apply to the raw materials and other products necessary for the manufacture and formulation of our marketed products and product candidates. In addition, the current U.S. administration has expressed an intent to impose tariffs on pharmaceutical imports, with the stated policy object of reshoring pharmaceutical manufacturing to the United States. Among other means, such tariffs may be imposed by the United States under Section 232 of the Trade Expansion Act of 1962, as amended, pursuant to which the U.S. Department of Commerce recently initiated an investigation to determine the effects of importing pharmaceuticals and pharmaceutical ingredients on national security.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant risks from the existing tariffs imposed by the United States (such as those discussed above) and potential new tariffs as well as their secondary effects, including other countries' imposition of retaliatory tariffs and non-tariff barriers. Like all U.S. importers, our Company could pay more for foreign-sourced inputs, which could adversely affect our operating costs in the United States. Our results of operations and financial condition could be materially adversely affected due to the impact of the foregoing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs, or modifications to cleared or approved drugs, to be reviewed and/ or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA&#8217;s ability to conduct routine activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections at domestic and foreign manufacturing facilities at various points. If a prolonged government shutdown occurs, or if funding shortages, staffing limitations, or renewed global health concerns otherwise hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_154"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_157"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_160"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_163"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended March 31, 2025, none of our directors or executive officers <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-816"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-817">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-818"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-819">terminated</ix:nonNumeric></ix:nonNumeric> any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule 10b5-1 trading arrangement.&#8221;</span></div><div id="ibc17e35e18524b0cae1e0a983b1038de_169"></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this report.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mschobelsignedconsulting.htm">10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting Agreement for Mark Schobel dated January 1, 2025.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12025ex311.htm">31.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12025ex312.htm">31.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12025ex321.htm">32.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q12025ex322.htm">32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*  Filed herewith.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="ibc17e35e18524b0cae1e0a983b1038de_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibc17e35e18524b0cae1e0a983b1038de_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey.</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.096%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aquestive Therapeutics, Inc.<br/>(REGISTRANT)</span></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel Barber</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Barber</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 12, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ A. Ernest Toth, Jr.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. Ernest Toth, Jr.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mschobelsignedconsulting.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>mschobelsignedconsulting</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- mschobelsignedconsulting001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="mschobelsignedconsulting001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">CONSULTING AGREEMENT  This CONSULTING AGREEMENT (this &#8220;Agreement&#8221;) is effective as of January 1, 2025 (the  &#8220;Effective Date&#8221;) and hereby confirms the engagement by Aquestive Therapeutics, Inc., with an office at  30 Technology Drive, Warren, NJ 07059 (&#8220;Aquestive&#8221; or the &#8220;Company&#8221;), and Alexander Mark Schobel,  an individual domiciled at the address set forth below his signature on the signature page of this Agreement  (the &#8220;Consultant&#8221;), as a consultant to perform certain transition services as the Company may from time to  time request (collectively, the &#8220;Services&#8221;).   1. The nature of the services to be performed by Consultant and the deliverables to be provided  (collectively, the &#8220;Services&#8221;), as well as the timing, cost, and payment schedule, shall be as specifically set  forth in Exhibit A attached to this Agreement and incorporated herein.  2. The term of this Agreement (the &#8220;Term&#8221;) shall commence on the Effective Date and continue  in full force and effect until June 30, 2026, unless earlier terminated pursuant to Section 3 below.   3. Consultant may terminate this Agreement at any time upon written notice to the Company.  Upon the effective date of the termination or expiration of this Agreement, Consultant shall immediately  cease all Services, deliver to the Company all work in progress and return all Confidential Information (as  defined below). The Company&#8217;s sole obligation to Consultant upon termination of this Agreement shall be  to pay Consultant, subject to Section 4, any monies due prior to the effective date of such termination and  reasonable expenses actually incurred (with the prior written authorization of the Company) prior to the  effective date of such termination.  4. The Company shall pay Consultant the fees for the Services performed by Consultant, and  related expenses, in each case as set forth on Exhibit A.  Consultant shall provide to the Company an invoice  each month for monthly fees and actual expenses incurred in sufficient detail and with sufficient  documentation so as to enable calculation of payment or reimbursement of such expenses.  Payments under  this Agreement shall exclude all sales, use, value added or other similar taxes or duties payable in  connection with the Services, any and all of which shall be the sole responsibility of Consultant.  5. The Company&#8217;s representatives may examine and audit the papers, correspondence,  copybooks, accounts, invoices, and/or other information of Consultant related to this Agreement for the  purpose of verifying fees and charges and otherwise confirming compliance with this Agreement.  6. At all times during the Term and after the termination or expiration of this Agreement,  Consultant shall hold in strict confidence and refrain from disclosing and/or using any and all materials,  information, and/or data received from the Company (&#8220;Confidential Information&#8221;) for any purpose other  than performing the Services under this Agreement. All Confidential Information shall be and remain the  sole property of Aquestive. Aquestive shall have the right to seek equitable and injunctive relief to prevent  unauthorized use or disclosure of any Confidential Information without the requirement of posting a bond  or other security. The restrictions expressed in this Section 6 in no way supersede or eliminate any rights  which the Company may have pursuant to applicable law pertaining to trade secrets or proprietary  information and, in the event that any such law provides greater protections of any Confidential Information  than the protections set forth in this Agreement, such greater protections shall apply to such Confidential  Information.  7. All of Consultant&#8217;s deliverables are and shall remain the exclusive property of, and all  ownership rights therein do and shall vest in, Aquestive. All deliverables created pursuant to this Agreement  are &#8220;works made for hire,&#8221; as defined in the U.S. Copyright Act, and shall vest in Aquestive upon their  creation. To the extent that such deliverables are deemed by competent authority not to be works made for  Docusign Envelope ID: B6FE7361-CDE1-4D77-B0C4-C45248E9B939 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- mschobelsignedconsulting002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="mschobelsignedconsulting002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2    hire, same are hereby assigned to Aquestive. Consultant shall execute any instruments necessary or  desirable in the opinion of the Company, and hereby appoint Aquestive as its attorney-in-fact in its name,  to record any assignment or registration of copyright or other transfer of ownership in any deliverable and/or  work transferred hereunder in any jurisdiction.  8. Consultant represents, warrants and covenants that: (a) all work product created under this  Agreement shall be original work of Consultant or in the public domain and shall not infringe any copyright,  trademark, trade secret, patent or other intellectual property right of any third party; (b) Consultant shall  perform the Services diligently and in accordance with the highest professional standards; and (c)  Consultant shall comply with all Company policies and procedures and applicable local, state and federal  laws, rules and regulations.  9. All notices, requests, demands and other communications under this Agreement (each a  &#8220;Notice&#8221;) must be in writing and shall be deemed to have been given: (a) when delivered personally, sent  by telecopy (with hard copy to follow), or sent by electronic mail (with hard copy to follow); (b) one  business day after being sent by nationally recognized overnight delivery service (with tracking); or (c)  three business days after being deposited in the United States mail, certified and with proper postage prepaid  (return receipt requested), to the appropriate party at its address set forth in this Agreement, or to such other  address specified in a Notice.  10. This Agreement shall be governed by, construed, and enforced in accordance with the laws of  the State of Florida without regard to its conflict of laws principles.  11. Consultant agrees that he is an independent contractor and has no authority to bind, represent,  obligate, or act on behalf of Aquestive. Consultant shall not be entitled to any benefits afforded by  Aquestive to its employees or to workers&#8217; compensation or similar benefits or insurance protection.  12. Consultant agrees that he is solely responsible for paying when due all income taxes, including  estimated taxes, payroll taxes, national insurance and other taxes incurred as a result of or in connection  with the compensation paid by the Company to Consultant for services rendered under this Agreement and  no income or employment tax withholdings will be deducted from such payments.  13. Consultant shall not subcontract, delegate, or assign this Agreement or any portion thereof.  This Agreement shall inure to the benefit of and be binding on the Company, Consultant and their respective  permitted successors and assigns.  14. This Agreement represents the entire understanding between the parties, and hereby supersedes  all prior understandings and agreements, whether oral or written, between the parties with respect to the  subject matter hereof. This Agreement may only be amended in a writing executed by the parties.  15. No failure or delay in exercising any right shall operate as a waiver of, or impair, any such  right. No single or partial exercise of any such right shall preclude any other or further exercise thereof or  the exercise of any other right. No waiver shall have effect unless signed by the waiving party. No waiver  of any such right shall be deemed a waiver of any other right.  16. If any portion of this Agreement or the application thereof is held by a court of competent  jurisdiction to be invalid, illegal, non-binding or unenforceable in any respect, the remaining portions hereof  or applications to a party shall remain in full force and effect.   17. This Agreement is for the sole benefit of the parties and their permitted assigns, and nothing in  this Agreement expressed or implied shall give or be construed to give to any person or entity, other than  Docusign Envelope ID: B6FE7361-CDE1-4D77-B0C4-C45248E9B939 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- mschobelsignedconsulting003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="mschobelsignedconsulting003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3    the parties and their permitted assigns, any legal or equitable rights under this Agreement (except as for  Aquestive who shall be an express third party beneficiary of this Agreement).  18. This Agreement may be executed in two or more counterparts (and by facsimile, portable  document format (.pdf) or any similar format), each of which shall be considered an original instrument,  but all of which shall be considered one and the same agreement, and shall become binding when one or  more counterparts have been signed by each of the parties hereto and delivered to each party.  19. Sections 3 through this Section 19 of this Agreement shall survive expiration or termination of  this Agreement.  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly authorized,  executed, and delivered as of the Effective Date.  CONSULTANT AQUESTIVE THERAPEUTICS, INC.      _______________________________  ALEXANDER MARK SCHOBEL  150 Island Sanctuary  Vero Beach, Florida 32963      By:________________________________  Name: Daniel Barber  Title: Chief Executive Officer      Docusign Envelope ID: B6FE7361-CDE1-4D77-B0C4-C45248E9B939 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- mschobelsignedconsulting004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="mschobelsignedconsulting004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  EXHIBIT A  Statement of Services  Fees and Expenses      1. Services. Consultant&#8217;s services shall include without limitation, knowledge transfer,  transition services and consultation with respect to the Company&#8217;s intellectual property portfolio and  Consultant&#8217;s former Chief Innovation and Technology Officer role as may reasonably be requested from  time to time during the Term. Consultant shall have discretion in selecting the dates and times he performs  such Services throughout the month giving due regard to the needs of the Company&#8217;s business.    2. Fees and Expenses. The Company shall compensate Consultant for services rendered  pursuant to this Agreement as follows:    2.1 Fees. The Company agrees to compensate Consultant for the Services  provided by him pursuant to this Agreement on a monthly basis during the Term a retainer in the amount  equal to One Thousand Seven Hundred and Fifty Dollars ($1,750.00) per calendar month (the &#8220;Monthly  Retainer&#8221;). In addition to the Monthly Retainer, the Company agrees to pay Consultant an hourly fee of  $500.00 for each hour (prorated for any partial hour) for Services and consultation provided by Consultant  at the request of the Company from time to time during the Term (the &#8220;Hourly Fee&#8221; and, together with the  Monthly Retainer, the &#8220;Fees&#8221;) on a reasonable basis to allow for the proper performance of the Services  but no greater than 20 hours per month during the Term unless otherwise agreed to in writing by Consultant  and the Company.  2.2 Expense Reimbursements. The Company agrees to reimburse Consultant  reasonable business expenses incurred by Consultant in performing the Services as approved by the  Company in writing. No expenses shall be reimbursed without proper documentation.  2.3 Payment Terms. The Company shall pay Consultant the Fees and for approved  reimbursable expenses within ten (10) days after receipt of a monthly invoice from Consultant for same, all  by Automated Clearing House (ACH) to an account provided by Consultant to the Company.  Docusign Envelope ID: B6FE7361-CDE1-4D77-B0C4-C45248E9B939 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>q12025ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0fee51660a4e4a25850a29f0a86887dd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer of Aquestive Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Barber, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Aquestive Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, consolidated results of operations and consolidated cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2025</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Barber</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Barber</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>q12025ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i54de91f45cad409ca658b2fc9f17b43a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial and Accounting Officer of Aquestive Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A. Ernest Toth, Jr, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Aquestive Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, consolidated results of operations and consolidated cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2025</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. ERNEST TOTH, JR.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8.28pt">Ernest Toth, Jr.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>q12025ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7f6fa2ab2726454ab9104754f19b3624_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as Adopted</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics, Inc. (the &#8220;Company&#8221;), hereby certify that, to the best of my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period-ended March&#160;31, 2025, to which this Certification is attached as Exhibit 32.1 (the &#8220;Quarterly Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Quarterly Report and the results of operations of the Company for the period covered by the Quarterly Report.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2025 </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Barber</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Barber</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aquestive Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>q12025ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if66a5ff868be4f8994abdd5fb3044677_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial and Accounting Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as Adopted</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), I, A. Ernest Toth, Jr., Chief Financial Officer of Aquestive Therapeutics, Inc. (the &#8220;Company&#8221;), hereby certify that, to the best of my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period-ended March&#160;31, 2025, to which this Certification is attached as Exhibit 32.2 (the &#8220;Quarterly Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Quarterly Report and the results of operations of the Company for the period covered by the Quarterly Report.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;12, 2025 </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A. ERNEST TOTH, JR</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8.28pt">Ernest Toth, Jr.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aquestive Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>aqst-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7fd918af-7463-495d-a5aa-7a090fe24bee,g:404d0fa2-95d9-41b4-b7eb-3a9cfeb5fb76-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:aqst="http://aquestive.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://aquestive.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://aquestive.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://aquestive.com/role/CondensedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://aquestive.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofChangesinStockholdersDeficit" roleURI="http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit">
        <link:definition>9952154 - Statement - Condensed Statements of Changes in Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://aquestive.com/role/CondensedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyOverviewandBasisofPresentation" roleURI="http://aquestive.com/role/CompanyOverviewandBasisofPresentation">
        <link:definition>9952156 - Disclosure - Company Overview and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://aquestive.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandUncertainties" roleURI="http://aquestive.com/role/RisksandUncertainties">
        <link:definition>9952158 - Disclosure - Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://aquestive.com/role/SegmentReporting">
        <link:definition>9952159 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNet" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNet">
        <link:definition>9952160 - Disclosure - Revenues and Trade Receivables, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MaterialAgreements" roleURI="http://aquestive.com/role/MaterialAgreements">
        <link:definition>9952161 - Disclosure - Material Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueMeasurements" roleURI="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurements">
        <link:definition>9952162 - Disclosure - Financial Instruments &#8211; Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://aquestive.com/role/Inventories">
        <link:definition>9952163 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://aquestive.com/role/PropertyandEquipmentNet">
        <link:definition>9952164 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLeaseObligations" roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligations">
        <link:definition>9952165 - Disclosure - Right-of-Use Assets and Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://aquestive.com/role/IntangibleAssetsNet">
        <link:definition>9952166 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNoncurrentAssets" roleURI="http://aquestive.com/role/OtherNoncurrentAssets">
        <link:definition>9952167 - Disclosure - Other Non-current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://aquestive.com/role/AccruedExpenses">
        <link:definition>9952168 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://aquestive.com/role/LongTermDebt">
        <link:definition>9952169 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://aquestive.com/role/Warrants">
        <link:definition>9952170 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenue" roleURI="http://aquestive.com/role/SaleofFutureRevenue">
        <link:definition>9952171 - Disclosure - Sale of Future Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://aquestive.com/role/NetLossPerShare">
        <link:definition>9952172 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://aquestive.com/role/ShareBasedCompensation">
        <link:definition>9952173 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://aquestive.com/role/IncomeTaxes">
        <link:definition>9952174 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://aquestive.com/role/Contingencies">
        <link:definition>9952175 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://aquestive.com/role/SegmentReportingTables">
        <link:definition>9955512 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNetTables" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetTables">
        <link:definition>9955513 - Disclosure - Revenues and Trade Receivables, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://aquestive.com/role/InventoriesTables">
        <link:definition>9955514 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://aquestive.com/role/PropertyandEquipmentNetTables">
        <link:definition>9955515 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLeaseObligationsTables" roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsTables">
        <link:definition>9955516 - Disclosure - Right-of-Use Assets and Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://aquestive.com/role/IntangibleAssetsNetTables">
        <link:definition>9955517 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNoncurrentAssetsTables" roleURI="http://aquestive.com/role/OtherNoncurrentAssetsTables">
        <link:definition>9955518 - Disclosure - Other Non-current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://aquestive.com/role/AccruedExpensesTables">
        <link:definition>9955519 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://aquestive.com/role/LongTermDebtTables">
        <link:definition>9955520 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenueTables" roleURI="http://aquestive.com/role/SaleofFutureRevenueTables">
        <link:definition>9955521 - Disclosure - Sale of Future Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://aquestive.com/role/NetLossPerShareTables">
        <link:definition>9955522 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://aquestive.com/role/ShareBasedCompensationTables">
        <link:definition>9955523 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyOverviewandBasisofPresentationDetails" roleURI="http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails">
        <link:definition>9955524 - Disclosure - Company Overview and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandUncertaintiesDetails" roleURI="http://aquestive.com/role/RisksandUncertaintiesDetails">
        <link:definition>9955525 - Disclosure - Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://aquestive.com/role/SegmentReportingDetails">
        <link:definition>9955526 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNetNarrativeDetails" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails">
        <link:definition>9955527 - Disclosure - Revenues and Trade Receivables, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNetRevenueDetails" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails">
        <link:definition>9955528 - Disclosure - Revenues and Trade Receivables, Net - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails">
        <link:definition>9955529 - Disclosure - Revenues and Trade Receivables, Net - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails">
        <link:definition>9955530 - Disclosure - Revenues and Trade Receivables, Net - Trade and Other Receivables, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails">
        <link:definition>9955531 - Disclosure - Revenues and Trade Receivables, Net - Changes in Allowance for Bad Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails" roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails">
        <link:definition>9955532 - Disclosure - Revenues and Trade Receivables, Net - Summary of Activity with Sales Related Allowances and Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MaterialAgreementsDetails" roleURI="http://aquestive.com/role/MaterialAgreementsDetails">
        <link:definition>9955533 - Disclosure - Material Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueMeasurementsDetails" roleURI="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails">
        <link:definition>9955534 - Disclosure - Financial Instruments &#8211; Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://aquestive.com/role/InventoriesDetails">
        <link:definition>9955535 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" roleURI="http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
        <link:definition>9955536 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetNarrativeDetails" roleURI="http://aquestive.com/role/PropertyandEquipmentNetNarrativeDetails">
        <link:definition>9955537 - Disclosure - Property and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLeaseObligationsNarrativeDetails" roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails">
        <link:definition>9955538 - Disclosure - Right-of-Use Assets and Lease Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLeaseObligationsMaturitiesDetails" roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails">
        <link:definition>9955539 - Disclosure - Right-of-Use Assets and Lease Obligations - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLeaseObligationsMaturitiesDetails_1" roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails_1">
        <link:definition>9955539 - Disclosure - Right-of-Use Assets and Lease Obligations - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails" roleURI="http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails">
        <link:definition>9955540 - Disclosure - Intangible Assets, Net - Components of Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetNarrativeDetails" roleURI="http://aquestive.com/role/IntangibleAssetsNetNarrativeDetails">
        <link:definition>9955541 - Disclosure - Intangible Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails" roleURI="http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails">
        <link:definition>9955542 - Disclosure - Other Non-current Assets - Summary of Other Non-current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNoncurrentAssetsNarrativeDetails" roleURI="http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails">
        <link:definition>9955543 - Disclosure - Other Non-current Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleofAccruedExpensesDetails" roleURI="http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails">
        <link:definition>9955544 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesNarrativeDetails" roleURI="http://aquestive.com/role/AccruedExpensesNarrativeDetails">
        <link:definition>9955545 - Disclosure - Accrued Expenses - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://aquestive.com/role/LongTermDebtNarrativeDetails">
        <link:definition>9955546 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleOfRoyaltyRightAgreementsDetails" roleURI="http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails">
        <link:definition>9955547 - Disclosure - Long-Term Debt - Schedule Of Royalty Right Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails" roleURI="http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails">
        <link:definition>9955548 - Disclosure - Long-Term Debt - Schedule of Term Notes and Unamortized Debt Discount Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDebtMaturitiesDetails" roleURI="http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails">
        <link:definition>9955549 - Disclosure - Long-Term Debt - Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsDetails" roleURI="http://aquestive.com/role/WarrantsDetails">
        <link:definition>9955550 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenueNarrativeDetails" roleURI="http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails">
        <link:definition>9955551 - Disclosure - Sale of Future Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenueRoyaltyObligationDetails" roleURI="http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails">
        <link:definition>9955552 - Disclosure - Sale of Future Revenue - Royalty Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicandDilutedNetLossPerShareDetails" roleURI="http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955553 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationExpenseDetails" roleURI="http://aquestive.com/role/ShareBasedCompensationExpenseDetails">
        <link:definition>9955554 - Disclosure - Share-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedStockUnitAwardsDetails" roleURI="http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails">
        <link:definition>9955555 - Disclosure - Share-Based Compensation - Restricted Stock Unit Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://aquestive.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>9955556 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPerformanceBasedDetails" roleURI="http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails">
        <link:definition>9955557 - Disclosure - Share-Based Compensation - Performance Based (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>9955558 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails" roleURI="http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails">
        <link:definition>9955559 - Disclosure - Share-Based Compensation - Valuation Assumptions for Determination of Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://aquestive.com/role/IncomeTaxesDetails">
        <link:definition>9955560 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://aquestive.com/role/ContingenciesDetails">
        <link:definition>9955561 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="aqst_TradeAndOtherReceivablesNet" abstract="false" name="TradeAndOtherReceivablesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent" abstract="false" name="LiabilitiesSaleOfFutureRoyaltiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_RoyaltyObligationsLiabilityCurrent" abstract="false" name="RoyaltyObligationsLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" abstract="false" name="SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_RoyaltyObligationLiabilityNoncurrent" abstract="false" name="RoyaltyObligationLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" abstract="false" name="TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_InterestExpenseSaleOfFutureRevenues" abstract="false" name="InterestExpenseSaleOfFutureRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_InterestAndOtherIncomeNet" abstract="false" name="InterestAndOtherIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_PublicEquityOfferingMember" abstract="true" name="PublicEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_PaymentsForRoyaltyObligationsFinancingObligations" abstract="false" name="PaymentsForRoyaltyObligationsFinancingObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable" abstract="false" name="CostsAssociatedWithPublicEquityOfferingInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" abstract="false" name="CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_WarrantsDisclosureTextBlock" abstract="false" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="aqst_SaleOfFutureRevenueTextBlock" abstract="false" name="SaleOfFutureRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="aqst_RoyaltyObligationActivityTableTextBlock" abstract="false" name="RoyaltyObligationActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="aqst_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_AmendedEquityDistributionAgreementMember" abstract="true" name="AmendedEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_LincolnParkAgreementMember" abstract="true" name="LincolnParkAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts" abstract="false" name="RevenueFromContractWithCustomerNumberOfCommercializedProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="aqst_SaleOfStockMaximumTransactionAmount" abstract="false" name="SaleOfStockMaximumTransactionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" abstract="false" name="SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_RightToSellCommonStockValue" abstract="false" name="RightToSellCommonStockValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_AgreementTerm" abstract="false" name="AgreementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" abstract="false" name="SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_SeniorSecuredNotes13.5DueNovember12028Member" abstract="true" name="SeniorSecuredNotes13.5DueNovember12028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_AnaphylmMember" abstract="true" name="AnaphylmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_AQST108Member" abstract="true" name="AQST108Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_LibervantMember" abstract="true" name="LibervantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_PersonnelCostsMember" abstract="true" name="PersonnelCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_OtherReceivablesAndAccruedExpensesMember" abstract="true" name="OtherReceivablesAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_TradeAccountsReceivableDoubtfulAccountsMember" abstract="true" name="TradeAccountsReceivableDoubtfulAccountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_IndiviorMember" abstract="true" name="IndiviorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_HyperaMember" abstract="true" name="HyperaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_ResearchAndDevelopmentProjectDuration" abstract="false" name="ResearchAndDevelopmentProjectDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="aqst_ManufactureAndSupplyRevenueMember" abstract="true" name="ManufactureAndSupplyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_LicenseAndRoyaltyRevenueMember" abstract="true" name="LicenseAndRoyaltyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_CoDevelopmentAndResearchFeesMember" abstract="true" name="CoDevelopmentAndResearchFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_TradeAccountsReceivableSalesRelatedMember" abstract="true" name="TradeAccountsReceivableSalesRelatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_CommercialExploitationAgreementWithIndiviorMember" abstract="true" name="CommercialExploitationAgreementWithIndiviorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember" abstract="true" name="LicenseAgreementWithSunovionPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" abstract="true" name="LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" abstract="true" name="LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_MarathonPangolinRoyaltyLLCMember" abstract="true" name="MarathonPangolinRoyaltyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" abstract="true" name="HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_AtnahsPharmaUKLimitedMember" abstract="true" name="AtnahsPharmaUKLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_LicenseSupplyAgreementMember" abstract="true" name="LicenseSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_AtnahsPharmaUKLimitedAmendedAgreementMember" abstract="true" name="AtnahsPharmaUKLimitedAmendedAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_MonetizationAgreementMember" abstract="true" name="MonetizationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_AssertioHoldingsIncMember" abstract="true" name="AssertioHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_LicenseAgreementTerm" abstract="false" name="LicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="aqst_AutomaticRenewalPeriodOfAgreement" abstract="false" name="AutomaticRenewalPeriodOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet" abstract="false" name="AdditionalProceedsFromSaleOfFutureRevenuesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_ProceedsFromSaleOfFutureRevenuesNet" abstract="false" name="ProceedsFromSaleOfFutureRevenuesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_ContingentMonetizationAgreementMilestonePayment" abstract="false" name="ContingentMonetizationAgreementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member" abstract="true" name="TwelvePointFiveSeniorSecuredNotesDueJune302025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_SecuritiesPurchaseAgreementMember" abstract="true" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_ExistingWarrantsMember" abstract="true" name="ExistingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_NewWarrantsMember" abstract="true" name="NewWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" abstract="false" name="SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants" abstract="false" name="SharesOfCommonStockToBePurchasedByCommonStockWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="aqst_DebtInstrumentCovenantTieredRoyaltyPercentage" abstract="false" name="DebtInstrumentCovenantTieredRoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm" abstract="false" name="DebtInstrumentCovenantTieredRoyaltyPercentageTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="aqst_InventoryPackingMaterialGross" abstract="false" name="InventoryPackingMaterialGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_ComputerNetworkEquipmentAndSoftwareMember" abstract="true" name="ComputerNetworkEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_NumberOfOperatingLeases" abstract="false" name="NumberOfOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_CumulativeRoyaltyReceivable" abstract="false" name="CumulativeRoyaltyReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_NumberOfGuaranteedRoyaltyPayments" abstract="false" name="NumberOfGuaranteedRoyaltyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="aqst_MinimumAnnualRoyaltyReceivable" abstract="false" name="MinimumAnnualRoyaltyReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_NumberOfAnnualRoyaltyPaymentsReceivable" abstract="false" name="NumberOfAnnualRoyaltyPaymentsReceivable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="aqst_RoyaltyObligationsMember" abstract="true" name="RoyaltyObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_ABLFacilityMember" abstract="true" name="ABLFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_DebtCovenantRedemptionScenarioAxis" abstract="true" name="DebtCovenantRedemptionScenarioAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="aqst_DebtCovenantRedemptionScenarioDomain" abstract="true" name="DebtCovenantRedemptionScenarioDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_RedemptionScenario1Member" abstract="true" name="RedemptionScenario1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_RedemptionScenario2Member" abstract="true" name="RedemptionScenario2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" abstract="false" name="DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" abstract="false" name="LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit" abstract="false" name="LineOfCreditFacilityAccordionFeatureIncreaseLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_DebtInstrumentInterestRateChangeInEffectivePercentage" abstract="false" name="DebtInstrumentInterestRateChangeInEffectivePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="aqst_DebtInstrumentExitFee" abstract="false" name="DebtInstrumentExitFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_MeasurementInputProbabilityOfSuccessMember" abstract="true" name="MeasurementInputProbabilityOfSuccessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_FirstAdditionalWarrantOfferingMember" abstract="true" name="FirstAdditionalWarrantOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_InitialWarrantOfferingMember" abstract="true" name="InitialWarrantOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_CommonStockWarrantsMember" abstract="true" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_Warrants0.96ExercisePriceMember" abstract="true" name="Warrants0.96ExercisePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_Warrants4.25ExercisePriceMember" abstract="true" name="Warrants4.25ExercisePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_Warrants5.38ExercisePriceMember" abstract="true" name="Warrants5.38ExercisePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_ClassOfWarrantOrRightWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" abstract="false" name="ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="aqst_SaleOfFutureRevenueRollForward" abstract="true" name="SaleOfFutureRevenueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="aqst_LiabilitiesSaleOfFutureRoyalties" abstract="false" name="LiabilitiesSaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="aqst_ManufacturingAndSupplyMember" abstract="true" name="ManufacturingAndSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="aqst_MarketBasedMember" abstract="true" name="MarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_A2023MarketBasedMember" abstract="true" name="A2023MarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_A2025MarketBasedMember" abstract="true" name="A2025MarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionAxis" abstract="true" name="VestingConditionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="aqst_VestingConditionDomain" abstract="true" name="VestingConditionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeOneMember" abstract="true" name="VestingConditionRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeTwoMember" abstract="true" name="VestingConditionRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeThreeMember" abstract="true" name="VestingConditionRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeFourMember" abstract="true" name="VestingConditionRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeFiveMember" abstract="true" name="VestingConditionRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeSixMember" abstract="true" name="VestingConditionRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeSevenMember" abstract="true" name="VestingConditionRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeEightMember" abstract="true" name="VestingConditionRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeNineMember" abstract="true" name="VestingConditionRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeTenMember" abstract="true" name="VestingConditionRangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeElevenMember" abstract="true" name="VestingConditionRangeElevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_VestingConditionRangeTwelveMember" abstract="true" name="VestingConditionRangeTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="aqst_NeurelisIncVAquestiveTherapeuticsIncMember" abstract="true" name="NeurelisIncVAquestiveTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="aqst_SuboxoneProduceLiabilityLitigationMember" abstract="true" name="SuboxoneProduceLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="aqst_LitigationSettlementAmountAwardPeriodDue" abstract="false" name="LitigationSettlementAmountAwardPeriodDue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>aqst-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7fd918af-7463-495d-a5aa-7a090fe24bee,g:404d0fa2-95d9-41b4-b7eb-3a9cfeb5fb76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aquestive.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_363aeaf3-c4a6-4e79-b905-5f65289a3622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6fbb57e1-409f-475b-96d6-e967021ce5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_363aeaf3-c4a6-4e79-b905-5f65289a3622" xlink:to="loc_us-gaap_CommonStockValue_6fbb57e1-409f-475b-96d6-e967021ce5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b8e8676f-5638-4b3e-9fbb-ff1bc31e0f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_363aeaf3-c4a6-4e79-b905-5f65289a3622" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b8e8676f-5638-4b3e-9fbb-ff1bc31e0f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ab6b7624-c274-4dc0-b0b9-bc69626ff629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_363aeaf3-c4a6-4e79-b905-5f65289a3622" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ab6b7624-c274-4dc0-b0b9-bc69626ff629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3ff509c2-a454-4137-af40-2f86eca0b2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f10468bd-4d37-4490-a3df-2f379afd759b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ff509c2-a454-4137-af40-2f86eca0b2ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f10468bd-4d37-4490-a3df-2f379afd759b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_edc6c392-568b-4d69-8255-572bf937031c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ff509c2-a454-4137-af40-2f86eca0b2ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_edc6c392-568b-4d69-8255-572bf937031c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_535c1a3f-f197-4fe5-a579-03abb416fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ff509c2-a454-4137-af40-2f86eca0b2ca" xlink:to="loc_us-gaap_AssetsCurrent_535c1a3f-f197-4fe5-a579-03abb416fc7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aa604e3d-c966-4499-89bb-8d76caa0cf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ff509c2-a454-4137-af40-2f86eca0b2ca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aa604e3d-c966-4499-89bb-8d76caa0cf7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_310ff12f-47b2-4d01-a1d9-853eb086d1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ff509c2-a454-4137-af40-2f86eca0b2ca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_310ff12f-47b2-4d01-a1d9-853eb086d1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_581b45a2-cef4-4816-912b-389f7f7ad609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_faf68ad9-9d14-4b3e-8cd8-2e23efeb1feb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_581b45a2-cef4-4816-912b-389f7f7ad609" xlink:to="loc_us-gaap_StockholdersEquity_faf68ad9-9d14-4b3e-8cd8-2e23efeb1feb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c15b05c9-3d29-49f0-befa-37bda937696a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_581b45a2-cef4-4816-912b-389f7f7ad609" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c15b05c9-3d29-49f0-befa-37bda937696a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0b410425-44e9-4fa3-8eb8-31669d040435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_581b45a2-cef4-4816-912b-389f7f7ad609" xlink:to="loc_us-gaap_Liabilities_0b410425-44e9-4fa3-8eb8-31669d040435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1b65f2f4-8b32-4a92-be62-548e695fcec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:to="loc_us-gaap_AccountsPayableCurrent_1b65f2f4-8b32-4a92-be62-548e695fcec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f080e792-cac1-4ca8-9150-cae0f23edd77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f080e792-cac1-4ca8-9150-cae0f23edd77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_297ca253-1436-4c61-ac10-12e53b0fcc50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_297ca253-1436-4c61-ac10-12e53b0fcc50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_481440e3-178b-42fc-967f-379d081f16ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_481440e3-178b-42fc-967f-379d081f16ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_87d94a31-057f-4581-bffe-63f008f80d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:to="loc_us-gaap_LoansPayableCurrent_87d94a31-057f-4581-bffe-63f008f80d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_2dbee798-0ec9-4dc5-b791-9be2c4094c02" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:to="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_2dbee798-0ec9-4dc5-b791-9be2c4094c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsLiabilityCurrent_8add1493-17eb-4e98-87ee-8f7e5c95cd1b" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4a57cfa5-9b43-4526-b48d-f5c47119df7e" xlink:to="loc_aqst_RoyaltyObligationsLiabilityCurrent_8add1493-17eb-4e98-87ee-8f7e5c95cd1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4f62af16-4da2-4b0d-ba3c-b4f41eeb2145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4f62af16-4da2-4b0d-ba3c-b4f41eeb2145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationLiabilityNoncurrent_cfb28406-359e-489b-83dd-2e51eaaa18aa" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:to="loc_aqst_RoyaltyObligationLiabilityNoncurrent_cfb28406-359e-489b-83dd-2e51eaaa18aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent_bc33eec2-0954-4136-82fa-70948437ed79" xlink:href="aqst-20250331.xsd#aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:to="loc_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent_bc33eec2-0954-4136-82fa-70948437ed79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bd88252b-531c-40be-aa7d-8007123dc1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bd88252b-531c-40be-aa7d-8007123dc1d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e11f209a-6e98-4120-875c-50cca5700d12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:to="loc_us-gaap_LiabilitiesCurrent_e11f209a-6e98-4120-875c-50cca5700d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent_cee91185-87cb-4148-8a81-27c438816a73" xlink:href="aqst-20250331.xsd#aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:to="loc_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent_cee91185-87cb-4148-8a81-27c438816a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3d5ddc43-93c4-480c-a4dd-be567413816b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bff56104-e6ed-4c7e-8330-fd6bedcb221c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3d5ddc43-93c4-480c-a4dd-be567413816b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f92d521b-7eb7-4b7a-974a-628405ff43e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_580c3b8e-3360-4f62-a0ba-74b9760ff08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f92d521b-7eb7-4b7a-974a-628405ff43e1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_580c3b8e-3360-4f62-a0ba-74b9760ff08d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6161300d-8cb2-44b0-b536-42823493d568" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f92d521b-7eb7-4b7a-974a-628405ff43e1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6161300d-8cb2-44b0-b536-42823493d568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAndOtherReceivablesNet_d57f3262-8786-431c-8ea4-6106d6fb21c0" xlink:href="aqst-20250331.xsd#aqst_TradeAndOtherReceivablesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f92d521b-7eb7-4b7a-974a-628405ff43e1" xlink:to="loc_aqst_TradeAndOtherReceivablesNet_d57f3262-8786-431c-8ea4-6106d6fb21c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1e5894f1-d3d6-4d3d-bb15-83f86101396f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f92d521b-7eb7-4b7a-974a-628405ff43e1" xlink:to="loc_us-gaap_InventoryNet_1e5894f1-d3d6-4d3d-bb15-83f86101396f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1987ee33-985d-4e82-962c-ca7b578e6c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b4097b99-eea0-4edd-9dd0-8fc89fc13fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1987ee33-985d-4e82-962c-ca7b578e6c7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b4097b99-eea0-4edd-9dd0-8fc89fc13fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7be96335-e5ff-4dbd-a92b-06407e9cb5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1987ee33-985d-4e82-962c-ca7b578e6c7b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7be96335-e5ff-4dbd-a92b-06407e9cb5b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f5d588a1-1fd1-48fc-b066-1e80d40812f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1987ee33-985d-4e82-962c-ca7b578e6c7b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f5d588a1-1fd1-48fc-b066-1e80d40812f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_df9c8742-02ca-4595-ad07-8ae470146374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_541752e3-2887-4a06-bf30-736bf6d93575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_df9c8742-02ca-4595-ad07-8ae470146374" xlink:to="loc_us-gaap_CostsAndExpenses_541752e3-2887-4a06-bf30-736bf6d93575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f61dfe3b-0327-42a7-b4f5-53f890d7e16d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_df9c8742-02ca-4595-ad07-8ae470146374" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f61dfe3b-0327-42a7-b4f5-53f890d7e16d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfc2d0f9-5587-4a5e-86f2-cc58f23243e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InterestAndOtherIncomeNet_868c0921-0a47-4b28-bc09-a3bed9ddf44c" xlink:href="aqst-20250331.xsd#aqst_InterestAndOtherIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfc2d0f9-5587-4a5e-86f2-cc58f23243e2" xlink:to="loc_aqst_InterestAndOtherIncomeNet_868c0921-0a47-4b28-bc09-a3bed9ddf44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_57b30d73-9cc5-471e-8472-ec449264699d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfc2d0f9-5587-4a5e-86f2-cc58f23243e2" xlink:to="loc_us-gaap_RoyaltyExpense_57b30d73-9cc5-471e-8472-ec449264699d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InterestExpenseSaleOfFutureRevenues_c5b1b3d8-d8a1-4f26-914d-82e35b7251d9" xlink:href="aqst-20250331.xsd#aqst_InterestExpenseSaleOfFutureRevenues"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfc2d0f9-5587-4a5e-86f2-cc58f23243e2" xlink:to="loc_aqst_InterestExpenseSaleOfFutureRevenues_c5b1b3d8-d8a1-4f26-914d-82e35b7251d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_d9ff429a-a95e-4944-965b-ae9711833e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfc2d0f9-5587-4a5e-86f2-cc58f23243e2" xlink:to="loc_us-gaap_InterestExpenseNonoperating_d9ff429a-a95e-4944-965b-ae9711833e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ff6acedc-08af-4888-861d-1349244a48c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfc2d0f9-5587-4a5e-86f2-cc58f23243e2" xlink:to="loc_us-gaap_OperatingIncomeLoss_ff6acedc-08af-4888-861d-1349244a48c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e34dd1d-74ef-4a4e-8864-c4cd06760633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_233b7f38-2032-4d28-99e8-1acd567eeb43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5e34dd1d-74ef-4a4e-8864-c4cd06760633" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_233b7f38-2032-4d28-99e8-1acd567eeb43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c8b7832e-5577-4339-af6b-6baba6a80ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5e34dd1d-74ef-4a4e-8864-c4cd06760633" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c8b7832e-5577-4339-af6b-6baba6a80ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bde8aba1-df68-4534-8ee3-0f82284e5028" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4879e7f-768b-46c2-a8d2-f97dd7af51dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bde8aba1-df68-4534-8ee3-0f82284e5028" xlink:to="loc_us-gaap_NetIncomeLoss_a4879e7f-768b-46c2-a8d2-f97dd7af51dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_86b31c30-e260-465f-94a0-5de128311af9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_DepreciationAndAmortization_86b31c30-e260-465f-94a0-5de128311af9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cb9199fc-a305-4a77-866a-57853032ac47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_cb9199fc-a305-4a77-866a-57853032ac47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6ebe7798-5f73-48cc-b5fa-4e79668362d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6ebe7798-5f73-48cc-b5fa-4e79668362d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9bb0c11b-12cc-407b-93a2-e9befcbef83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9bb0c11b-12cc-407b-93a2-e9befcbef83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0f376b57-e0a7-450d-baee-a740cdbdcfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0f376b57-e0a7-450d-baee-a740cdbdcfc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eccb4c4c-ee62-489b-af4f-ce21d61040ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eccb4c4c-ee62-489b-af4f-ce21d61040ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3a79e5a-255e-4f8d-80ea-a43cc5cd66af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_ShareBasedCompensation_d3a79e5a-255e-4f8d-80ea-a43cc5cd66af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15930726-605f-48a6-8bed-061d5b020105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15930726-605f-48a6-8bed-061d5b020105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9e0aa77c-dd2e-4ece-a386-4171e6f6aef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9e0aa77c-dd2e-4ece-a386-4171e6f6aef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_77838779-cb70-4ca0-adfb-b53d7793d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_77838779-cb70-4ca0-adfb-b53d7793d7c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1d9415ab-0111-4246-a2bb-4b50f594927c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e82b33c6-a27a-4beb-8e45-6251ce4ecb7b" xlink:to="loc_us-gaap_NetIncomeLoss_1d9415ab-0111-4246-a2bb-4b50f594927c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e7223c2-edb8-4f5f-b672-ac53bfe72633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d67ecab-116b-476f-8bbc-ff4585e77763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e7223c2-edb8-4f5f-b672-ac53bfe72633" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1d67ecab-116b-476f-8bbc-ff4585e77763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5880c166-4960-4cfc-b3bb-28c4ee67bf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e7223c2-edb8-4f5f-b672-ac53bfe72633" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5880c166-4960-4cfc-b3bb-28c4ee67bf2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9e929e37-a6e6-47ba-b373-d6e1c5971e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e7223c2-edb8-4f5f-b672-ac53bfe72633" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9e929e37-a6e6-47ba-b373-d6e1c5971e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5cda1a96-a0f7-4052-9d6c-bc144e677284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e7223c2-edb8-4f5f-b672-ac53bfe72633" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5cda1a96-a0f7-4052-9d6c-bc144e677284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations_83c54d71-1190-423d-8937-3d4d0f07282e" xlink:href="aqst-20250331.xsd#aqst_PaymentsForRoyaltyObligationsFinancingObligations"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e7223c2-edb8-4f5f-b672-ac53bfe72633" xlink:to="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations_83c54d71-1190-423d-8937-3d4d0f07282e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_794ce793-d213-4289-8690-55ab5ded878c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_077858d8-f018-445d-8234-9ca47a1a75fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_794ce793-d213-4289-8690-55ab5ded878c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_077858d8-f018-445d-8234-9ca47a1a75fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df3a3b0f-b3cd-4c54-b8b5-02777ecd9d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_794ce793-d213-4289-8690-55ab5ded878c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_df3a3b0f-b3cd-4c54-b8b5-02777ecd9d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_367308fa-76ab-4cd0-a6ec-286724c8bf43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_794ce793-d213-4289-8690-55ab5ded878c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_367308fa-76ab-4cd0-a6ec-286724c8bf43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21dcb924-cfcc-47ac-a174-87f1c390f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bba80e42-5c27-4f78-a9a7-5a618776aa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21dcb924-cfcc-47ac-a174-87f1c390f8e7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bba80e42-5c27-4f78-a9a7-5a618776aa5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#SegmentReportingDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cf7abff2-e927-447b-b6f1-c3370957f000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eb813099-046c-4034-b4cc-614fbbf5a248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cf7abff2-e927-447b-b6f1-c3370957f000" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eb813099-046c-4034-b4cc-614fbbf5a248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingExpense_cd30a882-7d03-455b-ba19-5e46a2804f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cf7abff2-e927-447b-b6f1-c3370957f000" xlink:to="loc_us-gaap_SellingExpense_cd30a882-7d03-455b-ba19-5e46a2804f8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAndOtherReceivablesNet_d897c5f4-7e15-4bc1-967e-960b8ad6461c" xlink:href="aqst-20250331.xsd#aqst_TradeAndOtherReceivablesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_14dac076-e885-4595-ad1a-16b85f5ca30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aqst_TradeAndOtherReceivablesNet_d897c5f4-7e15-4bc1-967e-960b8ad6461c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_14dac076-e885-4595-ad1a-16b85f5ca30c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_de905d6c-0d47-439f-9791-346cb37b9cde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aqst_TradeAndOtherReceivablesNet_d897c5f4-7e15-4bc1-967e-960b8ad6461c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_de905d6c-0d47-439f-9791-346cb37b9cde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_6df13f48-4d10-4b99-ab0e-e9a85ff5f398" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aqst_TradeAndOtherReceivablesNet_d897c5f4-7e15-4bc1-967e-960b8ad6461c" xlink:to="loc_us-gaap_AccountsReceivableGross_6df13f48-4d10-4b99-ab0e-e9a85ff5f398" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/InventoriesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7e913a73-c4f8-418f-8a12-83592960b2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_f3e68e63-8193-4473-a710-4c66cca4d9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7e913a73-c4f8-418f-8a12-83592960b2a3" xlink:to="loc_us-gaap_InventoryRawMaterials_f3e68e63-8193-4473-a710-4c66cca4d9ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InventoryPackingMaterialGross_d0343aae-d58f-401f-8021-8cae081c5908" xlink:href="aqst-20250331.xsd#aqst_InventoryPackingMaterialGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7e913a73-c4f8-418f-8a12-83592960b2a3" xlink:to="loc_aqst_InventoryPackingMaterialGross_d0343aae-d58f-401f-8021-8cae081c5908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_efc73cfc-c80b-4e0a-80d4-6aa609ea0c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7e913a73-c4f8-418f-8a12-83592960b2a3" xlink:to="loc_us-gaap_InventoryFinishedGoods_efc73cfc-c80b-4e0a-80d4-6aa609ea0c8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_546d523a-3770-410b-8e3d-d6cf0d855a17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_659c254c-7bbc-4325-bfcc-0a3da87df4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_546d523a-3770-410b-8e3d-d6cf0d855a17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_659c254c-7bbc-4325-bfcc-0a3da87df4ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_988bc1ac-133b-4fb8-9986-71a36adaa2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_546d523a-3770-410b-8e3d-d6cf0d855a17" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_988bc1ac-133b-4fb8-9986-71a36adaa2ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RightofUseAssetsandLeaseObligationsMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73faaba6-d7e1-4d5a-8eeb-b3286abc6138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_dad515fb-4e37-496d-96ac-40b2494dbc43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73faaba6-d7e1-4d5a-8eeb-b3286abc6138" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_dad515fb-4e37-496d-96ac-40b2494dbc43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e68e862c-4af4-4e33-b026-1a47635e599a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73faaba6-d7e1-4d5a-8eeb-b3286abc6138" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e68e862c-4af4-4e33-b026-1a47635e599a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d87a68d5-a997-4cf0-a89e-3955e7b46bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73faaba6-d7e1-4d5a-8eeb-b3286abc6138" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d87a68d5-a997-4cf0-a89e-3955e7b46bb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_83c75943-7d74-42d0-8a3b-0d71c1cb4c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73faaba6-d7e1-4d5a-8eeb-b3286abc6138" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_83c75943-7d74-42d0-8a3b-0d71c1cb4c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_45037ef0-1550-4f68-8cce-e6b8e5035f2a" xlink:href="aqst-20250331.xsd#aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_73faaba6-d7e1-4d5a-8eeb-b3286abc6138" xlink:to="loc_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_45037ef0-1550-4f68-8cce-e6b8e5035f2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails_1" xlink:type="simple" xlink:href="aqst-20250331.xsd#RightofUseAssetsandLeaseObligationsMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5177dc1b-3890-43d2-b726-5dfddfd1d23c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_509b2318-4c40-4d98-ad0a-bf0519e5b98a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5177dc1b-3890-43d2-b726-5dfddfd1d23c" xlink:to="loc_us-gaap_OperatingLeaseLiability_509b2318-4c40-4d98-ad0a-bf0519e5b98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3ba8067e-40b4-4bed-96e9-b32935386ede" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5177dc1b-3890-43d2-b726-5dfddfd1d23c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3ba8067e-40b4-4bed-96e9-b32935386ede" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5c1f849-8399-4525-8e6a-2f77d9fa09ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_82ec7330-4f64-41ba-bab7-b53dbed55766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5c1f849-8399-4525-8e6a-2f77d9fa09ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_82ec7330-4f64-41ba-bab7-b53dbed55766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dcbf0ef2-9f40-4661-b302-3c87f6188085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d5c1f849-8399-4525-8e6a-2f77d9fa09ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dcbf0ef2-9f40-4661-b302-3c87f6188085" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1e94ac44-ba85-4d36-b7e5-1472ea94bd13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_9c05dddd-ad26-4c4f-bedd-b046bfa56f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1e94ac44-ba85-4d36-b7e5-1472ea94bd13" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_9c05dddd-ad26-4c4f-bedd-b046bfa56f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CumulativeRoyaltyReceivable_ba20d0ea-cd36-42db-b2ba-a769f48d36ce" xlink:href="aqst-20250331.xsd#aqst_CumulativeRoyaltyReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1e94ac44-ba85-4d36-b7e5-1472ea94bd13" xlink:to="loc_aqst_CumulativeRoyaltyReceivable_ba20d0ea-cd36-42db-b2ba-a769f48d36ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#AccruedExpensesScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_053c7f28-16c2-4e32-b9f0-d253ffee0d16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_40045e87-cf6b-4883-aa2d-b5321f847d44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_053c7f28-16c2-4e32-b9f0-d253ffee0d16" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_40045e87-cf6b-4883-aa2d-b5321f847d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64e7da9b-cde8-4240-ba63-720a05d6580d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_053c7f28-16c2-4e32-b9f0-d253ffee0d16" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64e7da9b-cde8-4240-ba63-720a05d6580d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_44cffab3-d157-4625-b094-85e470f5a4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_053c7f28-16c2-4e32-b9f0-d253ffee0d16" xlink:to="loc_us-gaap_TaxesPayableCurrent_44cffab3-d157-4625-b094-85e470f5a4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b5951b0a-91cb-4415-b383-49cbbea0e7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_053c7f28-16c2-4e32-b9f0-d253ffee0d16" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b5951b0a-91cb-4415-b383-49cbbea0e7bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_442bd41e-bb5c-4f57-a797-bfba409f7c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_053c7f28-16c2-4e32-b9f0-d253ffee0d16" xlink:to="loc_us-gaap_InterestPayableCurrent_442bd41e-bb5c-4f57-a797-bfba409f7c75" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d39310bc-3a18-4243-9f57-dcd8ef5225b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_96eaedad-6572-438f-8732-2c0c92acf555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d39310bc-3a18-4243-9f57-dcd8ef5225b8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_96eaedad-6572-438f-8732-2c0c92acf555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ecc18ede-fff9-46d8-bb2d-237f847cd187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d39310bc-3a18-4243-9f57-dcd8ef5225b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ecc18ede-fff9-46d8-bb2d-237f847cd187" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c726a58f-5346-4885-8005-7887bfd269ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2558d689-b578-4b32-b2d7-0959c2d77af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c726a58f-5346-4885-8005-7887bfd269ca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2558d689-b578-4b32-b2d7-0959c2d77af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ea28cb97-71ab-4244-bd70-2c5d562d0b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c726a58f-5346-4885-8005-7887bfd269ca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ea28cb97-71ab-4244-bd70-2c5d562d0b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1a234df4-48e2-4e5b-9065-bf00205d8a46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c726a58f-5346-4885-8005-7887bfd269ca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1a234df4-48e2-4e5b-9065-bf00205d8a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_08c5677b-8b01-4f21-a7a4-be27b311a38c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c726a58f-5346-4885-8005-7887bfd269ca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_08c5677b-8b01-4f21-a7a4-be27b311a38c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>aqst-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7fd918af-7463-495d-a5aa-7a090fe24bee,g:404d0fa2-95d9-41b4-b7eb-3a9cfeb5fb76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedStatementsofChangesinStockholdersDeficit"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a2fd88ca-c625-4047-a56f-a632e511d514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a2fd88ca-c625-4047-a56f-a632e511d514" xlink:to="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_39334b6f-3534-4d5d-b982-84764479e24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_39334b6f-3534-4d5d-b982-84764479e24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39334b6f-3534-4d5d-b982-84764479e24c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_39334b6f-3534-4d5d-b982-84764479e24c" xlink:to="loc_us-gaap_EquityComponentDomain_39334b6f-3534-4d5d-b982-84764479e24c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_39334b6f-3534-4d5d-b982-84764479e24c" xlink:to="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95bf2b01-849c-4d18-a1dc-7fadb73dd91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:to="loc_us-gaap_CommonStockMember_95bf2b01-849c-4d18-a1dc-7fadb73dd91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e6ce2af2-0e22-4bae-9ff2-def5b0173b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e6ce2af2-0e22-4bae-9ff2-def5b0173b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ed883d6-1c85-4a06-a57b-98b2f53f0e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:to="loc_us-gaap_RetainedEarningsMember_1ed883d6-1c85-4a06-a57b-98b2f53f0e54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98d3226e-64e7-44f4-923e-4e398d800b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98d3226e-64e7-44f4-923e-4e398d800b8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98d3226e-64e7-44f4-923e-4e398d800b8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98d3226e-64e7-44f4-923e-4e398d800b8f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98d3226e-64e7-44f4-923e-4e398d800b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98d3226e-64e7-44f4-923e-4e398d800b8f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtTheMarketOfferingMember_fa50d159-5ad1-4a44-bce1-51bd15a5ed52" xlink:href="aqst-20250331.xsd#aqst_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:to="loc_aqst_AtTheMarketOfferingMember_fa50d159-5ad1-4a44-bce1-51bd15a5ed52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PublicEquityOfferingMember_817eed5b-aedd-44bc-89c3-85a8a1507794" xlink:href="aqst-20250331.xsd#aqst_PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:to="loc_aqst_PublicEquityOfferingMember_817eed5b-aedd-44bc-89c3-85a8a1507794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a2fd88ca-c625-4047-a56f-a632e511d514" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8c16273f-219c-4be9-a7b5-8d1e6e849029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_SharesOutstanding_8c16273f-219c-4be9-a7b5-8d1e6e849029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4312ba7-fc66-42af-a5b2-92d9b6eb009b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockholdersEquity_d4312ba7-fc66-42af-a5b2-92d9b6eb009b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_80de0368-e7c1-4883-8719-0e72cb7028ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_80de0368-e7c1-4883-8719-0e72cb7028ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c898b55-b603-4bdc-aa13-d483643648d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c898b55-b603-4bdc-aa13-d483643648d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4e8af994-4bfc-45d0-a840-712386b537e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4e8af994-4bfc-45d0-a840-712386b537e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_af991026-d1c4-4c49-9342-96bd6cc9ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_af991026-d1c4-4c49-9342-96bd6cc9ded2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cec4a26-8933-4685-a91c-379bf8f0d618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cec4a26-8933-4685-a91c-379bf8f0d618" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bae05493-f46c-4e7a-b3f7-b6df028b11fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bae05493-f46c-4e7a-b3f7-b6df028b11fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_e2b8836b-f40f-4e44-8f4a-e94a2f8fa0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_e2b8836b-f40f-4e44-8f4a-e94a2f8fa0bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_572bc93f-b6e0-4f42-ac7c-04ade41e8aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_572bc93f-b6e0-4f42-ac7c-04ade41e8aa1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_69d7c23e-578d-4b43-816c-8474e820a61f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_69d7c23e-578d-4b43-816c-8474e820a61f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52b7731b-d749-4766-9a44-62f498d78adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_NetIncomeLoss_52b7731b-d749-4766-9a44-62f498d78adc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_40c72319-fb17-41af-900a-4a093a29c8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b184f8f6-1b17-40ad-8f2c-795eace44769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ecd2847-6907-4fa5-8659-01f97aece004" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_StatementTable_4ecd2847-6907-4fa5-8659-01f97aece004" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_af6a1764-a95d-4561-b95f-d0391f1fb983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4ecd2847-6907-4fa5-8659-01f97aece004" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_af6a1764-a95d-4561-b95f-d0391f1fb983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_af6a1764-a95d-4561-b95f-d0391f1fb983_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_af6a1764-a95d-4561-b95f-d0391f1fb983" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_af6a1764-a95d-4561-b95f-d0391f1fb983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_af6a1764-a95d-4561-b95f-d0391f1fb983" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtTheMarketOfferingMember_61efd5f1-7b4f-4eed-8050-3486df9fa872" xlink:href="aqst-20250331.xsd#aqst_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:to="loc_aqst_AtTheMarketOfferingMember_61efd5f1-7b4f-4eed-8050-3486df9fa872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PublicEquityOfferingMember_19b84505-c8c9-4bdf-ae00-a9922e3093e5" xlink:href="aqst-20250331.xsd#aqst_PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:to="loc_aqst_PublicEquityOfferingMember_19b84505-c8c9-4bdf-ae00-a9922e3093e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c6618d20-7a1c-4ec2-b058-afe80e9ea80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:to="loc_us-gaap_NetIncomeLoss_c6618d20-7a1c-4ec2-b058-afe80e9ea80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_84b173fb-b68d-4a02-8b57-46fce29c6631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_DepreciationAndAmortization_84b173fb-b68d-4a02-8b57-46fce29c6631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e15c7949-ae7c-42bc-a458-35cf108e5979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_ShareBasedCompensation_e15c7949-ae7c-42bc-a458-35cf108e5979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_fbe944e7-339f-4da1-8d3d-7138ff796164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_fbe944e7-339f-4da1-8d3d-7138ff796164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_57a0a274-9d0a-40e1-b386-6ea6e5906cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_57a0a274-9d0a-40e1-b386-6ea6e5906cb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_37912720-83d4-47e3-90d7-3028ab536317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_37912720-83d4-47e3-90d7-3028ab536317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ce7aa6d5-15e3-4c49-b100-2e05520ccb44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ce7aa6d5-15e3-4c49-b100-2e05520ccb44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85da6ff0-2cc8-4f47-9971-77301c373717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85da6ff0-2cc8-4f47-9971-77301c373717" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ca77b5fe-0d39-4213-be92-30a38eb1aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ca77b5fe-0d39-4213-be92-30a38eb1aa3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_df2cfca3-025a-428f-836c-e0d33682d6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_df2cfca3-025a-428f-836c-e0d33682d6e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e2c6f31a-4792-4de0-b05b-e722056d4e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e2c6f31a-4792-4de0-b05b-e722056d4e1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07aeb6e3-22c4-411d-9f51-cd232b8ab38c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07aeb6e3-22c4-411d-9f51-cd232b8ab38c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67dfdbad-77b6-4709-886c-b827efd33e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67dfdbad-77b6-4709-886c-b827efd33e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_635f7df0-f9f5-4a69-bbf0-3771d7d87e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_635f7df0-f9f5-4a69-bbf0-3771d7d87e6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4ac0d21c-27c0-4ce5-ade8-20a1c2e6a429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4ac0d21c-27c0-4ce5-ade8-20a1c2e6a429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8d2a5942-649c-4e5e-945a-caf388e13dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8d2a5942-649c-4e5e-945a-caf388e13dbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_2d86e466-0be8-4fd8-9ce7-4989ea93daf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_2d86e466-0be8-4fd8-9ce7-4989ea93daf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations_3820d4a4-4583-4445-8761-eb6b6e868fa7" xlink:href="aqst-20250331.xsd#aqst_PaymentsForRoyaltyObligationsFinancingObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations_3820d4a4-4583-4445-8761-eb6b6e868fa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c549344d-f626-4675-8661-9feff0f20df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c549344d-f626-4675-8661-9feff0f20df3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0dbb6a63-bb5f-44ac-b0e2-6441b73fea03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0dbb6a63-bb5f-44ac-b0e2-6441b73fea03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f62709e-a101-49f3-83c6-11c5c5c3a6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f62709e-a101-49f3-83c6-11c5c5c3a6ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0df60e80-cf3b-45f7-8a05-7995db949f68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0df60e80-cf3b-45f7-8a05-7995db949f68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_832a11cd-c070-49d9-b360-2634a1aa8efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0df60e80-cf3b-45f7-8a05-7995db949f68" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_832a11cd-c070-49d9-b360-2634a1aa8efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_458f9e80-0992-44a4-830c-ef0b6bb41ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_25821428-01e0-4f32-8274-d970a4cda30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_25821428-01e0-4f32-8274-d970a4cda30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable_29f3a54b-9869-4859-8360-27a1695ce9ae" xlink:href="aqst-20250331.xsd#aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:to="loc_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable_29f3a54b-9869-4859-8360-27a1695ce9ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable_ba632ed4-89a4-4b03-bbfe-9892019dfddd" xlink:href="aqst-20250331.xsd#aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:to="loc_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable_ba632ed4-89a4-4b03-bbfe-9892019dfddd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#CompanyOverviewandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86dc31f1-142f-467d-a0ca-831956eb24b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86dc31f1-142f-467d-a0ca-831956eb24b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86dc31f1-142f-467d-a0ca-831956eb24b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86dc31f1-142f-467d-a0ca-831956eb24b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86dc31f1-142f-467d-a0ca-831956eb24b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86dc31f1-142f-467d-a0ca-831956eb24b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_EquityDistributionAgreementMember_4789910e-027a-4907-bc22-ee3dcb4e270b" xlink:href="aqst-20250331.xsd#aqst_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_EquityDistributionAgreementMember_4789910e-027a-4907-bc22-ee3dcb4e270b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AmendedEquityDistributionAgreementMember_b211b93f-9d54-4993-854d-60ba1cc550a4" xlink:href="aqst-20250331.xsd#aqst_AmendedEquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_AmendedEquityDistributionAgreementMember_b211b93f-9d54-4993-854d-60ba1cc550a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LincolnParkAgreementMember_3adff1e5-e0f1-4b01-a366-f8d11aed553b" xlink:href="aqst-20250331.xsd#aqst_LincolnParkAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_LincolnParkAgreementMember_3adff1e5-e0f1-4b01-a366-f8d11aed553b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_UnderwrittenPublicOfferingMember_82b5a925-8f59-4b07-b371-c384a2a3b984" xlink:href="aqst-20250331.xsd#aqst_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_UnderwrittenPublicOfferingMember_82b5a925-8f59-4b07-b371-c384a2a3b984" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3c2e6f2b-5320-47f8-9d9f-7a6cbf76b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3c2e6f2b-5320-47f8-9d9f-7a6cbf76b3ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_884d63aa-8024-468e-a30e-4e636c4aaf80" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:to="loc_srt_RangeAxis_884d63aa-8024-468e-a30e-4e636c4aaf80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_884d63aa-8024-468e-a30e-4e636c4aaf80_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_884d63aa-8024-468e-a30e-4e636c4aaf80" xlink:to="loc_srt_RangeMember_884d63aa-8024-468e-a30e-4e636c4aaf80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb901890-f1fa-4b99-9f0c-62fa170d7d19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_884d63aa-8024-468e-a30e-4e636c4aaf80" xlink:to="loc_srt_RangeMember_cb901890-f1fa-4b99-9f0c-62fa170d7d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4116001-9d17-4155-83f8-6e57356ffb47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb901890-f1fa-4b99-9f0c-62fa170d7d19" xlink:to="loc_srt_MaximumMember_a4116001-9d17-4155-83f8-6e57356ffb47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts_c1b650a0-1884-47b9-ad72-1d1bc26e3afd" xlink:href="aqst-20250331.xsd#aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts_c1b650a0-1884-47b9-ad72-1d1bc26e3afd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e39c2be0-97c6-4c0a-9895-75be09694a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e39c2be0-97c6-4c0a-9895-75be09694a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_edec52de-ae1e-4ef5-b393-d6083cef4013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_edec52de-ae1e-4ef5-b393-d6083cef4013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e04eb91b-46ea-48b7-bba8-2ced6fb41592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e04eb91b-46ea-48b7-bba8-2ced6fb41592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockMaximumTransactionAmount_371b5257-41d1-429d-a79e-876dcb98c9b4" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockMaximumTransactionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockMaximumTransactionAmount_371b5257-41d1-429d-a79e-876dcb98c9b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockAggregateOfferingPrice_960a5dc5-4267-48cf-9a40-080d6139a954" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockAggregateOfferingPrice_960a5dc5-4267-48cf-9a40-080d6139a954" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts_fd1b7157-61aa-41d8-ad53-dd99737dbc37" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts_fd1b7157-61aa-41d8-ad53-dd99737dbc37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_60392a5a-945a-4d08-baf8-6aaf11e9fb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_60392a5a-945a-4d08-baf8-6aaf11e9fb0f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RightToSellCommonStockValue_1613c47d-3c7c-4427-bfb2-a57ed8acff20" xlink:href="aqst-20250331.xsd#aqst_RightToSellCommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_RightToSellCommonStockValue_1613c47d-3c7c-4427-bfb2-a57ed8acff20" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AgreementTerm_2f4fd903-701e-4582-81d9-f59cb1e767a5" xlink:href="aqst-20250331.xsd#aqst_AgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_AgreementTerm_2f4fd903-701e-4582-81d9-f59cb1e767a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions_42d4b77c-520b-4990-9946-05b623649873" xlink:href="aqst-20250331.xsd#aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions_42d4b77c-520b-4990-9946-05b623649873" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1878eb30-9a1a-48eb-8e46-04b530a867fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1878eb30-9a1a-48eb-8e46-04b530a867fa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts_c0b193e3-f65c-416b-9a5c-12dc106e5b0d" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts_c0b193e3-f65c-416b-9a5c-12dc106e5b0d" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RisksandUncertaintiesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d5a7068e-a300-4d8d-869d-e5750db1104e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:to="loc_us-gaap_ConcentrationRiskTable_d5a7068e-a300-4d8d-869d-e5750db1104e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d5a7068e-a300-4d8d-869d-e5750db1104e" xlink:to="loc_us-gaap_DebtInstrumentAxis_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c065e5cb-bfa9-40ea-ab09-a0bce2968862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c065e5cb-bfa9-40ea-ab09-a0bce2968862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_e2ab3fa0-e65e-4c24-959e-b2254c645db9" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c065e5cb-bfa9-40ea-ab09-a0bce2968862" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_e2ab3fa0-e65e-4c24-959e-b2254c645db9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d48c8ba-0103-493f-8fae-a37f30c26062" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d48c8ba-0103-493f-8fae-a37f30c26062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fab36aa-3213-4f72-93c0-8b4b88b96236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fab36aa-3213-4f72-93c0-8b4b88b96236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7424dce-f068-47fd-83fe-cd3f2ad4013a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7424dce-f068-47fd-83fe-cd3f2ad4013a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3" xlink:to="loc_us-gaap_SegmentDomain_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_60b3f839-2c9b-48a8-bc44-900d15115da9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3" xlink:to="loc_us-gaap_SegmentDomain_60b3f839-2c9b-48a8-bc44-900d15115da9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ReportableSegmentMember_c3af741d-4cd2-4e06-a144-bd34024ce7d4" xlink:href="aqst-20250331.xsd#aqst_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_60b3f839-2c9b-48a8-bc44-900d15115da9" xlink:to="loc_aqst_ReportableSegmentMember_c3af741d-4cd2-4e06-a144-bd34024ce7d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:to="loc_srt_ProductOrServiceAxis_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d" xlink:to="loc_srt_ProductsAndServicesDomain_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d" xlink:to="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AnaphylmMember_bb03891d-923a-476e-b3a4-3693c7dc9856" xlink:href="aqst-20250331.xsd#aqst_AnaphylmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_AnaphylmMember_bb03891d-923a-476e-b3a4-3693c7dc9856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AQST108Member_7a3f00a9-fa80-428b-a5e8-e925e30c30bd" xlink:href="aqst-20250331.xsd#aqst_AQST108Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_AQST108Member_7a3f00a9-fa80-428b-a5e8-e925e30c30bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LibervantMember_988999cb-312c-4f4a-bdec-38128771de0a" xlink:href="aqst-20250331.xsd#aqst_LibervantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_LibervantMember_988999cb-312c-4f4a-bdec-38128771de0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PersonnelCostsMember_5faea1b2-06b4-476f-a64d-e6ed7b95ee96" xlink:href="aqst-20250331.xsd#aqst_PersonnelCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_PersonnelCostsMember_5faea1b2-06b4-476f-a64d-e6ed7b95ee96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_OtherMember_dae41af9-0e47-43ce-a454-be7d3e9d4102" xlink:href="aqst-20250331.xsd#aqst_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_OtherMember_dae41af9-0e47-43ce-a454-be7d3e9d4102" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d09e3483-53ad-4298-9d2b-91542ad08c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d09e3483-53ad-4298-9d2b-91542ad08c78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_28fbebaa-08d6-4e4c-ba79-0b65bdc8bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_NumberOfReportableSegments_28fbebaa-08d6-4e4c-ba79-0b65bdc8bd6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2108ab34-e0ac-40e7-aeef-6e423b6592cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2108ab34-e0ac-40e7-aeef-6e423b6592cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8dd5615e-996f-4218-be19-b681f3cc60ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8dd5615e-996f-4218-be19-b681f3cc60ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4e70992a-9a07-42ed-86ca-b567f7527c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4e70992a-9a07-42ed-86ca-b567f7527c90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_1ecfcb6b-5c81-4200-9c5d-69a1317eca89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_1ecfcb6b-5c81-4200-9c5d-69a1317eca89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingExpense_c6a76cb2-d0d8-459f-962f-c9486afe6387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_1ecfcb6b-5c81-4200-9c5d-69a1317eca89" xlink:to="loc_us-gaap_SellingExpense_c6a76cb2-d0d8-459f-962f-c9486afe6387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_7b43a95e-0083-4d63-858f-1647d3043c15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_7b43a95e-0083-4d63-858f-1647d3043c15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b172a299-6151-4a85-ac67-3a45b8ab34c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_7b43a95e-0083-4d63-858f-1647d3043c15" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b172a299-6151-4a85-ac67-3a45b8ab34c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fd710e84-b133-468c-9189-e3a4d1a5981c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fd710e84-b133-468c-9189-e3a4d1a5981c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_604c9255-a8f6-4ca2-afbe-dab229d5b94f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_CostsAndExpenses_604c9255-a8f6-4ca2-afbe-dab229d5b94f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ffcf19d1-d50b-483d-a1bd-20b002183ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_OperatingIncomeLoss_ffcf19d1-d50b-483d-a1bd-20b002183ab2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_90c731a3-14b8-44e3-a555-a345532f7f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_90c731a3-14b8-44e3-a555-a345532f7f19" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f9d6d9f-2abe-4729-803c-10a837ca177c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f9d6d9f-2abe-4729-803c-10a837ca177c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2ec59756-593f-453d-85ff-5936e966ca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_NetIncomeLoss_2ec59756-593f-453d-85ff-5936e966ca5f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_24379ec7-b0eb-4fed-9ef2-b5cdc4c365c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_24379ec7-b0eb-4fed-9ef2-b5cdc4c365c2" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_896fe99d-7ba1-40b7-a905-22864fc50e41" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_srt_RangeAxis_896fe99d-7ba1-40b7-a905-22864fc50e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_896fe99d-7ba1-40b7-a905-22864fc50e41_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_896fe99d-7ba1-40b7-a905-22864fc50e41" xlink:to="loc_srt_RangeMember_896fe99d-7ba1-40b7-a905-22864fc50e41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af123a67-ea58-476c-ab84-ad2136703d5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_896fe99d-7ba1-40b7-a905-22864fc50e41" xlink:to="loc_srt_RangeMember_af123a67-ea58-476c-ab84-ad2136703d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8387d4b0-6d48-48ef-a3a8-697fe0ebcb6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af123a67-ea58-476c-ab84-ad2136703d5c" xlink:to="loc_srt_MaximumMember_8387d4b0-6d48-48ef-a3a8-697fe0ebcb6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2db940c-e9a2-4c70-942a-b0b69f43855f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2db940c-e9a2-4c70-942a-b0b69f43855f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b2db940c-e9a2-4c70-942a-b0b69f43855f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2db940c-e9a2-4c70-942a-b0b69f43855f" xlink:to="loc_us-gaap_ReceivableTypeDomain_b2db940c-e9a2-4c70-942a-b0b69f43855f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2db940c-e9a2-4c70-942a-b0b69f43855f" xlink:to="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_344399a2-6f11-4c07-a124-a1f7ccc0964f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_344399a2-6f11-4c07-a124-a1f7ccc0964f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_OtherReceivablesAndAccruedExpensesMember_26a93599-6fbf-47a1-bc30-0465fccbe596" xlink:href="aqst-20250331.xsd#aqst_OtherReceivablesAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:to="loc_aqst_OtherReceivablesAndAccruedExpensesMember_26a93599-6fbf-47a1-bc30-0465fccbe596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_90cf2366-b7e0-4b0e-981a-79a6accddb44" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableDoubtfulAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:to="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_90cf2366-b7e0-4b0e-981a-79a6accddb44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_90ee9cb4-d4f1-4e11-adb8-94e8002fe764" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_srt_MajorCustomersAxis_90ee9cb4-d4f1-4e11-adb8-94e8002fe764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_90ee9cb4-d4f1-4e11-adb8-94e8002fe764_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_90ee9cb4-d4f1-4e11-adb8-94e8002fe764" xlink:to="loc_srt_NameOfMajorCustomerDomain_90ee9cb4-d4f1-4e11-adb8-94e8002fe764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_90ee9cb4-d4f1-4e11-adb8-94e8002fe764" xlink:to="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_IndiviorMember_74000df3-ba4c-4674-a538-2a04b24b2197" xlink:href="aqst-20250331.xsd#aqst_IndiviorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:to="loc_aqst_IndiviorMember_74000df3-ba4c-4674-a538-2a04b24b2197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_HyperaMember_a0dba7fb-4afd-44d1-9347-16ecd1ddf034" xlink:href="aqst-20250331.xsd#aqst_HyperaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:to="loc_aqst_HyperaMember_a0dba7fb-4afd-44d1-9347-16ecd1ddf034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_552ae984-2708-40be-b20c-64e84b8399b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_552ae984-2708-40be-b20c-64e84b8399b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_552ae984-2708-40be-b20c-64e84b8399b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_552ae984-2708-40be-b20c-64e84b8399b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_552ae984-2708-40be-b20c-64e84b8399b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_552ae984-2708-40be-b20c-64e84b8399b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_00fa0b13-4f49-43e9-a281-34be6e04dbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_00fa0b13-4f49-43e9-a281-34be6e04dbeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_92c6c44d-caf2-4f98-8af3-d3616d2e1ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:to="loc_us-gaap_AccountsReceivableMember_92c6c44d-caf2-4f98-8af3-d3616d2e1ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f9d2dc8b-a610-4eff-a305-79712072dbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f9d2dc8b-a610-4eff-a305-79712072dbe0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f9d2dc8b-a610-4eff-a305-79712072dbe0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f9d2dc8b-a610-4eff-a305-79712072dbe0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f9d2dc8b-a610-4eff-a305-79712072dbe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4ff385cf-9fc0-4a76-bb66-a5fed5710ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f9d2dc8b-a610-4eff-a305-79712072dbe0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4ff385cf-9fc0-4a76-bb66-a5fed5710ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_09e379d6-87a5-4db8-8cb6-618f56153a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4ff385cf-9fc0-4a76-bb66-a5fed5710ea1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_09e379d6-87a5-4db8-8cb6-618f56153a75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ResearchAndDevelopmentProjectDuration_72f3a91f-f299-44ed-b98d-74f5a21b1709" xlink:href="aqst-20250331.xsd#aqst_ResearchAndDevelopmentProjectDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_aqst_ResearchAndDevelopmentProjectDuration_72f3a91f-f299-44ed-b98d-74f5a21b1709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_e8985979-fd43-4847-bd50-04375b1a331b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_e8985979-fd43-4847-bd50-04375b1a331b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9e3e3bb3-8b23-40a1-9d92-ed7cefc5381f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9e3e3bb3-8b23-40a1-9d92-ed7cefc5381f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_f34f15fc-c1a4-492f-af39-16be76b76cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_CapitalizedContractCostNet_f34f15fc-c1a4-492f-af39-16be76b76cd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cf888f01-67e7-4084-a1f6-8092981bd75d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cf888f01-67e7-4084-a1f6-8092981bd75d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ea4b4039-01ca-431e-87a0-ed8acd6b9074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ea4b4039-01ca-431e-87a0-ed8acd6b9074" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b84894f2-c957-4bb8-981e-3c35fa6543b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b84894f2-c957-4bb8-981e-3c35fa6543b6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetRevenueDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_827107bd-dfbe-45f6-9730-907725df186d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7c0a6a1a-f3eb-4e2c-b64a-18490b5c2479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_827107bd-dfbe-45f6-9730-907725df186d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7c0a6a1a-f3eb-4e2c-b64a-18490b5c2479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_735f7a47-1829-4f4d-80a5-0e8bee11bbae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7c0a6a1a-f3eb-4e2c-b64a-18490b5c2479" xlink:to="loc_srt_ProductOrServiceAxis_735f7a47-1829-4f4d-80a5-0e8bee11bbae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_735f7a47-1829-4f4d-80a5-0e8bee11bbae_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_735f7a47-1829-4f4d-80a5-0e8bee11bbae" xlink:to="loc_srt_ProductsAndServicesDomain_735f7a47-1829-4f4d-80a5-0e8bee11bbae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_735f7a47-1829-4f4d-80a5-0e8bee11bbae" xlink:to="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufactureAndSupplyRevenueMember_5136ce45-ae9c-4865-bb59-f50103b15ae9" xlink:href="aqst-20250331.xsd#aqst_ManufactureAndSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_aqst_ManufactureAndSupplyRevenueMember_5136ce45-ae9c-4865-bb59-f50103b15ae9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAndRoyaltyRevenueMember_622c2088-afcd-4de6-9487-53142af60e2b" xlink:href="aqst-20250331.xsd#aqst_LicenseAndRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_aqst_LicenseAndRoyaltyRevenueMember_622c2088-afcd-4de6-9487-53142af60e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CoDevelopmentAndResearchFeesMember_039a1ce2-68c2-4289-bae0-2876c0cd7082" xlink:href="aqst-20250331.xsd#aqst_CoDevelopmentAndResearchFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_aqst_CoDevelopmentAndResearchFeesMember_039a1ce2-68c2-4289-bae0-2876c0cd7082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_f17cfcdc-dcce-4c5e-8d4a-4fad0ecceb03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_f17cfcdc-dcce-4c5e-8d4a-4fad0ecceb03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_158a29c8-c631-4b86-b8ab-84d16cd8f078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_827107bd-dfbe-45f6-9730-907725df186d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_158a29c8-c631-4b86-b8ab-84d16cd8f078" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fc3477f5-3bd0-45df-8295-16ae3556f9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4aebfb17-153c-4661-82b4-a18e0fb6362e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fc3477f5-3bd0-45df-8295-16ae3556f9b3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4aebfb17-153c-4661-82b4-a18e0fb6362e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d3e38295-7c88-4fb3-93a0-8f31a5d8945c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4aebfb17-153c-4661-82b4-a18e0fb6362e" xlink:to="loc_srt_StatementGeographicalAxis_d3e38295-7c88-4fb3-93a0-8f31a5d8945c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d3e38295-7c88-4fb3-93a0-8f31a5d8945c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d3e38295-7c88-4fb3-93a0-8f31a5d8945c" xlink:to="loc_srt_SegmentGeographicalDomain_d3e38295-7c88-4fb3-93a0-8f31a5d8945c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d3e38295-7c88-4fb3-93a0-8f31a5d8945c" xlink:to="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ffa3e070-8a35-4123-92c3-3f8639c18aed" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:to="loc_country_US_ffa3e070-8a35-4123-92c3-3f8639c18aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4f637195-4539-497c-b893-87cc1e8b9cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:to="loc_us-gaap_NonUsMember_4f637195-4539-497c-b893-87cc1e8b9cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_eaaf0660-54fc-481f-b6e0-7ceeb7765535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fc3477f5-3bd0-45df-8295-16ae3556f9b3" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_eaaf0660-54fc-481f-b6e0-7ceeb7765535" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1443dc8d-5f87-4997-bb48-8a88b3d08744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_eaaf0660-54fc-481f-b6e0-7ceeb7765535" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1443dc8d-5f87-4997-bb48-8a88b3d08744" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b64895bb-961d-4b78-9210-83bf674fedbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b64895bb-961d-4b78-9210-83bf674fedbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b64895bb-961d-4b78-9210-83bf674fedbc" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69" xlink:to="loc_us-gaap_ReceivableTypeDomain_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69" xlink:to="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_eed6df94-596f-4177-a5e6-ea9f8c2f8c28" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableDoubtfulAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:to="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_eed6df94-596f-4177-a5e6-ea9f8c2f8c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableSalesRelatedMember_701a0e1a-8ba7-4b13-8968-722ece0c879e" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableSalesRelatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:to="loc_aqst_TradeAccountsReceivableSalesRelatedMember_701a0e1a-8ba7-4b13-8968-722ece0c879e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_95d8e35a-cb22-40c0-84b4-e67936781800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_us-gaap_AccountsReceivableGross_95d8e35a-cb22-40c0-84b4-e67936781800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_83258421-efeb-459d-a61a-a6decf6ab240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_83258421-efeb-459d-a61a-a6decf6ab240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_20c83565-8f79-4c12-98ca-38f5d71e4143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_20c83565-8f79-4c12-98ca-38f5d71e4143" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAndOtherReceivablesNet_35bc1e84-b7be-4e08-84d2-ba767dd2873b" xlink:href="aqst-20250331.xsd#aqst_TradeAndOtherReceivablesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_aqst_TradeAndOtherReceivablesNet_35bc1e84-b7be-4e08-84d2-ba767dd2873b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_461d3434-9cde-4c42-b534-77f714d99468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2f1bad54-7dfb-4dd3-98be-bd1a88634ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_461d3434-9cde-4c42-b534-77f714d99468" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2f1bad54-7dfb-4dd3-98be-bd1a88634ad6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2f1bad54-7dfb-4dd3-98be-bd1a88634ad6" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3" xlink:to="loc_us-gaap_ReceivableTypeDomain_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_668c0614-ecc7-4d6b-a52b-e0ac693bfbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3" xlink:to="loc_us-gaap_ReceivableTypeDomain_668c0614-ecc7-4d6b-a52b-e0ac693bfbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_851b1f57-4650-45d4-86e9-d77bf2e08dd0" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableDoubtfulAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_668c0614-ecc7-4d6b-a52b-e0ac693bfbfb" xlink:to="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_851b1f57-4650-45d4-86e9-d77bf2e08dd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_461d3434-9cde-4c42-b534-77f714d99468" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f9e76e36-5369-498a-a170-0d191bb9ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f9e76e36-5369-498a-a170-0d191bb9ccaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c2dd01e7-e6d0-4c83-a9c5-68d10e159ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c2dd01e7-e6d0-4c83-a9c5-68d10e159ba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_76469623-ed58-4c2a-9215-0f4eed04955f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e038d3ba-561b-45b9-8e30-4bde8ee0048b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d1e538d6-eecb-4bfb-a46e-f2504749c351" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e038d3ba-561b-45b9-8e30-4bde8ee0048b" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d1e538d6-eecb-4bfb-a46e-f2504749c351" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1df7e394-47b4-44cb-b541-21cee9a8814f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d1e538d6-eecb-4bfb-a46e-f2504749c351" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1df7e394-47b4-44cb-b541-21cee9a8814f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1df7e394-47b4-44cb-b541-21cee9a8814f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1df7e394-47b4-44cb-b541-21cee9a8814f" xlink:to="loc_us-gaap_ReceivableTypeDomain_1df7e394-47b4-44cb-b541-21cee9a8814f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a64090d5-f4f6-4a94-80ab-0d8ab168fb96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1df7e394-47b4-44cb-b541-21cee9a8814f" xlink:to="loc_us-gaap_ReceivableTypeDomain_a64090d5-f4f6-4a94-80ab-0d8ab168fb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableSalesRelatedMember_e9dde58a-34fd-40ae-9d44-af7a13e3e6b2" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableSalesRelatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a64090d5-f4f6-4a94-80ab-0d8ab168fb96" xlink:to="loc_aqst_TradeAccountsReceivableSalesRelatedMember_e9dde58a-34fd-40ae-9d44-af7a13e3e6b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e038d3ba-561b-45b9-8e30-4bde8ee0048b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4be35a26-325d-4e47-a86d-15da02547ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4be35a26-325d-4e47-a86d-15da02547ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_a2b38cb1-c5ec-495c-b8ac-79021563c83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_a2b38cb1-c5ec-495c-b8ac-79021563c83c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_a857f272-61ed-4aa2-b0bb-0da01ae29563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_a857f272-61ed-4aa2-b0bb-0da01ae29563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8fff746d-b4d4-4a44-bbdc-857edf310437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/MaterialAgreementsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#MaterialAgreementsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/MaterialAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eec6395d-7ef3-4899-82a1-258c713d20ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eec6395d-7ef3-4899-82a1-258c713d20ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eec6395d-7ef3-4899-82a1-258c713d20ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eec6395d-7ef3-4899-82a1-258c713d20ef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eec6395d-7ef3-4899-82a1-258c713d20ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eec6395d-7ef3-4899-82a1-258c713d20ef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CommercialExploitationAgreementWithIndiviorMember_20615322-90f9-4ee0-b9a3-8d7464fe1c4c" xlink:href="aqst-20250331.xsd#aqst_CommercialExploitationAgreementWithIndiviorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_CommercialExploitationAgreementWithIndiviorMember_20615322-90f9-4ee0-b9a3-8d7464fe1c4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember_c38dda6b-fbc4-4510-acdd-fbbc2a3fd6f2" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember_c38dda6b-fbc4-4510-acdd-fbbc2a3fd6f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember_d94b5e9d-72c1-4af1-a447-0923d33c354b" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember_d94b5e9d-72c1-4af1-a447-0923d33c354b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarathonPangolinRoyaltyLLCMember_35cbe2e5-545c-4d91-af84-9fc410739e2d" xlink:href="aqst-20250331.xsd#aqst_MarathonPangolinRoyaltyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_MarathonPangolinRoyaltyLLCMember_35cbe2e5-545c-4d91-af84-9fc410739e2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember_2184906e-bba1-4a19-8eb1-f75969ebd1ec" xlink:href="aqst-20250331.xsd#aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember_2184906e-bba1-4a19-8eb1-f75969ebd1ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedMember_dabf6cc6-4c48-451a-88c4-d46eee3e0808" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_AtnahsPharmaUKLimitedMember_dabf6cc6-4c48-451a-88c4-d46eee3e0808" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseSupplyAgreementMember_d05eb4dc-50af-4d9a-bd55-a8e80c4d66de" xlink:href="aqst-20250331.xsd#aqst_LicenseSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_LicenseSupplyAgreementMember_d05eb4dc-50af-4d9a-bd55-a8e80c4d66de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember_c910be5c-664b-4d35-87e5-f8f9f4857414" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedAmendedAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember_c910be5c-664b-4d35-87e5-f8f9f4857414" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d1b2228-6f89-46be-9307-30e54b07d0e3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_srt_RangeAxis_7d1b2228-6f89-46be-9307-30e54b07d0e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d1b2228-6f89-46be-9307-30e54b07d0e3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7d1b2228-6f89-46be-9307-30e54b07d0e3" xlink:to="loc_srt_RangeMember_7d1b2228-6f89-46be-9307-30e54b07d0e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3087419-2763-4a61-8452-e1ce9375a3c9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7d1b2228-6f89-46be-9307-30e54b07d0e3" xlink:to="loc_srt_RangeMember_b3087419-2763-4a61-8452-e1ce9375a3c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdf7fa2b-8c00-4de7-b5bc-5593539d2df6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b3087419-2763-4a61-8452-e1ce9375a3c9" xlink:to="loc_srt_MaximumMember_fdf7fa2b-8c00-4de7-b5bc-5593539d2df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_503bf4af-1997-447a-8f3d-b8081a14a77b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_srt_ProductOrServiceAxis_503bf4af-1997-447a-8f3d-b8081a14a77b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_503bf4af-1997-447a-8f3d-b8081a14a77b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_503bf4af-1997-447a-8f3d-b8081a14a77b" xlink:to="loc_srt_ProductsAndServicesDomain_503bf4af-1997-447a-8f3d-b8081a14a77b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_503bf4af-1997-447a-8f3d-b8081a14a77b" xlink:to="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufactureAndSupplyRevenueMember_75b97f3b-470c-4224-9226-b62430f107b1" xlink:href="aqst-20250331.xsd#aqst_ManufactureAndSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:to="loc_aqst_ManufactureAndSupplyRevenueMember_75b97f3b-470c-4224-9226-b62430f107b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAndRoyaltyRevenueMember_115e0aef-977b-48f1-b424-2d58f9185419" xlink:href="aqst-20250331.xsd#aqst_LicenseAndRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:to="loc_aqst_LicenseAndRoyaltyRevenueMember_115e0aef-977b-48f1-b424-2d58f9185419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_us-gaap_CreditFacilityAxis_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96" xlink:to="loc_us-gaap_CreditFacilityDomain_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96" xlink:to="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MonetizationAgreementMember_d55c8020-e0a1-4c70-a4cf-d427956c6051" xlink:href="aqst-20250331.xsd#aqst_MonetizationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:to="loc_aqst_MonetizationAgreementMember_d55c8020-e0a1-4c70-a4cf-d427956c6051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseSupplyAgreementMember_edf9912d-4f5d-4c94-a398-a02e049cafb7" xlink:href="aqst-20250331.xsd#aqst_LicenseSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:to="loc_aqst_LicenseSupplyAgreementMember_edf9912d-4f5d-4c94-a398-a02e049cafb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedMember_291efd89-28d0-4980-b8fb-3a183a6bc0c7" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:to="loc_aqst_AtnahsPharmaUKLimitedMember_291efd89-28d0-4980-b8fb-3a183a6bc0c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b0697945-eddf-4ca1-9f48-e0654ef28337" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_srt_CounterpartyNameAxis_b0697945-eddf-4ca1-9f48-e0654ef28337" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0697945-eddf-4ca1-9f48-e0654ef28337_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b0697945-eddf-4ca1-9f48-e0654ef28337" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b0697945-eddf-4ca1-9f48-e0654ef28337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b0697945-eddf-4ca1-9f48-e0654ef28337" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_IndiviorMember_3dd174bb-0ecd-4531-b60f-eccca53dd6a8" xlink:href="aqst-20250331.xsd#aqst_IndiviorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:to="loc_aqst_IndiviorMember_3dd174bb-0ecd-4531-b60f-eccca53dd6a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AssertioHoldingsIncMember_c4979798-aebd-421b-bb84-7bbf59d09f4a" xlink:href="aqst-20250331.xsd#aqst_AssertioHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:to="loc_aqst_AssertioHoldingsIncMember_c4979798-aebd-421b-bb84-7bbf59d09f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementTerm_4013d645-4bc1-45e0-a90b-cd27ce9ebf05" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_LicenseAgreementTerm_4013d645-4bc1-45e0-a90b-cd27ce9ebf05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AutomaticRenewalPeriodOfAgreement_ae1fb971-a1b2-4c7d-bdc2-32f6cda0a41b" xlink:href="aqst-20250331.xsd#aqst_AutomaticRenewalPeriodOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_AutomaticRenewalPeriodOfAgreement_ae1fb971-a1b2-4c7d-bdc2-32f6cda0a41b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c23a31f-c007-4bd5-87e3-0f1e1c464c76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c23a31f-c007-4bd5-87e3-0f1e1c464c76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_385f4ff4-5de1-432c-90d5-92a8dd544709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_Revenues_385f4ff4-5de1-432c-90d5-92a8dd544709" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_0b14dc20-eac3-4377-a09f-a02bd149fd9c" xlink:href="aqst-20250331.xsd#aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_0b14dc20-eac3-4377-a09f-a02bd149fd9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_e05557d6-32ed-46be-a4f8-850e1676d665" xlink:href="aqst-20250331.xsd#aqst_ProceedsFromSaleOfFutureRevenuesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_e05557d6-32ed-46be-a4f8-850e1676d665" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ContingentMonetizationAgreementMilestonePayment_e9d0f722-05cf-4740-9a49-82702fdd16f7" xlink:href="aqst-20250331.xsd#aqst_ContingentMonetizationAgreementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_ContingentMonetizationAgreementMilestonePayment_e9d0f722-05cf-4740-9a49-82702fdd16f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_8807ccfd-5638-423b-a80a-08784f5898be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_8807ccfd-5638-423b-a80a-08784f5898be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_b32bdadd-bbfc-4803-bb9d-07f8e9fb6c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_ProceedsFromCollaborators_b32bdadd-bbfc-4803-bb9d-07f8e9fb6c17" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#FinancialInstrumentsFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a2753d9-ca47-4fdb-830d-6e588148253d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a2753d9-ca47-4fdb-830d-6e588148253d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a2753d9-ca47-4fdb-830d-6e588148253d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a2753d9-ca47-4fdb-830d-6e588148253d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a2753d9-ca47-4fdb-830d-6e588148253d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a2753d9-ca47-4fdb-830d-6e588148253d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_9fc6dfad-c1b6-4454-ab6a-6049c357f855" xlink:href="aqst-20250331.xsd#aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:to="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_9fc6dfad-c1b6-4454-ab6a-6049c357f855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_08a0e465-d8ba-4a30-8e7b-60134cf80ccc" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_08a0e465-d8ba-4a30-8e7b-60134cf80ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_632dfe05-d4aa-4824-83c7-f076fba6b814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_632dfe05-d4aa-4824-83c7-f076fba6b814" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_632dfe05-d4aa-4824-83c7-f076fba6b814_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_632dfe05-d4aa-4824-83c7-f076fba6b814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_632dfe05-d4aa-4824-83c7-f076fba6b814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47730ce9-7a6a-47eb-92f7-7457be83eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_632dfe05-d4aa-4824-83c7-f076fba6b814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47730ce9-7a6a-47eb-92f7-7457be83eb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SecuritiesPurchaseAgreementMember_72f53ea2-8c9e-46d1-944b-f215f8058fd8" xlink:href="aqst-20250331.xsd#aqst_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47730ce9-7a6a-47eb-92f7-7457be83eb96" xlink:to="loc_aqst_SecuritiesPurchaseAgreementMember_72f53ea2-8c9e-46d1-944b-f215f8058fd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ExistingWarrantsMember_28a11a83-3ac3-498d-9141-34976a935236" xlink:href="aqst-20250331.xsd#aqst_ExistingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:to="loc_aqst_ExistingWarrantsMember_28a11a83-3ac3-498d-9141-34976a935236" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NewWarrantsMember_2e3923c4-29eb-49db-9234-abfd5a0b995a" xlink:href="aqst-20250331.xsd#aqst_NewWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:to="loc_aqst_NewWarrantsMember_2e3923c4-29eb-49db-9234-abfd5a0b995a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9b129342-74a1-4e11-8b53-275cf0ab1c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9b129342-74a1-4e11-8b53-275cf0ab1c78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9b129342-74a1-4e11-8b53-275cf0ab1c78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b129342-74a1-4e11-8b53-275cf0ab1c78" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9b129342-74a1-4e11-8b53-275cf0ab1c78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51610786-4f4f-438c-990a-db8233728171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b129342-74a1-4e11-8b53-275cf0ab1c78" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_51610786-4f4f-438c-990a-db8233728171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fbbd6130-706d-4561-b117-65138c6a69d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_51610786-4f4f-438c-990a-db8233728171" xlink:to="loc_us-gaap_SeniorNotesMember_fbbd6130-706d-4561-b117-65138c6a69d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e779346-d4dd-491e-8caf-9833758ff1ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_srt_RangeAxis_7e779346-d4dd-491e-8caf-9833758ff1ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e779346-d4dd-491e-8caf-9833758ff1ac_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7e779346-d4dd-491e-8caf-9833758ff1ac" xlink:to="loc_srt_RangeMember_7e779346-d4dd-491e-8caf-9833758ff1ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7e779346-d4dd-491e-8caf-9833758ff1ac" xlink:to="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89f3bba3-3e78-4441-8781-f34966357647" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:to="loc_srt_MinimumMember_89f3bba3-3e78-4441-8781-f34966357647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d7cb81c-a2cd-45f5-b5bf-3bfd89518ed6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:to="loc_srt_MaximumMember_2d7cb81c-a2cd-45f5-b5bf-3bfd89518ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d1daded4-8e94-4881-aeb6-fc3a78b254f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d1daded4-8e94-4881-aeb6-fc3a78b254f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants_90bc541f-5a9a-404b-87a7-f81af5f803b6" xlink:href="aqst-20250331.xsd#aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants_90bc541f-5a9a-404b-87a7-f81af5f803b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants_58fd7264-ee87-4684-aef7-1013c88bb57c" xlink:href="aqst-20250331.xsd#aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants_58fd7264-ee87-4684-aef7-1013c88bb57c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ac467cb7-ffdd-49fb-9a23-107a5d3adc82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ac467cb7-ffdd-49fb-9a23-107a5d3adc82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45c69882-8b1c-42c7-b9b7-a4cc6517c93c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45c69882-8b1c-42c7-b9b7-a4cc6517c93c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0a7d0381-f7ed-48f3-8570-2fa0a1887324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0a7d0381-f7ed-48f3-8570-2fa0a1887324" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_e71963bf-bae5-47d1-82bb-3fd2baaf148a" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_e71963bf-bae5-47d1-82bb-3fd2baaf148a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_fb45d389-66f8-446b-a898-8628c317b57c" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_fb45d389-66f8-446b-a898-8628c317b57c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60bb0086-63c3-4364-84f2-4db88e53a1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60bb0086-63c3-4364-84f2-4db88e53a1b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60bb0086-63c3-4364-84f2-4db88e53a1b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60bb0086-63c3-4364-84f2-4db88e53a1b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60bb0086-63c3-4364-84f2-4db88e53a1b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60bb0086-63c3-4364-84f2-4db88e53a1b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c1655bec-4de0-412f-b218-286a0d303da0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c1655bec-4de0-412f-b218-286a0d303da0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4ee4d050-33f0-443c-9b1a-926a823296fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4ee4d050-33f0-443c-9b1a-926a823296fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cd24c04e-e55a-4799-81cf-fe6e103249be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cd24c04e-e55a-4799-81cf-fe6e103249be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ComputerNetworkEquipmentAndSoftwareMember_f19d4ead-25a5-4050-bafa-bdda3d484468" xlink:href="aqst-20250331.xsd#aqst_ComputerNetworkEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_aqst_ComputerNetworkEquipmentAndSoftwareMember_f19d4ead-25a5-4050-bafa-bdda3d484468" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ae6c4eb2-9cfb-416d-abd0-ca9064b934b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_ConstructionInProgressMember_ae6c4eb2-9cfb-416d-abd0-ca9064b934b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d10c6c19-e73c-4688-a815-325b17d06735" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:to="loc_srt_RangeAxis_d10c6c19-e73c-4688-a815-325b17d06735" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d10c6c19-e73c-4688-a815-325b17d06735_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d10c6c19-e73c-4688-a815-325b17d06735" xlink:to="loc_srt_RangeMember_d10c6c19-e73c-4688-a815-325b17d06735_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d10c6c19-e73c-4688-a815-325b17d06735" xlink:to="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_76748285-8a10-44ff-b029-42cc6990da58" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:to="loc_srt_MinimumMember_76748285-8a10-44ff-b029-42cc6990da58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c663980-f2cb-457a-88c9-d5025c4cb21c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:to="loc_srt_MaximumMember_1c663980-f2cb-457a-88c9-d5025c4cb21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d5661c2b-a5f8-482a-8874-15af1703df5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d5661c2b-a5f8-482a-8874-15af1703df5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_af2bf387-6f74-496f-959c-382e63a58349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_af2bf387-6f74-496f-959c-382e63a58349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a1e16ed4-905b-48cd-9b3a-12c6eab35638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a1e16ed4-905b-48cd-9b3a-12c6eab35638" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_88a61970-a9f1-40ff-a5f6-435cbab48895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_88a61970-a9f1-40ff-a5f6-435cbab48895" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RightofUseAssetsandLeaseObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cf130643-aa95-4e76-a221-57f3c94bb0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cf130643-aa95-4e76-a221-57f3c94bb0c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ca0e9b9-c455-4d05-87bb-8ed1297b671b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cf130643-aa95-4e76-a221-57f3c94bb0c3" xlink:to="loc_srt_RangeAxis_8ca0e9b9-c455-4d05-87bb-8ed1297b671b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ca0e9b9-c455-4d05-87bb-8ed1297b671b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8ca0e9b9-c455-4d05-87bb-8ed1297b671b" xlink:to="loc_srt_RangeMember_8ca0e9b9-c455-4d05-87bb-8ed1297b671b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8ca0e9b9-c455-4d05-87bb-8ed1297b671b" xlink:to="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a873903-9b47-4651-bcc9-0c8a45b9f3a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:to="loc_srt_MinimumMember_4a873903-9b47-4651-bcc9-0c8a45b9f3a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89e2d575-452e-4f6b-b732-dee970eb6aa1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:to="loc_srt_MaximumMember_89e2d575-452e-4f6b-b732-dee970eb6aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfOperatingLeases_1e3b14ed-bd73-4732-b200-2082817c8732" xlink:href="aqst-20250331.xsd#aqst_NumberOfOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_aqst_NumberOfOperatingLeases_1e3b14ed-bd73-4732-b200-2082817c8732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8ef6ad36-f229-45cf-9695-aeabf972592e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8ef6ad36-f229-45cf-9695-aeabf972592e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_9cd97520-1b70-4198-83d8-360447b4e406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_9cd97520-1b70-4198-83d8-360447b4e406" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6d635293-3083-4146-8c64-8caae358271e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_OperatingLeaseCost_6d635293-3083-4146-8c64-8caae358271e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_73c7d510-f573-4250-ba3d-e7d1037ed59a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_VariableLeaseCost_73c7d510-f573-4250-ba3d-e7d1037ed59a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b3112e03-ba19-4b7c-959f-c708442ea96c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4b107af-a6b6-471b-b7f0-4ef256cedb77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b3112e03-ba19-4b7c-959f-c708442ea96c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4b107af-a6b6-471b-b7f0-4ef256cedb77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_375c2a59-c8a8-4e9f-b425-52a6f133a92f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4b107af-a6b6-471b-b7f0-4ef256cedb77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_375c2a59-c8a8-4e9f-b425-52a6f133a92f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_375c2a59-c8a8-4e9f-b425-52a6f133a92f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_375c2a59-c8a8-4e9f-b425-52a6f133a92f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_375c2a59-c8a8-4e9f-b425-52a6f133a92f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_375c2a59-c8a8-4e9f-b425-52a6f133a92f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c057372-8efc-49d4-bcec-307ee344406f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c057372-8efc-49d4-bcec-307ee344406f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_54defabd-dc7b-4528-82f1-8acbce650f37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:to="loc_us-gaap_PatentsMember_54defabd-dc7b-4528-82f1-8acbce650f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b3112e03-ba19-4b7c-959f-c708442ea96c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_66a7093e-6fa0-4942-bde5-77c441bea610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_66a7093e-6fa0-4942-bde5-77c441bea610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_55caea66-b2cc-4c1f-9c56-9be964a9fbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_55caea66-b2cc-4c1f-9c56-9be964a9fbfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3a874c18-f812-4188-a711-84f81ff6e320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3a874c18-f812-4188-a711-84f81ff6e320" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#OtherNoncurrentAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:to="loc_srt_ProductOrServiceAxis_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a" xlink:to="loc_srt_ProductsAndServicesDomain_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_012e3234-0ed1-46f2-b0e9-4936849916c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a" xlink:to="loc_srt_ProductsAndServicesDomain_012e3234-0ed1-46f2-b0e9-4936849916c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_81dd7869-7a74-45a8-9da6-505c372080ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_012e3234-0ed1-46f2-b0e9-4936849916c2" xlink:to="loc_us-gaap_RoyaltyMember_81dd7869-7a74-45a8-9da6-505c372080ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba9467fa-7e08-40c8-a412-08bf3caa78e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba9467fa-7e08-40c8-a412-08bf3caa78e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_341cd7ac-0f52-48f8-9eb3-684f5a04b235" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba9467fa-7e08-40c8-a412-08bf3caa78e7" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_341cd7ac-0f52-48f8-9eb3-684f5a04b235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97753bfa-da72-41cd-85c5-4d30a2189b15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97753bfa-da72-41cd-85c5-4d30a2189b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfGuaranteedRoyaltyPayments_b9b5c0ca-aa62-4bc5-9a46-f61247cd885b" xlink:href="aqst-20250331.xsd#aqst_NumberOfGuaranteedRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_aqst_NumberOfGuaranteedRoyaltyPayments_b9b5c0ca-aa62-4bc5-9a46-f61247cd885b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MinimumAnnualRoyaltyReceivable_56b53978-cfc7-4dc0-8b10-e3ef9da1b02b" xlink:href="aqst-20250331.xsd#aqst_MinimumAnnualRoyaltyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_aqst_MinimumAnnualRoyaltyReceivable_56b53978-cfc7-4dc0-8b10-e3ef9da1b02b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfAnnualRoyaltyPaymentsReceivable_4f860e89-b718-4252-949e-305cf5b876fc" xlink:href="aqst-20250331.xsd#aqst_NumberOfAnnualRoyaltyPaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_aqst_NumberOfAnnualRoyaltyPaymentsReceivable_4f860e89-b718-4252-949e-305cf5b876fc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/AccruedExpensesNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#AccruedExpensesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/AccruedExpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_8203c8b8-2184-491e-9972-a853e56f5706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_8203c8b8-2184-491e-9972-a853e56f5706" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_911679b6-45c5-4747-b27a-c3e4d521a0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:to="loc_us-gaap_DebtInstrumentAxis_911679b6-45c5-4747-b27a-c3e4d521a0c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_911679b6-45c5-4747-b27a-c3e4d521a0c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_911679b6-45c5-4747-b27a-c3e4d521a0c5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_911679b6-45c5-4747-b27a-c3e4d521a0c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35586e9e-df56-4484-8f48-8bac883345b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_911679b6-45c5-4747-b27a-c3e4d521a0c5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35586e9e-df56-4484-8f48-8bac883345b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_471d6c1e-87d2-4698-b2e0-5e984e36488f" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35586e9e-df56-4484-8f48-8bac883345b1" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_471d6c1e-87d2-4698-b2e0-5e984e36488f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f7eb3abe-5342-444b-95f8-f60558d74902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f7eb3abe-5342-444b-95f8-f60558d74902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7eb3abe-5342-444b-95f8-f60558d74902_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f7eb3abe-5342-444b-95f8-f60558d74902" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7eb3abe-5342-444b-95f8-f60558d74902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7b3ac934-29ce-4e9a-add8-aeff366eae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f7eb3abe-5342-444b-95f8-f60558d74902" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7b3ac934-29ce-4e9a-add8-aeff366eae8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f4f203bc-f9c8-446f-a4a1-06fd586fe986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7b3ac934-29ce-4e9a-add8-aeff366eae8f" xlink:to="loc_us-gaap_SeniorNotesMember_f4f203bc-f9c8-446f-a4a1-06fd586fe986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25565c45-3868-4a51-b707-5d9c336568cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_8203c8b8-2184-491e-9972-a853e56f5706" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25565c45-3868-4a51-b707-5d9c336568cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d628401c-105a-4ae3-9c07-32476b4a532c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d628401c-105a-4ae3-9c07-32476b4a532c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d628401c-105a-4ae3-9c07-32476b4a532c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d628401c-105a-4ae3-9c07-32476b4a532c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d628401c-105a-4ae3-9c07-32476b4a532c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d628401c-105a-4ae3-9c07-32476b4a532c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_db2b838d-9841-47f3-9ca3-0cb0637c967e" xlink:href="aqst-20250331.xsd#aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:to="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_db2b838d-9841-47f3-9ca3-0cb0637c967e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_23c1ce08-76da-4b06-95fe-0a94a8e4a7de" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_23c1ce08-76da-4b06-95fe-0a94a8e4a7de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsMember_1122f1a7-e687-4617-8eb0-5b43b871d84a" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_23c1ce08-76da-4b06-95fe-0a94a8e4a7de" xlink:to="loc_aqst_RoyaltyObligationsMember_1122f1a7-e687-4617-8eb0-5b43b871d84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ABLFacilityMember_86b6ba0f-0331-4dfe-befd-e6797d016e98" xlink:href="aqst-20250331.xsd#aqst_ABLFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:to="loc_aqst_ABLFacilityMember_86b6ba0f-0331-4dfe-befd-e6797d016e98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2e527790-d02d-436d-961c-435c16eab2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2e527790-d02d-436d-961c-435c16eab2fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2e527790-d02d-436d-961c-435c16eab2fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2e527790-d02d-436d-961c-435c16eab2fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2e527790-d02d-436d-961c-435c16eab2fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2e527790-d02d-436d-961c-435c16eab2fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f8a252bf-33bb-40e6-af59-a007799a095c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:to="loc_us-gaap_SeniorNotesMember_f8a252bf-33bb-40e6-af59-a007799a095c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_314fea0a-df1f-4a03-8d95-a9d722493e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:to="loc_us-gaap_UnsecuredDebtMember_314fea0a-df1f-4a03-8d95-a9d722493e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b69a108-7969-49c6-931a-e6a17afce68b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_srt_RangeAxis_7b69a108-7969-49c6-931a-e6a17afce68b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b69a108-7969-49c6-931a-e6a17afce68b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b69a108-7969-49c6-931a-e6a17afce68b" xlink:to="loc_srt_RangeMember_7b69a108-7969-49c6-931a-e6a17afce68b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b69a108-7969-49c6-931a-e6a17afce68b" xlink:to="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b4520ee1-6203-4616-9d22-d4640d1cf828" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:to="loc_srt_MaximumMember_b4520ee1-6203-4616-9d22-d4640d1cf828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b0e8087-87f2-483f-af56-257b4e0a0c3c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:to="loc_srt_MinimumMember_3b0e8087-87f2-483f-af56-257b4e0a0c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtCovenantRedemptionScenarioAxis_21814381-ef9b-4862-b414-9fe66f1ebfb6" xlink:href="aqst-20250331.xsd#aqst_DebtCovenantRedemptionScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_aqst_DebtCovenantRedemptionScenarioAxis_21814381-ef9b-4862-b414-9fe66f1ebfb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtCovenantRedemptionScenarioDomain_21814381-ef9b-4862-b414-9fe66f1ebfb6_default" xlink:href="aqst-20250331.xsd#aqst_DebtCovenantRedemptionScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioAxis_21814381-ef9b-4862-b414-9fe66f1ebfb6" xlink:to="loc_aqst_DebtCovenantRedemptionScenarioDomain_21814381-ef9b-4862-b414-9fe66f1ebfb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:href="aqst-20250331.xsd#aqst_DebtCovenantRedemptionScenarioDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioAxis_21814381-ef9b-4862-b414-9fe66f1ebfb6" xlink:to="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RedemptionScenario1Member_4e93efde-c16c-4740-9a71-f6d891a9e6fc" xlink:href="aqst-20250331.xsd#aqst_RedemptionScenario1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:to="loc_aqst_RedemptionScenario1Member_4e93efde-c16c-4740-9a71-f6d891a9e6fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RedemptionScenario2Member_a9d6102a-48ae-43ce-8dd9-26d2bf92b2ea" xlink:href="aqst-20250331.xsd#aqst_RedemptionScenario2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:to="loc_aqst_RedemptionScenario2Member_a9d6102a-48ae-43ce-8dd9-26d2bf92b2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_351ecb1c-619f-4ccb-83b2-dae9b4fbb8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_351ecb1c-619f-4ccb-83b2-dae9b4fbb8a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_dbc24bf6-a5ba-481e-b185-900bdb879bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_dbc24bf6-a5ba-481e-b185-900bdb879bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6ea9706c-b7ae-400a-b4b6-0b2bf3b75b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6ea9706c-b7ae-400a-b4b6-0b2bf3b75b05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_936b72ec-56fe-4363-afd4-27ee79694493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_936b72ec-56fe-4363-afd4-27ee79694493" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bed82659-b4ba-4c64-9838-0e53d89fc3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bed82659-b4ba-4c64-9838-0e53d89fc3df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7cf75ef8-c332-4cfb-91bc-044291d61bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7cf75ef8-c332-4cfb-91bc-044291d61bef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate_abfded47-1576-48af-b143-7d0a7fa23cf7" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate_abfded47-1576-48af-b143-7d0a7fa23cf7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold_a44f62cc-f12c-4d01-bee6-8d0ca0940563" xlink:href="aqst-20250331.xsd#aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold_a44f62cc-f12c-4d01-bee6-8d0ca0940563" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit_184227ab-b4ca-416c-9b11-6d7666f5fd11" xlink:href="aqst-20250331.xsd#aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit_184227ab-b4ca-416c-9b11-6d7666f5fd11" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_acdaad7e-15f4-47a0-bbd1-e4f6f6ff54ff" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_acdaad7e-15f4-47a0-bbd1-e4f6f6ff54ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_edc3fd02-d620-4e10-81ba-163b33951520" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_edc3fd02-d620-4e10-81ba-163b33951520" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage_7ddc7273-5a49-46d1-9896-a900610136e4" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentInterestRateChangeInEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage_7ddc7273-5a49-46d1-9896-a900610136e4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_81cb4d34-1621-4818-bb7a-dc7357e48a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_LongTermDebtFairValue_81cb4d34-1621-4818-bb7a-dc7357e48a90" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_54f52a42-94ad-498f-b4ee-b75bc5a62431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_54f52a42-94ad-498f-b4ee-b75bc5a62431" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_92c63531-f5c4-4261-84e9-853d19081ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_92c63531-f5c4-4261-84e9-853d19081ed8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_3b2e0a3c-a893-427d-b7fb-2add96075d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_3b2e0a3c-a893-427d-b7fb-2add96075d57" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentExitFee_c12fd1ed-3910-4ed9-a9a4-e749ddb06ae6" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentExitFee_c12fd1ed-3910-4ed9-a9a4-e749ddb06ae6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b4f34e29-2161-40f5-a02a-d80e6a235993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b4f34e29-2161-40f5-a02a-d80e6a235993" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ecef3d98-b941-4a23-b1da-55ab185b2f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ecef3d98-b941-4a23-b1da-55ab185b2f1f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_eab694ed-8f26-418a-9d87-2c6b0536e328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_eab694ed-8f26-418a-9d87-2c6b0536e328" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtScheduleOfRoyaltyRightAgreementsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_37651ba6-0129-4676-9ea0-a55f22ae9dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_37651ba6-0129-4676-9ea0-a55f22ae9dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_37651ba6-0129-4676-9ea0-a55f22ae9dc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_37651ba6-0129-4676-9ea0-a55f22ae9dc5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_37651ba6-0129-4676-9ea0-a55f22ae9dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_37651ba6-0129-4676-9ea0-a55f22ae9dc5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1b22752d-9483-4f38-86a4-e6ba64527862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1b22752d-9483-4f38-86a4-e6ba64527862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MeasurementInputProbabilityOfSuccessMember_d3870758-bfcd-4f9c-95ed-787050b922d6" xlink:href="aqst-20250331.xsd#aqst_MeasurementInputProbabilityOfSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:to="loc_aqst_MeasurementInputProbabilityOfSuccessMember_d3870758-bfcd-4f9c-95ed-787050b922d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_49c0f702-4fc9-4cdd-82a1-81c995211c55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:to="loc_us-gaap_DebtInstrumentAxis_49c0f702-4fc9-4cdd-82a1-81c995211c55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_49c0f702-4fc9-4cdd-82a1-81c995211c55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_49c0f702-4fc9-4cdd-82a1-81c995211c55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_49c0f702-4fc9-4cdd-82a1-81c995211c55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35c35411-e105-45b5-b9d6-1522f44523b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_49c0f702-4fc9-4cdd-82a1-81c995211c55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35c35411-e105-45b5-b9d6-1522f44523b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_15101578-3547-40d4-8404-8368d7734cb5" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35c35411-e105-45b5-b9d6-1522f44523b0" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_15101578-3547-40d4-8404-8368d7734cb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9021a503-9898-4f5e-8338-c92a2470b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9021a503-9898-4f5e-8338-c92a2470b3f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9021a503-9898-4f5e-8338-c92a2470b3f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9021a503-9898-4f5e-8338-c92a2470b3f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9021a503-9898-4f5e-8338-c92a2470b3f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ee7a3f9e-f602-441e-b8fd-277775d316f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9021a503-9898-4f5e-8338-c92a2470b3f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ee7a3f9e-f602-441e-b8fd-277775d316f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_53fc9b6a-a539-4214-a787-4a7fe07b3e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ee7a3f9e-f602-441e-b8fd-277775d316f2" xlink:to="loc_us-gaap_SeniorNotesMember_53fc9b6a-a539-4214-a787-4a7fe07b3e83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMeasurementInput_d9ae2176-90ec-4de6-aba8-a4d10f50b6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:to="loc_us-gaap_LongTermDebtMeasurementInput_d9ae2176-90ec-4de6-aba8-a4d10f50b6ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b852a2ec-92b0-4dd7-9642-6170d4f14c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b852a2ec-92b0-4dd7-9642-6170d4f14c0f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_46465ca7-4785-4b3e-afbc-81e361476007" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:to="loc_us-gaap_DebtInstrumentAxis_46465ca7-4785-4b3e-afbc-81e361476007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46465ca7-4785-4b3e-afbc-81e361476007_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_46465ca7-4785-4b3e-afbc-81e361476007" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46465ca7-4785-4b3e-afbc-81e361476007_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_46465ca7-4785-4b3e-afbc-81e361476007" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_68a17fe3-64d4-4d9f-b804-ab7a20edafc6" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_68a17fe3-64d4-4d9f-b804-ab7a20edafc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsMember_3a26618a-17c6-47b6-be8c-8e465f534af4" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:to="loc_aqst_RoyaltyObligationsMember_3a26618a-17c6-47b6-be8c-8e465f534af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_40acf08e-f37a-4229-ad1f-46ed116ab1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_40acf08e-f37a-4229-ad1f-46ed116ab1d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_40acf08e-f37a-4229-ad1f-46ed116ab1d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_40acf08e-f37a-4229-ad1f-46ed116ab1d4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_40acf08e-f37a-4229-ad1f-46ed116ab1d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_40acf08e-f37a-4229-ad1f-46ed116ab1d4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_827458dd-8dfe-4e71-9813-fe41abe1eea7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:to="loc_us-gaap_SeniorNotesMember_827458dd-8dfe-4e71-9813-fe41abe1eea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_e02dcb9b-b143-4810-b451-77f1e1874d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:to="loc_us-gaap_UnsecuredDebtMember_e02dcb9b-b143-4810-b451-77f1e1874d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_06dec29c-edb0-42b1-b55d-5d57201e43ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_06dec29c-edb0-42b1-b55d-5d57201e43ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_80a72835-1f4c-442d-a8ff-9d4b80b85a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_80a72835-1f4c-442d-a8ff-9d4b80b85a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8de2a1ae-30a3-4322-9b1d-cb9c24953a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8de2a1ae-30a3-4322-9b1d-cb9c24953a81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8a1452de-c203-4c32-be5a-6dbcdfb74757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8a1452de-c203-4c32-be5a-6dbcdfb74757" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c270b29d-deee-44a9-b95e-e943ea7248a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c270b29d-deee-44a9-b95e-e943ea7248a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3c54c36f-aa41-4a20-9a2a-ec2dbbc311bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_117f3825-f31b-48f7-9a1a-ef0b2b445f96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d61ff549-0b13-49cd-95a0-07730458d8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_LongTermDebtCurrent_d61ff549-0b13-49cd-95a0-07730458d8f3" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/WarrantsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#WarrantsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/WarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:to="loc_us-gaap_DebtInstrumentAxis_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8936a119-73df-48f6-9e7a-2371fe5e41f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8936a119-73df-48f6-9e7a-2371fe5e41f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_721f8847-045e-4e7f-916c-3b5358399c9d" xlink:href="aqst-20250331.xsd#aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8936a119-73df-48f6-9e7a-2371fe5e41f1" xlink:to="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_721f8847-045e-4e7f-916c-3b5358399c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ca6f36c-8e19-4813-af49-28ba3ffca225" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:to="loc_srt_RangeAxis_3ca6f36c-8e19-4813-af49-28ba3ffca225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ca6f36c-8e19-4813-af49-28ba3ffca225_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ca6f36c-8e19-4813-af49-28ba3ffca225" xlink:to="loc_srt_RangeMember_3ca6f36c-8e19-4813-af49-28ba3ffca225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ca6f36c-8e19-4813-af49-28ba3ffca225" xlink:to="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bdea1c4-8f0c-494f-aa26-eab3a45b2dec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:to="loc_srt_MinimumMember_7bdea1c4-8f0c-494f-aa26-eab3a45b2dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ca09f40-e8df-4278-8988-dc2784364059" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:to="loc_srt_MaximumMember_6ca09f40-e8df-4278-8988-dc2784364059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7aa73f8b-4ab7-4038-b897-3b231ba63e66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7aa73f8b-4ab7-4038-b897-3b231ba63e66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7aa73f8b-4ab7-4038-b897-3b231ba63e66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7aa73f8b-4ab7-4038-b897-3b231ba63e66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7aa73f8b-4ab7-4038-b897-3b231ba63e66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7aa73f8b-4ab7-4038-b897-3b231ba63e66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_FirstAdditionalWarrantOfferingMember_1955d935-2391-4637-b348-e2b708317a72" xlink:href="aqst-20250331.xsd#aqst_FirstAdditionalWarrantOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_FirstAdditionalWarrantOfferingMember_1955d935-2391-4637-b348-e2b708317a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InitialWarrantOfferingMember_9e89593b-f608-47d4-bf62-6718f9acffda" xlink:href="aqst-20250331.xsd#aqst_InitialWarrantOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_InitialWarrantOfferingMember_9e89593b-f608-47d4-bf62-6718f9acffda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PreFundedWarrantsMember_f8454999-642b-45fb-90e7-b7c449b8df81" xlink:href="aqst-20250331.xsd#aqst_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_PreFundedWarrantsMember_f8454999-642b-45fb-90e7-b7c449b8df81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CommonStockWarrantsMember_0e35deae-f235-458c-be3a-c359eef80dee" xlink:href="aqst-20250331.xsd#aqst_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_CommonStockWarrantsMember_0e35deae-f235-458c-be3a-c359eef80dee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ExistingWarrantsMember_a1987a2e-5f3e-4f56-adb2-fb9b56feb766" xlink:href="aqst-20250331.xsd#aqst_ExistingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_ExistingWarrantsMember_a1987a2e-5f3e-4f56-adb2-fb9b56feb766" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NewWarrantsMember_8982666f-1fd9-4c91-93c7-5b24c1d22a62" xlink:href="aqst-20250331.xsd#aqst_NewWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_NewWarrantsMember_8982666f-1fd9-4c91-93c7-5b24c1d22a62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants0.96ExercisePriceMember_c191beb6-a813-4986-b024-793fdf74f8b7" xlink:href="aqst-20250331.xsd#aqst_Warrants0.96ExercisePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_Warrants0.96ExercisePriceMember_c191beb6-a813-4986-b024-793fdf74f8b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants4.25ExercisePriceMember_95159b9f-7357-4570-adfa-8a3cbcf2f562" xlink:href="aqst-20250331.xsd#aqst_Warrants4.25ExercisePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_Warrants4.25ExercisePriceMember_95159b9f-7357-4570-adfa-8a3cbcf2f562" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants5.38ExercisePriceMember_daf51399-ded6-4586-90b0-653f92ce9a51" xlink:href="aqst-20250331.xsd#aqst_Warrants5.38ExercisePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_Warrants5.38ExercisePriceMember_daf51399-ded6-4586-90b0-653f92ce9a51" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be297a2d-651e-40f2-8e97-9bb198b94c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be297a2d-651e-40f2-8e97-9bb198b94c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfddab3-59fc-4b8a-ab3b-3ce5c0ea31a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfddab3-59fc-4b8a-ab3b-3ce5c0ea31a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_4e41b306-bfa7-4e1a-8c58-180299bea48c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_4e41b306-bfa7-4e1a-8c58-180299bea48c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ClassOfWarrantOrRightWarrantsExercised_09dd9c7b-1cdb-4adb-ad6a-4b279b8e8e6e" xlink:href="aqst-20250331.xsd#aqst_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_aqst_ClassOfWarrantOrRightWarrantsExercised_09dd9c7b-1cdb-4adb-ad6a-4b279b8e8e6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b34358-ba3c-452d-a1af-768b1119b65d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b34358-ba3c-452d-a1af-768b1119b65d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_591d380c-1f21-451b-a741-7ea563121ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_591d380c-1f21-451b-a741-7ea563121ed3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_8bca6142-37a4-4c55-bf6d-5a8f76fa4d70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_8bca6142-37a4-4c55-bf6d-5a8f76fa4d70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_7d617baf-575b-4274-924f-8c202a7c2d13" xlink:href="aqst-20250331.xsd#aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_7d617baf-575b-4274-924f-8c202a7c2d13" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a6ee5d40-4790-4d12-8caf-e2c6da6b1b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a6ee5d40-4790-4d12-8caf-e2c6da6b1b3f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#SaleofFutureRevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2e226114-23c4-40ed-aa7d-4fa41b31c6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_us-gaap_CreditFacilityAxis_2e226114-23c4-40ed-aa7d-4fa41b31c6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2e226114-23c4-40ed-aa7d-4fa41b31c6ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2e226114-23c4-40ed-aa7d-4fa41b31c6ff" xlink:to="loc_us-gaap_CreditFacilityDomain_2e226114-23c4-40ed-aa7d-4fa41b31c6ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_102d97f1-7661-4101-969e-9b727baf5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2e226114-23c4-40ed-aa7d-4fa41b31c6ff" xlink:to="loc_us-gaap_CreditFacilityDomain_102d97f1-7661-4101-969e-9b727baf5d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MonetizationAgreementMember_dc7ea7c6-2f02-4f69-b592-918f28709245" xlink:href="aqst-20250331.xsd#aqst_MonetizationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_102d97f1-7661-4101-969e-9b727baf5d2b" xlink:to="loc_aqst_MonetizationAgreementMember_dc7ea7c6-2f02-4f69-b592-918f28709245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarathonPangolinRoyaltyLLCMember_e36c42af-0438-4263-bf35-5a89d0168766" xlink:href="aqst-20250331.xsd#aqst_MarathonPangolinRoyaltyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:to="loc_aqst_MarathonPangolinRoyaltyLLCMember_e36c42af-0438-4263-bf35-5a89d0168766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_f45864a7-fc4a-4f80-b31c-75f1d986e79d" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_f45864a7-fc4a-4f80-b31c-75f1d986e79d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0361ad0-8c17-42da-b4e1-88e666530150" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_srt_RangeAxis_c0361ad0-8c17-42da-b4e1-88e666530150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0361ad0-8c17-42da-b4e1-88e666530150_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c0361ad0-8c17-42da-b4e1-88e666530150" xlink:to="loc_srt_RangeMember_c0361ad0-8c17-42da-b4e1-88e666530150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5aaa98f7-be99-411e-b07d-2ab92a62514f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c0361ad0-8c17-42da-b4e1-88e666530150" xlink:to="loc_srt_RangeMember_5aaa98f7-be99-411e-b07d-2ab92a62514f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9214f361-129d-4e17-8409-28a575b88a0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5aaa98f7-be99-411e-b07d-2ab92a62514f" xlink:to="loc_srt_MaximumMember_9214f361-129d-4e17-8409-28a575b88a0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b876e3b-d098-48a8-9880-de7dfb1b7f35" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_srt_ProductOrServiceAxis_0b876e3b-d098-48a8-9880-de7dfb1b7f35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b876e3b-d098-48a8-9880-de7dfb1b7f35_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0b876e3b-d098-48a8-9880-de7dfb1b7f35" xlink:to="loc_srt_ProductsAndServicesDomain_0b876e3b-d098-48a8-9880-de7dfb1b7f35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e26b09ef-ed47-4c8d-95d3-5d979907c3d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0b876e3b-d098-48a8-9880-de7dfb1b7f35" xlink:to="loc_srt_ProductsAndServicesDomain_e26b09ef-ed47-4c8d-95d3-5d979907c3d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_46145d18-d347-4866-9b40-cf77a1539ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e26b09ef-ed47-4c8d-95d3-5d979907c3d1" xlink:to="loc_us-gaap_RoyaltyMember_46145d18-d347-4866-9b40-cf77a1539ce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_32460d5f-6f63-4d01-9a59-f7cc75a3f3af" xlink:href="aqst-20250331.xsd#aqst_ProceedsFromSaleOfFutureRevenuesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_32460d5f-6f63-4d01-9a59-f7cc75a3f3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ContingentMonetizationAgreementMilestonePayment_86a2d56e-9d7d-4220-870a-d4738e740480" xlink:href="aqst-20250331.xsd#aqst_ContingentMonetizationAgreementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_ContingentMonetizationAgreementMilestonePayment_86a2d56e-9d7d-4220-870a-d4738e740480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_b4820201-6f73-47ab-b7e0-910e2de82edc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_b4820201-6f73-47ab-b7e0-910e2de82edc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2800c2e-6a03-4130-8f6b-84d5827291fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2800c2e-6a03-4130-8f6b-84d5827291fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MinimumAnnualRoyaltyReceivable_1ad9e36f-92b4-4a01-8a4c-09c07fd9715b" xlink:href="aqst-20250331.xsd#aqst_MinimumAnnualRoyaltyReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_MinimumAnnualRoyaltyReceivable_1ad9e36f-92b4-4a01-8a4c-09c07fd9715b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5e42e25-abad-489f-94e8-72c92f965beb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5e42e25-abad-489f-94e8-72c92f965beb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_63d7dabd-2bef-4a5c-925d-66a1e32de9f3" xlink:href="aqst-20250331.xsd#aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_63d7dabd-2bef-4a5c-925d-66a1e32de9f3" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#SaleofFutureRevenueRoyaltyObligationDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_46bea0bd-bf0c-44a2-873d-715fea6a0bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_46bea0bd-bf0c-44a2-873d-715fea6a0bbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c6bba908-493b-4fab-8458-eccbe663ad65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46bea0bd-bf0c-44a2-873d-715fea6a0bbc" xlink:to="loc_srt_ProductOrServiceAxis_c6bba908-493b-4fab-8458-eccbe663ad65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c6bba908-493b-4fab-8458-eccbe663ad65_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c6bba908-493b-4fab-8458-eccbe663ad65" xlink:to="loc_srt_ProductsAndServicesDomain_c6bba908-493b-4fab-8458-eccbe663ad65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1c127c8-224c-404a-bc7a-860bcc8043ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c6bba908-493b-4fab-8458-eccbe663ad65" xlink:to="loc_srt_ProductsAndServicesDomain_f1c127c8-224c-404a-bc7a-860bcc8043ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_4020ed36-5fad-40d8-b787-cf23e94088d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1c127c8-224c-404a-bc7a-860bcc8043ae" xlink:to="loc_us-gaap_RoyaltyMember_4020ed36-5fad-40d8-b787-cf23e94088d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:href="aqst-20250331.xsd#aqst_SaleOfFutureRevenueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:to="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyalties_869b8374-694c-4af6-af58-9969ecd5caac" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:to="loc_aqst_LiabilitiesSaleOfFutureRoyalties_869b8374-694c-4af6-af58-9969ecd5caac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89f3320d-51d4-459b-9308-dcf0ddb1c05d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89f3320d-51d4-459b-9308-dcf0ddb1c05d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9ff381f1-4bae-425e-b9d3-dab9f6a49911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9ff381f1-4bae-425e-b9d3-dab9f6a49911" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyalties_7bc6fbeb-692f-459b-a478-9bfcab11f16e" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyalties"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_753a840e-a100-4b2b-8de5-c1174a6fbfad" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:to="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_753a840e-a100-4b2b-8de5-c1174a6fbfad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#NetLossPerShareBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_642055aa-6495-4c27-9ae2-f6cb4da83168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:to="loc_us-gaap_AwardTypeAxis_642055aa-6495-4c27-9ae2-f6cb4da83168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_642055aa-6495-4c27-9ae2-f6cb4da83168_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_642055aa-6495-4c27-9ae2-f6cb4da83168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_642055aa-6495-4c27-9ae2-f6cb4da83168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_642055aa-6495-4c27-9ae2-f6cb4da83168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_932885f0-69d5-4ff2-b79f-1a7852b425eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_932885f0-69d5-4ff2-b79f-1a7852b425eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69978515-ae52-450f-b558-85c19e801943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69978515-ae52-450f-b558-85c19e801943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_102d56ca-e300-48fa-93fb-9e8e7aca027d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_102d56ca-e300-48fa-93fb-9e8e7aca027d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_102d56ca-e300-48fa-93fb-9e8e7aca027d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_102d56ca-e300-48fa-93fb-9e8e7aca027d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_102d56ca-e300-48fa-93fb-9e8e7aca027d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_102d56ca-e300-48fa-93fb-9e8e7aca027d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_64f3860f-9b72-44be-b7fe-8a7279c09bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:to="loc_us-gaap_EmployeeStockOptionMember_64f3860f-9b72-44be-b7fe-8a7279c09bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a921b206-2194-4239-a275-1ba5df97c769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a921b206-2194-4239-a275-1ba5df97c769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c8c5cec3-a9ba-449b-8bbd-10d2f73ecf37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:to="loc_us-gaap_WarrantMember_c8c5cec3-a9ba-449b-8bbd-10d2f73ecf37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f7eacf2-4a27-4b48-b29e-b244e71d4d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_NetIncomeLoss_2f7eacf2-4a27-4b48-b29e-b244e71d4d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bb6cadf3-7581-4aac-892f-207bc4bea2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bb6cadf3-7581-4aac-892f-207bc4bea2b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94c56e4d-5537-4fa2-8e49-aa9c51a9a692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94c56e4d-5537-4fa2-8e49-aa9c51a9a692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5d34589f-e507-4192-84e1-6ba0d91347a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_EarningsPerShareBasic_5d34589f-e507-4192-84e1-6ba0d91347a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fdb324ad-2f13-47a3-ad88-675d0e6b421e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fdb324ad-2f13-47a3-ad88-675d0e6b421e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f3744f-cc09-4c36-8cff-6cd294204908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f3744f-cc09-4c36-8cff-6cd294204908" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/ShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4caec3f1-71a6-4e14-880b-47e545e97266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4caec3f1-71a6-4e14-880b-47e545e97266" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33dc1223-90b4-46ea-a8c7-02ac5008753b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33dc1223-90b4-46ea-a8c7-02ac5008753b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33dc1223-90b4-46ea-a8c7-02ac5008753b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33dc1223-90b4-46ea-a8c7-02ac5008753b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33dc1223-90b4-46ea-a8c7-02ac5008753b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33dc1223-90b4-46ea-a8c7-02ac5008753b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufacturingAndSupplyMember_2c1227f2-4c6f-44ec-901b-5a3ac075f269" xlink:href="aqst-20250331.xsd#aqst_ManufacturingAndSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:to="loc_aqst_ManufacturingAndSupplyMember_2c1227f2-4c6f-44ec-901b-5a3ac075f269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a07addca-2f26-4274-b323-ecaf7514dfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a07addca-2f26-4274-b323-ecaf7514dfb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab2313d5-8adb-4859-8a31-6768d9c51e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab2313d5-8adb-4859-8a31-6768d9c51e50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc114d85-40c8-41e1-b574-7a0e799f63a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:to="loc_us-gaap_AwardTypeAxis_dc114d85-40c8-41e1-b574-7a0e799f63a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc114d85-40c8-41e1-b574-7a0e799f63a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dc114d85-40c8-41e1-b574-7a0e799f63a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc114d85-40c8-41e1-b574-7a0e799f63a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dc114d85-40c8-41e1-b574-7a0e799f63a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f361be88-9f42-4443-b276-f061e9cac9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f361be88-9f42-4443-b276-f061e9cac9ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_679ed19e-a322-456f-bcf0-83b7e9fed370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_679ed19e-a322-456f-bcf0-83b7e9fed370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_5de8cb8f-5d83-4e3a-9a91-c08697b398f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4caec3f1-71a6-4e14-880b-47e545e97266" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_5de8cb8f-5d83-4e3a-9a91-c08697b398f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3dcef7b-da26-471d-8ee6-b2e131e36ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5de8cb8f-5d83-4e3a-9a91-c08697b398f4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3dcef7b-da26-471d-8ee6-b2e131e36ef1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationRestrictedStockUnitAwardsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb2ca10-feed-45d9-a64d-b84fcdb828d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb2ca10-feed-45d9-a64d-b84fcdb828d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5a2350b5-62cb-421f-9136-28b24b427d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb2ca10-feed-45d9-a64d-b84fcdb828d3" xlink:to="loc_us-gaap_AwardTypeAxis_5a2350b5-62cb-421f-9136-28b24b427d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a2350b5-62cb-421f-9136-28b24b427d5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5a2350b5-62cb-421f-9136-28b24b427d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a2350b5-62cb-421f-9136-28b24b427d5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3358c772-28d5-40b1-b78e-c05ab036b945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5a2350b5-62cb-421f-9136-28b24b427d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3358c772-28d5-40b1-b78e-c05ab036b945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_072860c7-ab2c-4ca5-bade-e944f9a89287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3358c772-28d5-40b1-b78e-c05ab036b945" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_072860c7-ab2c-4ca5-bade-e944f9a89287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7ca60f74-fe8e-4d18-8cd5-a3e17037f778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7ca60f74-fe8e-4d18-8cd5-a3e17037f778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e581c3f4-9811-4902-a0ba-2446c4323b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e581c3f4-9811-4902-a0ba-2446c4323b23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fee8a409-8508-4e8b-9519-5de4ec8d0ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fee8a409-8508-4e8b-9519-5de4ec8d0ad4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b3c2bff-9287-4bc0-b1bb-9cf03efe100a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b3c2bff-9287-4bc0-b1bb-9cf03efe100a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4afd384d-a118-4005-ab63-c0fcef216136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_0ac1edda-be1f-480a-8a93-c77d4f75ef53" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_0ac1edda-be1f-480a-8a93-c77d4f75ef53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64c674a3-4a78-4430-b15c-da75f37a1fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64c674a3-4a78-4430-b15c-da75f37a1fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ba3841a-0b7c-4eef-bfa4-8b1c639ce45a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ba3841a-0b7c-4eef-bfa4-8b1c639ce45a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3384a6d-ad97-4fcd-96de-e7fdaba8e1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3384a6d-ad97-4fcd-96de-e7fdaba8e1ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_555942fd-d0b0-4c68-9c6f-2898040640f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_555942fd-d0b0-4c68-9c6f-2898040640f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c7d49cf-727b-4c7d-92b3-ef30ad5cdd00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_b1457220-8049-45f6-b787-9365f12a66ff" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_b1457220-8049-45f6-b787-9365f12a66ff" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cbe31174-7883-4364-8535-2b8cbebb3b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_us-gaap_AwardTypeAxis_cbe31174-7883-4364-8535-2b8cbebb3b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbe31174-7883-4364-8535-2b8cbebb3b76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cbe31174-7883-4364-8535-2b8cbebb3b76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbe31174-7883-4364-8535-2b8cbebb3b76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cbe31174-7883-4364-8535-2b8cbebb3b76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b805311a-ab28-43ee-9f2f-dae22fe265b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b805311a-ab28-43ee-9f2f-dae22fe265b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f7c75989-f8ff-4fbb-b275-9f261020881e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:to="loc_us-gaap_PerformanceSharesMember_f7c75989-f8ff-4fbb-b275-9f261020881e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae144e8a-de62-4921-b9bc-f2f7fb8d9e36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae144e8a-de62-4921-b9bc-f2f7fb8d9e36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d74220f4-7d29-45c3-8494-3292189b003d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_us-gaap_PlanNameAxis_d74220f4-7d29-45c3-8494-3292189b003d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d74220f4-7d29-45c3-8494-3292189b003d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d74220f4-7d29-45c3-8494-3292189b003d" xlink:to="loc_us-gaap_PlanNameDomain_d74220f4-7d29-45c3-8494-3292189b003d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_19f92964-910a-4b1c-aadc-13d56563997a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d74220f4-7d29-45c3-8494-3292189b003d" xlink:to="loc_us-gaap_PlanNameDomain_19f92964-910a-4b1c-aadc-13d56563997a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:href="aqst-20250331.xsd#aqst_MarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_19f92964-910a-4b1c-aadc-13d56563997a" xlink:to="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_A2023MarketBasedMember_f3561634-4de9-4e4e-850e-ce3c6b6e8916" xlink:href="aqst-20250331.xsd#aqst_A2023MarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:to="loc_aqst_A2023MarketBasedMember_f3561634-4de9-4e4e-850e-ce3c6b6e8916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_A2025MarketBasedMember_a18db05a-9aee-4360-a73f-d17ed50b6835" xlink:href="aqst-20250331.xsd#aqst_A2025MarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:to="loc_aqst_A2025MarketBasedMember_a18db05a-9aee-4360-a73f-d17ed50b6835" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionAxis_2240e86e-4492-4120-bb5a-9d6f661d3670" xlink:href="aqst-20250331.xsd#aqst_VestingConditionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_aqst_VestingConditionAxis_2240e86e-4492-4120-bb5a-9d6f661d3670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionDomain_2240e86e-4492-4120-bb5a-9d6f661d3670_default" xlink:href="aqst-20250331.xsd#aqst_VestingConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_aqst_VestingConditionAxis_2240e86e-4492-4120-bb5a-9d6f661d3670" xlink:to="loc_aqst_VestingConditionDomain_2240e86e-4492-4120-bb5a-9d6f661d3670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:href="aqst-20250331.xsd#aqst_VestingConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aqst_VestingConditionAxis_2240e86e-4492-4120-bb5a-9d6f661d3670" xlink:to="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeOneMember_3065e2a5-74d4-4b34-bde0-ede81432087e" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeOneMember_3065e2a5-74d4-4b34-bde0-ede81432087e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTwoMember_6efd9ddb-38ef-496c-8a30-00c34c12547b" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeTwoMember_6efd9ddb-38ef-496c-8a30-00c34c12547b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeThreeMember_2ccb0ba8-f2a9-4e77-9867-785f13f8297c" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeThreeMember_2ccb0ba8-f2a9-4e77-9867-785f13f8297c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeFourMember_331977fc-74fb-4577-a57a-c7618b44abcf" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeFourMember_331977fc-74fb-4577-a57a-c7618b44abcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeFiveMember_eb7f326f-4a64-4203-a0a1-589dd8f26ee1" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeFiveMember_eb7f326f-4a64-4203-a0a1-589dd8f26ee1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeSixMember_006bd961-c4ab-4f3c-b70d-8fd07759e635" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeSixMember_006bd961-c4ab-4f3c-b70d-8fd07759e635" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeSevenMember_def10035-ac13-4cce-bf00-9bafcfd11c42" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeSevenMember_def10035-ac13-4cce-bf00-9bafcfd11c42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeEightMember_3bcc673e-23a4-40d0-9dbd-3f806feacf00" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeEightMember_3bcc673e-23a4-40d0-9dbd-3f806feacf00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeNineMember_519930ca-b6d1-46d0-a5f8-ab5ba5feec41" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeNineMember_519930ca-b6d1-46d0-a5f8-ab5ba5feec41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTenMember_ddc6f82f-ffe0-4087-9ee9-951795fe00a4" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeTenMember_ddc6f82f-ffe0-4087-9ee9-951795fe00a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeElevenMember_529a26dd-5991-4ebb-b406-203255a93ef7" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeElevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeElevenMember_529a26dd-5991-4ebb-b406-203255a93ef7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTwelveMember_fe145ed1-2dc3-443e-851d-f4bcde77d748" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeTwelveMember_fe145ed1-2dc3-443e-851d-f4bcde77d748" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_841a612a-c73b-4212-bad6-95b762c05b4d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_srt_RangeAxis_841a612a-c73b-4212-bad6-95b762c05b4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_841a612a-c73b-4212-bad6-95b762c05b4d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_841a612a-c73b-4212-bad6-95b762c05b4d" xlink:to="loc_srt_RangeMember_841a612a-c73b-4212-bad6-95b762c05b4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_841a612a-c73b-4212-bad6-95b762c05b4d" xlink:to="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05ccb3ff-28a3-45c8-a79c-4557f47c00d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:to="loc_srt_MinimumMember_05ccb3ff-28a3-45c8-a79c-4557f47c00d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8aa648e6-ab92-4470-9374-ec797ed85636" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:to="loc_srt_MaximumMember_8aa648e6-ab92-4470-9374-ec797ed85636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67b39649-9960-42d8-bfa6-11e04053aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67b39649-9960-42d8-bfa6-11e04053aa6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d1f5a364-ca89-4310-aec0-1d3430944592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d1f5a364-ca89-4310-aec0-1d3430944592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ebad8fa6-cb00-4713-b6be-9e275be0ca39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ebad8fa6-cb00-4713-b6be-9e275be0ca39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod_f5767246-0023-4007-9b81-ac1c6eab7005" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod_f5767246-0023-4007-9b81-ac1c6eab7005" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare_1b51533c-f49a-470b-89f8-7f79b7b55af5" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare_1b51533c-f49a-470b-89f8-7f79b7b55af5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ef8e2663-1728-4137-a9f4-948f313b525b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ef8e2663-1728-4137-a9f4-948f313b525b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods_17748e03-23af-41e0-b1b6-19f51d280628" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods_17748e03-23af-41e0-b1b6-19f51d280628" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod_64a36e93-51b0-45bd-84e4-2650a2ec2f90" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod_64a36e93-51b0-45bd-84e4-2650a2ec2f90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8b3057a-10e2-4d3d-8470-e368f6dd073f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8b3057a-10e2-4d3d-8470-e368f6dd073f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a46c5d8-b2f6-44e3-951e-1e029843518c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a46c5d8-b2f6-44e3-951e-1e029843518c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0b12eebb-f226-467d-9da5-44826e94f2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_SharePrice_0b12eebb-f226-467d-9da5-44826e94f2e5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5974ee57-4ab6-42c2-8415-63f45f4b9863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5974ee57-4ab6-42c2-8415-63f45f4b9863" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationPerformanceBasedDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8339700-7d6c-43a7-8cee-68db953ac741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8339700-7d6c-43a7-8cee-68db953ac741" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8339700-7d6c-43a7-8cee-68db953ac741" xlink:to="loc_us-gaap_AwardTypeAxis_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16f85268-2a3c-4e30-869f-ca77fe30c34f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16f85268-2a3c-4e30-869f-ca77fe30c34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5fa06650-808a-43b0-aeea-2cc566fe09df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16f85268-2a3c-4e30-869f-ca77fe30c34f" xlink:to="loc_us-gaap_PerformanceSharesMember_5fa06650-808a-43b0-aeea-2cc566fe09df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f4b7e984-babe-4588-86ef-8695eaa1b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f4b7e984-babe-4588-86ef-8695eaa1b4ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_982f5360-bd0c-463a-a443-a5a4796f46c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_982f5360-bd0c-463a-a443-a5a4796f46c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c253a833-3540-410a-bf03-2ff42ce6fad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c253a833-3540-410a-bf03-2ff42ce6fad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d6114cae-87d9-46cc-8514-67a2157ffbde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d6114cae-87d9-46cc-8514-67a2157ffbde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af126347-4834-4b96-a734-ef0bec834c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_7c7d797f-40d3-4cf0-8a31-c6e6d3d77891" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_7c7d797f-40d3-4cf0-8a31-c6e6d3d77891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd801066-0337-4b72-816f-1b2612b300ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd801066-0337-4b72-816f-1b2612b300ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddc6d29d-cf7c-45b9-8085-e1a23fe6798e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddc6d29d-cf7c-45b9-8085-e1a23fe6798e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c751b3d4-4c7d-49b2-bcb3-8b2959216ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c751b3d4-4c7d-49b2-bcb3-8b2959216ff0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f311ce5-4cf7-4b4a-a5cd-a7efa876a261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f311ce5-4cf7-4b4a-a5cd-a7efa876a261" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96e230a5-46e4-4693-aa34-ecda277c8a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_43dc109a-f09e-41f1-8d8f-22525fdb93bc" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_43dc109a-f09e-41f1-8d8f-22525fdb93bc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d691179-9823-4629-90c6-fd033a82f082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d691179-9823-4629-90c6-fd033a82f082" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0dfa0b90-e022-4e03-9804-10219e3268dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d691179-9823-4629-90c6-fd033a82f082" xlink:to="loc_us-gaap_AwardTypeAxis_0dfa0b90-e022-4e03-9804-10219e3268dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dfa0b90-e022-4e03-9804-10219e3268dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0dfa0b90-e022-4e03-9804-10219e3268dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dfa0b90-e022-4e03-9804-10219e3268dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3289c878-99b9-4690-a9ec-2e430b68b133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0dfa0b90-e022-4e03-9804-10219e3268dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3289c878-99b9-4690-a9ec-2e430b68b133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_488be7e3-5ae1-4c73-acc0-ef089894778c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3289c878-99b9-4690-a9ec-2e430b68b133" xlink:to="loc_us-gaap_EmployeeStockOptionMember_488be7e3-5ae1-4c73-acc0-ef089894778c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7021eb4e-3517-4f7c-a06b-97556d8dbcce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7021eb4e-3517-4f7c-a06b-97556d8dbcce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d2368c27-ebc5-4f8d-a5d1-2d61d6308415" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d2368c27-ebc5-4f8d-a5d1-2d61d6308415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f98aa587-68f4-47a2-b3af-922ee7dffba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f98aa587-68f4-47a2-b3af-922ee7dffba1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod_e5d1fa23-d1c5-4e8e-98df-f8f366d47697" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod_e5d1fa23-d1c5-4e8e-98df-f8f366d47697" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69d1fb46-95ef-40ae-b4ad-d0940d79862c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e4c408e2-327f-495f-8110-61aad9fba3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e4c408e2-327f-495f-8110-61aad9fba3e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ccb9752c-c866-41eb-8248-4e2acdf5c9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ccb9752c-c866-41eb-8248-4e2acdf5c9ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c1f2227-0336-42e8-90ea-024ab2b4e43a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c1f2227-0336-42e8-90ea-024ab2b4e43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dca43545-707b-4fd8-afa0-32d4802e0bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dca43545-707b-4fd8-afa0-32d4802e0bf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a801f88a-46fb-4114-8620-910a7c62bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a801f88a-46fb-4114-8620-910a7c62bf37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_933fb475-a549-403a-b0c3-328a34592f0d" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_933fb475-a549-403a-b0c3-328a34592f0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73885119-9cb9-4a7a-aee1-cd3cd9bb6cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_279d3507-a7b0-42ae-9e14-d26566ecf236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_279d3507-a7b0-42ae-9e14-d26566ecf236" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b54ea68f-5354-4bf8-bcf6-9b95d2dd4119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b54ea68f-5354-4bf8-bcf6-9b95d2dd4119" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c3513cde-010b-42d5-855a-4928bb33b99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:to="loc_us-gaap_AwardTypeAxis_c3513cde-010b-42d5-855a-4928bb33b99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3513cde-010b-42d5-855a-4928bb33b99f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c3513cde-010b-42d5-855a-4928bb33b99f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3513cde-010b-42d5-855a-4928bb33b99f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c3513cde-010b-42d5-855a-4928bb33b99f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_082aad6f-e65f-4c05-b031-6169478af253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:to="loc_us-gaap_PerformanceSharesMember_082aad6f-e65f-4c05-b031-6169478af253" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb1fc907-f1cd-41f1-82b7-b721ec078702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb1fc907-f1cd-41f1-82b7-b721ec078702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd258544-c495-4cb1-8f81-b971f0eac042" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:to="loc_srt_RangeAxis_cd258544-c495-4cb1-8f81-b971f0eac042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd258544-c495-4cb1-8f81-b971f0eac042_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cd258544-c495-4cb1-8f81-b971f0eac042" xlink:to="loc_srt_RangeMember_cd258544-c495-4cb1-8f81-b971f0eac042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cd258544-c495-4cb1-8f81-b971f0eac042" xlink:to="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8cbbeefc-9f4d-4fe7-ac6e-e11a55baaf6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:to="loc_srt_MinimumMember_8cbbeefc-9f4d-4fe7-ac6e-e11a55baaf6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6f78cbb-5e6e-4719-b1dc-6419506abbab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:to="loc_srt_MaximumMember_e6f78cbb-5e6e-4719-b1dc-6419506abbab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e97722a-91b4-4ee6-9f63-f7e87b9945ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e97722a-91b4-4ee6-9f63-f7e87b9945ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf0e0347-09fa-40e1-a61c-f19af5c3189e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf0e0347-09fa-40e1-a61c-f19af5c3189e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1850d9a6-85dd-4fa0-9937-25895d166c57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1850d9a6-85dd-4fa0-9937-25895d166c57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b1b46ab4-1fbd-4194-a882-5db82f421148" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b1b46ab4-1fbd-4194-a882-5db82f421148" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_f10999a5-557f-492a-8538-d1e1d8ecba85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_SharePrice_f10999a5-557f-492a-8538-d1e1d8ecba85" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://aquestive.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://aquestive.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:to="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_51753327-5617-46c4-837d-94ab369ed71c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:to="loc_srt_LitigationCaseAxis_51753327-5617-46c4-837d-94ab369ed71c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_51753327-5617-46c4-837d-94ab369ed71c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_51753327-5617-46c4-837d-94ab369ed71c" xlink:to="loc_srt_LitigationCaseTypeDomain_51753327-5617-46c4-837d-94ab369ed71c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_51753327-5617-46c4-837d-94ab369ed71c" xlink:to="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NeurelisIncVAquestiveTherapeuticsIncMember_9fba0195-8b63-4c90-84b0-00f067484bf7" xlink:href="aqst-20250331.xsd#aqst_NeurelisIncVAquestiveTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:to="loc_aqst_NeurelisIncVAquestiveTherapeuticsIncMember_9fba0195-8b63-4c90-84b0-00f067484bf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SuboxoneProduceLiabilityLitigationMember_63c1e0b0-9068-4701-89f1-0def04baa819" xlink:href="aqst-20250331.xsd#aqst_SuboxoneProduceLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:to="loc_aqst_SuboxoneProduceLiabilityLitigationMember_63c1e0b0-9068-4701-89f1-0def04baa819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:to="loc_srt_StatementGeographicalAxis_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0" xlink:to="loc_srt_SegmentGeographicalDomain_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f90e9b8-2072-4558-8f62-43e8da712d47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0" xlink:to="loc_srt_SegmentGeographicalDomain_1f90e9b8-2072-4558-8f62-43e8da712d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_b8e66e92-7911-456c-b1f0-ba9cf3bdfc70" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f90e9b8-2072-4558-8f62-43e8da712d47" xlink:to="loc_stpr_CA-BC_b8e66e92-7911-456c-b1f0-ba9cf3bdfc70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9a263723-2642-43fa-8f29-ba6b15cbf47b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9a263723-2642-43fa-8f29-ba6b15cbf47b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2a29c243-c42e-4b86-91b4-13028e10e6db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2a29c243-c42e-4b86-91b4-13028e10e6db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LitigationSettlementAmountAwardPeriodDue_e33a0d08-4f52-4a0d-88a0-4c9b285c8192" xlink:href="aqst-20250331.xsd#aqst_LitigationSettlementAmountAwardPeriodDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:to="loc_aqst_LitigationSettlementAmountAwardPeriodDue_e33a0d08-4f52-4a0d-88a0-4c9b285c8192" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>aqst-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7fd918af-7463-495d-a5aa-7a090fe24bee,g:404d0fa2-95d9-41b4-b7eb-3a9cfeb5fb76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_aqst_DebtInstrumentExitFee_e6270375-524b-47bd-b0fb-fffada0d1d0f_terseLabel_en-US" xlink:label="lab_aqst_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, exit fee</link:label>
    <link:label id="lab_aqst_DebtInstrumentExitFee_label_en-US" xlink:label="lab_aqst_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:label id="lab_aqst_DebtInstrumentExitFee_documentation_en-US" xlink:label="lab_aqst_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentExitFee" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentExitFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_DebtInstrumentExitFee" xlink:to="lab_aqst_DebtInstrumentExitFee" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants_51bd5b8f-5bd4-41c0-b21f-e0c0248ab224_terseLabel_en-US" xlink:label="lab_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock in connection with securities purchase agreements (in shares)</link:label>
    <link:label id="lab_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants_label_en-US" xlink:label="lab_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Of Common Stock To Be Purchased By Common Stock Warrants</link:label>
    <link:label id="lab_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants_documentation_en-US" xlink:label="lab_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares of Common Stock to be Purchased by Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants" xlink:href="aqst-20250331.xsd#aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants" xlink:to="lab_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca8be1ae-0885-4de6-92b2-9eb61940a272_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e9d23d79-7aec-4cb2-8d18-70b141484558_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_4132a1a6-84dd-42cd-9bd9-f6ad68dc87e3_verboseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_db971197-e8f5-4dac-a7e6-dcf29a5874e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_928662f6-5319-4cdd-8508-6b450e4cbcc6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract and other receivables</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_InterestAndOtherIncomeNet_28e73c62-d7f6-48c9-b1d8-f3cbd279c7d5_terseLabel_en-US" xlink:label="lab_aqst_InterestAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income and other income, net</link:label>
    <link:label id="lab_aqst_InterestAndOtherIncomeNet_label_en-US" xlink:label="lab_aqst_InterestAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest And Other Income, Net</link:label>
    <link:label id="lab_aqst_InterestAndOtherIncomeNet_documentation_en-US" xlink:label="lab_aqst_InterestAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest And Other Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InterestAndOtherIncomeNet" xlink:href="aqst-20250331.xsd#aqst_InterestAndOtherIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_InterestAndOtherIncomeNet" xlink:to="lab_aqst_InterestAndOtherIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_612ea5f3-7875-48cc-b2be-783f14acccc6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_60516a0a-e2a4-417d-85c8-1f9c40e2b46a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionDomain_7e8e83cd-4d19-4591-9492-efecc01ad9cd_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition [Domain]</link:label>
    <link:label id="lab_aqst_VestingConditionDomain_label_en-US" xlink:label="lab_aqst_VestingConditionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition [Domain]</link:label>
    <link:label id="lab_aqst_VestingConditionDomain_documentation_en-US" xlink:label="lab_aqst_VestingConditionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Conditions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionDomain" xlink:href="aqst-20250331.xsd#aqst_VestingConditionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionDomain" xlink:to="lab_aqst_VestingConditionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_ac6fa96d-2f70-46e6-a2c9-220348f196da_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_04e2c379-3e70-4987-b5ac-492a390aa790_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ClassOfWarrantOrRightWarrantsExercised_7c6e9339-7005-4feb-b01c-c9ba6d83d9b5_terseLabel_en-US" xlink:label="lab_aqst_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_aqst_ClassOfWarrantOrRightWarrantsExercised_label_en-US" xlink:label="lab_aqst_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:label id="lab_aqst_ClassOfWarrantOrRightWarrantsExercised_documentation_en-US" xlink:label="lab_aqst_ClassOfWarrantOrRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of class of warrant or right exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ClassOfWarrantOrRightWarrantsExercised" xlink:href="aqst-20250331.xsd#aqst_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ClassOfWarrantOrRightWarrantsExercised" xlink:to="lab_aqst_ClassOfWarrantOrRightWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1d0e9957-f241-4cd7-b7a0-a9f04f57a9af_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_898bb48c-fc6e-46ac-a6ba-01d51dfb387a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_45fe1638-3377-417c-a1e0-11184ebaa6a2_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Notes payable, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_CumulativeRoyaltyReceivable_e8f694b6-ca95-4629-a082-ab2e460b18b6_terseLabel_en-US" xlink:label="lab_aqst_CumulativeRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty receivable</link:label>
    <link:label id="lab_aqst_CumulativeRoyaltyReceivable_label_en-US" xlink:label="lab_aqst_CumulativeRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Royalty Receivable</link:label>
    <link:label id="lab_aqst_CumulativeRoyaltyReceivable_documentation_en-US" xlink:label="lab_aqst_CumulativeRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sum of the carrying amounts of royalty receivable as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CumulativeRoyaltyReceivable" xlink:href="aqst-20250331.xsd#aqst_CumulativeRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_CumulativeRoyaltyReceivable" xlink:to="lab_aqst_CumulativeRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_6636842f-e0a7-4bd3-ba9c-2525d7e047ca_terseLabel_en-US" xlink:label="lab_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Awards Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Awards Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="aqst-20250331.xsd#aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_NumberOfGuaranteedRoyaltyPayments_f1177a1e-085c-4d9e-81ed-64d384620d77_terseLabel_en-US" xlink:label="lab_aqst_NumberOfGuaranteedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of guaranteed royalty payments</link:label>
    <link:label id="lab_aqst_NumberOfGuaranteedRoyaltyPayments_label_en-US" xlink:label="lab_aqst_NumberOfGuaranteedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Guaranteed Royalty Payments</link:label>
    <link:label id="lab_aqst_NumberOfGuaranteedRoyaltyPayments_documentation_en-US" xlink:label="lab_aqst_NumberOfGuaranteedRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Guaranteed Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfGuaranteedRoyaltyPayments" xlink:href="aqst-20250331.xsd#aqst_NumberOfGuaranteedRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_NumberOfGuaranteedRoyaltyPayments" xlink:to="lab_aqst_NumberOfGuaranteedRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3ff3232a-b18d-495c-b8df-fd018510d5a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c3755590-d369-4298-abac-4d0bc4adb8e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_06727fdf-6e04-4deb-80ff-a7b467c00604_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments for interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RoyaltyObligationActivityTableTextBlock_d6ed2fce-4833-41a1-a5e2-6f362d778379_terseLabel_en-US" xlink:label="lab_aqst_RoyaltyObligationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Obligation Activity</link:label>
    <link:label id="lab_aqst_RoyaltyObligationActivityTableTextBlock_label_en-US" xlink:label="lab_aqst_RoyaltyObligationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligation Activity [Table Text Block]</link:label>
    <link:label id="lab_aqst_RoyaltyObligationActivityTableTextBlock_documentation_en-US" xlink:label="lab_aqst_RoyaltyObligationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligation Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationActivityTableTextBlock" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RoyaltyObligationActivityTableTextBlock" xlink:to="lab_aqst_RoyaltyObligationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_4d54dcb8-a5ed-4054-b44b-9f9026eb4a02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AtTheMarketOfferingMember_6757c09e-13d8-4e45-97c5-60cdff35d9b4_verboseLabel_en-US" xlink:label="lab_aqst_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Public Equity Offering - ATM</link:label>
    <link:label id="lab_aqst_AtTheMarketOfferingMember_db2b0867-3873-4d05-8cc1-71da0568b527_terseLabel_en-US" xlink:label="lab_aqst_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market offering</link:label>
    <link:label id="lab_aqst_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_aqst_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_aqst_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_aqst_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtTheMarketOfferingMember" xlink:href="aqst-20250331.xsd#aqst_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AtTheMarketOfferingMember" xlink:to="lab_aqst_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_a5242745-a833-4df7-a63f-51ad7fc88c5e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ComputerNetworkEquipmentAndSoftwareMember_04142304-4ea1-4764-8a04-3ce5bb23c699_terseLabel_en-US" xlink:label="lab_aqst_ComputerNetworkEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer, network equipment and software</link:label>
    <link:label id="lab_aqst_ComputerNetworkEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_aqst_ComputerNetworkEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer, Network Equipment and Software [Member]</link:label>
    <link:label id="lab_aqst_ComputerNetworkEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_aqst_ComputerNetworkEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets which are related to computer, network equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ComputerNetworkEquipmentAndSoftwareMember" xlink:href="aqst-20250331.xsd#aqst_ComputerNetworkEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ComputerNetworkEquipmentAndSoftwareMember" xlink:to="lab_aqst_ComputerNetworkEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_45ea846d-159f-44de-acbe-11a254c3fa61_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_d4ee6c48-8e49-4a1b-9d5e-c9ba4a77c33a_terseLabel_en-US" xlink:label="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_label_en-US" xlink:label="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Tiered Royalty Percentage</link:label>
    <link:label id="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_documentation_en-US" xlink:label="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Tiered Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage" xlink:to="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5d49a29f-ab0e-43fd-a245-ce5add250867_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments &#8211; Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_fd8f2af2-8bf7-4b3e-b6f2-d5f50727f3a3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable_64b650f1-18e2-495e-a6d3-8c449673a44e_terseLabel_en-US" xlink:label="lab_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs associated with public equity offering-ATM in Accounts Payable</link:label>
    <link:label id="lab_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable_label_en-US" xlink:label="lab_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with At-the-Market Public Equity Offering in Accounts Payable</link:label>
    <link:label id="lab_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable_documentation_en-US" xlink:label="lab_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs Associated with At-the-Market Public Equity Offering in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" xlink:href="aqst-20250331.xsd#aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" xlink:to="lab_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_9af98207-1ac2-4c18-84a3-56584a311f76_terseLabel_en-US" xlink:label="lab_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 and thereafter</link:label>
    <link:label id="lab_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_label_en-US" xlink:label="lab_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter</link:label>
    <link:label id="lab_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_documentation_en-US" xlink:label="lab_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:href="aqst-20250331.xsd#aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="lab_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_02de323c-95a2-47a7-a447-e79ee2f92b6a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Assets and Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d4981977-045d-450e-b185-63f14c9da00f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_fecfa3d9-1a0f-4861-888f-02baaeb467cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5ac6baa9-bcc9-4730-85bc-f453b88df0c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_PreFundedWarrantsMember_117016f2-1c7d-452d-b7b3-9079886bb41a_terseLabel_en-US" xlink:label="lab_aqst_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_aqst_PreFundedWarrantsMember_label_en-US" xlink:label="lab_aqst_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_aqst_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_aqst_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PreFundedWarrantsMember" xlink:href="aqst-20250331.xsd#aqst_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_PreFundedWarrantsMember" xlink:to="lab_aqst_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_UnderwrittenPublicOfferingMember_6770a065-ab72-4f09-8987-f5b388a2c6d2_terseLabel_en-US" xlink:label="lab_aqst_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_aqst_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_aqst_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_aqst_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_aqst_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_UnderwrittenPublicOfferingMember" xlink:href="aqst-20250331.xsd#aqst_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_UnderwrittenPublicOfferingMember" xlink:to="lab_aqst_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_55028691-978b-4c32-a7c4-aa4b16e9b4bf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMeasurementInput_9b238d76-4bce-4348-be7e-0da4bd7141ed_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMeasurementInput_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMeasurementInput" xlink:to="lab_us-gaap_LongTermDebtMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_deb0691d-e115-4e52-8e09-867ef74cb989_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_d05bcc27-acdf-44f1-ae75-257085e37c06_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of cases pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3a3a270e-4d3d-48bc-8ee3-a2a850e0b15b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a23b1230-73ec-4dc7-9923-97ac4fd64c34_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_641e8e1e-027c-4365-a9e7-82ba2b697b3b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_cfc1c491-7928-4fe4-8af6-ca84e92a79ed_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ca49b7e6-2560-4c3a-94b4-9d2e87993576_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_IndiviorMember_4e08729f-3191-45f8-9ee6-88a19ad98ccd_terseLabel_en-US" xlink:label="lab_aqst_IndiviorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indivior</link:label>
    <link:label id="lab_aqst_IndiviorMember_label_en-US" xlink:label="lab_aqst_IndiviorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indivior [Member]</link:label>
    <link:label id="lab_aqst_IndiviorMember_documentation_en-US" xlink:label="lab_aqst_IndiviorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indivior</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_IndiviorMember" xlink:href="aqst-20250331.xsd#aqst_IndiviorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_IndiviorMember" xlink:to="lab_aqst_IndiviorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_96a3f765-fbf1-4412-aaf1-9d25b03dfddc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_91122345-f342-44bb-b772-6ae9f03fd9d7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e51bddff-1449-4216-9fff-e450b79f44b1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeFiveMember_f136949a-1670-488a-8f2a-19d480ab9a26_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition Range Five</link:label>
    <link:label id="lab_aqst_VestingConditionRangeFiveMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Five [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeFiveMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeFiveMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeFiveMember" xlink:to="lab_aqst_VestingConditionRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_1e410d1e-db59-4f94-8bb7-c45390177128_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_48d62167-1038-431b-b2b7-656e9aa38fd8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8021f4bd-c322-4939-a0be-a209652d8e41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_488d90ea-722a-4bd2-b368-6b3a8512e335_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7bc9bb2f-b876-426e-b7c7-396da5c85403_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_32529881-8b0b-4fa3-974e-22a83905cdfa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2abafe63-bd30-4c93-9a7d-4b52185644f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used for operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_45b96a9e-cb08-4542-8aea-6fd3884719fd_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased patent</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_10f25be8-ac72-4d29-90bd-2e8bac7349e0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_76ccd887-bd39-45b3-8fb0-36979955c629_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LiabilitiesSaleOfFutureRoyalties_173d3913-8d6a-497b-a8f6-4ca4b181145f_periodStartLabel_en-US" xlink:label="lab_aqst_LiabilitiesSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future revenue, net at beginning of the period</link:label>
    <link:label id="lab_aqst_LiabilitiesSaleOfFutureRoyalties_6393de1f-4819-4fdb-99c4-1c9f16a2860d_periodEndLabel_en-US" xlink:label="lab_aqst_LiabilitiesSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively)</link:label>
    <link:label id="lab_aqst_LiabilitiesSaleOfFutureRoyalties_label_en-US" xlink:label="lab_aqst_LiabilitiesSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Sale of Future Royalties</link:label>
    <link:label id="lab_aqst_LiabilitiesSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_aqst_LiabilitiesSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities, Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyalties" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LiabilitiesSaleOfFutureRoyalties" xlink:to="lab_aqst_LiabilitiesSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_DebtCovenantRedemptionScenarioAxis_2c4f1691-91de-4768-b03d-66df2dad51d8_terseLabel_en-US" xlink:label="lab_aqst_DebtCovenantRedemptionScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant, Redemption Scenario [Axis]</link:label>
    <link:label id="lab_aqst_DebtCovenantRedemptionScenarioAxis_label_en-US" xlink:label="lab_aqst_DebtCovenantRedemptionScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant, Redemption Scenario [Axis]</link:label>
    <link:label id="lab_aqst_DebtCovenantRedemptionScenarioAxis_documentation_en-US" xlink:label="lab_aqst_DebtCovenantRedemptionScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant, Redemption Scenario</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtCovenantRedemptionScenarioAxis" xlink:href="aqst-20250331.xsd#aqst_DebtCovenantRedemptionScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioAxis" xlink:to="lab_aqst_DebtCovenantRedemptionScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_542208bf-12e4-4040-b96a-595027580587_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real estate and personal property taxes</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_ee00ca61-d8d0-4760-ac6f-c799301528a8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of common stock issued under public equity offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8f4aede5-5089-47f7-b44b-5c367bc5026e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_aa7baf30-c407-4fc9-8f98-3dd026eefdd2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d50c280f-16a9-4dbb-92c1-13708835bdd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_b547e7c5-b559-480b-913f-2ee9bf0a7dd8_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_NumberOfAnnualRoyaltyPaymentsReceivable_7923130e-27ba-43f7-9a53-c5a6e6673997_terseLabel_en-US" xlink:label="lab_aqst_NumberOfAnnualRoyaltyPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of annual royalty payments receivable</link:label>
    <link:label id="lab_aqst_NumberOfAnnualRoyaltyPaymentsReceivable_label_en-US" xlink:label="lab_aqst_NumberOfAnnualRoyaltyPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Annual Royalty Payments Receivable</link:label>
    <link:label id="lab_aqst_NumberOfAnnualRoyaltyPaymentsReceivable_documentation_en-US" xlink:label="lab_aqst_NumberOfAnnualRoyaltyPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of annual royalty payments receivable by the entity for the use of its rights and property by another party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfAnnualRoyaltyPaymentsReceivable" xlink:href="aqst-20250331.xsd#aqst_NumberOfAnnualRoyaltyPaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_NumberOfAnnualRoyaltyPaymentsReceivable" xlink:to="lab_aqst_NumberOfAnnualRoyaltyPaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8791512d-1fea-48ee-9741-bb1950b5402a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_002807b4-914d-4857-b5f1-069069ae35f6_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_670c0838-cdf2-4097-a1e0-8a753928fba2_terseLabel_en-US" xlink:label="lab_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued to purchase common stock (in shares)</link:label>
    <link:label id="lab_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_label_en-US" xlink:label="lab_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Warrants Issued During Period</link:label>
    <link:label id="lab_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_documentation_en-US" xlink:label="lab_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants issued during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:href="aqst-20250331.xsd#aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:to="lab_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_523f480a-346e-4bdf-b29e-3e799760cb77_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_4ebb4e46-74c2-4af9-b798-b8071988b6f0_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_38570823-5a65-4466-928f-ec022606e71a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f9c35b0c-d6f5-446a-9ce8-ba91da49a220_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2a300a89-db0e-4d13-a3df-fb2191ad3184_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ABLFacilityMember_d0378a6b-6c8b-406e-9917-899cd75488ee_terseLabel_en-US" xlink:label="lab_aqst_ABLFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ABL Facility</link:label>
    <link:label id="lab_aqst_ABLFacilityMember_label_en-US" xlink:label="lab_aqst_ABLFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ABL Facility [Member]</link:label>
    <link:label id="lab_aqst_ABLFacilityMember_documentation_en-US" xlink:label="lab_aqst_ABLFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ABL Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ABLFacilityMember" xlink:href="aqst-20250331.xsd#aqst_ABLFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ABLFacilityMember" xlink:to="lab_aqst_ABLFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AutomaticRenewalPeriodOfAgreement_09d7dfbc-5876-4eaa-8c9d-3af7d15c1c6e_terseLabel_en-US" xlink:label="lab_aqst_AutomaticRenewalPeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automatic renewal period of agreement</link:label>
    <link:label id="lab_aqst_AutomaticRenewalPeriodOfAgreement_label_en-US" xlink:label="lab_aqst_AutomaticRenewalPeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Automatic Renewal Period of Agreement</link:label>
    <link:label id="lab_aqst_AutomaticRenewalPeriodOfAgreement_documentation_en-US" xlink:label="lab_aqst_AutomaticRenewalPeriodOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period for which the agreement is renewed automatically.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AutomaticRenewalPeriodOfAgreement" xlink:href="aqst-20250331.xsd#aqst_AutomaticRenewalPeriodOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AutomaticRenewalPeriodOfAgreement" xlink:to="lab_aqst_AutomaticRenewalPeriodOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b24d8a42-5560-46f7-b4b2-eb0fb7ebadd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_d06c49c1-3142-4c78-8aea-c5dafa4e364f_terseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date Fair Value</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The estimated fair value of nonvested equity-based awards on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan) as of grant date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_b547dc4b-6b83-486c-b43f-9b52f93f569a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Non-current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_43488581-d81f-499d-9461-c2d50129c718_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_70ad31b3-0637-46ce-8208-8e1549abec23_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f33fa1c4-9a69-4586-bec9-ce2fffd9869b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_493603ec-f602-489f-b7cf-c681c429ae15_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fa9594fa-6f09-4d25-8242-3c759a4a379e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_10312294-63e7-4268-a04f-1a7b4360bd15_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_InitialWarrantOfferingMember_65afc8cf-a1d7-4420-bd5b-20a43f8250a2_terseLabel_en-US" xlink:label="lab_aqst_InitialWarrantOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Warrant Offering</link:label>
    <link:label id="lab_aqst_InitialWarrantOfferingMember_label_en-US" xlink:label="lab_aqst_InitialWarrantOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Warrant Offering [Member]</link:label>
    <link:label id="lab_aqst_InitialWarrantOfferingMember_documentation_en-US" xlink:label="lab_aqst_InitialWarrantOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Warrant Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InitialWarrantOfferingMember" xlink:href="aqst-20250331.xsd#aqst_InitialWarrantOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_InitialWarrantOfferingMember" xlink:to="lab_aqst_InitialWarrantOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_9a175972-471e-4cd1-9359-0db7fcc298c9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_167ea2b4-1ad5-4d1b-b53c-4340f2dc199c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f54f2f6f-95ad-4f37-867b-3d43cd7300e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_708f3a46-fb57-41a0-8cc7-56574895bc7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9d538c6a-0430-4796-8b0b-c49e677829c8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_d47a34cf-8505-4978-8285-8938bc661aa4_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_f338f00e-0cf3-4b8b-bf12-c9e3dc935857_negatedLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_f81a6b16-1b7d-4fd7-a930-b9e3e555262b_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_2b84cb60-a381-4507-9e1d-2ef34e7a2382_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of the period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_29169d63-adcd-485b-b601-559448d4176a_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued distribution expenses and sales returns provision</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_594e7c2f-e110-4358-b053-ae4f76687e7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for taxes on share-based compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_d40fcece-001e-4587-9838-1888b6869d14_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeEightMember_6d2f5ae5-47fc-41c9-ae9d-1dd1164410ab_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Eight</link:label>
    <link:label id="lab_aqst_VestingConditionRangeEightMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Eight [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeEightMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeEightMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeEightMember" xlink:to="lab_aqst_VestingConditionRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_f9be6e49-c2b4-4044-84a1-414b02581eb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_A2023MarketBasedMember_8c239132-b529-4cf4-a753-49cdbd2876eb_terseLabel_en-US" xlink:label="lab_aqst_A2023MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Market Based</link:label>
    <link:label id="lab_aqst_A2023MarketBasedMember_label_en-US" xlink:label="lab_aqst_A2023MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Market Based [Member]</link:label>
    <link:label id="lab_aqst_A2023MarketBasedMember_documentation_en-US" xlink:label="lab_aqst_A2023MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Market Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_A2023MarketBasedMember" xlink:href="aqst-20250331.xsd#aqst_A2023MarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_A2023MarketBasedMember" xlink:to="lab_aqst_A2023MarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_CommercialExploitationAgreementWithIndiviorMember_c39f4aa5-724f-44bd-8033-3a96245b5d97_terseLabel_en-US" xlink:label="lab_aqst_CommercialExploitationAgreementWithIndiviorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial exploitation agreement with Indivior</link:label>
    <link:label id="lab_aqst_CommercialExploitationAgreementWithIndiviorMember_label_en-US" xlink:label="lab_aqst_CommercialExploitationAgreementWithIndiviorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Exploitation Agreement with Indivior [Member]</link:label>
    <link:label id="lab_aqst_CommercialExploitationAgreementWithIndiviorMember_documentation_en-US" xlink:label="lab_aqst_CommercialExploitationAgreementWithIndiviorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The commercial exploitation agreement with Indivior.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CommercialExploitationAgreementWithIndiviorMember" xlink:href="aqst-20250331.xsd#aqst_CommercialExploitationAgreementWithIndiviorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_CommercialExploitationAgreementWithIndiviorMember" xlink:to="lab_aqst_CommercialExploitationAgreementWithIndiviorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AmendedEquityDistributionAgreementMember_79cc9188-4a94-4a6d-a2f8-ffce5382167c_terseLabel_en-US" xlink:label="lab_aqst_AmendedEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Equity Distribution Agreement</link:label>
    <link:label id="lab_aqst_AmendedEquityDistributionAgreementMember_label_en-US" xlink:label="lab_aqst_AmendedEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_aqst_AmendedEquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_aqst_AmendedEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AmendedEquityDistributionAgreementMember" xlink:href="aqst-20250331.xsd#aqst_AmendedEquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AmendedEquityDistributionAgreementMember" xlink:to="lab_aqst_AmendedEquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c1b5fe9d-9304-4bef-b104-1fddc24e3ff5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_42caf46b-80e8-4ae5-b3da-6cfb40c916ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ca746bef-efc5-4eb1-acd0-81bb9e110289_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_062de15f-3c4a-49fe-8ace-f9ce4dca45ae_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ce663644-35a6-4d38-a8d6-adfba5006304_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_368dbc3a-2e84-4f52-91d8-d7407a534678_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44890d76-c9b8-4940-9ed5-8ff88c147f40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d7bf75ac-2330-425c-994b-b9a2bd895650_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_fcd8028e-659d-42a6-bb9d-4be3b4ced475_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants on common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts_38db3652-3763-4d9b-a5a0-2b56429f4e8e_terseLabel_en-US" xlink:label="lab_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of commercialized products</link:label>
    <link:label id="lab_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts_label_en-US" xlink:label="lab_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Commercialized Products</link:label>
    <link:label id="lab_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts_documentation_en-US" xlink:label="lab_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Number Of Commercialized Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts" xlink:href="aqst-20250331.xsd#aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts" xlink:to="lab_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_43561608-6e90-4e8c-85b6-ee213e58e5ce_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7d993cc0-65cb-472b-ab31-5d0c8bd05375_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4bb963b3-2021-437e-9678-ae7a14450270_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_63ece16e-6af5-410c-9499-794b366fd91a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_00fea719-40b6-488a-9cc8-cb3fbf1ebd95_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5e3ecc84-12f7-4058-90e2-6cf795bdc4db_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_15df6724-fe75-4d4c-add3-64e4826487a1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_a3071099-1155-470f-9a32-81436dbaa57f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6ebfe58d-c2b1-4d77-995a-e5fd0dd530a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a9347d96-6d8f-4e70-a264-98f575f6ed48_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ac96b5ec-7e6f-4160-a88c-4f31c197f597_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88301bcd-1762-4e4e-92c1-994b93919a1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold_6caddc90-2bcd-429d-a6bb-e35284436cef_terseLabel_en-US" xlink:label="lab_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, accordion feature, net revenue threshold</link:label>
    <link:label id="lab_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold_label_en-US" xlink:label="lab_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Accordion Feature, Net Revenue Threshold</link:label>
    <link:label id="lab_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold_documentation_en-US" xlink:label="lab_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Accordion Feature, Net Revenue Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" xlink:href="aqst-20250331.xsd#aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" xlink:to="lab_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18311304-a12d-46d7-aa5d-f861266afe18_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4136496f-c574-4686-a7a7-2c9e48d04311_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e49e7947-7cac-49d6-b7af-8f54e54173a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RedemptionScenario1Member_6a112e8b-c8b4-4cf6-862e-547010931966_terseLabel_en-US" xlink:label="lab_aqst_RedemptionScenario1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption Scenario 1</link:label>
    <link:label id="lab_aqst_RedemptionScenario1Member_label_en-US" xlink:label="lab_aqst_RedemptionScenario1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Scenario 1 [Member]</link:label>
    <link:label id="lab_aqst_RedemptionScenario1Member_documentation_en-US" xlink:label="lab_aqst_RedemptionScenario1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption Scenario 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RedemptionScenario1Member" xlink:href="aqst-20250331.xsd#aqst_RedemptionScenario1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RedemptionScenario1Member" xlink:to="lab_aqst_RedemptionScenario1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_27879073-2b84-40e1-95bb-c95bfebf44ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_d60aeb0b-138e-4780-91ce-c502bf08579e_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Awards</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_783f4b86-ae8b-47cd-8294-2cc7dad40c23_terseLabel_en-US" xlink:label="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligation, term</link:label>
    <link:label id="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_label_en-US" xlink:label="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Tiered Royalty Percentage, Term</link:label>
    <link:label id="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_documentation_en-US" xlink:label="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Tiered Royalty Percentage, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm" xlink:to="lab_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_73ab4fdd-2e85-470c-9223-177724e3d308_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LicenseAndRoyaltyRevenueMember_af5b52a4-6614-4a1a-8deb-4b5f4a594b76_terseLabel_en-US" xlink:label="lab_aqst_LicenseAndRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and royalty revenue</link:label>
    <link:label id="lab_aqst_LicenseAndRoyaltyRevenueMember_label_en-US" xlink:label="lab_aqst_LicenseAndRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Royalty Revenue [Member]</link:label>
    <link:label id="lab_aqst_LicenseAndRoyaltyRevenueMember_documentation_en-US" xlink:label="lab_aqst_LicenseAndRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate revenue generated from licensing and royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAndRoyaltyRevenueMember" xlink:href="aqst-20250331.xsd#aqst_LicenseAndRoyaltyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LicenseAndRoyaltyRevenueMember" xlink:to="lab_aqst_LicenseAndRoyaltyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_25bc0647-0617-441f-9680-6a033e653e89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Allowance for Bad Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent_8bd08e0f-5dc3-46bf-8166-d6a167f28659_terseLabel_en-US" xlink:label="lab_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future revenue, net</link:label>
    <link:label id="lab_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent_label_en-US" xlink:label="lab_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent</link:label>
    <link:label id="lab_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent_documentation_en-US" xlink:label="lab_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" xlink:href="aqst-20250331.xsd#aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" xlink:to="lab_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_971ceef6-754b-46f9-90a0-8223f042f623_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ManufactureAndSupplyRevenueMember_350e7ab1-6b94-458f-82ca-7826a4173dea_terseLabel_en-US" xlink:label="lab_aqst_ManufactureAndSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacture and supply revenue</link:label>
    <link:label id="lab_aqst_ManufactureAndSupplyRevenueMember_label_en-US" xlink:label="lab_aqst_ManufactureAndSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacture and Supply Revenue [Member]</link:label>
    <link:label id="lab_aqst_ManufactureAndSupplyRevenueMember_documentation_en-US" xlink:label="lab_aqst_ManufactureAndSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate revenue generated from manufacture and supply.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufactureAndSupplyRevenueMember" xlink:href="aqst-20250331.xsd#aqst_ManufactureAndSupplyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ManufactureAndSupplyRevenueMember" xlink:to="lab_aqst_ManufactureAndSupplyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AgreementTerm_227f6ac9-334f-40d6-a449-2ebe4d36838a_terseLabel_en-US" xlink:label="lab_aqst_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_aqst_AgreementTerm_label_en-US" xlink:label="lab_aqst_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Term</link:label>
    <link:label id="lab_aqst_AgreementTerm_documentation_en-US" xlink:label="lab_aqst_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AgreementTerm" xlink:href="aqst-20250331.xsd#aqst_AgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AgreementTerm" xlink:to="lab_aqst_AgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4a326041-0b50-427e-9c61-9de168130797_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_71aa06e4-bf17-40ca-ad14-9bdafebe5ade_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercises, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ca5efee2-0257-4224-ace5-220dc28abfc5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0a8232c3-aa63-4f2a-be2f-77d77eb39f72_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_316e39eb-4743-43f9-940e-4368cab5dfbc_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_02325874-f2bb-4226-80b9-00b4d215b573_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a6fd75b5-b67c-4bfc-8e45-ea294a99620d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_TradeAccountsReceivableDoubtfulAccountsMember_bb10ec5a-5a4f-418e-9a8e-503761870746_terseLabel_en-US" xlink:label="lab_aqst_TradeAccountsReceivableDoubtfulAccountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Doubtful Accounts</link:label>
    <link:label id="lab_aqst_TradeAccountsReceivableDoubtfulAccountsMember_label_en-US" xlink:label="lab_aqst_TradeAccountsReceivableDoubtfulAccountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable, Doubtful Accounts [Member]</link:label>
    <link:label id="lab_aqst_TradeAccountsReceivableDoubtfulAccountsMember_documentation_en-US" xlink:label="lab_aqst_TradeAccountsReceivableDoubtfulAccountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable, Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableDoubtfulAccountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember" xlink:to="lab_aqst_TradeAccountsReceivableDoubtfulAccountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_aa203868-60da-488a-b879-dceae253f096_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_3b5d0bfd-14fb-4930-8b8a-cb8b4df5361c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SeniorSecuredNotes13.5DueNovember12028Member_12bfe3cf-db0e-4c09-b30e-6c326352050f_terseLabel_en-US" xlink:label="lab_aqst_SeniorSecuredNotes13.5DueNovember12028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">13.5% Senior Secured Notes due November 1, 2028</link:label>
    <link:label id="lab_aqst_SeniorSecuredNotes13.5DueNovember12028Member_label_en-US" xlink:label="lab_aqst_SeniorSecuredNotes13.5DueNovember12028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Notes, 13.5% due November 1, 2028 [Member]</link:label>
    <link:label id="lab_aqst_SeniorSecuredNotes13.5DueNovember12028Member_documentation_en-US" xlink:label="lab_aqst_SeniorSecuredNotes13.5DueNovember12028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Notes, 13.5% due November 1, 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member" xlink:to="lab_aqst_SeniorSecuredNotes13.5DueNovember12028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0e167911-4a5e-4395-baaa-8f5e2b8171e3_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b8d97517-6815-4ede-8b04-f622e8780121_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85d3e041-a2a7-4f48-bbbe-c42a99f57508_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_74e76546-6e65-4127-a9dc-5f1b653cbf73_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1aec3516-ccb1-4af7-a4f3-6b3dcb843437_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7c4fe48f-367b-469f-97a1-36ac9e0d3d91_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_63d2247d-18ac-43a0-bf8f-f68dbf13335b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5d2ef854-df3f-44c3-81f2-7e3e2b7a2f33_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_da91de73-506d-4fa5-ac8c-779c87e15afd_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_9202f913-2200-4eb5-abfe-f695163e024e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ResearchAndDevelopmentProjectDuration_e7d257e9-e833-4564-85e7-5c699fc82868_terseLabel_en-US" xlink:label="lab_aqst_ResearchAndDevelopmentProjectDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development, project duration</link:label>
    <link:label id="lab_aqst_ResearchAndDevelopmentProjectDuration_label_en-US" xlink:label="lab_aqst_ResearchAndDevelopmentProjectDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Project Duration</link:label>
    <link:label id="lab_aqst_ResearchAndDevelopmentProjectDuration_documentation_en-US" xlink:label="lab_aqst_ResearchAndDevelopmentProjectDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development, Project Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ResearchAndDevelopmentProjectDuration" xlink:href="aqst-20250331.xsd#aqst_ResearchAndDevelopmentProjectDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ResearchAndDevelopmentProjectDuration" xlink:to="lab_aqst_ResearchAndDevelopmentProjectDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_70350eac-73e7-4176-891a-54391d4d571f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_99f81e19-e8a5-4d8d-8696-a7e40964a1d1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_InterestExpenseSaleOfFutureRevenues_0d4e8524-7217-4f6e-b898-0d7ffe6c2c3a_negatedTerseLabel_en-US" xlink:label="lab_aqst_InterestExpenseSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense related to the sale of future revenue</link:label>
    <link:label id="lab_aqst_InterestExpenseSaleOfFutureRevenues_label_en-US" xlink:label="lab_aqst_InterestExpenseSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Sale of Future Revenues</link:label>
    <link:label id="lab_aqst_InterestExpenseSaleOfFutureRevenues_documentation_en-US" xlink:label="lab_aqst_InterestExpenseSaleOfFutureRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense, Sale of Future Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InterestExpenseSaleOfFutureRevenues" xlink:href="aqst-20250331.xsd#aqst_InterestExpenseSaleOfFutureRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_InterestExpenseSaleOfFutureRevenues" xlink:to="lab_aqst_InterestExpenseSaleOfFutureRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_18d0c38f-5680-4f40-b472-3895e3a758c6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7d4eeed9-b339-449a-b413-7ed638757f1a_totalLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_MinimumAnnualRoyaltyReceivable_630416db-2f64-4c13-8e5b-dff88274929f_terseLabel_en-US" xlink:label="lab_aqst_MinimumAnnualRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum annual royalty receivable</link:label>
    <link:label id="lab_aqst_MinimumAnnualRoyaltyReceivable_label_en-US" xlink:label="lab_aqst_MinimumAnnualRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Annual Royalty Receivable</link:label>
    <link:label id="lab_aqst_MinimumAnnualRoyaltyReceivable_documentation_en-US" xlink:label="lab_aqst_MinimumAnnualRoyaltyReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum annual royalty receivable by the entity for the use of its rights and property by another party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MinimumAnnualRoyaltyReceivable" xlink:href="aqst-20250331.xsd#aqst_MinimumAnnualRoyaltyReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_MinimumAnnualRoyaltyReceivable" xlink:to="lab_aqst_MinimumAnnualRoyaltyReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43049be3-b842-42f2-a40e-b7719adb9949_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fb997231-f77b-4461-a257-7e50a9fc76ec_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ReportableSegmentMember_dd9b3e35-e7a1-4f2c-9c92-abae727aa2b9_terseLabel_en-US" xlink:label="lab_aqst_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_aqst_ReportableSegmentMember_label_en-US" xlink:label="lab_aqst_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_aqst_ReportableSegmentMember_documentation_en-US" xlink:label="lab_aqst_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ReportableSegmentMember" xlink:href="aqst-20250331.xsd#aqst_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ReportableSegmentMember" xlink:to="lab_aqst_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_46f7c58e-b669-4d96-9336-5f3ff977e708_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1ee7a0b5-8c5c-4e6f-a026-82d48e39f89d_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f139d064-0b01-4bee-844c-893051c658b1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_24f1550e-899a-441b-b2f5-92a4a07d9209_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_1e377da6-cd07-4321-99ae-b8a237b108dd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_35eb09a0-61ea-4d6c-b232-6cd22198321e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeTenMember_4983bfc9-542f-428f-9761-604f09561f4c_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Ten</link:label>
    <link:label id="lab_aqst_VestingConditionRangeTenMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Ten [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeTenMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Ten</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTenMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeTenMember" xlink:to="lab_aqst_VestingConditionRangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3a63034c-fc16-4085-a35e-44e7f63397dd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_93ddd37e-0e66-413f-8d56-2bd9f6c0bd3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective annual interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LicenseSupplyAgreementMember_ca4edbd0-50a1-4150-b09d-e637d238af20_terseLabel_en-US" xlink:label="lab_aqst_LicenseSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License &amp; Supply Agreement</link:label>
    <link:label id="lab_aqst_LicenseSupplyAgreementMember_label_en-US" xlink:label="lab_aqst_LicenseSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License &amp; Supply Agreement [Member]</link:label>
    <link:label id="lab_aqst_LicenseSupplyAgreementMember_documentation_en-US" xlink:label="lab_aqst_LicenseSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License &amp; Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseSupplyAgreementMember" xlink:href="aqst-20250331.xsd#aqst_LicenseSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LicenseSupplyAgreementMember" xlink:to="lab_aqst_LicenseSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_00569a85-8c50-446e-9af8-1fde1d1990fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_WarrantsDisclosureTextBlock_1075d42d-aec6-41f0-8988-05e6ab3050d6_terseLabel_en-US" xlink:label="lab_aqst_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_aqst_WarrantsDisclosureTextBlock_label_en-US" xlink:label="lab_aqst_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Disclosure [Text Block]</link:label>
    <link:label id="lab_aqst_WarrantsDisclosureTextBlock_documentation_en-US" xlink:label="lab_aqst_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_WarrantsDisclosureTextBlock" xlink:href="aqst-20250331.xsd#aqst_WarrantsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_WarrantsDisclosureTextBlock" xlink:to="lab_aqst_WarrantsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86c4283b-275f-4e97-8b1d-8be3bf4ac81b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0d1b32b9-225b-4ecd-9542-536dcde41009_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_286afb46-3c28-46f4-b70a-4b44e4c4f731_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_86e05908-3a4f-47a8-87c2-6da5ed342712_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7418f52a-8d2e-48fa-9ba6-d207804192b6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_b11c940b-4423-4a83-bfb7-ece6315daf9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt principal including lease liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_06326000-90d1-425a-a6ae-61124c0b931e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for loan acquisition costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fff9449f-a30a-419b-b7fd-b41ee19c6b84_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b3bd0c2e-135b-469a-860c-955d0144ce0b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_d5d718c8-f519-492f-b6d2-c4c05e074155_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a16b58c-1090-4444-bddb-bf9b38bebf44_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_95aba4e4-79c8-4b55-a92d-413b99c3e907_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ex-United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_af832eb8-6fd7-43dd-a495-d451e8faa3ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense related to royalty obligations</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0e7331bd-0a03-41c2-b2f3-eec341991f01_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0c4353bf-87f2-4143-9d02-6e583b0fe534_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_a13f3c97-c5db-4c08-9f8f-e34f769f98a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discount, including exit fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_12f7a4d8-e3c7-47c7-a0f6-2f2eb88cb943_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized discount, including Exit Fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_97b20688-e174-448f-bc0d-a4094789cc6c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ef02a5be-0ca8-4fe0-bc0d-29c798b04359_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_974b1a0d-192d-485d-8615-feab1e675a6b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d4eaabd-6394-429b-bbd7-8818bba2af7d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod_a92831f6-9e93-40bb-9828-929e66581f35_terseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average closing prices period</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Closing Prices Period</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Closing Prices Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SaleOfFutureRevenueRollForward_349c5e61-4909-45f5-a280-9f8b40929067_terseLabel_en-US" xlink:label="lab_aqst_SaleOfFutureRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Future Revenue [Roll Forward]</link:label>
    <link:label id="lab_aqst_SaleOfFutureRevenueRollForward_label_en-US" xlink:label="lab_aqst_SaleOfFutureRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Future Revenue [Roll Forward]</link:label>
    <link:label id="lab_aqst_SaleOfFutureRevenueRollForward_documentation_en-US" xlink:label="lab_aqst_SaleOfFutureRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Future Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfFutureRevenueRollForward" xlink:href="aqst-20250331.xsd#aqst_SaleOfFutureRevenueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward" xlink:to="lab_aqst_SaleOfFutureRevenueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b831d5bb-d5ed-4035-bfc4-852af851e6e8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_237a5bbf-3341-423e-86e8-d3aca7c4df83_verboseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_197c884d-94b4-4ef4-8640-f1fab7ba58a3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_920b157f-67ac-473e-9bf8-4768a5549416_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_da622b0a-4d76-4ab5-a1be-9d595373f3a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss)/income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dd399ca-6fb2-4f5a-828a-cea925228a17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RightToSellCommonStockValue_abac0ba6-d1d7-4bc9-ba66-c8e8af7d8f34_terseLabel_en-US" xlink:label="lab_aqst_RightToSellCommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right to sell common stock, value</link:label>
    <link:label id="lab_aqst_RightToSellCommonStockValue_label_en-US" xlink:label="lab_aqst_RightToSellCommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right to Sell Common Stock, Value</link:label>
    <link:label id="lab_aqst_RightToSellCommonStockValue_documentation_en-US" xlink:label="lab_aqst_RightToSellCommonStockValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right to Sell Common Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RightToSellCommonStockValue" xlink:href="aqst-20250331.xsd#aqst_RightToSellCommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RightToSellCommonStockValue" xlink:to="lab_aqst_RightToSellCommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LicenseAgreementTerm_26f8c03a-f526-4402-8bf5-f612d985cf1b_terseLabel_en-US" xlink:label="lab_aqst_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement term</link:label>
    <link:label id="lab_aqst_LicenseAgreementTerm_label_en-US" xlink:label="lab_aqst_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Term</link:label>
    <link:label id="lab_aqst_LicenseAgreementTerm_documentation_en-US" xlink:label="lab_aqst_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreement term period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementTerm" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LicenseAgreementTerm" xlink:to="lab_aqst_LicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ebac8bb0-a58a-45e4-b598-f09df83d1779_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_fb43e21b-0126-49e9-b5c6-7a67c922aa60_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RoyaltyObligationsLiabilityCurrent_bd769f9c-15ea-4391-a5eb-899f1e080442_terseLabel_en-US" xlink:label="lab_aqst_RoyaltyObligationsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligations, current</link:label>
    <link:label id="lab_aqst_RoyaltyObligationsLiabilityCurrent_label_en-US" xlink:label="lab_aqst_RoyaltyObligationsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligations, Liability, Current</link:label>
    <link:label id="lab_aqst_RoyaltyObligationsLiabilityCurrent_documentation_en-US" xlink:label="lab_aqst_RoyaltyObligationsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligations, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsLiabilityCurrent" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RoyaltyObligationsLiabilityCurrent" xlink:to="lab_aqst_RoyaltyObligationsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_bd3b9d44-ce6c-4cd5-bab1-0a8448d0d8c9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_bb0348ab-cf28-42a6-9196-9b8ff9adcc10_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_b987bff3-64a7-41b7-aa41-f4be478b976a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and Other Receivables, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RoyaltyObligationsMember_3cc52d73-3e57-496e-99e7-4530bd1f2948_terseLabel_en-US" xlink:label="lab_aqst_RoyaltyObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Obligations</link:label>
    <link:label id="lab_aqst_RoyaltyObligationsMember_label_en-US" xlink:label="lab_aqst_RoyaltyObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligations [Member]</link:label>
    <link:label id="lab_aqst_RoyaltyObligationsMember_documentation_en-US" xlink:label="lab_aqst_RoyaltyObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsMember" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RoyaltyObligationsMember" xlink:to="lab_aqst_RoyaltyObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_4db85d27-2a31-4cbe-8a3d-aedb1246f194_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_aa80df59-ef0d-4801-bb86-96b31abb518d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_17ba8dde-57d9-44cc-9a0e-6d40961613c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_9d63b54b-c73b-4395-a911-483cb3218bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fc53bef6-8b54-4338-aa84-eeb7bb9ed7d7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_56a841bc-add1-472c-ab36-5075939979a0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7bc1c472-4740-4079-91b0-31eb02efe2f9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">(Loss) Earnings per common share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3808a0db-614b-4a14-a972-eebc977da36b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9df5eaf4-1b6e-4a7a-b841-bbf2497df77f_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_23bf4d5a-18bb-478f-a763-30e51a066bed_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ee3ab4c6-4306-4016-b471-0a1819144b56_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_d671c5e9-777b-4faf-bca9-90d887706d5d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7c22c131-184e-4a79-bbbb-c32040993f77_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_MarathonPangolinRoyaltyLLCMember_2476840c-7bee-4728-a29a-525886e8b04f_terseLabel_en-US" xlink:label="lab_aqst_MarathonPangolinRoyaltyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MAM Pangolin Royalty , LLC</link:label>
    <link:label id="lab_aqst_MarathonPangolinRoyaltyLLCMember_label_en-US" xlink:label="lab_aqst_MarathonPangolinRoyaltyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marathon Pangolin Royalty LLC [Member]</link:label>
    <link:label id="lab_aqst_MarathonPangolinRoyaltyLLCMember_documentation_en-US" xlink:label="lab_aqst_MarathonPangolinRoyaltyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marathon Pangolin Royalty LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarathonPangolinRoyaltyLLCMember" xlink:href="aqst-20250331.xsd#aqst_MarathonPangolinRoyaltyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_MarathonPangolinRoyaltyLLCMember" xlink:to="lab_aqst_MarathonPangolinRoyaltyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ebfcc2a1-f1c2-485e-8e81-b525f13ea0c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeNineMember_86dee835-1dca-4429-af66-47b5a7723a6b_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Nine</link:label>
    <link:label id="lab_aqst_VestingConditionRangeNineMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Nine [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeNineMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Nine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeNineMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeNineMember" xlink:to="lab_aqst_VestingConditionRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_cec2d220-ab25-4540-a99b-9d1504a4a541_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_bd4b499b-8233-435e-b7f2-090105519c38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price, percentage of principal amount redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1d729d81-4208-4b55-9c70-3109709c16f3_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b82b1f83-8a14-4c9e-be2a-fc062ca2775c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ade8f5b2-bc06-42b5-af82-2be9b69da2d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_OtherReceivablesAndAccruedExpensesMember_6b090802-ddb9-4a35-b90f-cbd97f3c8740_terseLabel_en-US" xlink:label="lab_aqst_OtherReceivablesAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Receivables And Accrued Expenses</link:label>
    <link:label id="lab_aqst_OtherReceivablesAndAccruedExpensesMember_label_en-US" xlink:label="lab_aqst_OtherReceivablesAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables And Accrued Expenses [Member]</link:label>
    <link:label id="lab_aqst_OtherReceivablesAndAccruedExpensesMember_documentation_en-US" xlink:label="lab_aqst_OtherReceivablesAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Receivables And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_OtherReceivablesAndAccruedExpensesMember" xlink:href="aqst-20250331.xsd#aqst_OtherReceivablesAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_OtherReceivablesAndAccruedExpensesMember" xlink:to="lab_aqst_OtherReceivablesAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2e68efd7-76f0-4a74-9e7e-568136b398c1_terseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/expired (in dollars per share)</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price of options that were either exercised, forfeited or expired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e61ba13e-bba3-4d0f-a8f4-4d061c3bddce_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ad6fe8fa-cc0b-4580-a904-3cc94400b616_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_abdef51e-66c2-441a-9a37-4251f332e403_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income/(expenses):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember_bae08fb5-fc83-4b67-a00b-d4454790f5d1_terseLabel_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement with Sunovion Pharmaceuticals, Inc. upfront</link:label>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember_label_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member]</link:label>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember_documentation_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The license agreement made with sunovion pharmaceuticals, inc. advance payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" xlink:to="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a80300e3-e9bd-40e3-8e28-650b055d49cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9774c392-72b8-43d9-9f50-19e6666b1d10_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_15a3741a-07a1-4599-ac4b-ce0700006cd2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4d1403eb-433d-4cfb-a383-25ebabc7afdf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_2882c9a3-0fe7-42ef-848f-fa70aa04cb3d_terseLabel_en-US" xlink:label="lab_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes due 2025</link:label>
    <link:label id="lab_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_label_en-US" xlink:label="lab_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twelve Point Five, Senior Secured Notes due June 30, 2025 [Member]</link:label>
    <link:label id="lab_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_documentation_en-US" xlink:label="lab_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member" xlink:href="aqst-20250331.xsd#aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member" xlink:to="lab_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb5193e6-61ba-4ab8-8a8e-2b4f43b3d982_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e69c0c92-b674-4e3f-b296-a7b477318196_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties related to the sale of future revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08c422f1-39d2-4d69-95c0-2cbda184e4af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LitigationSettlementAmountAwardPeriodDue_cac63223-5653-433d-b97c-ca8238bafc8f_terseLabel_en-US" xlink:label="lab_aqst_LitigationSettlementAmountAwardPeriodDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, period due</link:label>
    <link:label id="lab_aqst_LitigationSettlementAmountAwardPeriodDue_label_en-US" xlink:label="lab_aqst_LitigationSettlementAmountAwardPeriodDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Award, Period Due</link:label>
    <link:label id="lab_aqst_LitigationSettlementAmountAwardPeriodDue_documentation_en-US" xlink:label="lab_aqst_LitigationSettlementAmountAwardPeriodDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Award, Period Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LitigationSettlementAmountAwardPeriodDue" xlink:href="aqst-20250331.xsd#aqst_LitigationSettlementAmountAwardPeriodDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LitigationSettlementAmountAwardPeriodDue" xlink:to="lab_aqst_LitigationSettlementAmountAwardPeriodDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a351c098-da1a-4467-b088-3bf3399e78d6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_NumberOfOperatingLeases_f72a47fb-ed1b-467f-8aa5-37595f0be04b_terseLabel_en-US" xlink:label="lab_aqst_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_aqst_NumberOfOperatingLeases_label_en-US" xlink:label="lab_aqst_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Leases</link:label>
    <link:label id="lab_aqst_NumberOfOperatingLeases_documentation_en-US" xlink:label="lab_aqst_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfOperatingLeases" xlink:href="aqst-20250331.xsd#aqst_NumberOfOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_NumberOfOperatingLeases" xlink:to="lab_aqst_NumberOfOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7641ff17-c1c1-4955-87bb-ae825e98e289_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9bd3ea25-9d7f-4e83-993d-0d48aa0cea22_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used for investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a1ee151c-bff5-4f3c-9404-a346e23ccb62_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_caa0e3fb-9f59-45c3-a77b-ce4bafb3e683_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued under public equity offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_MarketBasedMember_865af2e0-9176-4cdb-b50f-42c960e52917_terseLabel_en-US" xlink:label="lab_aqst_MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Based</link:label>
    <link:label id="lab_aqst_MarketBasedMember_label_en-US" xlink:label="lab_aqst_MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Based [Member]</link:label>
    <link:label id="lab_aqst_MarketBasedMember_documentation_en-US" xlink:label="lab_aqst_MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarketBasedMember" xlink:href="aqst-20250331.xsd#aqst_MarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_MarketBasedMember" xlink:to="lab_aqst_MarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LincolnParkAgreementMember_10a2474b-49d8-439e-9c70-d759174829af_terseLabel_en-US" xlink:label="lab_aqst_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lincoln Park agreement</link:label>
    <link:label id="lab_aqst_LincolnParkAgreementMember_label_en-US" xlink:label="lab_aqst_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:label id="lab_aqst_LincolnParkAgreementMember_documentation_en-US" xlink:label="lab_aqst_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lincoln Park Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LincolnParkAgreementMember" xlink:href="aqst-20250331.xsd#aqst_LincolnParkAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LincolnParkAgreementMember" xlink:to="lab_aqst_LincolnParkAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_e06db219-7bb5-48a2-abd8-7ccff81aae78_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d52d838c-9261-4b85-8b00-ead512cb3132_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_PaymentsForRoyaltyObligationsFinancingObligations_5d5882a5-7fb8-4a3c-9b11-66b1a0b4b16e_negatedTerseLabel_en-US" xlink:label="lab_aqst_PaymentsForRoyaltyObligationsFinancingObligations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for royalty obligations</link:label>
    <link:label id="lab_aqst_PaymentsForRoyaltyObligationsFinancingObligations_label_en-US" xlink:label="lab_aqst_PaymentsForRoyaltyObligationsFinancingObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalty Obligations, Financing Obligations</link:label>
    <link:label id="lab_aqst_PaymentsForRoyaltyObligationsFinancingObligations_documentation_en-US" xlink:label="lab_aqst_PaymentsForRoyaltyObligationsFinancingObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Royalty Obligations, Financing Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations" xlink:href="aqst-20250331.xsd#aqst_PaymentsForRoyaltyObligationsFinancingObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations" xlink:to="lab_aqst_PaymentsForRoyaltyObligationsFinancingObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8c2c2e2a-92c0-4716-bdf8-7d2e2ce7f7a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a72d65a2-7039-4e4d-845b-730a43db040d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_808506f4-2c79-456f-8c95-9245576e02ef_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81b34657-128d-46c1-a672-a9cb0de0bc03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_16751d6d-c466-42b9-8852-b7c27302ba91_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionAxis_a968ca72-b025-4051-80b4-440b834920f8_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition [Axis]</link:label>
    <link:label id="lab_aqst_VestingConditionAxis_label_en-US" xlink:label="lab_aqst_VestingConditionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition [Axis]</link:label>
    <link:label id="lab_aqst_VestingConditionAxis_documentation_en-US" xlink:label="lab_aqst_VestingConditionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionAxis" xlink:href="aqst-20250331.xsd#aqst_VestingConditionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionAxis" xlink:to="lab_aqst_VestingConditionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eae5e5ff-b5c1-41ba-a092-fb772c44ad4a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_83a2b6a6-8508-4280-a22f-d93e8a56da4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Maturity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ddc99bbc-b7d0-414b-89b5-54ad18c4d651_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_TradeAccountsReceivableSalesRelatedMember_2678ce75-bbde-43bb-81f1-d7ef7efe8c36_terseLabel_en-US" xlink:label="lab_aqst_TradeAccountsReceivableSalesRelatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable, Sales Related</link:label>
    <link:label id="lab_aqst_TradeAccountsReceivableSalesRelatedMember_label_en-US" xlink:label="lab_aqst_TradeAccountsReceivableSalesRelatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable, Sales Related [Member]</link:label>
    <link:label id="lab_aqst_TradeAccountsReceivableSalesRelatedMember_documentation_en-US" xlink:label="lab_aqst_TradeAccountsReceivableSalesRelatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable, Sales Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableSalesRelatedMember" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableSalesRelatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_TradeAccountsReceivableSalesRelatedMember" xlink:to="lab_aqst_TradeAccountsReceivableSalesRelatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89a7738f-f5fb-4d85-a99e-be42c803d1bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_DebtCovenantRedemptionScenarioDomain_c343f327-38d3-4cb1-9686-637917d1310d_terseLabel_en-US" xlink:label="lab_aqst_DebtCovenantRedemptionScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant, Redemption Scenario [Domain]</link:label>
    <link:label id="lab_aqst_DebtCovenantRedemptionScenarioDomain_label_en-US" xlink:label="lab_aqst_DebtCovenantRedemptionScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant, Redemption Scenario [Domain]</link:label>
    <link:label id="lab_aqst_DebtCovenantRedemptionScenarioDomain_documentation_en-US" xlink:label="lab_aqst_DebtCovenantRedemptionScenarioDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant, Redemption Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtCovenantRedemptionScenarioDomain" xlink:href="aqst-20250331.xsd#aqst_DebtCovenantRedemptionScenarioDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioDomain" xlink:to="lab_aqst_DebtCovenantRedemptionScenarioDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9a6c8706-6b38-4bb7-99b3-86d295f6b3f3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_597d928f-64a2-4418-8b2d-875ec80ddbe7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_23570af7-ad59-4795-8d82-06ae515e0f4f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f8f24498-be6f-44dc-b191-7e952c73bf68_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_536d98c2-c994-4081-a6e0-c8e9242198d3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_29b46ff9-e976-4de7-a887-d0f7086bab82_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_36b0d352-cf00-4556-8bb7-28776dc5b1cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_257663f6-c750-4997-b7ca-e944e4366fd4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent_7f107bf3-ae02-4e86-b73b-7b4f6cb6f7bd_terseLabel_en-US" xlink:label="lab_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, net</link:label>
    <link:label id="lab_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes, Noncurrent And Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes, Noncurrent And Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" xlink:href="aqst-20250331.xsd#aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeTwelveMember_39f967c4-ea95-414d-9812-e4b67f74e5de_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Twelve</link:label>
    <link:label id="lab_aqst_VestingConditionRangeTwelveMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Twelve [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeTwelveMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Twelve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTwelveMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeTwelveMember" xlink:to="lab_aqst_VestingConditionRangeTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1ce352f9-b858-4abc-bcec-89d584ba838f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_bb79b91f-0e05-4421-9794-65c9a0cc0469_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_191f97c5-176f-4522-ab4e-a05d4540afdc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeThreeMember_da633022-9308-44e0-9ee5-5be5fcf67a79_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition Range Three</link:label>
    <link:label id="lab_aqst_VestingConditionRangeThreeMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Three [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeThreeMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeThreeMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeThreeMember" xlink:to="lab_aqst_VestingConditionRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_271f048f-e48b-4a8c-8a84-1a37d5974bd9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_757f7410-9665-41e0-a686-3d3770193ad6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13b1a7b0-4331-4425-8008-92c2f6ec3207_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_TradeAndOtherReceivablesNet_f543896d-e7ae-4d90-9a27-fae807769c11_terseLabel_en-US" xlink:label="lab_aqst_TradeAndOtherReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables, net</link:label>
    <link:label id="lab_aqst_TradeAndOtherReceivablesNet_a6239d7f-92f2-4353-bc37-4eef306b3d9b_totalLabel_en-US" xlink:label="lab_aqst_TradeAndOtherReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables, net</link:label>
    <link:label id="lab_aqst_TradeAndOtherReceivablesNet_label_en-US" xlink:label="lab_aqst_TradeAndOtherReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade And Other Receivables, Net</link:label>
    <link:label id="lab_aqst_TradeAndOtherReceivablesNet_documentation_en-US" xlink:label="lab_aqst_TradeAndOtherReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade and other receivables).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAndOtherReceivablesNet" xlink:href="aqst-20250331.xsd#aqst_TradeAndOtherReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_TradeAndOtherReceivablesNet" xlink:to="lab_aqst_TradeAndOtherReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2207b45c-b04d-4305-8924-bd64d43e5ea0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d450905e-a9bd-4563-a950-886a7b22d67a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized deferred debt issuance cost and deferred debt discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_234d42a1-1953-4258-971a-176e19cc6afc_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ManufacturingAndSupplyMember_eda17fa6-a25f-49a0-878e-847710e26610_verboseLabel_en-US" xlink:label="lab_aqst_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Manufacture and supply</link:label>
    <link:label id="lab_aqst_ManufacturingAndSupplyMember_label_en-US" xlink:label="lab_aqst_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing And Supply [Member]</link:label>
    <link:label id="lab_aqst_ManufacturingAndSupplyMember_documentation_en-US" xlink:label="lab_aqst_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Primary financial statement caption encompassing Manufacturing and supply expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufacturingAndSupplyMember" xlink:href="aqst-20250331.xsd#aqst_ManufacturingAndSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ManufacturingAndSupplyMember" xlink:to="lab_aqst_ManufacturingAndSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_446cd73e-ccc4-4c8a-b01c-f0511747a114_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_18a352aa-550b-49b2-a4c0-a2f4803e5364_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_fe9c1e75-eef8-490e-a41e-bf1344d75241_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c06e6993-14af-4edc-870e-d1ec4236bc61_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2a40643-68cf-4365-80dc-42b159a07862_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c9f33556-be22-4f10-ac13-287304793af8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_aaf810e5-df34-4b83-b86b-3b5624d604a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_44c8a62d-379a-4d81-8534-9d6f84bb3f15_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1459ec4c-3002-489c-a340-9466da79102d_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2f6ad5bc-b577-4286-b9bb-acdca863a2ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6f8158ea-cb57-4d22-ab7f-efb1b09a8ce8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_0b6d2585-e999-4ec2-93be-9996b0a930f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Allowance reduction</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_1d38686c-d98a-48a4-9021-3b23dd2a5d4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance reduction</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_878ba2cc-a8e8-4198-9414-c7bd3d704f56_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_aac60d31-70a4-4822-b748-72452661bba2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5b9500a6-20db-4f5e-819a-bd12aef320f4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_28e8cda1-756d-4f61-99c2-2bce931d4f46_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0d15a035-0bf7-4013-8fdb-6ac2b8e69103_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total outstanding notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_MeasurementInputProbabilityOfSuccessMember_396e99bb-9c42-4344-8407-5dc6e796cff0_terseLabel_en-US" xlink:label="lab_aqst_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Success</link:label>
    <link:label id="lab_aqst_MeasurementInputProbabilityOfSuccessMember_label_en-US" xlink:label="lab_aqst_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Success [Member]</link:label>
    <link:label id="lab_aqst_MeasurementInputProbabilityOfSuccessMember_documentation_en-US" xlink:label="lab_aqst_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Success</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MeasurementInputProbabilityOfSuccessMember" xlink:href="aqst-20250331.xsd#aqst_MeasurementInputProbabilityOfSuccessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_aqst_MeasurementInputProbabilityOfSuccessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ec215d55-51c6-4978-abe1-6e6cde93f889_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_a6b23222-bde9-4a67-8d11-6d230134e7a0_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SaleOfFutureRevenueTextBlock_2ae45757-d119-4093-baeb-45344128b314_terseLabel_en-US" xlink:label="lab_aqst_SaleOfFutureRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Future Revenue</link:label>
    <link:label id="lab_aqst_SaleOfFutureRevenueTextBlock_label_en-US" xlink:label="lab_aqst_SaleOfFutureRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Future Revenue [Text Block]</link:label>
    <link:label id="lab_aqst_SaleOfFutureRevenueTextBlock_documentation_en-US" xlink:label="lab_aqst_SaleOfFutureRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Future Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfFutureRevenueTextBlock" xlink:href="aqst-20250331.xsd#aqst_SaleOfFutureRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SaleOfFutureRevenueTextBlock" xlink:to="lab_aqst_SaleOfFutureRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_559993b5-800a-4650-be2d-196189f9905e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0c8bb2c3-a2a3-409d-a4c3-4297777839c3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f3c6ad85-f13e-4932-88fa-e919ab3bae63_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_97fe199f-b9f9-4ec3-9e07-f6d135b8e882_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_InventoryPackingMaterialGross_647afb12-ce02-4c36-9b2e-ef8e216d9a4a_terseLabel_en-US" xlink:label="lab_aqst_InventoryPackingMaterialGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Packaging material</link:label>
    <link:label id="lab_aqst_InventoryPackingMaterialGross_label_en-US" xlink:label="lab_aqst_InventoryPackingMaterialGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Packing Material Gross</link:label>
    <link:label id="lab_aqst_InventoryPackingMaterialGross_documentation_en-US" xlink:label="lab_aqst_InventoryPackingMaterialGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of packaging materials expected to be sold within one year or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InventoryPackingMaterialGross" xlink:href="aqst-20250331.xsd#aqst_InventoryPackingMaterialGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_InventoryPackingMaterialGross" xlink:to="lab_aqst_InventoryPackingMaterialGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_1ef3ccfa-cebf-4d3a-8344-b6655fd23be7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_fc43750d-d8aa-4617-ae93-66f5c3115cb3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_bf4fa2fe-176a-4bbb-a180-69fd356695df_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling expenses:</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1dad04a5-f662-42bf-ba37-93de96d52432_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f22ca3c3-402e-408d-8c00-fca43090919d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_838e15e4-a231-47e0-8696-fccdf7348c9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a198c5c6-9257-46e5-940c-5adaa3437b62_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember_2afbc462-f9de-4e3f-8890-987cd8cf958d_terseLabel_en-US" xlink:label="lab_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Haisco Pharmaceutical Group Co., Ltd, upfront payment</link:label>
    <link:label id="lab_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember_label_en-US" xlink:label="lab_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Haisco Pharmaceutical Group Co., Ltd, Upfront Payment [Member]</link:label>
    <link:label id="lab_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember_documentation_en-US" xlink:label="lab_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Haisco Pharmaceutical Group Co., Ltd, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" xlink:href="aqst-20250331.xsd#aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" xlink:to="lab_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2ade5de6-cbe2-4326-a40b-4ebcdcdfe04c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_NewWarrantsMember_062fae5d-b5e7-406e-8832-c409157f33b0_terseLabel_en-US" xlink:label="lab_aqst_NewWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Warrants</link:label>
    <link:label id="lab_aqst_NewWarrantsMember_label_en-US" xlink:label="lab_aqst_NewWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Warrants [Member]</link:label>
    <link:label id="lab_aqst_NewWarrantsMember_documentation_en-US" xlink:label="lab_aqst_NewWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NewWarrantsMember" xlink:href="aqst-20250331.xsd#aqst_NewWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_NewWarrantsMember" xlink:to="lab_aqst_NewWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_5293bf68-04a8-4a39-a417-6782ae850af4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7cc73906-e841-4cc1-8343-6d36cc4c980a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs of RSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6471225e-b5ff-4498-95e8-b07115a03a45_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeSixMember_ae0cb739-a952-44d1-a2ba-87d6ea40a41f_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition Range Six</link:label>
    <link:label id="lab_aqst_VestingConditionRangeSixMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Six [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeSixMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeSixMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeSixMember" xlink:to="lab_aqst_VestingConditionRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeFourMember_a6c1d70f-beef-4ba5-84b6-3ddadc393c41_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition Range Four</link:label>
    <link:label id="lab_aqst_VestingConditionRangeFourMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Four [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeFourMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeFourMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeFourMember" xlink:to="lab_aqst_VestingConditionRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_256ccfb1-87d4-4877-9730-90334e7bbd33_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ded4852c-fd7a-47fc-a300-f9a8a45fe0e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_0eb259d0-2949-4ca3-9a32-5c3d9cbbb99c_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Areas, Revenues from External Customers [Abstract]</link:label>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_label_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Areas, Revenues from External Customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c15169af-ff80-4271-87aa-20bdbc7a58d9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_9687e88e-4574-4e9c-8ebf-f50cc902514d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-current Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ac07f4b0-bab5-40e9-8141-964492d2f98d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_a3fe4fb4-6603-4345-bae1-7fa9ebfae25f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea1ba1c-562f-4f7f-82cd-b3c0dd9c5709_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LibervantMember_e1a3e01d-5cbe-4cf0-aaf1-a9286ee6c65e_terseLabel_en-US" xlink:label="lab_aqst_LibervantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Libervant project expenses</link:label>
    <link:label id="lab_aqst_LibervantMember_label_en-US" xlink:label="lab_aqst_LibervantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Libervant [Member]</link:label>
    <link:label id="lab_aqst_LibervantMember_documentation_en-US" xlink:label="lab_aqst_LibervantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Libervant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LibervantMember" xlink:href="aqst-20250331.xsd#aqst_LibervantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LibervantMember" xlink:to="lab_aqst_LibervantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbb3161a-f52d-4f8c-a8cb-9fe92bee2f36_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f8dd0336-5415-4f89-9a38-b488a620acab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_fa9571fc-dc09-4ae8-95bd-96ac2cd59c15_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d7943489-6dae-4e4d-b309-5694c23bb117_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_c2700345-2415-4212-b0a6-b3bbfe92934b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets, finite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b0503846-d5c8-4763-a8a5-3137166cc183_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5af72928-e85f-431e-a303-49c8c9febdac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_53212a60-b48d-4bfa-950e-a7b18f6a7952_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_cbbfb09a-e079-4caa-b3c0-708cefda8333_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RedemptionScenario2Member_66871fa9-5f75-45f5-9437-9a34a8dcfe88_terseLabel_en-US" xlink:label="lab_aqst_RedemptionScenario2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption Scenario 2</link:label>
    <link:label id="lab_aqst_RedemptionScenario2Member_label_en-US" xlink:label="lab_aqst_RedemptionScenario2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Scenario 2 [Member]</link:label>
    <link:label id="lab_aqst_RedemptionScenario2Member_documentation_en-US" xlink:label="lab_aqst_RedemptionScenario2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption Scenario 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RedemptionScenario2Member" xlink:href="aqst-20250331.xsd#aqst_RedemptionScenario2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RedemptionScenario2Member" xlink:to="lab_aqst_RedemptionScenario2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_7b163cfa-7913-456c-b69b-387fcb53da0c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f899ea59-6160-4f3d-b144-cd0cbdf57e19_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock issued under public equity offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7389c871-7edd-42e8-b9b4-ac75e648e404_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_9cfad49d-89bd-4795-b0ee-b071e03b4197_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Costs of common stock issued under public equity offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b424ecbc-c841-4c79-953f-25edeb40f4b2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod_39c1b3b4-8ff6-447c-80d4-e994406ed7d0_terseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average closing price, number of days utilized in pricing period</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Days Utilized in Pricing Period</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Days Utilized in Pricing Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3de2da7c-0586-4639-bd26-a6eb699a4e0e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b8b33f79-0223-4e4a-aeec-8eda96ae3653_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a8eb43b8-9137-4d30-8d5c-0aa19f1185b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_9a9dd977-1130-4205-af95-63e475baa34d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_366a616a-8597-4d7a-8ba7-e22e1e697890_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6141ffef-3c00-4ddd-bf0d-966f888bd471_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of royalty obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_72b1d820-b814-4cd8-b276-ace6ea5ee00a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage_0e6dd0e3-041a-494a-bc97-4c7e099957ed_terseLabel_en-US" xlink:label="lab_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, Interest rate, change in effective percentage</link:label>
    <link:label id="lab_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage_label_en-US" xlink:label="lab_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Change in Effective Percentage</link:label>
    <link:label id="lab_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage_documentation_en-US" xlink:label="lab_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Change in Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentInterestRateChangeInEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage" xlink:to="lab_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_a60569b5-4ff8-4685-bf43-248a27c45266_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proprietary product revenue, net</link:label>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_label_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturedProductOtherMember" xlink:to="lab_us-gaap_ManufacturedProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_314d4e70-f084-4284-aeb6-29d0f83d935e_terseLabel_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement with Sunovion Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_label_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement with Sunovion Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The license agreement made with sunovion pharmaceuticals, inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember" xlink:to="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cf9b75d8-5e2c-4c41-9c05-fddafd042d89_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ac6d6e59-c711-4536-8e6d-1b6fdd14f2e9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d2985d29-01fe-45ce-8760-b7eb31ab0aa5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_c3aa6eb0-23dd-45de-9a3c-576844026f1a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized contract cost, net</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable_c85aaba0-7cee-480b-b1c5-89d4b3f8bc47_terseLabel_en-US" xlink:label="lab_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs associated with public equity offering in Accounts Payable</link:label>
    <link:label id="lab_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable_label_en-US" xlink:label="lab_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Public Equity Offering in Accounts Payable</link:label>
    <link:label id="lab_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable_documentation_en-US" xlink:label="lab_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs Associated with Public Equity Offering in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable" xlink:href="aqst-20250331.xsd#aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable" xlink:to="lab_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_aaa84df4-03c7-4c40-bbdc-d95cca8c6b89_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f519d3de-9c36-45b6-8a87-e509f921d237_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_65771c18-cda9-47bd-bb21-bf3bac324468_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c5515166-b920-4d16-b372-9a6fc54e62eb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d6cfe5f9-9c06-47e1-a122-675042978046_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e236f1c8-c732-4521-981e-62b3ee9f39e1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ExistingWarrantsMember_99aac76d-0f20-46e2-830c-30c78f629b53_terseLabel_en-US" xlink:label="lab_aqst_ExistingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Existing Warrants</link:label>
    <link:label id="lab_aqst_ExistingWarrantsMember_label_en-US" xlink:label="lab_aqst_ExistingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Existing Warrants [Member]</link:label>
    <link:label id="lab_aqst_ExistingWarrantsMember_documentation_en-US" xlink:label="lab_aqst_ExistingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Existing Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ExistingWarrantsMember" xlink:href="aqst-20250331.xsd#aqst_ExistingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ExistingWarrantsMember" xlink:to="lab_aqst_ExistingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_a24533c5-cd15-42b3-92d6-0276dd05f722_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units, net</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_57379501-14ff-4f45-b698-7ecac42d25c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate_7cab0967-cce6-48db-95c6-95a0e4ea5473_terseLabel_en-US" xlink:label="lab_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price, basis points above treasury rate</link:label>
    <link:label id="lab_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate_label_en-US" xlink:label="lab_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Basis Spread On Variable Rate</link:label>
    <link:label id="lab_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate_documentation_en-US" xlink:label="lab_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Basis Spread On Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" xlink:to="lab_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_52aef372-f7c3-44fd-b790-6818b7f1f6cd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_cc4cd27d-027e-44e5-b7d0-882404fd9e66_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b0920f60-d65a-4c27-b7b0-b5060f65756f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_217867b8-632d-40f6-99b0-af1977bf7f48_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_75fb8402-5083-460a-8a48-067726713903_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2d814f6b-29a8-46ce-86b8-313e3662d5e6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8eec25b6-8fea-4a92-b1d8-952a52e2e2b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9f0e7aba-3ddf-4e43-8f9b-c298ef3cfe16_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, long-term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_CoDevelopmentAndResearchFeesMember_8205a496-c191-4ad1-91c5-67fbf420c371_terseLabel_en-US" xlink:label="lab_aqst_CoDevelopmentAndResearchFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-development and research fees</link:label>
    <link:label id="lab_aqst_CoDevelopmentAndResearchFeesMember_label_en-US" xlink:label="lab_aqst_CoDevelopmentAndResearchFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-Development and Research Fees [Member]</link:label>
    <link:label id="lab_aqst_CoDevelopmentAndResearchFeesMember_documentation_en-US" xlink:label="lab_aqst_CoDevelopmentAndResearchFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate revenue generated from Co-development and research fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CoDevelopmentAndResearchFeesMember" xlink:href="aqst-20250331.xsd#aqst_CoDevelopmentAndResearchFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_CoDevelopmentAndResearchFeesMember" xlink:to="lab_aqst_CoDevelopmentAndResearchFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99d18f06-1555-42ee-a485-871d02351023_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_deb54e9b-b9e7-4e0e-b3cd-aaac46ebe30f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b47a4bb7-4794-4a4e-99bf-3b5ba9b2db7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d5728101-4755-4525-bab1-ad0296bd69eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AssertioHoldingsIncMember_64851f26-62e4-4d0d-886f-aaa836fbdff7_terseLabel_en-US" xlink:label="lab_aqst_AssertioHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assertio Holdings, Inc</link:label>
    <link:label id="lab_aqst_AssertioHoldingsIncMember_label_en-US" xlink:label="lab_aqst_AssertioHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assertio Holdings, Inc [Member]</link:label>
    <link:label id="lab_aqst_AssertioHoldingsIncMember_documentation_en-US" xlink:label="lab_aqst_AssertioHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assertio Holdings, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AssertioHoldingsIncMember" xlink:href="aqst-20250331.xsd#aqst_AssertioHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AssertioHoldingsIncMember" xlink:to="lab_aqst_AssertioHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_NeurelisIncVAquestiveTherapeuticsIncMember_51c60e29-c5fc-4357-8cd2-0ba28b54d758_terseLabel_en-US" xlink:label="lab_aqst_NeurelisIncVAquestiveTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurelis, Inc. v. Aquestive Therapeutics, Inc.</link:label>
    <link:label id="lab_aqst_NeurelisIncVAquestiveTherapeuticsIncMember_label_en-US" xlink:label="lab_aqst_NeurelisIncVAquestiveTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurelis, Inc. v. Aquestive Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_aqst_NeurelisIncVAquestiveTherapeuticsIncMember_documentation_en-US" xlink:label="lab_aqst_NeurelisIncVAquestiveTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurelis, Inc. v. Aquestive Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NeurelisIncVAquestiveTherapeuticsIncMember" xlink:href="aqst-20250331.xsd#aqst_NeurelisIncVAquestiveTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_NeurelisIncVAquestiveTherapeuticsIncMember" xlink:to="lab_aqst_NeurelisIncVAquestiveTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_964c87ff-fa08-4a7f-b845-f4427ba1ad1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4eb0e489-50b8-4c7f-8cb8-c59ff32d7f00_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Overview and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_22841d3b-9dc3-46df-a697-d8e66d21e1f9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share attributable to common stockholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_3da273ad-56a6-4364-9692-139724155973_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod_d2ce4811-574a-4d18-93e9-6f365914a210_negatedTerseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/expired (in shares)</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Forfeitures And Expirations In Period</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">For presentations that combine terminations, the number of shares under options that were exercised, cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b857a908-2e27-48bb-9731-a0f05a496993_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0caa95cb-1d41-43be-9e62-27ec86a4e19c_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods_ba5cbe1e-4ba6-4914-b7a9-3e3693670e4f_terseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pricing periods</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Pricing Periods</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Pricing Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_e4ced69b-43ff-4dae-bc39-1e8f53cd460f_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans payable, current</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_48110266-5d97-427c-897b-41700fc31351_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_55f41496-98c1-4d13-af85-57bcf0538cd3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit_2aedccd3-1086-43e4-954a-a563f68f3749_terseLabel_en-US" xlink:label="lab_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, accordion feature, increase limit</link:label>
    <link:label id="lab_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit_label_en-US" xlink:label="lab_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Accordion Feature, Increase Limit</link:label>
    <link:label id="lab_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit_documentation_en-US" xlink:label="lab_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Accordion Feature, Increase Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:href="aqst-20250331.xsd#aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:to="lab_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9595b37f-1659-4aa1-939f-c9b05f0c4617_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_FirstAdditionalWarrantOfferingMember_2dab8bba-fe04-4424-ac7d-bed8590d28ca_terseLabel_en-US" xlink:label="lab_aqst_FirstAdditionalWarrantOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Additional Warrant Offering</link:label>
    <link:label id="lab_aqst_FirstAdditionalWarrantOfferingMember_label_en-US" xlink:label="lab_aqst_FirstAdditionalWarrantOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Additional Warrant Offering [Member]</link:label>
    <link:label id="lab_aqst_FirstAdditionalWarrantOfferingMember_documentation_en-US" xlink:label="lab_aqst_FirstAdditionalWarrantOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Additional Warrant Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_FirstAdditionalWarrantOfferingMember" xlink:href="aqst-20250331.xsd#aqst_FirstAdditionalWarrantOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_FirstAdditionalWarrantOfferingMember" xlink:to="lab_aqst_FirstAdditionalWarrantOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_18411b46-7224-4efc-ba1f-761c076f89b8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a906bd7c-b2e0-42bc-9651-77969a662961_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0b9e6eab-815f-450b-8323-8522434ee0db_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_5dc2a680-e37f-4471-b48e-6e4652b3b666_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fee amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2708a055-f329-447a-bf6f-35747a6ed85b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeTwoMember_52bef8e9-67bf-4519-a790-db8b6c31405c_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition Range Two</link:label>
    <link:label id="lab_aqst_VestingConditionRangeTwoMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Two [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeTwoMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTwoMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeTwoMember" xlink:to="lab_aqst_VestingConditionRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_8a4afbf8-3ff2-4134-b4df-cc69a80399dc_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_EquityDistributionAgreementMember_8cacffb3-e228-412c-8e88-6997a754325a_terseLabel_en-US" xlink:label="lab_aqst_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity distribution agreement</link:label>
    <link:label id="lab_aqst_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_aqst_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_aqst_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_aqst_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_EquityDistributionAgreementMember" xlink:href="aqst-20250331.xsd#aqst_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_EquityDistributionAgreementMember" xlink:to="lab_aqst_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_cc8e6401-54e1-496c-8996-4fea9a71099e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingExpense_94b50af9-1cfd-4350-ae9b-1715b4599620_terseLabel_en-US" xlink:label="lab_us-gaap_SellingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Selling expenses</link:label>
    <link:label id="lab_us-gaap_SellingExpense_label_en-US" xlink:label="lab_us-gaap_SellingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingExpense" xlink:to="lab_us-gaap_SellingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_Warrants0.96ExercisePriceMember_58a1b71d-f5d7-4067-9f79-91344c42fb84_terseLabel_en-US" xlink:label="lab_aqst_Warrants0.96ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, $0.96 Exercise Price</link:label>
    <link:label id="lab_aqst_Warrants0.96ExercisePriceMember_label_en-US" xlink:label="lab_aqst_Warrants0.96ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, $0.96 Exercise Price [Member]</link:label>
    <link:label id="lab_aqst_Warrants0.96ExercisePriceMember_documentation_en-US" xlink:label="lab_aqst_Warrants0.96ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, $0.96 Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants0.96ExercisePriceMember" xlink:href="aqst-20250331.xsd#aqst_Warrants0.96ExercisePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_Warrants0.96ExercisePriceMember" xlink:to="lab_aqst_Warrants0.96ExercisePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8d24dcfe-2bdb-443d-8437-6b5e396255e3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_a937af81-7b15-422a-a93c-325d3ba8287a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_24fda5cf-acb9-4731-89d5-19fa465b6b21_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AnaphylmMember_c06d326d-da36-4eeb-a2ea-a355b847895c_terseLabel_en-US" xlink:label="lab_aqst_AnaphylmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anaphylm project expenses</link:label>
    <link:label id="lab_aqst_AnaphylmMember_label_en-US" xlink:label="lab_aqst_AnaphylmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anaphylm [Member]</link:label>
    <link:label id="lab_aqst_AnaphylmMember_documentation_en-US" xlink:label="lab_aqst_AnaphylmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anaphylm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AnaphylmMember" xlink:href="aqst-20250331.xsd#aqst_AnaphylmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AnaphylmMember" xlink:to="lab_aqst_AnaphylmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SaleOfStockMaximumTransactionAmount_5f8d3bc3-f7b3-48cc-b511-31116eaa1a75_terseLabel_en-US" xlink:label="lab_aqst_SaleOfStockMaximumTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum transaction amount</link:label>
    <link:label id="lab_aqst_SaleOfStockMaximumTransactionAmount_label_en-US" xlink:label="lab_aqst_SaleOfStockMaximumTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Transaction Amount</link:label>
    <link:label id="lab_aqst_SaleOfStockMaximumTransactionAmount_documentation_en-US" xlink:label="lab_aqst_SaleOfStockMaximumTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Maximum Transaction Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockMaximumTransactionAmount" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockMaximumTransactionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SaleOfStockMaximumTransactionAmount" xlink:to="lab_aqst_SaleOfStockMaximumTransactionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_8389e613-29cf-4f68-9abe-6d1e5d1227e9_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3fcf9284-9853-47b3-a458-497d6f53f334_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeOneMember_e96317ee-a130-4873-9b93-72aa88ad1cc2_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Condition Range One</link:label>
    <link:label id="lab_aqst_VestingConditionRangeOneMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range One [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeOneMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeOneMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeOneMember" xlink:to="lab_aqst_VestingConditionRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_RoyaltyObligationLiabilityNoncurrent_38148c06-f3d4-46b6-86c8-06050adc911a_terseLabel_en-US" xlink:label="lab_aqst_RoyaltyObligationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligations, net</link:label>
    <link:label id="lab_aqst_RoyaltyObligationLiabilityNoncurrent_label_en-US" xlink:label="lab_aqst_RoyaltyObligationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Liability, Noncurrent</link:label>
    <link:label id="lab_aqst_RoyaltyObligationLiabilityNoncurrent_documentation_en-US" xlink:label="lab_aqst_RoyaltyObligationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationLiabilityNoncurrent" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_RoyaltyObligationLiabilityNoncurrent" xlink:to="lab_aqst_RoyaltyObligationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_04559a31-79b9-4882-92a2-55a218661d0d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b6b3bebc-18cd-46db-8502-1d285df2c859_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4d9a2e00-7845-43f9-94cd-110f3dbc32be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SuboxoneProduceLiabilityLitigationMember_870ed2a8-9699-46d5-b866-ca5e681af170_terseLabel_en-US" xlink:label="lab_aqst_SuboxoneProduceLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Suboxone Produce Liability Litigation</link:label>
    <link:label id="lab_aqst_SuboxoneProduceLiabilityLitigationMember_label_en-US" xlink:label="lab_aqst_SuboxoneProduceLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suboxone Produce Liability Litigation [Member]</link:label>
    <link:label id="lab_aqst_SuboxoneProduceLiabilityLitigationMember_documentation_en-US" xlink:label="lab_aqst_SuboxoneProduceLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Suboxone Produce Liability Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SuboxoneProduceLiabilityLitigationMember" xlink:href="aqst-20250331.xsd#aqst_SuboxoneProduceLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SuboxoneProduceLiabilityLitigationMember" xlink:to="lab_aqst_SuboxoneProduceLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2e351075-f88b-4cc8-9094-cd5abc353678_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e990b92e-decb-4c7b-8769-bf3e2d0c118c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_89adafff-a2ac-469f-9872-3e2a79c4fadf_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e4aa814-278a-4dda-b1be-f7e60b8d3197_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock issued under public equity offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_41679ba7-2ec4-4b86-b8f4-049b9b7c279f_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c63f6c0a-1421-465d-882f-91d744b35f9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_a66366eb-45e6-4264-9c68-4ea19d915ca6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants_d318be3b-5cbb-496b-81ca-2dd5c4b8b832_terseLabel_en-US" xlink:label="lab_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock (in shares)</link:label>
    <link:label id="lab_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants_label_en-US" xlink:label="lab_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Of Common Stock Entitled To Purchasers By Pre-Funded Warrants</link:label>
    <link:label id="lab_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants_documentation_en-US" xlink:label="lab_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Of Common Stock Entitled To Purchasers By Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" xlink:href="aqst-20250331.xsd#aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" xlink:to="lab_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_702516f7-1057-4fa5-9e58-ac13e94ab92e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d17d897b-75a2-45cc-91a2-024c51ccd5c7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_5a866c40-0ba6-41b2-a4f5-9c0bb4aed9c3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4c4270be-8551-4ca7-bd49-99801255e32e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value. Authorized $250,000,000 shares; 99,317,153 and 91,413,742 shares issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a42aeb7-0e3e-4724-8397-222ab4c9b20d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_99c60aad-446f-4ab1-87ec-7bbe8ac6158e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_CommonStockWarrantsMember_04684ab4-b7c9-4883-8877-7b7f01d88f96_terseLabel_en-US" xlink:label="lab_aqst_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_aqst_CommonStockWarrantsMember_label_en-US" xlink:label="lab_aqst_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_aqst_CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_aqst_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CommonStockWarrantsMember" xlink:href="aqst-20250331.xsd#aqst_CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_CommonStockWarrantsMember" xlink:to="lab_aqst_CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeElevenMember_ed4d4d49-cf06-4d9b-9ad8-983086f22c95_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Eleven</link:label>
    <link:label id="lab_aqst_VestingConditionRangeElevenMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Eleven [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeElevenMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Eleven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeElevenMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeElevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeElevenMember" xlink:to="lab_aqst_VestingConditionRangeElevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_A2025MarketBasedMember_b6a78b4e-930c-40ad-977a-0baf2efbf85c_terseLabel_en-US" xlink:label="lab_aqst_A2025MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Market Based</link:label>
    <link:label id="lab_aqst_A2025MarketBasedMember_label_en-US" xlink:label="lab_aqst_A2025MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Market Based [Member]</link:label>
    <link:label id="lab_aqst_A2025MarketBasedMember_documentation_en-US" xlink:label="lab_aqst_A2025MarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Market Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_A2025MarketBasedMember" xlink:href="aqst-20250331.xsd#aqst_A2025MarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_A2025MarketBasedMember" xlink:to="lab_aqst_A2025MarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_4857cf4e-4e1a-4fbc-92bd-c38b0a07e28b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a71e0199-0bb9-48db-88d3-3861bd4bc85c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_35b0568d-f3cb-4f9b-bc7a-863bc5583f74_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw material</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ProceedsFromSaleOfFutureRevenuesNet_da1bc489-b15e-41e2-b6b2-f89d28e98f28_terseLabel_en-US" xlink:label="lab_aqst_ProceedsFromSaleOfFutureRevenuesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future revenue</link:label>
    <link:label id="lab_aqst_ProceedsFromSaleOfFutureRevenuesNet_label_en-US" xlink:label="lab_aqst_ProceedsFromSaleOfFutureRevenuesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of Future Revenues, Net</link:label>
    <link:label id="lab_aqst_ProceedsFromSaleOfFutureRevenuesNet_documentation_en-US" xlink:label="lab_aqst_ProceedsFromSaleOfFutureRevenuesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of Future Revenues, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet" xlink:href="aqst-20250331.xsd#aqst_ProceedsFromSaleOfFutureRevenuesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet" xlink:to="lab_aqst_ProceedsFromSaleOfFutureRevenuesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37b752ac-60a7-43dc-9176-45fe446a4d8b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_44a6cef5-6499-46cd-8a68-0f11951cdf9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_HyperaMember_9952f81d-03e2-43c5-a4d9-b95e08de2fc1_terseLabel_en-US" xlink:label="lab_aqst_HyperaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hypera</link:label>
    <link:label id="lab_aqst_HyperaMember_label_en-US" xlink:label="lab_aqst_HyperaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypera [Member]</link:label>
    <link:label id="lab_aqst_HyperaMember_documentation_en-US" xlink:label="lab_aqst_HyperaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hypera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_HyperaMember" xlink:href="aqst-20250331.xsd#aqst_HyperaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_HyperaMember" xlink:to="lab_aqst_HyperaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d551ce3-45ad-4e21-a26d-a8f682d26dc7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_fb66e891-1ad6-4f50-b284-fd302e23ec71_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions_1027fdb1-ee73-40a8-ba4c-6546ca9319bb_terseLabel_en-US" xlink:label="lab_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or equity method investee, cumulative percentage ownership limitation after all transactions</link:label>
    <link:label id="lab_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions_label_en-US" xlink:label="lab_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary Or Equity Method Investee, Cumulative Percentage Ownership Limitation After All Transactions</link:label>
    <link:label id="lab_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions_documentation_en-US" xlink:label="lab_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subsidiary Or Equity Method Investee, Cumulative Percentage Ownership Limitation After All Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" xlink:href="aqst-20250331.xsd#aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" xlink:to="lab_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1519ff53-c9fb-490a-af62-c1e71f0310ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_76946623-58e6-4454-809a-a88b6d8e269c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization, and impairment</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ed99d3e8-ce85-4b15-a076-50b03fd7d181_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_abf41891-34c5-45b1-9327-18ea0d6492f3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">(Loss) Earnings per common share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_ea6c67af-b90c-4475-a631-0e22f83deef1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_c70c9483-c2b5-4833-be81-19c4909f017c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_VestingConditionRangeSevenMember_00bf2376-7191-486b-9455-316d97a43032_terseLabel_en-US" xlink:label="lab_aqst_VestingConditionRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Seven</link:label>
    <link:label id="lab_aqst_VestingConditionRangeSevenMember_label_en-US" xlink:label="lab_aqst_VestingConditionRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Seven [Member]</link:label>
    <link:label id="lab_aqst_VestingConditionRangeSevenMember_documentation_en-US" xlink:label="lab_aqst_VestingConditionRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Condition Range Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeSevenMember" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_VestingConditionRangeSevenMember" xlink:to="lab_aqst_VestingConditionRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_MonetizationAgreementMember_6b003b71-184f-462b-bd55-a8183ccc77ee_terseLabel_en-US" xlink:label="lab_aqst_MonetizationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monetization Agreement</link:label>
    <link:label id="lab_aqst_MonetizationAgreementMember_label_en-US" xlink:label="lab_aqst_MonetizationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monetization Agreement [Member]</link:label>
    <link:label id="lab_aqst_MonetizationAgreementMember_documentation_en-US" xlink:label="lab_aqst_MonetizationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monetization Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MonetizationAgreementMember" xlink:href="aqst-20250331.xsd#aqst_MonetizationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_MonetizationAgreementMember" xlink:to="lab_aqst_MonetizationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_78c48d08-a65e-432d-925d-b56ec7ef8b90_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2b68c5a7-0164-48d8-9618-1d7ef60b337a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SecuritiesPurchaseAgreementMember_8b560994-fdb6-4204-8d43-8c9486bb5000_terseLabel_en-US" xlink:label="lab_aqst_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities purchase agreement</link:label>
    <link:label id="lab_aqst_SecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_aqst_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_aqst_SecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_aqst_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SecuritiesPurchaseAgreementMember" xlink:href="aqst-20250331.xsd#aqst_SecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SecuritiesPurchaseAgreementMember" xlink:to="lab_aqst_SecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90e4c4dd-0e92-4eac-ba3d-da5b619f7524_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_05513e98-0c79-4535-a53c-4f2e526a87a2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9c663223-9136-4bba-b014-165dbad54a07_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacture and supply</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d8bf07ff-92b0-4724-9f8e-115b25b039f4_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Manufacture and Supply Expenses</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3593de06-f919-456a-94bb-f071aa208aca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_c97e9358-a951-4974-a37f-46d1f4122bab_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7e5e20c8-18ad-481a-a394-f5de0e33c329_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e5b4d605-1659-4d44-8525-2b1f52f0dfbc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3198dae8-b233-47fa-b473-0664915de56e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies (Note 20)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_OtherMember_fb3b2e07-cee0-4a74-828e-010a0c593cea_terseLabel_en-US" xlink:label="lab_aqst_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_aqst_OtherMember_label_en-US" xlink:label="lab_aqst_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_aqst_OtherMember_documentation_en-US" xlink:label="lab_aqst_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_OtherMember" xlink:href="aqst-20250331.xsd#aqst_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_OtherMember" xlink:to="lab_aqst_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember_4c6c9fc0-bca8-421d-aeaa-95630f25166f_terseLabel_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement with Sunovion Pharmaceuticals, Inc milestones</link:label>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember_label_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member]</link:label>
    <link:label id="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember_documentation_en-US" xlink:label="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The license agreement made with sunovion pharmaceuticals, inc. milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" xlink:to="lab_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts_d20c2b6d-5fa8-4171-8585-31d96e46f8cc_terseLabel_en-US" xlink:label="lab_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, unpaid commissions and other transaction costs</link:label>
    <link:label id="lab_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts_label_en-US" xlink:label="lab_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Unpaid Commissions and Other Transaction Costs</link:label>
    <link:label id="lab_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts_documentation_en-US" xlink:label="lab_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Unpaid Commissions and Other Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" xlink:to="lab_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_e4933a1b-3536-40a8-b289-9e089bc776c0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16ef0f61-8644-44df-be02-d906e0663351_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_bb9afb04-4873-42df-950f-3513b3b58726_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate payment</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ec1786ce-2cfe-423f-af5d-590c7cf0c002_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_19ebf44d-37a0-4ab9-ad8a-561768cde681_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e194b12a-aace-4c11-965e-d601066f2d77_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_1babd44b-5630-41db-af1b-12e4812c53c7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General &amp; Administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e6f81957-f572-4837-a83f-795d0bbfa15e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7f0fb7f1-950c-4a44-8a33-fa1c45fe7365_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b601d882-878c-488b-9a25-5e8976bc2bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_14af32b1-3f09-4db1-b22b-c855a787659f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments / credits</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_c9b11ea7-14fb-44a7-b474-2e062cdd47f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3076a716-fd78-49f2-825a-b9cf41b5bce0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_977ca280-29c0-4cb0-8770-9ba37556e974_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c1b61a71-560b-46f1-92de-726fe1bd400c_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a23cea30-5907-4b30-a840-9a590fac5766_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b4d08d9f-cdec-4cf6-98c4-4ad244fb3fa0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_77fee238-5927-4a9e-845c-487670bf38bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_88f85ffa-1c47-4654-a181-0d04446cca73_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount (premium)</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_f1922cbd-07a2-4c43-ad90-64be970daae1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4eb21bdf-65d2-4cc3-9ad0-157a1891e41c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a14f8741-1ab6-41e0-884d-c4bcc43d1e3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ContingentMonetizationAgreementMilestonePayment_a4af9997-6d97-4fbf-b7d4-f3c79b6f9a24_terseLabel_en-US" xlink:label="lab_aqst_ContingentMonetizationAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt, contingent on additional milestones</link:label>
    <link:label id="lab_aqst_ContingentMonetizationAgreementMilestonePayment_label_en-US" xlink:label="lab_aqst_ContingentMonetizationAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Monetization Agreement, Milestone Payment</link:label>
    <link:label id="lab_aqst_ContingentMonetizationAgreementMilestonePayment_documentation_en-US" xlink:label="lab_aqst_ContingentMonetizationAgreementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Monetization Agreement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ContingentMonetizationAgreementMilestonePayment" xlink:href="aqst-20250331.xsd#aqst_ContingentMonetizationAgreementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ContingentMonetizationAgreementMilestonePayment" xlink:to="lab_aqst_ContingentMonetizationAgreementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_Warrants5.38ExercisePriceMember_1c46c321-79c8-4c73-a768-72f15b3338ed_terseLabel_en-US" xlink:label="lab_aqst_Warrants5.38ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, $5.38 Exercise Price</link:label>
    <link:label id="lab_aqst_Warrants5.38ExercisePriceMember_label_en-US" xlink:label="lab_aqst_Warrants5.38ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, $5.38 Exercise Price [Member]</link:label>
    <link:label id="lab_aqst_Warrants5.38ExercisePriceMember_documentation_en-US" xlink:label="lab_aqst_Warrants5.38ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, $5.38 Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants5.38ExercisePriceMember" xlink:href="aqst-20250331.xsd#aqst_Warrants5.38ExercisePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_Warrants5.38ExercisePriceMember" xlink:to="lab_aqst_Warrants5.38ExercisePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a1681839-8b53-4137-9ff0-ec395db53eea_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2b1ef1e0-5639-4db2-8cb5-f6f35616e6c1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues and Trade Receivables, Net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c4f33e57-d8c6-4a67-acc4-e0d24199a6b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4077f68b-3093-4b9c-bcc3-25220bf29800_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b5e2574d-f43e-4fa1-a310-0713beb34930_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AtnahsPharmaUKLimitedMember_9bd9eadb-380c-44dd-a5d4-7a2f637404f5_terseLabel_en-US" xlink:label="lab_aqst_AtnahsPharmaUKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Atnahs Pharma UK Limited</link:label>
    <link:label id="lab_aqst_AtnahsPharmaUKLimitedMember_label_en-US" xlink:label="lab_aqst_AtnahsPharmaUKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Atnahs Pharma UK Limited [Member]</link:label>
    <link:label id="lab_aqst_AtnahsPharmaUKLimitedMember_documentation_en-US" xlink:label="lab_aqst_AtnahsPharmaUKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Atnahs Pharma UK Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedMember" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AtnahsPharmaUKLimitedMember" xlink:to="lab_aqst_AtnahsPharmaUKLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2af4a89c-3ff6-407b-8492-87b54f5ca13a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_edd2c6c0-bea9-4ae5-8dd7-bc7e3ab486f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_ac187bb9-dc67-4fa0-8f7c-6c4f0f8c7b4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a0a8ab3f-1254-4f1b-838d-2c5795489ddb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_e0f994e3-96e0-4ca6-a57d-d9034f2b22bb_terseLabel_en-US" xlink:label="lab_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future revenue, current</link:label>
    <link:label id="lab_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_label_en-US" xlink:label="lab_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Sale of Future Royalties, Current</link:label>
    <link:label id="lab_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_documentation_en-US" xlink:label="lab_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities, Sale of Future Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent" xlink:to="lab_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_ad62674e-61cf-431f-8b0d-82fa3296ba9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discount (premium), net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_49535e88-5957-47ae-89a2-c929dc013f1e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6faef950-1989-422c-8c34-6efdfe50adfb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts_84a3397e-6bcf-4b81-87e4-5e1e258dc5b6_terseLabel_en-US" xlink:label="lab_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting discounts</link:label>
    <link:label id="lab_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts_label_en-US" xlink:label="lab_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Underwriting Discounts</link:label>
    <link:label id="lab_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts_documentation_en-US" xlink:label="lab_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Underwriting Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" xlink:to="lab_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_9962b0ff-352b-4729-b61d-bd7ae099fbdc_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_771adaf3-a3d9-4d83-a683-ba65a07f9501_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ac3ec50c-9ce9-425d-8b65-46fced301080_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e897df7-6ebd-426b-95d0-08da6f1fc504_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_8bc5d3b3-a21d-4d55-b3f9-59dff476f556_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_812ed7ad-ee99-44db-9ea2-07a7ee65686c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b146cdf6-8b04-431b-851f-221471a119dc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare_9bde04e1-e5fc-4191-b743-0996bf83f64c_terseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance price threshold (in dollars per share)</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation, Arrangement by Share-Based Payment, Market Condition, Performance Price Threshold, Per Share</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation, Arrangement by Share-Based Payment, Market Condition, Performance Price Threshold, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_d6567fca-af9e-469d-aac3-c56749247dbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_18c7b118-cb64-48a8-a658-47c9e2751fb0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6e72ecb4-44b7-47f5-94d4-e1c1807870c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_2d13d839-7c62-41f2-b49f-e630b992df43_terseLabel_en-US" xlink:label="lab_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional proceeds from sale of future revenue</link:label>
    <link:label id="lab_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_label_en-US" xlink:label="lab_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Proceeds From Sale of Future Revenues, Net</link:label>
    <link:label id="lab_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_documentation_en-US" xlink:label="lab_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Proceeds From Sale of Future Revenues, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet" xlink:href="aqst-20250331.xsd#aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet" xlink:to="lab_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_3f49eb15-bdd2-4ba7-8433-3cb995c21393_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_341c973d-0974-40b1-a637-e890e4f51624_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cf55067-6e82-4182-a9e6-d2341531a2b4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_9ca3fb6d-4ff9-4875-8d31-e58dba739230_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_923dcd5d-3ddd-4d87-8b88-e29191eaaabc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_73c530b4-48ed-4bf3-84e9-1e634f159187_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b1bf6212-4042-454b-9dc1-5a6b45014d4d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_Warrants4.25ExercisePriceMember_2c451036-9ff0-4b10-9fb1-7c918b22a77c_terseLabel_en-US" xlink:label="lab_aqst_Warrants4.25ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, $4.25 Exercise Price</link:label>
    <link:label id="lab_aqst_Warrants4.25ExercisePriceMember_label_en-US" xlink:label="lab_aqst_Warrants4.25ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, $4.25 Exercise Price [Member]</link:label>
    <link:label id="lab_aqst_Warrants4.25ExercisePriceMember_documentation_en-US" xlink:label="lab_aqst_Warrants4.25ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, $4.25 Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants4.25ExercisePriceMember" xlink:href="aqst-20250331.xsd#aqst_Warrants4.25ExercisePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_Warrants4.25ExercisePriceMember" xlink:to="lab_aqst_Warrants4.25ExercisePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_19a2dd43-f55b-4399-9f59-4629187da885_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_414f7f51-1624-48a1-ae8c-41f1c23a04e1_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c81bce9a-35f7-4b4a-89ba-b01dd160b539_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9d9284a2-2fa5-4d3c-a6b8-e9aae9ec05ab_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_018eaae7-9276-43d5-b261-e92c9107d9f9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_18d157cb-7461-433f-a873-18700f630bbc_terseLabel_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_label_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, in Shares</link:label>
    <link:label id="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_documentation_en-US" xlink:label="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date in shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" xlink:to="lab_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AQST108Member_d9f5f3f7-a79b-45af-a518-2c91666fa6fa_terseLabel_en-US" xlink:label="lab_aqst_AQST108Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AQST-108 project expenses</link:label>
    <link:label id="lab_aqst_AQST108Member_label_en-US" xlink:label="lab_aqst_AQST108Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AQST-108 [Member]</link:label>
    <link:label id="lab_aqst_AQST108Member_documentation_en-US" xlink:label="lab_aqst_AQST108Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AQST-108</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AQST108Member" xlink:href="aqst-20250331.xsd#aqst_AQST108Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AQST108Member" xlink:to="lab_aqst_AQST108Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4958ad77-6357-4d53-bb7e-7a2b8b92c191_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2bff3f4-770b-4b8c-bd6a-882885f6b1ea_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_PersonnelCostsMember_e4536aa4-2d27-4c13-b3af-3153bf9fe5d8_terseLabel_en-US" xlink:label="lab_aqst_PersonnelCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel costs</link:label>
    <link:label id="lab_aqst_PersonnelCostsMember_label_en-US" xlink:label="lab_aqst_PersonnelCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel Costs [Member]</link:label>
    <link:label id="lab_aqst_PersonnelCostsMember_documentation_en-US" xlink:label="lab_aqst_PersonnelCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personnel Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PersonnelCostsMember" xlink:href="aqst-20250331.xsd#aqst_PersonnelCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_PersonnelCostsMember" xlink:to="lab_aqst_PersonnelCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_b9e22db0-815e-4556-9e15-f625bdaa52f4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ca24aff9-d61d-4659-9dda-2785c38a1562_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_79252408-231d-4fba-8974-3b0980e7b7ff_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs and discounts</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_SaleOfStockAggregateOfferingPrice_2d1bee2b-27e0-4365-8a74-14b82dda6e79_terseLabel_en-US" xlink:label="lab_aqst_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, aggregate offering price</link:label>
    <link:label id="lab_aqst_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_aqst_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_aqst_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_aqst_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockAggregateOfferingPrice" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_SaleOfStockAggregateOfferingPrice" xlink:to="lab_aqst_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37e1a8e4-d07d-4d13-b61b-d845f0edd349_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_07f5c25c-6a42-4ad5-b91a-fd938ffcb575_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_cda20456-44d8-4e15-8b05-8bf3def0c34e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount awarded from other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_PublicEquityOfferingMember_d0b85661-3760-413f-bfb1-75d8fed91771_terseLabel_en-US" xlink:label="lab_aqst_PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Equity Offering</link:label>
    <link:label id="lab_aqst_PublicEquityOfferingMember_label_en-US" xlink:label="lab_aqst_PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Equity Offering [Member]</link:label>
    <link:label id="lab_aqst_PublicEquityOfferingMember_documentation_en-US" xlink:label="lab_aqst_PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PublicEquityOfferingMember" xlink:href="aqst-20250331.xsd#aqst_PublicEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_PublicEquityOfferingMember" xlink:to="lab_aqst_PublicEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_47a0d991-6a78-40e2-9567-dc635b287e51_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cb6ca144-0d82-461d-bd1a-ab2fa3bb75ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember_22e08483-5307-482f-9064-cd8a8bba7a11_terseLabel_en-US" xlink:label="lab_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Atnahs Pharma UK Limited, Amended Agreement</link:label>
    <link:label id="lab_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember_label_en-US" xlink:label="lab_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Atnahs Pharma UK Limited, Amended Agreement [Member]</link:label>
    <link:label id="lab_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember_documentation_en-US" xlink:label="lab_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Atnahs Pharma UK Limited, Amended Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedAmendedAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember" xlink:to="lab_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_179ec01e-6516-4f5f-9100-b1b72748ef42_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>aqst-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7fd918af-7463-495d-a5aa-7a090fe24bee,g:404d0fa2-95d9-41b4-b7eb-3a9cfeb5fb76-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aquestive.com/role/Cover" xlink:type="simple" xlink:href="aqst-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9f83474d-afcc-4384-8f77-18ab30a87a8c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_DocumentType_9f83474d-afcc-4384-8f77-18ab30a87a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_451a99b0-ce38-4c07-ba64-2955b7482d54" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_DocumentQuarterlyReport_451a99b0-ce38-4c07-ba64-2955b7482d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c72a7d48-0b01-4ecb-9c72-2446164e510c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_DocumentPeriodEndDate_c72a7d48-0b01-4ecb-9c72-2446164e510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_57bdc360-3397-45be-92a7-2ada7f27c7a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_DocumentTransitionReport_57bdc360-3397-45be-92a7-2ada7f27c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f9e7d8fb-96ef-45be-86ac-7a3dc1b2e6e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityFileNumber_f9e7d8fb-96ef-45be-86ac-7a3dc1b2e6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_94803925-46f2-4c58-9708-fcf0bceb9bbd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityRegistrantName_94803925-46f2-4c58-9708-fcf0bceb9bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_30b1ce83-ee0a-426f-9cc1-81d7240fe8c9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_30b1ce83-ee0a-426f-9cc1-81d7240fe8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2877593c-263d-4b07-8b80-d240534e1600" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityAddressAddressLine1_2877593c-263d-4b07-8b80-d240534e1600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b970c7fd-39b3-4a04-a1fa-4eb54362ae69" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityAddressCityOrTown_b970c7fd-39b3-4a04-a1fa-4eb54362ae69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b43eb476-4c18-46f0-bab6-aed5a1ccea9a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityAddressStateOrProvince_b43eb476-4c18-46f0-bab6-aed5a1ccea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_48f35fd6-efed-4df6-9c20-9d0491162fa7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityAddressPostalZipCode_48f35fd6-efed-4df6-9c20-9d0491162fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_20492b7d-1091-44be-b3f6-570bea1e63cd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityTaxIdentificationNumber_20492b7d-1091-44be-b3f6-570bea1e63cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_da317872-d558-462b-91bd-80aa025d033c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_CityAreaCode_da317872-d558-462b-91bd-80aa025d033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8983ff8d-8a70-442b-853d-2a3d815792f4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_LocalPhoneNumber_8983ff8d-8a70-442b-853d-2a3d815792f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4ab993e8-e09b-45a1-9de1-e849c5b7d139" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_Security12bTitle_4ab993e8-e09b-45a1-9de1-e849c5b7d139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_78ed07b4-5ec0-4071-9403-8a400057e8e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_TradingSymbol_78ed07b4-5ec0-4071-9403-8a400057e8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c53a769a-4fa8-4bd8-a958-c78d30421c27" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_SecurityExchangeName_c53a769a-4fa8-4bd8-a958-c78d30421c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a28ad6c7-13a6-4404-8d07-6020f2c6fec4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityCurrentReportingStatus_a28ad6c7-13a6-4404-8d07-6020f2c6fec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_702039bf-d5f5-401a-8a39-4a7a0cd9215f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityInteractiveDataCurrent_702039bf-d5f5-401a-8a39-4a7a0cd9215f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f6a5c36f-1fc6-49e7-9fd6-ebc8cc96c8f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityFilerCategory_f6a5c36f-1fc6-49e7-9fd6-ebc8cc96c8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_90c2f4b0-3613-42c3-90b7-df2ef9acbec0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntitySmallBusiness_90c2f4b0-3613-42c3-90b7-df2ef9acbec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d6febd20-2b8b-49f8-bce3-b4f28bc97cd4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityEmergingGrowthCompany_d6febd20-2b8b-49f8-bce3-b4f28bc97cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_15e2dfd9-c555-4071-8568-fdf0bbdf957f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityShellCompany_15e2dfd9-c555-4071-8568-fdf0bbdf957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0adbfda1-0c2a-4f90-87ab-87e8acc780e8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0adbfda1-0c2a-4f90-87ab-87e8acc780e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9394203d-d6f9-4c0d-a192-de50fff3ea9e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_EntityCentralIndexKey_9394203d-d6f9-4c0d-a192-de50fff3ea9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_818fbd3b-f803-4266-bb98-1bde51633a75" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_CurrentFiscalYearEndDate_818fbd3b-f803-4266-bb98-1bde51633a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ad807da2-eedf-47f4-a356-bc5c1596ac19" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_DocumentFiscalYearFocus_ad807da2-eedf-47f4-a356-bc5c1596ac19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a64adc40-45ec-4c52-bb69-e149e854d432" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a64adc40-45ec-4c52-bb69-e149e854d432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_083ba279-4e52-4c18-8aca-41052e002d95" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d73ca12-1e9b-4a94-94e1-8bc7fe12b51a" xlink:to="loc_dei_AmendmentFlag_083ba279-4e52-4c18-8aca-41052e002d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fcb2c913-b6cd-441b-af93-af4407ec3e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fcb2c913-b6cd-441b-af93-af4407ec3e44" xlink:to="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a73c900e-4fad-40a2-a51b-aff1530573d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a73c900e-4fad-40a2-a51b-aff1530573d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_546bfba3-0a27-4670-879f-c9172393b606" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a73c900e-4fad-40a2-a51b-aff1530573d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_546bfba3-0a27-4670-879f-c9172393b606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAndOtherReceivablesNet_bfedacb0-9869-496e-be66-cec3b83e9da6" xlink:href="aqst-20250331.xsd#aqst_TradeAndOtherReceivablesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a73c900e-4fad-40a2-a51b-aff1530573d4" xlink:to="loc_aqst_TradeAndOtherReceivablesNet_bfedacb0-9869-496e-be66-cec3b83e9da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_94b6b24b-140c-4f24-8e3b-b6096a84322b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a73c900e-4fad-40a2-a51b-aff1530573d4" xlink:to="loc_us-gaap_InventoryNet_94b6b24b-140c-4f24-8e3b-b6096a84322b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_353dd37e-f7e5-4522-af99-deb28d076060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a73c900e-4fad-40a2-a51b-aff1530573d4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_353dd37e-f7e5-4522-af99-deb28d076060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7ee63bce-5e3b-4996-9a46-a0dda0ad75c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a73c900e-4fad-40a2-a51b-aff1530573d4" xlink:to="loc_us-gaap_AssetsCurrent_7ee63bce-5e3b-4996-9a46-a0dda0ad75c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0eaf6bc7-a63c-4008-b61e-1e2cda803029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0eaf6bc7-a63c-4008-b61e-1e2cda803029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_55bd715c-90a0-451b-9e1e-bc74bb1d3914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_55bd715c-90a0-451b-9e1e-bc74bb1d3914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4a89aaa4-ac80-474f-9f93-0d64d1fc9392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4a89aaa4-ac80-474f-9f93-0d64d1fc9392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_944e6913-95bf-43ca-a7cb-33e920c8b101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_944e6913-95bf-43ca-a7cb-33e920c8b101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_038b5bf7-2346-4b04-bc77-acc825bc2a59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bba82c7-37d4-4820-afa9-fcd158d91687" xlink:to="loc_us-gaap_Assets_038b5bf7-2346-4b04-bc77-acc825bc2a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fcb2c913-b6cd-441b-af93-af4407ec3e44" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_06ce689d-0d3d-4788-a11f-c6f6ba14b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_us-gaap_AccountsPayableCurrent_06ce689d-0d3d-4788-a11f-c6f6ba14b61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d8ab3802-e027-4e89-b4e1-3d891e9118df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d8ab3802-e027-4e89-b4e1-3d891e9118df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c7383c9b-630d-45c5-83b2-34ba9e3c0409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c7383c9b-630d-45c5-83b2-34ba9e3c0409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_56f7293c-4b9f-4536-8622-8c64dcf894d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_56f7293c-4b9f-4536-8622-8c64dcf894d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_7189e7c3-13a3-44c8-aced-f362c0522ef6" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_7189e7c3-13a3-44c8-aced-f362c0522ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsLiabilityCurrent_e86abae0-0f0f-4fcc-9d07-5aa7f93c75fe" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_aqst_RoyaltyObligationsLiabilityCurrent_e86abae0-0f0f-4fcc-9d07-5aa7f93c75fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_e8dfe9c7-5884-4df5-8e20-ae66bdd1c326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_us-gaap_LoansPayableCurrent_e8dfe9c7-5884-4df5-8e20-ae66bdd1c326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fd2082e1-8478-44b0-ae57-1f5bc7af28e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_24154019-ab14-401a-b7cd-09a2a4da5fa1" xlink:to="loc_us-gaap_LiabilitiesCurrent_fd2082e1-8478-44b0-ae57-1f5bc7af28e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent_b890297d-3f97-42c8-aeb6-603410448c64" xlink:href="aqst-20250331.xsd#aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent_b890297d-3f97-42c8-aeb6-603410448c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationLiabilityNoncurrent_2487f78a-06d6-4861-a5d4-35a905140cd5" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_aqst_RoyaltyObligationLiabilityNoncurrent_2487f78a-06d6-4861-a5d4-35a905140cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent_0d4007d4-f6d1-44ac-9d84-c83bcfb58dd0" xlink:href="aqst-20250331.xsd#aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent_0d4007d4-f6d1-44ac-9d84-c83bcfb58dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9379d145-6907-43c8-8b86-853c696c45ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9379d145-6907-43c8-8b86-853c696c45ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d01f3116-a51e-4fb3-8c72-c002ea2a1c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d01f3116-a51e-4fb3-8c72-c002ea2a1c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_76200b6e-8950-4af7-83ef-328b93069ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_76200b6e-8950-4af7-83ef-328b93069ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e62f0cbb-d9fc-4b4c-9115-0739e85c6b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_Liabilities_e62f0cbb-d9fc-4b4c-9115-0739e85c6b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7a76ad48-de83-4f25-8fb8-58f6e376a110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7a76ad48-de83-4f25-8fb8-58f6e376a110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e0d2c5c7-62a5-461b-934d-14d5ed176f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e0d2c5c7-62a5-461b-934d-14d5ed176f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_09c64494-e3ab-4056-972f-d78cae68bba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0d2c5c7-62a5-461b-934d-14d5ed176f7c" xlink:to="loc_us-gaap_CommonStockValue_09c64494-e3ab-4056-972f-d78cae68bba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fb794050-5f31-4914-ab82-89bae0db0169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0d2c5c7-62a5-461b-934d-14d5ed176f7c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fb794050-5f31-4914-ab82-89bae0db0169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b30077f-e1ab-4ee0-8291-b7eb1ccd88c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0d2c5c7-62a5-461b-934d-14d5ed176f7c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b30077f-e1ab-4ee0-8291-b7eb1ccd88c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c31148a4-9046-422c-a5dd-392f221f136c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0d2c5c7-62a5-461b-934d-14d5ed176f7c" xlink:to="loc_us-gaap_StockholdersEquity_c31148a4-9046-422c-a5dd-392f221f136c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_694ea671-b1e4-4590-b698-3f79d7c99709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c958b7f4-8fa7-4292-8df0-f5fdba3079a5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_694ea671-b1e4-4590-b698-3f79d7c99709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_372d09d7-2333-4048-97eb-7bdd127e48ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_99241b3b-9a3a-4e8f-8f58-5cffcc0f649e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_372d09d7-2333-4048-97eb-7bdd127e48ff" xlink:to="loc_us-gaap_StockholdersEquityAbstract_99241b3b-9a3a-4e8f-8f58-5cffcc0f649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_87b6af67-8f57-4d3c-a3f4-b5d757193a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99241b3b-9a3a-4e8f-8f58-5cffcc0f649e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_87b6af67-8f57-4d3c-a3f4-b5d757193a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_87e446c6-58a4-4c51-97f9-6b115822075a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99241b3b-9a3a-4e8f-8f58-5cffcc0f649e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_87e446c6-58a4-4c51-97f9-6b115822075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_da704a7d-6017-4771-9091-f090d6c2e612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99241b3b-9a3a-4e8f-8f58-5cffcc0f649e" xlink:to="loc_us-gaap_CommonStockSharesIssued_da704a7d-6017-4771-9091-f090d6c2e612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b29d35c6-1edc-484c-8860-bcc4a128d990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99241b3b-9a3a-4e8f-8f58-5cffcc0f649e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b29d35c6-1edc-484c-8860-bcc4a128d990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab725e7e-731b-45bb-bc31-fdeac8a20566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab725e7e-731b-45bb-bc31-fdeac8a20566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9c848c13-6458-455a-a490-48a3c98f1383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9c848c13-6458-455a-a490-48a3c98f1383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7b585328-1230-4b17-88a2-0321f0cf7d19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9c848c13-6458-455a-a490-48a3c98f1383" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7b585328-1230-4b17-88a2-0321f0cf7d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_8cc52ccc-d5f9-498b-99a3-652e6376fc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_7b585328-1230-4b17-88a2-0321f0cf7d19" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_8cc52ccc-d5f9-498b-99a3-652e6376fc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0fcb24be-e4ab-4814-b0f9-0d214056eaac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9c848c13-6458-455a-a490-48a3c98f1383" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0fcb24be-e4ab-4814-b0f9-0d214056eaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_645cd9fe-02b7-4aee-aa88-c8654d1a264d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9c848c13-6458-455a-a490-48a3c98f1383" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_645cd9fe-02b7-4aee-aa88-c8654d1a264d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_536091e9-cb46-424f-99df-84a4a861c743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9c848c13-6458-455a-a490-48a3c98f1383" xlink:to="loc_us-gaap_CostsAndExpenses_536091e9-cb46-424f-99df-84a4a861c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1eb4ff86-f8f8-446f-9925-a06e945ded27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_OperatingIncomeLoss_1eb4ff86-f8f8-446f-9925-a06e945ded27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e4ecae63-e24b-4e78-8133-b36c0dd96708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e4ecae63-e24b-4e78-8133-b36c0dd96708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_092ab00d-05c9-44e9-a01b-fd7b37346b58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e4ecae63-e24b-4e78-8133-b36c0dd96708" xlink:to="loc_us-gaap_InterestExpenseNonoperating_092ab00d-05c9-44e9-a01b-fd7b37346b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_05b40d1b-5c8e-47c3-a5e2-21063b1ac4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e4ecae63-e24b-4e78-8133-b36c0dd96708" xlink:to="loc_us-gaap_RoyaltyExpense_05b40d1b-5c8e-47c3-a5e2-21063b1ac4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InterestExpenseSaleOfFutureRevenues_9eb00978-b106-4199-bbb9-15e5f16b122c" xlink:href="aqst-20250331.xsd#aqst_InterestExpenseSaleOfFutureRevenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e4ecae63-e24b-4e78-8133-b36c0dd96708" xlink:to="loc_aqst_InterestExpenseSaleOfFutureRevenues_9eb00978-b106-4199-bbb9-15e5f16b122c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InterestAndOtherIncomeNet_95a36e78-5de4-4b43-af8f-c69985827d2a" xlink:href="aqst-20250331.xsd#aqst_InterestAndOtherIncomeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e4ecae63-e24b-4e78-8133-b36c0dd96708" xlink:to="loc_aqst_InterestAndOtherIncomeNet_95a36e78-5de4-4b43-af8f-c69985827d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f0aae11-84c8-4368-a8a2-dfb8514d2951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e4ecae63-e24b-4e78-8133-b36c0dd96708" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f0aae11-84c8-4368-a8a2-dfb8514d2951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11d6cc11-fb30-40b8-9efd-dd7d60b0a371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11d6cc11-fb30-40b8-9efd-dd7d60b0a371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e808dfe-492f-4aa7-8ea6-361faf6aeb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_NetIncomeLoss_7e808dfe-492f-4aa7-8ea6-361faf6aeb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d0c5183-53bc-404a-927c-70c52dc92781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d0c5183-53bc-404a-927c-70c52dc92781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_91317b7c-1b27-43b3-902f-72d8196986c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_EarningsPerShareAbstract_91317b7c-1b27-43b3-902f-72d8196986c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dddb7b9f-8075-4f7c-8b7a-d30407891b83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_91317b7c-1b27-43b3-902f-72d8196986c6" xlink:to="loc_us-gaap_EarningsPerShareBasic_dddb7b9f-8075-4f7c-8b7a-d30407891b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5c389ab0-08df-45e0-932d-b301a8c861b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_91317b7c-1b27-43b3-902f-72d8196986c6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5c389ab0-08df-45e0-932d-b301a8c861b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_e1c976df-baf1-41be-8d2d-264807a0e45c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8986201f-ba69-4a61-bf07-b658b9fc64f3" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_e1c976df-baf1-41be-8d2d-264807a0e45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_44512ef9-02d2-4ae1-be36-787d8d6c3f49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_e1c976df-baf1-41be-8d2d-264807a0e45c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_44512ef9-02d2-4ae1-be36-787d8d6c3f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6ff638f-6f9c-4879-b2f9-635fb5e924e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_e1c976df-baf1-41be-8d2d-264807a0e45c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6ff638f-6f9c-4879-b2f9-635fb5e924e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedStatementsofChangesinStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f439db7b-e5cd-4d3b-aabc-657e1270c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f439db7b-e5cd-4d3b-aabc-657e1270c43d" xlink:to="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_39334b6f-3534-4d5d-b982-84764479e24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_39334b6f-3534-4d5d-b982-84764479e24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_39334b6f-3534-4d5d-b982-84764479e24c" xlink:to="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95bf2b01-849c-4d18-a1dc-7fadb73dd91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:to="loc_us-gaap_CommonStockMember_95bf2b01-849c-4d18-a1dc-7fadb73dd91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e6ce2af2-0e22-4bae-9ff2-def5b0173b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e6ce2af2-0e22-4bae-9ff2-def5b0173b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ed883d6-1c85-4a06-a57b-98b2f53f0e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f49722b7-33a7-4ef2-bd11-163ad7709e54" xlink:to="loc_us-gaap_RetainedEarningsMember_1ed883d6-1c85-4a06-a57b-98b2f53f0e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98d3226e-64e7-44f4-923e-4e398d800b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98d3226e-64e7-44f4-923e-4e398d800b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98d3226e-64e7-44f4-923e-4e398d800b8f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtTheMarketOfferingMember_fa50d159-5ad1-4a44-bce1-51bd15a5ed52" xlink:href="aqst-20250331.xsd#aqst_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:to="loc_aqst_AtTheMarketOfferingMember_fa50d159-5ad1-4a44-bce1-51bd15a5ed52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PublicEquityOfferingMember_817eed5b-aedd-44bc-89c3-85a8a1507794" xlink:href="aqst-20250331.xsd#aqst_PublicEquityOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18e7a801-07e2-46f9-b4f7-3a7209bbfe68" xlink:to="loc_aqst_PublicEquityOfferingMember_817eed5b-aedd-44bc-89c3-85a8a1507794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a2fd88ca-c625-4047-a56f-a632e511d514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a2c7550-16b0-4152-ac70-1867a7354b1e" xlink:to="loc_us-gaap_StatementLineItems_a2fd88ca-c625-4047-a56f-a632e511d514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a2fd88ca-c625-4047-a56f-a632e511d514" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8c16273f-219c-4be9-a7b5-8d1e6e849029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_SharesOutstanding_8c16273f-219c-4be9-a7b5-8d1e6e849029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4312ba7-fc66-42af-a5b2-92d9b6eb009b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockholdersEquity_d4312ba7-fc66-42af-a5b2-92d9b6eb009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_80de0368-e7c1-4883-8719-0e72cb7028ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_80de0368-e7c1-4883-8719-0e72cb7028ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c898b55-b603-4bdc-aa13-d483643648d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c898b55-b603-4bdc-aa13-d483643648d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4e8af994-4bfc-45d0-a840-712386b537e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4e8af994-4bfc-45d0-a840-712386b537e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_af991026-d1c4-4c49-9342-96bd6cc9ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_af991026-d1c4-4c49-9342-96bd6cc9ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cec4a26-8933-4685-a91c-379bf8f0d618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5cec4a26-8933-4685-a91c-379bf8f0d618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bae05493-f46c-4e7a-b3f7-b6df028b11fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_bae05493-f46c-4e7a-b3f7-b6df028b11fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_e2b8836b-f40f-4e44-8f4a-e94a2f8fa0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_e2b8836b-f40f-4e44-8f4a-e94a2f8fa0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_572bc93f-b6e0-4f42-ac7c-04ade41e8aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_572bc93f-b6e0-4f42-ac7c-04ade41e8aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_69d7c23e-578d-4b43-816c-8474e820a61f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_69d7c23e-578d-4b43-816c-8474e820a61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52b7731b-d749-4766-9a44-62f498d78adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_NetIncomeLoss_52b7731b-d749-4766-9a44-62f498d78adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_40c72319-fb17-41af-900a-4a093a29c8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_SharesOutstanding_40c72319-fb17-41af-900a-4a093a29c8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b184f8f6-1b17-40ad-8f2c-795eace44769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bebdd653-3f6b-465d-9267-58be1cbca536" xlink:to="loc_us-gaap_StockholdersEquity_b184f8f6-1b17-40ad-8f2c-795eace44769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="aqst-20250331.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6d0cac3b-0217-4eed-9a22-c4df05aa6065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ecd2847-6907-4fa5-8659-01f97aece004" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d0cac3b-0217-4eed-9a22-c4df05aa6065" xlink:to="loc_us-gaap_StatementTable_4ecd2847-6907-4fa5-8659-01f97aece004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_af6a1764-a95d-4561-b95f-d0391f1fb983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ecd2847-6907-4fa5-8659-01f97aece004" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_af6a1764-a95d-4561-b95f-d0391f1fb983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_af6a1764-a95d-4561-b95f-d0391f1fb983" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtTheMarketOfferingMember_61efd5f1-7b4f-4eed-8050-3486df9fa872" xlink:href="aqst-20250331.xsd#aqst_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:to="loc_aqst_AtTheMarketOfferingMember_61efd5f1-7b4f-4eed-8050-3486df9fa872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PublicEquityOfferingMember_19b84505-c8c9-4bdf-ae00-a9922e3093e5" xlink:href="aqst-20250331.xsd#aqst_PublicEquityOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1be2b315-9e46-4494-a677-a7fb597096c5" xlink:to="loc_aqst_PublicEquityOfferingMember_19b84505-c8c9-4bdf-ae00-a9922e3093e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ecd2847-6907-4fa5-8659-01f97aece004" xlink:to="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c6618d20-7a1c-4ec2-b058-afe80e9ea80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:to="loc_us-gaap_NetIncomeLoss_c6618d20-7a1c-4ec2-b058-afe80e9ea80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_84b173fb-b68d-4a02-8b57-46fce29c6631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_DepreciationAndAmortization_84b173fb-b68d-4a02-8b57-46fce29c6631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e15c7949-ae7c-42bc-a458-35cf108e5979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_ShareBasedCompensation_e15c7949-ae7c-42bc-a458-35cf108e5979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_fbe944e7-339f-4da1-8d3d-7138ff796164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_fbe944e7-339f-4da1-8d3d-7138ff796164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_57a0a274-9d0a-40e1-b386-6ea6e5906cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_57a0a274-9d0a-40e1-b386-6ea6e5906cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2de30f47-64f7-49ab-8f5d-a3711a5e368a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_37912720-83d4-47e3-90d7-3028ab536317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_37912720-83d4-47e3-90d7-3028ab536317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ce7aa6d5-15e3-4c49-b100-2e05520ccb44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ce7aa6d5-15e3-4c49-b100-2e05520ccb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85da6ff0-2cc8-4f47-9971-77301c373717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85da6ff0-2cc8-4f47-9971-77301c373717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ca77b5fe-0d39-4213-be92-30a38eb1aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ca77b5fe-0d39-4213-be92-30a38eb1aa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_df2cfca3-025a-428f-836c-e0d33682d6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_df2cfca3-025a-428f-836c-e0d33682d6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e2c6f31a-4792-4de0-b05b-e722056d4e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be7a9647-3ba4-4975-99c4-3ad481bc6ee0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_e2c6f31a-4792-4de0-b05b-e722056d4e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07aeb6e3-22c4-411d-9f51-cd232b8ab38c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e9a1d43-16dd-49f9-b27c-0bc9f7e14d67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_07aeb6e3-22c4-411d-9f51-cd232b8ab38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67dfdbad-77b6-4709-886c-b827efd33e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67dfdbad-77b6-4709-886c-b827efd33e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_635f7df0-f9f5-4a69-bbf0-3771d7d87e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf703639-bb53-43d4-90e8-39caeb6daa2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_635f7df0-f9f5-4a69-bbf0-3771d7d87e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4ac0d21c-27c0-4ce5-ade8-20a1c2e6a429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4ac0d21c-27c0-4ce5-ade8-20a1c2e6a429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8d2a5942-649c-4e5e-945a-caf388e13dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8d2a5942-649c-4e5e-945a-caf388e13dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_2d86e466-0be8-4fd8-9ce7-4989ea93daf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_2d86e466-0be8-4fd8-9ce7-4989ea93daf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations_3820d4a4-4583-4445-8761-eb6b6e868fa7" xlink:href="aqst-20250331.xsd#aqst_PaymentsForRoyaltyObligationsFinancingObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_aqst_PaymentsForRoyaltyObligationsFinancingObligations_3820d4a4-4583-4445-8761-eb6b6e868fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c549344d-f626-4675-8661-9feff0f20df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c549344d-f626-4675-8661-9feff0f20df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0dbb6a63-bb5f-44ac-b0e2-6441b73fea03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_edeb8ca0-eae0-4e24-bf7a-f8b2b7ef24d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0dbb6a63-bb5f-44ac-b0e2-6441b73fea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f62709e-a101-49f3-83c6-11c5c5c3a6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f62709e-a101-49f3-83c6-11c5c5c3a6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0df60e80-cf3b-45f7-8a05-7995db949f68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0df60e80-cf3b-45f7-8a05-7995db949f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_832a11cd-c070-49d9-b360-2634a1aa8efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0df60e80-cf3b-45f7-8a05-7995db949f68" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_832a11cd-c070-49d9-b360-2634a1aa8efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_458f9e80-0992-44a4-830c-ef0b6bb41ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0df60e80-cf3b-45f7-8a05-7995db949f68" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_458f9e80-0992-44a4-830c-ef0b6bb41ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d7688f8f-8768-47d0-b1ac-79d9688df99f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_25821428-01e0-4f32-8274-d970a4cda30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_25821428-01e0-4f32-8274-d970a4cda30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable_29f3a54b-9869-4859-8360-27a1695ce9ae" xlink:href="aqst-20250331.xsd#aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:to="loc_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable_29f3a54b-9869-4859-8360-27a1695ce9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable_ba632ed4-89a4-4b03-bbfe-9892019dfddd" xlink:href="aqst-20250331.xsd#aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7159754c-0a62-4264-91b0-0046b554fbeb" xlink:to="loc_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable_ba632ed4-89a4-4b03-bbfe-9892019dfddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CompanyOverviewandBasisofPresentation" xlink:type="simple" xlink:href="aqst-20250331.xsd#CompanyOverviewandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/CompanyOverviewandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_063203e5-a4fb-46db-a6ef-fe823786e9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c0c28cde-9a26-4d27-aeb0-640ebfe6ef01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_063203e5-a4fb-46db-a6ef-fe823786e9fe" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c0c28cde-9a26-4d27-aeb0-640ebfe6ef01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="aqst-20250331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e1adb494-c5b2-40a7-9c0c-5e94801da366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a12b7181-be7f-4885-a451-6d618525e9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e1adb494-c5b2-40a7-9c0c-5e94801da366" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a12b7181-be7f-4885-a451-6d618525e9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RisksandUncertainties" xlink:type="simple" xlink:href="aqst-20250331.xsd#RisksandUncertainties"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_56c7748f-adc1-41b6-9f33-25720ac1b72c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_f4ea7169-3b8a-4214-ad01-05a315c0f2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_56c7748f-adc1-41b6-9f33-25720ac1b72c" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_f4ea7169-3b8a-4214-ad01-05a315c0f2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SegmentReporting" xlink:type="simple" xlink:href="aqst-20250331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3b195264-8969-46ff-af19-6accb17f07fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_6b1c2c22-4619-4e63-ad05-a7fd70761baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3b195264-8969-46ff-af19-6accb17f07fc" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_6b1c2c22-4619-4e63-ad05-a7fd70761baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNet" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNet"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d46007a6-a21f-408c-a3ee-a98a4bf14c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_77d55cee-51fc-4dc4-96a8-ff009a5121b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d46007a6-a21f-408c-a3ee-a98a4bf14c3a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_77d55cee-51fc-4dc4-96a8-ff009a5121b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/MaterialAgreements" xlink:type="simple" xlink:href="aqst-20250331.xsd#MaterialAgreements"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/MaterialAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db47cb71-e424-43ea-a453-74c7dc48c024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7a9b6fed-9bfd-4dfc-a750-2ece6f878f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db47cb71-e424-43ea-a453-74c7dc48c024" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7a9b6fed-9bfd-4dfc-a750-2ece6f878f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurements" xlink:type="simple" xlink:href="aqst-20250331.xsd#FinancialInstrumentsFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d4d56679-27da-4147-9903-f2022d6ee558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a1323fd6-cd2f-43ec-84ea-57f69ee60da4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d4d56679-27da-4147-9903-f2022d6ee558" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a1323fd6-cd2f-43ec-84ea-57f69ee60da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/Inventories" xlink:type="simple" xlink:href="aqst-20250331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d6410aff-1680-4246-ada0-cc17395d57d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_8a3024ca-3547-4477-8b91-045a3f52ffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d6410aff-1680-4246-ada0-cc17395d57d1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_8a3024ca-3547-4477-8b91-045a3f52ffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="aqst-20250331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f5b1f598-d381-491f-9441-5b86aa9ec4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c3db1c96-e645-43e3-ac25-60abe832e9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f5b1f598-d381-491f-9441-5b86aa9ec4e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c3db1c96-e645-43e3-ac25-60abe832e9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligations" xlink:type="simple" xlink:href="aqst-20250331.xsd#RightofUseAssetsandLeaseObligations"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RightofUseAssetsandLeaseObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_39132ba3-1617-4750-8814-8ad4991ef78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b96b7827-2e16-4c48-9706-42cddfd09ace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39132ba3-1617-4750-8814-8ad4991ef78b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b96b7827-2e16-4c48-9706-42cddfd09ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="aqst-20250331.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f057f27b-9524-4e49-a8ec-3ceccb24e327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_df18427f-16b4-4653-8bcd-fda6596a8e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f057f27b-9524-4e49-a8ec-3ceccb24e327" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_df18427f-16b4-4653-8bcd-fda6596a8e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/OtherNoncurrentAssets" xlink:type="simple" xlink:href="aqst-20250331.xsd#OtherNoncurrentAssets"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/OtherNoncurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_72c77e65-fb86-449a-a61c-eea76ab515b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_a3aacc9d-0334-4eae-8c4f-dcd269e0b96a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_72c77e65-fb86-449a-a61c-eea76ab515b6" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_a3aacc9d-0334-4eae-8c4f-dcd269e0b96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/AccruedExpenses" xlink:type="simple" xlink:href="aqst-20250331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9a4e399b-c2e4-4280-9d96-e61bcc3e40d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_92c38e94-703c-4f5e-8570-e2b085fa5c97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9a4e399b-c2e4-4280-9d96-e61bcc3e40d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_92c38e94-703c-4f5e-8570-e2b085fa5c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebt" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_07a6bce4-1b72-4447-b06f-12798e371a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4edb3ae7-4e81-4a45-bcf9-b4820af253cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_07a6bce4-1b72-4447-b06f-12798e371a74" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4edb3ae7-4e81-4a45-bcf9-b4820af253cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/Warrants" xlink:type="simple" xlink:href="aqst-20250331.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_fda610d2-3d92-4a66-a1e9-460aea498ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_WarrantsDisclosureTextBlock_098f2994-74e8-4d46-840b-aa1c0380df60" xlink:href="aqst-20250331.xsd#aqst_WarrantsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_fda610d2-3d92-4a66-a1e9-460aea498ee2" xlink:to="loc_aqst_WarrantsDisclosureTextBlock_098f2994-74e8-4d46-840b-aa1c0380df60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SaleofFutureRevenue" xlink:type="simple" xlink:href="aqst-20250331.xsd#SaleofFutureRevenue"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SaleofFutureRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6cb21c2-c116-479c-a2a0-b7eb4dc6e839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfFutureRevenueTextBlock_ea58e936-0b54-4b14-a373-b43f9e2a1911" xlink:href="aqst-20250331.xsd#aqst_SaleOfFutureRevenueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6cb21c2-c116-479c-a2a0-b7eb4dc6e839" xlink:to="loc_aqst_SaleOfFutureRevenueTextBlock_ea58e936-0b54-4b14-a373-b43f9e2a1911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/NetLossPerShare" xlink:type="simple" xlink:href="aqst-20250331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5a855ea8-a4a8-450a-a124-fe2d0697a685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b085801d-58fa-4ca0-aeb9-85c212135b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5a855ea8-a4a8-450a-a124-fe2d0697a685" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b085801d-58fa-4ca0-aeb9-85c212135b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3f6afbde-26b5-47fc-8082-179c05e73c93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_00199a96-d743-4bdb-8571-2c43783d77c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3f6afbde-26b5-47fc-8082-179c05e73c93" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_00199a96-d743-4bdb-8571-2c43783d77c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/IncomeTaxes" xlink:type="simple" xlink:href="aqst-20250331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3da0ef18-1a66-456b-8b44-523ac3d4a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_54b6de00-e399-4ed7-b0d9-dccf56a1c506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3da0ef18-1a66-456b-8b44-523ac3d4a02b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_54b6de00-e399-4ed7-b0d9-dccf56a1c506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/Contingencies" xlink:type="simple" xlink:href="aqst-20250331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_35d235c5-29bc-42e3-b1fb-dbc10bf4a528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5deb5546-45c1-4e90-a453-9cf1065322fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_35d235c5-29bc-42e3-b1fb-dbc10bf4a528" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5deb5546-45c1-4e90-a453-9cf1065322fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="aqst-20250331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6e29f330-859e-4665-8cf1-e135f18127dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45782afa-ade7-4dc5-b824-397d839c5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e29f330-859e-4665-8cf1-e135f18127dd" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45782afa-ade7-4dc5-b824-397d839c5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f3213de-d946-4adc-b324-c877013bd0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e29f330-859e-4665-8cf1-e135f18127dd" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2f3213de-d946-4adc-b324-c877013bd0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_dcd90e50-c30f-4615-9769-15dbac2b5b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e29f330-859e-4665-8cf1-e135f18127dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_dcd90e50-c30f-4615-9769-15dbac2b5b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6a863a1f-4e9d-43a5-b12b-e5038471fa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_380343f4-53b1-4f60-a18c-c3865d5e1549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6a863a1f-4e9d-43a5-b12b-e5038471fa8d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_380343f4-53b1-4f60-a18c-c3865d5e1549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52378841-0f85-4885-bf50-a01f0e265646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_cec8c1fa-dd5f-47aa-ade3-b804e0fee4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52378841-0f85-4885-bf50-a01f0e265646" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_cec8c1fa-dd5f-47aa-ade3-b804e0fee4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_293b2fd7-f32c-40d0-bacb-fd39a9d213a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52378841-0f85-4885-bf50-a01f0e265646" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_293b2fd7-f32c-40d0-bacb-fd39a9d213a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_72313765-e9b6-41d0-bad0-5fc40eeeafc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52378841-0f85-4885-bf50-a01f0e265646" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_72313765-e9b6-41d0-bad0-5fc40eeeafc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_aec7a108-fa96-4161-a919-e602b557a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52378841-0f85-4885-bf50-a01f0e265646" xlink:to="loc_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_aec7a108-fa96-4161-a919-e602b557a06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/InventoriesTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_435ac943-d233-4552-9332-9a13c17d14e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_707e1945-9e96-48e3-9d44-52f765970382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_435ac943-d233-4552-9332-9a13c17d14e5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_707e1945-9e96-48e3-9d44-52f765970382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63af43e0-e101-4d69-b443-9b269f66ff43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_224d039e-7bee-4cd3-b271-589525087067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63af43e0-e101-4d69-b443-9b269f66ff43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_224d039e-7bee-4cd3-b271-589525087067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#RightofUseAssetsandLeaseObligationsTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6cbf1265-7bf0-43bd-925e-aebe4c6c5502" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6565a05c-721a-421b-831f-50f63f8a230e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6cbf1265-7bf0-43bd-925e-aebe4c6c5502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6565a05c-721a-421b-831f-50f63f8a230e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3061779-2aff-4719-93da-9ebd116a0058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_cf53ea04-c668-410a-aa66-a9d93a4eba25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3061779-2aff-4719-93da-9ebd116a0058" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_cf53ea04-c668-410a-aa66-a9d93a4eba25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/OtherNoncurrentAssetsTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#OtherNoncurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/OtherNoncurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_217c4674-ac0d-4905-b88e-67fedc4df8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_e3722c8a-5661-4393-8108-34678956620b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_217c4674-ac0d-4905-b88e-67fedc4df8ea" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_e3722c8a-5661-4393-8108-34678956620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d6f30656-1ff2-4116-9260-13c71f08f726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0f0250a1-a155-4cbc-a792-2a124ae29525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d6f30656-1ff2-4116-9260-13c71f08f726" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0f0250a1-a155-4cbc-a792-2a124ae29525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_967e5a16-19be-430e-b0e8-81a739c23e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a2209e5e-e97c-4303-aa69-ab384c987ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_967e5a16-19be-430e-b0e8-81a739c23e3a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a2209e5e-e97c-4303-aa69-ab384c987ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_efecfb80-23b3-443c-9139-13737dfc947e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_967e5a16-19be-430e-b0e8-81a739c23e3a" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_efecfb80-23b3-443c-9139-13737dfc947e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d22f70f5-b20f-49f6-8e73-dd0bcb1cd480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_967e5a16-19be-430e-b0e8-81a739c23e3a" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d22f70f5-b20f-49f6-8e73-dd0bcb1cd480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SaleofFutureRevenueTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#SaleofFutureRevenueTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SaleofFutureRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d660c2e0-b59a-4c0b-89cd-f61a40847820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationActivityTableTextBlock_4e58b876-1d02-4c61-bbe1-7d1afb83c3a7" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d660c2e0-b59a-4c0b-89cd-f61a40847820" xlink:to="loc_aqst_RoyaltyObligationActivityTableTextBlock_4e58b876-1d02-4c61-bbe1-7d1afb83c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dd6d8cda-a901-4163-9470-7c5a64656434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c6d7f09d-d063-4fed-9429-13d902866bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd6d8cda-a901-4163-9470-7c5a64656434" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c6d7f09d-d063-4fed-9429-13d902866bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923b93a0-0fa1-4ed7-a9cd-4a6f7c0ea163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8ac92f9e-7e8c-4b7e-b0c8-f4eba5997246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923b93a0-0fa1-4ed7-a9cd-4a6f7c0ea163" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8ac92f9e-7e8c-4b7e-b0c8-f4eba5997246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_5018b46b-25be-4194-bfc8-ac4887956d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923b93a0-0fa1-4ed7-a9cd-4a6f7c0ea163" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_5018b46b-25be-4194-bfc8-ac4887956d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_5af54f43-0553-4d69-bbf3-aa6856dd852e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923b93a0-0fa1-4ed7-a9cd-4a6f7c0ea163" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_5af54f43-0553-4d69-bbf3-aa6856dd852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_9a333240-4b45-40a9-a5d6-6379b1e36c3e" xlink:href="aqst-20250331.xsd#aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923b93a0-0fa1-4ed7-a9cd-4a6f7c0ea163" xlink:to="loc_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock_9a333240-4b45-40a9-a5d6-6379b1e36c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5eb4995f-25a6-439c-a1bf-e1222cb433c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923b93a0-0fa1-4ed7-a9cd-4a6f7c0ea163" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5eb4995f-25a6-439c-a1bf-e1222cb433c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#CompanyOverviewandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4492e6a-5bd3-4d69-9165-0a64f7bf4af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4492e6a-5bd3-4d69-9165-0a64f7bf4af3" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86dc31f1-142f-467d-a0ca-831956eb24b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86dc31f1-142f-467d-a0ca-831956eb24b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86dc31f1-142f-467d-a0ca-831956eb24b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_EquityDistributionAgreementMember_4789910e-027a-4907-bc22-ee3dcb4e270b" xlink:href="aqst-20250331.xsd#aqst_EquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_EquityDistributionAgreementMember_4789910e-027a-4907-bc22-ee3dcb4e270b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AmendedEquityDistributionAgreementMember_b211b93f-9d54-4993-854d-60ba1cc550a4" xlink:href="aqst-20250331.xsd#aqst_AmendedEquityDistributionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_AmendedEquityDistributionAgreementMember_b211b93f-9d54-4993-854d-60ba1cc550a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LincolnParkAgreementMember_3adff1e5-e0f1-4b01-a366-f8d11aed553b" xlink:href="aqst-20250331.xsd#aqst_LincolnParkAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_LincolnParkAgreementMember_3adff1e5-e0f1-4b01-a366-f8d11aed553b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_UnderwrittenPublicOfferingMember_82b5a925-8f59-4b07-b371-c384a2a3b984" xlink:href="aqst-20250331.xsd#aqst_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_aqst_UnderwrittenPublicOfferingMember_82b5a925-8f59-4b07-b371-c384a2a3b984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3c2e6f2b-5320-47f8-9d9f-7a6cbf76b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_540261e2-8a0d-443e-9e39-88425bcf14a1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3c2e6f2b-5320-47f8-9d9f-7a6cbf76b3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_884d63aa-8024-468e-a30e-4e636c4aaf80" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:to="loc_srt_RangeAxis_884d63aa-8024-468e-a30e-4e636c4aaf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb901890-f1fa-4b99-9f0c-62fa170d7d19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_884d63aa-8024-468e-a30e-4e636c4aaf80" xlink:to="loc_srt_RangeMember_cb901890-f1fa-4b99-9f0c-62fa170d7d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4116001-9d17-4155-83f8-6e57356ffb47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb901890-f1fa-4b99-9f0c-62fa170d7d19" xlink:to="loc_srt_MaximumMember_a4116001-9d17-4155-83f8-6e57356ffb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_180ff992-bca8-411e-9858-d04f4d1d06a1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts_c1b650a0-1884-47b9-ad72-1d1bc26e3afd" xlink:href="aqst-20250331.xsd#aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts_c1b650a0-1884-47b9-ad72-1d1bc26e3afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e39c2be0-97c6-4c0a-9895-75be09694a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e39c2be0-97c6-4c0a-9895-75be09694a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_edec52de-ae1e-4ef5-b393-d6083cef4013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_edec52de-ae1e-4ef5-b393-d6083cef4013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e04eb91b-46ea-48b7-bba8-2ced6fb41592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e04eb91b-46ea-48b7-bba8-2ced6fb41592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockMaximumTransactionAmount_371b5257-41d1-429d-a79e-876dcb98c9b4" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockMaximumTransactionAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockMaximumTransactionAmount_371b5257-41d1-429d-a79e-876dcb98c9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockAggregateOfferingPrice_960a5dc5-4267-48cf-9a40-080d6139a954" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockAggregateOfferingPrice_960a5dc5-4267-48cf-9a40-080d6139a954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts_fd1b7157-61aa-41d8-ad53-dd99737dbc37" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts_fd1b7157-61aa-41d8-ad53-dd99737dbc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_60392a5a-945a-4d08-baf8-6aaf11e9fb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_60392a5a-945a-4d08-baf8-6aaf11e9fb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RightToSellCommonStockValue_1613c47d-3c7c-4427-bfb2-a57ed8acff20" xlink:href="aqst-20250331.xsd#aqst_RightToSellCommonStockValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_RightToSellCommonStockValue_1613c47d-3c7c-4427-bfb2-a57ed8acff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AgreementTerm_2f4fd903-701e-4582-81d9-f59cb1e767a5" xlink:href="aqst-20250331.xsd#aqst_AgreementTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_AgreementTerm_2f4fd903-701e-4582-81d9-f59cb1e767a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions_42d4b77c-520b-4990-9946-05b623649873" xlink:href="aqst-20250331.xsd#aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions_42d4b77c-520b-4990-9946-05b623649873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1878eb30-9a1a-48eb-8e46-04b530a867fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1878eb30-9a1a-48eb-8e46-04b530a867fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts_c0b193e3-f65c-416b-9a5c-12dc106e5b0d" xlink:href="aqst-20250331.xsd#aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_4e3375e8-c2fe-47ce-9d86-7b30c216173c" xlink:to="loc_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts_c0b193e3-f65c-416b-9a5c-12dc106e5b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RisksandUncertaintiesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_bfeadb33-3116-43b2-98c3-8e1d84cf45e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d5a7068e-a300-4d8d-869d-e5750db1104e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_bfeadb33-3116-43b2-98c3-8e1d84cf45e5" xlink:to="loc_us-gaap_ConcentrationRiskTable_d5a7068e-a300-4d8d-869d-e5750db1104e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d5a7068e-a300-4d8d-869d-e5750db1104e" xlink:to="loc_us-gaap_DebtInstrumentAxis_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c065e5cb-bfa9-40ea-ab09-a0bce2968862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dbdd3f9a-0a38-45a0-bb67-afeac70d75fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c065e5cb-bfa9-40ea-ab09-a0bce2968862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_e2ab3fa0-e65e-4c24-959e-b2254c645db9" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c065e5cb-bfa9-40ea-ab09-a0bce2968862" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_e2ab3fa0-e65e-4c24-959e-b2254c645db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d5a7068e-a300-4d8d-869d-e5750db1104e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d48c8ba-0103-493f-8fae-a37f30c26062" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d48c8ba-0103-493f-8fae-a37f30c26062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fab36aa-3213-4f72-93c0-8b4b88b96236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fab36aa-3213-4f72-93c0-8b4b88b96236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7424dce-f068-47fd-83fe-cd3f2ad4013a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6a594c95-be9f-40b1-98ff-6b6053888902" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b7424dce-f068-47fd-83fe-cd3f2ad4013a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e3a1640f-d5c3-4902-88bb-80a3f4957ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3a1640f-d5c3-4902-88bb-80a3f4957ea8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_60b3f839-2c9b-48a8-bc44-900d15115da9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3dfcb22a-945e-48d1-8ae5-54f01ebb1fd3" xlink:to="loc_us-gaap_SegmentDomain_60b3f839-2c9b-48a8-bc44-900d15115da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ReportableSegmentMember_c3af741d-4cd2-4e06-a144-bd34024ce7d4" xlink:href="aqst-20250331.xsd#aqst_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_60b3f839-2c9b-48a8-bc44-900d15115da9" xlink:to="loc_aqst_ReportableSegmentMember_c3af741d-4cd2-4e06-a144-bd34024ce7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:to="loc_srt_ProductOrServiceAxis_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2c8e6ae9-a76d-44ec-8c8d-3085aebcdb0d" xlink:to="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AnaphylmMember_bb03891d-923a-476e-b3a4-3693c7dc9856" xlink:href="aqst-20250331.xsd#aqst_AnaphylmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_AnaphylmMember_bb03891d-923a-476e-b3a4-3693c7dc9856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AQST108Member_7a3f00a9-fa80-428b-a5e8-e925e30c30bd" xlink:href="aqst-20250331.xsd#aqst_AQST108Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_AQST108Member_7a3f00a9-fa80-428b-a5e8-e925e30c30bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LibervantMember_988999cb-312c-4f4a-bdec-38128771de0a" xlink:href="aqst-20250331.xsd#aqst_LibervantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_LibervantMember_988999cb-312c-4f4a-bdec-38128771de0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PersonnelCostsMember_5faea1b2-06b4-476f-a64d-e6ed7b95ee96" xlink:href="aqst-20250331.xsd#aqst_PersonnelCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_PersonnelCostsMember_5faea1b2-06b4-476f-a64d-e6ed7b95ee96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_OtherMember_dae41af9-0e47-43ce-a454-be7d3e9d4102" xlink:href="aqst-20250331.xsd#aqst_OtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d9716c9-7a56-48bb-b8f6-e3120b86852b" xlink:to="loc_aqst_OtherMember_dae41af9-0e47-43ce-a454-be7d3e9d4102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bcb5bd9f-f65f-4386-b7fc-2680876a487d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d09e3483-53ad-4298-9d2b-91542ad08c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d09e3483-53ad-4298-9d2b-91542ad08c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_28fbebaa-08d6-4e4c-ba79-0b65bdc8bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_NumberOfReportableSegments_28fbebaa-08d6-4e4c-ba79-0b65bdc8bd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2108ab34-e0ac-40e7-aeef-6e423b6592cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2108ab34-e0ac-40e7-aeef-6e423b6592cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8dd5615e-996f-4218-be19-b681f3cc60ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8dd5615e-996f-4218-be19-b681f3cc60ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4e70992a-9a07-42ed-86ca-b567f7527c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_7d19ec8e-d1ce-459f-99e3-61543a6941ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4e70992a-9a07-42ed-86ca-b567f7527c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_1ecfcb6b-5c81-4200-9c5d-69a1317eca89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_1ecfcb6b-5c81-4200-9c5d-69a1317eca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingExpense_c6a76cb2-d0d8-459f-962f-c9486afe6387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_1ecfcb6b-5c81-4200-9c5d-69a1317eca89" xlink:to="loc_us-gaap_SellingExpense_c6a76cb2-d0d8-459f-962f-c9486afe6387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_7b43a95e-0083-4d63-858f-1647d3043c15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_7b43a95e-0083-4d63-858f-1647d3043c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b172a299-6151-4a85-ac67-3a45b8ab34c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_7b43a95e-0083-4d63-858f-1647d3043c15" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b172a299-6151-4a85-ac67-3a45b8ab34c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fd710e84-b133-468c-9189-e3a4d1a5981c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fd710e84-b133-468c-9189-e3a4d1a5981c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_604c9255-a8f6-4ca2-afbe-dab229d5b94f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_CostsAndExpenses_604c9255-a8f6-4ca2-afbe-dab229d5b94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ffcf19d1-d50b-483d-a1bd-20b002183ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_OperatingIncomeLoss_ffcf19d1-d50b-483d-a1bd-20b002183ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_90c731a3-14b8-44e3-a555-a345532f7f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_90c731a3-14b8-44e3-a555-a345532f7f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f9d6d9f-2abe-4729-803c-10a837ca177c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f9d6d9f-2abe-4729-803c-10a837ca177c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2ec59756-593f-453d-85ff-5936e966ca5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_NetIncomeLoss_2ec59756-593f-453d-85ff-5936e966ca5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_24379ec7-b0eb-4fed-9ef2-b5cdc4c365c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_83f4f8cf-f912-439c-8e36-f8bddc114a3d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_24379ec7-b0eb-4fed-9ef2-b5cdc4c365c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_92adecfb-711e-4a41-b384-94118066c118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_92adecfb-711e-4a41-b384-94118066c118" xlink:to="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_896fe99d-7ba1-40b7-a905-22864fc50e41" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_srt_RangeAxis_896fe99d-7ba1-40b7-a905-22864fc50e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af123a67-ea58-476c-ab84-ad2136703d5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_896fe99d-7ba1-40b7-a905-22864fc50e41" xlink:to="loc_srt_RangeMember_af123a67-ea58-476c-ab84-ad2136703d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8387d4b0-6d48-48ef-a3a8-697fe0ebcb6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af123a67-ea58-476c-ab84-ad2136703d5c" xlink:to="loc_srt_MaximumMember_8387d4b0-6d48-48ef-a3a8-697fe0ebcb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2db940c-e9a2-4c70-942a-b0b69f43855f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2db940c-e9a2-4c70-942a-b0b69f43855f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b2db940c-e9a2-4c70-942a-b0b69f43855f" xlink:to="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_344399a2-6f11-4c07-a124-a1f7ccc0964f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_344399a2-6f11-4c07-a124-a1f7ccc0964f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_OtherReceivablesAndAccruedExpensesMember_26a93599-6fbf-47a1-bc30-0465fccbe596" xlink:href="aqst-20250331.xsd#aqst_OtherReceivablesAndAccruedExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:to="loc_aqst_OtherReceivablesAndAccruedExpensesMember_26a93599-6fbf-47a1-bc30-0465fccbe596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_90cf2366-b7e0-4b0e-981a-79a6accddb44" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableDoubtfulAccountsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_9c9ede34-f487-434a-bd46-3583c13084ae" xlink:to="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_90cf2366-b7e0-4b0e-981a-79a6accddb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_90ee9cb4-d4f1-4e11-adb8-94e8002fe764" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_srt_MajorCustomersAxis_90ee9cb4-d4f1-4e11-adb8-94e8002fe764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_90ee9cb4-d4f1-4e11-adb8-94e8002fe764" xlink:to="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_IndiviorMember_74000df3-ba4c-4674-a538-2a04b24b2197" xlink:href="aqst-20250331.xsd#aqst_IndiviorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:to="loc_aqst_IndiviorMember_74000df3-ba4c-4674-a538-2a04b24b2197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_HyperaMember_a0dba7fb-4afd-44d1-9347-16ecd1ddf034" xlink:href="aqst-20250331.xsd#aqst_HyperaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c8063a3f-8ae8-40f9-9199-e29d2a2a5a4e" xlink:to="loc_aqst_HyperaMember_a0dba7fb-4afd-44d1-9347-16ecd1ddf034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_552ae984-2708-40be-b20c-64e84b8399b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_552ae984-2708-40be-b20c-64e84b8399b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_552ae984-2708-40be-b20c-64e84b8399b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_00fa0b13-4f49-43e9-a281-34be6e04dbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_00fa0b13-4f49-43e9-a281-34be6e04dbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_92c6c44d-caf2-4f98-8af3-d3616d2e1ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5fb9d056-bf94-4c30-b87b-d38d0a36131c" xlink:to="loc_us-gaap_AccountsReceivableMember_92c6c44d-caf2-4f98-8af3-d3616d2e1ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f9d2dc8b-a610-4eff-a305-79712072dbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f9d2dc8b-a610-4eff-a305-79712072dbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4ff385cf-9fc0-4a76-bb66-a5fed5710ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f9d2dc8b-a610-4eff-a305-79712072dbe0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4ff385cf-9fc0-4a76-bb66-a5fed5710ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_09e379d6-87a5-4db8-8cb6-618f56153a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4ff385cf-9fc0-4a76-bb66-a5fed5710ea1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_09e379d6-87a5-4db8-8cb6-618f56153a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_c707049c-8e8b-42cc-bb06-0637440aaa64" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ResearchAndDevelopmentProjectDuration_72f3a91f-f299-44ed-b98d-74f5a21b1709" xlink:href="aqst-20250331.xsd#aqst_ResearchAndDevelopmentProjectDuration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_aqst_ResearchAndDevelopmentProjectDuration_72f3a91f-f299-44ed-b98d-74f5a21b1709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_e8985979-fd43-4847-bd50-04375b1a331b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_e8985979-fd43-4847-bd50-04375b1a331b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9e3e3bb3-8b23-40a1-9d92-ed7cefc5381f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9e3e3bb3-8b23-40a1-9d92-ed7cefc5381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_f34f15fc-c1a4-492f-af39-16be76b76cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_CapitalizedContractCostNet_f34f15fc-c1a4-492f-af39-16be76b76cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cf888f01-67e7-4084-a1f6-8092981bd75d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cf888f01-67e7-4084-a1f6-8092981bd75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ea4b4039-01ca-431e-87a0-ed8acd6b9074" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ea4b4039-01ca-431e-87a0-ed8acd6b9074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b84894f2-c957-4bb8-981e-3c35fa6543b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c0ec9b16-3f6b-494f-bae8-7c856d648933" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b84894f2-c957-4bb8-981e-3c35fa6543b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetRevenueDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_434b5452-2322-4b5e-9834-cde8d0826e14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7c0a6a1a-f3eb-4e2c-b64a-18490b5c2479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_434b5452-2322-4b5e-9834-cde8d0826e14" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7c0a6a1a-f3eb-4e2c-b64a-18490b5c2479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_735f7a47-1829-4f4d-80a5-0e8bee11bbae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7c0a6a1a-f3eb-4e2c-b64a-18490b5c2479" xlink:to="loc_srt_ProductOrServiceAxis_735f7a47-1829-4f4d-80a5-0e8bee11bbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_735f7a47-1829-4f4d-80a5-0e8bee11bbae" xlink:to="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufactureAndSupplyRevenueMember_5136ce45-ae9c-4865-bb59-f50103b15ae9" xlink:href="aqst-20250331.xsd#aqst_ManufactureAndSupplyRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_aqst_ManufactureAndSupplyRevenueMember_5136ce45-ae9c-4865-bb59-f50103b15ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAndRoyaltyRevenueMember_622c2088-afcd-4de6-9487-53142af60e2b" xlink:href="aqst-20250331.xsd#aqst_LicenseAndRoyaltyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_aqst_LicenseAndRoyaltyRevenueMember_622c2088-afcd-4de6-9487-53142af60e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CoDevelopmentAndResearchFeesMember_039a1ce2-68c2-4289-bae0-2876c0cd7082" xlink:href="aqst-20250331.xsd#aqst_CoDevelopmentAndResearchFeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_aqst_CoDevelopmentAndResearchFeesMember_039a1ce2-68c2-4289-bae0-2876c0cd7082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_f17cfcdc-dcce-4c5e-8d4a-4fad0ecceb03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f8a9f6db-3414-4407-b2e6-62c3c3cf2dde" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_f17cfcdc-dcce-4c5e-8d4a-4fad0ecceb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_827107bd-dfbe-45f6-9730-907725df186d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7c0a6a1a-f3eb-4e2c-b64a-18490b5c2479" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_827107bd-dfbe-45f6-9730-907725df186d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_158a29c8-c631-4b86-b8ab-84d16cd8f078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_827107bd-dfbe-45f6-9730-907725df186d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_158a29c8-c631-4b86-b8ab-84d16cd8f078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bd66a91c-7b23-4c79-a899-52ab72d2f6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4aebfb17-153c-4661-82b4-a18e0fb6362e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bd66a91c-7b23-4c79-a899-52ab72d2f6cc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4aebfb17-153c-4661-82b4-a18e0fb6362e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d3e38295-7c88-4fb3-93a0-8f31a5d8945c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4aebfb17-153c-4661-82b4-a18e0fb6362e" xlink:to="loc_srt_StatementGeographicalAxis_d3e38295-7c88-4fb3-93a0-8f31a5d8945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d3e38295-7c88-4fb3-93a0-8f31a5d8945c" xlink:to="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ffa3e070-8a35-4123-92c3-3f8639c18aed" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:to="loc_country_US_ffa3e070-8a35-4123-92c3-3f8639c18aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_4f637195-4539-497c-b893-87cc1e8b9cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a12825c8-f399-41cc-8661-fa9980de7e49" xlink:to="loc_us-gaap_NonUsMember_4f637195-4539-497c-b893-87cc1e8b9cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fc3477f5-3bd0-45df-8295-16ae3556f9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4aebfb17-153c-4661-82b4-a18e0fb6362e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fc3477f5-3bd0-45df-8295-16ae3556f9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_eaaf0660-54fc-481f-b6e0-7ceeb7765535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fc3477f5-3bd0-45df-8295-16ae3556f9b3" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_eaaf0660-54fc-481f-b6e0-7ceeb7765535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1443dc8d-5f87-4997-bb48-8a88b3d08744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_eaaf0660-54fc-481f-b6e0-7ceeb7765535" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1443dc8d-5f87-4997-bb48-8a88b3d08744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b8bfe775-1576-4bf8-a6bb-2015e19a1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b64895bb-961d-4b78-9210-83bf674fedbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b8bfe775-1576-4bf8-a6bb-2015e19a1b5b" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b64895bb-961d-4b78-9210-83bf674fedbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b64895bb-961d-4b78-9210-83bf674fedbc" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d11e7ded-3bbb-4a66-bb7f-ec624fa73a69" xlink:to="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_eed6df94-596f-4177-a5e6-ea9f8c2f8c28" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableDoubtfulAccountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:to="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_eed6df94-596f-4177-a5e6-ea9f8c2f8c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableSalesRelatedMember_701a0e1a-8ba7-4b13-8968-722ece0c879e" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableSalesRelatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_d012b4fb-e372-4e9b-9967-e1940a429103" xlink:to="loc_aqst_TradeAccountsReceivableSalesRelatedMember_701a0e1a-8ba7-4b13-8968-722ece0c879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b64895bb-961d-4b78-9210-83bf674fedbc" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_95d8e35a-cb22-40c0-84b4-e67936781800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_us-gaap_AccountsReceivableGross_95d8e35a-cb22-40c0-84b4-e67936781800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_83258421-efeb-459d-a61a-a6decf6ab240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_83258421-efeb-459d-a61a-a6decf6ab240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_20c83565-8f79-4c12-98ca-38f5d71e4143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_20c83565-8f79-4c12-98ca-38f5d71e4143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAndOtherReceivablesNet_35bc1e84-b7be-4e08-84d2-ba767dd2873b" xlink:href="aqst-20250331.xsd#aqst_TradeAndOtherReceivablesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_09147557-18e4-4ca1-a412-681203658b9a" xlink:to="loc_aqst_TradeAndOtherReceivablesNet_35bc1e84-b7be-4e08-84d2-ba767dd2873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d3736a30-d8ce-4872-8b46-dcaef6f0760e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2f1bad54-7dfb-4dd3-98be-bd1a88634ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d3736a30-d8ce-4872-8b46-dcaef6f0760e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2f1bad54-7dfb-4dd3-98be-bd1a88634ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2f1bad54-7dfb-4dd3-98be-bd1a88634ad6" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_668c0614-ecc7-4d6b-a52b-e0ac693bfbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d3422e5a-a6d9-4c60-a8ad-a36dc15474c3" xlink:to="loc_us-gaap_ReceivableTypeDomain_668c0614-ecc7-4d6b-a52b-e0ac693bfbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_851b1f57-4650-45d4-86e9-d77bf2e08dd0" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableDoubtfulAccountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_668c0614-ecc7-4d6b-a52b-e0ac693bfbfb" xlink:to="loc_aqst_TradeAccountsReceivableDoubtfulAccountsMember_851b1f57-4650-45d4-86e9-d77bf2e08dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_461d3434-9cde-4c42-b534-77f714d99468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_2f1bad54-7dfb-4dd3-98be-bd1a88634ad6" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_461d3434-9cde-4c42-b534-77f714d99468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_461d3434-9cde-4c42-b534-77f714d99468" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f9e76e36-5369-498a-a170-0d191bb9ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f9e76e36-5369-498a-a170-0d191bb9ccaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c2dd01e7-e6d0-4c83-a9c5-68d10e159ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c2dd01e7-e6d0-4c83-a9c5-68d10e159ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_76469623-ed58-4c2a-9215-0f4eed04955f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_6d6f6f5d-c965-4bb1-9346-da6dd2ccbf43" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_76469623-ed58-4c2a-9215-0f4eed04955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_66175d73-e3cc-4964-b494-5566ce408306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d1e538d6-eecb-4bfb-a46e-f2504749c351" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_66175d73-e3cc-4964-b494-5566ce408306" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d1e538d6-eecb-4bfb-a46e-f2504749c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1df7e394-47b4-44cb-b541-21cee9a8814f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d1e538d6-eecb-4bfb-a46e-f2504749c351" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1df7e394-47b4-44cb-b541-21cee9a8814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a64090d5-f4f6-4a94-80ab-0d8ab168fb96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1df7e394-47b4-44cb-b541-21cee9a8814f" xlink:to="loc_us-gaap_ReceivableTypeDomain_a64090d5-f4f6-4a94-80ab-0d8ab168fb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TradeAccountsReceivableSalesRelatedMember_e9dde58a-34fd-40ae-9d44-af7a13e3e6b2" xlink:href="aqst-20250331.xsd#aqst_TradeAccountsReceivableSalesRelatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a64090d5-f4f6-4a94-80ab-0d8ab168fb96" xlink:to="loc_aqst_TradeAccountsReceivableSalesRelatedMember_e9dde58a-34fd-40ae-9d44-af7a13e3e6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e038d3ba-561b-45b9-8e30-4bde8ee0048b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d1e538d6-eecb-4bfb-a46e-f2504749c351" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e038d3ba-561b-45b9-8e30-4bde8ee0048b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_e038d3ba-561b-45b9-8e30-4bde8ee0048b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4be35a26-325d-4e47-a86d-15da02547ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4be35a26-325d-4e47-a86d-15da02547ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_a2b38cb1-c5ec-495c-b8ac-79021563c83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_a2b38cb1-c5ec-495c-b8ac-79021563c83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_a857f272-61ed-4aa2-b0bb-0da01ae29563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_a857f272-61ed-4aa2-b0bb-0da01ae29563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8fff746d-b4d4-4a44-bbdc-857edf310437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_402bb0c2-ec10-4c3f-aead-83eff232e10c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8fff746d-b4d4-4a44-bbdc-857edf310437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/MaterialAgreementsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#MaterialAgreementsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/MaterialAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e107f093-afc6-423c-b329-250587122fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e107f093-afc6-423c-b329-250587122fd1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eec6395d-7ef3-4899-82a1-258c713d20ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eec6395d-7ef3-4899-82a1-258c713d20ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eec6395d-7ef3-4899-82a1-258c713d20ef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CommercialExploitationAgreementWithIndiviorMember_20615322-90f9-4ee0-b9a3-8d7464fe1c4c" xlink:href="aqst-20250331.xsd#aqst_CommercialExploitationAgreementWithIndiviorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_CommercialExploitationAgreementWithIndiviorMember_20615322-90f9-4ee0-b9a3-8d7464fe1c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember_c38dda6b-fbc4-4510-acdd-fbbc2a3fd6f2" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember_c38dda6b-fbc4-4510-acdd-fbbc2a3fd6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember_d94b5e9d-72c1-4af1-a447-0923d33c354b" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_27a8c523-2460-49fc-a8b6-2804e2fb5fca" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember_d94b5e9d-72c1-4af1-a447-0923d33c354b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarathonPangolinRoyaltyLLCMember_35cbe2e5-545c-4d91-af84-9fc410739e2d" xlink:href="aqst-20250331.xsd#aqst_MarathonPangolinRoyaltyLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_MarathonPangolinRoyaltyLLCMember_35cbe2e5-545c-4d91-af84-9fc410739e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember_2184906e-bba1-4a19-8eb1-f75969ebd1ec" xlink:href="aqst-20250331.xsd#aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember_2184906e-bba1-4a19-8eb1-f75969ebd1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedMember_dabf6cc6-4c48-451a-88c4-d46eee3e0808" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_AtnahsPharmaUKLimitedMember_dabf6cc6-4c48-451a-88c4-d46eee3e0808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseSupplyAgreementMember_d05eb4dc-50af-4d9a-bd55-a8e80c4d66de" xlink:href="aqst-20250331.xsd#aqst_LicenseSupplyAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_LicenseSupplyAgreementMember_d05eb4dc-50af-4d9a-bd55-a8e80c4d66de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember_c910be5c-664b-4d35-87e5-f8f9f4857414" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedAmendedAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76fbacf7-192a-4ed9-afd4-cbc05a69a6b4" xlink:to="loc_aqst_AtnahsPharmaUKLimitedAmendedAgreementMember_c910be5c-664b-4d35-87e5-f8f9f4857414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d1b2228-6f89-46be-9307-30e54b07d0e3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_srt_RangeAxis_7d1b2228-6f89-46be-9307-30e54b07d0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3087419-2763-4a61-8452-e1ce9375a3c9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7d1b2228-6f89-46be-9307-30e54b07d0e3" xlink:to="loc_srt_RangeMember_b3087419-2763-4a61-8452-e1ce9375a3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fdf7fa2b-8c00-4de7-b5bc-5593539d2df6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b3087419-2763-4a61-8452-e1ce9375a3c9" xlink:to="loc_srt_MaximumMember_fdf7fa2b-8c00-4de7-b5bc-5593539d2df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_503bf4af-1997-447a-8f3d-b8081a14a77b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_srt_ProductOrServiceAxis_503bf4af-1997-447a-8f3d-b8081a14a77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_503bf4af-1997-447a-8f3d-b8081a14a77b" xlink:to="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufactureAndSupplyRevenueMember_75b97f3b-470c-4224-9226-b62430f107b1" xlink:href="aqst-20250331.xsd#aqst_ManufactureAndSupplyRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:to="loc_aqst_ManufactureAndSupplyRevenueMember_75b97f3b-470c-4224-9226-b62430f107b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAndRoyaltyRevenueMember_115e0aef-977b-48f1-b424-2d58f9185419" xlink:href="aqst-20250331.xsd#aqst_LicenseAndRoyaltyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78b73d72-85a0-4e64-bbaa-9bfb56fed493" xlink:to="loc_aqst_LicenseAndRoyaltyRevenueMember_115e0aef-977b-48f1-b424-2d58f9185419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_us-gaap_CreditFacilityAxis_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ca4bab5e-6dae-4fe7-a92c-5fc739be7f96" xlink:to="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MonetizationAgreementMember_d55c8020-e0a1-4c70-a4cf-d427956c6051" xlink:href="aqst-20250331.xsd#aqst_MonetizationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:to="loc_aqst_MonetizationAgreementMember_d55c8020-e0a1-4c70-a4cf-d427956c6051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseSupplyAgreementMember_edf9912d-4f5d-4c94-a398-a02e049cafb7" xlink:href="aqst-20250331.xsd#aqst_LicenseSupplyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:to="loc_aqst_LicenseSupplyAgreementMember_edf9912d-4f5d-4c94-a398-a02e049cafb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AtnahsPharmaUKLimitedMember_291efd89-28d0-4980-b8fb-3a183a6bc0c7" xlink:href="aqst-20250331.xsd#aqst_AtnahsPharmaUKLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c2096eaa-562a-4474-baa3-0e4ecce88f1d" xlink:to="loc_aqst_AtnahsPharmaUKLimitedMember_291efd89-28d0-4980-b8fb-3a183a6bc0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b0697945-eddf-4ca1-9f48-e0654ef28337" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_srt_CounterpartyNameAxis_b0697945-eddf-4ca1-9f48-e0654ef28337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b0697945-eddf-4ca1-9f48-e0654ef28337" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_IndiviorMember_3dd174bb-0ecd-4531-b60f-eccca53dd6a8" xlink:href="aqst-20250331.xsd#aqst_IndiviorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:to="loc_aqst_IndiviorMember_3dd174bb-0ecd-4531-b60f-eccca53dd6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AssertioHoldingsIncMember_c4979798-aebd-421b-bb84-7bbf59d09f4a" xlink:href="aqst-20250331.xsd#aqst_AssertioHoldingsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09870d6d-494e-4b1d-862f-e8608190c205" xlink:to="loc_aqst_AssertioHoldingsIncMember_c4979798-aebd-421b-bb84-7bbf59d09f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9c87f599-cdc9-4474-b201-72fdffa4343c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementTerm_4013d645-4bc1-45e0-a90b-cd27ce9ebf05" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_LicenseAgreementTerm_4013d645-4bc1-45e0-a90b-cd27ce9ebf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AutomaticRenewalPeriodOfAgreement_ae1fb971-a1b2-4c7d-bdc2-32f6cda0a41b" xlink:href="aqst-20250331.xsd#aqst_AutomaticRenewalPeriodOfAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_AutomaticRenewalPeriodOfAgreement_ae1fb971-a1b2-4c7d-bdc2-32f6cda0a41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c23a31f-c007-4bd5-87e3-0f1e1c464c76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c23a31f-c007-4bd5-87e3-0f1e1c464c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_385f4ff4-5de1-432c-90d5-92a8dd544709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_Revenues_385f4ff4-5de1-432c-90d5-92a8dd544709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_0b14dc20-eac3-4377-a09f-a02bd149fd9c" xlink:href="aqst-20250331.xsd#aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_0b14dc20-eac3-4377-a09f-a02bd149fd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_e05557d6-32ed-46be-a4f8-850e1676d665" xlink:href="aqst-20250331.xsd#aqst_ProceedsFromSaleOfFutureRevenuesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_e05557d6-32ed-46be-a4f8-850e1676d665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ContingentMonetizationAgreementMilestonePayment_e9d0f722-05cf-4740-9a49-82702fdd16f7" xlink:href="aqst-20250331.xsd#aqst_ContingentMonetizationAgreementMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_aqst_ContingentMonetizationAgreementMilestonePayment_e9d0f722-05cf-4740-9a49-82702fdd16f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_8807ccfd-5638-423b-a80a-08784f5898be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss_8807ccfd-5638-423b-a80a-08784f5898be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_b32bdadd-bbfc-4803-bb9d-07f8e9fb6c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b2cc878-4795-4b00-b564-dbbc8e2f5714" xlink:to="loc_us-gaap_ProceedsFromCollaborators_b32bdadd-bbfc-4803-bb9d-07f8e9fb6c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#FinancialInstrumentsFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b44c9540-e69f-47a5-a243-20d6d0fbba40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b44c9540-e69f-47a5-a243-20d6d0fbba40" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a2753d9-ca47-4fdb-830d-6e588148253d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a2753d9-ca47-4fdb-830d-6e588148253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a2753d9-ca47-4fdb-830d-6e588148253d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_9fc6dfad-c1b6-4454-ab6a-6049c357f855" xlink:href="aqst-20250331.xsd#aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:to="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_9fc6dfad-c1b6-4454-ab6a-6049c357f855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_08a0e465-d8ba-4a30-8e7b-60134cf80ccc" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7158f524-0ccb-4c0d-8968-a9d2250e8621" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_08a0e465-d8ba-4a30-8e7b-60134cf80ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_632dfe05-d4aa-4824-83c7-f076fba6b814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_632dfe05-d4aa-4824-83c7-f076fba6b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47730ce9-7a6a-47eb-92f7-7457be83eb96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_632dfe05-d4aa-4824-83c7-f076fba6b814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47730ce9-7a6a-47eb-92f7-7457be83eb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SecuritiesPurchaseAgreementMember_72f53ea2-8c9e-46d1-944b-f215f8058fd8" xlink:href="aqst-20250331.xsd#aqst_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47730ce9-7a6a-47eb-92f7-7457be83eb96" xlink:to="loc_aqst_SecuritiesPurchaseAgreementMember_72f53ea2-8c9e-46d1-944b-f215f8058fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_987ce20e-8d05-48f4-94a8-88ad1ff0f3b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ExistingWarrantsMember_28a11a83-3ac3-498d-9141-34976a935236" xlink:href="aqst-20250331.xsd#aqst_ExistingWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:to="loc_aqst_ExistingWarrantsMember_28a11a83-3ac3-498d-9141-34976a935236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NewWarrantsMember_2e3923c4-29eb-49db-9234-abfd5a0b995a" xlink:href="aqst-20250331.xsd#aqst_NewWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4868e683-9d6d-4b66-9494-27a142e8e834" xlink:to="loc_aqst_NewWarrantsMember_2e3923c4-29eb-49db-9234-abfd5a0b995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9b129342-74a1-4e11-8b53-275cf0ab1c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9b129342-74a1-4e11-8b53-275cf0ab1c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51610786-4f4f-438c-990a-db8233728171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b129342-74a1-4e11-8b53-275cf0ab1c78" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_51610786-4f4f-438c-990a-db8233728171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fbbd6130-706d-4561-b117-65138c6a69d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_51610786-4f4f-438c-990a-db8233728171" xlink:to="loc_us-gaap_SeniorNotesMember_fbbd6130-706d-4561-b117-65138c6a69d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e779346-d4dd-491e-8caf-9833758ff1ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_srt_RangeAxis_7e779346-d4dd-491e-8caf-9833758ff1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7e779346-d4dd-491e-8caf-9833758ff1ac" xlink:to="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89f3bba3-3e78-4441-8781-f34966357647" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:to="loc_srt_MinimumMember_89f3bba3-3e78-4441-8781-f34966357647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d7cb81c-a2cd-45f5-b5bf-3bfd89518ed6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_16806831-7dd4-4194-bf5c-7bf9173a73c5" xlink:to="loc_srt_MaximumMember_2d7cb81c-a2cd-45f5-b5bf-3bfd89518ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2af08a08-bc3a-49fd-90dc-794f1c46c6c9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d1daded4-8e94-4881-aeb6-fc3a78b254f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d1daded4-8e94-4881-aeb6-fc3a78b254f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants_90bc541f-5a9a-404b-87a7-f81af5f803b6" xlink:href="aqst-20250331.xsd#aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants_90bc541f-5a9a-404b-87a7-f81af5f803b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants_58fd7264-ee87-4684-aef7-1013c88bb57c" xlink:href="aqst-20250331.xsd#aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants_58fd7264-ee87-4684-aef7-1013c88bb57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ac467cb7-ffdd-49fb-9a23-107a5d3adc82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ac467cb7-ffdd-49fb-9a23-107a5d3adc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45c69882-8b1c-42c7-b9b7-a4cc6517c93c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45c69882-8b1c-42c7-b9b7-a4cc6517c93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0a7d0381-f7ed-48f3-8570-2fa0a1887324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0a7d0381-f7ed-48f3-8570-2fa0a1887324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_e71963bf-bae5-47d1-82bb-3fd2baaf148a" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_e71963bf-bae5-47d1-82bb-3fd2baaf148a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_fb45d389-66f8-446b-a898-8628c317b57c" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_05d647fd-a31f-477c-9b29-0cf82471037e" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_fb45d389-66f8-446b-a898-8628c317b57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/InventoriesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1284d635-a7b3-469a-b5b0-2c145f58d61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_9df15a64-b809-44fb-8207-50ac2cd172b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1284d635-a7b3-469a-b5b0-2c145f58d61d" xlink:to="loc_us-gaap_InventoryRawMaterials_9df15a64-b809-44fb-8207-50ac2cd172b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InventoryPackingMaterialGross_3c86fd50-deff-4682-a452-44b39e7aa267" xlink:href="aqst-20250331.xsd#aqst_InventoryPackingMaterialGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1284d635-a7b3-469a-b5b0-2c145f58d61d" xlink:to="loc_aqst_InventoryPackingMaterialGross_3c86fd50-deff-4682-a452-44b39e7aa267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_af03905f-2b67-45aa-afe5-b98991f177a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1284d635-a7b3-469a-b5b0-2c145f58d61d" xlink:to="loc_us-gaap_InventoryFinishedGoods_af03905f-2b67-45aa-afe5-b98991f177a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8ca8160e-339c-40c6-92cd-b07e902b690a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1284d635-a7b3-469a-b5b0-2c145f58d61d" xlink:to="loc_us-gaap_InventoryNet_8ca8160e-339c-40c6-92cd-b07e902b690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a0143c21-839e-49c4-97c7-9fd67782a5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a0143c21-839e-49c4-97c7-9fd67782a5c3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60bb0086-63c3-4364-84f2-4db88e53a1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60bb0086-63c3-4364-84f2-4db88e53a1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60bb0086-63c3-4364-84f2-4db88e53a1b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c1655bec-4de0-412f-b218-286a0d303da0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c1655bec-4de0-412f-b218-286a0d303da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4ee4d050-33f0-443c-9b1a-926a823296fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4ee4d050-33f0-443c-9b1a-926a823296fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cd24c04e-e55a-4799-81cf-fe6e103249be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cd24c04e-e55a-4799-81cf-fe6e103249be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ComputerNetworkEquipmentAndSoftwareMember_f19d4ead-25a5-4050-bafa-bdda3d484468" xlink:href="aqst-20250331.xsd#aqst_ComputerNetworkEquipmentAndSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_aqst_ComputerNetworkEquipmentAndSoftwareMember_f19d4ead-25a5-4050-bafa-bdda3d484468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ae6c4eb2-9cfb-416d-abd0-ca9064b934b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_476caf96-2d47-41a7-b923-b3c457cd8362" xlink:to="loc_us-gaap_ConstructionInProgressMember_ae6c4eb2-9cfb-416d-abd0-ca9064b934b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d10c6c19-e73c-4688-a815-325b17d06735" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:to="loc_srt_RangeAxis_d10c6c19-e73c-4688-a815-325b17d06735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d10c6c19-e73c-4688-a815-325b17d06735" xlink:to="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_76748285-8a10-44ff-b029-42cc6990da58" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:to="loc_srt_MinimumMember_76748285-8a10-44ff-b029-42cc6990da58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c663980-f2cb-457a-88c9-d5025c4cb21c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40766ee1-1e82-4c6a-8705-39adff30a552" xlink:to="loc_srt_MaximumMember_1c663980-f2cb-457a-88c9-d5025c4cb21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5a52568-d193-495b-a258-d4ba77d7d201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d5661c2b-a5f8-482a-8874-15af1703df5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d5661c2b-a5f8-482a-8874-15af1703df5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_af2bf387-6f74-496f-959c-382e63a58349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_af2bf387-6f74-496f-959c-382e63a58349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a1e16ed4-905b-48cd-9b3a-12c6eab35638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a1e16ed4-905b-48cd-9b3a-12c6eab35638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_88a61970-a9f1-40ff-a5f6-435cbab48895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_28f3d565-bc85-45cd-a292-89cd989cf0bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_88a61970-a9f1-40ff-a5f6-435cbab48895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#PropertyandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3ba2e711-8e64-408a-b42f-a3231e9fbc60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a78e696d-1461-4383-9eb0-12b9fe635df0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3ba2e711-8e64-408a-b42f-a3231e9fbc60" xlink:to="loc_us-gaap_Depreciation_a78e696d-1461-4383-9eb0-12b9fe635df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RightofUseAssetsandLeaseObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a0f61aab-3309-489e-b754-ffe998cfb0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_cf130643-aa95-4e76-a221-57f3c94bb0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a0f61aab-3309-489e-b754-ffe998cfb0fa" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_cf130643-aa95-4e76-a221-57f3c94bb0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ca0e9b9-c455-4d05-87bb-8ed1297b671b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cf130643-aa95-4e76-a221-57f3c94bb0c3" xlink:to="loc_srt_RangeAxis_8ca0e9b9-c455-4d05-87bb-8ed1297b671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8ca0e9b9-c455-4d05-87bb-8ed1297b671b" xlink:to="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a873903-9b47-4651-bcc9-0c8a45b9f3a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:to="loc_srt_MinimumMember_4a873903-9b47-4651-bcc9-0c8a45b9f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89e2d575-452e-4f6b-b732-dee970eb6aa1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07b723b1-73f6-43ed-b53f-056383ccab2d" xlink:to="loc_srt_MaximumMember_89e2d575-452e-4f6b-b732-dee970eb6aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_cf130643-aa95-4e76-a221-57f3c94bb0c3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfOperatingLeases_1e3b14ed-bd73-4732-b200-2082817c8732" xlink:href="aqst-20250331.xsd#aqst_NumberOfOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_aqst_NumberOfOperatingLeases_1e3b14ed-bd73-4732-b200-2082817c8732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8ef6ad36-f229-45cf-9695-aeabf972592e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8ef6ad36-f229-45cf-9695-aeabf972592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_9cd97520-1b70-4198-83d8-360447b4e406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_9cd97520-1b70-4198-83d8-360447b4e406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6d635293-3083-4146-8c64-8caae358271e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_OperatingLeaseCost_6d635293-3083-4146-8c64-8caae358271e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_73c7d510-f573-4250-ba3d-e7d1037ed59a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87f6a693-0b3a-4dc1-934c-9820adcf4820" xlink:to="loc_us-gaap_VariableLeaseCost_73c7d510-f573-4250-ba3d-e7d1037ed59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#RightofUseAssetsandLeaseObligationsMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_943a5a4c-02ac-4139-919a-a631a7e78f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_943a5a4c-02ac-4139-919a-a631a7e78f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c07340ae-7744-4c18-a097-ac0548723b09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c07340ae-7744-4c18-a097-ac0548723b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3da1c9e5-de37-430c-9be8-53a768410d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3da1c9e5-de37-430c-9be8-53a768410d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e4dfd5e2-2b76-4d18-84f8-5189d0229802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e4dfd5e2-2b76-4d18-84f8-5189d0229802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_2ff78818-0d71-4c32-80a4-4a9d25c9cb36" xlink:href="aqst-20250331.xsd#aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_2ff78818-0d71-4c32-80a4-4a9d25c9cb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5a151a5-5d19-4dd5-af7c-93b6404d9964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5a151a5-5d19-4dd5-af7c-93b6404d9964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_73ba8ec3-13c4-4c8b-bde3-6633e5678aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_73ba8ec3-13c4-4c8b-bde3-6633e5678aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9d8dad2e-a84e-4b89-b84e-ac259fce1471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e3af028-e234-4858-b98b-b4e0605e6189" xlink:to="loc_us-gaap_OperatingLeaseLiability_9d8dad2e-a84e-4b89-b84e-ac259fce1471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a1a8e27-b5bd-4f1d-ae72-2d5b6dd5a51e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4b107af-a6b6-471b-b7f0-4ef256cedb77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a1a8e27-b5bd-4f1d-ae72-2d5b6dd5a51e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4b107af-a6b6-471b-b7f0-4ef256cedb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_375c2a59-c8a8-4e9f-b425-52a6f133a92f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4b107af-a6b6-471b-b7f0-4ef256cedb77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_375c2a59-c8a8-4e9f-b425-52a6f133a92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_375c2a59-c8a8-4e9f-b425-52a6f133a92f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c057372-8efc-49d4-bcec-307ee344406f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_6c057372-8efc-49d4-bcec-307ee344406f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_54defabd-dc7b-4528-82f1-8acbce650f37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bc2d5c1b-b5a7-420e-a77b-64b495c50897" xlink:to="loc_us-gaap_PatentsMember_54defabd-dc7b-4528-82f1-8acbce650f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b3112e03-ba19-4b7c-959f-c708442ea96c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e4b107af-a6b6-471b-b7f0-4ef256cedb77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b3112e03-ba19-4b7c-959f-c708442ea96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b3112e03-ba19-4b7c-959f-c708442ea96c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_66a7093e-6fa0-4942-bde5-77c441bea610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_66a7093e-6fa0-4942-bde5-77c441bea610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_55caea66-b2cc-4c1f-9c56-9be964a9fbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_55caea66-b2cc-4c1f-9c56-9be964a9fbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3a874c18-f812-4188-a711-84f81ff6e320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_75ab3af7-bcc5-4afa-939c-57fb34831661" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3a874c18-f812-4188-a711-84f81ff6e320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/IntangibleAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#IntangibleAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/IntangibleAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ab17991b-90ac-48ab-9358-4c02ce67b934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e5485d52-6014-472f-b39e-c1a705a29c29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ab17991b-90ac-48ab-9358-4c02ce67b934" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e5485d52-6014-472f-b39e-c1a705a29c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9bde577a-fd3c-4362-8af1-307fb9d8f7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ab17991b-90ac-48ab-9358-4c02ce67b934" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9bde577a-fd3c-4362-8af1-307fb9d8f7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_400116e6-0652-4dd8-bf99-80ca22ba38d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CumulativeRoyaltyReceivable_128b96c6-1918-4091-af98-2065056bc7b7" xlink:href="aqst-20250331.xsd#aqst_CumulativeRoyaltyReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_400116e6-0652-4dd8-bf99-80ca22ba38d1" xlink:to="loc_aqst_CumulativeRoyaltyReceivable_128b96c6-1918-4091-af98-2065056bc7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_89af40ee-2fe6-420c-b2ec-38ad6d5992b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_400116e6-0652-4dd8-bf99-80ca22ba38d1" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_89af40ee-2fe6-420c-b2ec-38ad6d5992b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f36610d3-4083-4e42-b536-95819fab50dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_400116e6-0652-4dd8-bf99-80ca22ba38d1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f36610d3-4083-4e42-b536-95819fab50dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#OtherNoncurrentAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dfe3f750-b0c7-4800-a93f-267e9b12d3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_dfe3f750-b0c7-4800-a93f-267e9b12d3fe" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:to="loc_srt_ProductOrServiceAxis_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_012e3234-0ed1-46f2-b0e9-4936849916c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e3cf0e60-1f8f-4c2c-9089-e78ad1b85e4a" xlink:to="loc_srt_ProductsAndServicesDomain_012e3234-0ed1-46f2-b0e9-4936849916c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_81dd7869-7a74-45a8-9da6-505c372080ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_012e3234-0ed1-46f2-b0e9-4936849916c2" xlink:to="loc_us-gaap_RoyaltyMember_81dd7869-7a74-45a8-9da6-505c372080ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba9467fa-7e08-40c8-a412-08bf3caa78e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_81a5d0a1-0e6a-48bd-aefd-eb7ac7c9a29e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba9467fa-7e08-40c8-a412-08bf3caa78e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_341cd7ac-0f52-48f8-9eb3-684f5a04b235" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ba9467fa-7e08-40c8-a412-08bf3caa78e7" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_341cd7ac-0f52-48f8-9eb3-684f5a04b235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f7db9ce9-7625-400f-a9b8-2b57973ffea4" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97753bfa-da72-41cd-85c5-4d30a2189b15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97753bfa-da72-41cd-85c5-4d30a2189b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfGuaranteedRoyaltyPayments_b9b5c0ca-aa62-4bc5-9a46-f61247cd885b" xlink:href="aqst-20250331.xsd#aqst_NumberOfGuaranteedRoyaltyPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_aqst_NumberOfGuaranteedRoyaltyPayments_b9b5c0ca-aa62-4bc5-9a46-f61247cd885b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MinimumAnnualRoyaltyReceivable_56b53978-cfc7-4dc0-8b10-e3ef9da1b02b" xlink:href="aqst-20250331.xsd#aqst_MinimumAnnualRoyaltyReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_aqst_MinimumAnnualRoyaltyReceivable_56b53978-cfc7-4dc0-8b10-e3ef9da1b02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NumberOfAnnualRoyaltyPaymentsReceivable_4f860e89-b718-4252-949e-305cf5b876fc" xlink:href="aqst-20250331.xsd#aqst_NumberOfAnnualRoyaltyPaymentsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c2131f5b-9b20-4bac-a36d-4e36476efea2" xlink:to="loc_aqst_NumberOfAnnualRoyaltyPaymentsReceivable_4f860e89-b718-4252-949e-305cf5b876fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#AccruedExpensesScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d3f90fa2-5d42-4f8a-a152-666a7abaceef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_602d9e26-24e8-42d1-9eee-c467bc233010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3f90fa2-5d42-4f8a-a152-666a7abaceef" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_602d9e26-24e8-42d1-9eee-c467bc233010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_ffd61ca7-63ca-41a8-99de-aee89eb2036b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3f90fa2-5d42-4f8a-a152-666a7abaceef" xlink:to="loc_us-gaap_TaxesPayableCurrent_ffd61ca7-63ca-41a8-99de-aee89eb2036b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_5af76228-fc36-4afe-aaf9-4b31436f50a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3f90fa2-5d42-4f8a-a152-666a7abaceef" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_5af76228-fc36-4afe-aaf9-4b31436f50a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_2aa31c85-1d36-4101-866f-9405e9df8ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3f90fa2-5d42-4f8a-a152-666a7abaceef" xlink:to="loc_us-gaap_InterestPayableCurrent_2aa31c85-1d36-4101-866f-9405e9df8ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1f06e690-e1c4-41f1-a417-3e2190f7e5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3f90fa2-5d42-4f8a-a152-666a7abaceef" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1f06e690-e1c4-41f1-a417-3e2190f7e5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1175d549-c31a-4bd5-bb65-2b947a7ad5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3f90fa2-5d42-4f8a-a152-666a7abaceef" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1175d549-c31a-4bd5-bb65-2b947a7ad5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/AccruedExpensesNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#AccruedExpensesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/AccruedExpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_aa42d9ef-6482-4b37-87e4-61332c94a2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aa42d9ef-6482-4b37-87e4-61332c94a2e0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_911679b6-45c5-4747-b27a-c3e4d521a0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:to="loc_us-gaap_DebtInstrumentAxis_911679b6-45c5-4747-b27a-c3e4d521a0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35586e9e-df56-4484-8f48-8bac883345b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_911679b6-45c5-4747-b27a-c3e4d521a0c5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35586e9e-df56-4484-8f48-8bac883345b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_471d6c1e-87d2-4698-b2e0-5e984e36488f" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35586e9e-df56-4484-8f48-8bac883345b1" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_471d6c1e-87d2-4698-b2e0-5e984e36488f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f7eb3abe-5342-444b-95f8-f60558d74902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f7eb3abe-5342-444b-95f8-f60558d74902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7b3ac934-29ce-4e9a-add8-aeff366eae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f7eb3abe-5342-444b-95f8-f60558d74902" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7b3ac934-29ce-4e9a-add8-aeff366eae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f4f203bc-f9c8-446f-a4a1-06fd586fe986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7b3ac934-29ce-4e9a-add8-aeff366eae8f" xlink:to="loc_us-gaap_SeniorNotesMember_f4f203bc-f9c8-446f-a4a1-06fd586fe986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_8203c8b8-2184-491e-9972-a853e56f5706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_917b8ac2-525c-48b1-91ea-eef600397c34" xlink:to="loc_us-gaap_ShortTermDebtLineItems_8203c8b8-2184-491e-9972-a853e56f5706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25565c45-3868-4a51-b707-5d9c336568cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_8203c8b8-2184-491e-9972-a853e56f5706" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25565c45-3868-4a51-b707-5d9c336568cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d641917a-8943-4b10-9f16-00fd8fadcc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d641917a-8943-4b10-9f16-00fd8fadcc21" xlink:to="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d628401c-105a-4ae3-9c07-32476b4a532c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d628401c-105a-4ae3-9c07-32476b4a532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d628401c-105a-4ae3-9c07-32476b4a532c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_db2b838d-9841-47f3-9ca3-0cb0637c967e" xlink:href="aqst-20250331.xsd#aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:to="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_db2b838d-9841-47f3-9ca3-0cb0637c967e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_23c1ce08-76da-4b06-95fe-0a94a8e4a7de" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_23c1ce08-76da-4b06-95fe-0a94a8e4a7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsMember_1122f1a7-e687-4617-8eb0-5b43b871d84a" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_23c1ce08-76da-4b06-95fe-0a94a8e4a7de" xlink:to="loc_aqst_RoyaltyObligationsMember_1122f1a7-e687-4617-8eb0-5b43b871d84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ABLFacilityMember_86b6ba0f-0331-4dfe-befd-e6797d016e98" xlink:href="aqst-20250331.xsd#aqst_ABLFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84127f8c-eda1-4298-955d-29abd60afb5d" xlink:to="loc_aqst_ABLFacilityMember_86b6ba0f-0331-4dfe-befd-e6797d016e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2e527790-d02d-436d-961c-435c16eab2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2e527790-d02d-436d-961c-435c16eab2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2e527790-d02d-436d-961c-435c16eab2fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f8a252bf-33bb-40e6-af59-a007799a095c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:to="loc_us-gaap_SeniorNotesMember_f8a252bf-33bb-40e6-af59-a007799a095c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_314fea0a-df1f-4a03-8d95-a9d722493e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c2b87fcf-2201-4b69-af00-2bd87e99fee8" xlink:to="loc_us-gaap_UnsecuredDebtMember_314fea0a-df1f-4a03-8d95-a9d722493e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b69a108-7969-49c6-931a-e6a17afce68b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_srt_RangeAxis_7b69a108-7969-49c6-931a-e6a17afce68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b69a108-7969-49c6-931a-e6a17afce68b" xlink:to="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b4520ee1-6203-4616-9d22-d4640d1cf828" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:to="loc_srt_MaximumMember_b4520ee1-6203-4616-9d22-d4640d1cf828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b0e8087-87f2-483f-af56-257b4e0a0c3c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87ecf39f-faec-4dee-bdbb-aabcd30126e8" xlink:to="loc_srt_MinimumMember_3b0e8087-87f2-483f-af56-257b4e0a0c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtCovenantRedemptionScenarioAxis_21814381-ef9b-4862-b414-9fe66f1ebfb6" xlink:href="aqst-20250331.xsd#aqst_DebtCovenantRedemptionScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_aqst_DebtCovenantRedemptionScenarioAxis_21814381-ef9b-4862-b414-9fe66f1ebfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:href="aqst-20250331.xsd#aqst_DebtCovenantRedemptionScenarioDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioAxis_21814381-ef9b-4862-b414-9fe66f1ebfb6" xlink:to="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RedemptionScenario1Member_4e93efde-c16c-4740-9a71-f6d891a9e6fc" xlink:href="aqst-20250331.xsd#aqst_RedemptionScenario1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:to="loc_aqst_RedemptionScenario1Member_4e93efde-c16c-4740-9a71-f6d891a9e6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RedemptionScenario2Member_a9d6102a-48ae-43ce-8dd9-26d2bf92b2ea" xlink:href="aqst-20250331.xsd#aqst_RedemptionScenario2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_DebtCovenantRedemptionScenarioDomain_502cc41d-427f-4b20-a358-930ddd5a66c4" xlink:to="loc_aqst_RedemptionScenario2Member_a9d6102a-48ae-43ce-8dd9-26d2bf92b2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d76aef8-1b9f-43b3-8c57-d2ce3051eb1f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_351ecb1c-619f-4ccb-83b2-dae9b4fbb8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_351ecb1c-619f-4ccb-83b2-dae9b4fbb8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_dbc24bf6-a5ba-481e-b185-900bdb879bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_dbc24bf6-a5ba-481e-b185-900bdb879bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6ea9706c-b7ae-400a-b4b6-0b2bf3b75b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6ea9706c-b7ae-400a-b4b6-0b2bf3b75b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_936b72ec-56fe-4363-afd4-27ee79694493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_936b72ec-56fe-4363-afd4-27ee79694493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bed82659-b4ba-4c64-9838-0e53d89fc3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_bed82659-b4ba-4c64-9838-0e53d89fc3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7cf75ef8-c332-4cfb-91bc-044291d61bef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7cf75ef8-c332-4cfb-91bc-044291d61bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate_abfded47-1576-48af-b143-7d0a7fa23cf7" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate_abfded47-1576-48af-b143-7d0a7fa23cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold_a44f62cc-f12c-4d01-bee6-8d0ca0940563" xlink:href="aqst-20250331.xsd#aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold_a44f62cc-f12c-4d01-bee6-8d0ca0940563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit_184227ab-b4ca-416c-9b11-6d7666f5fd11" xlink:href="aqst-20250331.xsd#aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit_184227ab-b4ca-416c-9b11-6d7666f5fd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_acdaad7e-15f4-47a0-bbd1-e4f6f6ff54ff" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage_acdaad7e-15f4-47a0-bbd1-e4f6f6ff54ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_edc3fd02-d620-4e10-81ba-163b33951520" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm_edc3fd02-d620-4e10-81ba-163b33951520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage_7ddc7273-5a49-46d1-9896-a900610136e4" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentInterestRateChangeInEffectivePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage_7ddc7273-5a49-46d1-9896-a900610136e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_81cb4d34-1621-4818-bb7a-dc7357e48a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_LongTermDebtFairValue_81cb4d34-1621-4818-bb7a-dc7357e48a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_54f52a42-94ad-498f-b4ee-b75bc5a62431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_54f52a42-94ad-498f-b4ee-b75bc5a62431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_92c63531-f5c4-4261-84e9-853d19081ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_92c63531-f5c4-4261-84e9-853d19081ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_3b2e0a3c-a893-427d-b7fb-2add96075d57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_3b2e0a3c-a893-427d-b7fb-2add96075d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_DebtInstrumentExitFee_c12fd1ed-3910-4ed9-a9a4-e749ddb06ae6" xlink:href="aqst-20250331.xsd#aqst_DebtInstrumentExitFee"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_aqst_DebtInstrumentExitFee_c12fd1ed-3910-4ed9-a9a4-e749ddb06ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b4f34e29-2161-40f5-a02a-d80e6a235993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b4f34e29-2161-40f5-a02a-d80e6a235993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ecef3d98-b941-4a23-b1da-55ab185b2f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ecef3d98-b941-4a23-b1da-55ab185b2f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_eab694ed-8f26-418a-9d87-2c6b0536e328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb35b226-a911-4dd8-ba0c-3d5d7bc9678d" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_eab694ed-8f26-418a-9d87-2c6b0536e328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtScheduleOfRoyaltyRightAgreementsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b577687c-693c-4c3b-a1b4-e7649a3d8cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b577687c-693c-4c3b-a1b4-e7649a3d8cd8" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_37651ba6-0129-4676-9ea0-a55f22ae9dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_37651ba6-0129-4676-9ea0-a55f22ae9dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_37651ba6-0129-4676-9ea0-a55f22ae9dc5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1b22752d-9483-4f38-86a4-e6ba64527862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1b22752d-9483-4f38-86a4-e6ba64527862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MeasurementInputProbabilityOfSuccessMember_d3870758-bfcd-4f9c-95ed-787050b922d6" xlink:href="aqst-20250331.xsd#aqst_MeasurementInputProbabilityOfSuccessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cbc35b7b-ed35-4cf6-8ca8-6d30be5bc849" xlink:to="loc_aqst_MeasurementInputProbabilityOfSuccessMember_d3870758-bfcd-4f9c-95ed-787050b922d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_49c0f702-4fc9-4cdd-82a1-81c995211c55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:to="loc_us-gaap_DebtInstrumentAxis_49c0f702-4fc9-4cdd-82a1-81c995211c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35c35411-e105-45b5-b9d6-1522f44523b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_49c0f702-4fc9-4cdd-82a1-81c995211c55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35c35411-e105-45b5-b9d6-1522f44523b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_15101578-3547-40d4-8404-8368d7734cb5" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_35c35411-e105-45b5-b9d6-1522f44523b0" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_15101578-3547-40d4-8404-8368d7734cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9021a503-9898-4f5e-8338-c92a2470b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9021a503-9898-4f5e-8338-c92a2470b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ee7a3f9e-f602-441e-b8fd-277775d316f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9021a503-9898-4f5e-8338-c92a2470b3f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ee7a3f9e-f602-441e-b8fd-277775d316f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_53fc9b6a-a539-4214-a787-4a7fe07b3e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ee7a3f9e-f602-441e-b8fd-277775d316f2" xlink:to="loc_us-gaap_SeniorNotesMember_53fc9b6a-a539-4214-a787-4a7fe07b3e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_337a1b85-7ef1-41ef-bc17-ec08ae72bdf9" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMeasurementInput_d9ae2176-90ec-4de6-aba8-a4d10f50b6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:to="loc_us-gaap_LongTermDebtMeasurementInput_d9ae2176-90ec-4de6-aba8-a4d10f50b6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b852a2ec-92b0-4dd7-9642-6170d4f14c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c0d34892-3411-4bcd-b837-f3510472898c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b852a2ec-92b0-4dd7-9642-6170d4f14c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_02e83cb0-aa4c-421e-89dc-6ded91d628c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_02e83cb0-aa4c-421e-89dc-6ded91d628c1" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_46465ca7-4785-4b3e-afbc-81e361476007" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:to="loc_us-gaap_DebtInstrumentAxis_46465ca7-4785-4b3e-afbc-81e361476007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_46465ca7-4785-4b3e-afbc-81e361476007" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_68a17fe3-64d4-4d9f-b804-ab7a20edafc6" xlink:href="aqst-20250331.xsd#aqst_SeniorSecuredNotes13.5DueNovember12028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:to="loc_aqst_SeniorSecuredNotes13.5DueNovember12028Member_68a17fe3-64d4-4d9f-b804-ab7a20edafc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_RoyaltyObligationsMember_3a26618a-17c6-47b6-be8c-8e465f534af4" xlink:href="aqst-20250331.xsd#aqst_RoyaltyObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1c833e79-1456-4a8d-a98a-0976661d4761" xlink:to="loc_aqst_RoyaltyObligationsMember_3a26618a-17c6-47b6-be8c-8e465f534af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_40acf08e-f37a-4229-ad1f-46ed116ab1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_40acf08e-f37a-4229-ad1f-46ed116ab1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_40acf08e-f37a-4229-ad1f-46ed116ab1d4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_827458dd-8dfe-4e71-9813-fe41abe1eea7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:to="loc_us-gaap_SeniorNotesMember_827458dd-8dfe-4e71-9813-fe41abe1eea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_e02dcb9b-b143-4810-b451-77f1e1874d97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa1b66bd-3aa1-46cb-81fe-ea081de64c06" xlink:to="loc_us-gaap_UnsecuredDebtMember_e02dcb9b-b143-4810-b451-77f1e1874d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a95af9d4-92d6-4115-ad8d-36f3a0ed69e1" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_06dec29c-edb0-42b1-b55d-5d57201e43ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_06dec29c-edb0-42b1-b55d-5d57201e43ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_80a72835-1f4c-442d-a8ff-9d4b80b85a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_80a72835-1f4c-442d-a8ff-9d4b80b85a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8de2a1ae-30a3-4322-9b1d-cb9c24953a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8de2a1ae-30a3-4322-9b1d-cb9c24953a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8a1452de-c203-4c32-be5a-6dbcdfb74757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8a1452de-c203-4c32-be5a-6dbcdfb74757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c270b29d-deee-44a9-b95e-e943ea7248a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c270b29d-deee-44a9-b95e-e943ea7248a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3c54c36f-aa41-4a20-9a2a-ec2dbbc311bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3c54c36f-aa41-4a20-9a2a-ec2dbbc311bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_117f3825-f31b-48f7-9a1a-ef0b2b445f96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_117f3825-f31b-48f7-9a1a-ef0b2b445f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d61ff549-0b13-49cd-95a0-07730458d8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c243446e-2669-4210-94fe-93adfd4bfc2c" xlink:to="loc_us-gaap_LongTermDebtCurrent_d61ff549-0b13-49cd-95a0-07730458d8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#LongTermDebtDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5a6d5a6d-3cff-4177-9c29-ffe550974977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_476a8770-9824-4104-bdf9-f2f120da70b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a6d5a6d-3cff-4177-9c29-ffe550974977" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_476a8770-9824-4104-bdf9-f2f120da70b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ec03e618-c89f-4ee3-a68f-20fe25cd2758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a6d5a6d-3cff-4177-9c29-ffe550974977" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ec03e618-c89f-4ee3-a68f-20fe25cd2758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98ba8211-00d2-49f0-9c64-35b0d184cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a6d5a6d-3cff-4177-9c29-ffe550974977" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98ba8211-00d2-49f0-9c64-35b0d184cca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_504ea4e7-40b0-4817-ab07-d48d177b6d95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a6d5a6d-3cff-4177-9c29-ffe550974977" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_504ea4e7-40b0-4817-ab07-d48d177b6d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d5dda3cf-304e-493c-9125-7d8e00490c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a6d5a6d-3cff-4177-9c29-ffe550974977" xlink:to="loc_us-gaap_LongTermDebt_d5dda3cf-304e-493c-9125-7d8e00490c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/WarrantsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#WarrantsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/WarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0169aff0-07e4-4f31-bab0-2852f28d8de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0169aff0-07e4-4f31-bab0-2852f28d8de3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:to="loc_us-gaap_DebtInstrumentAxis_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8936a119-73df-48f6-9e7a-2371fe5e41f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a5daaa93-fdf1-4f0a-9bc4-25b1c7cbd5a9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8936a119-73df-48f6-9e7a-2371fe5e41f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_721f8847-045e-4e7f-916c-3b5358399c9d" xlink:href="aqst-20250331.xsd#aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8936a119-73df-48f6-9e7a-2371fe5e41f1" xlink:to="loc_aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member_721f8847-045e-4e7f-916c-3b5358399c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ca6f36c-8e19-4813-af49-28ba3ffca225" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:to="loc_srt_RangeAxis_3ca6f36c-8e19-4813-af49-28ba3ffca225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ca6f36c-8e19-4813-af49-28ba3ffca225" xlink:to="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bdea1c4-8f0c-494f-aa26-eab3a45b2dec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:to="loc_srt_MinimumMember_7bdea1c4-8f0c-494f-aa26-eab3a45b2dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ca09f40-e8df-4278-8988-dc2784364059" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e640d802-fff9-4984-8da8-e5a33e3752c6" xlink:to="loc_srt_MaximumMember_6ca09f40-e8df-4278-8988-dc2784364059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7aa73f8b-4ab7-4038-b897-3b231ba63e66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7aa73f8b-4ab7-4038-b897-3b231ba63e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7aa73f8b-4ab7-4038-b897-3b231ba63e66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_FirstAdditionalWarrantOfferingMember_1955d935-2391-4637-b348-e2b708317a72" xlink:href="aqst-20250331.xsd#aqst_FirstAdditionalWarrantOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_FirstAdditionalWarrantOfferingMember_1955d935-2391-4637-b348-e2b708317a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_InitialWarrantOfferingMember_9e89593b-f608-47d4-bf62-6718f9acffda" xlink:href="aqst-20250331.xsd#aqst_InitialWarrantOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_InitialWarrantOfferingMember_9e89593b-f608-47d4-bf62-6718f9acffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_PreFundedWarrantsMember_f8454999-642b-45fb-90e7-b7c449b8df81" xlink:href="aqst-20250331.xsd#aqst_PreFundedWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_PreFundedWarrantsMember_f8454999-642b-45fb-90e7-b7c449b8df81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_CommonStockWarrantsMember_0e35deae-f235-458c-be3a-c359eef80dee" xlink:href="aqst-20250331.xsd#aqst_CommonStockWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_CommonStockWarrantsMember_0e35deae-f235-458c-be3a-c359eef80dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ExistingWarrantsMember_a1987a2e-5f3e-4f56-adb2-fb9b56feb766" xlink:href="aqst-20250331.xsd#aqst_ExistingWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_ExistingWarrantsMember_a1987a2e-5f3e-4f56-adb2-fb9b56feb766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NewWarrantsMember_8982666f-1fd9-4c91-93c7-5b24c1d22a62" xlink:href="aqst-20250331.xsd#aqst_NewWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_NewWarrantsMember_8982666f-1fd9-4c91-93c7-5b24c1d22a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants0.96ExercisePriceMember_c191beb6-a813-4986-b024-793fdf74f8b7" xlink:href="aqst-20250331.xsd#aqst_Warrants0.96ExercisePriceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_Warrants0.96ExercisePriceMember_c191beb6-a813-4986-b024-793fdf74f8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants4.25ExercisePriceMember_95159b9f-7357-4570-adfa-8a3cbcf2f562" xlink:href="aqst-20250331.xsd#aqst_Warrants4.25ExercisePriceMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_Warrants4.25ExercisePriceMember_95159b9f-7357-4570-adfa-8a3cbcf2f562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_Warrants5.38ExercisePriceMember_daf51399-ded6-4586-90b0-653f92ce9a51" xlink:href="aqst-20250331.xsd#aqst_Warrants5.38ExercisePriceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ba822294-86c3-494e-b7bb-c54982f1310c" xlink:to="loc_aqst_Warrants5.38ExercisePriceMember_daf51399-ded6-4586-90b0-653f92ce9a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8066f713-ca8d-4cf5-aef7-cf67e9d5bf16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be297a2d-651e-40f2-8e97-9bb198b94c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_be297a2d-651e-40f2-8e97-9bb198b94c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfddab3-59fc-4b8a-ab3b-3ce5c0ea31a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfddab3-59fc-4b8a-ab3b-3ce5c0ea31a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_4e41b306-bfa7-4e1a-8c58-180299bea48c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_4e41b306-bfa7-4e1a-8c58-180299bea48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ClassOfWarrantOrRightWarrantsExercised_09dd9c7b-1cdb-4adb-ad6a-4b279b8e8e6e" xlink:href="aqst-20250331.xsd#aqst_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_aqst_ClassOfWarrantOrRightWarrantsExercised_09dd9c7b-1cdb-4adb-ad6a-4b279b8e8e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b34358-ba3c-452d-a1af-768b1119b65d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b34358-ba3c-452d-a1af-768b1119b65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_591d380c-1f21-451b-a741-7ea563121ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_591d380c-1f21-451b-a741-7ea563121ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_8bca6142-37a4-4c55-bf6d-5a8f76fa4d70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_8bca6142-37a4-4c55-bf6d-5a8f76fa4d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_7d617baf-575b-4274-924f-8c202a7c2d13" xlink:href="aqst-20250331.xsd#aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod_7d617baf-575b-4274-924f-8c202a7c2d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a6ee5d40-4790-4d12-8caf-e2c6da6b1b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0444ac1e-eff2-4a51-9423-6746e3e2f58a" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a6ee5d40-4790-4d12-8caf-e2c6da6b1b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#SaleofFutureRevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a8c1881-dd3d-4162-8bd0-2f2cf9dc823c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a8c1881-dd3d-4162-8bd0-2f2cf9dc823c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2e226114-23c4-40ed-aa7d-4fa41b31c6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_us-gaap_CreditFacilityAxis_2e226114-23c4-40ed-aa7d-4fa41b31c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_102d97f1-7661-4101-969e-9b727baf5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2e226114-23c4-40ed-aa7d-4fa41b31c6ff" xlink:to="loc_us-gaap_CreditFacilityDomain_102d97f1-7661-4101-969e-9b727baf5d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MonetizationAgreementMember_dc7ea7c6-2f02-4f69-b592-918f28709245" xlink:href="aqst-20250331.xsd#aqst_MonetizationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_102d97f1-7661-4101-969e-9b727baf5d2b" xlink:to="loc_aqst_MonetizationAgreementMember_dc7ea7c6-2f02-4f69-b592-918f28709245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7bd7e8f-be39-4f1f-ad88-c5655fb347cf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarathonPangolinRoyaltyLLCMember_e36c42af-0438-4263-bf35-5a89d0168766" xlink:href="aqst-20250331.xsd#aqst_MarathonPangolinRoyaltyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:to="loc_aqst_MarathonPangolinRoyaltyLLCMember_e36c42af-0438-4263-bf35-5a89d0168766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_f45864a7-fc4a-4f80-b31c-75f1d986e79d" xlink:href="aqst-20250331.xsd#aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2eec764a-97a9-421a-a806-dd79a10f110c" xlink:to="loc_aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember_f45864a7-fc4a-4f80-b31c-75f1d986e79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c0361ad0-8c17-42da-b4e1-88e666530150" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_srt_RangeAxis_c0361ad0-8c17-42da-b4e1-88e666530150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5aaa98f7-be99-411e-b07d-2ab92a62514f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c0361ad0-8c17-42da-b4e1-88e666530150" xlink:to="loc_srt_RangeMember_5aaa98f7-be99-411e-b07d-2ab92a62514f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9214f361-129d-4e17-8409-28a575b88a0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5aaa98f7-be99-411e-b07d-2ab92a62514f" xlink:to="loc_srt_MaximumMember_9214f361-129d-4e17-8409-28a575b88a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b876e3b-d098-48a8-9880-de7dfb1b7f35" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_srt_ProductOrServiceAxis_0b876e3b-d098-48a8-9880-de7dfb1b7f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e26b09ef-ed47-4c8d-95d3-5d979907c3d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0b876e3b-d098-48a8-9880-de7dfb1b7f35" xlink:to="loc_srt_ProductsAndServicesDomain_e26b09ef-ed47-4c8d-95d3-5d979907c3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_46145d18-d347-4866-9b40-cf77a1539ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e26b09ef-ed47-4c8d-95d3-5d979907c3d1" xlink:to="loc_us-gaap_RoyaltyMember_46145d18-d347-4866-9b40-cf77a1539ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_31e53684-228e-4ca5-a442-ccedbb5d89f1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_32460d5f-6f63-4d01-9a59-f7cc75a3f3af" xlink:href="aqst-20250331.xsd#aqst_ProceedsFromSaleOfFutureRevenuesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_ProceedsFromSaleOfFutureRevenuesNet_32460d5f-6f63-4d01-9a59-f7cc75a3f3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ContingentMonetizationAgreementMilestonePayment_86a2d56e-9d7d-4220-870a-d4738e740480" xlink:href="aqst-20250331.xsd#aqst_ContingentMonetizationAgreementMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_ContingentMonetizationAgreementMilestonePayment_86a2d56e-9d7d-4220-870a-d4738e740480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_b4820201-6f73-47ab-b7e0-910e2de82edc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_b4820201-6f73-47ab-b7e0-910e2de82edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2800c2e-6a03-4130-8f6b-84d5827291fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2800c2e-6a03-4130-8f6b-84d5827291fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MinimumAnnualRoyaltyReceivable_1ad9e36f-92b4-4a01-8a4c-09c07fd9715b" xlink:href="aqst-20250331.xsd#aqst_MinimumAnnualRoyaltyReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_MinimumAnnualRoyaltyReceivable_1ad9e36f-92b4-4a01-8a4c-09c07fd9715b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5e42e25-abad-489f-94e8-72c92f965beb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d5e42e25-abad-489f-94e8-72c92f965beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_63d7dabd-2bef-4a5c-925d-66a1e32de9f3" xlink:href="aqst-20250331.xsd#aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a834b1f7-d60f-4c0f-afa0-687bb579f465" xlink:to="loc_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet_63d7dabd-2bef-4a5c-925d-66a1e32de9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#SaleofFutureRevenueRoyaltyObligationDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6658ad41-985c-4219-b667-f7e72f9fc8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_46bea0bd-bf0c-44a2-873d-715fea6a0bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6658ad41-985c-4219-b667-f7e72f9fc8ed" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_46bea0bd-bf0c-44a2-873d-715fea6a0bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c6bba908-493b-4fab-8458-eccbe663ad65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46bea0bd-bf0c-44a2-873d-715fea6a0bbc" xlink:to="loc_srt_ProductOrServiceAxis_c6bba908-493b-4fab-8458-eccbe663ad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1c127c8-224c-404a-bc7a-860bcc8043ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c6bba908-493b-4fab-8458-eccbe663ad65" xlink:to="loc_srt_ProductsAndServicesDomain_f1c127c8-224c-404a-bc7a-860bcc8043ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_4020ed36-5fad-40d8-b787-cf23e94088d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1c127c8-224c-404a-bc7a-860bcc8043ae" xlink:to="loc_us-gaap_RoyaltyMember_4020ed36-5fad-40d8-b787-cf23e94088d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_46bea0bd-bf0c-44a2-873d-715fea6a0bbc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:href="aqst-20250331.xsd#aqst_SaleOfFutureRevenueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:to="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyalties_869b8374-694c-4af6-af58-9969ecd5caac" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:to="loc_aqst_LiabilitiesSaleOfFutureRoyalties_869b8374-694c-4af6-af58-9969ecd5caac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89f3320d-51d4-459b-9308-dcf0ddb1c05d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89f3320d-51d4-459b-9308-dcf0ddb1c05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9ff381f1-4bae-425e-b9d3-dab9f6a49911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9ff381f1-4bae-425e-b9d3-dab9f6a49911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyalties_7bc6fbeb-692f-459b-a478-9bfcab11f16e" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_SaleOfFutureRevenueRollForward_7535b397-9c7c-41bf-9269-209ac46ff25d" xlink:to="loc_aqst_LiabilitiesSaleOfFutureRoyalties_7bc6fbeb-692f-459b-a478-9bfcab11f16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_753a840e-a100-4b2b-8de5-c1174a6fbfad" xlink:href="aqst-20250331.xsd#aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7dec4e60-f4a1-4e34-88ad-dc25237db2cf" xlink:to="loc_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent_753a840e-a100-4b2b-8de5-c1174a6fbfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#NetLossPerShareBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7937207f-6609-40de-a3d9-fdd885755cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7937207f-6609-40de-a3d9-fdd885755cd3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_642055aa-6495-4c27-9ae2-f6cb4da83168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:to="loc_us-gaap_AwardTypeAxis_642055aa-6495-4c27-9ae2-f6cb4da83168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_642055aa-6495-4c27-9ae2-f6cb4da83168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_932885f0-69d5-4ff2-b79f-1a7852b425eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_932885f0-69d5-4ff2-b79f-1a7852b425eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69978515-ae52-450f-b558-85c19e801943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e4811c9-8b81-46bb-9880-cbc59233d7b3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69978515-ae52-450f-b558-85c19e801943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_102d56ca-e300-48fa-93fb-9e8e7aca027d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_102d56ca-e300-48fa-93fb-9e8e7aca027d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_102d56ca-e300-48fa-93fb-9e8e7aca027d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_64f3860f-9b72-44be-b7fe-8a7279c09bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:to="loc_us-gaap_EmployeeStockOptionMember_64f3860f-9b72-44be-b7fe-8a7279c09bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a921b206-2194-4239-a275-1ba5df97c769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a921b206-2194-4239-a275-1ba5df97c769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c8c5cec3-a9ba-449b-8bbd-10d2f73ecf37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4406b62-6dc4-4cb0-80ca-a3fad5265358" xlink:to="loc_us-gaap_WarrantMember_c8c5cec3-a9ba-449b-8bbd-10d2f73ecf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f1dc7b8e-05fb-4057-a2e5-b15561ce56e6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f7eacf2-4a27-4b48-b29e-b244e71d4d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_NetIncomeLoss_2f7eacf2-4a27-4b48-b29e-b244e71d4d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bb6cadf3-7581-4aac-892f-207bc4bea2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bb6cadf3-7581-4aac-892f-207bc4bea2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94c56e4d-5537-4fa2-8e49-aa9c51a9a692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94c56e4d-5537-4fa2-8e49-aa9c51a9a692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5d34589f-e507-4192-84e1-6ba0d91347a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_EarningsPerShareBasic_5d34589f-e507-4192-84e1-6ba0d91347a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fdb324ad-2f13-47a3-ad88-675d0e6b421e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fdb324ad-2f13-47a3-ad88-675d0e6b421e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f3744f-cc09-4c36-8cff-6cd294204908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db32919-b00c-49c2-a88a-e4eac60a1676" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f3744f-cc09-4c36-8cff-6cd294204908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_015e3fed-d9c2-4890-8a7e-3de023a7daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_015e3fed-d9c2-4890-8a7e-3de023a7daa7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33dc1223-90b4-46ea-a8c7-02ac5008753b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33dc1223-90b4-46ea-a8c7-02ac5008753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33dc1223-90b4-46ea-a8c7-02ac5008753b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ManufacturingAndSupplyMember_2c1227f2-4c6f-44ec-901b-5a3ac075f269" xlink:href="aqst-20250331.xsd#aqst_ManufacturingAndSupplyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:to="loc_aqst_ManufacturingAndSupplyMember_2c1227f2-4c6f-44ec-901b-5a3ac075f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a07addca-2f26-4274-b323-ecaf7514dfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a07addca-2f26-4274-b323-ecaf7514dfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab2313d5-8adb-4859-8a31-6768d9c51e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c4ed10e-00eb-4f86-ae74-20e717737937" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab2313d5-8adb-4859-8a31-6768d9c51e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc114d85-40c8-41e1-b574-7a0e799f63a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:to="loc_us-gaap_AwardTypeAxis_dc114d85-40c8-41e1-b574-7a0e799f63a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dc114d85-40c8-41e1-b574-7a0e799f63a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f361be88-9f42-4443-b276-f061e9cac9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f361be88-9f42-4443-b276-f061e9cac9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_679ed19e-a322-456f-bcf0-83b7e9fed370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f4ceb95-bba8-4071-9a53-7dca0fa9482b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_679ed19e-a322-456f-bcf0-83b7e9fed370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4caec3f1-71a6-4e14-880b-47e545e97266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7dabfb48-6a96-47ba-8347-d71bb4629599" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4caec3f1-71a6-4e14-880b-47e545e97266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_5de8cb8f-5d83-4e3a-9a91-c08697b398f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4caec3f1-71a6-4e14-880b-47e545e97266" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_5de8cb8f-5d83-4e3a-9a91-c08697b398f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3dcef7b-da26-471d-8ee6-b2e131e36ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5de8cb8f-5d83-4e3a-9a91-c08697b398f4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3dcef7b-da26-471d-8ee6-b2e131e36ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationRestrictedStockUnitAwardsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a2c6b97-0ccd-4c1c-9db5-50457f7cfb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb2ca10-feed-45d9-a64d-b84fcdb828d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a2c6b97-0ccd-4c1c-9db5-50457f7cfb3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb2ca10-feed-45d9-a64d-b84fcdb828d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5a2350b5-62cb-421f-9136-28b24b427d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb2ca10-feed-45d9-a64d-b84fcdb828d3" xlink:to="loc_us-gaap_AwardTypeAxis_5a2350b5-62cb-421f-9136-28b24b427d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3358c772-28d5-40b1-b78e-c05ab036b945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5a2350b5-62cb-421f-9136-28b24b427d5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3358c772-28d5-40b1-b78e-c05ab036b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_072860c7-ab2c-4ca5-bade-e944f9a89287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3358c772-28d5-40b1-b78e-c05ab036b945" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_072860c7-ab2c-4ca5-bade-e944f9a89287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb2ca10-feed-45d9-a64d-b84fcdb828d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7ca60f74-fe8e-4d18-8cd5-a3e17037f778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7ca60f74-fe8e-4d18-8cd5-a3e17037f778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e581c3f4-9811-4902-a0ba-2446c4323b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e581c3f4-9811-4902-a0ba-2446c4323b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fee8a409-8508-4e8b-9519-5de4ec8d0ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fee8a409-8508-4e8b-9519-5de4ec8d0ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b3c2bff-9287-4bc0-b1bb-9cf03efe100a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8b3c2bff-9287-4bc0-b1bb-9cf03efe100a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4afd384d-a118-4005-ab63-c0fcef216136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32b8a463-2284-460f-bf64-fa5e946d336f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4afd384d-a118-4005-ab63-c0fcef216136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_0ac1edda-be1f-480a-8a93-c77d4f75ef53" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_0ac1edda-be1f-480a-8a93-c77d4f75ef53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64c674a3-4a78-4430-b15c-da75f37a1fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64c674a3-4a78-4430-b15c-da75f37a1fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ba3841a-0b7c-4eef-bfa4-8b1c639ce45a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ba3841a-0b7c-4eef-bfa4-8b1c639ce45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3384a6d-ad97-4fcd-96de-e7fdaba8e1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3384a6d-ad97-4fcd-96de-e7fdaba8e1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_555942fd-d0b0-4c68-9c6f-2898040640f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_555942fd-d0b0-4c68-9c6f-2898040640f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c7d49cf-727b-4c7d-92b3-ef30ad5cdd00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e273817-aeb6-4359-8862-0efccbba1c2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c7d49cf-727b-4c7d-92b3-ef30ad5cdd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_b1457220-8049-45f6-b787-9365f12a66ff" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32786377-53b8-452b-9db1-5e18b81d7cc1" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_b1457220-8049-45f6-b787-9365f12a66ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d80f91ec-1248-45a5-b53e-0b5d805bd80f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d80f91ec-1248-45a5-b53e-0b5d805bd80f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cbe31174-7883-4364-8535-2b8cbebb3b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_us-gaap_AwardTypeAxis_cbe31174-7883-4364-8535-2b8cbebb3b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cbe31174-7883-4364-8535-2b8cbebb3b76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b805311a-ab28-43ee-9f2f-dae22fe265b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b805311a-ab28-43ee-9f2f-dae22fe265b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f7c75989-f8ff-4fbb-b275-9f261020881e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:to="loc_us-gaap_PerformanceSharesMember_f7c75989-f8ff-4fbb-b275-9f261020881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae144e8a-de62-4921-b9bc-f2f7fb8d9e36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a80b0c53-8d38-4db8-b3c3-5d6d7bc57b33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae144e8a-de62-4921-b9bc-f2f7fb8d9e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d74220f4-7d29-45c3-8494-3292189b003d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_us-gaap_PlanNameAxis_d74220f4-7d29-45c3-8494-3292189b003d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_19f92964-910a-4b1c-aadc-13d56563997a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d74220f4-7d29-45c3-8494-3292189b003d" xlink:to="loc_us-gaap_PlanNameDomain_19f92964-910a-4b1c-aadc-13d56563997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:href="aqst-20250331.xsd#aqst_MarketBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_19f92964-910a-4b1c-aadc-13d56563997a" xlink:to="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_A2023MarketBasedMember_f3561634-4de9-4e4e-850e-ce3c6b6e8916" xlink:href="aqst-20250331.xsd#aqst_A2023MarketBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:to="loc_aqst_A2023MarketBasedMember_f3561634-4de9-4e4e-850e-ce3c6b6e8916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_A2025MarketBasedMember_a18db05a-9aee-4360-a73f-d17ed50b6835" xlink:href="aqst-20250331.xsd#aqst_A2025MarketBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_MarketBasedMember_8d4785a6-37d6-446d-b480-a254dac6ac47" xlink:to="loc_aqst_A2025MarketBasedMember_a18db05a-9aee-4360-a73f-d17ed50b6835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionAxis_2240e86e-4492-4120-bb5a-9d6f661d3670" xlink:href="aqst-20250331.xsd#aqst_VestingConditionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_aqst_VestingConditionAxis_2240e86e-4492-4120-bb5a-9d6f661d3670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:href="aqst-20250331.xsd#aqst_VestingConditionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionAxis_2240e86e-4492-4120-bb5a-9d6f661d3670" xlink:to="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeOneMember_3065e2a5-74d4-4b34-bde0-ede81432087e" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeOneMember_3065e2a5-74d4-4b34-bde0-ede81432087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTwoMember_6efd9ddb-38ef-496c-8a30-00c34c12547b" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeTwoMember_6efd9ddb-38ef-496c-8a30-00c34c12547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeThreeMember_2ccb0ba8-f2a9-4e77-9867-785f13f8297c" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeThreeMember_2ccb0ba8-f2a9-4e77-9867-785f13f8297c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeFourMember_331977fc-74fb-4577-a57a-c7618b44abcf" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeFourMember_331977fc-74fb-4577-a57a-c7618b44abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeFiveMember_eb7f326f-4a64-4203-a0a1-589dd8f26ee1" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeFiveMember_eb7f326f-4a64-4203-a0a1-589dd8f26ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeSixMember_006bd961-c4ab-4f3c-b70d-8fd07759e635" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeSixMember_006bd961-c4ab-4f3c-b70d-8fd07759e635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeSevenMember_def10035-ac13-4cce-bf00-9bafcfd11c42" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeSevenMember_def10035-ac13-4cce-bf00-9bafcfd11c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeEightMember_3bcc673e-23a4-40d0-9dbd-3f806feacf00" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeEightMember_3bcc673e-23a4-40d0-9dbd-3f806feacf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeNineMember_519930ca-b6d1-46d0-a5f8-ab5ba5feec41" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeNineMember_519930ca-b6d1-46d0-a5f8-ab5ba5feec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTenMember_ddc6f82f-ffe0-4087-9ee9-951795fe00a4" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeTenMember_ddc6f82f-ffe0-4087-9ee9-951795fe00a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeElevenMember_529a26dd-5991-4ebb-b406-203255a93ef7" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeElevenMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeElevenMember_529a26dd-5991-4ebb-b406-203255a93ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_VestingConditionRangeTwelveMember_fe145ed1-2dc3-443e-851d-f4bcde77d748" xlink:href="aqst-20250331.xsd#aqst_VestingConditionRangeTwelveMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aqst_VestingConditionDomain_9ec47f2b-ff47-4079-9704-75222cf0a9fd" xlink:to="loc_aqst_VestingConditionRangeTwelveMember_fe145ed1-2dc3-443e-851d-f4bcde77d748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_841a612a-c73b-4212-bad6-95b762c05b4d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_srt_RangeAxis_841a612a-c73b-4212-bad6-95b762c05b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_841a612a-c73b-4212-bad6-95b762c05b4d" xlink:to="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05ccb3ff-28a3-45c8-a79c-4557f47c00d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:to="loc_srt_MinimumMember_05ccb3ff-28a3-45c8-a79c-4557f47c00d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8aa648e6-ab92-4470-9374-ec797ed85636" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4160ee8c-9ce8-497a-8b11-807e3a8dba6c" xlink:to="loc_srt_MaximumMember_8aa648e6-ab92-4470-9374-ec797ed85636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dfa6d8c0-b315-49be-9692-3367bfaf4240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67b39649-9960-42d8-bfa6-11e04053aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_67b39649-9960-42d8-bfa6-11e04053aa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d1f5a364-ca89-4310-aec0-1d3430944592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d1f5a364-ca89-4310-aec0-1d3430944592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ebad8fa6-cb00-4713-b6be-9e275be0ca39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ebad8fa6-cb00-4713-b6be-9e275be0ca39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod_f5767246-0023-4007-9b81-ac1c6eab7005" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod_f5767246-0023-4007-9b81-ac1c6eab7005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare_1b51533c-f49a-470b-89f8-7f79b7b55af5" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare_1b51533c-f49a-470b-89f8-7f79b7b55af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ef8e2663-1728-4137-a9f4-948f313b525b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ef8e2663-1728-4137-a9f4-948f313b525b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods_17748e03-23af-41e0-b1b6-19f51d280628" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods_17748e03-23af-41e0-b1b6-19f51d280628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod_64a36e93-51b0-45bd-84e4-2650a2ec2f90" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod_64a36e93-51b0-45bd-84e4-2650a2ec2f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8b3057a-10e2-4d3d-8470-e368f6dd073f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8b3057a-10e2-4d3d-8470-e368f6dd073f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a46c5d8-b2f6-44e3-951e-1e029843518c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a46c5d8-b2f6-44e3-951e-1e029843518c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0b12eebb-f226-467d-9da5-44826e94f2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_SharePrice_0b12eebb-f226-467d-9da5-44826e94f2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5974ee57-4ab6-42c2-8415-63f45f4b9863" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb47b500-41f3-4984-96c9-c355795977f4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5974ee57-4ab6-42c2-8415-63f45f4b9863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationPerformanceBasedDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2baeb8f-3e38-46df-8ffc-566df2e4739f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8339700-7d6c-43a7-8cee-68db953ac741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2baeb8f-3e38-46df-8ffc-566df2e4739f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8339700-7d6c-43a7-8cee-68db953ac741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8339700-7d6c-43a7-8cee-68db953ac741" xlink:to="loc_us-gaap_AwardTypeAxis_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16f85268-2a3c-4e30-869f-ca77fe30c34f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f0f0be4a-792a-4dfe-9078-4f3a292e3bd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16f85268-2a3c-4e30-869f-ca77fe30c34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5fa06650-808a-43b0-aeea-2cc566fe09df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16f85268-2a3c-4e30-869f-ca77fe30c34f" xlink:to="loc_us-gaap_PerformanceSharesMember_5fa06650-808a-43b0-aeea-2cc566fe09df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8339700-7d6c-43a7-8cee-68db953ac741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f4b7e984-babe-4588-86ef-8695eaa1b4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f4b7e984-babe-4588-86ef-8695eaa1b4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_982f5360-bd0c-463a-a443-a5a4796f46c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_982f5360-bd0c-463a-a443-a5a4796f46c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c253a833-3540-410a-bf03-2ff42ce6fad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c253a833-3540-410a-bf03-2ff42ce6fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d6114cae-87d9-46cc-8514-67a2157ffbde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d6114cae-87d9-46cc-8514-67a2157ffbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af126347-4834-4b96-a734-ef0bec834c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19c9045c-6631-42bc-88ed-bedce1f526ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af126347-4834-4b96-a734-ef0bec834c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_7c7d797f-40d3-4cf0-8a31-c6e6d3d77891" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares_7c7d797f-40d3-4cf0-8a31-c6e6d3d77891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd801066-0337-4b72-816f-1b2612b300ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd801066-0337-4b72-816f-1b2612b300ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddc6d29d-cf7c-45b9-8085-e1a23fe6798e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ddc6d29d-cf7c-45b9-8085-e1a23fe6798e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c751b3d4-4c7d-49b2-bcb3-8b2959216ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c751b3d4-4c7d-49b2-bcb3-8b2959216ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f311ce5-4cf7-4b4a-a5cd-a7efa876a261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3f311ce5-4cf7-4b4a-a5cd-a7efa876a261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96e230a5-46e4-4693-aa34-ecda277c8a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8e77a06e-a645-4f79-a48e-7262fc9edad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_96e230a5-46e4-4693-aa34-ecda277c8a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_43dc109a-f09e-41f1-8d8f-22525fdb93bc" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0724fc5c-4ee5-4626-8429-8d292a5d1693" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue_43dc109a-f09e-41f1-8d8f-22525fdb93bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_84e43633-f757-44d6-89e6-571f6a00ab8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d691179-9823-4629-90c6-fd033a82f082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_84e43633-f757-44d6-89e6-571f6a00ab8a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d691179-9823-4629-90c6-fd033a82f082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0dfa0b90-e022-4e03-9804-10219e3268dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d691179-9823-4629-90c6-fd033a82f082" xlink:to="loc_us-gaap_AwardTypeAxis_0dfa0b90-e022-4e03-9804-10219e3268dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3289c878-99b9-4690-a9ec-2e430b68b133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0dfa0b90-e022-4e03-9804-10219e3268dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3289c878-99b9-4690-a9ec-2e430b68b133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_488be7e3-5ae1-4c73-acc0-ef089894778c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3289c878-99b9-4690-a9ec-2e430b68b133" xlink:to="loc_us-gaap_EmployeeStockOptionMember_488be7e3-5ae1-4c73-acc0-ef089894778c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d691179-9823-4629-90c6-fd033a82f082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7021eb4e-3517-4f7c-a06b-97556d8dbcce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7021eb4e-3517-4f7c-a06b-97556d8dbcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d2368c27-ebc5-4f8d-a5d1-2d61d6308415" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d2368c27-ebc5-4f8d-a5d1-2d61d6308415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f98aa587-68f4-47a2-b3af-922ee7dffba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f98aa587-68f4-47a2-b3af-922ee7dffba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod_e5d1fa23-d1c5-4e8e-98df-f8f366d47697" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod_e5d1fa23-d1c5-4e8e-98df-f8f366d47697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69d1fb46-95ef-40ae-b4ad-d0940d79862c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b390e488-ee81-4500-b893-e2b7f4f74839" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69d1fb46-95ef-40ae-b4ad-d0940d79862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e4c408e2-327f-495f-8110-61aad9fba3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e4c408e2-327f-495f-8110-61aad9fba3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ccb9752c-c866-41eb-8248-4e2acdf5c9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ccb9752c-c866-41eb-8248-4e2acdf5c9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c1f2227-0336-42e8-90ea-024ab2b4e43a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c1f2227-0336-42e8-90ea-024ab2b4e43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dca43545-707b-4fd8-afa0-32d4802e0bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dca43545-707b-4fd8-afa0-32d4802e0bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a801f88a-46fb-4114-8620-910a7c62bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a801f88a-46fb-4114-8620-910a7c62bf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_933fb475-a549-403a-b0c3-328a34592f0d" xlink:href="aqst-20250331.xsd#aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_933fb475-a549-403a-b0c3-328a34592f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73885119-9cb9-4a7a-aee1-cd3cd9bb6cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6050dde3-57d7-49d4-8dde-47a1783f8efe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73885119-9cb9-4a7a-aee1-cd3cd9bb6cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_279d3507-a7b0-42ae-9e14-d26566ecf236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_279d3507-a7b0-42ae-9e14-d26566ecf236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b54ea68f-5354-4bf8-bcf6-9b95d2dd4119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_797dc658-b4b0-4387-ab72-dcbe1255fce2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b54ea68f-5354-4bf8-bcf6-9b95d2dd4119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f833b5e-9cbd-467d-b5eb-a27bee0b6179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f833b5e-9cbd-467d-b5eb-a27bee0b6179" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c3513cde-010b-42d5-855a-4928bb33b99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:to="loc_us-gaap_AwardTypeAxis_c3513cde-010b-42d5-855a-4928bb33b99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c3513cde-010b-42d5-855a-4928bb33b99f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_082aad6f-e65f-4c05-b031-6169478af253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:to="loc_us-gaap_PerformanceSharesMember_082aad6f-e65f-4c05-b031-6169478af253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb1fc907-f1cd-41f1-82b7-b721ec078702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5b5af0b-fc0c-417b-b3a1-1e78dc6a66e7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb1fc907-f1cd-41f1-82b7-b721ec078702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd258544-c495-4cb1-8f81-b971f0eac042" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:to="loc_srt_RangeAxis_cd258544-c495-4cb1-8f81-b971f0eac042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cd258544-c495-4cb1-8f81-b971f0eac042" xlink:to="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8cbbeefc-9f4d-4fe7-ac6e-e11a55baaf6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:to="loc_srt_MinimumMember_8cbbeefc-9f4d-4fe7-ac6e-e11a55baaf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6f78cbb-5e6e-4719-b1dc-6419506abbab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f7baf59-9a7b-4cd3-946c-2d6e35b3955f" xlink:to="loc_srt_MaximumMember_e6f78cbb-5e6e-4719-b1dc-6419506abbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6eeecf2f-ae61-4d31-bfa0-10299cf8f1f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e97722a-91b4-4ee6-9f63-f7e87b9945ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e97722a-91b4-4ee6-9f63-f7e87b9945ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf0e0347-09fa-40e1-a61c-f19af5c3189e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf0e0347-09fa-40e1-a61c-f19af5c3189e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1850d9a6-85dd-4fa0-9937-25895d166c57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1850d9a6-85dd-4fa0-9937-25895d166c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b1b46ab4-1fbd-4194-a882-5db82f421148" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b1b46ab4-1fbd-4194-a882-5db82f421148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_f10999a5-557f-492a-8538-d1e1d8ecba85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2571dc-3b3f-4d4e-9a36-1c2073b88958" xlink:to="loc_us-gaap_SharePrice_f10999a5-557f-492a-8538-d1e1d8ecba85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bea5b872-ca50-498e-9e05-2726ddefef76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_381a16ab-4c89-4e61-a9ea-06511f8f2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bea5b872-ca50-498e-9e05-2726ddefef76" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_381a16ab-4c89-4e61-a9ea-06511f8f2e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01cfa3c3-191b-4c59-b60b-83977fb876f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bea5b872-ca50-498e-9e05-2726ddefef76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01cfa3c3-191b-4c59-b60b-83977fb876f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f8c751d4-f6b9-4c9e-941b-a8cafbfbce41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bea5b872-ca50-498e-9e05-2726ddefef76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f8c751d4-f6b9-4c9e-941b-a8cafbfbce41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://aquestive.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="aqst-20250331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d267de02-aabe-49b5-bee5-f7335df38249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d267de02-aabe-49b5-bee5-f7335df38249" xlink:to="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_51753327-5617-46c4-837d-94ab369ed71c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:to="loc_srt_LitigationCaseAxis_51753327-5617-46c4-837d-94ab369ed71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_51753327-5617-46c4-837d-94ab369ed71c" xlink:to="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_NeurelisIncVAquestiveTherapeuticsIncMember_9fba0195-8b63-4c90-84b0-00f067484bf7" xlink:href="aqst-20250331.xsd#aqst_NeurelisIncVAquestiveTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:to="loc_aqst_NeurelisIncVAquestiveTherapeuticsIncMember_9fba0195-8b63-4c90-84b0-00f067484bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_SuboxoneProduceLiabilityLitigationMember_63c1e0b0-9068-4701-89f1-0def04baa819" xlink:href="aqst-20250331.xsd#aqst_SuboxoneProduceLiabilityLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6735506e-0601-499b-804b-895a17ad6df0" xlink:to="loc_aqst_SuboxoneProduceLiabilityLitigationMember_63c1e0b0-9068-4701-89f1-0def04baa819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:to="loc_srt_StatementGeographicalAxis_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f90e9b8-2072-4558-8f62-43e8da712d47" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dbb8bee2-29bf-46b5-a7ce-60f69fe00af0" xlink:to="loc_srt_SegmentGeographicalDomain_1f90e9b8-2072-4558-8f62-43e8da712d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_b8e66e92-7911-456c-b1f0-ba9cf3bdfc70" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA-BC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f90e9b8-2072-4558-8f62-43e8da712d47" xlink:to="loc_stpr_CA-BC_b8e66e92-7911-456c-b1f0-ba9cf3bdfc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cd66d212-f590-4d9e-8ae2-3d2b5e907ee8" xlink:to="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9a263723-2642-43fa-8f29-ba6b15cbf47b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9a263723-2642-43fa-8f29-ba6b15cbf47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2a29c243-c42e-4b86-91b4-13028e10e6db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_2a29c243-c42e-4b86-91b4-13028e10e6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_aqst_LitigationSettlementAmountAwardPeriodDue_e33a0d08-4f52-4a0d-88a0-4c9b285c8192" xlink:href="aqst-20250331.xsd#aqst_LitigationSettlementAmountAwardPeriodDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e50ad39f-058a-4be1-9754-69f6b7ec4836" xlink:to="loc_aqst_LitigationSettlementAmountAwardPeriodDue_e33a0d08-4f52-4a0d-88a0-4c9b285c8192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mschobelsignedconsulting001.jpg
<TEXT>
begin 644 mschobelsignedconsulting001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *I6^D:99WLMY;:=:074W^MGB@57?
M_>8#)_&KM% !1110 4444 %%%% $<L$4X431)(%8.H=0<,#D$9[@]ZDHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2:A;:;9S6[Q-=+"?F&!RWM[5T&DZMXDN[]8=2\+KI]L02TXU%)L'' V@ \T
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M]O2;?(R%0N !CKUIFJ>%;R\\%Z/':LEOX@T>&*6SE)X69$ 9">Z,,J?8Y[4
M9'@GPYI_BKX>:%<ZP;V>>..4!TOIHB096Z['&>@ZUG_#/PGI>K:++J-\VH37
M4&I3QQN=1N  L<F%!4/@XQW'/>NT^'^D7N@^!M,TS48EBNX%?S$5PP4EV;J.
MO!%0?#W0K_P]X?N;348UCF>_N)U"N&^1W)4Y'M0!UE%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM0^(&@Z;<W\4[W9BL"5NKJ.U=X(GQG8S@8W<CCU('4T =317,W/CO1;?4(+
M?;)[R>"*XC@M[9Y',<F<-@#@#:<D]./44]O&^C)JQL"UUA;D6C78MG^SK.3C
MRS)C&[) ],G&<T ='17.7?C?1K+4Y;*5KHK#*D%Q=);.UO!(V-J/(!@'YE^F
M1G%1ZIX]T;2KW4+.1;Z>XT_:UVEM:/+Y*% ^]B!@+@CGZ^AH Z>BN:L_'>AW
M^IV=E;O<E;[(M+IK9U@G8#<520C!. ?R-.MO&^C7>J1V4;76V6=K>&[:V<6\
MTJYRBR8P3\K#T.#C- '1T5R-Q\2/#]L;AF-ZT%K</;7=Q':.T5LZOL/F.!@<
MC\L'H11_PFCR^.KSPS!87 :&T61+A[=R@D8MRQ' CPH^;N<B@#KJ*XVSU+Q?
M+;:$T\6F%YIY8K\1)("T88A)8L_=&!N.[KD =16WH^L&]O-0TVY"+J&GR*LP
M3[KHXW)(H[ C/'8JPYQD@&O169K%S);K9K%J=G8O)=1H?M(!\Y2V#&G(^9N@
M//TJ>;5M-M[M;2>_M8[AF55B>90Q9ON@ G.3V'>@"Y115"+6])GGF@AU.SDF
M@0O*BSJ611U8C/ 'K0!?HKSV/QS)?07VLVNK:7'8Z;>3Q3V<C M+!'E=ZL#D
M.S#Y>Q! ]SI^'=>N[ZRM=<O-9TIM)N;1'FC!"M;7#!6V!\X(PV"&^;('KB@#
MKZ*IIJVG2:<-02_M6LCTN!,IC/./O9QUXK-U/QCH6EZ;;W\FHVTD%S<I;1-'
M*I#.SA3SG'RYR?0 T ;U%8ZZG$VM,ZZUIYL5LO.-L&7S!\V?.+;ON;2!T]\U
M:76=+>Q6^34K-K1FV+.)U,9;.,!LXSGC% %ZBJ4NL:9!?I8RZC:1W<A"I TR
MAV)&0 N<YQS5MW6-&=V"HH)9B< #UH =17-Z7XYT;5KI(8C=PB:%I[>:ZMGB
MCN(UQN:-F&& !!^ASTJ31O&6E:Y>1VMLE[$\T1GMFN;5XEN(QC+1E@-P^93Z
MX(- '045F:WKUCH%I'/>M(3-*(88H8S))-(>BJJ\D\'\JYW6OB#:P>$=;U'3
MH+S^T-/C97MIK1Q)!(4+(TB8X3C.[I[T =K17)?#K4;_ %7PI;WNI7M_=W,Z
MI([W=FMN 6121& HW)SPW.?6I/%>H:QI6HZ'/97ENMC<7\-G<6[V^YGWMC<'
MW?+@=L&@#J:*YM/'.C2:NNGK]KPUR;-;LVSBW:<9!C$F,;L@CTR,9S5:[^(V
M@6;7>_[=)'8SM!>30V<CQVS*VTEV P!G].: .MHJA::S97VJWNFP2%KBR2)Y
MAMX D!*8/?(4UC-X^T5K&PN;9;Z\-]$\T,-K:/++Y:G:SE0. #@<^O% '445
MS-[X^T"RM=,N#/-.NJ0M-9+;P/(TP7;E0H&=WSCCKU]#6CHOB&PUY+LVAF22
MTE\FXBGC,;QMM#<J?9A0!JT5GZ)K-GX@TF'4]/9WM)BWENR%=P#%<@'MD''K
M7/2Z]K\7Q%TS2I[:UM])O$NO*&=\TGE!#O)Z*#OX7D\<]<  [&BBL/Q"?$,K
MV5IH/D0":1OM5],HD%N@&1B/<-S,>!V'.: -RBO-CXQU^SCU#19)+.ZUB/5H
M-,M;X0E(G\V,2;W0'JB[L@'J!6E#K/B72M5U'0KDV^M:@-.-_ITD<8MO-(;8
MT;@L0,,4.<]#0!V]%</:ZCXGT;Q5HFFZWJ%EJ$6KI-N6"U,)M7C3?E3N.Y/X
M>><D>N*I>#M6\1^(K73-0G\5Z2GVC$\FFK8#S?*W?=W>;D94?>V\9Z4 >BT5
M'/-';023S.$BC4N['H !DFO.1X\U'3O"=OXFO;>XG&LWT2V-G' 66VMV<*N2
MHR79"6Y/)( H ]*HK@AXX:U\9ZG;7$6HSVW]GVEQ;6,%DSS(6\S>2H&X=$!W
M=#@=36U)XXT4:;IM[;-<WHU)6>TAM+=I)9%7[QV 9 7H<XP>.M '1T53TK5;
M/6M-AU"PE\RWE!VDJ5(()!!!Y!!!!!Z$5<H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BD+JI + $] 3UHWJ6*[AN SC/- "T444 %8OC%6?P1KZJ"S'3;@  9)/EM
M6PSJI 9@"QP,GK3J .*BC?\ X4BL6QO,_P"$<V[<<Y^S=,>M4+R!QI7PU58F
M'EWEON 7[H^RR#GTKT2B@#QO08+"/PSXL_MH:A;6_P#PE]Q(EW:J0]LV4*39
M[*",9P1SR,9KMO FJ7NHV^I)-J#:K96]P([/4F@$1N$**3D  -M)*[@,''M7
M744 <%XH,_AOQ_IWBYK6>XTMK!]-OF@C,C6PWB1)"HY*YR#CI5Z#Q_8ZOJEE
M8^&[>;5C+(/M,Z(\<5K%W9G9<%O11R?:NOHH \UT'6;;X?7^LZ-XA$MI:3:A
M->V-\8F:&:.4[MA90<.IR"#CM5K3ISXQ^(MEKUC!.NBZ19RQ174L31BYFE(!
MV!@"555^]ZUZ!10!Y5H'AZ\U'X3Z'=:</(U[2Y9KFQ9QC+>:^Z-O]EU^4_4'
MM4?A+78_^$.\0:M?Z#<W%C>Z]*UW:/#O:&)UCW,R8)<*>H ]3VKUFB@#RK0%
MT"+QOI0\!2W'V)_-.JPPF7[(L>P["0_RJ^_;@+SC.14WA#Q+IO@;2+CP[XCD
MEL+RTN[AHR\#LMS&\C.KQE00V0V,#G(Z5Z?10!XUJ-C?2_"7QWJ<UE/!_;%[
M)>6UO*A$OE$QJI9>H)VDX^E=5H_Q'\*6VB6$$VINLL=M&CJ;2;@A0"/N5W=%
M ''_ !+/VOX6ZZT :3S;,E JG+ X(XZUT>C C0]/!!!%M'D'_=%7:* /#/"5
MM.G[/OBN)H9!(TEYM0H<GY5Z"NP\4V%UI%K8^+],A>2:WLQ;:E;QC)N+4CD@
M=VC/S#VW"O0Z* /'M-M+[2_"WP\\40V-Q=1:3:/#>V\*%I1%*@!=5ZG:5!('
M.*E\8>(-+\1VT\GA;7_$,VNO"([6RTUYHT#]FD7: O7DL1TKURB@"&WWQ647
MGM\ZQCS"3GD#GFO,O#.E^(_$FJZKXSL]832UU&4V]K%/IXF86L1*H>6&W<=S
M$8]#7J=% 'C47AK5!H'B[X;RS":5XQJ.ESB+RHY%9P[(!DA0)5QC/\6:W+[Q
MQX?UK1H+76=1UG0-3C8-/:6ZS0W D (*C:IWJ2<C'7BO2:* /&-3LM6N?A5'
M#JG]JL9]?B:#[9(QN5MC.-A8YW*=OT(K3\7>#K70)-,UW&IZMI-G< ZA87=Y
M-<@H2 )E5F.2AP<8((SZ5ZI10!Y)XR_X1N;XJ6%SXD4R:4^@GRI%64J9#."O
M,?/W=WM6[X7N/ 45[<0>&,K>SP,&&R?YE'/5QBN^HH \$\$1_#:+P9IB:]$R
MZH(C]H#)<Y#;C_=&.F.E=CK,NG7TOP_DT(-)IL6J[(R$<;56-UYW#/48R:]*
MHH \?BT:_'B<?#PV\G]@1ZA_:XEQ\AM,[Q!]/.XQZ"H-0MYCX ^*2"&0M)J\
MY0;3EAB+D>M>ST4 >0VI^$:00ET(E55)^2[ZX^E=*(H-5^*<CM%Y]A=^&54[
MT.UU:=N#GU!Z5W-% 'D.F6VI:/\ $WPSX:NXYYK72Q>-8WC D/:R1?(C'^\A
M4K[@+71^/8I)/%7@9D1F":J2Q SM'EGK7=T4 %<5#')%\:;IY<[)]!3R">GR
M3'>!^+J?Q%=K5*^TV*]GMKG<8[JU8M#,HY7(PRD=U(ZCV!X(! !Y[/=0VMY\
M3;2=FCFGC\V)64_.AM%4$'IC<-OUXZU%IYLH-3^&!A\B,BQF279@8W6Z\-]7
M'?O[UZI10!Y-IZV%QX?\0PMJ;:9GQ1++;WD(4B!]P:-R#P4)7'/!]>XZ_P #
M7NH7EIJ0U*.T>XAO#&;VR!$-[A$Q(H/?&%..,J:ZJB@ KSSQ[;WWBGQ'H_A&
MPF^SQ)_Q,[ZX>'S$58SB)"N0&W/R1GL#7H=9M[I,MY<>:FK:A;# 'EP.@7Z\
MJ3^M 'G_ (ATSQ#X8U[2/&5]K":G':2"SO$AL!"PMI3@L<,V[:VUL?6L^]U6
MVTCP=X]T*]@G.ISW.H3Q0B%CYT4H+)*&QC:%/)SQM^E>C_\ "/S_ /0P:Q_W
M\B_^-UA:C\/KW47N8&\9:Y_9EV"+JS<QOO!&&57*Y12.PXY/K0!1\)PG_A82
MSF,X_P"$7LD5]O'WV)&?RKG;'3[,0S^'-7U[7X[YM5D_XE-M%&5D#7)D2528
MR=F"KEMW&#]*]+B\-/!"D46O:NL:*%51)%@ < ?ZNG?\(_/_ -#!K'_?R+_X
MW0!YE<6%FD_B+0]:UW7K::]U2=DTRSBC;[5',^Y&CW1DG@X)W<;3TQ73VMNZ
M^(/B03&Q\R*W"L5^_BT _'FNF_X1^?\ Z&#6/^_D7_QNC_A'Y_\ H8-8_P"_
MD7_QN@#B8[>0>$?A:@B8-'=6A<!>5_T63.?3FLCPK86?V30M!U+7M?;5+&]0
MOI*11[(I(G+!R?+R(N,[MW(;J<UZ;_PC\_\ T,&L?]_(O_C='_"/S_\ 0P:Q
M_P!_(O\ XW0!P4]M)_PJ7QX@A;S)-0U)@NWELRM@^_:M:RO(=.^+TT=VS1&_
MT:VCMBR'$K*[[@#C&1FNG_X1^?\ Z&#6/^_D7_QNI(-$F@N(Y3K>J2A&!,<C
MQE6]CA <4 :]<5IL<DGQAUZXBSY$6E6L,I[&0N[#\=O\Z[1SA&.X+@=3T%4]
M-T^"QCE>)O,EN9#--,<9E<@#)^@  '8 "@#EOB0T*6_AQI"@9->LW!/55$F6
M/L .IK'U:YGT[Q->76D7T%_%/J=O]NT*Z7]Z9/W06:!ASP%1N<K\C=,5Z=10
M!E^)(;VY\+ZM!IQ(OI+*9+<J<$2%"%P>W.*XGPI?>'=>O-#N8GU!M6TJ!T>W
ME0Q"P!CVNLGR@8X  )/8CH<>E4A(4%B0 .230!YEH5Y;?\*Y\8_OX^;S4V W
M<D.SE"!WSD8]<U7N-373-#\ :K/-<)HUM9>1>SVR[S;2M#&$9Q@XQAU/'&[W
MKU8$$9!R#10!Y-<S:7H5QHOB'3TO9?#9U:>YOKAT9@998MJSA,9"!B1D#&22
M.V;GB672)/#,>K:/;-'8/X@L[VYN1&P64B5-\N#SMX ST.#]3Z;10!PMO<6L
MWQD\Z%EQ+X? R1M+'SMP!SWV\XZXJ#PUIMU8:_>^%'MW&DZ==_VE;28^0Q2$
MM'%_P&7S#_VS6O0:* /(K*;2[Q;[POXD?4_[835);B.S1"/M),QDBEC<+TP5
MYW# 7G KU#6)KFVT2_GLX?.NHK>1X8B,[W"DJN/<X%7:* /%K/4K:XUOPK?3
M:IJFLQF*>*\#PJL,<TD! @10B@,2"NW/' )Y%;W@S4DB\06.E:#K-YJ>BFU<
MRVMY#^\TW:%V*9, ]RNQLD8Z\5Z2KJX)1@P!P<'/-.H XOQLW]G^(/"NNW".
M=-L+J9;IU0MY(DA9%<@?P@\$]MU<UJTHUV#XA:WIJO+ILNB+:0S!"%N9$24L
M4R/F W@9]>E>LT4 8G@U63P/X?5E*L--MP01@@^6M<IK/B*/Q#K.EZ#':7$.
MK6>NQR36[1L0L$19O.W8QL9=I'NV*]&HH \1OM8DO8+*\U#5-1:^M-=BEOM.
M2$);V$*7.-S )GIM.2Q)SGH#C<$#GX;_ !'"Q-NEO=391MY?*\$>M>I44 >9
MZ1K-IX:\9:H=4\V(ZAINGM9J(F8W!1'5E3 Y;)''7FN>\.:E/9Z-X<T[4M1U
M#1[/^RWDB^QP@S7-QY[@Q!BC'( 4[1C.[VKVVB@#QKP>ADU/X=QO%)YMC'JD
M-PLB_-#)\ORMZ'!_6M+QZNH:#XEFDTF-BWBNU73,J.([H$*DA]/W;O\ ]^Q7
MJ+.JD!F +' !/6L$^&S+XG37=2U.6Z2T#_8K5D5(K8L,,W'+-C(R>@)H U=+
MTZWTC2K33;5=MO:PK#&/]E1@?RKSWQ%XPT*+XE>'Y7O'$>G)?0W;"WD(B=A&
M .%YR5;IGI7IO49%% &=9ZW97^IW>GV[NT]K%%-("A VR!BA!/7[I^E<_P"/
M_%3^'[:PLH)Q:7&I2-']M>%I4M8U +OM4'+<@*.A)YX!KJ8[*"*_GO50_:)T
M2.1RQ.53<5&.V"[?G5B@#RJXDT)?#^E7?AN2XOH-#U>*^U"0Q2--('5TDE;<
MH+M\Q8X[+Z8JW+XEL[GQ3J'C"Q2:[TC1]%>#S8XV GF>17V)D<X"*">@+5Z5
M10!YKX.US1;_ %7[??:G]O\ $U]$46)8)%CMTQN\B(LH ''+$Y8C)["L&];P
MI?:+IVF^%M"_L_Q/'?0-#;K:,EQ9LLH,C2/C[H4-DDD$$5[,'4YPP.WK@]*0
M2QL0%=22,@ ]10!F>*;>:\\(:U;6X)GFL)XXP.I8QL!^M>?ZS<Q3?!KPG?P@
MFUMI-,FE9%+>6B,@<D#TP<UZM6/H&@1^'EO+>UG8V,T[3P6Q7BW+<NJG^Z6R
M0.V30!A>'YHK[XDZ[J%N?,MI],L6AFVD!@3,>,_A7 Z-;-IUKX;U+4-5U#1;
M$VE]:F[MD7]W)]K+A7WHP4,H.#@9*CFO<Z* .;\#VEI;>'/,LIM0G@NKB:Y\
MW4$5)9"[DE]H5<*QRPX'!KI*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?$<>M/'8-HJ6\ACN
MT:YBFE:,/%@@X8#L2IQWQCV.U10!YCX^?7+/P1XLDU)HX[;[3;M:7%O._F-$
M9T!4J/N87 ^7KR>])I,?PUFUBS33Y=2:\,RF$/-J&W>#D9WG;C/KQ72_$;3[
MC5O ]]869A^U2O"T2S2B-6*2HY&X\#A35.+Q?XB>9%D\,V$<98!G_MR([1W.
M-O- '*6MEK6I_&C7IYK'1;J[T^WMS;FYDD*VX()4Q_*<,3R?QQFJ'@74+K0M
M,UWQ-=:=IMQ?7.J3623^:PGDG>9%6,N5P(@><_[/2NYTBS^Q_$KQ'K<UU9BQ
MOK:VC@87"DED4ALC/%<[:>%)/^$$U'3+F73'O/[:?4K>":=&BF42APC]>&4$
M'CC- &Z_CZXTBVUA-9M[.:[L+:.YA_LZ<O'<+(YC5<L,JV\ '.>&!]JDU#6O
M&5CI&K?;-+T^.:+3WNK>ZMIW:%&7[T;Y4'>!D@C@X[5CS:##K/A_6;2'1_#_
M (;DGBB%KY+Q&1I$<29D:/C9N5  ,GJ?05JMJ&N^(;74K74$TS2K273I;=8C
M>I,TL[C ;<OW4 S[G/;% &1%KETNC_#R37M.LK^\U"XA$-P9&9HLQ*1+R!^\
M/.>WO7367C-?[(\27>J0);3:#/-'/&K9W(J[T89_O*1CWKDTTS4[[3O D5S%
M96LF@W<0N1]NC?=&D07>,'N<\=:M^*O#KZKXM62RO;$:-JHMUUD-<*"1 ^]<
M#/.X?(?84 7(_&VO7BI!:Z?I<-[!8PW=[%>731C?*"RPIQ][:.6/ )%=EHFK
M0Z[H5CJUN&6&\@295;JNX9P?<=*X37M(ME\5W^K1:'H?B"._@B4+=S0AK:6,
M%<_.#\C KG'.5Z&NUTJYLK+2;2V>?3('CB57CM&5(5;'(1<\+G.* .!\(^%=
M,\2S>)[S4VOI+F/7[R".2/4)XMB*PP %< 8R>U:&BZMK6AW_ (G\.[IM<FTN
M.&XT]KB4++)'*#\DCGKM(/S'DC\!5+0[KQ#X9GUV"VT?3KZ*]U:YO89VU>.(
M;9&&,K@GH/UJ.[\,WESX?UR\O=1TV\U[5[BWEN+:*X"0&"%U(ME8\X*A@2>I
M;F@"[?\ C+6QHOB>TQI)U33M-^W17%E<,\)C(<'MD.NPX'0Y'2I[/Q5KD&D>
M'=/==,?6-0L_M)GN+AQ"D*JGS.<9+L7 P/<YXK'_ +%N;B[UUHK#1]+M=7T1
M[".&"YB'V>0;]OF;>&+;^JYP !0^ES7-KX=U#4-"TF^GTVS;3[C3;F[@D#IB
M/;*C-\H(9#P><,>: .CL9;GQBNE:FD\]A=Z7?2PW<5M=$P.48!P1C]X& &W.
M,!R>O!6;1M0\/^'=:O;;4+R:Y@FEO[-;JX,I"A03$Q[HQ5N.VX$<C-:_A*!;
M?1 HL-+L':1W:UTW;Y<>3\H)7 +;=N2 ,GIQ4OBJY^R>%-5D"EY#;.D4:C)D
MD8;44>Y8@#ZT 7-(U*'6=&LM3M\^3=P).@/4!E! /OS6-%XUL9+JR3[)>);7
MMY)8V]TRJ$:9-V1C=N )1@"1V^E7O"NDOH7A+2-*E(,MI:1Q2$="P4 X]LYK
MAF\/>*[J31[F^TNWN-2L-9-S-=O>#]]#^\"^6,'8@#+\O!XS@DDT ;UU\1K&
MUM]3N6TG56M]+NC;7LJQ)B' 4[^7^9?F'W<GC) &,ZNI:Y T]WIEO:WE[/%;
MB6X6S<*8D;.WYBRG<<,0 <\=N,\E?>&M<N?#/CFP33B)]9NWEM,S1X*M&B?,
M=W'W"?Q%:-GINOZ+XPU/4K?3!>66LP6Y=3<(CVDT2;,-D\H1@Y7)'I0!=^&,
MTMQ\-=!FGD>65[4%G=BS,<GDD]:Y^Q\2CPQJWC:XN+74[ZSM=01Y'C;S/L\1
M@C).789 ))VKDCTQ73_#_2]0T3P+I.EZG D-W:P^6Z)(''7U''\ZY^]\.ZU<
M:;X^MTT]M^ML?L>9H\$&%8_F^;CE<_3WXH ZC4_%5II[2I%!->RQ6XNI$@:,
M%8SG:?G9<D[6P!SQVXSF-\1=-E>T33]/U/46O+ W]N+6%3YB @$#+###=T..
MF.N <N31_$&DZ_'JMEH5MJMO>V,%O=6DTZ1R6TL0(#*QRI4AN0.>*TX=)U9/
M'FEZG+91_9H=,EM9G@=0B2/(C@*I()4;2,X!/7% %C5/'FF:3;W%U/;W+6EK
M(L5W,FS]PQQG*EMS;=PW;0<<]<''.VWB-M \7>-)18ZMJEM%):R[;;]]Y,9@
M#,1O8<9).U<GT&*M6VC^(M%U[5K:VT33]2T_4;M[N"^FF53:F3EE=""6 .2-
MOTX[7H=-UG2?$WB2ZM].%Y%JJP&VE69%5&2(1D2@D$#(S\H;CMVH T;;QGIU
MYJNDV5O#<R)JUL;JSNP$$4B@ D<MNW $<;?Y&M33=334S=&.WFC2WG>#?)MQ
M(RG#%<$\ Y'..0:XO6/"S:+\.]'L-/ND_M?1'@>QF<<23[@I4CKM?<RX]_:N
MVTNP72]+MK)7+^4@#2'K(W5F/N223[F@#+U3Q;:Z:-09+*\O8]-"F\>U56\G
M(#8P6!8A2&(4' /X5+<>)85N9[:QLKO4)[>!+B:.W"@QJ^2H.]E^8@$A>O'.
M,C.##8^)_#WBK66TS3;?4=,U>=;I)9+H1&UEV*C;P02RG:"-O/:K%KI6KZ#X
MRU;5(K5M3M-7@@,GE.D;Q3Q)LZ.0-C#!X)((Z4 6#X^TJ0:(UG!>WJ:RLC6C
MV\8()12S*V2-K<8YX!ZD $U0UGQM)-\/O$&K:997D%]IXGMY8I1&'M9D7.YO
MF*D#*GY2V<CBJ6F>#M2T6Y\'1QP"XCTV:[N+V2.10JM.K\*&() 9_0<#UXIL
M_AW6Y?"OCC3UTYOM&LWD\MH#-'@K)&B L=W&"I)^HH DAM](T_5_#MY=66M0
M7FH2)%$GVK,)F6-CYDBK(025W<\Y[BMN#QM#=:K=:?:Z+J\\EI=?9;ATA3;&
MVP.&)W_=(/\ CC(S5U?3-4OIO",L6GO_ ,2Z[6>Z4RQY11$R<?-R<MGCL*L>
M&M/U'3M:\475U8NL5]>BYM\2(2ZB)$QC=P<IGGCGK0!6M_B1IUQ9:5?C2]52
MPU.7R(;DPJ0)26"H5#%LG:<$ C) SUQ;C\<V(CU7[;97EC<:;)"DUO<>7N/G
M$+$05<KAB<9+#'.<5S5GX8UVW\#>%-*?3B;O3-4BNKE5FCQY:2,QVG=R2&&!
M['I6A>:'J4OB#Q3<RZ%'?6.I164*P32QXE2-B)<@MP=KDKGN.U '8:?J#WSW
M*265Q:R6\@1EFVG?E0VY2I((YQ]0:Q;GQ'=K\0(/#BZ;,]L^GO<O.CH"3YB(
M#RP(5<MGN2>!QFF>"]"O- &I6Y>Z32FE0Z?:7<PEDMUV_.-P+?+NZ#)P![TM
M]IFIQ_$6RUNUM$N+,Z:]E,?-"-$3*K[L'KP".._7 YH YOPAXJ31-%,=];:E
M/;OK=S:&^8ATB9KADC#LS;R.@R 0.YKJ-:\;:=HB7LLD%Q/!8,JWDL)3]R2
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M)D*,CIN[$AL@GC(K'DT#6];N/$>L7UE'97-YH[:996?GK(P&'8L[#Y02S
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M1VQ03+*'"(J[P1TR0>*WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+1_^@58_^ Z?X5PFG-=:UJ'AOP[_ &A>65A#X=AOY?L<QBDF<E44%QR% !.
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M?]3=ZA)"Q[C=;R#(]QUK,DUN\\0^!M+\*32,NM7UXVCZCM/S(D/-P_XQ@?\
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M7+R&)83.N]G !*A<Y) (..N#1::SI=_=S6EGJ5G<7,'^NAAG5WC[?,H.1^-
M&+>>$':Z@O-+UF[TR[2T2REEACC<31+DKE74@,"3AAZGK4\7A.V75-+O+B[N
MKM=+MC#;17+[P'(PTS$\LY'&3P 3@<UK7FI6.G@&]O;:V!5G!FE5,JN-QY/0
M9&3VS3(M7TR?33J46HVDE@ 2;I)U,0 ZG?G'ZT <V/A_%;6UO%INK7=D;*]D
MN[!E1'%J'4J\2AA@H0S8!Y&>M-B^'=O&\Y;5KZ5)]0M]2D$NPEKB(J2V<#AM
M@R.@[8KI[75M-OK!K^TU"TN+-<EKB*97C&.N6!QQ3;+6M*U+9]AU.RNO,W%/
M(G5]VW&[&#SC(SZ9% &?J7A.PU;5KJ^O&D=;G3'TR6'@*8V;<3GKFLNS\!/'
M?:/=7_B'4+]M'?-FDJQJ%784PVU1N."/F//R]LG/2V6LZ7J4\T%CJ5G=30'$
ML<$ZNT9_V@#Q^-27VHV.EVQN=0O+>TMP<&6XE6-0?J2!0!SUAX,?3KR);?7=
M0328+AKF+34V*BL26VEP-YCR2=I..QR.*U-!T"#0(]02":207M]-?/OQ\K2'
M) QV%4?$WC33/#_A"Y\01W-K=Q+&3;K'<+MN&[*K<Y_#/0U-X8UR75?#@U34
M+C2QP7=K&Y\R*-=H.&8XPPR<^E %C5] @UB_TB[EFD1],NC<QJF,.VQEP?;#
M54M/!VFV?C6]\41F3[9=0B,QDC8A^4,ZCLS!$!/^S68_Q$T^[TFPU#1WAN$N
M-6BT^5'D&Z-6F:/>0I.,[2RYZC%=#%KFGZA8W<VDZEI]VUNK;F2Y5HT8 D!R
MI.T<<T 82> (;;2[.WL=4NK6ZLKZ:^M[L(C,K2[]ZE2,%<.1^51?\*XMC]J5
M]7OI4N;VWOY1($):>(KEL[>-VT9 X'8"MRVUZUMM M-0UK4M*MC,HW31W0^S
MLWHCMC(K6BECGB26)UDC<!E=#D,#T(/<4 9E[H$%]XDTK6GED6;3HYXXXQC:
MXE"@Y^FT5'X?\.6_AO[;#8SR_8;B<SQ6C8V6Q;E@G<*3SCMDXK(\8?$"W\):
ME:6;6,EV'C^T7CQOC[);^8L?FL,'(W-TXZ&NLFNK>VMGN9YXHK=%W-+(X55'
MJ2> * .<OO"%PVL76IZ-K][I$U[M-U'%''+'*RC:'VNIVM@ 9'7 J%O %E'I
M5I!:ZA>P:A:W;WL>I95YFG?(=FR-K!@2"N,8QZ5O0:[I%S 9X-5L981$9C)'
M<(RB,'!?(/W0>IZ4HUS2&BN91JED8[4 W#BX3$.1D;SGY<CUH PX? T 2V>Z
MU.\N[R/4TU.6YEV@RR*A0+M  5 #@ #M5K4O!^G:MJ&J7-ZTDB:E8)830Y
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M?C.4T:Q3Y8T^6%1Q&0R#_@) (^E:!L;5K];\V\9NUB,*S;?F"$@E<^F0#^%
M'">+/^2Q_#__ '-0_P#1(KF;K3++_A4/C6]-K$;HZC?2"8J"X9;@[<'J,8X_
M'UKU^?3+&YU"UOY[2&2[M-XMYF4%HMPPVT]LC@U$VBZ8VG7&GM86YL[EG>:
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M-/;O&%F69,ID@<\$CU'(H NZO\1YDTG1KW2M'O9'O-6&GW$$BQAX75\/$07
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M&, UYA=Z;J.H^'/$FEZ"FO7&D/IH,,&K12*Z7 ?/EQ&4!R-H/'(!Q@\UT/\
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MOO /_",W>LVC;M/6T:12<!@@4,/H0"/I61I<6G6_@?7=-O\ Q'I]QK6LI/\
M:+H%MF]T\M.HSM"A?UKU*B@#RJ%+;2K'PS<:5X@TDZKH]A]@E6X+^3<1E5SR
M!N7#("#CZU+)<M_Q+=6/BG2KK7;26=F6<,MNT4V,PK@%@%VI@G)X.>O'J%%
M'GK^(;Y=-@=?$F@S7OFR-<6TL;+;O&WW4# %AMXY(YYR.F-KP'9P66@3)!=6
MDYENY9Y%LE*PPL[;MB \X (_,GBNHHH P?&32MX3U&SM5\R]OH'M+:/^])(I
M4?@,[B>P!/:GZ3INHZ.NEZ; ]HVCV=@MNQ8-Y[2J%52/X=N <]\ULE%+ARHW
M@$!L<@'K_(4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:\M9(5<]%8J0"?;.* .8LK'QYJVD1:N?$MO87=Q&)XM-6Q1X(P1E8W<_.3C
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M,$@X)K)\9_$".'PSXB_LJ#4E:R26W&IQPCR([A1C:&SG(;C.W&>,U"UC=?\
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M,I@G'&17':C:7NNW'BK5;>PU.&V&J:;>1B.%HYY88E4,\8(SNP"P&,\#C/%
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M+L$292Q"CDX'/%9\&LVVB>-M5UN[AO3I>M65J]I<I92OAHMZM&RA=RL=P(!
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M\7<@(=RS94G&, ;1QS75W_C/6?"USK=MKIL+U[734U"VEMHF@4EI#'Y;AF;
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M!U&]LAV+'<<], <<5T^MW=U8Z)>75DENUS%$6C%S)Y<0/J[=E'4_2@"MX?\
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M$ $+D?>&3P:?)X^U.PT>Y@U";2X=4BUHZ0+R7,=L!L$GG,I;(^0GY=W7'/-
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MSB>-2Q,;]N2<$'UK,GT_5+WX_N)9]+E\C2%FB\^R9PD/VCHOS\2?[?3_ &:
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M8ND<\6,') )!&0>.C&NLKG-8\<:+HFK'2[MKQ[P0K,8[:REGPA) )**<<@T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7GOQKLHKGX7:K.[3![=49 DS*I)D0?,H.&'/0Y]:]"K*\2^'[3Q3X>
MN]%OGF2VN@H=H6 <88,,$@CJ!VH XTZ5'<>+-*\*F\U)-)CTN3498Q?S;YY"
MZ( TF[?M7).T'&2*PM3OM5MM-NM$MM7OD^Q^*[6RM[LS,TJPR!&V,QY?:7(^
M;.1C->CZQX6M]5GLKN*]O+"_LD:.&[M&4.$;&Y6#*RLIP#@CJ.,543P)I2Z9
M;V1FO',6I)JDEP\@,L]PK!MSG&"#@#  X  Q0!R]UX6L;+XI>&+1+G4WC2QN
MI0TFH3,Q970\G=T))R.AX!S@5A/ITEK\._$WB.#4=0AU"PU2]EM/)NG2.+;<
M-D% 0K;N<[@>#CM7J&L>%[?5]9TW5A?7MG>6 =4>U=1O1\;D8,IR#M'3!J&3
MP7ILOA?4O#[2W7V/499I9F#KO!E<NVT[< 9/&0: -36)'30-0E1BCK:R,K*<
M$':>0:\KT"?4-:T;X;VUQJVH*E_#=_;'CN762<*N0"P.>W7J!G!%>NW5LEW9
M36DA81S1M&Q7K@C!Q6#I?@G3-)BT".WFNF&AI*EKO=3N$@PV_"C/MC% %'P2
MLECKGBG15N;F:RL+R+[,+B9I6C62!'*[F))&2<9/>LF^;7E^,&H_V#%ILDG]
MC6_FB^D= !YLF,;%//UKMK#1;;3M6U7487E,VIR1R3!R"H*1A!MXXX4=<\UR
M>O\ A^XOO%$VK6UOXIM;@P+:M+IMW9QQRHK%@<2-NZL>N/I0!KSV&O:OX;O[
M76[JTTRY(W076EW$G[K'(8E@O0CD=",@URO@_7;[QLVH:O?W7D_V;9_9H[&&
M1E25G3+7+*<;E?\ @SD  GK5QM"U"?2[S3KV#QG>VUV%65;B^L2=@.2H(<$!
MNC=R.XJ_/8&76+?4X?"^M6LT-HUDRV\]FJ2PGHC#S3D*>5QC'TXH Y'1=/DT
M?P7X!UJWU'4/MEQ=6-O*#=/Y302?*8_*SL  (YQG(SG-5M9OKRZ\+_%*.>[F
MD6WU%$@$LA98EW)PH/0>PKLQI170=&T<>&]>^S:1-;S6[?:+/>S0G*[CYN".
M.< ?A5.;PS#<67B&TD\-^(#%KTXGN_\ 2;/*L"#A/WG X[YH G:P?POX^\-P
MVFHZA/'JR7,5ZEU=/,)&2/>L@#$A3D$?+@8.,5P=JLVO?#KPQ/J5[?3S'Q2L
M!D-W(&*-,1C(;J,#!ZKVQ7?:=I5U8ZU#JD^D>)M0FMHFAM%O+JS9;9&QNVXD
M!)( &YB3@=:HIX3CA\*Q:!!H/B2**"]^W0W"W5EYT<P?>"#YF."3P10!Z+&L
M5C9*A=A#!&!OE<L0JCJS$Y/ Y)->%2ZC!XHTCQ-K+V&M'5=1N$ETB:'2YY%A
MC@.;?:X4@;CDG']ZO3-2%_JOAF;0[G1/$/ESV_V>6Y2XLQ,ZXPQ)\S&6&<\=
MSC%7;&^N].L+>RM?"6J1V]O$L42":U^55& /]=Z"@"QX3U^/Q/X6T_6(QM-Q
M$#*G_/.0<.OX,"*\[\5:A(EQK&LZ;_;]S/8W\<8OUNA%:6Q5T5H1$9!YB]0Q
MV')8\\5W?A/28]*_M0PV&H6,=Y=M=F"[DA=5=_O>7Y;-@9&<$]>E4;_X<Z;J
M U&&74=36ROIFN6LXYE$4<[')D7Y<YW?, 25!YQTH YB/0K6;QA\2':>_#10
M0,FR^F7EX&<]&Y&>@[#@8%1:1;VEK\//!NGJ^N7,FH0K<&PL;M@]SB$;AYC2
M+Y4:Y4X#*,XXYKN8O!EK%KMUJO\ :.H,][;I!>PLZ>7=;4*!W 7(;!_A(&>U
M4+;X=6UG8:=;6^O:S')II86=P)(C)#$RA3$,QX*X4=03D=: .3TS4-1U&'2O
M#5Q<ZC:6T^O7EI+ONLW"P0QM(L)E5B3S@$ALX&,UH^+/#TNEZ;I>GPZQ>26T
MWB*S-MYLADEM%/!59&)+<Y(STSWK>7X<Z5%:36\-[J46Z\6^@D693);3A=K.
MC%226YW!MP.3QS4\'@/38XT,UW?7-U_:$6HRW<TBF6:6,80-A0-H'&T <4 <
M=KUU=^"K_P 3VFCWE\T/]B0W<27%R]P8IFF>(NID8D<8.,XR*7[3K7AN'4[_
M $[2O$%K8PZ/<RSG5[I9P;E%#1R+^]<@GY]P&!TXKOM0\*:9JFIWM[>+)*;S
M3QITT18;#%N9N.,ALL><^E5[#P?!;&?[=JFIZLLMLUF$OI594A;[R@*J@DX&
M6.3QUH XJ\T)-,7P!>+J-_<37.J6[7/VF[>832&"1O, 8D*>H^7 PWL*VOBW
M91W?A>R\QYUVZG:+^ZF>/(:90<[2,^WH>1@U=M/AU8VTVEO-J^KW:Z3*LEC'
M<3(5A !4+P@W#!')R>!@CG.WXC\/VOB;1GTV[EGA1G25)8&"O&Z,&5E)!&01
MW% '*1:4FO>-M5T6[O-173=%L[5+:"*^FC+/(')D=U8,[#: "Q/?O6O\/;^[
MO_"@%]</<S6MU<6GVB0Y:58Y616)[G &3W(I]UX+2>YBO8-<U:TU!;<6T]Y
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MI)H+J.5/-!<DL#E=K*=QX*^E;6AZ)!H5B]O#-/.\LK3S3W#!I)9&ZLV !Z#
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M%9VI?#S3=4DU1)[_ %);'4V,ES8QRJL)E*A?,'R[L\ XSMR <4 9@TMO$GQ
M\365]J.HK8VUO9M%;V]Y)"JNZ/EOD(/&.G0GD@X&,/PW=WOB[_A#]*U74+TV
MYTB>\N#%</$]S(DJQ)O="&. 2W7D\FO1=)\.P:3J%Y?K=75S=7D,$4TEPRG=
MY0(4_*HY.XY_I62/A[I\&GZ1;V.H:C93Z2LB6UY!(GF['.65LH58'C^'L* *
MGPYMC9W7BZV-Q+<>7K;J))6W.0(8L GN0,#)Y..:S-1U&^3XE^*K9;VX6WA\
M-^='$)6"H^3\P&<!O<<UV7ASPQ9>&8KU+.:YE-[<FZF>YDWLTA55)S@==N3[
MD_2HI_"&G7&OZCK+RW(N;^P^P2J&78(_51C(;WR1[4 </9VUSIFF> ==75=2
MFU#4KBU@O&FNY'CFCE@9BIC)VC! P0,\9))YK0\.:5<^*--/B:36]0M-4?49
MC&5N',,44<[((?)W!"I5,'(SDYS75OX5L'TS0K R7'DZ++#+;'<-S&)"B[^.
M1@\XQ6;-\/=-FO96-]J*Z=-=?;)=+65?LSS;@V2-N[!8!BH;!/:@#FQ:3>(=
M'\6Z_<ZIJ,%_8WEY#8F"\DC2U6#(7Y%(5LE<MN!SFFZ4UYXO\:V7V_4+Z&T?
MP[9:A):VUP\2M,S,<G:>G)R.^!GI747_ (!L;ZXU IJ>IVEGJ3^9?6-M*JQ7
M#$ ,3E2R[@ &VL,UJVOARQL_$#ZS!YB3-91V(B!'EK&C%EP,9SSZ]* /-#97
M=UX)\6>(GUO5%U'3+Z_>Q9;V0) L4C$)L!VL#C'S \$ <"MS386\<>)M9&J7
M=_#!806B6UO:7<EN$:6$2-(=A&YLM@9R!MZ5#H/@(ZEIVKPZG=ZM9VMWJ]W)
M<6*,$CND,S%2=RE@&7'W2,BNHU+P=!>ZI+J-EJ>HZ3<SPK!<&P=%$R+G;D,K
M8(!(##! /6@#S^RO=5\3?\(!97>KWL:W:ZE!>R6\S1M<+"0JDE>YV=>OS-C&
M:M>,G$7]NG33XBNY]%L56.:WO1#!I[I%O!;=(OG,1M9LASC KNK;P;I-G<Z#
M+:K+"NB12Q6L:L-I$BA6+Y&2>,YR.2<YJKJ7@/3]4OM2FEOM0CM=3 ^V644J
MK#,P0(&/R[@<!> 0#@9!H Y2&%/^%G7NLNUT]Q%X;AOP@NI ADW/D;0V-O'W
M>F><9YJ'PG)KDTOAO58-.\1-/=;9-4NKRZ1[:XBDC)+*GFG;ABI7:HXX-=G;
M^![:VU>PU--5U(W%K9K92;GC(NH58LJR#9S@D\KBETGP3;:1=VKQ:IJDMG9%
MC9V$LRF&#((XPH9@ 2 &)Q0!YO?64FI_"!/%5UJ-\^I7UQ#-.'NG,3*UTH$8
MC)V +QC !RO7DUZ-\2?^2:>(_P#KPE_]!JE+\,=+FM)+ ZGJRZ69_M$5@LR"
M*!]^_*_)G&<\$D#)XS@CI];TBWU[1+W2;MI%M[R%H9&B(#!2,'!((S^% '!7
M-O+X4\0^&KJUOK^X>^M[H7J3W3R).4MS(I"$[4(9>-H  .*S_"<NN7#^&]6@
MT[Q$UQ=E)-4N[NZ1K6>*1"25C\T[0K%2NU0<#!KT>ZT"TO-1TB]E:7S-+,A@
M4$;6WQF,[ACG@]L<UFZ5X)M=(N[5X=4U22RLV9K2PDF7R("01QA0S  D ,Q
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MX41R+Y>?,+YX"C'49SD8SF@#HZ*Y"[^(-E9:-J=[-I]YY^EW"6U[:+L+Q,Y
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MGMYHG()CD0X9<@D'L00<$$5RMEI\-]\6?$=I</<-;165K)'$MS(J(S;MQ #
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MD*.PZGVH NT444 %%8,?BW3Y_%4_AVVAO+B[M@OVF2* F&W+*64._0$@5O4
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MUWQ!IOAK3OM^JS216V[:72%Y<'!/(0$@8!YZ5H0RI<01S1-NCD4.IQC((R*
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MBR]RN5.,E20*ZVU\&[([B._U[5]062U:TC\Z94\F-L9(\M5R_ ^<Y/'UJ)/
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MO',DH$.XC/89'&,;<G;@UD?V7>-8>.8#X@UKRM"=VT[%_('B;R%E^9LYD )
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MPL&X%AWP>>:D7P);W*7HUG5=0U9[JR>PWW/EJ8H6(+!=B*-Q(4[CD_**;;>
M8%O]/O=1UG4]3FL$DBA^TM&%$;QE&4A%&>#UZD@<]J .3T+4KF+Q)X9N+6;Q
M'-;ZI-*D]YJ4H%O>(87D5HX?,)CY4%<*OR_6J8_M)/AHWBQM=U9]3M;]_)S>
M/Y8C%X8]C)G:X(SRP)Z#H *[.U^'<-L=*9M>U:5](D4V!=HOW$84H8\!,,"I
MP2<MP,$5>/@G3SX-D\,?:+K[')*TIDW+YF3-YW7&/O<=.GYT 8/AO2XU^+WC
M"X^TWI:%;1E1KJ0H?,CD)!7."!_"#PO;%'C32X[[XF>"A)<WL0E^UJP@NI(@
M-D6X$;2,$Y()'4<'BNEC\+QV_C"X\16^H7<+W4:)=6J[#%/L5E0G*[@1N[$=
M!1XA\,1Z]>:9>KJ%W87NG2.\$]ML) ==K@AU8$$>U '%^3>Z]HGBOQ%)K.IV
MU]8W5Y'8K;W;QQ6ZP9"@Q@[6R5RVX'.:[[1;QM9\+:??7("->64<T@'&"Z G
MZ=:Q;_P#;7DVHI#J^I6>GZG(9;ZPMV01S,0 QR5++N ^;:1FNBN8(8-)DMX[
M%KB!8?*%K%M&],8VC<0.GJ10!YZR:[X'\+?8M4TS3?$/A.RA"M)&=LZ6Z\[G
MB8%),#'0C.,UG:GJFJZUJ/B.XL(?$LMU9W'D:4^G2!;6(K$C#>A=0^YFRVY3
M\I %7QX5NC9+I4EOXRDT)0%&FM<V.PH.D9?S/,*=L;NG&:NW^BW5U?W<]IIO
MBG3H+_;]MMK.>R5)RJA<Y,I9"5 4E",@#ZT )!;7WC+Q)KMO?:EJ6FG38;:*
MWAL[EH1%+)")&=@I&\@L  V1A>G-00:,_P#PN>S%YJ5[/<Q>'UFDDCG>)))%
MF5"=@; 5L9*?=)YJSJ^C76HZC/?6FF>*=+ENX%M[P6<]CBX1<A<[Y6PP!(##
M!Q2C17M]9TK4M.T+Q%8-IUHMB(H9;(I-;JP81MNE)ZCJ"#[T <UHVN:Q=^#(
M+9M5O!-J/BE].>Z\XF6*$L20C'.WA=H],\5IZZ]WX6O=?TK3]3U%K27PU<W\
M7VB[DFDMYHSMW([$L 0P/7J.*MV_AF&W\.3Z,OAWQ)Y<E\=0CN//LQ+!.6#!
MD(EP,$<9!]\T]-"N)8=5.I:3XFU"\U*R:PDNYI+%7CA(/RHJR!5Y.>AR>M $
M4%O>:/J_@J^&L:E<S:JQAODGNG>*7-NSY$9.U,,HQM ]\UWNHVMK<I ;B"WF
MFAE$MJL_03 ':1Z'D\CWKF)[>6X?0V;PWKP.COO@Q+9_.?+,?S?OO1B>,<T_
MQ#%-XCLHH+CPWK]O+;S+<6]S;SVBR0R+G#*3,1T)&"""": *7AB2^?XC:L_B
M""*VUF33XO(AM6WP&V5V^8.<%FWL0<JN!C&:;XBTW^UOBMH]JUW<VT)TBY,I
MMIC$[J)8OE#KAEYP>"#QCO4NAV-YI&IW&JW6D>)=4U.>)8&N;N6R!2,'(152
M5549.3QR:36M/NM7UNUUF/1_$MCJ%I \$$MM+984,022K2D-TQ@\<^N" #E9
M-9U.UN#X6:XUF^M8M=FMR]I-F[DMU@$PB\PL#PS<MN!VKC-5O&C:FOPF\26]
M[;:I#91W]L; ZHP:?RB\9*EMS$@/NP22<$5U">'6BTI+>/1?$RWZ7K:@-3$U
MEYYN&&&<_O=I!4[=NW&.,4:AX>EU?PM>:'J6E>*KK[;.MQ/=/<67F%E*D!1Y
MNU5^0# 4#\>: +C6LOBKQWK]A>:CJ-O9Z3%;1V\-E=O;Y>1"[2,4(+'H #P,
M'BL'P[XGU&TN="U/5]1GFLYK6_L+AF<[&DMI&9)=O3<T:.">^*W-4T^_O=8D
MU6PTSQ/I-Y/"L%R]I)8D3(N=N0\C ,,G##!&:JZIX8M=3\'VGAD^&/$-O96K
M!XWAN+3S,X8,2QF.=P=\^NXT <_9Z[X@M/"&L:==:A<MK6JBSGL'>5B\7VW"
M;4/4!&5R,=*]C@B\B".(.[[%"[G;<QP,9)[FN'U#2DU+Q-I.NR^&->2?3%*Q
M0I-9B-^#MW#SLG;N)&".376V5@T-_>7[75XWVP1G[+/(&CM]JXP@'"YZG!.3
M0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ#)QV"L0OX&L3Q/JWB&U^(7AC3=,^R?9+N.Y=TEE=?,**,[L*>@8%?4YSC%
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M'&2 2!GVKQF/6_$&J>"?#6IZC#!=3OXD0VRQS-OD(EF&ULKA0"  1GY1GVH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGG@OFNE58_-B5&5D/S;@5..QR,D5;M/"^JQ>./"^J/"@M=/T4V=PWF#*RX'
M'?ZUWU% 'E$/A;Q%%X5CT2XT..Z@L-9-XT1NDV:C TDC[<'I@LAP^ =M$_@[
M79;7Q%!!H=G91:I)8W$$-M*BI#Y,J;HV Q\VU2V0,9R 3W]6=@B,[=%&35/2
M-4M=;TBUU.R9FM;J,2Q,R[25/3CM0!AZQH5[?^,[*_B51:II=W:O(6'RO(8]
MO'4_=-+\/K/5=+\'V.E:OIXM)[");<$3K()0H^^-O0'T/-=))<012Q1231I)
M,2L2,P!<@9(4=^ 3QV%24 <Y)I%XWQ)@UH(OV%-(DM2^X9\PS(P&.O13S7.7
M/A'6)?AOXAT98$-[>ZC/<0IY@P4>X\Q3GH/EKT:B@#R?Q#X*UG4AXIMH]!L+
MJ[U&9IK;5[B5"R1[%VQ*"-RD%2HZ*,YSV,WQ#T^]OM2\/-9$6>J:U$^D7EOO
M#.+9P'D;(X/E[6Y_VO>NW@\6:7=^)9] MC<SWEOQ<-';NT4)*[@KR8V@D=L^
MW6I1I&AZ?K3ZP;>VAU*[(A^TR-\[D]$4D]\=!UQ0!I6]O%:6T5M @2&)!'&@
MZ*H& /RKA]0\.ZI/XTUX_8A+I6NZ8EG)=+,H-L5613E#RV=XZ5UUGJ]I?:EJ
M-A [&XT]T2X!4@ N@=<'OP15Z@#S[PEX;GT^^TU)_!6B:?)91%9]2C$3/,X7
M:&BVC<-W));'!QSUJ&#PCK$?P1N/##0)_:CP3HL?F#;EI68?-TZ$5Z/4:7$,
MLTL,<T;RQ$"1%8%DR,C([9'- '.ZAHU[<>-?#6IQQJ;6PMKN.=MPRK2",+@=
M_NFN2UOP3KE[I&JV\%O&TEQXH34HP95&8 $!;Z_*>.M>IT4 <[I.DWEIXV\2
M:G,BBUODM%@8,"6,:.&R.W)%<3IO@W6=-LO#2WWA^TUE;+3I;9K2>>/9;SM(
M&$GS9!!7@D D=A7K%4K[5(;"YLX)8KEVNY?*0Q0LZJ<9RY PH]S0!YO:^%O$
MNEZ/X<6/28;FXT/5KF5H8ITC6XAD,A#IDX4#S!\IYXJ>;P=<6^K:KCP9HVK-
MJ%X;J&_O/*(@\S!=) 1O.UMQ&W.01TKTZB@!%540*H"JHP !@ 5Y?+X6\1-I
M/B71AIJ&.[UP:G;70N4VR(;F*0KMZ@A5;KZ<5Z:UQ EQ' \T:S2AFCC+ ,X7
M&2!U.,C/U%5M.U2'4VNQ#%<Q_9;AK=_/A:/<R]2N1\R\\,.#0!CW^CWD_CVQ
MU6.-3:0Z9<6SMN&0[O&5&.O13S7+>'_#.M:+\,M%T'4/#ECK"Q-,+ZQDE3<-
MTC,C(S'8<9YSSSP>*].HH YWP3I-YHOAQ;2\3R3Y\KPVWG&7[-$SDI%O/7:,
M#].U9&J>#9/%7CR2^UZ!CH^GVHBTZ-+AD9Y7.9)/D(*X "XSS7<T4 <!<^ D
MT+Q-HFN^%K9Q+%,;>_BENW?S;5QR<R,>5(# #&:Y'58]7T[X4S>'XHK&;3K6
M[2"/48;M9!<+]J&U%0<B3)"D'I@]:]MK"'@WPX-9_M8:/:_;O-\[S=G_ "T_
MO[>F[_:QF@"GHVA7=MXK\77EU&!::I);F!@P)95@"-D=N<]:YWPKX/GT>;2K
M";P9HBO8-B76BL1:54!V.@ WB0G:26X'/)XKTNB@#S'0?!<NCW%IIS>#-%G^
MS79?^VI5B):'>64A<;_- P.> 1G/:KEQX4U:3P1XVTQ84^U:K?7<UHOF##+)
MMVDGMT/6O078(C,02%&>!DU4TO4HM7TV&^@BN(HY02J7$+1.,$CE6Y'2@#F/
M$GA:[US5M$& MI%I][:74FX90S1*BX'?H:H>$_#4^GWNFI/X*T33Y+*(K/J<
M8B9YG"[0T6T;ANZDMCC(YZUZ%4;7$"7$=N\T:S2AFCC+ ,X7&2!U.,C/U% '
MG\7A+5T^%6CZ"8$_M"VN;:25/,& J7 D;GH?E%:NBZ;JVE^/_$5Q)8!],U5X
M9X[M9E^0I$$*E/O9R.HXKHM.U2'4S=B&*YC^S7#6[^?"T>YEQDKD?,O/##@U
M=H Y?QUI%YK&D64=K9I?I!?17%Q8O($%U$N<IEOE/)5L'@[:XZ\\%Z[=Z1XP
MLH-%L;!-9MH)+2&WE0)$\9QY38Q\Q SN VY.,\9KUFB@"GI=Q=W6FPS7UB;&
MY8'?;F59"G./O+P>.?QKS;Q'X+U?4Y?%=NF@V%W<:H2]IJ]S(A,,?E*!$%(W
M*0RD C ^;.>,'U6L33?%FEZQK5YI=@;F>6S=HIYEMG\E)%QN3S,;=PSTS0!G
M>&M+U*#Q'KFJ7UH+9+^"S$<?FJY#1QL'!QZ$CGO7*:MI%YX9^#VBS3B.'6]!
MEBGMTW;@\OF;?*!'7>KE<#UKU.2XAAEBBDFC229BL2,P!<@$D*.YP">.P-8<
M%MX>\3:H=4^R)<WFE7+VBRRH?W4B'G:#QP3PV* )?".BMX?\+6.GRMON53S+
ME_[\SDM(WXL367XITW5G\7>&=<TRP%]'I_VF.>'SEC8"55 8%N"!MY'6NB;5
M(5UI-*,5SYS0&<2"%O*VYQ@OC&[VZXJ[0!Y=>^"M;FT[XBPI;QE];E5K$>:O
MS@+CG^[^-=9J&CWEQXW\.:G'&IM;&VNXYVW %6D$>W [_=-=+69I_B+2-4U2
M^TVQOXI[VP8+<PKG,9R1SZ\@CCI0!P5YX&OY)[N_FTFTU+R_$$]\EA<,A6YM
MY(5C/WLJ&!&X;O[M=?X2TUK"SN7;P_IVA^=-E+6S5-VP  &0I\I;.[IP!CDU
MT-% ')>*-/U9?$N@Z]I5@-0^PK<0SVPF6)RLH7#*6XX*<C/>N,US2]>L-+N[
MJ\M[:&]U#Q58W5L@EW(,^4JAB!G@K@G';(%>P55OM.M-2CA2\@6989DGC#9^
M61#E6_ T <)J7AC6/&>I:I<ZI8KI,+Z/+IMLC3K,S22,&,AV<!1M4 =3STJP
MNG^)?$%WX=M]7TF+3[?2+A;NXG%TL@N)$1E41A>0I+9.[' Q7>T4 >=R>$M7
M;X3:AH @3^T9KF:1$\P8*M=&0<]/NG->B444 >=Z;X(O1XSU@W\<9T!ENFL@
M'!):Z$9F!7M@J^/]\UEVO@?Q')\-_$EGJ$43Z[J,,5K&%E!5HX8T1,MT!.'8
M_P"]7JCW$$4T4,DT:2S$B-&8!G(&3@=\#FI* .,\=^'=1UW2-!M[")7DL]6M
M;J8,X7$:9W'GKUZ5&NBZQ!XX\32K8K)IVN6T*K=B91Y#1Q,F&3[QR2.E=5JV
ML:=H5@]]JEY#:6R$ R2M@9/0#U/L.:S]%\9>'O$-T]IIFI1RW*+O,#HT<FWU
M"N 2/<4 <-;^$=7E\->%UU/PQ:7D^@*UM)87$\4BW431A3(A.5!!52 V.AZ5
MK1^&+UXM!E@\/Z;I M];%Y+:V>Q=D(B= 7*X#/DC.WL1Z5Z!10!SNGZ1>6_C
M[6M6D11:75G:Q1-N&2R&3=QU'WA1XJTF\U6X\//:(K"RU:*ZFRP&(U20$C/7
MEAQ7144 <!XF\&:AK^J>)3&T<,5_IEK#;2LV1YT4KR ,!R!G;S[FK4=GK_B'
MQ/H=_JND)I5MI!EF8&Y28SS.A0!=O10&8Y.">.*Z'6O$&GZ!]@^WR.GV^\CL
MH-J%LROG:#CH.#S6@MQ ]Q) DT;31!6DC# L@;."1U&<''T- 'DEQX-\37'P
MQN?"ATN-;BVU 303_:4*7"&X:0D#JN 1P>M=5>V7B#0O%FKZMHVE1ZI#JT$(
M9#<K"8)HU*@G=U0@CIR,=*[6B@#S;4/"FH#6EU?4O#6E^)[BZL(8;E7$:>3<
M1[LLGF#[C;L''/RC@UW6B6;6&B6=J]K9VLD<0#P62;84;JP0>F<U;BN()WE2
M*:.1H7V2!&!*-@'!]#@@X/8BI* . O?#.J7/BKQ9 ]F&TKQ'8QP?;5F4&W9(
M73E#R<EATID>E>)M:C\.:7JFE164&D7,-S<WBW2R+<-"#M$:CY@&;!.[&!ZU
MVAU>T77DT8NWVU[9KH+M./+#!2<^N2.*O4 %>7:/X6\10:#HNBW.FI&-)UU;
MO[0+E&6>$R2N6 ZC =>#R<UWNO\ B#3_  SI9U'4Y'2V$B1Y1"QW,<#@>YH7
MQ!I[>*'\.B1_[12T%X4V';Y6[;G/3.>U '*^*?!M]XAUG7600K;WFC0VL+R$
M%3-',\@#+UV\KGZFKGA71VMM6:Z/@K2- 1(-AD@$332.2,A3&.$P#UY)QP,5
MTNK:I#H]@UY/%<RQJRJ5MH6E?DX^ZHSWJ[0!@^,/#S^)?#TEC!<"VO(Y([BT
MG(R(YHV#(2/3(P?8UBRW_P 0-2M%TY-$L])NGPDNJ?;%FCC'\31QXW$GL&P!
MWS7<44 <0;+Q#X<\2:W>:7I2ZM;ZMY4RG[2D+0S+&(SO#=5.U3E<D<\57\/>
M"]0T+4_"F]HYHM.T^[BNI5; \Z5T?Y0>2,AORKOZ* //KCPIJTG@KQMIBPI]
MJU6]NIK1?,&&60+M)/;H>M4].NM<TSQYXM_LW2%U+]U8HT0N%B9'$'!RW!4\
MYQR,# .>._UC5[30M-?4+YV2W1XT)52QR[JB\#_:856L7TY?$FJQV]G/'?,L
M3W4[0L$EPN$PY^5B!Q@=.] '!6G@?5-'704N-%L_$$=MI\D#PS2H(K>Y>7S&
MDPX.5.2N0"V%Z<U;\,>%-;TZY\+1WEI%''H\VH++)'(NUTEYC=5!R <XQU&*
M])J."X@NH5FMYHYHFSM>-@RG!P<$>] '*VOAII=0\9KJD:#3M8D0(=X^:/[.
ML;$^F"#U^M8OPJM-0ET.[U^^=+J\G1+.TD!P)+>W!1&!/3>V]O?(-=-XVG\/
MVOAJ6?Q-"9=,21 Z;6;+%MJ\+R>36]!!%;6\<$$210QJ$2-% 55'   Z"@"'
M3);R?3+:74;9+:\>,&:%'WJC=P&[_6K5%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<-\5N/"5L
M3T&J69)_[;+7<UGZYHMCXBT:YTK48R]K<+A@IPP(.0P/8@@$'VH Q/B80/AG
MXBR<?Z#)_*L&"#4-8\96^C'6+^RTV/P]:W#16DOEL9"[KG=C(X'..N!VX.G+
MX!N]2BCL=<\5:EJ>DQLK&SDCBC\[:<@2NJAG' STS5:_T74+WXK7-S87USIK
M1Z)#&ES'"KQM^^ERA##:?X3ZCCL3D QM-UK6=6DT;PO/JUTA.I:C:W5_"0D\
MT5J?E&['!;<N2.?E/K3=;U;6M"LO%FCVNKW4C6$NG2V5U</OEC6>4*R,W!89
M4]><-C-=6O@"UM])TZWL]1NK?4=/N)+J+4<*TC2R9\TN"-K!MQR,>GI0_@&"
MXTO4H+W4KFYOM3G@GNKUD56;R65D55 PJC;C'N3F@"M8Q7NA?$>STS^V-0OK
M2_TV:>5+R4/MEC>,!EX&W(<\#CVJ'XL6IN?#^F8NKF ?VM:(1#)MW!I5&3[C
MJ/0UU,^AQ3^)[/7#,XEM;:6V6, ;6$C(23[C8/SJ/Q1X>C\3:-]@>ZEM72:.
MXBGB +1R(P93@\'D=* .-M/#\NH?$/Q)9#6=3MH8+&P5I+>?9-*VV0*S/C)Q
M@G'<GGI6/9^*M4U?3?"]G?3ZU(LNG37-W)I$9\^=TE$2Y*\JO4G'4D5Z1I'A
MXZ9JU]JDU]+=W=[!!%,[HJ F(,-P"\#.\\5DP> 5T_3M)BTO5[FSOM,26**[
M$:.7CD;<R.A&",@$>A% %[P1=:G=>'0-6CO%GAN)8HWO(O+EEB#'RW=?4KC/
MN#7$:UK>KW^K^)'LW\2"ZTZ<V^FQZ= 7M@Z1JW[W'#EF;D'HN,5Z9I&GMI>F
MQVLE[<WLBEF>XN7W.[,22>. ,G@#@# %8E_X.FGU*^N=/UZ^TR'42K7L%NJ?
M.P4+N1B,QL5 !(] >#S0!QMYI4FI?&?2))K[4[26ZT1KATCG*M"V\9C7CA?4
M>M9FE+-X9NOB3K-MJ&H2W&ERDQ+-/N65C"<-(,?,02#^%>I2>&;>3QC:>)/M
M$HGMK)K-8NJE6;=DD\YJM;>"]/AD\2>?))<0Z^^ZYB; "@IL(4CVH X^RUK5
M]$G>ZAC\37=HFFW,UZ=8@*H)HTWHR'^'<0RE1QR/2MO0/#^KW.G:5JC^*-2D
M>^M-^H1R."C>9'G,( 'E%6(P1V'.:U=,\*W-LY74]?OM5MEMFM8[>941-C8!
M+A /,;  R??CFJ^C^"'TR[TXS:]?WECI8(L+.4(JQ?*5&YE ,FU3@9Z4 >;V
MESJ&@_ .SU2PU6^2ZN+Q 6,V=@-RRD+Z ]_6O0#KDWA[QSKEMJMW(VFS:>-4
MM"YR(A$-LR+_ ..MCW-0?\*RB;PC+X8DUJ[DTT7"SVRF) T $ADVY ^;)/4^
ME:WC#P59>,8[);NXFMS:R,=T.,R1L,/&<_PL,9^E '!6^L:W,NB6>KW&O,;^
MSFU>X32E+3+OD BCR.41%/('?%>@^";K4[KPVG]K1W:W$4\L2O=Q>7++$KGR
MW9>Q*[<^^:DUKPVVHWMGJ.GZC+IFH6D;PI/%&KAHFQE&5A@C*J1Z$5HZ3I[:
M7IL5H]Y<WLBEF>XN7W.[,223V R> . , 4 <7LU'Q)XB\5.-9OK*/272VLX;
M>0+&&\D.SR+C#Y+8P>P_&N>T.Y$OA#PEIZZEKNX:.LIL=%CQ+R0!*\F<!1@@
M*>ISUQ7<7_@MKC6M0OK+6KRPAU-$74+>%$(FVKM!5F!*$KP2/T/-5+3X>C34
ML%T[7;VT^SV":=.R(A:>%6++R1\C99OF'K0!R$#7GB75/AG?7VI7T=Q=6]V)
M6@E\O+1QGY\ 8#-DAO4<4^+Q#KE^T^L6:^)9K]=3=(;>&W+6)MTF,9C/8G8I
M);J&^E=5'\.A:V>BQ6.N75M-HTTS64WDQN4BD&&C((PW'0GFKL?@V6WOY#9Z
M]?VNERW9O)+"(* 9"V]@),;E1FY*@]R,X- &OXDU-]&\,:KJD2!Y+.SEG13T
M)5"0#^5<,Z:KH%CX6UAM?U*\GU*\MK:_BGE#12"<8)1,80JQ!&W' YS7HUU:
MPWMG/:7,8D@GC:.1#T96&"/R-<K8>!6MYM+2]UR]O]/TEQ)8VDT<:A&4%4+L
MH!<J#QG'J<T <Y\.-&$'C?QC+_:.HR?9=1";9)\K-F/K(,?,1G@UI?$RQ-YJ
M/@]1>WEN)-9CB(MY=G6.0[O]X8X/N:Z;1/#4&AZKK5_%/)(^JW(N)%<#"$+C
M ]J;XH\-CQ';V(2^FL;JQNTO+>>)%?:Z@CE6&",,: .+BT6XU#Q9X[\O6M1L
MEMVMC&;2;8S2"T3YG;&6Q@<=.3G/&*,?BC4=<_L"VO9==\M]!AOYSHD9\R2:
M0E=S%>BC83@<$MSTKT2P\.1V5WK-TUW+--JOEF9F4#!2(1Y&/4+GZFLJ/P(;
M"UTD:1K-S87FGV0L/M(B23SH1@@.K#&01D$=,GUH TO!EUJ=YX4LI=8BGCOQ
MOCD^T1>7(X5V579>Q90K?C7GAFNO#M]\2]:M;Z]ENK.2-84EEWIN>%-K,N.=
MI/'L,5ZMIEC_ &9IL%F;FXNC$N#/<OODD/4EC_D#H.*Y^?P-;W&K:Y<27\YL
M-;B"7ECL7:6$80,KXW*< 'ZT <M;:AK%A)>K:'Q.]FVDW+SSZO"5\JX104=&
M/W<_/E1QP,5"TFNV?PUT?6AXAOY-4U:73=TDC@QQ!W485,=PWS9SNQ796WA.
M]\FZBU+Q)J&H++9O9QJZI&J(PP6(4 ._ ^8^_ R:EF\(6TWA;2=!-S*(=-:U
M9) !N?R"I7/UV\T <U'I.H_\+ NO#?\ PDVM'3'TR._8FY_?"7S&CPLF,JIQ
MD@=P.V0<>T\2:T^G_#\2:E.\EQJ\]G=/G!N$C=T&_'7A1GWKTL:'$/%C^(/.
M?SGL5LO*P-NT2%]WKG+8K#B^'EE%%H48O;@C1[^6^C.T?O&D=F*GV&Z@#G+E
M=7U+3?'.HGQ#J=NVD7ES]ACMY=BH8X5<;N/F7)QM/'7UJ36M7GU-+9UU373=
M#2(KEK31HMH@D<%A+*^<$'& A[*3@YKL(_"EO'IGB&R%S*4UN::65L#,9DC"
M$+] N>:SSX#5+C-MK-Y;6T]G#9WL$:I_I*1*54[B,H2"0=O;I@\T <K9BX\0
M>-O NIW6H7L<UWH+7<BPR[$WXA+ #' 8GD=\"H[;Q1K?]A^*D349?M3^+&TJ
MUG?#?9HWD1?E!XX!./>NKMO +V1\/R6NNW4=QHL#6L<IAC/FVYV_NV!&. H&
MX<U)%\/=.72=>T^2ZN735]1?46D4A7@E+*P*''\)4$9H R=0:_\ "?B&+3H-
M7U&\M-1TN\DQ>3>:\,T*J0ZL>1D,1CID"L^QDU>QT?P-K\NO:C<W6J7%K!=P
MRR P/'+$3PF.&&!\W4G.>M=7;^#9'O)[[5]9N-3O7LWLH9'B2-8(W^\551C<
M<#)/ICBK#>$;9M$\/:9]IE\O1);>6)\#,AA4J WUSVH 3QYK%WH/@G4]1L65
M;N-%2%V&0C.ZH&QWQNS^%8S07OA3Q=X<MH]:U*_MM5>:VNH[Z;S?G6(R+(G'
MRG*D$#C!Z<5UVLZ1::]HUWI5\A:VNHS'(%." >X/8@\CW%8VG>$IX=8L]3U;
M7+K59K"-X[,2Q)&(MPPS':!N<@8R?4\<T 9'PM34M2\.VWB#5-9OKR>X6:%8
M))/W2*LK ';CE_E^\3T.*7QKJ]P/%&EZ*K:RMF]I-=SC1T)GD*LB*,CE5&XD
MXZG:*Z;PQH$/ACP];:/!,\T4!<B20 $[G9ST]VJ+7/#KZI>V>HV6HS:=J5HK
MI'<1(KAHWQN1E88()53[$4 <<^J>(+#P1'X@N9[Z&71;N7?#?KY37]INP Z]
M/,VD;3W8>]5K[6=;NOAGJ7BRWU62&YU*[MC91(^4LXOM"1A"!_$03O\ <D=J
M[ ^#DN(])BO]4O;Z*PN&NW2X8'[3,22K/Z*I)*H, <>E<[XX\)+:^$]?73VN
M7@U2]M)GLHUR(Y/M$7F.F.1N W'W&>.: +,@O_#'C2PL5UG4+ZUU2QNFD2\E
M#F.6(*P=.!MR&(P..G%<QINMZ_J7PX\ R+K-U%>ZGJC6US=!LNT9\X'KP2 H
MQGN!7?V7A&1-9.J:GK-UJ=Q';/:VWFQH@A1R-QPH&YC@9/MTJMIWP^L].T+P
MYI27L[QZ'>&[B=E&9&^?AO;]X>GI0!A^)-]E=-IEOKOB>ZEL=/#B*P&YXG)8
MB6>4D!LXP%/92<'-4K);C7_'/@C4KK4+V.:ZT%KN189=J;_W)8 8X5B>1WP*
M[+4O!_V[6KR^AU:[M(-0A2&_MHE3$ZIN PQ&Y.&(.WMZ'FJ=MX!>R;P_+;:[
M=1W&C0-:)*88SYUN2OR,", @*!N'- '*6GBC6SH/B=%U&7[5)XM;2;6=\,;:
M)Y(U^4'C@%L>YK3UN74/"&J26%MK&HW5M?Z-?3+]KG\UX)H45@ZL>1D-TZ9
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M/%3-X.MFT?Q)IWVJ;9KLLTLKX&8C)&J$+] N>: .5N+[5/#NL:!J+ZM>WO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9]@VH#\Y(90,]%''6HM#M[?4K3P5:W"V\]J/$&H@)$O[DJHG90JG/R=, ]J
M/78-;TJZMX[BWU.RF@EE$,<D=PK*\AZ("#@M[=:LRW-O!+%%+/%'),VV)7<
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MB "OSY+$8P:I>./&LUW\/+Z]TIK[2]0L]1AM;F&3"30MO7*G:2""K Y!((-
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M.K03K#&N7<1S([ #N<*>*Y^_U"37O&$&I6NFZC'IT.B7T1N;FT>$&1C&=N'
M(X'4C!YQG!KTJHKF!;JUFMW)"2HR,5ZX(QQ0!Y%I=W-KW@/P3X?M=,OUNXY;
M">:1K5Q#'#%M<R>;C8<A1@ YRV, U<,MWHWA3Q-X3?2-2N-3O)[U;(Q6CO%<
M+<%BKF4#8H&_YMQ&,&O2='TR'1=%L=+MFD:"S@2"-I""Q50 "< #/'I5B:Y@
MMVB6::.-IG\N,.X!=L$[1GJ< G'M0!QOA32+O2O&6HI/%(8H]'T^V6X*'9(R
M"4, W?MGZBKOPWM;BR\"6-O=P2P3+)<%HY4*L,SR$9!YY!!_&NJHH \<?3;Z
MXT+Q)I7]GZHMW;>)'U4+##)&9K?SU?,4F "Y7) !SD4_6-)M=1\)>*KC1K+Q
M+=W#Z<MM'/J7GLTV7W&.-)/G.TC)(&.>.]>P5#=7=M8V[7%W<16\"?>DE<(H
M^I/% '*>)K*YFU#P68;:61+?4E>4HA(B7R)!EL=!D@9/K4=E972>+?'4S6LP
MBN8+40N8SB4B!@0I[X)QQ73RZUI4,-O-+J=G'%<X\AWG4++G^Z<_-U[5>H \
MB\/Z1J4/B+X:22Z?=I'::++'<LT+ 0N8P KG'RG/8U8ETK4#\$=5L187/VQ[
MNX9;<0MYC WC,"%QDY7GZ<UZK39)$AB>65U2-%+,[' 4#J2>PH \B\9V^HZJ
M?%MA<V_B"YOV1DTJVM6F2T,'DJ=Q*81CNWY5B23A0*V]-NGA^)D%^]AJ(M-2
MT2W@@E-G)M619')5_E_=D @_-BO0+>X@N[=+BVFCFAD&Y)(V#*P]01P:DH \
M6\,Z/JNF> ?"]_-I=Z7TG69KBYM/(;SO)<RIO"8RV-X. ,D9Q5[Q/!>>*%\6
M:SIVG7_V0Z -.MA+:O')<R;V<E(V 8@9 SCDDXKUNB@#D-8L[F3QEX*FCMI6
MAMS=><ZH2L6;<@;CVR>.:3QE#<6NN^&O$"6MQ=6NF7$PNH[>,R2*DL13>$'+
M!3C. 3@FNKM[F"[B\VVFCFCW%=T;AAD'!&1W!!!J6@#RS5+:\U^U\>ZU::?>
MK;7>CK8V:2V[QRW+(DA+"-@&QEP!D<\UW?A.&6W\&Z'!/&\4L>GVZ.CJ0RL(
MU!!!Z$&MBB@#QR_MKW_A&?B#H?\ 9>H->W&J27L 6TD*31,\."K@;6/!X!SP
M?2NXUJUN)?B-X5N8X)7MX;>^$LJH2J%EBVACT&<'&>N*ZNJKZE81WZ6#WMLM
M[(,I;F51(PQG(7.3P#0!Y)X:TR.S^&^G6WB#1M9BV:E<R+<6<4JW%DQ9ML@"
M#?@@D9 (YYKT'P/+J<OA]CJ4EW*%N)5M9;V+RYY+<'Y&D7 PV,]0"1@D<UTE
M% 'F6A>'-:\1:WJ_BR?5=4T.:\F-M:P+!&'%K&<(6$J$J6.YL<=<UCZAX6US
M2[+Q;X6MEO-2MM2A75;.Y>( -.'!EB8J H9MH(&!UKV6J6K16-QIDUIJ,J1V
MUT/(8M)Y>=_R@!LC!)/&.<T <'<ZZ-=^(W@N6+3;^UA3[9N>]MF@;>8.5"L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(M6M_#HM]8@N(9HIY5A6YF667R-Q,>]E)!(4@9SVKHZ "BBB@ HHHH ****
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M&>]T^W\T))&RE<]"58 E3SST-;6F>+M"U;46TVSU&*6]5"_EA6&X X)4D88
M]U)H HVO@33[?4;34);_ %.[O;96B$US<!S)$P ,3#&"G&<  YYSS1I7@'2M
M)O[2XCN=0GBL=QL;2XN"\-KD$?(N,\ D#). >*F\5^,M/\(_V:+T,6OKI8%
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MZSN!=^8L=Y'$T4<Q7<3M4Y(P%/?G'O0!EZAI$GBOXBZ5>3:1<6UEH+2L;JX
M7[5(2-BH <E 5W[CW ]Z[RL2S\7Z!?Z9>:C!J<7V6R)%R\@:,P\9^96 (]N.
M>U4[CQ_H$?A[4]8M[SSXM/3=+'Y;HX)&5!4KD;NQQC\J %F\"://!X@A<W.W
M7G#WF)!U P-O''ZUJW>BVE[J^FZG+YGVC3Q*(<-\O[Q0K9'?@5AP>+;;5?\
MA'+FSU6WM(]1=@UK- S/.P0$HC<;2N>N,&KU_P"-O#FF:B]A>:K#%<1E5E!5
MBL1;H'<#:A.1]XB@"G8?#_2-/OK6>.>_>ULY3/:6$MQNM[>0Y^9$QGC<<9)
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M/*=H_ '\J[D1QB4R!%$C  MCD@=!FF"V@4(%@C C)9,(/E)ZD>AY- $M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIM)U!)I=PPTK)#(X!V[@R*"W?=UH ]8JEJVKZ?H>G2ZAJ=U':VL7WI)#QST
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M/T6R-YJ5W#:VX8+YDK8!)Z >I/H*KP^)-%N+6SNH=3MG@O9?)MI!(-LDG/R
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M?5=/N]*75(+R%[!HS(+G> FP=6STQP>:I:?XLT#5;2[NK'5K6>&S3S+AT?\
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MH-GH]H\KV]I&(XVE(+$>Y  _2M*H;2[M[^TBN[2>.>WE4/'+&P97![@CK4U
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<-\5(([GP_I5O,@>*76K)'4]"IE (KN:BGMH+I56X@CE
M5'#J)$# ,.01GN/6@#@/$BWT'Q-T]K75+#2U;2)$MY;VV\U"PE!D5?G3#;=A
MZ]!7-WEG%96WP]CM]3AU&!O$4DD=Q!"8HR&=V*HI)^4$D#D\#BO7K_3+#5(!
M!J%E;7D(.X1W$2R*#ZX(/-.;3[)UMU>TMV%L0T ,8/E$< KQ\OX4 >.^)-6>
MYT;59Q?:786XUY8_[.BMLSR/%<(&E=]WRDA-V=O"XYYJ_JLK2:G\5K:TF7[9
M/86Y@C5AOD'V4YVCJ>,]*],?1-)DGN)WTNR::Y39/(UNA:5?1CC+#CH:>NDZ
M:E['>+I]J+J)/+CG$*[T3&-H;&0,=J /++FUN;^R@GM_%.E7ES#H5Y]@M-.L
M#&[QM"% +"5L -Y> 1U%/NM0T.YT+X906,]M).E_9F-(F!:-!$0^0.GS;0<]
M\5ZA9:1ING2RRV.G6EK),<RO!"J%S_M$#G\:CAT'1[:5I8-*L8I'D$K/';HI
M+CHQ('49//7F@#D_'PNU\1^$I8+^UL8UN9U%Q=P>;$DIB.S(W+R1O .>IK%N
MX-.MO!GB7[;JD&M3ZCJ6V!-.@,&+XJ@58LLWS;E5BP/!W9Z$5Z?=V=K?VSVU
MY;0W-N_WHID#JWU!X-1Q:7I\$=M'#86L:6I)MU2%0(B>NT ?+U[4 >1OYMI\
M.?'=AK1SXJ6!Y=1E8@_:$*XB>,X'[L*-H'8@^M;6IW%A>ZIX BT":![F/S6B
M$+ F. 6S YQT&=@Y[UU_BSPZGB'P]J=G"EO'?7=F]JES(G*JW8D#.W/.*OV.
MC:=I\K7%O86D-W(H$T\4*J\G^\P&3^- 'E7A&TFN]#\&17/BC2X_LURCQ6,=
M@1<^<BMYL;-YIY_U@9BH]>](;>&/X":C(D:AWU"65F Y+B^P#]< #\*]9BTC
M38-0DU"'3K2.]DX>X2%1(_U8#)I_]GV7V,V?V.W^RDDF'REV$D[B=N,=>?KS
M0!YQK5U%HE_K%[8ZAI>I6$NHQ'4=&O8OWRS_ +M<Q-W/", 5(XX-8[V=U=Z=
MXIT^\\4:7I<4NMS"6&:P,EP&:4&%E(E!)(\O;A>P]*];DT?2YM1349=-LWOD
MQLN6@4R+]&QD4LND:;/J$>H2Z=:27L8PER\*F1?HV,B@#SO5KJ+1-0U2[L=0
MTO4].FU2(W^CWD6)TN"T:YB;N>$8 J1QP:]'MK^TO);F*VN(Y9+:3RIU1LF-
M\ [3Z'!!_&HY-'TN745U&33;-[Y/NW+0*95^C8S26&EP:?=:A<19WWTXGEX
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MZ+IESJ-YJEJ;N.V#I'Y40(#-(S' ^8[>,Y--D^(EG%I$%X^FWOVE]3_LJ6R
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MW^HR7NGS0J/(?S0ORR/G]WM8'.>W3-*SZKHWBKQ2#HE]=MK"0/:2VT>Z'>L
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M'V17\]8E#[7)Z#' Q@]3GI0!Z=17FUG+J>H_%^UN%U-HK:30(KO[/Y*D!&D
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ML2RCG('/%<QK7B_Q!X?T3Q9:R745WJ.C-9R6]WY*H9HIW PRCY=PPXR/4'%
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MC!!)4[<?=XQF@#U2BO.[O6_%&A:CKVE?:EUFYBT@:C9M]E".K;V0IM3[XX!
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M88JR,IRK*P(*L#T(.:HV/A#1K"TU"W6"6?\ M%/+O);J=YI)TP5VL[$G !(
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M *\G=]0*]B    X Z5B:3X0T;1+FUN+&WE66UM6M(6DG>39"S!M@W$\9 QZ
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M$SM)(K2,7=RVXN7SNW;N=V<\"H=1\#Z%JEX]S=0W!>5$2X5+J5$N54842JK
M28''S9XX/% '$^(M*DL]0O?$&OZ/'JUGY4#RWMI<A;G2FCC7?L!_ASE_E(/S
M'(->KJ0RA@<@C(-<]J'@?0M3OY;NX@G!GV_:(8KJ2.&XV@!?,C5@KX  Y'0
M&NBH X!])T_Q1\2]=M=>M8KVWTZRM19V\XW(HD\PNX4\;LJ!NZC%<?:VPUI/
M!6EWDLT]DFL:E9JS2',MO&) JENI!5=OTKU36/"FE:W>1WERMS%=I&8?/M+J
M2W=HR<E&*,"5SS@T^+PMHT']D"&R6)=(+&R5&8"(LI5N,_-D$]<]<]: -&SL
M[?3[*&SM(5AMH$$<4:# 10, "N*UG3K/Q!\5;72]7MX[NPMM&:ZAMIANC,K3
M!"Y7H2%  ]-U=Y6-K7A?2]?N+:YO$N$N;8,(KBUN)()%5OO+N0@X.!Q0!Y?H
MD,5IJ&G6\$C-#%XWNXT+.6.! X )/7&,<^E6/'$%O>2_$M9D27R-*LI%#<['
M"RD'V/.:[P^ O#G]CMI<=D\-M]J^VIY4[H\<V -Z.#N4X'8^OK4EMX(T"VMM
M1@6S=UU. 07K33O(TZC=C<S$DGYVYSGIZ"@#BKVPM-+\>?"ZUL;>.WM_+OF\
MN(;5R8%)./<DFLS2=-UG6+5-<M]"M!JK:L\IUF34 LH"W!5HBFW.S8#'LW8[
MUZ3:>"]%M)](G6*XEFTCS?L<D]U)(T?F+M899CD8  !Z=L4A\$:$VKG43;S;
MS<?:C +F3R#/U\PQ;MF[/.<=>>O- ''?V7%H?BQ=0U?2%N4NM7W6NOV=QF6-
MI)-J0RKUV D1\$KC&0*]2KG4\$:''JHU!8;C<+@W2V_VJ3[.)B<^8(MVP-DY
MSCKSUKHJ /)(/#>C:TOQ!NM3B6:>WU"?R7=CFVQ C!T_NMGN.NT>E5F*>*M,
ML9+O0X]8OK;P];2W<VH7GDPVQD0MO0;&/F':26P, #FNET_X?VU_?^))M;MK
MF-;W4WD00WCQK<VYCC #A& 9<A^&YZ^M=#>>#=#OM1CO9;6176)(&CBG>.*6
M-"2JR(I"NHR< @]<=* .&TB]DT9_!/BJ\G/V;5M*AT[4I7/'F>6)(I&]R0ZD
M_P"T*K6UM%J6D6%U?:5)J6H^*-3DU&*QEG\J%H50^6LQ(.46/:=N#EB.*W_$
MGA*6\T&V\#Z5I,BZ)(T;37T]T'6VC63<40,Q<MA0!QM ;KQ75:KX9TS6+:SA
MN(Y8OL3;K:2UG>!XOEVX5D((!4X(H \E:W$WAV+2KE([.VA\;16JV]M<%T@0
MJI:-'PI R[= ,9XK;U33++P]XB\3:9H]NEI87/A6:ZFMH1B,2JS(K[>@)4D>
M^VNN;X>>&&AE@.GM]GEGCN&A^T2;/-1=@?;NQNQU/4X!.2*LV7@[1K&'48UB
MN)FU&+R;J:YNI)I'CP0$WLQ8  G@'O0!YCIT=SJ.B_#_ $K^R(-7LSHTMR;*
MYN!%%+(OEJ&;*L&VAS@$?Q9[5Z-X$L-0TS09;2_BC@6.[E^S01W'GB&$G*Q[
M\#.TDCV %6)O!FB2Z1I^FK!-##IPQ9R07$D<L QCY9%(;D<'GGO6EI.DV6B:
M>EC80^5 I+8+%F9B<LS,22Q)))).: .*^-9(^&=X02#]IM^G_75:)= TW7_B
MKKD.JVJ7=M'IEH1;R\QEBTPW%>A(&<'MDUV&NZ#IWB32WTW58#/:.RNR!V3)
M4@CE2#U J6+2K.'6+G58XB+RYB2&63<?F1"Q48Z#&YOSH YWX8.[_#S35>1W
M\IIX5+MD[$FD11GV50/PKKZI:5I5GHFG1V%A$8K:-G94+%L%F+MR>>K$U=H
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MXEO=2126<8EGCNH)+=DC.</B0 [>#STKS+5]=DN](7[9?6^MV5CXAT[;J=K
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M/ *Z5>1W@C-P97A.Y8R;5L*Q[-P?EZ\4 1Z9\2KJQ\%7^LZNKW<Z:S)8P+%
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MRZ:5RC8^4Y[#;Q]3ZF@#HJY'QV;:Y32=+EM;R^FN[HF*QMYQ"EQL1BWFL?X
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MQ\NW%+X9\-3:QX*UJ_M;J4ZU+<WEM;32W+JL<7GG,8P?E#8/S8R-WL*[G3O
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MNWW59P-JL<C )!.12R^+M"AUH:.^HI_:)F$/V<(Q;>5##.!P,,O/3D<UY?-
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M;(W8P5+*/FX^4Y]J)=78>/\ 2;.ZT*,:[+I$LRRK?MY<9!YBQMP03_'C(]*
M.UEMH+B P301R0D8\MT!7\CQ1]G@^S_9_)C\C;M\O:-N/3'3%>*>&=;U72Y/
M%WB[4-#2^>SU:X@N)AJ;E[>)60-&B&/:RH"3GY20.@KU/4O$BVFLZ%IMI;B[
MEU9W8,)-HBA1-S2=#GJH XSNZT :R65I''Y:6L*Q[-FU8P!M],>GM4ABC)0F
M-28_N$C[O&./3BO-?#_C6TL/ FEW^E^'I$COM6:PCLUO#(P=F?YM[CG)7H<
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M#:X# \9'7GBLF'XCZJ^GZ%J<GA<K8:TR0VVR]#2^<Z%E#*4 "$@C=GIR0.E
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MB@!B0Q19\N)$W  [5 R ,#]*BEL;2:!8);6"2%""L;Q@J,>@Z58HH   !@#
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M-4OGFA:>\8HZ,R/ORR9;<=Q'8 '%;,GA?66^$&H:&+,_VE+<S2)#YB\JUV9
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MN(;RUAN;>020S(LD;CHRD9!_*I: "BBB@ HHHH **** "BBB@ HHHH ****
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M84;<\8SWH [2HXX(HF=HXD1I&W.54 L?4^IK,\1:Y_85E;R1VK7=S=7*6MO
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MSW&@V$[PW%\LZACL;;(Z1XRRJ<\Y&<' H [![*TEN5N9+6%[A5*+*T8+!3U
M/7')I4M+:-8E2WB5823& @ 3Z>G4UP+ZKY/QNF=[MQIR>%_M)7>?+&)_OXZ9
MQWJGK'BS4]7M_"MT='N=.L;_ %FT:VG^TJQEC+$@2*O*[EYQR..>: /3/(A#
M2-Y29E_UAVCY^,<^O'%13Z;8W,444]E;RQQ8\M)(E8)CI@$<4:C(D6F7<DBL
MR)"[,JMM) 4YP>U<-HWC6VM/"?A4Z;H]Y,NK^9%:V[7/F2(RAF^9WZCCDD\#
MZ4 =U=:?97OE_:[2WG\LY3S8P^T^HR.*L5@>'/$<NM7.IV-[IS:?J.G2HD\'
MG"52'7<C*X R"/;C%,UKQ)=V.L0Z1I>D-J5\]NUTZ&X6%5C#!>K9R23T_,B@
M#;NK.UOHA%=VT-Q&#N"2QAQGUP:&LK5X9(6MH3%+_K$,8VOVY'?H/RKBV\6Z
MY/X_T?2X-(DCL;K36NI8IY%21<O&"S C(*98;0><^PJ./QP^O>'-;O&T"Y32
M;2VNUN)_M01F>+<"B8^;E1G>,8)QU% ';QZ?911>5':6Z1^7Y6Q8P!L_NXQT
MY/'O3Y+:"6)8I((WC7!5&0$#'3 ]JXZR\6+!H'AJVT729[R\U*Q6>WM)+K!C
MA5%):25LGC<HS@DDU0UGQSKJOX=6PT*:":[U%[6ZM[F148LBOF,$@@J<!A(.
M"![T >A+%&LCR+&HD? 9@.6QTR>]86OZ)J%Y%9C1[FQMTMF8M:7=H);>8'ID
M @J0>00>YR#6U-<QVMG)=7+"*.*,R2$G(4 9/Y5R^D>,[S4)["2Y\.W=GIFH
MH9+2\,JR?+MW@RJO^KW+R,D^AQ0!I>%] ET&SN_M5VMU?7UT]W=2I'Y:%V &
M%7)PH55 R3TK:=$EC:.1%=&!#*PR"/0BN)@^(4LEK::O+H4\/AZ[G2&'4&G4
ML [;$D:+&50DCG)."#BEO?'MY&VN&P\.3WD.B3.EW)]I6,;50.2F1\S8)^7C
MH.>: .P@L;2U""WM8(0BE%\N,+M4G) QT&>:5[.UDAEA>VA:*4DR(4!5R>I(
M[UY3XVU;4M;\8^#["TL[J72+^*>Y2&'4#;&\ A5QN*X*[,YQGFMVR\4Z1I-_
MXVNI+6[A.D>0UV6N6E$I,9*B-2<*>W'4G)H [N"WAM8%AMX8X8D&%2-0JCZ
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MKTV,%Y+* YDR0K&+&0C%3@Y[@XP:S[OXB7,-KK%];>'+BXL-&NIK>]G^THA
MC/S,BD9?CYB..N,DYP =C'IFGPH$BL;9%$GFA5A4 /\ WNG7WZU+]EM_($'D
M1>2""(]@V@@YZ=.O-<Y=>+KA]<DTS1=&DU0VUO'<W4BSK$(UDR450WWG(4G'
M Z<U#\,+J2^^'FF7,LDDCR-.=TI)8CSGQG//3% '3RV%E/<K<RVD$DZJ565X
MP6 /8'&<5,B)'&J(JJB@!548 'H*Y9_&%Q)XRNO#ECHLMU):&![BX\]42.*0
M9+\]2.RCD\],5#8^.WNYK&Y?1IHM%U&X^S6=^9U)=CD(6CZJK%2 <GJ,@9H
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MI/%'BQ]6L;FV2S\/(\UFESD'!F8F-UQU7 W8!!'M0!Z68HS*LIC0R*"H?;R
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MLK:-8F+QA(E 1CU(P.#0NF6"!@EC;*&D\UL1*,O_ 'CQU]ZX'P]XVL;+X?\
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MVEA&T=G:P6Z,=Q6&,("?7 J2&"&WC$<$21("2%10HY]A7/7GC*TA\/:/JUI
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MN0<<Y&<'B@#9L[2*PL;>S@!$-O&L48)SA5&!^@J>BB@ HHHH **** "BBB@
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M>*XC*J&5D# CE5(PW!'>D7P%+);&2[U19M2GU>WU2ZN%@VJYA*[8U7=\JA5
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M/$(]P*IPN &XV^YHUGP7J/B#PW;:?J.N"6[CU".^><6V$^5L^6B;LA>P))-
M"V_B6XTGQ/XGL-;N=UK:6RZI9N452+;:0Z\ 9VNIY//S"N3B\7ZRR:/9:WKM
MSI4UUI[:G--::>)Y!YDA$4( C8*%4<DC)/>NN\:>!4\77-A*+XV?D[H;H+'N
M-Q;,RL\6<C&2@YYQD\5<UCP_?RZU;ZSH=_;V5]';FTD6XMS+%+$6# 8#*05.
M2"#W(H Y73O$NO>)7\.Z3'?R:;/<174U[=QVJK)(D,@C4HDBD+OR&.1P.*U/
MA]'=Q:QXQCO9UN+A-556F"!=X$$>"0. 2,9QQG.*M7OA/5GDT;4;374.MZ<D
ML3W-U;;X[E),%E9%9< $ K@\8[]:N^%?#5QX?EU>>ZU+[=/J5T+J1_)\O:VQ
M5( R>,KQZ# YQD@'(?$*PO;CXD>"/)U>XMA-/<+$$BB;R&$62R[E.2>GS9 [
M8K2TR^\07WCCQ!:RZV\>EZ'+;GRUMXR]QN@5F5CC@9R>.<MQ@#%;VN>&3K/B
M7P[JXNQ$-'EED,7E[O-WIMQG(QCKT-2Z5X>_LWQ!X@U1K@2KJ\D+^5LQY>R(
M1XSGG.,]!0!Q U_Q+#X(M?'DNLEHY7BGDTK[/'Y(MWD"[5;;OWA6!W%NHZ5/
MJ.I^)[R3QM-::\UE#H3EK6..VB?>1 LA5RRGY<^F#\QYX J_%X U :7;^'9=
M:B?PS!.LJV_V4BX:-7WK"TF_&T$#D+D@8K6'A)A#XKC^VC_B?%B#Y7^HS"(O
M7YNF>WI0!A6.K^(8-7\(7MYJWGVWB!6$]B($6. F RKY; ;N,8.XG/M6U\2A
M/_PKC7VM[I[=TLI6+(JDLNTY7D' (XR.?0U*?"9/_"*?Z8/^)#U_=_Z_]R8O
M7Y>N>_I6GX@TA=?\.ZCI#RF%;VW>#S ,E-RD9QWQZ4 >>OI^J'Q'X'M(=:E%
MP^E79:]:&,R(A$!PJ[=N1P 2#QSR:2X\8ZOI>DW6G7FK,;F/Q!_90U,6@>18
M?*$V_P M%P7QE>%QT.*ZK3/"VHPZEH>H:EJ=O<3Z7:SVN(+8QK(K^6 >7."!
M'SZY[5!<>!I'_M&>WU,17LVKC5K28P;EA<1K'M9=WSJ5# \C[WM0 O@;7;G5
M+K5[*6]N=1MK-XFMKZYM#;O(KJ<JPVJ"5*GD <$55\0VT.M_%#0='U%%ET^W
ML9]06WD&4EF#HB[AT.T,2/K73:)9:M:I<2:QJ<=[<3.&58(/*BA4#&U02S>Y
M))_"J?B;PN==EL+ZROWT[5]/=FM;M$#@!AAD=#]Y6 &1D=!S0!8G\-:-_;%I
MK8LT@O;)7"2P#RRRD8*MC[P[@'H:X0>(/$J>!8?'SZPQB=TN&TG[/'Y(MVD"
M[ VW?O"G.[=U[8KJ;'PUK5QK-KJ7B/78[S['N-O:6=N8(0Y!4N^68N<$@ G
MR:S$^'^H#2H_#;ZU"WAB.<2"W^RG[08P^\0F3?C;G SMS@8H IZAJ/B:^O?&
MQM->:Q@T0A[1([:)RY^SK(5<LI^7.>G/S'G@"I+'6/$45]X.U*\U83V_B#Y9
M[ 0(L<.Z!I5\M@-^1C!R3GVKH5\*%6\5'[8/^)]T_=_ZC]R(O7YNF>WI3?\
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M!( ,,  =P"CD''M0!9F\<:S8Q>/YC)'.VE7D-MI\;H L9DPHS@ L-S \^E;
MN-<\-^*M#L+[7)=6M=6$T3^?;Q1F&5(S(&38H^4A6&#G''-9!T71YE\6Q75S
MJSQ>()DF'EZ+=*UN5'RD'8=Q! /;I5JR>6?7;#5/$&HWEZ^FQR):1VOA^[A&
M]UVM(^0V6VY&!@#)H R].UWQ4/!WASQ7=ZZ93=7=O!/8BVB$3QR2B,G(7<'Y
MW9! [8KL+OP%HUY::O;R6EJ$U282S 6XP",_.!G_ %GS,=_J>G&*YV+3["/P
M+I'AO[5J9.GSV\IN/[$NOG\J428V[.,XQU.*]*!R 1G!]1B@#DM5O&T7XAZ
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MW:)PH\P[XF/_ &T!!)_OUQGB.-K[X<ZCXIE!$NNZY;S19X(MDD"0C_OD;O\
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MN^,=.>E9FO>-(Y_ OB._T::>UU+3+=B\5S;F.6!]N5+(XZ$<@X(- &O9^#-
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MYU((D9RVYCD#J3T Z5>U#0].U2^T^]O+?S+C3Y#+;/O8>6Q&"< X/'KFL?\
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M6[MT0KYJD,8W+HP7(8$=,[37?^"+.UL_"MLME+?2V\LDLZO?($E;?(S$E0
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M2/6O0:R7T-'\70Z_Y[!X[%[+R=O!#.K[L_\  <8]Z /+5B-]-I^IQPN;&_\
M'*W5L60@/&(2HDP>Q9"0?I6WXGV:9\0[F_U'Q#J&AV=WIL*07-LD921XWDW1
MDO&^&^=2 ,9R>N*]-IKR)'C>ZKDA1DXR3T% 'EE]:0>$?#_A/Q181ZA);:86
MBN%N8P)VM;C.=ZJ!RKE"!CBJ4VB7>E^&O"VKZA>7>GR2:A-J&JWEJBL]O)<1
MOAB&5@ N50DC@&O8J* /(;BTL9[""_T_4=2U9;OQ-I_FW=Y&@68HRKNCVHH*
M@8&['5?:M7Q?;37'BOQ&D,+R/)X.FC0*I.YB\F%'J>>E>DT$@#).!0!SO@34
MK/4_!.D26<XE6&TB@DP"-KK&H93GN*Z*FHZR('1@RL,AE.013J "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *P_$FN2Z(-)\J%)/MVI0V3[R?E5\Y(]QBMRN:\:Z1J&JZ;8R:7'%+>
M:?J$%\D,K[%E\L\INP<$@G!H I^(O&-UHNHZ[;16L,BZ=H?]J(7)R[[I%VGV
M^0?G4=GXHUZ/7="@U6PL8['6U?R!!(YE@98S( ^>#E0>G0^O6LS4_#7B77;G
MQ)?75G:VKZEH)T^VMUN-Y1]TA =L <[\Y' SCG%;VH:!?7.I>$9XM@32WD:X
M.[E<V[1C'K\Q% &?%XQU>W\0Z?::I!I44-_=M:K:0W6^[MSABC2 $J00G..F
MX<FGS>-[N/X>ZQXD%I"9[">XB2+)VL(YC&">_(&:Y[3O!OB&RL_#\2Z'I<<V
MC7J33W"3@RZ@<,K/NVY7[Q8AB23QVYDU'PMXL?PGK_A6TL;)K>\NIYX+Y[K&
MY))#)LV;<ALG;G.._/0@&E_:7B&?XD>(+!YK4Z7;Z;&WE;GR%;S<,HZ;R< G
MT K+\(>(=>T;P;X,DGLK'^Q[O[-8 "1OM"EQM60_PX)'3K@CGTZ*?1=9M_'^
MHZE;6<-QI^IZ?';/*9PC0.F_^''S [AT-5T\*:FO@7PCI)6+[5I=U8RW(W\!
M8B"^#WZ4 1W'C37Y-,U;Q!IVG6$FAZ9-,ACED<7%PD)(D=2/E7HV <YQVS5H
M^+=8U'QBVBZ)9V3VZV=O?&ZN7< 1.6R,+U8@#';KFLV7PYXGL]!UGPI86=I)
M8:C-<>1J+W.W[/%.Q9PT>,LR[FQ@X/'2MS1?#5QI7C6\OU"_V>VEVMG"=WS$
MQELY'T(H S_#&J76HGQ>FBZ9I=G>VNLR0;G#!)R-NZ23;SN(ST]JK6WCW6;?
M3?$-_J-GITUMIDJ6EO-:2.J7%RS!"F7_ (59E!;'KUQ4<'AKQ7I&C^,QI2VZ
MZAJ^JR7%H_G8V1/@%LXX8#./?%3MX:U/4O LOAC^P;/2H;>.)K,O>"X222.1
M7 D 0<,5^8\YW'B@!S?$&?2(]6361IMU+9Z<=0B?3)BR2 -M,9W9*L&*<]"&
MS@8JI>7'B&3QSX'&NVU@ADGN9$:S9R$/V9\HP;J>1R.N#P.\\WA"[UW0M;L'
M\-Z+X?%W9>1";8*\K29W99T4 1Y"\8).,\=*L+8>+-9\3^&=2U33;2Q@TJ28
MW"I=>:TK/"R;EX&%R1QU^8],<@'0>)=<ET0:28H4D^VZE!9/O)^57SDCW&*R
MO$/C2?0M4UBW%FDT=AI":@IW$%F:1TP3SA1M!)QZU=\:Z1J&JZ98R:6D4MYI
M^H07R0ROL67RVY3=@X)!/-8\>E^+)O$FJ:^;+3K>>?2X[:VM99C*H9968J[
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M%-K?]HVMV+3[;ITXBE>SDWPRJR!U=2>1D'!!Z$&JEYK^NW_B34=(\/6VG_\
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M Z2;2&4L" RE!UZ@GFLZ?PWK4$6A:Q8:/I-OJ&FW<\K:9:,(HVBE0H5WXP9
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M">GG6;B2?4I8_.N&D/*LYW;/8+D+^%<MX5_M34I_$NK7FMW[)I^IWUK:VJR
M1!%)P6&,L1G YP-H]Z .[TO48=6TV&^@CGCBF!*K/$T;C!(Y5N1TIFKZO::'
MI[7U\[) LD<9*J6.7<(O ]V%>7^'=:UG7_"G@+3I]7O(I=7:ZDO+R)\3.D.\
MA0W;)V\CG JKXE?58K'QGI$^K37D=E<Z2+-[G#&,/,K?-C&3G&3W &>: /:*
MC@N(;J!)[>:.:%QE9(V#*P]B.M>?W%K?Z5XO?1QKVJW%K?Z-<7#M-."\4L;H
M \9 &S(<\#CVKG= M]2L?AKX3G@N->FTN6,R7XTY]T\7RX0( -PC!R2%YZ4
M>S45B^$[J*\\-6LT&K2:K$=X2[E39(P#$!7''S+]TY )(Z"MJ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,C"LH9HUC*,AX=<+GGD'D'BM/P_H8T.UN%>[EO+J[N&N;FXD55,DA &0J@
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MWR#\ZLZWX0NM8FOHAXAOH--U!0EW9!$<%=H5A&S F,,HY [Y(P36U?:WI.F
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M7G4/O?[BX)SENP[U5TS5VD@U2XU&]TGR;2ZDC$EK<;EBC7'$Q. L@_B'0<4
M<AJ?A:U\)^$O#MK!/JV[2+EO)U&SMUFD@#[]S/'@[D(;:< ]C57P]X6/B)O%
M$\\^H_8]1NK)XKR[A\N6X: AV?80-J%L*.!P.*[+4O&N@:=X8N?$ U*UNK"
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M)ST"2*GTS4#6U]=Z3HWB BU27Q!XB%XWVY"T2Q^7(MJC@$$@!4(_VF%>L_\
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MNS1%MM"T^(1SBX39;J-LHZ,..",G'I2V_A#PY:7T%[;:'I\-U;J%BE2W4,@
MP,''''% 'ENLFX75_C&;8D/]EL-Q&?N>2=_3G[NZNNT+3+R/QEIMY/?>'X]N
MFR1QVVF1NC30%DVL06.54@8/^T:[.+2["&[N[N*S@2XO HN95C :8*,+N/?
M)'-5M)\.:)H3S/I.E6=D\W^L:WA5"WL<=O:@#4KQ30;B.+PSXEMWLK:[>\\:
MRV\*73$0K(7C*L^.2H*YQW.!7M=9;^'-$EL+NQ?2K-K2[E,]Q"85VRR$@EV'
M=L@<]>* /*KRSO+I_'P\ZPGU'3EL-0C-A"8HQ-#O?A2S?-A-I.?;M4W]M6Z:
MX?B27/V!M1;3MW_3J(-H.?\ KNOZUZA:>'=%L)$DM-*LX'2 VRM'"JD1$Y*<
M#[N><>M!\.Z*=%&BG2K,Z6.EGY*^5][=]W&/O<_6@#+^'VGRV'@C3C<C%W=J
MU[<D]3),QD;/TW8_"LOXFI9R?\(FFH;#:MX@@$@D^Z?W<F ?;.,UW0 50J@
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M%4)'7&0.GMTH Y;X.Z=:6WPXTNZBMXUN9Q*99MHWO^\8#)ZX  &/85U?B/\
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MK_VGI=S#(;..,ARTBLPV*2VTC8W.>E '5Q^-=-D\*6'B,0W7V.]EBBC0JOF
MR2"-<C.,9///2J^I^/;'3;R]C&G:E=6FG.$O[VWB5HK9B 2#E@S8!!.T' -<
M);R7W_"NM%\+KHNJG4M/U"V%VILY D:)<@[PY&U@1@_*3QD] :Z&RU6\\'7G
MB2Q?1-2OKR\U.2]T\6]N[17(E"X!E *IM((.[& ,\T /C\87.G^,/%D(LM3U
M>"V-M+'#9A6$$1@5F/S,HY.3@9)YXKL[;4[?5?#T>J6,A:WN;;SX7Q@X*Y'T
M-<[HMI=IXJ\;3S6DL:W)M3$Q4[9,6P!VMCYL'(XJ?P1:W%K\,-'M;BWEAN$T
MY4>&1"KJVWH0>0?:@##\">+;J+X6^'KZ_CU#5]3OGEB1(L/+*PDDZLQ  "KU
M)'2N@L?'.G7MSIUL;6\MY[VYGLRDR*#!/$NYD?#'DCD8R#7G_AZ#5-*^''@N
MRU"'6['3Q)<C4ELH95N%.YS$K!!YBJ2>W^SZU+::=>P>&M8EATK55OM+U^/5
M[6"X2226:$A. [9WL8_,! )(/![4 >AZ?XPTO4=:UK2XS+'+I 4SR2* C YR
M4.>0I4@\#!IK>,+%/ W_  EKV]VEA]F^U>447S=AZ<;L<C!Z]Z\WU+0]>M/#
M.D7-GI]TVIZ[;7-GJ(2)BT#7<@EWOQ\H3+@D],UVOQ%M8K'X2:U:0+MA@T\Q
M1KZ*H  _(4 7M/\ &MK?:U:Z;+INHV1OD>2QGNHU6.Z"C)VX8D';\V& .*IZ
M;\2-*U+3+K519:A;Z5:P/++>SQ*(PRMM,8PQ+-] 1VSGBL][R7Q+XM\*I;:;
M?VXTIY;B^>XM7B2$F$QB,,P <EF_A)&!G-9FG^'M4NO@&VDQV4L>HAI9EMI4
M*.Y6[:0+@_W@.,^HH ZJ#QS$UP+:]T/5K"XEMI+FTBN(X]UTJ+N94VN</C^%
ML&K-QXTTN#P9;^* L\ME<)$T44:@RNTA"J@&<;LG!&>QK#:^;Q;XT\-7-AI^
MHPV^EF>XNY;RTDM]C-$8UC&\#<V6R<9&!UK&TK0-27QA;>%Y;&X70-'U*;5H
M+@QD1.K -#$K="5DDD)'^P* .EL_$^DV6J^,)Y[W4]NE>4]XETRM#"#&6 A
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M4/)L(W!>3R0.%S77>(_-T?QWI'B.6UNKC3ELI[*=K:!IF@9F1U<H@+$':1D
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M2**)[@V\CNA17*+\N0.<C Y],T :6F>+-(L;7Q5J$MYJDD.FZB\-P+LA]LG
M"0!>=I)  /.35^R\9PSWSV-_I.HZ7=_9GNH8KM8_WT:XW;2CL,C(RI((S7!)
MX?U>71_'!CTVY,P\2C4((6C*FZCCD1SLS][(4XQU-;][<2>+O%6G7VG6&H1V
MFEV%X9I;JTD@W22HJK$H< L1@DX&.G- &E8?$:POSI,RZ5JD.GZJZ16U]-$@
MB,K#(0@,6'((SC&1P2.:N6'C.WU'48H(M*U,6<T\EO#J!B4P2.A8$<,6 RK
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M,NUXW5BK*PYP0016G7*?#ZUN+/0+N.YMY8';5+UPLJ%25:=RIP>Q!!![UU=
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MXDR,G!SUQ6'?>)O$/AZ;Q!IVHW-E>W-MHDNK65S%;&(?)E61TW'.#M((/0T
M>AT5YZ?$?BB#0=)N)I=/.H^(+B"*RB$#;+-70NS/\V9"%7.!MYXZ50\4ZYXD
MT[2_$^A76HVLEW#HS:C;7T-J8RT661T*[SM8'&&![YQQ0!ZC17G%]XGOO#^B
M>&=.O-=TRUNM2B9WU*[AV1Q1(BG 0O\ ,Y+J,EO4X[5'8>/=1UBVL]*TV[TV
M?5;C4YK#^T8D+VYCCB\TS*@;DE2HV[L;B><"@#TNJXO[,ZB=/%W ;T1><;;S
M!Y@CSC=MZ[<\9Z5YOXRF\86V@6MO=W]G#(-;M8$NX(#BYC:1"K%-^4(8$,N3
MN ZC-:?_  D-SI_Q(N-,OTLY8[3PY]NFNH[?9*[K)AL')PAP2%R<'O0!WM%>
M<Q>)O$]IH>C>*=0FT]]-U&:W$MA';LKV\4[ (PEW'<PW+D%0#DXQ3+OQ)XMG
MTWQ7JEE<Z;;VV@75RB126S2-<K$H<J3O&WCC(!R?3'(!Z317G>H>,-5N-=2S
ML]3TK26>S@N;.#4HF(OV<$E1)N 4 X7@$Y.<=J[G4+F>TTFZNH;<SW$4#R)
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M&5#HR[F!&'!!^HJ3QOK]UH4.FB&\MM.@N[DQ3ZC=0F6.V&PD9 (&6("Y)P*
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MG:>21C<>#BN]T;P[-IWB3Q+J$SQ/;ZK) T4:YRJI$(R&X]1VK0T*7SM)C?\
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M@$K@D]13KSP_X@LM:U2[T"72S%JFQY3>AMUO*J"/>@4$."JJ=I*\CKS7944
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MN\>=K$#&1GG%;-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "D) ZD"EKE/&NC>%GTZZU_Q!I,%X;*V.&<98J,D(
M/<DX'N: .K!!Z&BN9\!>'!X9\+0VK0I#<W#M=7,<?W(Y'Y**/11A1_NYKIJ
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M9T084G+8R,@=!0!ZG17)Z[XZL]';4?+BCN1IN/M2"X1).5#$1H?OL%8'''7
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MM%_:7Q1BV_)]FA?&3P?LI;/Y\T >F=1D45B>#?\ D1O#_P#V#;;_ -%+6W0
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MEV8$8W,Q[=!WKK[VY-G8SW(MYK@Q1EQ# H:23 SM4$C)/;FEM+@W5G!<&&6
MRQJYBF7#ID9VL.Q'0T <<? 5OHOBS1]:\+6=E8)'YD&HP(/+$\#@$$8!RRL
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M7B/1=1U6RTZVBMK2ZM;I8;MG+>:$&Y/D']TX!_.IO"FF^,-'M;30[]M-?3;
M".*_BD;SIHEX1#&5PIP "<GCISS73:SJD&B:+>ZK<K(T%G \\BQ@%BJC)QDC
MGBLD^-=-#^&5\FZSXB3?:?(OR#RP_P _/'##IGF@#G;GP?KUQX&\4Z-Y=DMU
MJVH3W,!^T-L5)'#?,=F<C'8&M_Q5X?O=>T[3IK&=++5[&YCGAFSN$8/RR#..
M049OJ0*Z>B@#D/$/A[58;O0]4\,?9?M.DQO;?9+IBL<\#A05W $@C8I!Q]:B
MU;1_$FK?V!<SQV'VBSU1;Z:%9V"1H$9/+1MF7/S9R0.<CI7:5!>WMMIUE+>7
MDR06T*[I)'. H]Z ./\ $GAS7=5UG4C&MC<Z?=Z:;:V^TRLILI2'#.J!2&+;
MEYR",8Z=8[#P[KNG7OAK4C!9SRZ=I3:=<6Z7!'7R\.K%?F_U?(..O?'/;SR^
M3;R2B-Y"BEMD8RS8'0#UJ'3KPZAI\%VUK<6AE7<8+E0LB>S $X/XT <3J/@O
M4Y/#US#;?97U"_UF/5+G=*RQIMD1MBG:2<+&JYP,G)XZ5:_LGQ5HWB?4KO14
MTVYT[5G2>6.[F=&M9@BHS#:IWJ0JG'!R.U=M10!P7BCP??Z^[[H+<:A"L?\
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M<*=FT '=\Q8C(Z?-UKN998X(7EE<)&BEF9C@*!R2:R?#?BG2?%NG/?:/<--
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M-&IW=[X>/B?0M,GU%[4:EIT$")<EYHDG"^8L<DC<$X(&6X+=17HL/A33;<:
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M&CMRC9 4;<D=OF)(' (JX_@>Q;4I;F/4-2AM9KD7<VGQ3A8))<AMQ&-W) )
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MTC6MN\QF:")I63RRY0%BG]W/I[4 0Z9J$&JZ9;WUM-#-#.@97A?>A^C8&1^
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M;1S.$& "R@G'MS6=;:]'%>ZZVH:KIAL]/9,B(E7ME*Y/G$G&3U&,<59\+?\
M(H:+_P!>$'_HM:\GU/\ X]_C)](?_11H ]8L?%&A:GJ<VFV.JVEQ>P@EX8Y
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M8*79F"J,GIDL.>U<EXRU.QUWQ%X0TC2KN"\O(M8COY4MY _E0QH^YF(^Z/F
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M%?&>U&N7WA]KKPQ>:08HK$>*'\Z8?+&\WER!V!/!!;N."<T >HHZR(KHP96
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MVTSI%=D&W8,%B,'R@XZ X.![&ND\:V]C=^&)H-0U#^SHGFAV797<(I1*IC+
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M'X+M$EMVO$U"Q A!!D283#S21U!SNR3Z^];)U.QT_1/B;;W=U%%<&\N2L+L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<MXWT^^N;?2-0T^U>[FTK4H[QK9" \L85D<+D@;L.2
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M=[I?^>2K;.I)^C$#\:[FB@#E/'EA?75CI-]I]J]W+I>IPWS6T9&^5%W*P7)
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MD^YZUQ/A^;Q!X9TY?#%OX?N;BXCOI/*OF*_93;O,7,C-NR&"L1MQG(%>B44
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>mschobelsignedconsulting002.jpg
<TEXT>
begin 644 mschobelsignedconsulting002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *I6^D:99WLMY;:=:074W^MGB@57?
M_>8#)_&KM% !1110 4444 %%%% $<L$4X431)(%8.H=0<,#D$9[@]ZDHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT# E<],CMFGT %%%% !1110 4444 %%%% !114<UQ#;A#/-'$'8(I=@NYCT
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MY,5N+M@@=Q'\P"X#8&0V6!Z5=M_%6N:QXSN=(TB"P%A;PVEV]S<!]QBE!)4
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MPMK&VJ"V,4-O(7$0C5E*DD#/4<XY)-=!JMFVHZ/?62,$:XMY(0QZ LI&?UH
MX+1/$?B*+PMX0TX/976L:S;"2*XG$A2.!(49GE^;<[_,!P0"6[5TOAK7=0O=
M4U?1=7BMEU'3&B+2VH8131R*2C ,25/RL",GIUKG+#PWXFM=)\+77V*P&J^'
M4:T%O]K)CNX&B5&._9\C94$#!''7FNA\,Z-J,&L:SKNKI!#>:F85%M!(9%AB
MB4A07(&YB68GC'- '35XUKKZAKVI:UXYTV21D\-7*1:=$K$+<)"2;KCN&#,
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M+NWDF>:]D9X)'1PH2(@KDL#NY.0.QJ:?2]>CT2UMVT'P]?0R&4WFF#]U$"S
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M)3EC8JRR,Q],%2H)Z^817IJJJ($10JJ,  < 4 <WXCUS4;76-*T/1H[4ZAJ
MED,UT&,<,48&YBJD%B2R@#(^M<_J7C[5]&T/7/M=C:2ZOH]Y:PR+!N$4\<S)
MM903E3AB,$G!'4UO>)-'U.37=(\0:/'!/=V"S0R6L\IC$T4@7.'P<,"JD9&#
MS7/:AX*UO5](URYN?LD6JZO?6<Y@24M'#% Z87?M&YL*Q)P!DT =QH_]KFP!
MUO[$+PL3ML]VQ5[#+<DCUXSZ"M"BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN0\?7%SY&AZ9
M!=3VJ:IJL5K/+ Y1Q%M=V56'*D[ ,CGDT ;RZS:MXCDT,"3[7':+>$[?DV,[
M(.<]<J>U:->.Z\9_!WB3Q/-IEW=2/%X<A-L9Y3,\&Z=UP&<DG!)8;B>N.E:-
MC;>(HKJ[MM"LO$-G'<:7.AEUJY64+=@#RI%/F.5)RV0,#IQQ0!Z9=3_9;2:X
M\J67RD9_+B7<[X&<*.Y/84RPN_MUA!=?9Y[?SD#^3<)LD3/9E['VKS.QNTLM
M&\10)+XBTW58M&FFDL=3N7E^95/[^*4LV>>,J0.1P*IVLNI:U:_#*QDUC488
M]2T^Y:]DAN6628+%&W+9SG/&>H!.,&@#V"LZ'6;6?Q!=:*@D^U6UO'<.2OR[
M7+ 8.>OR&O-_&,OD'7#ITWB6[N-&L5$<MK=B*"P=(MX+EI%\YB-K-D.<'%6X
M-+'B7XD7IO+N[AA;0[*62.TN'@+N6DP2R$-@9/&<<C.<4 =OK/B.QT.^TJTN
MUF,FIW/V:#RU! ?&?FYX'YUKUXB]]=WB> H[VYDNIK/Q+/9_:)3EI5C=E5F/
M<X R>^*MW6H:[JESKFH6%AXDN-5M=3FAL)+:X5;-$A?:(VC,@#!MIW$J3\W'
M04 >OW$OV>VEF\N23RT+[(URS8&< =S46GWG]H:?!=_9KBV\U=WDW,>R1/9E
M[&JOB&62'POJLT3M'*EE,RLIP5(0D$'L17FND7&I:QI'PVM9M7U!%U"WN3>2
M1W#+).%BW8+9SG(Z]1DX(/- 'KM0?;+87PLO.3[48_-\K/S;,XW8],\5RG@H
M2V6N^*=$^U75Q9V%W#]F^TS-*\:R0HY7<Q)(!)QDUFG2H9?CO),T]X"NAQW(
M5;J0+N\YEQM!QMP!\O3/.,T =GH6LVOB'1;;5;(2"WN%+()%PV 2.1D^E:->
M):-8S:5\+_#WB.WU/4%OH[V! BW+B'RGN1&8S$#M((8Y)&<]ZMW]_KFJWGB&
M]L+'Q'/JEGJ$L&G26DZK:1B(@!&C,@#!B"6)4_>XZ4 >Q45C>)]4N-(\&ZMJ
ML"8N;6QEG16&<.J$C/XUQDEG<>&8?".K6^K:E<W5_?6]K?BYO))8[E9E.X[&
M)52#@C:!@#% 'IE4H]2\S6)M.^QWB^5$LGVEHL0OG^%6SRP[BO)!'J ^&.H^
M+3KNJ'5;"YN9+8F\?RU2.X8>6R9VN" 1\P)P0.@ K<EU6_;XB^*X!>7*V\7A
M])XH?-;;&Y!^91G ;W'- 'IE4M/U+[?+>)]CO+?[-.8=UQ%L$N/XDY^93ZUY
MI90WFG:-X"U_^V-3GO\ 4;BTANS-=N\<L<L3$J8R=O&!@XSD9)).:J)X@UB+
M1_&XCU*Y$Q\2C3[>9I"QM8Y)$0[,_=P&.,=#0!ZM'HVF1:M+JL>GVRZC,H22
MZ$0\UE   +=<8 _(5=KSJ^MI/"7BO3K+3K_49+34["\$T5U>23[9(D5ED4N2
M5/)!P0.1Q6/I\5[9>&/ GB(ZSJD^HWUU90W)ENW:.6*48*F,G;P,<XR2,DDT
M >NT5RWQ!U&\T[PHYL)VMKBYN;>T%PG6(2RJC,/< G!]<5CS:6-!\::1HUKJ
M&J/I^M6EU'<Q37\LC*\81A(CLQ9&.X@[2.HH Z+0?%UAXDO;R#3K>]>"UD>)
MKQX=L#NI 958G)//I6PUY;)>QV;3(+F2-I$B)^9E4@,0/0%E_,5YQ\%]*@M_
M#MW>I-=M(;ZYAV27,C1X$G783MW<?>QD^M6]0TJ&Y^..G2//>*1H\EP%CNI%
M7<LT8 P#C:>Z]#W!H WM-L_#'BZ.V\3+HMI-.S,([BYM4,H*.4Z\]"IQS72U
MXEIUC-IOPJL_$UOJ>H)?V]^/*1+EUA$;7NQD,8.U@0Q))!.3UP *O:G>ZUJV
MI>);BRL_$DVHV5X]OIDEC.J6L)C5<!T,BAMS$EMRGAACI0!Z_7*7OQ&\-65W
M<6[75Q/]E8I<RVMG+-% 1U#NBE01WYXK8U.>\'A>\GAC:.]^Q.Z(.JR;"0/S
MK)^&\5I%\-_#XLPOE/91NY7^*1AER??<6S0!T5E>VVHV4-Y93QSVTRAXY8VR
MK ]P:GKS[4H+.X\1^'_"NE3_ &/1)([NYG339C#YK1LH\O>A! W.Q8 CD5@:
MQ>ZII=KXBT*SU:^5+#5]-6TN7G9Y8DG9"T9<G+ '/#9X.#F@#V"BO-5\/X^(
MT_A\:QK)TF;2EOI8#J,I9IA*R9$F[>H(Y*@@$@=ABL;2)]3U@^"]+N=:U%89
M9M5M[EX[EDDN(X7P@9@<YPH&[KC.""<T >QT5Y2]X^DGQ-X<EU76&M+>_LX[
M+R)#+=N)D#FW21CD9VM\Q.0">:S[S4]5L/#7C*SM7U;3?L<U@]HE[=^=/;^:
MZAAO#N2IQG!8]2.] 'LU01V5K#>3WD=O&ES<!5FE50&D"YV@GOC)Q]:X"[T:
M;3_&EOHUGK.K"+6-)NQ.\M[)(RRH8]LJ9/R,-Y^[@>U4K?Q!J7B#P[X9T#[3
M/;ZS-?&UU1XI"LB):G,QW#D%L(/^VE 'J=%%><^-95O-;O;>!O$-W/9V ?R=
M+N1;Q6;MN*RNQD3<QQPOS8"].: /1J*\NTV2]\5:_P"'H+_4[Z.VNO"\=[=1
M6UP\(FE+IR2A!'WCTP>,=,BJ5E>:A>II/A:75+_[+)XAOK.2X%PPG>W@#NL9
MD!W<X )SG ZT >FVVLVMUKM_I$8D^TV,<4LI*_*1)NVX.>?N'/X4/K-K'XBA
MT,B3[7-:O=J=OR[%95/.>N7':N2\(:>-,^)'BVT2YGGB2UL/+-Q*9'12)CM+
MMEFP<XR2<$4FOZ8NK_%?2[62YN8(3HMPTOV:9HFD7SHOEWJ0P&<'@@\8Z$T
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MLMP[W+2EQ+.[J")7'RAB0OOC&3R: .UU+4K31],N=1OYA#:6T9DED()VJ.O
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M<>(=&M=(CU:?5;./3I,;+IIE\M\],-G!_"@^(=&6PM[\ZK9"SN21#.9UV2$
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M"^OK:V+H\BB:0+E4&789[*.2>U $.AZ+!H5@UM#-/.\DKSS3SL#)+(QRS-@
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M&VD&_,N#YF_S=F.N,8]JU;'Q'HFIZA-I]CJUE<WD&?,@BG5G7!P<@'L>#Z4
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MCBA17&XR!F;[P,>>?X17K<NGV4VG_P!GRV=N]D4$?V=HP8]@Z+MQC'M67?\
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M@C\*]6U/0='UHQ'5-*LKXQ',9N;=9-GTW XJS]BM#+;RFUA\RW4K _EC,0(
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M%Y\2OL!C:-[731,T1^5I/-8-@COTS[Y[YKNM5M8+7XF^%$MX8XD_L^^BVHH
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M2X+HW,.FV<=P96F\U(%#^8PVL^<9W$<$]2* /)_$ZQ0^(O$HE"KIW]NZ-)?
M\)Y1"[BW;&0N:U];UK3-(^*%]JT#PO+9^%YY9S&0<E94**2._P#0CVKT633+
M"870EL;9_M8"W.Z)3YP P _'S8''-4HO"OAZ&U-M%H6FQP%2AC2U0*5)#$8
MZ$JI^H'I0!P2Z6-"C^&MKJ9 MHYI7NFE^Y]K>%F4G/&=[/CWK'\>>5,/B(UD
MRFU-OIJSM$>/M'G<\C^((5S^%>R7MC::E:/:7UK!=6TGWXIXPZ-]0>*KPZ#H
M]OI9TR'2K&/3V.3:K;H(B<@Y*XP3D _A0!:M;2WL;9+>U@C@A0!5CC4*  ,=
M!4U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9.JZ[%I.J:19SPN5U.=K=)@1MC<(74'_>VD#WK
M6KF?'>G7-]X9,UA"TU_87$-];1H,LSQ.&*CW*[E_&@!^G>,K#4/$FM:,(Y(F
MTM0SSOC9*,?/M_W20#6;:?$%]5BL%TC0+N\O+JS%\T!ECC$,+,0A9F.,MC(
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MI$LA*_@V.:YKXB_\C9X!_P"PO_[)56Y&JZ8WC?28]"U"ZFU>:2>RGAC!@8/
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MY\F)L8W*G3.*W:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML[>ZG_U,$LZH\G;Y5)R?PIM[KFD:;YGV_5+*U\LJ'\^X1-I;.W.3QG!QZX-
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M;.S5C(UM<(^6 SL&#C<<8 S4R^*-"_LVVU"76+"&VN?]5)+<HJL>Z@YP2.A
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MQ0I<H7=2,@JH.2,<Y%4O$/BG3]$T_4<7UDVIVUG+<QV3SJ)'V(6'RYW8X]*
M-ZBL>+Q'IL6FZ;<:GJ%E8RWT*/''/.J;F90<+N(SUJW>ZQIFF[OM^HVEKM02
M-Y\ZIA2<;CD],\9]: +M%(655+,0% R23P!7%WOQ&TV3P_J&HZ-+!=RV5]':
M/&95.X-,D1<;23M.XD'OB@#M:*S[?6M-U 72:=J5C=36X/F+%<*_EG_;P3MZ
M=ZJ6.O01>'+;4];U'2+?S,AYX+L&V)R0 KMC/ _/- &W14<$\-S D\$J2PR
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M"2+N97C\S<>G'#@<'GFNB31]-CDLG2QMT:P1DM"L8'D*P (3T!  XH \QO\
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MZT>SELK=R\,#Q K&Q))(';.3^=$?A30(=9.L1Z/9)J)8N;@0C?N/5L^I]>M
M&G!<P7(D-O/'*(W,;^6X;:XZJ<="/2N/\=2QZ+JOASQ/*=L-C=M;7+=A#.A4
MD_1Q&:Z32-'AT@7ODD$W=W)=OA=H#/CM^ R>YR>]6-0TZRU:QEL=0M8KJUEQ
MOAE4,K8((R#[@&@#Q'S+S1-%N(^4OO&FF+*@/7[5+<88#W$=TGX1^U:?BFWB
MCTCQC;Z?9:/;6>EV,=A//>(\D\Q6 &,1@, F ZA3SEN<5ZO<:/IMU+92W%C;
MRR6+;K5GC!,)QC*^G0?E5:Y\,:%>:H=3N=(LYKXIY9GDA#,5P1@YZ\$CZ'%
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M/HUE+<WD?E7,CP@F5>.&]?NC\A5G2-"TK0;=[?2K"WLXG;>ZPH%W'U)[GZT
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MO!"D=O;BPTRWB)(A@&"S'C[S$ 8'0*!DUT<L4<T3Q2HLD;J5=&&0P/!!'<4
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M]5%KX5#+-C?'*PE51(,]<@D@^]=]J/A3P_JPMAJ&CV5S]F0)#YL0.Q1_"/\
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MC<+J=Q/;VL<<2[W>(D8P6XW%>/KSCFK=YXW^RN88]!U2YN(+5+J^A@$9-FC
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M1F,F[Y6RQP ,<#.<U?U_XCS6>I:Z\&NZ39C1Y3%%IERF9;XJH9_FW KDDJN
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MDOI\FE6S:3)!)8>6! UNP9"HXX(ZU<KC?A/_ ,DL\/\ _7M_[,U=E0 4444
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MJWAF^$\2QZ.TK3!LY<- T?'XG//:NBJM>WUI8I#]LF6-9Y5MX]W\;L<*OXT
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MQAF"*V1@],..OO6G0!YUJ/@?Q!<Z?KNDVM_IT5AJ%Z]^DS(YF9V8.(W[!0P
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M_P"$GNK,6T=WLD>WCB,JP^8[#"Y]6R0N*[OP?X/30]*T&6\R=4L---DVQLH
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M;6T=X7NK9RC0.RQ["&'0G!'H>0>* .'UO[3I<>N^']/O[N"TM->TT6C^<S/
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M+BU>Z=["VDM;<2R[@D3L&V].@V@#VJ+4? >E:CJ-[=O/?PI?@"]MK>Y*0W)
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M D0$GA2T73/7&*H>-)8[WP)\1-3LF5]+N]4M/LTB?<E9/)61U/0@L",CK@T
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MB..1T81EB>!SD9]Z .]\->*?^$A\4:];6\\<VGV<=JT!5"K!G#[PV>005'!
M(K4U;Q1HVAW*6VHWRPSR1&5(MC,SJ"%.T*"6.2.!S^5<QX-OK'4OB-XUN].D
MCFMW6Q FC.4E(20$J1P1D8R/2DU[4-.TSXOZ'<:E-%!'_9-RJ33,%1',D>,L
M>!D9'/<X[T =$/&7AXZ/!J_]JPBPGF\A)F! \SGY6!&5/!SG&*9)XW\.Q:;9
MW[:@?(O2XM@L$C22[20VV,+O(&.N,=/6O,;I;?48&NH0DNEWWCRW:!ARDRX5
M78=BI8-SWP:[34[RUT?XM6M]JMQ%:V=QHK6]M/.X2,2B;<Z[CP"5*GWVT =
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M1&3E<JV R;L9QMYJ[K>H:?KWCO6?['FBO6_X1"ZA,MLP=7<R*0@8<$C<./\
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M9)[=PZ?ZR,A=PXR,YQVW#UH [/5];T[0;1;G4KD01NXC3Y6=G<]%55!+'@\
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M'+8Z9-<QX<\5ZAK[6=R= >#2KZ-I+:\2Z64@#D>:@ V$CT+<\&NJH ABL[:
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M-M"99!M=S&,L/0GO4]%% $:P1)$8EB18SD% H YZ\4D-M!;P^3#!''%S\B(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;ZZAM8Y=  1YG"*Q6=BP!/&0"#7(:*;?41X7EVB2&3Q9J$J;E_Z[LIP??!H
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M$>E=;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !116+XCN=8MH[!])L'O5-VBW4<<RQL(B#\P+<8#
M;21U(S0!M45YSXRU7Q%:^$?%CRQ7&G/!-$MC?0W"_O(VE4?(!RI"]<]2Q[#
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MQW%W$[,)&E*[#\HVJ&R!NQP*TK/Q=H]X-3)FEMCIBB2[6[@>$QH02'PX!VD
M\^U %<>%(+;Q7I>J:?#:6EI9VUQ$UO#$$W-*8SN  Q_!S6M%HNE02O+#IEG'
M(\@E=T@4%G!R&) Y(]:HP>+-,GU2WTS%W'>7,(GAC>UD^>(\;\@$*.F=Q!&1
MG&15[4]7M-)2W-T[;[F8001HI9I9""0H'T!/H * 'MI>GOJ"Z@]A:M>J,+<&
M%3(!Z!L9I#I6G'41J!T^U-Z!C[3Y*^9CI][&:R9?&^A0:2=2FN)8[=+O[%)N
M@?,4V[:4<8^7DCD\>]6-/\5:5J-Q?VZ2302V""2=;N!X"L9!(?YP,K\IY]J
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MTVU$8RTL,8=(F^K;B2?0C/2O0:K27]I#?P6$DZ+=7".\41/S.JXW$?3</SH
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MASV"CL/SKDKGP!>:A87\E]J4#ZKJ-_:W=Q+'"5B58&7;&BDDXPIY)ZDFN\H
M\^\5>(=1L?%+V+Z_%H%M]GC:QEN;0/!=RDMN5Y#PH&%& 0?FSS6=X@\;WD6N
MZS:1:_!I<FE1QK#;"S,ZW<QC$AW-@D)\RJ,8/4YKJ?$FA^(-5-[:V>IV TR_
M@\F6"\M#(8.""T95AG(.<-G!'7M50^$]:TJ[N6\.:O:VT-[##'/]LMS*\;QQ
MB,2H0P!8J%R&&,J#[4 4H-;\0>)?$L5CI^HC2K.;0[742?LZR2QO(SC:-PQV
M&<@_=X'.1SKZCKWB*?P)++J_V:Y?4+RWD>*W0J985F3S0#W*@C'09.*]&M-
MEM_%T^MO=^:)=.ALBK)ABR.[%R1QSOZ 5SI\!:E:6&C'3M2M1?Z7J-U>(UQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME92IZ$'@T[('>O&X/#UU?1^-=%M+"STN[LQ97]C:6$QDB@N0KLI7*KM+;%!
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M%'9=B[F!'WN3\YH ]601+(VP(';YFQC)]S5;3]6L]4>\2TE\PV=PUM-P1MD
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M#..AQD4 =2CK(BNC!E89!!R"*6N5^&MQ-<_#7P]+.29/L4:Y/4@# _0"NJH
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M,<\-L+IU$3MB,N(UZ Y)8X"]2>@J;1?$&GZ\DYLFF$ENP2:&X@>&6,D9&Y'
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M<DXV?>Z<<U->?$'28?#FKZI EVTNF1;Y;6:TEBE4E24W(R[@K8^]C &3G@T
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MY[\<UL6_CC0)],O[\W4L$6GNL=U'<6TD4L3-C:#&RALMD8P.<\5%-XMTV_\
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M@9.U$!) ')/054D\;>'HM-L-0>__ -&OV9+9A$Y+NH)*;0,AOE(VD9SQUXH
M%\$Z"-)FTUK662*:87$DLES(TS2C&)/-+;PPP,$'CI0G@K0ETB;3&M9)8)YT
MN9FEN)'DED4J59I"VXX*KW[8Z46WC;0;G2M0U$W<EO!IQQ>+=0/#)"< C<C
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MJ7CN#0-%\3:F=0DU9]/O&@6V6S:,6[XXB9@.5_VSQV]*?-X\BM_&$,4C7?\
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MY5:KF_ 6KW>O>"M/U.^E66XG\S<ZJ "!(RC@<= *Z2@ HHHH **** "BBB@
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ME-<9XFNH?%FO^*CH#?:PWAE(UE@&X3E9V9@AZ/Q\O&>>.U>SD9&#TI  H
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M[SPYIQ@F\F)TG\N-@Z9D1OF!8':.3O[UZ3H6DQ1?#VVTNRDN&A>Q,<+7:;)
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M:^9\[=/:Q-N4X.9%?=NS_LXQC\:UB$("$+@] : / -;NHI/ ?BJW%[/=3?\
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MUO9BW,F.&;;@GZ9S7':#X;\0QZ)X.L+W3$MGT*^!F<7*.)(Q%(N]<>[+P>:
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M% !2,H92K $$8(/>EKG/&M[]CT6%1JEQIYGN8XMUI 9;B8'),<0 .'(!YP<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ<1G:#TRH[5!J7A*:^\$>);71O!D.C3WD,<5O"9(A-/AMS;]K%% [?-Z].*
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MM*\?FS2*XDVMY;, F449SGJ<5J*GB+7O&OAK5+GP_+IEEIZW(G\^XB=]\D6
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MDXK3^'K,_P .O#C,26.G0$DG)/R"L#^S]?T'4?$UCINB->6NL2>?:723QI'
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M.Y>O# 9'OTKC])DUC6?B-XBAEUJZATS2;FV,-K"$ D+PJQ5R03MSDX&,ENO
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MBDI'\N  ,@9!QG/- 'L-%>5W&O:YHR:YH,6JS7%PFL66GV=]=*KR0K<JA).
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MBWMVE2-GV X&2<D=ADX[XQ7G4/B37KF7X>W]S8R37UW;7!\B*=0+HFWC(D;
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M49<,IY!.2K9''7/';^#+;4[3PO;PZJ;C[0'E*+<R"25(B[&-9&!(+!-H)R:
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MD:@LNTG*DYP3@\=*P+)O$?A=]8TFPT":]FO-2EN[*\W)]F"3/N/FG<&4J2W
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MWDR75KX>N9]">[-HM_%*&<D.4,GD@9\L,"-V<XYQBN.TS0-2AF\,WS^%;_\
MM/3[Q7U:]GE5Y9W*.C-&2YW)N;<3Q@8P#SCH/#K>)/#>FV_A:WT"666"\=5U
M&1E^RFV:4OO)#;M^UB-N.OM0 S1?'NIQ6/BK4]?T_P NRTR^D@C$,JNP8"-5
MA4 #<2S9W$]6QVK>L/%5_P#V[::3K>B'3)[Z)Y;1DNEG60H 61B -K '/<'G
MGBN1F\.ZW<Z9XST--+G2XN=5;5K*Y<H()@'B=8]V<ACL(Y&!ZUO(-3\3^,M#
MU&31;W3+/2$GDD:]V!I)9$V!$"L<@ L2W3I0!>\%^+[KQC91ZBFB26>FRQ;H
M[B2=6+N#AE"@9P.?F.,D'CO5G7=?U73;MH--\/3:BL5N;B:9IQ#&!DC8K$'<
M_!..,<9/-5OAOIEYHWP]T?3]0MVM[N")EDB8@E3O8]OK6)XHT6[U'Q9>B\T*
MYU>VGLXXM,/F@6UM)E_,,@+#'5#NP20,#TH U)/'37-YI=IH^D2W\VIZ:-1M
M]TPB54RO#D@[>&'(SS@8[U&OQ!,FC6\L>CRMK$VHOI8TXSJ,3IG?F3&-@52=
MV/3BLWP5H^K6NK>'9[S39[5++PX=/F,I7B99(^."<@A"0?2J9T#6M.N5UJ/2
MYKE[+Q-=WOV:-E\R6VE0IO3) )&<@$CH: -GPOJ5_?\ Q'\1QW]K+9RPV-FK
M6QF\Q%8F4[D8<$$8YP#V(XINN:GJ-C\4K&+3[.2^DET:;;;>=Y<>[SD^=F.0
M  ",X)Y [U/X8AU6Y\=:]K5[I4]A9W=I:QVRSE=Y"&3.X*2 ?FSC/0COD"_+
MIUVWQ.M=3$#&R31Y;=ILC D,T;!?7H"?PH KVGC*\O\ 0OM-IX?N9=36^?3Y
M;(2C;#*A.XO*!@( /O8YR!CFHAX[F-DL8T9AK)U(Z8;%KE0@F$?FY\W&-NSD
M'&3G&*YVYT'5H4G^UZ5>W>ER>([NZNK.U<"2>%T/E-C<-R[\$KG\.*BT_1)[
M"QUG3]0\"2W.E76IK>"VAD0M%$T*A2GS#,BLF&P1C)()% 'I6C7]WJ-B9+[3
M9=/N4D:-X)&#C(_B5A]Y3V/%<S>^.[^.;74T_P .27B:)*5NI#=+&"HC5\ID
M'<V"?E]ASR*O^!;34++1;B.]2\B@-V[6,%]+YD\5O@;5=LGON(!)(! JA9Z-
MJ$=MX[5[5@=0N97M1D?O0;9$!'_ @1SZ4 6I_&DEU=V-GH&E-J5U=6*:BPDG
M$"10/]PLV&^8G. !V-:OAS7HO$6E&[2"2VFBFDM[BWD(+0RHVUE)'!Y'4=01
M7&:18:OX4O=*U-]&O+V&;0+6PN8K38TMO/$,\J6&5.XC()P1[UT?@?2K[3=*
MOI]1A^SW6I:A/?O;[@QA$C?*A(X)"@9QWS0!#J_C"^TBYNII/#UP='M)HX9[
MYY@C?-M!>.,C+H"P!.1T.,XK0MO$J7-SXAA%LRG1G",=_P#K<Q+)QQQ][%>=
M>)?#6J:FGB**3PY=W^KR7C3VE_+*ODI; JR)'EN&P"NW:.2236WC6['5?%*P
M>'KZ<:ZL<]I*#&$B)MUC99B6RI4KV!SVS0 ]/&^M:CXG\*16&F*-/U736O9(
MVN%!((C.<E<C9N/ ^]GVK-T3QEJ.A>']5OI='GO=,L]7NQ=7;7(5HU^T,/D0
M@EPH([CT'0U/IVE:QHMYX!O)-'N[A+/1S87:0;"T$C+%@L"PXRIR1GI4EQX=
MU9_A1XFTI;)S?7=W>O!#D9=7G9E(YQR#F@#HK_Q7??VW>Z7H>AG5);"-'NW:
MZ6!4+C<J+D'<Q7GL!D<\UGR_$=+C^PTT;1Y]0GUFUEGMHC*L15HRH9')R%QE
MLG_9P,Y%(/[4\+>*]>O(]#O=3M=6\F>!K,H2DJ1B-D?<PV@[5(;D<FL[PSX2
MU;1=9\'FY@#+9V%Z+N1&!6.6:17V^_)89'I0!<F\0K:^+/$2VNDRMK%GI45S
M)OO3Y3C&=H7[H(YY YQ2^%?&VHS:;X4CUZPV2:U!B.]692LD@C5P64* I?YL
M#MMIK>'M4E^(OBN]%JRVE]H\=M;S,1M>3!!'K6;)8WLGP5@BN[&?2]4\.P13
MPM=[0/.MU#;E(8_*<,N3CJ: .YL]?6^\5:EHL-LQ73H8GGN=W DDR1&!CKM
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M.K1[%!"Y4C!SP:YZWUSQ2/ ECXPGU]W=;R.)[$6T0BEB-R(3N.W=NP<Y! &
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M)[*P_MG4-9M[NVD:Y>ZTQK86TRX(*'RT&QAN&TY(P.:]&H ;))'#$\LKJD:
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M<6.AWNKSZK9ZE9S31O<Q1K)%+$4W#,:J"I#]",@CK78R-LC=R5&T$Y8X ^M
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M\%02<<D'C/UK'E\:ZK:V::+?:K+%<QZU/I\VJ06?FRF&.,2!A&JL-Y#(N=I
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MYJV? I/P^?PK_:/+3&7[3Y/3-QYV-N[_ (#U]_:NQIAFC$RPEU$K*7"9Y(!
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M)9(VWX&5^4D@]R,9Q6?X[T_3?$NM:#X6TN9_[0M)O+NU@S_H]BT>)5<]MR[
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M3\M>EVGA/1K*]L+V*WE:ZL(GAMYI;B21E1R2P)9CNSGOG':IO^$;TC_A)?\
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MVS?:)#)"P& 4D+;A@<8SC''2M2PTRUTU)1;(P:9_,ED=R[R-@#+,22> ![
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M[MC9'T/0BM'6+36M&M[:ZM)]4UR&68W%[9K=".?9L _<8VG:&(8H#R2*UX?
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M_EQQ12LIB>$+MY0 Y)SDYR.E:O@7PJNG>%="CU2TN([^PB'[F>X,B12X(+*
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MJMI.9-\EM)\ZE-[9)!*9&3D<X-=CX7L)[;3DO+C5+Z]EO(89&6Y<,L;;!G8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ J*XN8+.!I[F>."%/O22N%4?4GBI:X'
MXNZ/:7_@/4[ZY$DCV5L[01ESY8<E1O*]"P&0">F3B@#N;BY@M+=[BYGCA@09
M>21PJJ/4D\"H[+4++4[<7%A>6]U 3@202!USZ9!Q6?KFC:7K%E:OK&#9V4HN
MRDC 1$JIP9 >"HSG!XX%8'@:UBN-=U_7]-M1::-J'D):((_+$YC#!IPO8-N
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MGH>!SUH [&BO/9_$>J-XVN=-DUZUTN:.[C2STV[M<)>P$*2RRGDL<N %/!4
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MD&& 9BPS[X(KK*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *X?XE-<R6FA6$-JMW#>ZHD4]L\_E
M+.HCD<1LV#@%E7(QSC'>NXJCJ^CV.N6#66H0F2$LK@JY1D93E65E(*L#T(-
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M.T3/_P ?"!0KYSD_=&?4\G.30!S&N:#HZZSI_AS3?#%OJ*V=E)<+9W-UY-I
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M5O0(5&YC\NT  =!VH \TU2%M(?Q'X?TBU TV37M/A%BDQA39+$C/&&YV*[
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M4DCH)!A\EF.[CCG..V* /-6TNQOOA9KGBZ[0#Q&DMW<+?D_OH)8I7$:*W50
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M@,*,P8$ Y#%L@\CIVKA/#U[;:-8?#35]3F2WTU-,N+<W,IQ'%*ZH5W-T&0K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX4^*]!6UC.H:AJLEU;Q^<N&C,L; DYP.%/!KU.:%WTN2!1F0PE ,]]N*M44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+I-M(=1673+V5K*34;.=3%:N4)&^0'Y#T /8D=*Y[P?J&E:)KOB@6.J"_P!
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M+;F2.!G =T^QCY@O4CWH [S1/&FBZO/;:?'J,;ZE)#O,81E#D ;]C$;6P<Y
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MO[@U;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHK+UO0XM=@BBEO=1M1&VX-8W;P,>,8)4C(]J
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M<1\L&^X.HZ'ZC KCK7QY<:W;Z6OA_25N;V]M7NY8KJY\E+=%?80S!6);>"H
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MLDUT%S<16EK-<S$B*%&D<A2Q"@9/ Y/T%,L+ZWU.P@O;5F:WG0/&S(4)!]F
M(_$4 >=>&M&UT0^!(KS1I[,Z$9H;II)8F!'V=D#KM8Y!8@>OMCFG>(O!NHZM
MJ'BB?[!'<137>GW=M#+(H6[$*CS(SS\N1E<G')':O2Z* ./\&Z/;6=[>W=MX
M130(FC2-#(Z&:7DELA&8!1QCG)YX%5&77M"\<^(]5@T"XU*QOXK5(?LTT2OO
MC1AR'8?+EL$]1QP>W=T4 >/V_P /YM+AT2ZU?PXNO;;&6"[M8'3?!*\S3!EW
MLH89D93SV!YKH].\.7=MK'A"YAT2#3;:S2^:YM[>4,MN90NT9_B)QSC(SGMS
M7>T4 >8:YX,U#4KC7[B33$NXCK5KJ$%K)(H%W&D"QNH.?E/+XW8Y [<U:B\-
M^9X1\50Z7X0319+ZPDM[:)I$\ZX8QL!OVL54;FP/F]2<5Z+10!YKJ'A?69_#
MWPXM8[(M-I%W927R^8O[E8X\.>O.#Z9K8\/V6IZ7X]\2F?3)C8ZE-%<P7JR(
M8QMB52K#=N!R/2NRHH XJ>'5_#GC/6-5M-%N=6L]6A@.+62-7AFB4IA@[+\I
M!!R,XP>*PI_!>MQ>&/!]J+=)KRU\11ZG?B.1=L2M)([X)(R%W@<=<<5ZE10!
MS7CK3[[4O#1M[&"2YQ<PO<6L4@C>X@60&2,,2 "5![C/3O7 7WA'57LO%<&D
M^$ETZVUC2X8[2WA>%-DD;OE90&P'8,#D9&."<BO9** .4\2:'=ZKXK\/3QQ$
MV<$5['<RAA^[\R(*O!.3DYZ5R0TSQ7-X0T#PRWAZ2-])O+/[1=FXB\J6*&5<
M-'\VXD@!B"!C!')P*]8HH Y3QYIVJZA9Z,^D6BW5Q9ZM!=M&T@0%$W$\G\!^
M-<SKWAG6/&]WK-_+I+Z<G]F1V=I;7LD9:=UG$S;MC,%4E%7KW)KU&B@#B/"&
MBVMKK$MY;^"4T%5M_+,TLD9E=R0650C,-G Y)!)QQ27<>MZ1\0]2UNWT.XU'
M3KC3H+?_ $:6(2>8K2'A79>!NYY[C&><=Q10!Y1%X,UY$\'S26:F>'6I]2U!
M$E4BW$K,V,Y^;&0.,\YK>M] U-/#WCRU:U(FU.[NY+-=Z_O5>!$4]>,L".<5
MW-% 'G.FZ?KOA;6HKZ'0Y]2BO=(M+69+>:)6@GA###;V VD-U!.,=*R;?PAX
MC_L?P?%<6"_:;'Q%+?7@252J1-+(V\'/(PP..O/2O7** .+M-#U&*T\<H]L0
MVIW,KV@WK^]4VZ(#UX^8$<XK(TBQUGPQK.FSQ:2=0DG\/VEI<VL-S$LMO+#D
M;B&8 H=Q&1GD=Z]+K&UGPKHVOSPSZA:LT\*E$FAGDAD"GJNY&!*GT)Q0!@?#
M*.6?P=>"ZV&2;4K[S#$<J29G!*GTSG%8:Z'XCG\#6O@*7194$3Q02ZKYT?V<
MVZ2!MZC=O+%5 V[1R>M>EZ?I]GI.GPV%A;I;VL"[8XHQ@**LT <;9Z)J,2>.
M ]L0=2N'>T^=?W@-NB ]>/F!'.*NZ?I%XOPSMM%EC$=\-'6U9&8863R=I!(X
MZ]ZZ6B@#S?0=)UN5/ ?VO1I[(Z(LEO=^;+&>!:^6'7:QRI;@=_;'-0^(_!FH
MZKJOB*[.FI=P-?V%Y;V\DB@7:Q1;)$SGY3@L!G SCM7IU% ')>#-(MK&>_N;
M;PFF@12!$C#NAFF R27",RJ 3QR3UZ53N;/7/"_B_4]8TK2FU?3-6$;W-M#*
MB303(NW<H<@,K*!D9SD5W-% ' :MIGBKQEX=UR"\MH=*AGAC&GV,KK))YB.'
MWRNN0-Q"C:"<"IUBUKQ-XIT"\O-"N-)M=(:6>8W,L3&65HS&%CV,V5&XG<<9
MP.*[BB@#S2T\+:S'\,_#6DO9$7UGJ5O//%YB_(BW&]CG.#A>>#5?XF:7>J/%
M6K&'%B_AQ+99=PYD$SL5QG/1@<XQ7J=5-4TRSUK2[C3;^+SK2X39+'N*[E],
M@@B@#BY[7Q!XCU_0WETB73$TA)II+F66-DEF:(QH(@K$E<L6RP7@8QFN>T?P
MOJ5G=^%[Y?!SP7VFW _M2\>:%KBZ9HG1I%;?EDW-N.X@\C XKU\   #H*6@#
MS9_#&LGX/7FABS/]I27,TBP>8O*M>&0'.<?<.>OZU#\1]*NI?%&EQ:7*J3>(
M87TB]4'#>0")&D [E4\P9_VQ7I]95MX<TJUUR?6H[4G49UV-/)*[E5[JH8D(
M#CHH% #)-0.G:YI6AP6 ^RSV\I$RR "$1; %V8R00W7/&/>LKQ;H^JG6-(\2
M:%#'<W^F^9%)9R2"/[3!(!N4,> P*@C/'6NK,:&02%%\P J&QR <9&?P'Y4Z
M@#D[/5/%6LZO9@:(^B:9"Q>[>\DCDEGX($:*C' R02Q(Z<5RO]@^(E\!R?#]
M=%E*L[6ZZKYT?V?[,9-V\C=OW[3C;MZ]\5ZM10!R>F:-?6VO^,;AX"L%^T'V
M5MP/F!;=4/?CY@1SBN7_ .$=NX_"6@:7JW@V;4I+338XXI[.YCCN+6X PRER
MZ[5^Z=RD]#D=*]4HH \ZL;+Q-X>U^RU&YTN?6I;C0[>RN9;>:,%+F-F)+;V7
M*G?]X9Z=*RAX0\1'PQX/M9;!3=V'B?[?>*DJ[4A\^5RX)/(PP..O/2O6J* /
M.-2TCQ'%XB\;+IUC,!KEE%]BOXYD58I(X&3#98,I+8 (!ZYXK+MO#%W%J]G?
M:7X+.EVYTZZLIAYD/GM(ZKAY"'.Y<J0#DMDDD#->MT4 <$_A[53X.\"6(M3]
MITRYL9+M-Z_NECC(<YS@X/IFK?@ZRU/2-?\ $MI>:9,EM>:E+J%O>B1#&ZN$
M 3&[<&X/48XZ]*[*B@#R'Q3X/U35V\40/X974-3NY&DL-4N)8S'%"$7;&F6W
M(^0P "@9.2<5V?ARPU!/%OB#5KNQDM8+^"R\E970MN1'#J=I/() ]/3-=710
M!Y5X?T'Q!X5A\+ZF=&FO9+;3)M/OK2"6/S8]THD5EW,%;E<'YN]=1X%T_5K(
M^(+C5[,6DM_JKW448D5\1M'&!R.XVD'W![8KK:* /*;SP]X@;0?&^A)HTSMJ
M&I/?VER)8_+E5GB.WELA@%8\C''7I73^*/#UWK7BC2'CC/V);"_MKB8,/W9E
M2-5XSDYP>GI77T4 >9>$/"R:?>Z3%-X%@L[RQ3%UJC2H49U3:&AVL68L>?F"
MX!/>J-AX.U^'P'_9TFGD7?\ PDBWOE^:G^I$ZMNSG'0$XZ^U>MT4 4]6ADN=
M&OH(5W2RV\B(N<9)4@"N%NO"%]=_"KP[I<^G)<7NEBTFFL))% F,8P\>[.,D
M%L'.,XKT:B@#SNQT5;;2]5FL/A[;6T,_E1&QN)(_.NX@?WF0&9!C/R@MR0<X
MXKG-6TK4-+\.7#6>F7&FV$NLZ<=-TV]N YC<2C<?E9PB,VW@$XP3@9KV>J>I
M:79ZO!%#?0^;'%-'<(-Q7#HP93P>Q .* //M>\.ZSX[O[^:?2IM)ACTB:RMQ
M>21LTL\CJV?W;,-@V 9SDYZ4NG^$;?48;ZUC\$1>'VGTV:UDO))(V82R+LQ&
M$9LI@DECCMQ7IE% '&>';WQ41I.E76@"Q@M(/+O[J:5'64JFU?(V-GDX)+ 8
M&1UKCCX7\27'PET_PR=#FCO]-OH22TT6R9%E9BZ$-T QUP>>]>R44 >??$'P
M[KM[J,%_X<B#7%[9R:3>MO5?+AD((EY(SL._IS\W%1>(_!EK!K.DW@\-G7-,
MM=._L\VD;()(=I!C=0[*",;@><\@UZ-10!C>%=/&F^'K>#^R;?2F)9VLX'WK
M&2Q.,]"<8SCC.<5LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5R7C^_P!4L=/TA-)O/LEQ=ZM;
MVIEV!@$<D'(/7U_"NMKBOB5:27NGZ#!%)+$[:Y:8EB&6C.3AAGC@\\\4 8>M
MZ_K'@>^UNR_M2YU2,:-]OM'O41GBF\T1$?(J[ERZG&.Q%+I^O:G;7=W!;7^O
MW]J^EW$TEQJ>FO;_ &>X0 J58QH-K M\O."H]:W_ /A!&U&759_$.J'4+B_L
MOL >& 0+!#DM\HRWS;B&R3U XJW:^'-8>*ZCU?Q))?++:/:QHEJ(47<,&1P&
M.]^!SP.O'- '&_VAXFM?A?8>(FU^>74]2.G[5>-/*A#R(IPH )W!OFR>3TQ6
MF+/71X\E\-?\)7J36,VFB_>8K#YZ.)"A5&"853D'H3Q@8R:W9O!B2^"=+\-_
M;6"V'V7$_E\OY#*WW<\9V>O&:T?["7_A,?\ A(?M!W?V?]A\C9QCS-^[.?PQ
MB@#SN'Q9KW]E^"Q)J+M-<:]+I]W*$4&XC21T&1C@D*,XQ49TZ\-_\3YEUW4T
M:W0;0K1X;_1@XS\G;[HQCY3Z\UU"_#J,0:+'_:3_ /$KU:74P?)'[PN[/LZ\
M8W8S[=*MMX,E.N>(+I=5*V&N0[+JT\@%@WE>7N63/''.,'F@#B[35+G2]#\'
MZ(VKZVEM=Z4+Z>:SM?/N% 2)4B0)&=J L3D@G@#/-7K37]>U<:!H,E[?V3WE
M]>1R7[VOD7$UO NY&"NN%9@R G;V.*V[3P/JEEI^D>3XB4:GI436UO=&Q&QK
M8J@\MX]_S<HIW!AR*M7G@Z]N;32YEU^;^V].GDGCU"6!7#>8"'0QY V$'  /
M&!S0!0\%6US9^._&=O=7CWCQFR"SR*H=U\IB-VT 9'3( SC-5?%NJWUCXEG6
M^US4M"T\01_V?=P6JR6IE.[?Y[%3CG;P2HQWS71^&_"\VAZIJ^I76J/?W6J&
M)IF:(1A612OR@'@8( '8#J>M1:]X9U75Y;V.V\1/:Z??P^3<VLEJ)MHVE6,3
M$C82#SD,,\T )H6IWMUXR\464]SYMO:+:&!0 %7?$68CZGGDFN3\-:SK?BV#
MPYI4NM7=F9-&.I7EU;*@FF<R>6J@LI"CAB<#GBNFD\%W5OK-Q=Z1K<EA;7EO
M#;W<'V<2,PB4JK(Y(V-M.,X/K5:U^'\^E66C?V-K9M-1TRT:R^TO:B1)X68-
MM9-PZ$ @@^O7- $%PWB*35]$\)W6N/%-);W-U=ZA9QJDLT<;*L:C<I56.\%B
M!VXQFJNO:GK6@G1="U+6+V07<UR[W^G69ENFMXPNQ2JHP#$NH9@N,+VS6P_@
M>YC@TRXL]?N$UJP,Q^WW$0F$PE.9%9,CY<@8 (VX&*4^"KM+6RGBU^X.MVMS
M+<B_FB$BL91AT\K( C(QA01C:#F@#F?[>U^718_/FU^/2[?4I89]0AT\I>/;
M>6&C<QM'G&YMK,J?P>YJQ?:S>?V3HMP/$FIW6@.+C[1J^EVBM,&##RA*H1MH
M WAB%'S*,@5T[>'==6SMVA\53C48YI)9)I;8/#('&-GE;AA1@;?FR.>3DU6M
M_"&K:;;QG2_$CP7C2S37;RV@DAN'E?<6\H,-I!Z8/3.<T 9D6HZCKVKZ)H-M
MXE=K9M+?4+C4[&-$>Z D$: 9#!.I+8'48XZ5DZAXD\1VFESZ7#JA;4++Q+;Z
M:EY)$N989 K+O  !.'P< 9Q731> I-.BTN;1]7:UU.QBEB:YEMQ*EPDK^8X=
M 5XW_,,$8]Z!\/XVTZ&&;4Y);S^V(M7NKIH@#/*A!VA0<*N  .N .] &-XAE
MU/P_>6UKJ7B77;?24M"R:M%;1RYN3(Q/GD1G:@79@8 (SD\5WT5R5T)+J2]M
MY"+82-=@8B;Y<F3&>%[]>G>LW6M$UB^O'FTSQ ;&*: 0S02VHG0\GYD!8;6P
MQ!Z@X''%64\/6<?A$>&E:3[$+'[#N)^?R]FS.?7% '#^&?$%[_PE.BVXUG5]
M3M]3MYC/)>V)@@9U4.KVY**=O48R>"/K5&PU3Q(G@70O%UQXANI;B2\@BEM/
M+C$$D3SB(@C;NW$'.[/7H*ZFS\$ZG%J.BW]WXC-S/I.8XE%F$C:$IM92H;[Y
M 'S9XP,+US.G@:-/ UAX9^WL4M)H91<>5RWES"7&W/&<8ZT <MJTFL>(?"WC
MC5O[:N8(K-KZS@L45/(,42%6W@KN+-\QSD8X^E=]HDHA\':=*9$C":?$Q>3[
MJXC')]JYZ_\ A_=W":Y96?B"2TTG67DFN+46JNZR.N'VR$\*Q&2,>N",UT_]
MC1/X9_L.:1GA:S^QNZ\$KLV$CT.* //O#_B'4/\ A)-&AAUG5=534X)_.>]L
M3!;/(L>]7@)13MR",9/!!]Z70=8UJ6&XB&N7[>)QITSS:-JEJL:M<!?E: A5
M&P-QP6!!&<=:VH/ FIBXT:YNO$SS3:4#%!LM!&ODLA1A@-G>1CY\\;1A>N9E
M\%ZI<SP/JOB>>Y-G!+%9RPVZPS1LZ;/,9\G<P'H ,\D4 8FDZY.-%UV2'Q+J
M<U_;:5)-+8:K:K%<6TX4D2+\J_)GC&&&<<^K-+UK6O$&G^"-,.K7%K)J6GR7
MM]=P*@E<($ 525(7+/D\=JZ >#;^\DO)]9UT7MS+ILVG0R168A$:28W,0&.Y
MLJO<#@\<UBZSHMOX2TKPF!JEY:3Z4CVD>II9>="$9!N$R Y ;:,$=".M &==
M:YXHLSJ]C_;1DN;?Q!86$$[PI_JI%3[R@ $G=EL8YSC'2M2ZN/$NBZYK>C:;
MJEWJL[Z(;^S^V+&72<.4PNU5!!X(!&,BJGA;PR^O)JU\UY=&VEUZVU""ZN(-
MK77D*A9@IQM1F# >@%=AJ?A9M0UVXU:+4Y[.>73?L"- H#1GS-XD!^O&,<T
M9O@?4H[VZO8HO$.H7_EQH9;'5;8175M(2<DX5?E/'&",C@UVE<I;^%=6^T7^
MH7GB'S-5GLOL5O=06:Q+;KDMNV;CN;=@\G''2NG@1X[>..20RNJ@-(1C<0.3
MCWH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN(^*,FMVO@^]OM*U4Z
M?%:P-+*T*_OI&!&U0W\*]2<<G@<<T =O169K6LPZ%H<VHSJTFQ0(XD^]-(Q
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MTZ^@M+F-ITD6,2%"KJ<88,' Z#&<]JUVU>%OB'HEE>Z=<0:I/ITLH*WA:*(
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M'*4V;8AO8/NRW/  ]^*N:5I5S8_"'2=*U+PZVI-'!''>:>64.%S\Q4'@LO!
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MQOKO2=+GL+.6\>PU>UO9((<;VCC?+;02,G':G>';2]/BOQ-J<]E/;0:A'9M
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ML00:R#=^(-!\5Z%;ZAK!O[?6/.BE@:WC1;>58S(#&5 .WY2,,2>AS5KXJ?\
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M DBB\FU,?F1&$1*#ES\PZD]^F!UI^H>!FO;_ %B_BU+R+J[N[6]M7$.[[/+
M@49&?G!P<CC@D>] $?@G7KC4=3U73WO[K4[2W6*6WOKFS-N[;]P:-AL0$J5!
MR!T;VI_BN^UH>+/#>C:5J'V&+45NOM,HB21@(U1@5W C/)'ISD@XQ6WHEEK%
MLUS-K.J17DTQ79';P>5#"H'1069B3G))/I@"N9\96]Y<_$#P<-/NTM;M([YX
MY)(_,3(2/(9<C((R."#W[4 4O^$@U?3[;Q'I%_XAACGTR\MHX]5FMU,C0S*K
M8$:+AI1\RC"X)QQ67=^-=9LO"?BM[+4[F\GTN:S-I=7MD()665T#*Z,BC^\
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M6*Z:^O+*R\]W:&7R0$78X4,<L25XQ@8S5[3M'U2V^(&O6V@:E#;-9Z9I]O\
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M2P)[X^M 'K8((R#D4W>FX+N7<1D#/)%0V5C::;9QV=C;Q6]M$,1Q1*%51G/
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M\#_%A9@,7]\O)[FZ8 ?J*FU"PM++Q[XTU6TL8!J-GH*7=M*(QN28I+E@?4X
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MU2[,5O"LF0' V.3(WEDEL# '6H='L8?$]]\/(-7W7<$NA3M/'(Q(FVF/ ?\
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M(FR,@X(_ T 6Z*** "BJFI:I8Z-8O>ZE=16MJA :65L*"3@<_4BK= !1110
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M=(S=/^!5G7_A_7K?7-1O_#VHV5NNJ)']I6[@:0Q2(NP21X(!.W'RMQE1SU%
M&3J7CN\T*TTOQ)>PM)H.JV*,L")^]M[HIO1,]2'Y7GHP'8U7U;Q/K.C1:%IF
MMZU;:7?Z@DUU=W:VXD%NJ[=L,:\@G+@;CG[I/<5OZAX-&O:NDNOW"7^G6]H8
M(+5DQND==LDSXXW8X7 ^7)(Y-4XO">O6<&DW%OJ]M/JFDB:WBFNHF*W%J^W"
MRX.=XV(=P[KTYH PCXXUV\T31UTV[M9+R?76TE[PP8CF38S+*$/(XV,0#U!&
M1FMK[1XFO]?F\.VFOQP2:991375\;)&:XEE9]HV9VJH"<XY.>U7;KPQJVI1Z
M#+J6J0SW>GZG]OE9(=B%=K@1H.H W  DDG'-/U7P_K,?B277?#M[907%U:K;
M74-[$SHVPDHXVD'<-S#'0CTH S+C7M=M/&W@G2=02S26_M[HWRPKO7?'&""C
M$9 SSC\.:B\,>(]4U3Q"(+K7;..[6:5;K0I[;RI(8P6"M$WWG/"DGE2">E:
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M*NK7:W"(JD&,!<8/K0 WQ9J^H6U[HFC:5+';WFK7+Q_:9(]XAC1"[L%Z%L
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MK;SV*VJJH65<!P^<[LX)'3G&.*U?^$5\1W>KV.IW^I:;YD%I-9-;V\#K&(Y
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MSV=NL+2*,!B.X%;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+Q5X9&OJ]Q'-X3CN;B)F(69_-7!8#J,MNQZX]*[/XHDI\,=?*L5(M>".W(H
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M?FF%E/F;3:[NJ*N!']"3_%4?B#2M2T;P7XS(T>#1=,EL(GBLH+L2JDP<AG4
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M1DY'T/\ *N(N=!TOP]9^"]3TB(1WUY?6UM<W"L2UY',C>9YAS\^?O9/3'&*
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MN9E8EKR*2)RYDY^?H&R>A%)\-_#VD6OC7QA-!I\$<EEJ0BMF5>8E,?(7VY-
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M6\<5S:_V=O\ LTUK=212IO\ O_.K;CN/)R3D\TY/ WAZ/1KK2DL2MI<W NG
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MHKBU^P[_ +//:W4D4R;SE_W@.X[CR<DY//6KL7B71YO#1\11WJ'21"TYN-K
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M<'->?WD4"OXLT76/%DNF_;-3E)TU+6*26XCEV^6T>5+OD8'R]"O;%>S@!0
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MIN<88[1DCT-."J,X4#/H* /'UN/^$8\%^!?&ZH[16.FQ6=^$'+6\L:[?^^9
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MH2ZG!=>)9KK[3-"(P[E)"64  ;=RE@1P<YKUB^$1T^Y$\;R0^4V]$!+,N#D
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M1>W-GJLVJ1WE_+.UT\(C5WX5B@4 %<J3D<')KJ'C25"DB*ZGJK#(-*H"@*H
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M.,C!)'49'K5OXC75K9:EX/NKS MXM9#NQ&0@$,GS'T"]2>P&:[A(8HE CC1
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MSSG?TQVK8>*.10KHK $$!AG!H \1LI8+NQT&WDG:XEC\;O)()U59?F\UT9T
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MJ-45)\L492=VX$D#C'(R14=UX,EM=5FO9_!MCXA-Y96R*9FA!M9HXPA5B_\
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ME4S1)Y70DX4G8W7'2NZL[W5+C4$2XTG[+:-:+*96G5G28L08BJYZ#!W XYH
MTZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH S+_ ,/:3J>I6FH7UDEQ<VAS TA)"'.0
M=N=N1V.,BM.BB@ HHHH **** "BBB@"GJ>EV.LV$ECJ5K'<VLF-T<@R,@Y!]
MB#W%0:-X>TGP_',FEV26_G,&E;)9Y"!@;F8DG';)XK3HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *S-8\/Z5KZP+JMFETD#[T21CMSQU4'#=!P<BM.B@  P,#I1110 444
M4 %%%% !1110!B:QX0T#7[I;K4]-CGG5/+\S<REDSG:VTC<OL<BM>"&*V@C@
M@C2*&-0B1H,*J@8  ["I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***Y3QYXHU+PMH<M[IND_;'CB::265]L,**1]X]2QS@*/<DC% '5T5A>)M
M=GT:QLULK=+C4=0N$M;2*1BJ;V!)9B.=JJK,<>F.]/T&X\0.]W!KUG9HT14P
MW5FY\N=2.1M8[E*D<YX.1B@#:HHKE;_Q7-8_$.P\.F&+[)<:?+>23'.]2A(P
M!Z<4 =517G7A#QY<>*O&>J6R7]I'I]K.\%M:K:2&6=57/F&0G"\]L5W6I:G9
M:/82WVH7,=O:Q8WR.>!DX ]R20 .] %NBL6#Q=H-SI,VJ1:E%]C@E6&61E93
M&Y( 5E(!!)9>H[U!;^.?#5T+TPZM"XLH3<3_ "L-L0ZN./F7_:7(H Z&BJ%W
MK6G6&EIJ5S=QQV;[-DO)#;R N,=<DC\ZNR.L4;2.<*H+$^@% #J*YZS\=>&-
M0OK:SM=8@EGN@#  &"R$C< &(QNQ_#G/M3[_ ,:^'-,U%["\U:&*XC*K("&*
MQ%N@=@-J9X^\10!O45BZGXMT'1KP6>H:E%!<D(RQ$$LP<D+@ <Y*M^1K&M/B
M!IFLP^(X;*[2TETM9-MQ-&S)M6-292N!P&;&W.3MSWH [.BL >*-,TWP]IE_
MJFJV[_:XD,<T4;#[2Q4',<8RV#UQS@5,OBS0'TF+5!JMO]AEF$"S%L*),XVM
MG[I^N,4 ;-%9.C>)]&\027$>EWR7$EOCS4VLK*#T.& .#@X/2KNH:C9Z382W
MVH7,=M:PC,DLC85>W\^* +-%8%OXT\/W5C>7D&HJ\=F%,ZF-U>,-]TE"-V#V
M.*P?ACXOOO&6F2ZE?7EH7DRRV-O:NAMAO8#,C,0^0 > ,4 =[17,^(O&^E^&
MM;TG3+UB)+]GRP#$1($8[N <Y90N/?/:LVQ^(>FVMWK<&OZA;VQM-4DMH $;
MB()&0SXS@99AN.!^5 '<45AOJO\ Q64&GKJMH(Y+$SBQ\HF5_FQY@?.-O;&*
M=I7B[0-;O6L]-U.&XN%4N%4$;U!P64D88 D<KD4 ;5%%<#'\0IG\=_V8;*(:
M$UXVF)?[CDWBH'*>F.J_44 =]167K/B+2?#ZP'5+U+<SL5B7!9G(&3A5!)QW
MXXJN/&7ATV/VT:O;&T^T"V\X-\GF%0X7/3[I!STH W**YZ7QQX;ATVTU!]40
M6UYO^SD1N6D"'#$*!NP".3C%6;[Q3H>G:?:WUSJ,0M[L VS1YD,PQG*A02PQ
MSP* -BBL:;Q9H-O8V=[+JMNMM>AFMI=V5EV@DXQWP#QUSQUJ@WQ%\)+9"[;6
MH1#O:,_(^Y"N-VY<94#(Y( Y% '445BZKXMT'13 -0U.&(SQ^;& "^8_[YV@
MX7_:/'O2ZAXKT+2F1;S4H8VDA$\:C+F1"< J%!W?AGUH V:*Y'5_B/H&F:9I
M.H1W*W5MJ5TL$3Q[L ;L.QX/W?[O![5U<,T=Q!'-$VZ.10ZG&,@C(H ?16!>
M>-?#FGZDVGW6K017*,J2 ABL;-T#N!M4G(X)%2ZCXLT+2;\6-]J44-V3&!"0
MQ8[R0N !SG:WTQS0!M45!>7<%A9S7=R^R"%"[M@G '4X'-<%_P +.MK_ $/P
M_K%F\5M;7>HK;WHG!/DQ^7(Q^8@#/R Y% 'HE%8VG>+-"U6SO+NTU*%H;+FZ
M9\QF$8SE@P! P"<].*DT;Q+H_B#SAI=\D[0X,B;61E!Z':P!P<'!Z&@#5HJI
MJ6IV6CV$E]J%REO;1XW2.>!DX ]R20 !UK/@\7Z!<:3+JD>I1?8H95AED8,O
MEN2 %92 5)++U'>@#;HK#T[QCX?U:6YCL=4AF>VB,TJ@,"(_[XR/F7W&14=E
MXX\-:C?V]C::O!+<7*AH0 P$F5W85B,$XYQG/M0!T%%<#IOBZ_O(/&QNKRTL
MDT>\>"WN7A++$@7.YP#EOPQ6_<>*](T?2-.N=5U6#==PJT;QQL?/^4$LJ#+;
M><^V1F@#?HK$O/%_A^QT^SOY]4A^S7@S;-&#(90!DE0H)('?CCO6=K/Q#T+1
MSHK&X6>'59,1RQ9*K'M8[^ <\@#'7GVH ZRBL'3M76;Q!KEO)J]I-#9K"WV9
M8BCVH9"Q,CDX;=U'3 I=*\9>'M;O19Z=J<4T[*71-K+YBCJ4+ !Q[KF@#=HK
MG%\>>%WN;>W768#)<2>5'PVW?N*A2V,*21P"1FNA=UC1G8X5023[4 .HKSJZ
M^)UM?>&-2U#1V19K+48K4^<K%6C:X2,OR!C()('4=ZZO2_%N@ZU<7%OI^I0S
M2VZ>9(N"N$_OC<!E?]H9'O0!M45BZ5XNT'6YI8M.U**>2*/S64!AE,XWKD#<
MN>XR*BM/&_AJ^BN9;;6+=XK:!;B:3)"QQD9!)(QW''7D<4 ;]%9&F^*-%U:T
MNKJSU")H;09N"X,9B&,Y8, 0,9.3QQ5:P\;^'-3\\6FJ1R&&%KAE*.I,0ZNH
M(!9?=<T =!17GO@'QQ=>,-<U4R7UHEK!/-%;6,=JXD,:,H65I2<<Y^[CO73^
M)]2;2[&UE75+73C)=Q1>9<PF17W'[@ (PQ['M0!MT5B7OB[0-.U8:7=ZG#%>
M$JI0@X4M]T,P&%)XP"1G-;= !17#>&OB+IEWIUJFLZE;0ZE/=30!%1@HQ,Z(
M">0I(4=2,UOWWB[0--U5=,O-3ABNR5!0@D(6^Z&8#"Y[;B,T ;5%<E;^([Z3
MXJWOAQO*^P0Z4EVOR_/O,FTY.>F*IZK\0]-DFTJ#0M1M[F6XU6"UE!1L-$S[
M7*$X#8.!E<@9H [FBHKJ1H;2:5<;DC9AGU KD/"/Q!TK6=*T6*^U*W&L7MO&
MSQ*I53*5W% ?N[O]G.: .THJC9:SIVH:=)J%K=QR6D9=7DY 0H2&!STP0:FL
M+ZVU.P@OK.42VTZ"2*0 @,IZ$9H L45B3>,/#]OK0TB74X5OC(L7EX. [?=0
MMC:&.1@$YYK;H **PSXQ\/#6_P"QSJL'V[S?)\OG'F?W-V-N[_9SGVIE[XU\
M.:=J3Z?=ZM!%<HRI("&*QLW0.X&U2<C@D4 ;]%58=1M+C4+JPBG5[JU5&FC&
M<H'!*Y^N#^59=QXT\.6MA:WT^K01VMVCO!(<XD"8#8X[$@8ZG/% &]17*:5\
M0-&UCQ7-H5I(6=;>.:.7:P$A8.Q7!7C"J#DGG=CM737%Q#:6TMS<RI#!$I>2
M21@JJHY))/04 2T5S]CXW\.:BMP;74T<P0FX=3&ZMY8ZNH(!9?<9KGOAYXVN
M_&.HZE+/>VBP1RRI;V,5JX=8U<!9&E)P<@_=P.N?:@#T&BJ.K:QI^AV1O-3N
MH[:#<$#/GYF/10!R2?0<U33Q;H$FAR:TNJ6_]GQOY;S$D;7SC:0>0V2/EQGD
M<4 ;5%8EKXPT"\TV]U"'4HS;6(W71965H1C.64@,./;FJX\>^%C//#_;-OYD
M";V!#?,,A?E./GY('RYY.* .CHK"3QGX<DTF/5!JUN+%YS;B9\J!( 258$94
MX!/.*DTSQ7H6KP7<]EJ4+QV8S<[\QF$8SE@P! P"<].* -FBN=B\=>'+C3KV
M^M]226*RC$LP",&"'HP4C)![$#%0:7X_T._\)V>OW%RMI#<;$,;!F9964-Y:
MC;ER,_PCM0!U-%8Q\6Z NE6^J-JMNMC<2&*.9FPI<!B5/H0$;(.,8K.N_B%X
M?A\.ZIK%M>"Y33D/FQ!61]^"54@C(W8X)&* .JHK/T36+77M(M]1LVS%,H/0
MC![CD#H:T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%^+.K:=:?#_
M %FRN;^UAN[BU/DP23*KR<C[JDY/X5W55[BPL[QE:YM()V48!EC#8_.@#S[Q
MO<Z-K=KX:U5=1@NM$L]4$=]/:W 9(U>)D^=E/"Y90W/1^>*7PQ=Z)HOBCQ+)
MHMS#'X6M;*&:=H7W6\-QER^S&0/D"%@.^*]!CLK2&W>WBM84A?.Z-8P%;/7(
MZ&DBL;2"U-K%:P1VY!!B2,!#GKQTH EBE2>%)8F#1NH96'<'D&O/M4_Y+WH7
M_8&G_P#0S7H8 50J@  8 ':F&"%IUG,2&91M$A4;@/3/I0!P?PU_Y#'CG_L8
M)O\ T%:U?'NH'3]*T\+]BC-QJ,$/VJ\B$D=H221+@D#(*@ DC!(KIXX(H2YB
MB1#(VYRJ@;CZGU-$]O#=0M#<0QS1/PR2*&4_4&@#P[5;F&\TWQW!+JL>J&6;
M3#YWEJ@G02HC%57@J"-NX>E>@:S;0S_%'1+>6)6BFT>]BD0CAD+0C:?;DUUI
MT^R.,VD'"",?NQPH.0O3H",XHNH7>*22V6 7@C989)4W!6(XSC!QG&0".E '
ME'AR*YO];TGP-=AWC\+7<MQ<.X_UD:8^Q_F) <?],Z]6U'_D&7?_ %Q?_P!!
M-9/AKP]/I$NH:AJ-XEYJVI2*]S/''Y:!5&U(T7)(51GJ2223WK:N8C/:S0@X
M,B,N?3(Q0!XS8ZCI5Y\)_!>DZ?<0-JGVVQ\NV1AYJ2+*&=RO4#;N;/H<]ZT(
M]3TO3/!7CO3-5N((]1>]O]]M(P$LYESY153RVY2@&/3VKO\ PQX;@T#0],M)
M([>:\L[1+9KI8@&8*,=>N/;-:DEA9S74=U+:0/<1_<E:,%U^AZB@#SSPO9R0
M_$NT6^3-[;^$K2-RW)5_,8-^.16;]KMD\/\ Q7L&N(A>&>]F$!<"0QFV0;MO
M7'O7K7DQ"8S>6GFE=I?:-Q'IGTJ)K"S>>2=K2!I94\N20Q@LZ_W2>X]J /+O
M#]S;Z;J'P^O]3FC@L7\-FW@FF8*B3E8F(R> 2@./7!JA>"#4KO4+RWV3:1>>
M,; 0LO,<I58UE9>Q!8$9Z'!KV&6RM)[46LUK#);@ ")XP4P.G!XIPM;<11Q"
M"(1QD&- @PA'3 [8H Y- !\99\#&?#\>??\ TAZ9\2"(M-T2[GXL+36K6>\8
M_=2($C<W^R&*$_2NQ\J/SO.\M?-V[=^.<=<9]*<Z+(C(ZAE88*D9!% '!QWE
MKJWQ7:ZTNXANH+;0GBNYH'#H&:56C0L.,X#G'H?>E^"__))-!_W9O_1TE=K;
M6=K91&*TMH8(R<E(HPHS]!4D,,5O$L4$211KT1%"@?@* .'\:W=O8>._ UW>
M3Q6]M'<W8>:9PB*3;L!DG@9-9=K#$?"OQ1DV*6>\OE9L?> MDP/U/YUZ3<VE
MM>1B.ZMXIXP=P65 P!]<&G"WA"2((8PLI)D&T8<D8.?7B@#R;33&?B7X=,^Y
MHSX,7?@$DC=SP.2?I6CX2U&.SUK0M'L=:T_7]*DM9/L4@B47=A&B# <J?ND8
M4Y"G.,UZ.MM LJRK!&)$38KA!D+Z ^GM3(+"SM99);>T@ADE.9'CC"ES[D=:
M ,?QMXA/ACPG?:E&N^Z"B*UCQDR3.=J #OR0?H#7 2> ?&:?#Y/#Z3:'NA(N
MDF43?:/M ?S-^XG&XMD9QC!KUN6"*<*)8DDV,'7>H.UAT(]ZDH \JTKQ;8:E
MXN\->)-3GAL[:[T.>!7G8(D5VLJ>:F3P#A3UZ@5SX^P:C8RFWB5K&X^(,)52
MN%D5E0YQZ-G/N#7JFO:%?W7V5]&N;&V$+L\MK=V8E@G+?Q$ A@P/((/<YIWA
MOPV-&L)UO9X[Z]NKQ[ZXF\H*OG-C[BY.T !0.2>* .7\2M<VGQ/CN/[?M=$B
MET<1PSW4"NCE96,B LR@'!0^X'M6!9VITK4_#,EGXJ@MK"73KP6NIW-D!&[O
M.)"BJ[ )E3\ISRJ<<5Z_=6=K>QB.[MH;B,'<%E0. ?7!I;BSM;N#R+FVAFAX
M_=R(&7CIP>* /*["QM(]6\#^1J2:K;SZQJ%RMP+?RD+&.5CL7D;0X)!'!ZBM
M"*"(:A\4V\M=SHBL<=1]C!P?S/YUZ-]GA'E8AC_=?ZOY1\G&./3CBCR(<RGR
MH\R_ZSY1\_&.?7CB@#QC0Y)[.[BDG\26>BQW'AS3FC:]MDE6>)8F#A2S#HQ)
M(']X5N^%-.MK+QMX>@AN&O(K?PL?L]Q)$8V93,FT[3RORG&*]%FT^RN8XHY[
M.WE2+'EJ\2L$QTP".*F\J/SO-\M?-"[=^.<=<9]* /&;J6*TTR&>9TAMX/B"
MS.[G:L:^8^23T YKV:*6.>%)H9%DBD4,CH<JP/(((ZBHY+*TE@D@DM87BD;<
M\;1@JQSG)'<U*B+&BHBA44855& !Z"@#R)=2TRP^&_C32-2N(%U9[K4$DM78
M>;-+*S&(JO5MP9,$?TK8\,6CQ?$^;[8@-[!X;LHW9N2&W-NY^HKOWL+.6[2Z
MDM('N4&$F:,%U^AZBI1#&)C,(T$K *7VC<0.V: $G!,$@ R2I_E7C.@3V5]X
M"^&MNLT$[V^L0K-&&#&-PDY 8=CD9YKVJJT>GV4+%HK.W0E_,)6)1E_[W3KR
M>: /*?',,TFK>-Q;Y7&G:9+*0F_]VL[ER5[@(#D=P,5T?AI(KSQJVH-XMM=:
MNH]-\HQVEHJ(L;2!E+.K,,Y4X!YP2:[D0QB1I!&GF, K-M&2!T!/XFH[6RM;
M)&2TMH;=6.YA%&$!/J<4 <WX]U Z?IFFA391&XU*&$7=Y$)([0\L)<$@;@5
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M"<X8@;,XSR>*W=8L]2MOB7H^M6^F3WMD;&6QE:!D!A9I$8,P9A\N >F3QTH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSPK<Q[!*HR4(((.#UP0..]:E% '$R^"-4O-2.I7_ (B6:ZEL)]/G"V6R,Q2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@)P2,D@<9VFMS01J>H?$;4-;N-(NK&PETN&W@-R '8K(Y.X G:?FZ>F#WH
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M3G!X/ R.M9^A/<>&TUS4M/TG6;?0+:Q$L>GZA+\WG*6+"(,S%5VXSDXSTZ4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D) &2<"EK@_BNEV_AJQ%M?R6JMJEHCA$5MV9DP3N!Z$ ^^.:
M.RCU&TEU*;3DG5KN"-)9(AU56)"G\=I_*F7VKV&F36<-Y<I#)>3""W5L_O'/
M117!QZ;K%S\2]6M+779+21-(L_/O%MXVED8-*!\K*4 /)/'IC%54\::Y+HO@
M2X:YC$^HZL;*^98EQ*J.Z$@$?+G9GC'6@#U.BO.['Q!J<WC.6QO?$(L+M;]X
MX](NK-4BN+4$A6BDV[G<KAN&/.1MKO[JYALK2:ZN)!'!"C22.W15 R2?P% $
M?]HV)U$Z<+RW^W!/,-MYJ^9L_O;<YQ[U9KY\7Q#I*6D?Q$.LZ?\ V^=5-T]B
M+I#-]A/[KR-F<Y"8;ZUZCJ^JZCJWBO2M#T35?L%O/82:E->11)*[QAD5%3>"
MH!+Y)P>!VH [*BO)I_%?BV#3+F(W]NVHQ^*HM)23R%"-$R)U7W+;CSD9P#5[
M6]?O]'UJS\.7WBNYMFCLC=SZC'IRR2SLTC*B;%1E50%.>,G YZT >ET5Y.?'
M][>VNA6MWJDNCO<6]Q-=WD%@9'D,4OE+L1D;:'Y?)7@8'>I[?Q9XAU.#PU:V
MU\L,]YJ-U8SW36FWSHXT=EE5&'RDJ V.F?;B@#U&BO+UN_%\A\66(\3LK:!\
M\%U]CA,EQNA$H60;=H Z?* 3GKQ5>;QY=:G<6T3ZZ^A@:3:W9-O8?:3-/,A;
M!RC810!P,$[NO% 'K%(2!U.*\WL/$/B/Q-JVB6<%Z=)6]T,WMUMMU9XY5D5#
ML#@XY/\ $",=L\UB:Q?ZYJVBZ-!<ZRZW-IXN73)+B.",>?LD^24J1@,N!P."
M>H- 'LE%4+^\.C>'[J]G=KAK*U>5V("F0HA)/' SCM7G?ASQAJ%[JFBQMKT^
MH-JJ,MW;C3O*2R<QEU:-R@RH(V_,6SD&@#U.JNHZ=::OIUQI]_ L]I<(4EC;
MHP/\OK7 V/B;Q%?:Y%X,:=(]:LIC+J.H+&FU[08*.BG@/)N52,?+ACZ4W[=X
MLU5?%MS::^+./1[V:*TB6TC<2;(U?;(6&=O..,'D\GB@#K=&\(Z9HE\U]"UY
M<7AB\A9[RZDG=(\YV*7)VC.#QUK=KS2#Q#XA\4>)=(LM-U-=+M+WP_#JDI6W
M25D=GP0NX=\@<Y& >,G-9M_\0;U;G5;^#69EDL=0>WAT:/3BZ3Q1OL;=)L)W
MMAB,, . 1UH ]=HKSI/$&IMXUFL+OQ"-,N!?B.UTNYLU6&[MN/F24KEG89(P
MW!XVT:)X@U.[\6&SO_$(M+X7<ROHEU9K&CP L$:&3:&=MH5L[B.O H ]%JMJ
M.H6FDZ?/?WTZP6L"[Y)6Z*/6O*]'^(-[?S:5J::S-<&_OEBDT<:<1'# [[%*
MR[,EE!5B2Q!YXJMXFO-?\0_"OQ#XA;5]ME,9XXM-^SIY:P)*8\[\;]_R[LYQ
MVQ0![-15#5]172-!O]39-ZV=K)<%?[VQ2V/TKATU3Q-I&G>'->U#6A>1:I<V
MT-W8FVC2.$3\#RV4;_E)'WB<C/2@#T>J6HZO8:2+8W]RD'VJ=;:'=GYY6SM4
M8[G!KD_"-]XAUS7]:N;O5@NFZ;JUS91VB6Z9E5>FY\9 7<,8Y.#DFK'Q!UW4
M-"3PV=/F$1O=<MK.?**VZ)]VX<@XZ#D<T =C17G&H:CXFO\ 6?&<-EKOV"WT
M41O;*EK'(78VZR%6+ _+G/O\W48IMCKGB-)/!VL7FJI+;:^ZQS:>MNBQPAX6
MD4HV-^1M&<D@Y/ H ])J@NM:<^IW6FK=H;RTB6:>'G*(>A->9Q^(?%J?#]_&
MDNMJPM)Y"U@+6,)/"DY0[FQN#8!P5(' X/)K1T^1HOC)XQEC.&72;=E/N%-
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M5A=7RQ+.2V01&"%P.WWC7E7A74M:TWX=:.+;56DO-;U=[.&2:!"+7,TS22
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M(E=(Y-V>,!^F/X178T4 <E>^&M;AU;4[G0=9M[&#52KW*S6IE>*0($,D1W
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M)/;RQS0N,I)&P96'J".M24 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6!XHM]"2&VU?7E5X=/9GB1QO5I&&T8C_C?G"C!.3Q6_7/\ B/PP?$%U
MIMRFK7EA+I\CR1&W2-P78;=Q$BL,@9P<<;C0!!X&TJ?2]&NGGM19"]O9;R*R
M&/\ 14<C:F!P#QD@< L173UGZ187>G6KQ7FK76IR,Y837*1JRC &T"-5&.">
MF>:T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mschobelsignedconsulting003.jpg
<TEXT>
begin 644 mschobelsignedconsulting003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)\2ZT?#WA
MZ[U46WVDVX4B+?LW$L%ZX..OI6M7/>.-/O-5\&ZC96$!N+J14\N(,JEB'4XR
MQ ' /4T 1P>)=1M]6LK#7-%6P%\[16UQ#=B>-I I;8WRJ5)"L1P0<5IVGB'1
MK[4)-/M-4LY[R/.Z&.9688X/ /8]?2N>O+?6_%6IZ4MSHT^CV-A<&[>6XGB>
M21PC*BH(V8 9?))(Z8[UDV?A[6KG2?#>@OI;Z<^C9$NI>;&4?$+Q9BVL7.\N
M&.X+CG.30!V4?BKP_,UTL>M6#FU0O/BX4^6H."3ST!X)[&KEUJFGV32K=7MO
M 88O/D$D@79'G&XYZ#/&:\_GT/6M2\%+X='AN&UN+32)+,7<\D9#2;%4"$J2
M0KE<DL%XQWZ3ZGINL>(=0U&^G\-W,5O)ID5O';RWD<<KR+/YAVLC,%(ZJ2<$
MKS@4 =6GB33[N&VFTV[L[N*6Z6V9EN578Q!./=NGR\$YJ2'Q-H5QJ)TZ'5[*
M2]#F/R%G4N6&25 SR1@Y],5QEGH?B&XG@DN(+IK>/5K:XC>^^SB[\M8W5VD:
M([6 )4+U;K[5FZ/+*K> =(^Q0NME>2!;^*XC=;@+;S N@4EP"<%MP7#8'- '
MHMAXFT+5;L6FGZQ8W5P4\P1PSJQ*\<C!Y'(_.J6L>(-0L_$%IHVF:3%?7$]K
M)=%I;OR%54=%(^XV3F05BZ#X:U'3].\!Q262Q2:7'(+T!U_=%H&4]#SER.F?
M6E\8:%+?^+=-U"7PY/K5C#8SPM'#/%&4D:2,J?G=,C"MTSUH Z)=>%A8"X\2
M?8=(D:0JBF\$BL ,\,57GKQCM5NRUK2]1%N;+4+:X%PC20^5*&\Q5(#$8ZX)
M /H37*VFBRS7GAM[?PY-I=II]_-++!<31.5#6[J'&UVSEV ZY'7&.:IW?AS7
MK33KN_TFTC_MBWUBZNK.-I%"RPS94Y.< 88/@\Y04 ===>)]!L88YKK6+&&.
M5G1&>=0&*':^.?X2"#Z=ZC_X22T36;^SG:*&VL[*"\>[>4!"LC2#Z #R\YSS
MFN/N_".H:)JEK+IT>J75HFDQV'_$OE@63S$9F)?SN"K[\D@YR.0>*@_X0O5[
M>%!#8B1+6RTK;;O<JXF:WGED>'<<= RX) !./? !W<?B?09=.?4$UBQ-FCB-
MYO/4*C'HI.>#R.#3X_$>BRZ7+J::K9FQB;;)/YR[$;C@GL>1Q[BO/_$MMJ$M
M[-KTVBR01W-]I4$5A-)'YD[1SL2S;6* G>%&3_#S@5-JWAS6]7O;C78K&[L\
MZA:W"V*2PBX=(HW0ODEHP^9 0">D8Y!Q@ ]#T_4K+5;076GW<-U 25$D3AAD
M=1QW'I7,3^-KDF&&PTA+BZFU:XTQ(Y+KRUS$KL7+;#C(0\8[]:M>#M+N;+^U
M+NZ@O87O;D2 7L\;RN%15W,(QM4G&, G@#)SQ7/OHFN:?<VE]%I$UX;?Q'>7
MQAAFB5FADCE56!=P.KCC.?:@#I+#Q4?MEY8Z[9+I-U:V_P!K8M<"2%X,D%Q)
M@?=(P00,9'K5SQ'K@T'PW<ZO' +H1*A6,2; ^Y@H^;!Q][TK&M;?6+SQ!=^)
M+W17M_(TYK2TT]IXWEG+,'8L0Q1<E44#<>Y.*M^.--N]:\#7]C:69FN9DCVV
M^]5+8=25R2!T![T ,B\675IJ3V6OZ4FG'['+>I+#="X0QQ;=^?E4J1N!Z8//
M-1VWB^]>SN;RYT-H;>.QDO(V6Z60@*NX1R@#]VY!R!\PX//%<VO@VXO[ZX73
M?#LOANUN=.N;2[:>YC?[1YB;8P$C=Q\K$MDX].]%MX6OY(%6T\.#2)8-&N;.
MY821?Z=,Z*% *L2PW!FWO@_-[F@#J=,U_7KRTAOKK0+6WL9+<W'F)J)D<#9N
M4;?+'7@=>,TS0O$/B'6K33K_ /X1VT@L;V..;S/[3+.D;@'.WRADX/3/XTFB
M>#M/T?08S;Z<L.IFP$,A$A/S% &'7'45SOA#0?['M]%CN/ -]#?VT44<U[]K
MMV17"A6DP)B2.IX&?:@#H7\4:S!XBT_2;CP]&IO9&VO'?ARD2_>D*[!@#([]
M6 J6V\5W1U:RMM0T=[&WOVE6UDDF!D_=J6)DCP-@*J2.3VSC-6-,TVZ'BW6]
M7O8MH<0VMD2P/[A4W,1@\9D=\YY^4>U<]-I&K:UK^G7-QH?]FZA \D=_J<<R
M&*>W*,OEH Q9@Q*-AE&W;Z]0#9T3Q5=:U=6K+I#1Z=>1F2"X6X#NJ8RC2QX'
MEAQRO)[ XJQH?BJ#7M9U2QMK6XCBL4A99YD*>=O+C*J0#M&S@]^W&">4\+^%
M;S3;SPW N@KIT^D*Z7VI*\>+U?+* *58NP9BK_.!MVXKJ(=)O6\4^(+K?);0
M7ME:PP7,3(6#IYVX@'."-ZGD8Y[\T 6-<UZ33+JRT^RLC?:G>[S#!Y@C4(@!
M=W?!VJ,J. 22P %9=[XOU+2](U">_P##[17MI);HL:W!:"?SI!&I2;8.A/(*
MY''J#45YHFK:/JNEZU:2W>O2VL<]O<1SO$DSQ2E&RA 1,JT8X.,@GFJVOQ^)
M_$.@:D1HS01":T>SL'EB^T2>7.KR,S!]BY P%W=CSSB@#8M?$E_%K-KIFMZ.
M+"2]#_99H;H3QR,J[BA.U2K;02.,$ \U5T#Q/XAU_3[#4HO#EI%8W:JX=M3)
M=4)Z[?*Y..V?QIIAUGQ'XATBYO-&ETJQTN62Y_TB>)Y)I3&T:@"-F 4!V))/
MIQ7-^$/#K:+8:3%>> +[^T;8()+Q;NW*AP?OX\[.._3\* .U_P"$J@?QA%X>
MBM;AG:&61[ED*QADV9121\Y^<9QP.._38O;RWT^RGO+N58K>!#)([=%4=:R;
M_3[J;QIHNH1Q9M;:TNXY7W#Y6<P[1C.3G8W3TK/O_!^HWD<:?\)5?2JEREP$
MO((9$RN=HPJID D-SGE5]* (5\=W%SX<TS4[316-SJ&I2:?':7%QY11E:5<L
MVTX/[H\8XSUXJ[:^)=1>^N-*O-$%MJPMC<VT(NP\5R@(4XDVC!!*Y!7^('FN
M8@\/>)=-T'2S+;/J5S:>(9KYK>$Q1-Y3-.=P+.%.[S%;&<C=CM71:?:ZKJ_B
MZ#7-1TQM,M[*SDMK>"69))9&D9"S-L)4 "-0!DGD]* &V/BG6[W5-1T[_A'(
MEN+&%78KJ 9/,8C;&6V<-MRW? QZBK/A_P 1ZAJ^LZCI]WHR6@L0HDFCNQ,O
MF,,^7]T<A2"?3(]:D\(Z==Z9X>+W\&W4[N:6[NDW GS'8G;D''"[5'.,**K^
M'] OH/!5O97%W<:?JMP3=7D]L8VD6=VWR#+!E/)*]#P.* 'ZCXCU6+Q--HNE
M:+#>O#:1W4DDM[Y. [NH &QL_P"K/<=:KP>-)-1L]*_LK2VGO]02:06T\XB6
M)86"2%G ;C>0!@'.<\"L+6?"TQ\6-=7_ (=O?$UJ=,AMDN#/;H_F+)*6W O&
M.CKT&*DT70]<\.'1]1;39;L6\-W:&P@G1Y+:"25)(5#.RA]@C"GGOQG% &TO
MC4WMMIL>E::]SJ=\)3]DEF$:P")MDID< X"O\O .2>!6CIVN7#PWYUK3SI;V
M #2R&3S('3;G>DF%R!@Y! (QR.17+Z;H&M>'IM-UR/3_ +9=%+M;^RAE0.@N
M)_/&PL0K%#\I&1G.16C=:;XA\6V\PO"-$LUN(I+>UDC2>214R3YP5BN"VTA0
M3]SG.<4 ;'A?Q$OB?2Y;Y+26U5+F6 1S??PC8R1V)ZX[56N_$6H3:Q>:;H6D
MQW\ECM%U+<77D1H[+N"*0C%FVD$\ #(YK+\/^%]>AT[4K>^UVZLY)=3FN(Y;
M.*%6=&9N3N#C#9!Q@$8J6"#5_"VM:K);Z3=ZS9:E(ERLEO+"LJ3"-8V#AV08
M.Q6RO3)XZ4 7[OQ=%I_A%M<O-/N[>8!E%A*N)6E!(V#UR5)W#C;\W2JVH>,Y
M+:/1A:Z?%-/J5HUWLFO%@6) (^K$')S( /7!K/U/PUXFURP74+O48+;45M+B
M-+&.!9(T,A; #$CY]FU"WUQ@$Y:FC7EC8:*NJ^&8/$#P:;]F=T2'S87X^3$C
M!=F."02<KGH: -R[US6HFBAM?#WG3BU%S<%[KRX8^2-BR;"'?@\8  P21D55
MU3Q]8:?X3T_78K>:?^T(XY+>V^ZY5@"2W7 4'D],X'<5SKZ7XIM-#TCPW+I%
M[=Z5':YOFL+J%7D)8XMPTDBD1JN 6'+# &.:L>)?!VL:KIEW>:;,;66XM(+>
M+2Y((B;=%928U</M'(R<=< 9.!0!MZ_XRDT:]U"*#3!=0Z9:)>7TC7 B*QL6
MQY:D'>V$8X)4=!G-+)XFU>XUV^TW2-#@NTLTA=Y9[XP$^8I8 +Y;>GK6!XC\
M,7]YJ6H27VC2:Y//9Q1:=>1RQQ"TE53N)#.#'E\/N4,>W8 PW/AJZ7Q-?W>K
M>%;G7_.MK5$NK>XAC!=(\2</*AY;VH ZFX\1ZHE_!I=OHD<^I_9?M=S%]L"Q
MPH6*J Y3YF)5L# '')%4X_&UWJE[:0:!H\=ZMQIR7Y:XO/(**SLNW&QN05.>
M:IZGI=R[:;=6OAO5;<I9-;".RU".*:,!OEBE._:8R.0RL67GIFL1/ \VF7FE
MQWOA>37;:WT:.U8VT\2".;S'=P/,D0X^;@T =7!XVDU"VTM-.TEI=1OS<#[-
M-.(TB$#[)2T@#9 8@# .<CI4\7BJ]U"SMGTK1))[AWGCN$GG$4=L\+;'5I K
M9);[H Y )X%<W;>&M4L=#TL2Z5?%K6YN#;QZ??(+FP@<_)$&=@LBX # DX^7
M&<9JUI^B:AHWAN/3;SP]_:MA?2W$][9I,DDL3O)OC!,CA7 '#'.=PSR* -.W
M\:RZJFFKHFDM=7%Y9_;7CGN!"L,>[;@MALL6R!@8.,Y KH-&U6#7-'M=3M@Z
MQ7";@KCYE/0J?<$$?A7!Q>'=6L-,T8SZ;J,]U!;S0F33-05)H4:3=' [.RAT
M"X7<"2"N1US77^$-&D\/>$].TN79YL,9\P(255F8L0">2 6(S[4 ;=%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 52M](TRSO9;RVTZT@NIO];/% JN_
M^\P&3^-7:* "BBB@ HHHH **** (Y8(IPHFB20*P=0Z@X8'((SW![U)110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !13!-$TS0B1#*H#,@8;@#T)'X&GT %%%% !1110 445'#<0
MW*%X)HY5#%2T;!@".HX[T 24444 %%%% !113/.B,QA\Q/-"[RFX;@O3./2@
M!]%%,2:)Y)(TD1GC(#J&!*Y&1D=N* 'T45')<0PO&DLT:/*=L:LP!<^@]: )
M**** "BBB@ HHHH **CEN(+<QB::./S&")O8#<QZ 9ZGVJ2@ HHHH **8LT3
M2O$LB&1 "Z!AE0>F1VS@T^@ HHHH **C>XACFCA>:-99<^6C, SXZX'?%24
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MUX%85YXL\3:O<>%TM'LK&Z.K7%C>1'S&C:>%9 0<,"8R/FQUSCTK0D&LZ?\
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M;YE9BQ96P>C$94XQ6/\ $_6+>;4M$\+2I<RV]U,+S4DM;=YV%M&V0I5 3AW
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MZ<DG.:ZVB@#G+?P?;QZYI>LW.I7]Y?Z=;R6Z2S&/]XKDDEPJCD=!C'3O2_\
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MP#@CJ 16U10!S#^#%2VLULM=UBTNK82*;M9DD>82-N;>'5E//(P!CM@<5$/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%(S*B[F( '<FEH **175U#(P93T(.12T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 44A(52S$ #DD]J4$$9'(H ****
M"BBB@ HHHH **** "BBB@ HI%977*D$>H-(75652P#-T!/)H =1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%(64,%+#<>@SR:6@ HHI&944LQ  ZDF@!:**0,K$@$'!P<'H: %HHHH
M **1F"J68@ =2:4$$ @Y![B@ HHHH **;O7?LW#?C.W/.*=0 44A8*I9B !R
M2>U)YB?+\Z_/]WGK]* '4444 %%%% !1110 444A95QN(&3@9/4T +12$A02
M2 !R2:%8,H92"#T([T +1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5PGQ9M+R7P1J%Y!JEU:16ENTAAMVV&5\KM+,.=HY^4=21GIBN[KCOB+::]J
M_AR\T31](CNUO8"CW#W:Q>4<C^$CYOS% $/Q'G^SZ-I,ES/+'I/]H1+J*PR%
M9)8BK *-IW,-^S*KR1FJ_P /IK677?$2Z-+.-!B,"P6\[/NCFVL9,))\Z*?D
MZ@ G)%3ZI9>(]6CT76#HT$%_I%\TO]G/>*ZSQM$4+!P,!AN)&1VZ\TZPL?$1
MUK7/$\FEP6UY-8QVMGIS7(;S#&78-(Z\#)? QG % ';5YA\6?#>FVO@[6_$-
MN+N+5!Y;"9+Z=0"9$4X0/MZ$]J]+@,C01M,@24J"Z@Y ;'(S7.?$31+WQ'X#
MU/2=.17N[A8Q&KL%!Q(K'D^P- '-^.O"^D>&_AWK<^FV]RKR" .'NYIMP$Z'
M $CD _3%;MIXAUN'Q1!H^N:?8Q)?6DMS;-:S,Y0QE=R/D#)PXY''%7/'.D7>
MN^#[[3;%5:YF,10,VT?+(K'GZ TW5='O+OQOHFJ1(IM;2TNXI6+ $-)Y>W [
M_=- '(^&O&7E^ ?##:1I6EZ8VJSSPQ1S3,EM!L:0GG&26*\#N2?2O1-'N-1N
M=.1]5LX[2\#,KQQ2^8AP2 RGKAA@@$ C.#7 >'O#&MZ%\--&T*]\/Z?JXB:8
M7UC-(N2&D9D9&;Y,C/(/KP1BNK\$Z1=Z)X=%I=QB#,\LD-JLQE%M$S$I$&/7
M:/P[#B@!?&^OOX<\*7=[;KOOGQ;V<8ZR3N=J #OR<_0&N9\$PWG@[Q/+X2U&
M]FNX[RSCOK2>:0N6E50EP@)_V@' [ FM/Q/X4G\6^+=+CU*$-X<L(GN&43%6
MFN3\JC"D$!5R0<CDU0UWX<VUC]@UCPG9F/6M.NDFC$EU(1+'G;)&2[$ %2>?
M:@"6_P#&^MI:>(=6T[2+2?2-&DF@?S)V6>9XA\[* -NT'L3DA3["I%\8ZYJ'
MB.UT;2],LFDETRWU&2:XF94C1R0PX!)/ Q]3GI7.ZP-5TCPKX[T^S&GSZ=+)
M>7#WOVQ<VWFIN>%XP,^9DD#G'S#Z'IO#&A7]OXG@U>6,+:/X?M+0$M\PD4LS
M CKT(H K2?$"\5I=36VT_P#L*&_^Q-FY/VI@)/*:4+C&T/GY>I49]J-1\?WE
MK)JE_!;:>VC:5=&VN!)<D7,FP@2.BXQA23P3D[3TXJE8^#+C3;Z2Q'A#0KY'
MU!YTU>Z6-F6%Y"Y#+C>74$J.<<*<]J5_!MQ9ZMJ<2>$-#U5;Z_>ZBU*]6-O)
M60AG612-[;3NQM."".E &EJ'BW7VU?Q'8Z/IEA(FBI'*\MU,RB56B$FU0H/S
M=>3P..N>&6/C?5YY?#E_<Z5:P:-KTBPP8G9KB)FC9T+#&T@[3P#QD?2KUOX?
MOHM8\9W!C00ZK'"MIAASMM]AR.WS527POJ8\-^ [(QQ^=H]Q;27@WC"A('1L
M'O\ ,PH CL?B!>73Z?J,EMIXT34;P6D 2Y)ND#,4CD=<8PS < Y 8=>:@NO'
MGB!-)UK6K?1[$Z=HU[<6\XDN&$LZ12%2T8 P/EP>3R<C'&3%X<\&W&B2Z?IC
M>$-"D6SN,G6I%C9WB#$J0N-XE^Z,DX!!.35R7PIJK_#_ ,6Z0(H_MFI7=]+;
M+Y@PRRR%DR>W!H EL]8U^Y^+%YIZM:'28].AF$9D?(5F?#@8QO)&#VP!S77:
MK>-IVCWU\B!VMK>28*3@,54G'Z5S$&DZQI_Q&&J16*7&GW>FPVDTHG56@=&8
MDE3RP.X=*Z36[66^T'4;2  S3VLL2 G +,I _4T <2GCGQ+Y7AZ[?0[ VVO*
ML=K&MRPDCD:/>ID.W&P@$G&2!ZGBM"T\5:\\>NV$NE6<NLZ7-#'B&X*V[I*
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M7H@.X@@8&.U'AR\UB+5M,,0\3S07-M(-1EU2,^2'\O<LD?\ <^8%<# PP]*
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MFSU)+*!Y%,,P>-F49VEE)K-7QK<G7/!=A]DBV>(+.6XE;<<Q%8EDPOKR<<T
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MM:R8V33SJB-GD88G!S0!DZ)X7NM)NH)+CQ#J-_!:PF&VMYMB*BG R^P R,
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M))BOS*A()4'T) _*H=6T73-=M!:ZK8P7D 8.J3(&VL.X]#[B@#S&%;'5]?\
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MJ>F7QVR)$H=@8W&=NX,W!&"1G-=SI^E:?I,;QZ=906D<C!F2&,("0H4' ]E
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MYF_,U:BTK3X);66*SA22TA-O;LJ &*/CY%]!\J\>PH \C:"V2Z-E-'&NE?\
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M6\^Y=B1&4;B-N_(R0,#FM:>SN6^*UC>BWE-JFBSQ--L.P.9HB%STR0"<>QH
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M=:-<6*+;:AYD;@L80QB$?F'&%9@N=O;D=JT?"5I<VVM^+9)[>6))]5$D+.A
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MXQT% &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!G6&BVVG:KJFHPM*9M2DCDF#D
M%040(-O''"CKGFM&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7
M4/ .FZE=7;RW^J)9WL@EN[".YQ!.W&<C&0#@9 (!KJJ* $50JA5   P .U+1
M10 4444 %8NO^&;7Q)Y$5_=7GV.,YELXI0L5QR"!(,9(R.F0/7-;5%
M, =J*** "BBB@ HHHH **** "BBB@ HHHH SK31;:SUS4M7C:4W&H)"DRL1M
M C#!=HQD?>.>36C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9UYHMM>ZWINK2M*+
MC3A*(54C:?, #;AC)X QR*T:** "BBB@#$L_#%I:^(9]<EN;R\O9%:.(W,@9
M;:-CDI&H "C./4\#FMNBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7(?%(@?#+7P2,_93_,5U]8^L^%- \0S12ZQI-K>R1*5C:>/<5!YP*
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M_P SS?.^QR9W_P!_&_&[_:ZUHQZ5K<4]Y-'_ &&LMX0;EA;29E(4*-WS\_*
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MYTR#2;5+.Z_X^(MF1+_O$\G\:T9M/L[F>UFFMXWEM&+V[,.8V*E21Z<$C\:
M/-8= TE]<^)*MIULR)'&(T,8*Q[K4,Q4=%)."2.N!Z50\/.TGC;X<.[%G;PO
MDD]2?+6O5QI=BLM[*+6(/? "Y;;S+A=HW>OR\5##H.E6]S9W$-A DUE!]FMG
M5>8HL8V+Z#% 'DB:78Q? ]]22UB%]_:/G"YV#S PO]H(;J,*,5-XZD^UZ/XU
MU*TL=)MH+:<6\UU=%Y+J69$3:8^<1XRH4>Q..:]6_L+2O[)_LK[!!]@+;_L^
MWY,[]^<?[W/UJK<^$O#UYJ,^H7.CV<MW<(8Y97C!+J5VG/OMXSUQQ0!SFDVM
MJ?C)KDIMX?-&EVLBML&0Q:0%@?4^M<)X42.;P!X*MKQ5;39O$<JW*ORCD&4Q
MJPZ$%PO![XKV!?"NA)?V5\NEVXNK&(0VTP7YHT'10?09/7UIZ^&M$717T8:7
M:_V:Y):U,8*$DY)QZYYSZT >9>.8(+/4O&T&G11Q6[^&4DNTA4!?.\QPA('\
M13/X 5T-WI5CI7C;P&+&UBMRR7<3M&@!=?(W88]^0#SWKJ;7PKH-EI=SIMOI
M5M'9W6?M$03(E[?,>K<>M7Y=/M)KFUN9+>-I[3=]G<CF/<-IQZ9'% ')>+XH
MKGQSX+M;Y$DT]YKIC'*,HTZQ#R\@\$\N1[BN0\3V=HEO\4+>VMX1916=M,$5
M!LCN3&^\J.@;;LSCGFO6-4TC3];LC9ZG9PW5N6#;)5R PZ$>A]Q5>W\-:+:Z
M--I$&F6T>GSY\V )\LF>I;U)]30!%X2MH+;PEI(MX(X@]G"["- NYC&N2<=3
M[UM5'!#';01P0HJ11J$1%'"J!@ 5)0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+^.?%,_A32+>Z
MMK&6ZEGNX8 %3<JAI%!S\PY()"^^,\5U%<9\3XIG\*0S1033"VU&TN)5AC+L
M(TE4L0HY.!SQ0!2_X3&ZM?'.HV[V.K74;:9:W$.G00JTD1+2;R06"@\*#\W7
M&,U<O?%FDZA;^%=0AU#4X(=3O5CMTMU5?-?D&.8-R%!!!QSD4NA-]L^(VL:G
M%%-]DN-*L_)EDA:/=\TI(^8 @\C(Z\BN)ATR_&A?#U#8W(:#Q#-),OE-F-#-
M*0S<<#!')]: /18_&MC+JWV)+'4F@^U&S^WB#-OYP.TINSN^\"N=N,]ZZ,D*
M"20 .237F)G%GXL3_A'CK=GJ$^J 7^DS6[M:R1F3$LX8J53*Y<,K<G (R:Z+
MXBW&HGPP=*TF*5K[5IEL4DC0D0*_#R,1T 7//J10!SV@^.-8O/%5I>WKQ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6'K7AU]4O8+VUUG4=,NH8VBWVC(5="02&1U93R.#C(]:W** ,W0M$M/#V
MDQZ=9F5HT9G:29MSR.S%F=CW)))K2HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD9W,@QQZ?PC\A0!Y.=&UC6K;Q'=PV?A^.Y76I@FJWMV\=Q;-%*!$!B,[0%"
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MB0QLF(VVJN=X.1DDYKT>[\'>'[[5O[4N=,CDNRRNS%F"NR_=9D!VL1@8)!/
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MH9G4,T2[%SL)^[G><XZ]ZZ>T\$^'+'4UU&VTJ*.X1VDC^9BD;GJR(3M4G)Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[:RM[1[E
MX4VM<R^=*2Q)9]H7//LJCZ"K%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(/Y5Z1=_#[29[ZZNK6[U733=N9+F+3[YX(YG/5F4'&3W(QFK5SX*T.X\)?\
M",+:M;Z7\I$<#E6!5PX.[KG<,D]30!6@A\?"XB-Q?>&S!O'F".TG#%<\X)DQ
MG%5M0T751XEU#6/">MV"7DJQQ7]C>1^;$SHOR$E"&C;:1ZY&#BI?^%?6O_0Q
M>*?_  =3_P"-6M1\$Z=?ZB^HQ7>IV%Y*BQSS6%X\)G"C"[\<,0.^,^] $GA#
M6I-:TRY:YL8[*^M+R6UNXHFW)YJD996P,@Y!YYYK"^%O^I\7?]C/??S6NMT;
M1;'0-.6QT^(QPAF<EG+L[L<LS,<EF)ZDTS1M!L=!6^6Q5U%]>27LV]MV99,;
MB/0<=* .#MO^3D[S_L7Q_P"C$JU%=P>!/B#K$-T_E:/K-O)JL3=DGB7]^H]R
MN'_"NL3PQIJ>+9/$RI)_:4EK]D9M_P OEY!^[ZY YIGB?PEI'B^R@M-7@>2.
M&7S4*.48'!!&1V()!'>@#@K>PN#\'_%WB+4(RNHZ_:7%]*#UCB,9$4?T5,?F
M:V] A\?'PYI9@OO#8A^R1>6)+2<L%V#&2).N*[+4M+M=5T>ZTJY0_9+F!H)%
M0[?D88('IQ7-1?#FQ@B2*+7_ !/'&BA41=9F 4#@ #/ H [!-VQ=^-V.<=,U
MP?BK_DK?P_\ IJ/_ *)6NVL[465E!:K+-*L2!!)/(7=L#&68\D^YJG>Z#8ZA
MKFEZQ.KF[TSS?LY#8 \Q0K9'?@4 <=\61=-'X16R>)+H^(K;R6F4L@;:^"P!
M!(SZ$5F?$6W\;I\/=;;4=2T&2S%N?-2"SE1R,C[I,A /X5Z)K&@V.N/I[7JN
MQT^\2]@V-C$B9P3ZCD\5)K6CVFOZ-=:5?*[6MTFR0(VTD>QH \ZUA=5;QWX+
M&C2V<=Y_8\^&O(V>/;B//"D'/XUV^C1^*TO&.N7.C2VNP[5LK>5'WY&,EG(Q
MC/;TJ#5_!.F:Q<6%S)<:C:SV$)@@ELKMH7"'&02O)^Z*72_!T&E:C%>)K6OW
M#1YQ%=ZI++&V01RC'!Z_GB@#SWP5JGC'2OAJUYI.D:5>V5O)=R(KW4@G?$SE
M@$"8SG.!NY^M;FC:C;^$?AEJ?BMKV'4)]3EDU+="A6-YY<*D:*><9"KSSUS7
M;Z%H=EX=TF/3=/5UMHW=U#MN.78L>?JQK*7P#H2110+'.+6+4?[3CMO-/E+-
MUX7^[DD[>F: /+9)KKP[X7T#4U\/:^NL:-<M?7]U-:!4F67/VD%MW0@\$C^
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MY"''!4'H"..U5;GP3:Q>&;G2M,>9);FYCN)KJ:X=I9'5T)=G.2QPN,=.W H
MZJO"O!W_ "03QM_UVO\ _P!%K7NM<W8>!M$TWPSJ/A^WCF%AJ#2M.K2DL3(
M&P>W H YBVSX*U*UG'RZ#XAB19?[MM?%!AO99 ,'_: ]:Y_P\42#X1/>8%EY
M-RH+?=^T&,>5GW^]CWKUG4="T_5M DT2]A\VQDB$)0GG Q@@]B, @^HJDW@S
M0I/"D'AJ>S\_3+=56))'.Y,=&##!##U'- &AJ\VEP:>9-9:U6S#IDW6W8&W#
M;][C.[&/>K]<I:?#[2(+VVNKNZU35&M7#VR:C?/.D+#HRJ3C([$Y(K>M=+M[
M34[_ %"-I3->F,RAG)4;%VC:.W'7UH NT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1103@9/2@ HK NO''ABRG:"?7
M+(2+PRK)NP?0XS4'_"PO"7_0=M?U_P *OV4WT9'M(=T=-17/#QKHMSIVH76E
MW(U*2RMGN&M[8$NP49P!CJ>E96C_ !#BU6T2<P62J]Y!:J\%\9D)ESQP@97&
M.595'3YL<U+33LRDTU=';45R@^(WADQ32_;)A%%#]H,AM90KQ>8L8="5^=2S
M  KG]*DD^('AV*R%U)=3JOFR1-&;27S8VC +[DV[E"@@DD  $4AG3T5RM]X]
MTNWU>RTVT#WDUQ>16KNB.(XS(A<?O-I4MMP=N<X;-277C;3]/\37.C7Z2P")
M+<K<A'>,F8LH#D+B,94 %CR6]J .FHK!A\8:/<QQO;RSS&2%Y@D=N[.%201M
ME0,@ASC'7@^AK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]"*R9Y6^(EY]AM 5\)6TG^DW X&HNI_U4?K$"/F;^+&!QDUW:JL:!$4*JC
M& !0 M<AXN\?V'AN.>WMPM[J<4?F/ KX2W7^_,_\"],#[S$@ '-5-4\17/B)
MKNTT.^&GZ+:;AJ.O$@!0OWD@)X+=<OT7MDUG^$O"UGK$D&IFQ-MX?@D\[3K2
M4$R7DG_/W<$\LQZJ&Z Y]* -?X=GQ5=Z;=:MXIN@9+^026MF(A&+:(9QQU!;
M(."21@9YS79T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ/;23MDY_A12<<=<8K&_X3W1/^>>K_\ @FN__C5 '345S/\ PGNB?\\]7_\
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M=W"RF5&((8G<"&W9.X$8-<UJ7@36+/7=*GT.5;F3=<3W>I:A(&D2X=419B@
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MDK2RW?F>7)-O01NC;, (455VCLHJQ_PGNB?\\]7_ /!-=_\ QJC_ (3W1/\
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M HHHH **** "BBB@ HHHH **** "BBB@ KCKSX@VEGXZB\.&SD:$R1V\M^'
MCBN)%9XXB,<DA>N?XA70Z[K%MX?T&^U>[.(+2%I6&>6P. /<G 'UKR.V\/\
MC#4/A_>6<OAJ$ZCJDYU1KXZDJ2).6#HP39QM 5<9['IF@#T_Q'XE3P]<:+"]
MJT_]J:A'8@A]OEE@3NZ<].E;M>2:UXA3Q-HOPYU8@1RR:];K<(>/+E4.KJ?3
M# _ABO6%EC8X61"?0&@#AM'\<>)->TN'4].\%^;:3;O+=M4C4G:Q4\%<CD&M
M;4_%DNA#2)M8TMK6TO6$5Q<"<.MG*WW5? Y4GC?G /6N+^'6B:M=> ]-GM_&
M=]81/YNVVC@MV6/]Z_0LA;WY/>NK\9ZG;Z?X5329X1K.H:FGV*VM' S=R$8+
M-C "C[S$8 ]N* -"^\3I!XIL?#UE:M>7DR&:Y*OM6TAZ;W.#R3P%[^U4_'VO
M6>BZ$D5SI)U>2^E\B*P! ,O!9CR#C"J3GZ5SG@"TD\"ZY-X8UQUFO]15;BUU
M0DG[8$0*T1+$G='C@?W3GBHY+_6==^)UWJVDZ-%JEAH*/IT'F7@@5;AL&9AE
M6R0,)0G8"];Z-8/X/_X2#1M>U^WTXV1NXK6&^^50%W;1N5B.F/K5;P7"GC/0
MQJ$/B;Q/:SHVR>UDNT+1$@%?X.05(8'N#6?X?N+S1](\8^$=3LUL9([2XU&P
MMUF$JK;RA\JK #(5\]OXJLVB/X5T+PQXTM58VC:5:6VM1(,[H?+79/CNT9//
M^R3Z5I[6?<S]E#L5)-6F'@.*Z@FU?49O$<LVCP6U[>(RQ2'S4#YV#O'^1K;E
M\27MEXJMKSQ7X?ETJQFA%E!<+,ES")'<-^]9>4Y50,C&2>:Y;3W4^ OAXX92
MA\4$A@>"/-N.<UU_Q8OK6?P7<Z##)'/JFJM';V=JK N[EU.['8+C)/08J&VW
M=EI)*R,V6[U@3:?X6L- 2^N_#\%C-<7 NTC!./NKN&<$QGGV'%,OEO\ 0? G
MB;4]6TFYMKB:28)"-3:2-A<RD?<!V KY@YQSCMFI4TN_O?BCXC2U\17.E-%8
MV(=H8HG\[B3KYBMC&#T]:E\?V-Y8_";6H;G6YM4F:6!EGGCC4H#-$ N(PH(R
M"?7FD-:%:^UC7?"_A>[:[\.7UE;O"L$E^VLF\^S9^02;&)*@%L_+[>E=/KNG
MWT<-M;65E;OH=I &EA%P8GEV?=0G:?D &<?Q'@\9#<OXLT_7DGTK3_%'B%;O
MPUJ%RMO>-;62VY5\@QJYRV$9AM)&,<>M>DZGQI-Y_P!<'_\ 030!Y_X0\1W7
MC&#6O$&C:?;6MX]M;VR6EU+D+(K22!V(7E2LRL/4@CCK6#+=7FN>+)?!]LJ1
MWEK%)<3W5P_GI-<_NRS9 7#A6"\#"@E0!5?P]J:> ]!\.>)Y%)T_4]%%M=*O
M>XB1GA/U90Z?E6OX9TF70_'GAU;\C^T+C1[R\OW/&9Y)4=\_3.WZ** *'CJ[
ME\*7]S;"U%T]ZEU<SW,-PX:.VD7RV\R,@@(LD@88)^[V))K4\1VNHZ#X9U+7
M-JK;B*U0V[7TEY]I_>XP6DP50^8/E!P>>.>:FC2ZWXEU#Q#XCA\-0ZIINLJ;
M&U>:_$&+1"R8"E&.&.YC6?=:A>O\#];\/:G^ZUC0IK>RF5CO.SSHS$_N"I S
MWVF@"_J-YXGT3PA:6VOZ"L6GV)@4W\%T#]G97&)7C5CO4<?*0>5SW^7:T8SZ
M=\2[G2C;HUX+"XOVF%PQ2=);@;0%(Q$00<[<@]3D\U2\6:?KT<^E:?XH\0K=
M^&M0N5M[QK:R6W*OD&-7.6PC,-I(QCCUJOXJT"[\2_%^[TJUU:;3$F\,A998
M4!9U\]AMSV&<9QU (XS0!W&A^*_^$AUB]M]/LC)IMHQC;4A+^ZDD!^Y&,?-C
MN>@Z9-6_$>O#P_8P2K:27EU=7"6MK;1L%,LK9P"QX48!)/H*Q/ NMA8F\*ZC
M9P:=K.E1A'MH1MBFBZ+-%ZH>_<'@UH^,(-#OK&ST_6[J2U^U7:+9SQ.T;QW
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M)_Z;R4 >@T4@(8 @@@]Q2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&>F65A\/M"EMK:*.6XL())I%4;Y&* _,>IQDXST%==0 4444 %%%% !1110
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MC,B%N2Z%N<>M5/#L6M?\(K!K^K^*;^\AN-+%S);K;01["T88E&5 <CG&3]:
M-V3P5X9EFO)9-#L6DO3FX8Q#YSN#$^Q+ 'CJ0#5Y=$TQ;6]M5L81!?%C=1[>
M)MRA3N]<J /PKA%\=RV6E>#AI-AJVIVVJN<RW)B:>1 CG:274>9D YZ8!YS5
MC2/$DMIX\^(+ZI?2C2]+CLY4C=B5@4PEGVCW([=30!VYTNQ:6RE-K$9+$$6S
M;>8LKM.WT^7BJ5GX5T'3M5?5+/2+2"]<L3,D8#9;[Q'IGOCK5;2/%D>IZA]@
MN-*U'3;I[<W,$5XB S1 @$KM9L$$KE3@C(XK4TC43JVE6]\;*[LC,I/V>\C\
MN5.2,,N3@\4 /LM.L].$XL[:. 7$S7$NP8WR-]YC[FL_6/"'AWQ!=I=:OH]I
M>W"((UDFC#$*"3CZ9)_.N>BN=>\9:[JZ6&M2:/H^F71LE:VAC>:XF4 N2S@A
M5!(  '//-4_$EWXH\.>"=4DU35$F%M>6GV748%\N:2)IHPXD11@$ D?+U!Z#
MN =QI6B:7H5L;?2M.M;*%CEDMX@@8^IQU/UK/B\$>&(1((M"L4\R59FQ$!\Z
MDD$>F"3T]346F^+HM0UB72+G2]2TVZ^S&ZA%VB#SH@0I9=K-@@D<'!&1Q63X
M>\8Z='X%T:^L_P"VM3.H2R0V<-T4>\G<,^=QR%  5CDD *!0!U3:'I;:9/IK
M6$!LIV9Y8-ORN6;<Q(]R<U*NEV*:J^J+:1"^>(0M<!?G,8.0N?3->>>/?']Y
M#\.=3OM&M-0L]0AF%K.SK&&L7WIG?\Q^\KC:5W#D'BNV\+QRQ:#"DZ:HL@+9
M&J2I)/UZDH2,>G/2@ T[PKH.D:A)?Z?I-I;74@(:6*, X)R0/0$]<8J[IVEV
M.DP/!I]K%;1/(TK)&N 7;JWU-><>&KG7/$&E/J%S\09;&1KJXC%NMM:814E9
M%^\F>BCK791:U%HUQH^D:C=W%Y+?JRPZD\<:QS2#Y@AVX 8KR,#!P><T /U;
MP9X;UV]^V:IHMG>7.T)YLT89L#H,U8MO#&A6>E3Z7;:/90V%P")K>.!0DF?[
MPQS^-9A\=Z:VFW-_#;7L\*7OV"V\M%)O9LXQ#\W(R"-QP/E/.!2?\)W81:9>
MW%[9WUI=V<T=O+I\B*T[228\M4"L5;=G@@XZYQ@T 78/!OARV2-(=&LT$:21
MJ1'SMD&'!/4Y'!S5V;1-,N-.M]/FL()+.VV>3 Z HFS[N![8K ;X@65O97\N
MH:9J-C<V+0":TF1#)MF<(CJ58JRY/.#Q@UJZGXC@TW58],^R75S=RVDUW&D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH @O;I;&RFNGCFD6%"Y2&,R.P'95')/L*X#P;KF[Q5XA5M(UF$:I?
M":VDN-.EBCVK B_,Q7"\H1S[5Z*6"C+$ >]+0!Y-JTR:[X9M_#>G>#[O2M9%
MW$RQ)8E(+)EE#-*)@H0C ."O)SC'-:(O[SPC-XGTTZ1J5W-?WDMYIKVMJTD<
MQE0?(7 PA5P<[B..:]'#!LX(.#@XI: ,?PII+Z#X2TC2I2#+:6D<4A'0L%&[
M'MG->>:%IGV;PUXLCUO0M2GM9_$\\P6&)UF6,LA6>,##$ @'*\]<9KUNB@#Q
M;Q):ZUJGPTU^SM5UK4[);VV_LYKVV?[5(@9"^05#LH.<,PSUZXK<\61WM]XA
MUJQNXM>F5[1$TB"P>:*WD9E;>9'CPN0V,[SC;C .:]*,L:M@NH/H33Z /-_!
M5O=-XBT6Z>QO(8H_"L-J[3V[Q[94EPR'<!SP3[C!'!!K*MK*_P!'O--UVXTV
M^>VL?$.J-/'%;N\BQ3%U64(!EEZ<@'@YKUVB@#A_!\ES?>./%FJ/IUY:6=TE
MD+9[F!HC*JI("<,,CGL>0",@9JSXHU.UAO\ ^S]?\-2ZAHDL(>.YBLVNU67)
M#*\:J2O&"&QSDUULDD<,3RRNJ1HI9G8X"@=23V%$<D<T22Q.LD;J&5U.0P/0
M@]Q0!Y#;VNHZ9HUZ^E6FM:9X9N-7@*6\4<@NH;7R_P!ZT:#,B*TFW@<@9( S
M52YTZY>Q\5VUII6M^7>S:;<6?VQ)YI)8TF0.2SY((P3L)R%YP,''M=-:2-3A
MG4'T)H X;Q=HUYJ_BV&&WBD$<^@ZA:^?M.Q'D\L*"W0'J?P-2>%?$EW);:'H
M:Z!J,5S!;K%J#W$#PQ6NQ,<.1MDRP  4]#GC%=?<7]G:1K)<W<$*.XC5I) H
M9CT4$]SZ58H \8TE+VU^'?ANWDTG4Q<^'M9CFOX?L<FX)YDN608_> !@?ESQ
M6CJ=YK5]K/B?6=$T[4X ^C6T5I,UJR22!9I-Y16&=X4M@$9Z''(KU:H([RUE
MNYK2.YA>YA ,L*R N@/3<O49[9H \AGM-VIZK-IMCXBGM+WPY=VD%Q?K<RO+
M/PVW$F3&".F0H8@@9XSV,WAR76?A'9Z.4:WO5TR P[AM:&>-%9,YZ$,HS^-=
M?+<P0/$DTT<;S-LB5W +M@G SU. 3@>E4->T4:]I_P!B?4+ZRB8_O#9R*C2+
M@@H25) .>V#[T <O\-);C7[>^\97T)BN-6,<<49_Y9PQ+MP/J_F-^(KO*@LK
M.VTVQ@LK2)8;:WC6.*->BJ!@"I(Y8YEW12(ZYQE6!&: 'T4Q9HG=D21&=/O*
M&!(^M'FQB41>8OF$9V9YQZXH ?13))8X@#)(J G W'&3Z4LDD<2%Y'5$'5F.
M * '44@(8 @@@\@BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Q_%L,MQX,UV""-Y9I-/N$2-%+,S&-@  .I)K.
MTZUN$^%-I:-!*MRNAI$82A#A_( V[>N<\8KJ:* /';&TOM(\(?#:\NM,O]NF
MSL;N.*U=Y80T<B@F, MU([=ZEOO#NJ:MK/Q12"RN5_M"WL39NZ-&)V2+)56/
M&<C:?0GFO7:* //O"UMIEUXBBOK:V\4RS6MJ^9]7DGV0LY7,2B7[S'&25R/E
M'/2NTTC4AJ^E6]^MI=V@F4GR+N+RY4Y(PR]NE7:* //+&]N? >O:Y;7^EZA<
MZ3J-Z^H6MY96S3A&D WQNJ LN&&0<8.:B\1WNM^*/!^I/_85S;6AO;/[%#)$
MWVF5%GC+N\?.T<< \X!)Q7I%% '(ZE:7+_$S3;I+>5K=-'NHVE"$H&,D1"D]
M,G!X]C7GN@^'[ZU^'7@BXU"TUFVCTZ>[%['9B6.ZA21I '"K\^ =N0!G#=*]
MPHH \>\3Z*+OX3^)3HNFZ[+-?7<#+]N\R6XN0DD0\P*WS@8!&" <+G&*]@'0
M4M% 'B_AF#PS8:5+;^(/ MY=:D+RY9YF\//.74S.5._8<C:172^((1XOT/2?
M#.D:7=V%C=8EDN);)H/L$,+8 0$#;(2H"CL,GIBO0Z* /);O3M1F\(:1IUWI
MM_!+X9U*-+G^S4>-IX!&Z": KR>'#$+R"&%$^CQR63:YHNG^(+K[)JME=2MJ
M#2M->10[L^6DOS_*)&P"!DCBO6J* /.?%6JWWBWPCK4>F:%J!M;8VTT,DT+Q
M2W+),KR*D3*&.%7KW)P!Q4T5]+XA^(VFZA9Z;J$>GQZ5=0_:;FU>$&1FB.W#
M@$=.I&#SC.#7H%% 'AZVFH7?PK\):3'I.IK?:7K%JMW"]G(I0*SDL,C!4#&6
M&0,UT7CW3M9L]?GFT&TGE_X2*Q&F7#PQEA!(' 29R.@$;R#/^R*].HH \PUS
MP_:Z)XHLIY!KL.CII$=A#)H[3;HWB=B%<0_-AE?@D8R#ZUVGA&QAT_PO9P6]
MG=V<9#RB"\DWS*7<N=YR>26)]LUMT4 ><Z!J4W@"*[T#5=*U.6SCNIIM/O+*
MT>X26*1RX5M@)5P6(P1S20Z=J>K6_C+Q)<Z=<6C:CIQM+"SE3]_Y21ORRCHS
M,QPO48%>CT4 >1ZQI&I2? SPY8)I]TUY$;'S+=86,B;67=E<9&._I6[K6F7E
MU\8M(N4MI_L@T>XA>Y6,E$9CP"W0'VKOZ* /._!NM7^DZ)H7A9M U!M2M2MI
M=L\+QP11KD&82E=K @ @ Y)..*PO#>@6UK'I>A:C:^*9M1M+T;X1-.+)0DA=
M)P3^ZV<*< YSQC->PT4 <AX"LKFSE\5&XMI8?/U^YEC,B%?,0JF&&>H.#S[5
MU]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!C>+- B\4>%M0T>4A?M,1$;_W)!RC?@P!KFM-\>&'X
M4S:_J"_\3+3XWM;J ]3=H=FPCU9MI^C5WU>>WOP]NKGQX-02Z@7P]-=1:E=6
M9SO:[C5E4@8QM.48Y/)6@#/M;F?P!X=\/Z)+J.G6&JZNTUY?ZCJ3#RTDP&D.
M-R[FRZJ.1P,]J>WQ$U:?2-/&F_V3>W\NN'1Y)XB6MY,QEUE0AB0,%"1D_P 0
MKJ?%&A7M_J.E:OID=G/>:<94^SWA*QS1R !AN"L5(*J0<'I[U0N?#.M:E%H$
MMXVFQ7%CK OYHK8,L:Q!'4(IQEV&X<D+GGI0 CZIXGN=>C\-VEYIL=[;6*W=
M]?/:.Z$N[*B)'O&/NDDEC6OX0UVYUW2IVOHHHK^RNYK*Z6'/EF2-L%ESS@C!
MY]:IZIHVLVGBP^(=!2RN'N+-;2ZM;R9H@=K%D=756Y&Y@01R.]7?"6A3Z#I4
MR7D\<U]>74M[=/$"$\V1LD+GG:!@#/I0!YJUOX>F^(OC,ZUX5N]:<7,'EO;Z
M>;CRQY"Y&1TS5OPUXB'ACP%J]W;R1PJVL&"QL;^4K_9RR,JJD^3E N6<C/ [
M]ZZ&/0_%^C^*_$&I:1'HD]KJLT4JB[N)4=-D83!"H1V/>H#X U2\M-:O[^]L
MCKVHW=K>((HV^S1-;X\M,'YF! (8^_3B@!VF>-;V=M:T^'4]!UF\M+);RVO+
M241P$$E2LOSMMVD _>Y!'2J=O\2)+"+7?M.I:3KJZ?IZWL4^EC8I8L4\IOG?
M^+;@YZ'I6EJ7AOQ#KWA[5;2\@T6QDG$/V:VMRSH3'(';S)-JDJ^T+@+P/6JF
MH>"==\07M]+JATVVM]0TMK!H;61V^R%6WQLI*#S/FZYVX& ,XY +6J-XNAT#
M6(]:&FW5G-I%R[2V<;1&VE"'Y"&=BZD$X88Z<CFJ6@ZSXBT?3_!AO6T]]+U1
M(;-;>.)A-!F LC&3=AB=G(VC&>,]:U6TOQGJ]G=VVK7.EVT+:=-:B*T=G%S,
MZ[1(Y9 44?W5SU.2<"I[CPO>RZ7X/M5E@#Z+<02W!+'#A(7C.SCDY8=<<4 =
M;7D&MMX.7XK:]_PEUM!.OV*S^S>=:O-@_O-V-JG'\->DZ%>:C>-J@U".%1!?
MR0VS1*P#P@+M)SU;)()'&1Q573]"N;3QOK>MO)$;:^MK:*-%)W@Q[]V1C&/F
M&.: ///&'_"-'P-I#>%K>&&P/B.UW+% T0,G<X8 ]-O-=?+K'B76M:UJV\/R
MZ;;6^D.L&;N!Y6N9M@<KD.NQ0&49P3G-6_'GAJ\\4:7I]K92P1O;:E!=N9B0
M"B$D@8!YYJI-HGB32-:UJY\/?V;-;ZNZS,+R5XVMI@@0L JMO4A5.,KSWH R
MT\<ZYKUQX9M]!AL;<ZUITMR[W2,XMW0J&Z$;ARPQQDD'@9I[>+WTGQ/XW-U8
MV)&C:=;W)FABV2W#&(MM=LG(R,#T!J_HW@:70]7\-26]Q')::3IDUG(6R'D=
MRAW 8QC*L>O?O45UX#N=0\0>,[FYN(5LM?L8K6+829(RL94LPQCJ<C!H RM0
M?Q(^N>!9=<ET^5+C4/.Q:PM&8'-O)\ARS;Q@GGC[O0YXMMXWU&S\46=I=ZIH
M$HNM1^Q-I-L^ZYMT)8)(SASD\*2NT8W>U3Q^'O%VHZAX:FU9])BAT6??(+:6
M1S<?NF3?R@VGD?+SU// !S[?P5XHM=(TS38O['$>D:@EY$_FN&OB)"?WAV?N
MSM8YQNRV.@Z@'=Z_HL/B'29--N9YXK>5D,OD-M,B!@2A/]UL8..<$UY]X:M=
M,O/'.J6_AZTG\.VAT@P30&'[++)*7^69(B/X!D;R.K <UW_B*RU2^THIHU^M
ME?QR)+$[C,;[6!*.!SM89!QSS7-?V'XMU#67UV].DV=_::=/:Z?#;RO*AEDP
M=\C%1\H*K\H![T 9<?AO1=+\;>'=-\+VJ1ZAIQ,NJW<0^;R#&PVSL/O.[%2
M>>">!7)WUQH%IX&U?5+R:!/'EK?33%V;_2UF28E0!][R_+ Z?+MS7H'A+1O%
MGAZ"WLI;+03;M)YE[=)=S//.Y^_(<Q@,Q]S[=!3-6\,^)M<>[TN^?2&TNZG_
M 'NH(I6[:VW;O)VA=N<#;NW=.<9H P-2E@\1>-?$*WWA:X\0II\%O#%;@H$M
MD>(2.R[V ,C%L#;\V$'(XSN/IOAK5_"VC:_/%J.LZ/9686WL'A-R7+%5WO&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@N[VUL+<W%Y<PVT*\&2:0
M(H_$\4 3T5'!/#<P)/;RI+$XRLD;!E8>H(ZU)0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %8OB#2;:^6WOY=+_ +4N;#>]M:,ZJKNP )PWRY S
M@GID^M;58NN^'1K%Q9WL&H7.GZA9;_(N;?:2%< ,K*X*LIP.HZ@8H QOALJQ
MZ/JB>2+2;^U)VFT]1Q9,VT^4.Q&"&R.#NXKLZR?#^@0Z!:W$:W,]W<74[7-S
M<W!&^60@ D[0 !A0    !6M0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mschobelsignedconsulting004.jpg
<TEXT>
begin 644 mschobelsignedconsulting004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *I6^D:99WLMY;:=:074W^MGB@57?
M_>8#)_&KM% !1110 4444 %%%% $<L$4X431)(%8.H=0<,#D$9[@]ZDHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*
M\3NT?A/671BKK8SE64X(.P\BM6L_7K26_P##VIV< #33VDL48)P"S(0.?J:
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M.KW DLR) =XPXY]/O#K0!YUIU_X3C^&L%ZVI:Y%XE-GE9XKF\4?:.=I+,?*
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M2TUK5=;MM<>*3[58Z@F;>Z8#):W8#: IY 4YQU'>O2: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS'5-0DOY X V,_51CM6E<ZKIUG=PVEUJ%K!<S_ZJ&695>3_=4G)_"B[U?3+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '"?& .WPYNQ&P1S=6H5B,X/GI@X[UIVFD^,HKR"2[\5V$]NKJ98DTC877/(
M#>:<9'?!Q2^-+/7=0L8+71].T:^A9]UQ'JCN%!4JR%=HY.03SZ"LG[5\5O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **J:;J5IK&FP:A83":UG7?'( 1N'K@\U-=3BUM)K@J6$2,Y [X&:
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MUIIA<.8 W(8L!EBV,GDXSC)]*UJ "BBB@ HHHH **** "BBB@ HHHH ****
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MA'('/7(QFL[PY;V[Z?I&@:GXKO5U"VU)=VC1VT)D26.8N&.$W[#C=OSC!ZT
M>A2_$'P\ES=VT=Q<3SVAE6=(+263RS&2&!PO'*G'K@XJ+POX^TSQ%8Z.9!+:
MWVI1,T=O)!(JLRJ&<([* P 8<C@\XZ&LGP7!G1/'(CCS)+KFHC@<L> *PK"2
M'4O@QH6J:1-'<:GX92&Z,<9RRM&O[V)NX)0L,?2@#U)-8L7UR31DFW7\5NMR
M\81L+&6*@EL8R2#QG/&:75M6LM#TR;4=1G\BTAV^9(5)VY8*. ,]2*YKX?K_
M &E#JGBN16#ZY<F2#<,$6T8V0C';(!;_ ('3?BSC_A6.LY0N-L64'\7[U.*
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M!3\HV]ADY%9'C/Q%=:C\/O&>EZC9I9:KIMNGFK!,9(W23!1T8A3@X88(X(H
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M=S;1G)P.1ZU#_P )S?:I<A/#>E6]\B6$%^Z7%YY,LB2@E5C7:P) 7DD@9(%
M';,BN,,H8>A&:7%>?IXIUN'XAZS!>06\>BV&FQW,H-P=\:?O&+A=G+G&"N[
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M0.P.W* Y4'@]*ZYM5M5UI=)/F_:V@-P/W3;-F=OW\;<Y[9S5V@#@?"O@^_\
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MLC$8SGHPYQBNDHH YOP%I-[HG@VTT_4(?)N8Y9V9-P; :9V7D$CHP-=)110
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M%/C'5;E5?44U0V2LPRT=ND:;%'H#N)XZFI?%R0^%=(U35=#ABM=7U2>VMWG
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MS<LW5U#Y(7CKU.!0!S4]S>>'?$/Q*UJ#4;V::P2W,,,C*T;-)""NX!<D(6X
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MRO#^BKH.F&U^T/<S2327$\[J%,DDC%F.!P!D\ =!6K0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M<]Q#:P--<31PQ)RSR,%4?4FI*Y?QMI+ZQ:Z9#;S:?]KAO1<06FH<PW95'!0@
M<G )8$ X*@XH Z%+RUE2%X[F%TF_U3*X(D[_ "^O0]*D$T3221B5"\8!=0PR
MH/3([5Y3;3VQUCPQ#'I$>D36WB*XAN[6*7?$LQM6;*'@;6#*< #DGC.:K>+;
MD?VA\05CEQ#NTB"[9&QMB9B) 3V^1CGV)H ]&UOQ+:Z=X5U76K&2WOQ80/*4
MBF!!*C.TD9Q6A9:I:7N(XKF!KD1J\D"2AG3([CJ.M<'XWTCPWI7A_P 2C3HK
M>SU*709=UM;@(KPKT<H.,@G ;KSBEET?3M'\6> 'T^SAMY)/M$4LD: /*OV9
MF.\]6^8 Y.>>: .P\1:]'X?L(IS;374]Q.EM;6T. TLK9PN20 ."23T -5-(
M\1W]UK']EZMH%SIEP\)FA?S5GBD4$ C>O1AD<$4OB^TT?4K*RT[5KV6RDN+M
M!8SPN4D2X4%E*-@@-@-C/7I7*:KJ'BCPO+/H\^LKK(O=+O)K28VZQ7-O)%'E
M=VWA@<@9P#F@#T2"_L[F:6&"[@EEA.)4CD#,A_V@.GXTP:KIS2)&M_:EW **
M)ERP)P,#/.3Q7FOA70;^&Y\)7Z0>'+"W2V;#VEP_GWL3PDD$%!O.=KGDX()J
MAX6\'6NJ? R*6QM8EUN:!KB*["#S3+'(6C&[K@%%7'3% 'L$D\4)19)41I#M
M0,P&X^@]:S](U.:XT*._U065J_S&3R+D2Q* Q /F8 / &?0\5Q6AZK'X]\8Z
M;JT8_P!"T?2UF*_W;NX7E?JJ _3=7)>"XXKKP#\.;&^17TRXU:Z%Q'(,I(ZF
M=HE8=""X'!ZD"@#V]+ZTEL_MD=U ]K@MYRR I@=3NZ4B7]G+9_;([N![7!/G
M+("F!U.[I7F?BW3M,LYK;3/#\5B3<Z];_P!H6$SE+8.869%95!"ABL9( Y.,
M]:1O"M])'K-K<7/ANRDN+ZSN(--AE9[=IT!)21"JD>8%0X .=N<&@#U"WN8+
MN!9[:>.:)ONR1.&4_0BL*\\9:9"VNVUM-'-?:1;&>2'> '.QFV@]<C;SQQFJ
MG@B2%)-8LFT2#2-0M[E3>06LN^!V:-2LB< #*@9& <CG/6N6DT^R3Q'\4YEM
M+=9H[&)D<1J&4O:N6(..-QY/K0!Z%HVNVFK6-E()X%NY[6.X>U64,Z!E#=.N
M.>N*N)?V<LRPQW<#RL"519 6(!P<#V/!KS%-'T[2M+^&E[96<,-W)>6Z27"(
M!)()+60ON;J<D<YK-T_3X[/X5>,=:LK=/[6\_456Z"YECC$K A6ZJ -QP.Y)
MH ]?M]1L;R:2&VO+>>6+B1(I58I]0#Q3_M=M]G^T?:(O(SCS-XVYSCKTZ\?6
MO/=3TK2-&U3P%+H%K;0327@A5K= IEMC Y?<1]X<*V3WYK#::./]GY5=U5FO
M_+ )Y+?VAG'UP#^5 'KLM]:07$=O-=01SR#*1O( S#V!Y-8TGBJVA\4C2I&M
MTLSIOV_[8TP"_P"L" >F.<YS7')IVDZE/\1;S6H8'NK>X*":4#?;PK;HT90G
ME>2S C'/-4/!FEV.J:YX46_M8KF.+PA"ZQS*&7=YBC.#P3@G\Z /6C>6HM/M
M9N81;;=WG;QLQZ[NF*9'J%E-:?:XKRW>V_Y[+*"GI][.*\@TRVMY+K0M%N(D
M_L1?%.I1_9V'[K*>8T*$=,;LD#ID4>,K>WTZ;QW::=%'!8_8M/GGBB4*B3F8
M@G X!*!2?7 - 'L<US;VY FGBC)4M\[@?*.IY[#O5'0=?T[Q)IBW^FSB2%F9
M<9&X88KR >,X)'M7.:_]GNOBEX8M)1'*&T^_\R)P&!1O*'(/8X(_ U%\'K6V
M@^&>DRPP11R3+(971 "Y$K@;B.N!QS0!KWWC33((O$$=K+'/>Z-;-/)#O #D
M1L^T'D_PX/'&:TM)UJTU2UMBL\ NY;=)WMEE#/&&4'D=<<]<5YO<:?91ZE\6
MIDM+=98[-=CK&H9=UF2V#CC)Y/J:G.CV&DQ_#B[T^SAANWG5'G1 'E#VLA;<
MW5LD G- 'I:7UG)>/9I=0-=(,O"L@+J/4KU%2R2QPJ&ED1 6"@LP&2> /K7C
M7A+1]6O-$\+:JT7AZT?[<EQ)?M<.+N=V9O.C;Y.78%UV[NWM79_%&%+CPK:P
M29V2:K9(V#@X,Z \]J .H_MC3#!+/_:-IY,+;99//7:A]"<X!^M32WMI!:?:
MY;J&.VP&\YY $P>AW=*\_3PSH8^+\ML-*LQ:_P!A1RFV$*B(R"9T#E,8+!20
M#C.":YWPC;6]Y=^#-,OXDETV(ZLUO!*-T;2QW!5!@\$JA;'IS0![$EY:R6\=
MPES"T,A 219 58DX !Z')J'^V--^S7%R+^U:&VSYSK*I$?LV#P:\BUNSMTF\
M3:3:QB/21XBTH)%#\J)(YC\T+CH<X)QT)K;UG2--L?&NJ6EII]K!;3^%9GE@
MBA54=DE&TE0,$C)P: .D7QS973>&I;()+::TSYD>0*8 L)E^8#(S@ $9XS72
MVMY;7T(FM+B&XB)P'B<.N?J*\DT_1].N=&^%=J]G!Y%P#+/&$ 65OLA)+ ?>
MR0,YZ]ZZOPE:V^G^//&=G9P1V]LKV<BPQ*%16:$[B .!G S0!U]Q>VMH\27%
MS#"TK;8UDD"ESZ#/4U2OM3GCN-/%BMG/#<3F.9Y+D(5 Z[!@[VR,8XKE(].T
MW6/B?XE36[6WNEM].M$MDN5#!(F\PR%<],L!D^PKA=)\L^'OA@8I&DC_ +?N
M=CL<EAYTN"3WH ]UBGAGC\R&5)$R1N1@1D=>16<NIS3:Y!;6XLI=/DMC+YZW
M0,A8-C 0#E?]K/7BO.-6OKCPI+XN\,V7RW&KRQSZ0O\ M73>7)CTVN&;\:N6
M>EP:)\9O#^EVHQ!:>&6A3W"R8R?<]: /15U33WGB@6^MFFE7='&)E+./4#/(
MX-/EO[."Y6WENX(YV4LL3R ,5'4@=<5XS9:/I]M\&M$U:*TA&HKJ-M*+O8/-
M#?:U7[W7&WC'I6I)IVDW^A?$?4-7A@:^AO;E!<R >;"D<*^3M;JN.",=2: /
M6$=)8UDC971@&5E.00>A!K USQ5;:6;-+9[>[EFU&"QEC28;H?,;;D@9Y'H<
M55TB6>#X36,MKG[0FAQM%CKN$ (_6N&DTK1+7P1\-[RUM[>.[EU'3CYZ*!)*
MS8:3<1RW.2<]P* /7_M-OY<LGGQ>7$2)&WC"$=<GMBHY]0LK7ROM%W;P^<<1
M>9(%WGT&3S^%>8R31P_#;XEF1U4"_P!27DXY90%'XY'YU7&G7^M>)-6A_L[0
M[Z*+2;*)1JLKJ8H6C8DQX1L MNR>.5'I0!Z_5:+4+*>3RX;RWD?9YFU)03LS
MC=@'IGC-4?"L%Q;>$])@N[R&\GCM(T:YA?>DV% #!NX(YSWKR32]+M[/X #4
M;2V@%_>,L5S<O\K-"UV$9&<#<$V#! Z#)Q0![7:WUI?1M)9W4%PBG:6AD#@'
MTR*9!J5A<D"WO;:4ER@\N56RP&2.#UQSBO)O$FE:QHNE>);Y8]"TW?H31/::
M3,^]@' $I4HN %,B[O<>E:FK:9X?T3QSX"DTRWM[;BY.VV4+YL2VKD,0/O8S
MP3_>/K0!Z/%?V<UW):Q7<$ES'S)"L@+I]1G(H2_LY)U@2[@:5MVV-9 6.TX;
M ]CU]*\BTM/+U+P+J5OI>E:9;7]Z\MN(96DNWBDAD8^:Y'S9RI/)P2.:33M/
MAM?AOXYUJUMT.JBYU-$NMH,L:!VR$;JHY8X'<DT >BZCXKMK;4]'M+-[>\%_
M>FTD:.8'R2(W?)QGGY,8..M7M=U_3_#MBMYJ,PCC>6.)1D99G8*, GMNR?09
M-<#J&D:%INM_#EM+MK:"1[@A#"H4RQBW8Y./O8)')_O'UK6^*]K;W'AFP,\$
M4NW5;, R(&P#,H(Y]1P: .PGU33[:**6XO[6*.;_ %3R3*H?_=)//X5:R",Y
M&.N:X#2](TO4/B+XHM]1L+2:.SMK.&SAFB4I%;M&Q;8I& "^[./05?\ A<[R
M?#VP#,SQ))/' S'.85F=8_PV@ >V* 'ZEX_TZ'P_JVI::T=X^FW*V\D7F ;B
M71201GY?GZXY(KIH+ZSNII8K>Z@FDA.)4CD#%#Z$#I^->+SZ;90_#?QZ8+6&
M%_\ A(98 \2!&5!<184$= .P[5T7B73K?P]XML7T"SAL[A]!U)0+:,(7*+&4
MSCJ0Q[T >C0WUG<SRP074$LT)Q)&D@9D/N!T_&I)9XH=OFRI'N.%W,!DXS@?
M@#^5>6>$M"OXY?!VH1P^'+&!(<B6UN'^T7L;PDLI!0;SG#GDX*DUT'Q#LX+^
M\\(VMS&)()-;02(>CCR9<J?4'H1W&10!U]M?6=[ T]K=03PJ2#)%(&4$=>12
MVM[:7T1EM+J&XC!VEX9 X!],BO'O%EJNF:GXQLM+M[>VM9TTCSXA^ZBVO,R.
M6VC@%<!B!TS4GB32M8T?2_$MWLT'3A/I<44MGI<[@E?. \UEV+M&QI%W#T]J
M /7+6^M+Y7:TNH+A4;:QAD#A3Z''0UC:GXJMK2_TBVLWM[S[=?\ V*4QS ^2
M?+=\G&>?DQ@XZUP>L:3K.BVFM:C##H&F,OAZYC^S:3._F2@8*2;2B_<^8;O]
MNK-_I6@Z9>?#>73K>U@D:Y78T2A3+%]G<EF(^]R5.3_>/K0!Z9%?V<]S);0W
M<$D\7^LB20%D^H'(J2>>&VA::XE2*)!EGD8*JCW)KS/PSIT7AS6- MKO3=,O
M(;AY4TS7K"3$DI:-W_?+_%N0,=P+#(!P."-KQI#%>^+O!MA?(LFFS7=PTL4@
MS')*L),08'@\[B >XH Z'4_$6G:9X=N];-S#-:6\+RAHY5(DVJ3M4YP2<8JE
MX,\0W?B?0H]4NK6SMA.JR116]WYY5&4$!_E7:W/3FN%UK3K&&;XEV-M9VXL(
MM(CN3"L8\N*Y,,OS*O16*A#D<]#7:_#RSM;3X?Z UM;0PM-IUO)*8XPI=C$N
M6;'4^YH U-6UJ#2],U*\5&NFT^$S300E=X 4MW('09JQI=\NIZ19:@J&-;J!
M)@A.2H90V/UKS>.RAA'Q2D1IMR^8 &G=A\UFK'()P3DGD].@XJ71DFTK5_ +
M6][>NNI:9(ES#)<,T;A($=,(3M4@\94#KSF@#TZJFIZG9Z-IEQJ.H7"P6ENF
M^21N@']3V [FO/O#C:EXBT;0/$R:ZEK,;E6O!YLCK+N;:]N8RVU>2 .,C /<
MU<^+ZR#PKI]R0QLK75K6>^ &1Y ;YL^V2IH W;KQ3/9:/-JUQH&I)91Q&4_Z
MLRA0,Y*;LCC\1W YKHZBDEMS:--(\9MBA9G8@H4QUSTQBN'LY)/$^J^+K6ZO
M+NTDT^9+>T6"=XC AB#++@$9)8L<G/ QTS0!WM%>4Z/J&I^(K[P++J-Y>PG4
M])NI+N*"=HEE*^7M?"D;20Q.1@\\&J-R;VU\!:]J*:OJANM#UJ6WL7:\D.V-
M;A0%<9_>?*Q'S[N/2@#V2BO-SI,VO^+_ !GI\VN:M;06RVKVP@O7C$+M$S;A
M@] >=O3U' Q1T?5K[Q#HFB_;+RZFU*30GN);5)FMT +;5N7=3G<0OR@ \DGC
MK0!ZM17E.GW>H:O'\-6N-4OU.H6<PO/*N&3SL6^<MCOG/S=>>"#@U+:V&K:E
MX1\46.G:GJ'VS2-8G73F-W)O94".(6;=N93N9>2>H]* /3I7,4+R!&D*J6")
MU;'8>]9_A_65U_2([\6=S9LSO&]O=*%DC96*D$ D=16-X7U:+Q9=C7K26X6P
M2UC@CB,K!3*PWR;ES@E047.,@[QVJ7Q7;:A;Z191:##$[17(9K#SS;_:HPKE
MHU<=&SAO0[3G@F@#IZY[2/%=K?W&IPW;V]FUIJ4EA$))@#-M5&R <<_/T&:;
MX)U*WU/07D@%_&T5S+%-!?L6F@D#9,9))R!D <],5P]IHVA:A8?$JXU&VMII
MX[ZY#22J&:%!"K*5)^[SDY'<>U 'K FC,QA$B&4*&*;AN /0X].#4,NHV,%M
M]IFO;>.#=M\UY5"YSC&2<9R#7GO@>>>;Q9:2WK$W4OA+3Y)"YY+;I-Q/XGGZ
MUD:!I;ZUX<T6\TXZ3?7-M>:G+'IVHG]W<QO<,"ZX!P5^4!L$?/[T >GWNH7,
M5]ID=HEI+;W3D2R27(1@N,@QK@[S[9%6)=4T^%T26^MHW=S&JO,H+..JCGKS
MTKR>>XL[G5?AH;'3SI\,>I7L36ADWB%TRKJ&[J&#8QQC& .E/ET/3+SP?\3+
MZZLH)[I+S4/+FD0,T>R,,NTG[N&YX[T >L7%]9VCQ)<W4$+RG;&LD@4N?09Z
MT7%_9VDD4=S=P0O*<1K)(%+GT /6O(X[#4O$&LZZ)+'0[U1IME&9-6F=6BB:
M#<63"-@%RY)R.1[5:O=#N8;(ZG<PZ'XI6+1;>#4X))_WJ*B,WF0R$' <,6YV
MDX!!H ]2EO[."YBMIKN".>7_ %<3R ,_T!Y-6*\FUJUM$&I^)UTW3M=T.:W@
MENXI9=E[8JD2D;&YY"X?;E6R<@\UZK%<0S,R1R*SJ 64'E0>1D=LT 24444
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MF+.P';+,3CWJ34-+L]46%;N-G\B7S8F21D9'P1D,I!!PQ'XU<HH KV5A;:=
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MU."Z@^A- #Z*0,&&5((]12T %%%% !1110 445$]S!%/%!)-&DTV?*C9@&?
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M;4QKWA&?5K!Y_,M3=I';21RXR@;D@KM3#%><'(&: )?^%B7<VD6^W4-'@?\
MM233KG5RIDLUVQ[U< .,;P5'+X!SR:[O0I[^YTF*34FLY+@EOWMDQ,4JY.UU
MR3C(P<9./4UQ+>(3'I$6W6O!<TSS2-=:>;Q$@:)AA5$F"2RX')3G)X&!5WP=
MJGA[P]H;VMQXAT"-Y;F6X^SVMZGDVX=B1&F2/E'T')/ H V_%NJ7FE6-O):W
MVEZ?')-LGO=2?]W"NTGA=R[F)  &1ZURL7C_ %:Y\/Z?-8C3+R\FUW^R&GCW
M?9Y5VL1*N&) ^Z2,GN/2K'BG5]*O=6T35=,UWPW<RZ<\N;:]U%(T;S%"[PP#
M89<>G0FL*TCMDFB%WXJ\,R+'XA36#+'?JI93&P= G;#$;>3D=<$<@&W>>--:
M\-+XEM]9%E?7.FV<-W:R6L30K+YK,@1E+-C#@<@]#4=POB"'XC>#(]<GL+DL
M+QUDLX6B"-Y/S(0S-D=,-QWR*J^)(-!\0:AX@D_X2S0X8=1TR"U@;[:A9)8I
M'D#$9QMR5[YZTL.KOJ?BS0-9UGQ%X4MXM+6=7@M-3$AD,D>W?E@,<@?+V&>3
M0!ZC7AV@V_A&2;7&UGP??:I=_P!LWF;F'2I+A2/-; WJ,<>E>K?\)CX8_P"A
MCTC_ ,#8_P#&N T?6=0\/?VC;V&M^";BVN-0N+N-Y]797 D<L 0$(R,^M '2
M3ZO'X2TC1KVPTU++PIDI=PO;M%-9[VRLA4GA=Q.X$9&[/K5*[\9>(H_#,&N0
MV%HJZCJD%OIUM,K*YMY&"JTASPS?>&!\H(R#5>_U.U\3KIMIX@\0^%XM,C<S
M7]M::D'%RRG]W'\P'R?Q-GJ0!C'-<_KE[;:;X:LM&M?%&C7-O;:[9MIDPO%D
MD@@\P$"49^[&>,YY4#.,4 =5>^,M8\*7NJ6OB$V-Z(=*?4[:6TB:$-L8*T3!
MF;NRX;/0GBH=/\>7BWYL[C6- U66?3Y[J(Z8V?L\L:AC&XWMN4@\-\I^4\5F
MW@T[Q3>ZI=>(/$?ANS\[2WTRVBL]268)O8,TK%@O.57"XZ#K5VSUJ.YAN8=2
MUGP9:(;*2W!L[U7::5A@.20NQ>ORC=UZ\4 3V'BOQ0+3PKK&H#3#8:W+! ]I
M#"XDB,L997#ER#R.5V\ XR<9JQX<\6:MK.I/*][HWV>*::.[TP*R7=FB%@K,
M2QW'@9&T#YN#Q5!Y=&;PSX/TT>*- \[1;BTEN&^WIM811E6V>IR>,X_"JKW5
MKJFOZ;<:OK7A "PG:0ZE;7ZBXN8RK*(RF %!##=\Q'' H GT7XDSWUWHUU-J
MFA36VKW @&F6[YNK0/GRV8[SN.0H8;1@M[5J>%?%&LZ_J8<WFC-")I8[K3%5
MDN[(*6"EB6.XY S\JCYL@\5C^&[ZVT7^S=+?7?!_]FZ>=HO5O$:XGB4$(I0@
M!&^[EMQZ<#FG6UQ'JWBK1KC4-8\)&XL;DLM_97JFYO 59%CV8&T'<,C<W(X%
M 'J-9>L^'-&\11Q1ZQIMO>I"2T:S)N"D]<5/I?\ :?V5_P"UOLGVCS7V_9=V
MWR]QV9W<[MN,]LYQ5V@#RKX:^#/#<T6JWDNBV;W-GKUTEO*8_FB6.3Y /3':
MJNGZOXCT'POXEUJP;3A8:?K%]));SQ.TEPOGDOAPP"8!P.&Y%=YX.T"Z\/6F
MJ17<D+M=ZI<WB&(D@)(V5!R!SZUDR^#-1D\ ^)-!$UM]JU.YNYH7+-L42R%E
MW'&<X/. ?QH I>(/'UQ;:UJUK9:OH-@NE1(WD:D_[R\D9/,VK\Z[!@J,X;D^
MU=UI.HQZOHUCJ4*E8KNWCG0'J ZA@/UKD[SPUKEEK>I7FC6VCW2:FD1<WY8&
MVE1!'O4!&WJ553MRO(Z\UV=O&T-K%$[*S(@4E5V@D#L.P]J .&U>QA\6?$LZ
M'J@,VD:;IR79LRQ"3S2.RAG ^\%"\ \9-:*>%]%\'W5WXATQ'T^VAM)&NK*U
MPL$P4;@Q3H& !Y&.M.\0^'=5;Q%:^)?#MQ:QZG% ;2>WO-WDW,.[< 2N2K*<
MD$ ]:C@T7Q)K=S<2>);NUM;)[26U73M.D9T;S!AGD=@-Q Z # S0!F0>)_$]
MG8:%KNJ_V:VFZM/!$]I!"ZR6JS<1GS"Q#D$KN^4=3BJ=]XS\5)I'B36[9=+2
MRT+4)X#!)"Y>YCC89^;?A#M/7!R>P'6];^%O$UW8Z'H>K/IHTO29X)6NH)7:
M6Z$/^K!C*@)DA2WS'IQ4MQX+U&7P;XNT=9K47&L7MS<6[%FVJLA&T-QD'CG
M-  _B3Q'I>NVMMJG]G20ZEI]S=6Z01.K6TD2JVQF+'>,-U 7D=!5&Q\7>*4T
M;PWXBU)=,_LW59;:&:UAA<20^=@+('+D'YB#MV\ XR2,UM>)M!NKG4--U5)(
M1!INGWL<RDG<QDC4+MXQ_"<Y(KFO#.A^(==\&>#K*[.GKH]LEG?-.DCF:544
M.D7E[<#!V@MN.0.@SB@"_JOC?4=)\1+%<:GH'EMJ,=F-)1]UV8G<()=P?AOF
MW;=G3OWIUUXE\67*^*I].;2H+?0;B14$\#NUR%B638<.-IY/S<YR.!@YK3>"
MO$PTF?2K;^R!%'JG]I1W+R/YEV?M'G!)?D^3'3<"WW5XQ6]:>&+^+2_%T$LE
ML)=:GFEAVNQ5-\"1@,<#NIZ \?E0 FB^+;J^\306%Y##%::CI46HZ>R@AN@\
MV-B3@D;E(P!P:O>#M<O/$>EW.J3I"EI+>2K8>6I!>W5MJNV2<EB&/&.,5Q?C
MC39;7POX5TJQOH8_%%L8K*U$1W,0\7E3''78%RV2.-HKTK2].M](TJTTZU7;
M;VL*PQC_ &5&!_*@#!\:>(;G0ETR."ZLK!+VX,,FH7T9>&W 0L,@,O+$8&6
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MQROBVE0.JK]SYE(?);@YS\N.@!C2_P#(8^#?_7I)_P"DL=>O5PK^"]1:_P#
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M9;8OCS $"D2#()'S+UYH 8_BO5[OQ;>:;87NC0?998EBT^\5EGO8F16:1'W
M ?,P&%;E>>M=[7"^*/#>O^())M/>WT:6Q>9)+6_D++<V2@J3L4(06!!P=R]>
M:[J@#A[3Q)K]]XNUZT7[!!I&B3IYTC1,TLJ-$K[5^; (^8DX]!CJ:RM"^(UQ
M?7VB37&J:%/!K$HB_LZT?-S9;E+1ESO.[H%;Y5P6KJ-(\-S6>L^*;F[>)[;6
M)T>-4)W!!"L9#9'!R#TS6=X:\/>(-(.F:;/#HHT_3E\O[;&&:XN452J J5 1
MONDG<V<<=: ,9?&GBL^$SXK==*6PM[QH);00N9)HQ<&(L'WX0CTP>A.><#4O
MM;\0ZM?^)(M(.GQZ?I'^CM'/$S274GE!W 8,!& & !PW-(W@G43\+KCPQY]K
M]MDN))1)N;R\-=&8<XS]TXZ=?SJ2X\.^)++5]?&C/IQL-;82M)<2.LEK(8Q&
MY"A2'!"@@97F@#F]$\72Z=X:\*:';ZOH^D.=#ANY;K5#E6!^5$1=Z9)*L2<\
M =.:T4\>ZYK \*V^BQ::MQK,=XLTLNZ2**2W95+J58;E/SD#OE>1R:GLO!>L
MZ);Z'<V<&E7]Y::3'IEW!=R,D;;#N5T?8QX);@KR#VQ6K'X9U1]?\+:I=36)
M;3(+M;L0(8U9Y@N/+7'0;3U(]>] &%K/CZ_L;_58(]8\/6LFC1HLEO>MMDOY
M?+#N(_G&Q>0H.&YSZ5J0>)=;\2:Y-;>'7L+:TM+*VNI7O(6D:9YE+J@VL-H"
M@9;GD]*6^\-ZY9ZYJ]UHMOH]Q#JK)*7ORP:UE"!"P4*?,4A5.,KSGUJ270O$
M.E>*+W5-"_LR>+4K:"*X6[=XO)DB!59%"J=PVG[N1T'- !\*69_AOI;NFQF>
MX)7.=I\^3BNSKG_!&A77AKPA9:1>S1SW$!E+R1YPVZ1F!Y [,,^]=!0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5) ..<<5BZ9-X]NX[.YFD\-BVF"2.J13[PAP2!EL9Q5OXA_\DX\2?]@V?_T
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MJ]YX_P#"]A-+%<ZHJ-#*89L0R,(6!VG>0N%&>,G //->:W&OI=VNB7ESKEK
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M2%([@XQ7E46H?;/$/AU8O$UOJ4DNFW<,8MXHHH+>62)=D2%1U..%)) 4=,T
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MEM4DCLX$F;=*L:ASZG'-<E\17%M::!J$_%C9:U;SWCD?+''AE#M[!F4Y[=:
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M5V+-;0LQ.23&"37&0^+O$\^K:AH:>&[(ZM9QI<$_V@?L[1.#MP_E[MY((QM
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M,0E4Q+)A $/S<D8. ,#GG ICQ=K>I>-O#46F6MO_ &5J.EM>E);@JS*QBRQ
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M4\CMS@GBLOQ-XYU^V\'>)A'86UEK.D2Q13-'<ET5)0"LD9*#<?F VD#N<]J
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M@BC5R2P1  Q/KZU(JA5"J % P !P*XC_ (3^XNX_#2Z7H_GW&NP3NB37'EK
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MP_A^S?/I+Q&]'F+^Z"VS(>_S?,0.,UJ>.]-O=4\/)!9VSWBK=PR7-FD@C-S
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MB8J2O)&T_+UH Y(>*M9M? NIZ7)=&3Q3:ZA_8\,K !I))&'E2XQC_5MN_P"
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MHL:JBL0=O+Y)QGCM3;_7O$%A'?Z'#J\CW=CK]C9PWTJ*7:&<(P5P  Q&X@G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-Z1'=)*%!\PX. "#SSD8K$U?<GP[U6W(M46#Q<D:Q6F?)CYC)5,]!N+<>I-
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MBAMO#_B#3-/NC_;46DS702($M&@&-Q(X4\Y&>>.* .H@O[.YGD@@NX)98O\
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M737]K;WMA-;W4$4\#J=T<J!E;OR#P>:\-\/6"_\ "G_!8L[#3WEU#55BN_M
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MP07VH7%Y:+>6R6,'F&6)C@$<CL,\X&/RK<U?5;71-*N-1O"X@@7+;%+,23@
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M:%P[%D900N"3G: 3\O3D\5@>%O&C1^!_#LE\E]JNK:A;O((K6,/*ZJWS.<D
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MMK-/!&[JZ;59BBL63D_(2>">:W: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?%5[-96<!;1&U?3
M9)/+OH8X_-=(R#AA'CYQNQD=<<X-;U% 'B/@^R_T*6YT;PY?S:4=-N1J-E.K
M107TOF#RUC1^-P4."0,=!UK>#Z3XA\3>%_\ A&='GM'L)7>\F-@]LMO 8F4P
ML64 DL5^49Z$UZ;%%'#&(XHUC0=%48 _"GT >/;[B3X;)\.OL-]_;F1I[#[*
M_E"(2<S^9C9LV<]<YXQ6Y#K'_"$ZKXGM+NQOI7OKPW^G?9[6247)>- 8P5!
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M3SE)3=TR/Z5UGCFZU"R\*SS:<\\<GFPK++;Q^9+%"9%$KHN#DA"QZ'UKHZ*
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M1\H P&ZG&*[RS\17-S?^*K=H8@NCR*D)&<N# LGS<^K8XQQ7'S>#_%H\%?\
M"&P1:;]AMYU:*^:Y;?-"LPD5#'L^5N "<D<>];5UH?B2TU[Q&=+@L);/7 C"
MXFG9&M6$0C;*!3O^Z".1Z&@"G'XV\1:E)X8M-,L].%WK6D?;GDGW^7 XV$\
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MSW<;2B%I"Y0QXR7&2H;=C&#VQ0!T=]X%^U66N6Z7EW$-1NEN8L7LG[F09/F
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M^5++"H>WFB4,?N;04(/0\@CK7/:1XH\2RZ%X0UR[U""6/5+];*XM5M@H(<R
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M0IVY..1GC)[U-JVI^+]'TKQ)=DXM+;3VNK.XO$A,JRH"60K$=I7 !!QQSG-
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MVA,:S%?OX  PV>.<'/%<]X1$^GZ_966N2:]9Z]+'*LS7%PT]GJ+ 9+1DDJI
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M(60S3+$ZN.AVJDS8- 'L-8/B#Q;8^';NPLIK>\N[Z_+BVM;.'S)'"#+'J
M1WJEX2N+G4];\3ZI)<2M:&_^Q6L3.2B+ H5V4=!ER^2.NT5R_C'0K6]^,?A$
M2S7R_:X;PR>5>RQ[=D2XV;6&SWVXSWS0!ZDIW*#@C(S@]12UY:EG/X@TCQ9K
MD^K:G!>Z?=W<%@8+R2-+98!A?D!VL25RVX'.:9I$E[XP\:61OM2OX+23P[9:
MC):VUPT2M,S,<\'IR<COA<]* /3YEMXS]KF$:F%&/FL.57J>?3C]*H2>(;!-
M0TBS1FE;5DDDM9(P"A5$#DDY[@C%4_'=NMSX!U]&>5 MA-(#%(R-E4+#E2#C
M(&1T(R#P:X*WT.)S\-+&.[OHHKBSGEE=;J0R8-M&2JN22@/3"D8&<8H ]>HK
MQZ_U'4-#BUSP_9W.J7%LNNVEI#Y=P7N4AEA61TCD=L@G! )/&[K76>"4U*WU
M75(&T[6+31C'%):IJLXED23YA(JMO<[2 AY/!)H [6F/#$YR\:,?4J#7$^+8
M;C4/'OA?2QJ%Y:V5S;WK7,=M.T1F"B(@94@CD]1SC(!&:Y/6+S5-*TWQ#H=C
MJU\JZ?KEA'9W,D[/)''-Y;&,L3EE!8\$G@X- 'L'V:#_ )X1_P#? H^S0?\
M/"/_ +X%<#=:2/\ A+=(\(C4=4&EBRN-0G)OI/-N7#HH5I 0VT;B< @=.U8.
MHW>J6JWGAZWUB^2.T\365K;W9G9I5AF56,9<\MM+'&[/;.: /7/LT'_/"/\
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M+!9">-^2 /2@#U:BN?\ !ES:W/AV,V=[?7,22R1_\3#/GPD,<Q/N^;*].<G
M')KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<5<LO"FF:=J.G7EFLD/]GV+6$$*L-@C8J>>,D_(.<^M:,VIV-O=FTFNHTN!
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MM5\5:#HDT,6IZM:6LDR[XUDD RN<;O9?<\47OBS0-.U&+3[S5[2&[EVE(GD
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M%'=K>ZUJVHM<6C68:ZE3]U$W7:%4 MT^9@3Q5Y/%6@RVSW,>KVCP))'&TBR
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M2.*)](TRZO8KVXTZTFNXL>7/) K.F/1B,B@#F?B<-W@DR2(39I>6LEXI'_+
M3(7R/0#D^P-9OB"ZM=2\?Z4VE3PW#PZ/?&[:W8,!$P3RPQ'JP) ]C7HC*KHR
M.H96&"",@BJMAI6G:6KKI]A:V:R'+BWA6,,?4X S0!Y1HKV>H>&/A7$'AN!%
M=*'4,&V.MO(0".Q! /X4>,8Y#JOCGRG2*,-HTMP[1[U6,2-O9ER-P &2,C('
M6O5;?1M+M"#;:;9PD2&4>5 JX<C!;@=<'&>M3_9;?S)I/L\6^90LK;!F0#.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5FZWJLFD6"S0:?<W\\DJPQ6]N!EF8X!)/"J.I8\"M*N3\>Q7LUAIH@
MAOY[ 7RG48=/9A,\&UN!M(8C?LR <XS0!%-\0(;+1;Z]U#2[JWN=/O8;.ZM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 50UK1[37M*ETV]#FWE9&;8VTY5PXY^JBK]% !1110 5CV7AFPLM=N=
M:W7-Q?S@H)+F=I/)0MN*1@\(N>P]!6Q10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !117&:AXYNTU#4H-&\-W>K6^EMLO;B.=(@KA=Q1
MW+L 1D#'I0!V=%4M'U6UUS1[/5+)BUM=Q++&6&#@C."/6N4OOB%<Q2:I<:;X
M:O-1TK2I'BO+V.:-,,G^L\M&.7V]^G0XH [BBJ]C>0:CI]M?6K[[>YB6:)L8
MRK $'\C5B@ HHHH **** "BBB@ HJIJFI6VCZ3=ZE>,RVUK$TTI49(51DX'>
MN;C^(=C,B/'H?B9D< JPT6<@@]#G;TH Z^BBB@ HHHH **** "BBB@ HKD7^
M(FE_:[RW@T[7+LV=P]M-):Z9++&)$.&&Y01Q6]HNN:=XATU;_3+CSH"Q0Y4J
MR,#@JRD J1Z$4 :%%4]4O9-.TV:[BL;F^>,#%O;!3(^2!QN('?/7M5M&W(K%
M2I(S@]10 M%%9FDZW;ZQ/J<,$<J-IUX;.4N!AG"*V5P>F''7'>@#3HHHH **
M** "BBB@ HHHH **KR7]K#?P6,DRK=7"/)%$>K*FW<1]-R_G5B@ HHJEJNI)
MI.GR7DEM=W"H0#':0--(<G'"*"30!=HKBH_B=I,UW/:1:3XB>Y@"F:%=(F+Q
MAONEEVY&<'&>N*W]-\06VJ:MJ&G10W$<UC'!)(94VY$JEE &<@@#D$"@#6HH
MHH **CGGAM;>2XN)4BAB4O)(YPJJ!DDGL*Y!?B=H&Q+EX=4BTUV"KJ<FGRK:
MG)P#O(X!/<\4 =G12*RNH92&4C((.012T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !15>:_M;>\MK2694N+K=Y,9ZOM&6Q]!5B@ HHHH ***I27\D>
ML0V L+IXY(FD-VH7RHR/X6.<Y/TH NT450UK58="T.^U:X21X;.!YW6, L54
M9(&2!GB@"_14<$RW%O%.H(61 X!ZX(S4E !1110 4444 %%8.N>+M,T&[@L9
MA=76H3J7CL[*W:>8H."VU1PON<5)H/BG3/$37,5H9XKNU(%Q:74+0S19Z;D8
M9P>Q'% &U1110 4444 %%8L7B:TE\93^&!#.+R&R6]:0@>64+;< YSG/M6E8
M7]KJ=E'>64RS6\F2DB]&P<?S!H L445'/-';6\D\SA(HU+NQZ*H&2: )**BM
MKB&\M8;FW<20S(LD;CHRD9!_*I: "BBB@ HHHH **** "BBB@ HHHH ****
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M?:/^>N_=][MTQCC&*<GA^;^SWM;C0]6NGDO(KR6XN-1A:622,J4R<X &T#
M&* *5SHUSIGC#4]#\.7ES:MJ'AV:9/.N9) MR) BR98D@X?DCZUD7>H?\(_X
M>UR&RLM;T76_L<0:SGN_/C<-,L;3PR%F&X;\9RO49'>NOU/3)=7U":\O/#%Z
M\DMB]@ZB]B4>4S!CC#9#948.>*I0>')=EXNH:)J^JM=6QM'>_P!1A=EA)R57
M!&.<'/7('/% #_"6G:IIWB@^3H>I:7HTEFPF2\OTN TX9=CKB1R"5+@] <"N
M^KB-&TW4-&O'O#I6LW]RT0A66^U*&0QQ@YVK@@=<9/4X&36Y_:VL?]"W<?\
M@5#_ /%4 <!X?U;Q1I5OXPN-(T*SU&UAUR^E.^]:.5F#9*J@0@]!CGFH&%W;
M>"M-N;>9M0?Q5K@NKM--E\G<LD;,84=BI7_5*I)(/WA7:Z1%>Z(MZ+3PW>8O
M+R2\EWWD)_>2'+8^;@<=*S/^$=VZ3<Z9'X;U&.VEO#>Q"._A4VLV[=NB(;Y/
MFYQTY/8T <MXF36]&^&_C(BQU#2-/ M9+".:]662)C(HE"LKL0O"G!/\1Q71
MW.G)KOQ)@TZ_N+IK#_A'HYGMH[AXUD?SF +;2">I_3TIT_AB2\\/ZEI%[HFL
M7::DR-=7$^HPM,^T@J <X &T< #O6M%!>0ZZNL+X;O/M2V2V0S>0[?+#;AQN
MZY/6@#S^&SD@^&L7B-M1U"75;#5%@MIWNY#LB6\$(0KG# KG.02<_2M2U\.6
MFL3>/[JYNKM);?4I3;&&Y>(0.((SY@"D9;IR<_=^N=XZ$Y\,OH'_  C>H?8G
MN#<G_3H=V_SO.ZYZ;OTJE>>$Y+N?4I5TC7+;^U)3)>I;ZG"BS@J%VD9X7 [8
M/)YH 7P5JU[JWBG3KB[FD9KCPI9W$BDG:9&D?<V.F37/^9=ZEI7ANV.HW<:W
M7BB]@EDBF96:+=."H8'(&!@>G&.E=3?Z!/>7MG=V^AZMILUK;"S5K#488MT
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MPU^]6TANC'X6!:&=-\;CSW'SKW4 DD>F: .I_P"$UTG4M'U6;1;Y)[JSLWN
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MZM=^+M L8;:6?5(0EU"9[<KE_.0%1E=H.[EEX'/-,_X33PZ=%35QJ<9LI)3
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MJQ9>+=!U#6&TFTU**6] 8B,!@'"\-M8C:V.^"<5PKQ1GPW\6'*+O:>Z4G')
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M1E,LB$ %AA <A<\MTKBM2D\#7]YJ>IC7+CPMKD$KQW12\^S3%D. S19*R @
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MY'7&3@UU/B36_P#A'_#5[K*VK7:VD7G-$C;24!&X@X[#)_"@"\UA9M-),UI
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MHPDP $PP)) P :P_%WB6]OO 'C"TNK)],U73K9"ZQ7'F+M?E&5P >S#H,8H
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MA3D<C.,'/;.?;>$;_2HM#T[5-#N-;M+?2$@BABF400W>]C(9 6'&"H#8/"G
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MG,0 !Y]1CBMCQ_8:G?:=I+:59_:[BUU:VNC%O"Y5&)/)Z?\ UZZRB@#R_7-
MU;QS?:U=C2[C38O[%.GVJ7Q16FF,HD)PK-A1L49SW.*U/"6CV<>N)=P>"[G2
M&AMV5[F[N-S"1B 4C4.VY< Y;CH.O;O** .5US2[VZ^(/A/4(;=GM+-+T7$H
M(Q'OC4+GZD&N8UOPO'!XIUR[NO"=UK@U(QS6DD$X15<1JC1RY==HRH.[!X8^
MF*]1HH X*'P[>VWQ3T>_@T\0Z7:Z ;/<C[DB</Q&">3@=\5G6WAO6$^%F@Z4
MUBXOK;4X)I8<C*(MUO)ZX^[S7IU% 'FWCKP[JVJ:IXAELK)YDN?#8LX2I WS
M><S;.3UP0:N>5K&O^)O#0N=$N;"'1GDN+N>9DV/)Y1C58BK$L"6)R0.!Z\5W
MM% 'D,.F>(QX#T[PF/#MV+C3[Z!I[EGC\EXDN0^Z,[LL2,'! P >^ >Q\/Z9
MJ-CXF\97CVN$O+F*2T+L LH6!5ZC) W#'2NMHH \C_X16[U5KNSTG0+_ ,.1
M7FGW,.I133+]D>5TPGEHKL#A^=RA?ESZXJ[HOA>VO"+<>#+C2KE;&6&>^N;C
M*QRNFS$0#MO!W-SQ@8[\5Z?10!Y2MOXDO?#_ (2T)_#=W;RZ/?6)O;B1X_*9
M(6"EHR&);(&[H, 'O7;^-=(FUSP=J5E:C-X8O-MO^NR$/'_X\HK?HH \DO\
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MP5XCCDG.L/>V*-=M,Q9HWE"&/KC9M.,8]^N373_#K1M/L_$GC&Y@M@DT>JO
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MX$9;+J!DKDD=5[UU%IXPT;5UOX+&^DBN;:W,[>?:R1LL?.) KJ-ZY'49'YT
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MMY?LTHB=V&0GF%=H8_W2<^U:7B37(/#7AR^UBX0NEK'N$:]9&/"J/<L0/QH
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MI6.G3S[;N^+BWB"DE]@W,>!@ #N<5G:QJ:VGB70;(ZPMH;QY@+,VID-YM0'
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MI,9Q&@7<XQR"H(-/3QIX??1KC5C?^7:6TRP7!EB='AD9E4*Z$!E.67J.^>E
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MIC!'< ??\O.W<#SZ9YZUV.G:)8Z4=0-M&1_:%R]U<!VW!I& !Z]!A1Q65?\
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M>N>,8]#FM811K%Y0C41XQM XQ]* ,#Q*?^$@^'^L#19TNC>:?,ML\#AA(2A
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M'8?#)44*%NH5  Q@?9).*R?#6A+XDT'XDZ3NV23^(;OR7Z;)5VLC?@P!KUO
MXX''3VJAJ]KJ%SI[PZ3?Q:?=,?\ 7O;^< ._R[AS[G\C0!Q'@"^N/&.N3>*+
MV!XFL;./3(T=<8GP'N2!_O;5S_LFI/&O_)4_AW_UVOO_ $2M=AX?T.W\.Z);
MZ9;.\BQ99Y9#EY78EF=CZEB36D0"02!D=#Z4 >321H/A7\1B%&6U'5&;CJ=Q
MY_05)XLU&X\%ZI!KUG&SG6M)^P!5'6\09MR?<AF7\*]5VK@C P>HQUH*@XR
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M@'(P2.H'M0!@6'B+3?&'Q3N+&QU+^T-&?P\RS0([>49#. 25Z;MIQGK@UN>
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MK*"."V@0)'%&,*JCL*L444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $-U:PWMG/:7";X)XVCD7)&Y6&",CGH:+.T@L+*"SMDV6
M]O&L429)VJHP!D\G@5-10 4444 99\.:4WB :Z]KYFI*NQ)I)&81C&#M4G:I
M(X) !-:E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aquestive Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30 Technology Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3827296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AQST<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,327,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001398733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 68,657<span></span>
</td>
<td class="nump">$ 71,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_TradeAndOtherReceivablesNet', window );">Trade and other receivables, net</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="nump">7,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">7,198<span></span>
</td>
<td class="nump">6,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,870<span></span>
</td>
<td class="nump">3,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">89,169<span></span>
</td>
<td class="nump">88,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,801<span></span>
</td>
<td class="nump">3,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">5,049<span></span>
</td>
<td class="nump">5,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4,215<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">102,234<span></span>
</td>
<td class="nump">101,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,280<span></span>
</td>
<td class="nump">10,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,314<span></span>
</td>
<td class="nump">5,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent', window );">Liability related to the sale of future revenue, current</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_RoyaltyObligationsLiabilityCurrent', window );">Royalty obligations, current</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, current</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,298<span></span>
</td>
<td class="nump">18,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent', window );">Notes payable, net</a></td>
<td class="nump">33,746<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_RoyaltyObligationLiabilityNoncurrent', window );">Royalty obligations, net</a></td>
<td class="nump">21,559<span></span>
</td>
<td class="nump">20,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent', window );">Liability related to the sale of future revenue, net</a></td>
<td class="nump">62,777<span></span>
</td>
<td class="nump">62,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">4,822<span></span>
</td>
<td class="nump">4,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">19,744<span></span>
</td>
<td class="nump">20,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,218<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">163,164<span></span>
</td>
<td class="nump">161,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies (Note 20)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value. Authorized $250,000,000 shares; 99,317,153 and 91,413,742 shares issued and outstanding at March&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">325,115<span></span>
</td>
<td class="nump">302,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(386,144)<span></span>
</td>
<td class="num">(363,214)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(60,930)<span></span>
</td>
<td class="num">(60,156)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 102,234<span></span>
</td>
<td class="nump">$ 101,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Sale of Future Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_RoyaltyObligationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_RoyaltyObligationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_RoyaltyObligationsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligations, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_RoyaltyObligationsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Senior Notes, Noncurrent And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_TradeAndOtherReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade and other receivables).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_TradeAndOtherReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">99,317,153<span></span>
</td>
<td class="nump">91,413,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">99,317,153<span></span>
</td>
<td class="nump">91,413,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Manufacture and supply</a></td>
<td class="nump">$ 3,652<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Proprietary product revenue, net<span></span>
</td>
<td class="text">Proprietary product revenue, net<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,361<span></span>
</td>
<td class="nump">$ 5,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">19,072<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">28,085<span></span>
</td>
<td class="nump">21,010<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,365)<span></span>
</td>
<td class="num">(8,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income/(expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(2,782)<span></span>
</td>
<td class="num">(2,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Interest expense related to royalty obligations</a></td>
<td class="num">(1,437)<span></span>
</td>
<td class="num">(1,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_InterestExpenseSaleOfFutureRevenues', window );">Interest expense related to the sale of future revenue</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_InterestAndOtherIncomeNet', window );">Interest income and other income, net</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (22,930)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">95,497,056<span></span>
</td>
<td class="nump">73,614,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">95,497,056<span></span>
</td>
<td class="nump">73,614,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_InterestAndOtherIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest And Other Income, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_InterestAndOtherIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_InterestExpenseSaleOfFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Sale of Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_InterestExpenseSaleOfFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Public Equity Offering - ATM</div></th>
<th class="th"><div>Public Equity Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Public Equity Offering - ATM</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public Equity Offering - ATM</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public Equity Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,533,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="num">$ (106,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (319,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common Stock issued under public equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666,667<span></span>
</td>
<td class="nump">4,557,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common Stock issued under public equity offering</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">$ 12,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">74,983<span></span>
</td>
<td class="nump">$ 12,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Costs of common stock issued under public equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Costs of common stock issued under public equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Vested restricted stock units, net</a></td>
<td class="num">(893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercises, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised, net</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,478,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="num">(36,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(331,905)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,413,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="num">(60,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(363,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common Stock issued under public equity offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,457,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common Stock issued under public equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Costs of common stock issued under public equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vested restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Vested restricted stock units, net</a></td>
<td class="num">(702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,930)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,317,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="num">$ (60,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (386,144)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 20A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-20A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,930)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation, amortization, and impairment</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discounts</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables, net</a></td>
<td class="num">(3,129)<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">423<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(2,776)<span></span>
</td>
<td class="num">(1,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(23,400)<span></span>
</td>
<td class="num">(10,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Repayment of debt principal including lease liabilities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_PaymentsForRoyaltyObligationsFinancingObligations', window );">Payments for royalty obligations</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for taxes on share-based compensation</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(893)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,646<span></span>
</td>
<td class="nump">81,741<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(2,889)<span></span>
</td>
<td class="nump">71,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">71,546<span></span>
</td>
<td class="nump">23,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">68,657<span></span>
</td>
<td class="nump">95,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash payments for interest</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable', window );">Costs associated with public equity offering in Accounts Payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable', window );">Costs associated with public equity offering-ATM in Accounts Payable</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_AtTheMarketOfferingMember', window );">At-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from common stock issued under public equity offering</a></td>
<td class="nump">21,360<span></span>
</td>
<td class="nump">11,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_PublicEquityOfferingMember', window );">Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from common stock issued under public equity offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 70,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs Associated with At-the-Market Public Equity Offering in Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs Associated with Public Equity Offering in Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_PaymentsForRoyaltyObligationsFinancingObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Royalty Obligations, Financing Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_PaymentsForRoyaltyObligationsFinancingObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aqst_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aqst_PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Overview and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Company Overview and Basis of Presentation</a></td>
<td class="text">Company Overview and Basis of Presentation<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(A) Company Overview</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aquestive Therapeutics, Inc. is a pharmaceutical company advancing medicines to bring meaningful improvement to patients&#8217; lives through innovative science and delivery technologies. The Company is developing pharmaceutical products to deliver complex molecules through alternative administrations to invasive and inconvenient standard of care therapies. The Company is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis, under the Anaphylm&#8482; trade name, and its Adrenaverse&#8482; epinephrine prodrug pipeline platform. The Company has four licensed commercialized products which are marketed by its licensees in the U.S. and around the world. The Company is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm&#174;, and has proven drug development and commercialization capabilities. The Company&#8217;s production facilities are located in Portage, Indiana, and its corporate headquarters and primary research laboratory facilities are based in Warren, New Jersey.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B)&#160;Equity Transactions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Offering of Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company established its first ATM facility in September 2019, and since inception to March&#160;31, 2025, the Company has sold 27,315,145 shares of Common Stock under its ATM Facility which has generated net cash proceeds of approximately $81,829, net of commissions and other transactions costs of $3,814. On April 3, 2024, the Company filed a new shelf registration statement on Form S-3, the 2024 Registration Statement, which was declared effective by the SEC on April 23, 2024. Included as part of the 2024 Registration Statement are (i) a base prospectus registering the offer, issuance and sale of up to $250,000 worth of Common Stock, preferred stock, debt securities, warrants, rights and units and (ii) a $100,000 ATM facility prospectus. During the three months ended March 31, 2025, the Company sold 7,457,627 shares of Common Stock pursuant to the ATM prospectus and the Amended Equity Distribution Agreement with Piper Sandler &amp; Co. (successor to Piper Jaffray &amp; Co.), which provided net proceeds of approximately $21,306 after deducting commissions and other transaction costs of $694 of which $89 remains unpaid as of March 31, 2025. For the three months ended March 31, 2024, the Company sold 4,557,220 shares under the ATM facility which provided net proceeds of approximately $12,012 after deducting commissions and other transaction costs of $373. The remaining authorized balance of the ATM facility was $78,000 as of March&#160;31, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2022, the Company entered into the Lincoln Park Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth in the Lincoln Park Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $40,000 worth of shares of Common Stock from time to time over the 36-month term of the Lincoln Park Purchase Agreement. The Lincoln Park Purchase Agreement contains an ownership limitation such that the Company will not issue, and Lincoln Park will not purchase, shares of Common Stock if it would result in Lincoln Park&#8217;s beneficial ownership exceeding 9.99% of the Company&#8217;s then outstanding Common Stock. Lincoln Park has covenanted under the Lincoln Park Purchase Agreement not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company&#8217;s Common Stock. The Company did not sell shares in connection with the Lincoln Park Purchase Agreement during the three months ended March 31, 2025 or in 2024. The Lincoln Park Purchase agreement expired on May 1, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2024, the Company completed the underwritten public offering of 16,666,667 shares of its Common Stock at the public offering price of $4.50 per share. At closing, Aquestive received net proceeds of $70,500 after deducting underwriting discounts of $4,500. In addition to the underwriting discounts related to this offering, the Company incurred professional fees and other costs totaling $687 as of March 31, 2024. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the partial exercise of the underwriters' option, on April 22, 2024, the Company sold an additional 559,801 shares of Common Stock, for additional net proceeds of $2,368, after deducting underwriting discounts of $151. In addition to the underwriting discounts related to the partial exercise of the underwriters' option, the Company incurred professional fees and other costs totaling $207.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Basis of Presentation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed financial statements were prepared in conformity with U.S. GAAP and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and related notes for the fiscal year ended December&#160;31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;5, 2025 (the &#8220;2024 Annual Report on Form 10-K&#8221;). As included herein, the Condensed Balance Sheet as of December&#160;31, 2024 is derived from the audited financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of interim periods have been included. The accompanying condensed financial statements reflect certain reclassifications from previously issued financial statements to conform to the current presentation. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying condensed financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in the Notes to applicable guidance refers to the authoritative U.S. GAAP as found in the ASC and ASU of FASB.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted as of March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company adopted the new disclosure requirements as of December 31, 2024. Refer to Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the required disclosure.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Accounting Standards Update was issued to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Among other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. More specifically, the ASU reduces the number of models that may be used to account for convertible instruments from five to three, amends diluted EPS calculations for convertible instruments, modifies the requirements for a contract that may be settled in an entity&#8217;s own shares to be classified in equity and requires expanded disclosures intended to increase transparency. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Accounting Standards Update was issued to clarify the guidance in Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, and to introduce new disclosure requirements for such equity securities. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the Statements of Operations, and Comprehensive Loss as well as qualitatively describe the remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company&#8217;s definition of selling expenses. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact from the adoption of ASU 2024-03 on disclosures to its financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#8212;Improvements to Income Tax Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Accounting Standards Update was issued to enhance the transparency and decision usefulness of income tax </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures. The ASU requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). It further requires disclosure on an annual basis of the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). Additionally, it requires the following information disclosure: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The ASU eliminates certain current disclosure requirements. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2025, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2023-09 on disclosures to its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text">Risks and Uncertainties<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company&#8217;s cash requirements for the remainder of 2025 and beyond include expenses related to continuing development and clinical evaluation of its products, manufacture and supply costs, costs of regulatory filings, patent prosecution expenses and litigation expenses, expenses related to commercialization of its products, as well as costs to comply with the requirements of being a public company operating in a highly regulated industry. As of March&#160;31, 2025, the Company had $68,657 of cash and cash equivalents.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has experienced a history of net losses. The Company&#8217;s accumulated deficits totaled $386,144 as of March&#160;31, 2025. The net losses and accumulated deficits were partially offset by gross margins from sales of commercialized licensed and proprietary products, license fees, milestone and royalty payments from commercial licensees and co-development parties. The Company&#8217;s funding requirements have been met by its cash and cash equivalents, as well as its equity and debt offerings, including the 13.5% Senior Secured Notes as further discussed in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ATM facility and other equity offerings, including the underwritten public offering as discussed in Note 1, Part B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Transactions.</span></div>While the Company&#8217;s ability to execute its business objectives and achieve profitability over the longer term cannot be assured, the Company&#8217;s on-going business, existing cash and cash equivalents, expense management activities, including, but not limited to the ceasing of R&amp;D activities, as well as access to the equity capital markets through its ATM facility, provide near term liquidity for the Company to fund its operating needs for at least the next twelve months as it continues to execute its business strategy.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate discrete financial information is available for evaluation by the CODM in deciding how to allocate resources and in assessing performance. For the three months ended March 31, 2025 and 2024, the Company has identified one operating and reportable segment. The Company defines its operating segment based on internally reported financial information that is regularly reviewed by the CODM to analyze financial performance, make decisions, and allocate resources. The Company's Chief Executive Officer (&#8220;CEO&#8221;) is the CODM. The Company manages its operations as a single segment for purposes of assessing performance and making operating decisions. This segment encompasses the development and advancement of a product pipeline for the treatment of severe allergic reactions, including anaphylaxis, and the Adrenaverse epinephrine prodrug pipeline platform. Additionally, the Company serves as the exclusive manufacturer for its proprietary product, Libervant, and four licensed commercialized products.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM reviews the segment's profit or loss based on net loss reported on the Condensed Statements of Operations and Comprehensive Loss. The CODM also considers forecast-to-actual variances on a monthly basis for expenses deemed significant. Furthermore, the CODM reviews the segment's assets based on total assets reported on the Condensed Balance Sheets. All long-lived assets are held in the United States. While the Company generated $8,720 and $12,053 in revenues for the three months ended March 31, 2025 and 2024, respectively, management expects the Company to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials, ultimately seeking regulatory approval. The CODM uses cash forecast models to guide investment decisions and assess entity-wide operating results and performance. Net loss is used to monitor budget and rolling forecasts versus actual results. The CODM views specific categories within research and development expenses, selling expenses, and general and administrative expenses as significant due to their direct correlation with cash burn and profitability.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles reported revenues to net loss under the significant expense principle for the three months ended March 31, 2025 and 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,053&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Manufacture and Supply Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D Project expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anaphylm project expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AQST-108 project expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libervant project expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D other expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Research and Development Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selling expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Selling expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General &amp; Administrative expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total General and Administrative Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Selling, General and Administrative Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - R&amp;D Personnel costs include payroll expenses,  share-based compensation expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - Selling Personnel costs include payroll expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - Other Selling expenses include commercialization and other related expenses</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - G&amp;A Personnel costs include payroll expenses,  share-based compensation expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues and Trade Receivables, Net</a></td>
<td class="text">Revenues and Trade Receivables, Net<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues include (i) sales of manufactured products pursuant to contracts with commercialization licensees, (ii) license and royalty revenues, (iii) co-development and research fees generally in the form of milestone payments, </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (iv) sales of its proprietary CNS product, Libervant, for patients between two to five years of age while Libervant had U.S. market access. The Company recognizes revenue to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve this core principle, a five-step model is applied that includes (1) identifying the contract with a customer, (2) identifying the performance obligation in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the current revenue recognition standard.&#160;A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a distinct good.&#160;When identifying performance obligations, the Company considers all goods or services promised in a contract regardless of whether explicitly stated in the contract or implied by customary business practice. The Company&#8217;s performance obligations consist mainly of transferring goods and services identified in the contracts, purchase orders, invoices or statements of work.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacture and supply revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; this revenue is derived from products manufactured exclusively for specific customers according to their strictly-defined specifications, subject only to specified quality control inspections. Accordingly, at the point in time when quality control requirements are satisfied, revenue net of related discounts is recorded.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Revenu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e &#8211; license revenues are determined based on an assessment of whether the license is distinct from any other performance obligations that may be included in the underlying licensing arrangement. If the customer is able to benefit from the license without provision of any other performance obligations by the Company and the license is thereby viewed as a distinct or functional license, the Company then determines whether the customer has acquired a right to use the license or a right to access the license. For functional licenses that do not require further development or other ongoing activities by the Company, the customer is viewed as acquiring the right to use the license as, and when, transferred and revenues are generally recorded at a point in time, subject to contingencies or constraints. For symbolic licenses providing substantial value only in conjunction with other performance obligations to be provided by the Company, revenues are generally recorded over the term of the license agreement. Such other obligations provided by the Company generally include manufactured products, additional development services or other deliverables that are contracted to be provided during the license term. Payments received in excess of amounts ratably or otherwise earned are deferred and recognized over the term of the license or as contingencies or other performance obligations are met.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is estimated and recognized when sales under supply agreements with commercial licensees are recorded, absent any contractual constraints or collectability uncertainties. Royalties based on sales of licensed products have been recorded in this manner.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition arising from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., an NDA filing or obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales occur or the performance obligation to which the sales relate to has been satisfied.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-development and Research Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development defined within a contractual development or feasibility study agreement with a customer. The nature of these performance obligations, broadly referred to as milestones or deliverables, are usually dependent on the scope and structure of the project as contracted, as well as the complexity of the product and the specific regulatory approval path necessary for that product. Accordingly, the duration of the Company&#8217;s research and development projects may range from several months to approximately three years. Although each contractual arrangement is unique, common milestones included in these arrangements include those for the performance of efficacy and other tests, reports of findings, formulation of initial prototypes, production of stability clinical and/or scale-up batches, and stability testing of those batches. Additional milestones may be established and linked to clinical results of the product submission and/or approval of the product by the FDA and the commercial launch of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary product revenue, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - this net revenue is recognized when product is shipped and title passes to the customer, typically at time of delivery. At the time of sale, estimates for various revenue allowances are recorded based on historical trends and judgmental estimates. For sales of Libervant for patients between two to five years of age, returns allowances and prompt pay discounts are estimated based on contract terms and historical return rates, if available, and these estimates are recorded as a reduction of receivables. Similarly determined estimates are recorded relating to wholesaler service fees, co-pay support redemptions, and other rebates, and these estimates are reflected as a component of accrued liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once all related variable considerations are resolved and uncertainties as to collectable amounts are eliminated, estimates are adjusted to actual allowance amounts. Provisions for these estimated amounts are reviewed and adjusted on no less than a quarterly basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, customer contractual payment terms provide for invoicing in arrears. Accordingly, some, or all performance obligations may be completely satisfied before the customer may be invoiced under such agreements.&#160;In these situations, billing occurs after revenue recognition, which results in a contract asset supported by the estimated value of the completed portion of the performance obligation. These contract assets are reflected as a component of other receivables within Trade and other receivables within the Condensed Balance Sheets. As of March&#160;31, 2025, and December&#160;31, 2024, such contract assets were $718 and $578, respectively, consisting primarily of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, customer contractual payment terms are structured to permit invoicing in advance of delivery of a good or service. In such instances, the customer&#8217;s cash payment may be received before satisfaction of some, or any, performance obligations that are specified. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. These contract liabilities are reflected as deferred revenue within the Condensed Balance Sheets. As remaining performance obligations are satisfied, an appropriate portion of the deferred revenue balance is credited to earnings. As of March&#160;31, 2025 and December&#160;31, 2024, such contract liabilities were $20,792 and $21,053, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, the Company may incur incremental costs of obtaining a contract with a customer. These costs, if expected to be recovered, are recognized as an asset and reflected as other assets within the Condensed Balance Sheets. The asset is amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. As of March&#160;31, 2025 and December&#160;31, 2024, such costs to obtain contracts were $472 and $480, respectively.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues were comprised of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-development and research fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides disaggregated net revenue by geographic area: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025, United States revenues were derived primarily from Indivior (manufacture and supply revenue, and co-development and research fees), and Assertio (manufacture and supply revenue, license and royalty revenue and co-development and research fees). Ex-United States revenues were derived primarily from Indivior (manufacture and supply revenue, license and royalty revenue and co-development and research fees), and Hypera (manufacture and supply revenue, and license and royalty revenue) for revenue markets outside of the United States. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024, United States revenues were derived primarily from Indivior (manufacture and supply revenue, and co-development and research fees), and Assertio (manufacture and supply revenue, license and royalty revenue, and co-development and research fees). Ex-United States revenues were derived primarily from Indivior (manufacture and supply revenue, license and royalty revenue and co-development and research fees), Zambon (manufacture and supply revenue, license and royalty revenue and co-development and research fees), and Pharmanovia (co-development and research fees). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sales-related allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract and other receivables totaled $2,213 and $2,473 as of March&#160;31, 2025 and December&#160;31, 2024, respectively, consisting primarily of contract assets and other receivables. Contract assets consist of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties. Other receivables include the current portion related to the Monetization royalty receivable and other receivables. Sales-related allowances as of March&#160;31, 2025 were estimated in relation to revenues recognized for sales of Libervant for patients between two to five years of age.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses on accounts receivable, which is recorded as a reduction to accounts receivable. Changes in the allowance are classified as Selling, general and administrative expenses in the Statements of Operations and Comprehensive Loss. The Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when it identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status. It also considers customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. On an ongoing basis, management evaluates the adequacy of these reserves. The allowance for credit losses was $0 as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the allowance for credit losses:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance reduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-Related Allowances</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of prompt payment discounts, wholesaler service fees, returns allowances, chargebacks, rebates and co-pay support redemptions. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provides a summary of activity with respect to sales-related allowances:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for returns allowances and prompt pay discounts are reflected as a direct reduction of trade receivables and accruals for wholesaler service fees, co-pay support redemptions and other rebates are reflected as current liabilities. The accrued balances relative to these provisions included in Trade and other receivables, net and accrued expenses were $77 and $609, respectively, as of March&#160;31, 2025, and $48 and $665, respectively, as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Major Customers</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers are considered major customers when net revenue exceeds 10% of total revenue for the period or outstanding receivable balances exceed 10% of total receivables. For the three months ended March 31, 2025, Indivior and Hypera, represented approximately 67% and 17%, of total revenue, respectively. As of March&#160;31, 2025, Indivior and Hypera exceeded the 10% threshold for outstanding receivable balances and represented approximately 56% and 14% of total trade and other receivables, respectively. For the three months ended March&#160;31, 2024, Indivior exceeded the 10% threshold for revenue and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total revenue. As of December&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Indivior and Hypera exceeded the 10% threshold for outstanding receivable balances and represented 41% and 16% of total trade and other receivables, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Material Agreements</a></td>
<td class="text">Material Agreements<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Exploitation Agreement with Indivior</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2008, the Company entered into the Indivior License Agreement (with subsequent amendments) with Reckitt Benckiser Pharmaceuticals, Inc. who was later succeeded to in interest by Indivior.&#160;Pursuant to the Indivior License Agreement, the Company agreed to manufacture and supply Indivior&#8217;s requirements for Suboxone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a sublingual film formulation, both inside and outside the United States on an exclusive basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Indivior License Agreement, the Company is required to manufacture Suboxone in accordance with current Good Manufacturing Practice standards and according to the specifications and processes set forth in the related quality agreements the Company entered into with Indivior. Additionally, the Company is required to obtain API&#160;for the manufacture of Suboxone directly from Indivior. The Indivior License Agreement specifies a minimum annual threshold quantity of Suboxone that the Company is obligated to fill and requires Indivior to provide the Company with a forecast of its requirements at various specified times throughout the year. The Indivior License Agreement provides for payment by Indivior of an agreed upon purchase price per unit until January 1, 2025 and, thereafter, that is subject to annual adjustments based on changes in an agreed upon price index. In addition to the purchase price for the Suboxone supplied, Indivior is required to make certain single digit percentage royalty payments tied to net sales value (as provided for in the Indivior License Agreement) outside of the U.S., subject to annual maximum amounts and limited to the life of the related patents. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indivior License Agreement contains customary contractual termination provisions, including with respect to a filing for bankruptcy or corporate dissolution, an invalidation of the intellectual property surrounding Suboxone, and commission of a material breach of the Indivior License Agreement by either party. Additionally, Indivior may terminate the Indivior License Agreement if the FDA or other applicable regulatory authority declares the Company&#8217;s manufacturing site to no longer be suitable for the manufacture of Suboxone or Suboxone is no longer suitable to be manufactured due to health or safety reasons. The initial term of the Indivior License Agreement was seven years from the commencement date. Thereafter, the Indivior License Agreement automatically renewed for successive one-year periods.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of March 2, 2023, the Company and Indivior entered into the Indivior Amendment to the Indivior License Agreement. The Indivior Amendment was entered into for the primary purpose of amending the Agreement as follows: (i) extending the term of the Agreement until August 16, 2026 and thereafter providing for automatic renewal terms of successive one-year periods unless Indivior delivers notice to the Company, at least twelve months prior to the expiration of the then current term, of Indivior&#8217;s intent not to renew, subject to the earlier termination rights of the parties under the Agreement, and providing that the Agreement will not automatically renew for any renewal term beginning after the expiration of the last to expire of the product patents covered under the Indivior License Agreement; and (ii) agreeing to transfer pricing and payment terms for supplied product under the Indivior License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Sunovion Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2016, the Company entered into a license agreement with Cynapsus Therapeutics Inc. (which was later succeeded to in interest by Sunovion), referred to as the Sunovion License Agreement, pursuant to which Sunovion obtained an exclusive, worldwide license (with the right to sub-license) to certain intellectual property, including existing and future patents and patent applications, covering all oral films containing apomorphine for the treatment of off episodes in Parkinson&#8217;s disease patients. Sunovion used this intellectual property to develop its apomorphine product KYNMOBI, which was approved by the FDA on May 21, 2020. This approval triggered Sunovion&#8217;s obligation to remit a payment of $4,000, due on the earlier of: (a) the first day of product availability at a pharmacy in the United States; or (b) within six months of FDA approval of the product. This amount was received as of September 30, 2020 and was included in License and royalty revenues for the twelve months ended December 31, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective March 16, 2020, the Company entered into the First Amendment. The First Amendment was entered into for the primary purpose of amending the Sunovion License Agreement as follows: (i) including the United Kingdom and any other country currently in the EU which later withdraws as a member country in the EU for purpose of determining the satisfaction of the condition triggering the obligation to pay the third milestone due under the Sunovion License Agreement, (ii) extending the date after which Sunovion has the right to terminate the Sunovion License Agreement for convenience from December 31, </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 to March 31, 2028, (iii) modifying the effective inception date of the first minimum annual royalty due from Sunovion to the Company form January 1, 2020 to April 1, 2020, and (iv) modifying the termination provision to reflect the Company&#8217;s waiver of the right to terminate the Sunovion License Agreement in the event that KYNMOBI was not commercialized by January 1, 2020. This Sunovion License Agreement will continue until terminated by Sunovion in accordance with the termination provisions of the First Amendment. The Sunovion License Agreement continues (on a country-by-country basis) until the expiration of all applicable licensed patents unless earlier terminated under the termination provisions contained therein. Upon termination of the Sunovion License Agreement, all rights to intellectual property granted to Sunovion to develop and commercialize apomorphine-based products will revert to the Company. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company amended the Sunovion License Agreement to clarify the parties' agreement with respect to certain provisions in the Sunovion License Agreement, specifically the date after which Sunovion has the right to terminate the Sunovion License Agreement and the rights and obligations of the parties regarding the prosecution and maintenance of the Company&#8217;s patents covered under the Sunovion License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the rights granted to Sunovion under the Sunovion License Agreement, the Company received aggregate payments totaling $22,000 to date. In addition to the upfront payment of $5,000, the Company has also earned an aggregate of $17,000 in connection with specified regulatory and development milestones in the United States and Europe (the &#8220;Initial Milestone Payments&#8221;), all of which have been received to date. With the Monetization Agreement (defined below) entered into on November 3, 2020 relating to KYNMOBI as described in the paragraph below, the Company is no longer entitled to receive any payments under the Sunovion License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase and Sale Agreement with an affiliate of Marathon</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2020, the Company entered into the Monetization Agreement with Marathon. Under the terms of the Monetization Agreement, the Company sold to Marathon all of its contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#8217;s apomorphine product, KYNMOBI. In exchange for the sale of these rights, the Company received an upfront payment from Marathon of $40,000 and an additional payment of $10,000 through the achievement of the first milestone. The Company has received an aggregate amount of $50,000 through March&#160;31, 2025 under the Monetization Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Monetization Agreement, additional contingent payments of up to $75,000 may be due to the Company upon the achievement of worldwide royalty and other commercial targets within a specified timeframe, which could result in total potential proceeds of $125,000. In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets; therefore, the Company likely will not receive any of the additional contingent payments under the Monetization agreement. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the accounting for the Monetization Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement to Terminate CLA with Zevra Therapeutics, Inc. (formerly KemPharm)</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2012, the Company entered into an agreement with Zevra to terminate a Collaboration and License Agreement entered into by the Company and Zevra in April 2011. Under this termination arrangement, the Company has the right to participate in any and all value that Zevra may derive from the commercialization or any other monetization of KP-415 and KP-484 compounds or their derivatives. Among these monetization transactions are those related to any business combinations involving Zevra and collaborations, royalty arrangements, or other transactions from which Zevra may realize value from these compounds, including the product Azstarys</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Supply Agreement with Haisco for Exservan&#8482; (Riluzole Oral Film) for ALS Treatment in China</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Haisco Agreement with Haisco, a Chinese limited company listed on the Shenzhen Stock Exchange, effective as of March 3, 2022, pursuant to which Aquestive granted Haisco an exclusive license to develop and commercialize Exservan&#8482; (riluzole oral film) for the treatment of ALS in China. Under the terms of the Haisco Agreement, Aquestive was the exclusive sole manufacturer and supplier for Exservan in China. Under the Haisco Agreement, as amended, the Company received a $7,000 upfront cash payment in September 2022 and was entitled to receive regulatory milestone payments and double-digit royalties on net sales of Exservan in China and earn manufacturing revenue upon the sale of Exservan in China. In June 2024, the Haisco Agreement was terminated, and the Company will not receive any contingent payments under the Haisco Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Supply Agreement with Atnahs Pharma UK Limited </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Pharmanovia Agreement, effective as of September 26, 2022, pursuant to which the Company granted Pharmanovia an exclusive license to certain of the Company&#8217;s intellectual property to develop and commercialize Libervant&#8482; (diazepam) Buccal Film for the treatment of prolonged or acute, convulsive seizures in all ages in the Territory during the term of the Pharmanovia Agreement. Under the Pharmanovia Agreement, Pharmanovia will lead the regulatory and commercialization activities for Libervant in the Territory and the Company will serve as the exclusive sole </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer and supplier of Libervant in the Territory. Pursuant to the Pharmanovia Agreement, the Company received $3,500 upon agreement execution and, upon the occurrence of certain conditions set forth in the Pharmanovia Agreement, will receive additional milestone payments and profit shares, as well as manufacturing fees and royalty fees through the expiration of the Pharmanovia Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective March 27, 2023, the Company amended the Pharmanovia Agreement to expand the scope of territory for the license of Libervant to cover the rest of the world, excluding the U.S., Canada and China. Under the Pharmanovia Amendment, Pharmanovia will be responsible for seeking applicable regulatory approval in the expanded territories, which include Latin America, Africa and Asia Pacific. Pursuant to the terms of the Pharmanovia Amendment, the Company received a non-refundable payment of $2,000 from Pharmanovia in connection with the execution of the Pharmanovia Amendment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreement with Assertio Holdings, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of October 26, 2022, the Company entered into the Assertio Agreement to license Sympazan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox&#8208;Gastaut syndrome in patients aged two years of age and older. Under the terms of the Assertio Agreement, the Company granted to Assertio an exclusive, worldwide license of its intellectual property for Sympazan to Assertio during the term of the Assertio License Agreement for an upfront payment of $9,000. In addition, Aquestive received a $6,000 milestone payment subsequent to Aquestive&#8217;s receipt of a notice of allowance from the PTO of the Company&#8217;s patent application U.S. Serial No. 16/561,573, and payment by the Company of the related allowance fee. The Company received the notice of allowance from the PTO and paid the related allowance fee on October 27, 2022. Further, under the Assertio Agreement, the Company will receive royalties from Assertio for the sale of the product through the expiration of the Assertio Agreement. The Company also entered into a long-term supply agreement with Assertio for Sympazan pursuant to which the Company is the exclusive sole worldwide manufacturer and supplier of the product and will receive manufacturing fees from Assertio for the product through the expiration of such supply agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreement with Mitsubishi Tanabe Pharma America, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that Aquestive granted an exclusive license to MTPA for the commercialization of Exservan in the United States. MTPA is a multinational pharmaceutical company with a focus on patients with ALS. The product was launched by MTPA in June 2021. Under the terms of the MTPA license agreement, Aquestive was the exclusive manufacturer and supplier of Exservan for MTPA in the United States. In June 2024, under the Second Amendment to the License and Supply Agreement, MTPA and the Company mutually agreed to terminate the agreement. As of June 30, 2024 and as part of the termination, the parties were released from any existing or ongoing obligations (except for certain limited non-material post-termination obligations).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments &#8211; Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments &#8211; Fair Value Measurements</a></td>
<td class="text">Financial Instruments &#8211; Fair Value Measurements<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&#160;Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 1 &#8212; Observable quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 2 &#8212; Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</span></div><div style="margin-bottom:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity, such as pricing models, discounted cash flow&#160;methodologies and similar techniques.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the Condensed Balance Sheets for Trade and other receivables, prepaid and other current assets, accounts payable and accrued expenses, and deferred revenue approximate their fair values based on the short-term maturity of these assets and liabilities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted warrants to certain noteholders in connection with its debt repayment and debt refinancing of the 12.5% Notes during 2020 and 2019, respectively. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation. See Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on these warrants.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company issued pre-funded warrants to purchase up to 4,000,000 shares of Common Stock and Common Stock Warrants to purchase up to 8,850,000 shares of Common Stock in connection with its Securities Purchase Agreements with certain purchasers. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide. See Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on these warrants.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, the Company entered into the Letter Agreement with the Exercising Holder of the remaining warrants to purchase 5,000,000 of the shares of Common Stock. Pursuant to the Letter Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise all of its Existing Warrants for shares of Common Stock underlying the Existing Warrants at $0.96 per share of Common Stock, the current exercise price of the Existing Warrants. Under the Letter Agreement, in consideration of the Exercising Holder exercising the Existing Warrants, the Company issued to the Exercising Holder new warrants to purchase up to an aggregate of 2,750,000 shares of new warrants at $2.60 per share. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide. See Note 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on these warrants.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, in connection with the issuance of the 13.5% Notes, the Company and the Note Holders entered into the Royalty Right Agreements dated as of November 1, 2023, which provides the Note Holders:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">a tiered royalty between 1.0% and 2.0% of annual worldwide net sales of Anaphylm&#8482; (epinephrine) Sublingual Film for a period of eight years from the first sale of Anaphylm on a global basis, and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">a tiered royalty between 1.0% to 2.0% of annual worldwide net sales of Libervant&#174; (diazepam) Buccal Film until the earlier of (1) the first sale of Anaphylm and (2) eight years from the first sale of Libervant. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those Royalty Agreements were valued based on Level 3 inputs and their&#160;fair value was based primarily on internal management estimates developed based on third-party data and reflect management&#8217;s judgements, current market conditions, and forecasts. The initial fair value measurement of the Royalty Right Agreements was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and the estimated amount of future sales of Anaphylm and Libervant. See Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Inventory are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw material</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Packaging material</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful<br/>Lives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer, network equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation, amortization, and impairment related to property and equipment was $139 and $168 for the three months ended March 31, 2025 and 2024, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right-of-Use Assets and Lease Obligations</a></td>
<td class="text">Right-of-Use Assets and Lease Obligations<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases all realty used at its production and warehouse facilities, corporate headquarters, commercialization operations center and research and laboratory facilities. None of these three leases include the characteristics specified in ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which require classification as financing leases and, accordingly, these leases are accounted for as operating leases. These leases, as amended, provide remaining terms between 3.0 years and 8.5 years, including renewal options expected to be exercised to extend the lease periods. Commitments under finance leases are not significant, and are included in Property and equipment, net, and Notes Payable, net on the Condensed Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize a right-to-use asset and lease liability for short-term leases, which have terms of 12 months or less on its Condensed Balance Sheets. For longer-term lease arrangements that are recognized on the Company&#8217;s Condensed Balance Sheets, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company&#8217;s short-term leases, as well as variable costs relating to the Company&#8217;s lease arrangements, are not material to the Company&#8217;s financial results.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implicit interest rates of the Company&#8217;s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. Measurement of the operating lease liability reflects a range of an estimated discount rate of 14.8% to 15.6% applied to minimum lease payments, including expected renewals, based on the incremental borrowing rate experienced in the Company&#8217;s collateralized debt refinancing. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease costs are recorded in manufacture and supply, research and development and selling, general and administrative expenses in its Condensed Statements of Operations and Comprehensive Loss. For the three months ended March&#160;31, 2025, total operating lease expenses totaled $427, including variable lease expenses such as common area maintenance and operating costs of $93. For the three months ended March&#160;31, 2024, total operating lease expenses totaled $444, including variable lease expenses such as common area maintenance and operating costs of $115.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s payments due under its operating leases are as follows: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of identifiable intangible assets, all of which are finite lived:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased intangible</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased patent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>There was no amortization expense incurred during the three months ended March&#160;31, 2025. Amortization expense was $39 for the three months ended March&#160;31, 2024. In June 2024, in connection with a termination of an agreement, the Company recorded an adjustment to the remaining balance of $1,200 of the intangible asset<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Non-current Assets</a></td>
<td class="text">Other Non-current Assets<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of other non-current assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other non-current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, under the Sunovion License Agreement, the Company recognized $8,000 of royalty revenue and corresponding royalty receivable, related to the eight $1,000 annual minimum guaranteed royalty payments that are due to the Company. In connection with the Monetization Agreement, the Company performed an assessment under ASC 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfer and Servicing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to determine whether the existing receivable was transferred to Marathon and concluded it was not transferred. As of March&#160;31, 2025 and December&#160;31, 2024, Royalty receivable consists of four annual minimum payments due from Sunovion, the last of which is due in March 2028. The current portion of the royalty receivable is included in Trade and other receivables, net. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on how this receivable relates to the Monetization Agreement transaction.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of costs to obtain contracts capitalized under ASC 340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs, </span>is recorded within Other non-current assets on the  Condensed Balance Sheets as of March 31, 2025 and December 31, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate and personal property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued distribution expenses and sales returns provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reduction in Accrued compensation is mostly related to payments of accrued bonuses during the three months ended March 31, 2025, partially offset by the current year accrual of bonuses. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued distribution expenses and sales returns provision mostly represent estimated liabilities for wholesaler service fees, co-pay support redemptions and other rebates related to the proprietary product Libervant and returns and other expenses related to the proprietary product Sympazan (prior to outlicensing to Assertio in October 2022).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">13.5% Senior Secured Notes</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, the Company entered into an Indenture Agreement with certain institutional investors (the &#8220;Note Holders&#8221;) and issued $45,000 aggregate principal amount of its 13.5% Notes due 2028. The Company received net proceeds of approximately $4,326 from this transaction after the repayment of the 12.5% Notes and deduction of debt discount, and debt issuance costs.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 13.5% Notes are senior secured obligations of the Company and mature on November 1, 2028. The 13.5% Notes bear interest at a fixed rate of 13.5% per year, payable quarterly commencing on December 30, 2023. On each payment date commencing on June 30, 2026, the Company will pay an installment of principal of the 13.5% Notes pursuant to a fixed amortization schedule, along with the applicable Exit Fee. The Exit Fee totals $2,000.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, at its option, redeem the 13.5% Notes in full or in part:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">if such redemption occurs prior to November 1, 2025, at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest, plus the applicable Exit Fee, plus an Applicable Premium which is the greater of </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">1.0% of the principal redeemed; and </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">the amount, if any, by which the present value of the principal to be redeemed on November 1, 2025, plus all required interest due on such date, computed using a discount rate equal to the Treasury Rate, plus 100 basis points, exceeds the amount of principal to be redeemed; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">if such redemption occurs after November 1, 2025, the redemption price is equal to 108.5% of the principal amount plus accrued and unpaid interest, plus the applicable Exit Fee. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a change of control, the Note Holders may require the Company to repurchase for cash all or any portion of the 13.5% Notes at a change of control repurchase price equal at 108.5% plus the Exit Fee of the remaining principal, plus accrued interest at the election of the Note Holders. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture permits the Company, upon the continuing satisfaction of certain conditions, including that the Company has at least $100,000 of net revenues for the most recently completed twelve calendar month period, to enter into an ABL facility not to exceed $10,000. The ABL Facility may be collateralized only by assets of the Company constituting inventory, accounts receivable, and the proceeds thereof. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of 13.5% Notes, the Company and the Note Holders entered into the Royalty Right Agreements dated as of November 1, 2023, which provides Note Holders:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">a tiered royalty between 1.0% and 2.0% of annual worldwide net sales of Anaphylm&#8482; (epinephrine) Sublingual Film for a period of eight years from the first sale of Anaphylm on a global basis, and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">a tiered royalty between 1.0% to 2.0% of annual worldwide net sales of Libervant&#174; (diazepam) Buccal Film until the earlier of (1) the first sale of Anaphylm and (2) eight years from the first sale of Libervant. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the 13.5% Notes and Royalty Right Agreements, represent freestanding instruments which were issued in conjunction with each other. They are classified as debt within the scope of ASC 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and are subsequently measured on an amortized cost basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial fair value measurement of the Royalty Right Agreements was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and the estimated amount of future sales of Anaphylm and Libervant. These inputs are derived using internal management estimates developed based on third-party data and reflect management&#8217;s judgements, current market conditions, and forecasts.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Royalty Right Agreements&#8217; fair value is estimated by applying probability-weighted cash flows for future sales, which are then discounted to present value. Changes to fair value of the Royalty Rights Agreements can result from changes to one or a number of the aforementioned inputs. A significant change in unobservable inputs could result in a material increase or decrease to the effective interest rate of the Royalty Right Agreements liability.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant unobservable inputs used in the fair value measurement of the Royalty Right Agreements:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Methodology</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Input</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average (range, if applicable)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Right Agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted<br/>income approach</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Success</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Years of Payments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has updated the projected years of payments to 2034 and the effective interest rate by 0.56% as of December&#160;31, 2024. The Company periodically re-assesses the projections and, to the extent the future projections are greater or less than its previous estimates or the estimated timing of such payments is materially different than its previous estimates, the Company will adjust the effective interest calculation. As of March&#160;31, 2025, there were no material changes to the significant unobservable inputs used to recognize the Royalty Right Agreements liability.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Royalty Right Agreements were issued in connection with the 13.5% Notes, the Company allocated the proceeds to the two instruments based on their relative fair values. The Company allocated approximately $13,856 to the Royalty Right Agreements. The Company determined the allocated fair value by calculating the present value of estimated future royalties to be paid to Note Holders over the life of the arrangement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of future estimated royalty payments of $56,926 over the $13,856 of allocated fair value is recognized as a discount related to the Royalty Right Agreements and is amortized as interest expense using the effective interest method.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocated amounts of $13,856 when combined with the Exit Fee of $2,000, original issue discount of $1,125 and debt issuance costs of $3,517, resulted in a debt discount of $20,498. The debt discount is being amortized over the term of 13.5% Notes using the effective interest method.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense arising from the discounts related to the 13.5% Notes for the three months ended March&#160;31, 2025 and 2024 was $1,254 and $1,257, respectively. Amortization expense arising from the discounts related to the Royalty Right Agreements for the three months ended March&#160;31, 2025 and 2024 was $1,437 and $1,358, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized discounts totaled $11,392 for the 13.5% Notes and $35,269 for the Royalty obligations as of March&#160;31, 2025. Unamortized discounts totaled $12,646 for the 13.5% Notes and $36,706 for the Royalty obligations as of December&#160;31, 2024, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term notes and unamortized debt discount balances are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount, including Exit Fee</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, long-term</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease, long-term</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,559&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled principal payments on the 13.5% Notes as of March&#160;31, 2025 are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants Issued to 12.5% Senior Secured Noteholders </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants that were issued in conjunction with the Initial Notes (the &#8220;Initial Warrants&#8221;) and Additional Notes (the &#8220;Additional Warrants&#8221;) expire on June 30, 2025 and entitled the noteholders to purchase up to 2,143,000 shares of Common Stock and included specified registration rights. Management estimated the fair value of the Initial Warrants to be $6,800 and the Additional Warrants to be $735, each based on an assessment by an independent third-party appraiser. The fair value of the respective warrants was treated as a debt discount, amortizable over the term of the respective warrants, with the unamortized 12.5% Notes portion applied to reduce the aggregate principal amount of the 12.5% Notes. The 12.5% Notes were refinanced with the 13.5% Notes on November 1, 2023. Additionally, since the Initial Warrants and Additional Warrants issued do not provide warrant redemption or put rights within the control of the holders that could require the Company to make a payment of cash or other assets to satisfy the obligations under the warrants, except in the case of a &#8220;cash change in control&#8221;, the fair value attributed to the warrants is presented in Additional Paid-in Capital in the Company&#8217;s Condensed Balance Sheets. There were no warrants exercised as it relates to the Initial Warrants and the Additional Warrants during the three months ended March&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase a total of 1,683,784 shares of Common Stock with exercise prices of $4.25 and $5.38 for 1,571,429 warrants and 112,355 warrants, respectively, remain outstanding as of March&#160;31, 2025 and December&#160;31, 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants Issued Under Securities Purchase Agreements</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company issued pre-funded warrants and Common Stock warrants to certain purchasers in connection with the Securities Purchase Agreements. The pre-funded warrants entitled purchasers to purchase up to 4,000,000 shares of Common Stock and were exercised in full during the year ended December 31, 2022. The Common Stock warrants expire on June 8, 2027 and entitled the purchasers to purchase up to 8,850,000 shares of Common Stock at an exercise price of $0.96 per share. Management estimated the fair value of the pre-funded warrants and Common Stock warrants to be $5,874 based on an assessment by an independent third-party appraiser. The fair value of the pre-funded and Common Stock warrants is treated as equity and presented in Additional Paid-in Capital in the Company&#8217;s Condensed Balance Sheets. On June 14, 2023, 3,689,452 Common Stock warrants issued pursuant to the Securities Purchase Agreements were exercised with proceeds of approximately $3,542.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, the Company entered into the Letter Agreement with the Exercising Holder of 5,000,000 of the remaining Common Stock Warrants. Pursuant to the Letter Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise all of its Existing Warrants for shares of Common Stock underlying the Existing Warrants at $0.96 per share of Common Stock, the current exercise price of the Existing Warrants. Under the Letter Agreement, in consideration of the Exercising Holder exercising the Existing Warrants, the Company issued to the Exercising Holder New Warrants to purchase up to an aggregate of 2,750,000 shares of Common Stock. The New Warrants became exercisable after February 2, 2024, expire on February 2, 2029 and are issuable only for cash, subject to exception if the shares of Common Stock underlying the New Warrants are not registered in accordance with the terms of the Letter Agreement, in which case the New Warrants may also be exercised, in whole or in part, at such time by means of a "cashless exercise". The New Warrants have an exercise price of $2.60 per share. Management estimated the fair value of the warrants to be $4,671 based on an assessment by an independent third-party appraiser. The fair value of the New Warrants is treated as equity and is presented in Additional Paid-in Capital in the Company&#8217;s Condensed Balance Sheets.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no warrants issued or exercised as it relates to the Warrants Issued Under Securities Purchase Agreements during the three months ended March&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the warrants to purchase 2,750,000 shares of Common Stock described above, there remain outstanding warrants to purchase 160,548 shares of Common Stock at an exercise price of $0.96 and warrants to purchase 1,683,784 shares of Common Stock outstanding related to the original issuance of the 12.5% Notes prior to the debt refinancing referenced in Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with exercise prices of $4.25 and $5.38 for 1,571,429 warrants and 112,355 warrants, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfFutureRevenueTextBlock', window );">Sale of Future Revenue</a></td>
<td class="text">Sale of Future Revenue<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2020, the Company entered into the Monetization Agreement with Marathon. Under the terms of the Monetization Agreement, the Company sold all of its contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#8217;s apomorphine product, KYNMOBI, an apomorphine film therapy for the treatment of off episodes in Parkinson&#8217;s disease patients, which received approval from the FDA on May 21, 2020. In exchange for the sale of these rights, the Company received an upfront payment of $40,000 and an additional payment of $10,000 through </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the achievement of the first milestone. The Company has received an aggregate amount of $50,000 through March&#160;31, 2025 under the Monetization Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Monetization Agreement, additional contingent payments of up to $75,000 may be due to the Company upon the achievement of worldwide royalty and other commercial targets within a specified timeframe, which could result in total potential proceeds of $125,000. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the upfront proceeds of $40,000 and subsequent first milestone of $10,000, reduced by $2,909 of transaction costs, as a liability related to the sale of future revenue that will be amortized using the effective interest method over the life of the Monetization Agreement. As future contingent payments are received, they will increase the balance of the liability related to the sale of future revenue. Although the Company sold all of its rights to receive royalties and milestones, as a result of ongoing obligations related to the generation of these royalties, the Company will account for these royalties as revenue. Its ongoing obligations include the maintenance and defense of the intellectual property and to provide assistance to Marathon in executing a new license agreement for KYNMOBI in the event Sunovion terminates the Sunovion License Agreement in one or more jurisdictions of the licensed territory under the Sunovion License Agreement. The accounting liabilities, as adjusted over time, resulting from this transaction and any non-cash interest expenses associated with those liabilities do not and will not represent any obligation to pay or any potential future use of cash.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, under the Sunovion License Agreement, the Company recognized $8,000 of royalty revenue and corresponding royalty receivable, related to the $1,000 annual minimum guaranteed royalty that is due. In connection with the Monetization Agreement, the Company performed an assessment under ASC 860, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transfer and Servicing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to determine whether the existing receivable was transferred to Marathon and concluded that the receivable was not transferred. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As royalties are remitted to Marathon from Sunovion, the collection of the royalty receivable and balance of the liability related to the sale of future revenue will be effectively repaid over the life of the agreement. In order to determine the amortization of the liability related to the sale of future revenue, the Company is required to estimate the total amount of future royalty and milestone payments to Marathon over the life of the Monetization Agreement and contingent milestone payments from Marathon to the Company. The sum of future royalty payments less the $50,000 in proceeds received and future contingent payments has been recorded as interest expense over the life of the Monetization Agreement. At execution, the estimate of this total interest expense resulted in an effective annual interest rate of approximately 24.9%. This estimate contained significant assumptions that impact both the amount recorded at execution and the interest expense that will be recognized over the life of the Monetization Agreement. The Company assesses the estimated royalty and milestone payments to Marathon from Sunovion and contingent milestone payments from Marathon to the Company. To the extent the amount or timing of such payments is materially different from the original estimates, an adjustment will be recorded prospectively to increase or decrease interest expense. There are a number of factors that could materially affect the amount and timing of royalty and milestone payments to Marathon from Sunovion and, correspondingly, the amount of interest expense recorded by the Company, most of which are not under the Company&#8217;s control. Such factors include, but are not limited to, changing standards of care, the initiation of competing products, manufacturing or other delays, generic competition, intellectual property matters, adverse events that result in government health authority imposed restrictions on the use of products, significant changes in foreign exchange rates as the royalties remitted to Marathon are made in U.S. dollars (USD) while a portion of the underlying sales of KYNMOBI will be made in currencies other than USD, and other events or circumstances that are not currently foreseen. Changes to any of these factors could result in increases or decreases to both royalty revenue and interest expense related to the sale of future revenue. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets. Therefore, the Company likely will not receive any of the additional contingent payments under the Monetization agreement. Further, the Company discontinued recording interest expense related to the sale of future revenue during the fourth quarter of 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity of the liability related to the sale of future revenue:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net at beginning of the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties related to the sale of future revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,777&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SaleOfFutureRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Future Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SaleOfFutureRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted EPS is adjusted by the effect of dilutive securities, including options and awards under the Company&#8217;s equity compensation plans, warrants and ESPP. As a result of the Company&#8217;s net loss incurred for the three months ended March&#160;31, 2025 and 2024, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations.&#160;Therefore, basic and diluted net loss per share are the same for the three months ended March&#160;31, 2025 and 2024 as reflected below.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares &#8211; basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,497,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,614,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per common share &#8211; basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">For the three months ended March&#160;31, 2025 and 2024, outstanding stock options of 6,977,367 and 6,169,489 to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the three months ended March&#160;31, 2025 and 2024, outstanding restricted stock units of 5,167,351 and 3,918,451 to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">For the three months ended March&#160;31, 2025 and 2024, outstanding warrants of 4,594,332 and 4,624,977 to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation in its Condensed Statements of Operations and Comprehensive Loss during the three month periods ended March&#160;31, 2025 and 2024 as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Equity Awards</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information about the Company&#8217;s restricted stock unit and stock option activity during the three month period ended March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s awards of service-based and market conditions vesting-based restricted stock units for the three month period ended March&#160;31, 2025:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Restricted Stock Unit Awards (RSUs) - Service-based:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, $8,369 of total unrecognized compensation expenses related to unvested service-based restricted stock units are expected to be recognized over a remaining weighted average period of 2.14 years. The service-based restricted stock units granted to employees are subject to a three-year graduated vesting schedule and are not subject to performance-based criteria other than continued employment.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Restricted Stock Unit Awards (RSUs) - Market conditions vesting-based:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, $2,798 of unrecognized compensation expense related to unvested market condition vesting- based restricted stock units are expected to be recognized over a remaining weighted average period of 1.87 years.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 market conditions vesting-based restricted stock units vest based on a Performance Price measured as the 30-day average of the closing prices of the Company&#8217;s common stock as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the three-year performance period (which ends on the third anniversary of the grant date). To the extent the Performance Price is less than $1.75, the Vesting Percentage will be zero. To the extent the Performance Price is $1.75, the Vesting Percentage will be 50%. To the extent the Performance Price is $1.76 or greater, but less than $2.50, the Vesting Percentage will be a prorated amount between 50.01% and 99.99%, based on straight-line interpolation. To the extent the Performance Price is $2.50, the Vesting Percentage will be 100%. To the extent the Performance Price is $2.51 or greater, but less than $3.25, the Vesting Percentage will be a prorated amount between 100.01% and 149.99%, based on straight-line interpolation. To the extent the Performance Price is $3.25 or greater, the Vesting Percentage will be 150%. In no event will the Vesting Percentage exceed 150%.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 market conditions vesting-based restricted stock units were measured over a three-year performance period. The performance period is split into two pricing periods. The first pricing period commences on the grant date and ends on the calendar day immediately proceeding the second anniversary of the grant date. The second pricing period commences on the second anniversary of the grant date and ends on the third anniversary of the grant date, The performance price for the first pricing period is calculated based on the 30-day average price observed for the last 30 days of the first pricing period. The performance price for the second pricing period is calculated based on the highest 30-day average for any 30-day period </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">throughout the second pricing period. To the extent the Performance Price is less than $6.00, the Vesting Percentage will be zero. To the extent the Performance Price is $6.00, the Vesting Percentage will be 50%. To the extent the Performance Price is $6.01 or greater, but less than $7.00, the Vesting Percentage will be a prorated amount between 50.01% and 99.99%, based on straight-line interpolation. To the extent the Performance Price is $7.00, the Vesting Percentage will be 100%. To the extent the Performance Price is $7.01 or greater, but less than $8.00, the Vesting Percentage will be a prorated amount between 100.01% and 149.99%, based on straight-line interpolation. To the extent the Performance Price is $8.00 or greater, the Vesting Percentage will be 150%. In no event will the Vesting Percentage exceed 150%.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimates of the fair value of the 2025 market conditions vesting-based awards at their grant or valuation dates were based on a Monte Carlo simulation and considered various variables and the following assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price at grant date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.65</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Inducement Equity Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Nasdaq Listing Rule 5635(c)(4), the Company adopted the 2022 Equity Inducement Plan approved by the Compensation Committee of the Board of Directors of the Company effective as of July 29, 2022.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Stock Option Awards:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of stock options granted were estimated using the Black-Scholes pricing model based on the following assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock options granted during the three months ended March&#160;31, 2025 was $2.15. During the three months ended March&#160;31, 2025, stock options were granted with a weighted average exercise price of $2.65 and accordingly, given the Company&#8217;s share price of $2.90 at March&#160;31, 2025, the intrinsic value provided by certain shares granted during this period was de minimis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, $3,849 of unrecognized compensation expense related to non-vested stock options is expected to be recognized over a remaining weighted average period of 1.97 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as net operating loss carryforwards and </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax asset will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items. For the three months ended March&#160;31, 2025, the effective income tax rate was 0%, and the Company recorded no income tax expense from its pretax losses of $22,930. For the three months ended March&#160;31, 2024, the effective income tax rate was 0%, and the Company recorded no income tax expense from its pretax losses of $12,828.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary factors impacting the effective tax rate for three months ended March&#160;31, 2025 is the anticipated full year pre-tax book loss and a full valuation allowance against any associated net deferred tax assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has been and may again become involved in legal proceedings arising in the course of its business, including product liability, intellectual property, securities, civil tort, and commercial litigation, and environmental or other regulatory matters.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kentucky Litigation - Humana</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Humana Inc. v. Indivior Inc, Indivior Solutions Inc., Indivior PLC, Reckitt Benckiser Group plc, Reckitt Benckiser Healthcare (UK) Ltd., and Aquestive Therapeutics, Inc. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2021, Humana filed a complaint in state court in Kentucky, alleging conspiracy to violate the RICO Act, fraud under state law, unfair and deceptive trade practices under state law, insurance fraud, and unjust enrichment against the Company relating to Indivior&#8217;s launch of Suboxone Sublingual Film in 2010. The Humana action was stayed pending related litigation, and the stay was lifted on October 30, 2023. The parties to this case reached a settlement in November 2024, the terms of which are confidential. Aquestive had no obligation, cost or liability in the settlement as all were assumed by Indivior.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Litigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Neurelis, Inc. v. Aquestive Therapeutics, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 5, 2019, Neurelis, Inc. ("Neurelis") filed a lawsuit against the Company in the Superior Court of California, County of San Diego alleging the following three causes of action: (1) Unfair Competition under California Business and Professional Code &#167; 17200 (&#8220;UCL&#8221;); (2) Defamation; and (3) Malicious Prosecution. Neurelis filed a First Amended Complaint on December 9, 2019, alleging the same three causes of action. The Company filed a Motion to Strike Neurelis&#8217;s Complaint under California&#8217;s anti-SLAPP (&#8220;strategic lawsuit against public participation&#8221;) statute on January 31, 2020, which Neurelis opposed. On August 6, 2020, the Court issued an order granting in part and denying in part the Company&#8217;s anti-SLAPP motion. The parties cross-appealed the ruling to the California Court of Appeal. The appeals court held oral argument on the appeal on October 14, 2021, and issued its ruling on November 17, 2021. Under the ruling, the court struck the entirety of the malicious prosecution claim and struck portions of the UCL and defamation claims. On April 12, 2022, Neurelis filed a Second Amended Complaint in response to the Court of Appeal&#8217;s decision. The Second Amended Complaint also added a cause of action for Trade Libel. On May 3, 2022, the Company filed a "demurrer" challenge to the sufficiency of the allegations of the Second Amended Complaint. Oral argument on the Company&#8217;s motion for attorney fees related to the anti-SLAPP motion and on the Second Amended Complaint and demurer challenge was held on June 17, 2022. The Court entered an order granting the Company&#8217;s motion for attorney fees, awarding $156 and ordering Neurelis to pay the fees within 60 days of June 17, 2022. The Court denied the Company&#8217;s demurrer and the parties proceeded with discovery on the claims in the Second Amended Complaint. The plaintiff filed a motion to file a third amended complaint, which the Court granted on November 17, 2023. The Third Amended Complaint alleges additional facts but includes the same claims as the Second Amended Complaint. Hearings on motions for summary judgement are scheduled for May 16, 2025. The trial in this matter is scheduled for July 18, 2025. The Company is not able to determine or predict the ultimate outcome of this proceeding or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurelis FDA Lawsuit</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Neurelis v. Califf, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, U.S. District court for the District of Columbia</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, Neurelis filed a complaint in the U.S. District Court for the District of Columbia against the U.S. Food and Drug Administration, the U.S. Department of Health and Human Services, and certain government officials. The complaint in this matter alleges that the defendants violated the Administrative Procedure Act by approving the Company's NDA for Libervant for ARS patients aged between two and five years, and asked the Court to vacate that approval and enjoin the defendants from approving Libervant for this pediatric patient population until January 10, 2027, the scheduled date for the expiration of the U.S. orphan drug market exclusivity granted by the FDA to the Valtoco nasal spray product of Neurelis. The Company intervened in this litigation to defend the approval of Libervant for this ARS pediatric patient population and, on June </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25, 2024, the Court entered a scheduling order governing further proceedings in the case. Pursuant to that order, Neurelis filed a motion for summary judgment on August 19, 2024; the Company and the federal defendants each filed their own cross-motions for summary judgment and opposed Neurelis&#8217;s motion for summary judgment on September 18, 2024. Neurelis filed its combined reply brief in support of its motion for summary judgment and in opposition to the defendants&#8217; cross-motions on October 9, 2024, and the Company and the federal defendants filed their closing briefs on October 30, 2024. Following the FDA's award of ODE to Libervant for ARS patients between two and five years of age, Neurelis filed a motion for preliminary injunction requesting an expedited order to vacate FDA's approval and enjoining the sale of Libervant. On February 14, 2025, the Court ruled in favor of Neurelis, granting its summary judgment motion, and against the FDA's and the Company's cross-motions for summary judgment. In an accompanying opinion, the Court directed the FDA to vacate the approval of Libervant. Because the Court entered a final appealable judgment in favor of Neurelis, Neurelis' motion for an expedited preliminary injunction was denied as moot by the Court. On February 18, 2025, the Company filed an appeal of the District Court's decision with the U.S. Circuit Court of Appeals for the District of Columbia (the "DC Appellate Court") and, on the same day, filed an emergency motion with the District Court to stay its order pending a decision on the appeal with the DC Appellate Court. The District Court denied the motion for a stay. On March 27, 2025, the DC Appellate Court denied the Company's emergency motion for stay. The FDA filed an appeal of the District Court's decision to the DC Appellate Court and the Company withdrew its appeal. As a result of the District Court's ruling, the FDA converted the approval of Libervant to a "tentative approval" and the Company has ceased marketing activities in the United States. The Company is communicating with the FDA on a path forward for approval of Libervant for ARS patients aged between two and five years but the Company has not yet received any decision from the FDA on market access for these Libervant pediatric patients. No dates have been set for arguments on the appeal proceedings at the DC Appellate Court. The Company is not able to determine or predict the ultimate outcome of these proceedings or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter or whether the FDA will grant U.S. market access to Libervant for ARS patients aged between two and five years in advance of the ODE expiration period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Suboxone Product Liability Litigation</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was named as a defendant in a multitude of product liability lawsuits, along with Indivior and several other named defendants, in which the individual plaintiffs in those cases allege that their use of Suboxone&#174; Sublingual Film, a prescription drug product for opioid use disorder, caused them dental injuries. On February 2, 2024, this litigation became a Multidistrict Litigation (&#8220;MDL") consolidated in the U.S District Court for the Northern District of Ohio. One case alleging the same allegations as contained in the MDL has been filed in a state court in the State of New Jersey. The parties to the MDL have agreed to a tolling of unfiled claimants in several states. Indivior has agreed to defend the Company in these litigation matters. Discovery is underway and no trial date has been set in the MDL matter. The Company's motion to dismiss the MDL matter was granted as to all claims by plaintiffs except design defect claims. The Company is not able to determine or predict the ultimate outcome of this litigation or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was named as a defendant in three proposed class action lawsuits filed in Canada, along with Indivior and several other named defendants, in which the individual plaintiffs in those cases allege that their use of Suboxone&#174; products caused them dental injuries. Two of these cases have been filed in British Columbia, and the plaintiffs in those cases are seeking assignment of a case management judge. The anticipated next step in British Columbia will involve applications by the plaintiffs to determine which of the two cases will proceed towards a certification hearing and which will be stayed. The third case has been filed in Quebec and is proceeding towards an authorization hearing, the date of which has not yet been set. The authorization and certification hearings will determine whether the Courts will allow the cases to proceed as class actions. Pre-discovery and case management proceedings are underway and no trial date has yet been set. Given the early stages of these proceedings, the Company is not able to determine or predict the ultimate outcome of this litigation or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this litigation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,930)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed financial statements were prepared in conformity with U.S. GAAP and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and related notes for the fiscal year ended December&#160;31, 2024 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;5, 2025 (the &#8220;2024 Annual Report on Form 10-K&#8221;). As included herein, the Condensed Balance Sheet as of December&#160;31, 2024 is derived from the audited financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of interim periods have been included. The accompanying condensed financial statements reflect certain reclassifications from previously issued financial statements to conform to the current presentation. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying condensed financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in the Notes to applicable guidance refers to the authoritative U.S. GAAP as found in the ASC and ASU of FASB.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted as of March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company adopted the new disclosure requirements as of December 31, 2024. Refer to Note 4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the required disclosure.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Accounting Standards Update was issued to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Among other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. More specifically, the ASU reduces the number of models that may be used to account for convertible instruments from five to three, amends diluted EPS calculations for convertible instruments, modifies the requirements for a contract that may be settled in an entity&#8217;s own shares to be classified in equity and requires expanded disclosures intended to increase transparency. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Accounting Standards Update was issued to clarify the guidance in Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, and to introduce new disclosure requirements for such equity securities. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the Statements of Operations, and Comprehensive Loss as well as qualitatively describe the remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company&#8217;s definition of selling expenses. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact from the adoption of ASU 2024-03 on disclosures to its financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#8212;Improvements to Income Tax Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Accounting Standards Update was issued to enhance the transparency and decision usefulness of income tax </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures. The ASU requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). It further requires disclosure on an annual basis of the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). Additionally, it requires the following information disclosure: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The ASU eliminates certain current disclosure requirements. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2025, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2023-09 on disclosures to its financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Performance Obligations</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues include (i) sales of manufactured products pursuant to contracts with commercialization licensees, (ii) license and royalty revenues, (iii) co-development and research fees generally in the form of milestone payments, </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (iv) sales of its proprietary CNS product, Libervant, for patients between two to five years of age while Libervant had U.S. market access. The Company recognizes revenue to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve this core principle, a five-step model is applied that includes (1) identifying the contract with a customer, (2) identifying the performance obligation in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the current revenue recognition standard.&#160;A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a distinct good.&#160;When identifying performance obligations, the Company considers all goods or services promised in a contract regardless of whether explicitly stated in the contract or implied by customary business practice. The Company&#8217;s performance obligations consist mainly of transferring goods and services identified in the contracts, purchase orders, invoices or statements of work.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacture and supply revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; this revenue is derived from products manufactured exclusively for specific customers according to their strictly-defined specifications, subject only to specified quality control inspections. Accordingly, at the point in time when quality control requirements are satisfied, revenue net of related discounts is recorded.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Revenu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e &#8211; license revenues are determined based on an assessment of whether the license is distinct from any other performance obligations that may be included in the underlying licensing arrangement. If the customer is able to benefit from the license without provision of any other performance obligations by the Company and the license is thereby viewed as a distinct or functional license, the Company then determines whether the customer has acquired a right to use the license or a right to access the license. For functional licenses that do not require further development or other ongoing activities by the Company, the customer is viewed as acquiring the right to use the license as, and when, transferred and revenues are generally recorded at a point in time, subject to contingencies or constraints. For symbolic licenses providing substantial value only in conjunction with other performance obligations to be provided by the Company, revenues are generally recorded over the term of the license agreement. Such other obligations provided by the Company generally include manufactured products, additional development services or other deliverables that are contracted to be provided during the license term. Payments received in excess of amounts ratably or otherwise earned are deferred and recognized over the term of the license or as contingencies or other performance obligations are met.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is estimated and recognized when sales under supply agreements with commercial licensees are recorded, absent any contractual constraints or collectability uncertainties. Royalties based on sales of licensed products have been recorded in this manner.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition arising from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., an NDA filing or obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales occur or the performance obligation to which the sales relate to has been satisfied.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-development and Research Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development defined within a contractual development or feasibility study agreement with a customer. The nature of these performance obligations, broadly referred to as milestones or deliverables, are usually dependent on the scope and structure of the project as contracted, as well as the complexity of the product and the specific regulatory approval path necessary for that product. Accordingly, the duration of the Company&#8217;s research and development projects may range from several months to approximately three years. Although each contractual arrangement is unique, common milestones included in these arrangements include those for the performance of efficacy and other tests, reports of findings, formulation of initial prototypes, production of stability clinical and/or scale-up batches, and stability testing of those batches. Additional milestones may be established and linked to clinical results of the product submission and/or approval of the product by the FDA and the commercial launch of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary product revenue, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - this net revenue is recognized when product is shipped and title passes to the customer, typically at time of delivery. At the time of sale, estimates for various revenue allowances are recorded based on historical trends and judgmental estimates. For sales of Libervant for patients between two to five years of age, returns allowances and prompt pay discounts are estimated based on contract terms and historical return rates, if available, and these estimates are recorded as a reduction of receivables. Similarly determined estimates are recorded relating to wholesaler service fees, co-pay support redemptions, and other rebates, and these estimates are reflected as a component of accrued liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once all related variable considerations are resolved and uncertainties as to collectable amounts are eliminated, estimates are adjusted to actual allowance amounts. Provisions for these estimated amounts are reviewed and adjusted on no less than a quarterly basis.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, customer contractual payment terms provide for invoicing in arrears. Accordingly, some, or all performance obligations may be completely satisfied before the customer may be invoiced under such agreements.&#160;In these situations, billing occurs after revenue recognition, which results in a contract asset supported by the estimated value of the completed portion of the performance obligation. These contract assets are reflected as a component of other receivables within Trade and other receivables within the Condensed Balance Sheets. As of March&#160;31, 2025, and December&#160;31, 2024, such contract assets were $718 and $578, respectively, consisting primarily of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, customer contractual payment terms are structured to permit invoicing in advance of delivery of a good or service. In such instances, the customer&#8217;s cash payment may be received before satisfaction of some, or any, performance obligations that are specified. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. These contract liabilities are reflected as deferred revenue within the Condensed Balance Sheets. As remaining performance obligations are satisfied, an appropriate portion of the deferred revenue balance is credited to earnings. As of March&#160;31, 2025 and December&#160;31, 2024, such contract liabilities were $20,792 and $21,053, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - in certain situations, the Company may incur incremental costs of obtaining a contract with a customer. These costs, if expected to be recovered, are recognized as an asset and reflected as other assets within the Condensed Balance Sheets. The asset is amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. As of March&#160;31, 2025 and December&#160;31, 2024, such costs to obtain contracts were $472 and $480, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles reported revenues to net loss under the significant expense principle for the three months ended March 31, 2025 and 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,053&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Manufacture and Supply Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D Project expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anaphylm project expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AQST-108 project expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libervant project expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R&amp;D other expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Research and Development Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,932&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selling expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">3</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">4</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Selling expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General &amp; Administrative expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">5</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">6</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total General and Administrative Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Selling, General and Administrative Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - R&amp;D Personnel costs include payroll expenses,  share-based compensation expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - Selling Personnel costs include payroll expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - Other Selling expenses include commercialization and other related expenses</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - G&amp;A Personnel costs include payroll expenses,  share-based compensation expenses and severance</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues were comprised of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-development and research fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary product revenue, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides disaggregated net revenue by geographic area: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Trade and Other Receivables, Net</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables, net consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: sales-related allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract and other receivables totaled $2,213 and $2,473 as of March&#160;31, 2025 and December&#160;31, 2024, respectively, consisting primarily of contract assets and other receivables. Contract assets consist of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties. Other receivables include the current portion related to the Monetization royalty receivable and other receivables. Sales-related allowances as of March&#160;31, 2025 were estimated in relation to revenues recognized for sales of Libervant for patients between two to five years of age.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for credit losses on accounts receivable, which is recorded as a reduction to accounts receivable. Changes in the allowance are classified as Selling, general and administrative expenses in the Statements of Operations and Comprehensive Loss. The Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when it identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status. It also considers customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. On an ongoing basis, management evaluates the adequacy of these reserves. The allowance for credit losses was $0 as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provides a summary of activity with respect to sales-related allowances:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock', window );">Changes in Allowance for Bad Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the allowance for credit losses:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance reduction</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss of financing receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory, Net</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Inventory are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw material</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Packaging material</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful<br/>Lives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer, network equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-7 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s payments due under its operating leases are as follows: </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Components of Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of identifiable intangible assets, all of which are finite lived:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased intangible</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased patent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Summary of Other Non-current Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of other non-current assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other non-current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate and personal property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued distribution expenses and sales returns provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant unobservable inputs used in the fair value measurement of the Royalty Right Agreements:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Methodology</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Input</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average (range, if applicable)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Right Agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted<br/>income approach</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of Success</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Years of Payments</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term notes and unamortized debt discount balances are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outstanding notes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount, including Exit Fee</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, long-term</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease, long-term</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty obligations, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,559&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Debt Maturity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled principal payments on the 13.5% Notes as of March&#160;31, 2025 are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_RoyaltyObligationActivityTableTextBlock', window );">Royalty Obligation Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity of the liability related to the sale of future revenue:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net at beginning of the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties related to the sale of future revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,777&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_RoyaltyObligationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_RoyaltyObligationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted EPS is adjusted by the effect of dilutive securities, including options and awards under the Company&#8217;s equity compensation plans, warrants and ESPP. As a result of the Company&#8217;s net loss incurred for the three months ended March&#160;31, 2025 and 2024, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations.&#160;Therefore, basic and diluted net loss per share are the same for the three months ended March&#160;31, 2025 and 2024 as reflected below.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares &#8211; basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,497,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,614,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per common share &#8211; basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">For the three months ended March&#160;31, 2025 and 2024, outstanding stock options of 6,977,367 and 6,169,489 to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the three months ended March&#160;31, 2025 and 2024, outstanding restricted stock units of 5,167,351 and 3,918,451 to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt">For the three months ended March&#160;31, 2025 and 2024, outstanding warrants of 4,594,332 and 4,624,977 to purchase shares of Common Stock, respectively, were anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation in its Condensed Statements of Operations and Comprehensive Loss during the three month periods ended March&#160;31, 2025 and 2024 as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted Stock Units Awards</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information about the Company&#8217;s restricted stock unit and stock option activity during the three month period ended March&#160;31, 2025:</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s awards of service-based and market conditions vesting-based restricted stock units for the three month period ended March&#160;31, 2025:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Restricted Stock Unit Awards (RSUs) - Service-based:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Performance Share Activity</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Restricted Stock Unit Awards (RSUs) - Market conditions vesting-based:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimates of the fair value of the 2025 market conditions vesting-based awards at their grant or valuation dates were based on a Monte Carlo simulation and considered various variables and the following assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price at grant date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.65</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Stock Option Awards:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest as of March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of stock options granted were estimated using the Black-Scholes pricing model based on the following assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-Based Payment Award, Awards Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Overview and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">67 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 23, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 03, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>product </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts', window );">Number of commercialized products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_EquityDistributionAgreementMember', window );">Equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,315,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_EquityDistributionAgreementMember', window );">Equity distribution agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfStockAggregateOfferingPrice', window );">Sale of stock, aggregate offering price</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_AmendedEquityDistributionAgreementMember', window );">Amended Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,457,627<span></span>
</td>
<td class="nump">4,557,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,306<span></span>
</td>
<td class="nump">$ 12,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfStockMaximumTransactionAmount', window );">Sale of stock, maximum transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts', window );">Sale of stock, unpaid commissions and other transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_LincolnParkAgreementMember', window );">Lincoln Park agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_RightToSellCommonStockValue', window );">Right to sell common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_LincolnParkAgreementMember', window );">Lincoln Park agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions', window );">Subsidiary or equity method investee, cumulative percentage ownership limitation after all transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts', window );">Underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts', window );">Underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Number Of Commercialized Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_RightToSellCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to Sell Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_RightToSellCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Underwriting Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SaleOfStockMaximumTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Maximum Transaction Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SaleOfStockMaximumTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Unpaid Commissions and Other Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Or Equity Method Investee, Cumulative Percentage Ownership Limitation After All Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aqst_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_AmendedEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aqst_AmendedEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_LincolnParkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aqst_LincolnParkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aqst_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Risks and Uncertainties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 68,657<span></span>
</td>
<td class="nump">$ 71,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 386,144<span></span>
</td>
<td class="nump">$ 363,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total Manufacture and Supply Expenses</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total Research and Development Expenses</a></td>
<td class="nump">5,361<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total Selling, General and Administrative Expenses</a></td>
<td class="nump">19,072<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">28,085<span></span>
</td>
<td class="nump">21,010<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,365)<span></span>
</td>
<td class="num">(8,957)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8,720<span></span>
</td>
<td class="nump">12,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total Manufacture and Supply Expenses</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total Research and Development Expenses</a></td>
<td class="nump">5,361<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Total Selling expenses</a></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total General and Administrative Expenses</a></td>
<td class="nump">16,116<span></span>
</td>
<td class="nump">9,617<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total Selling, General and Administrative Expenses</a></td>
<td class="nump">19,072<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">28,085<span></span>
</td>
<td class="nump">21,010<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,365)<span></span>
</td>
<td class="num">(8,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses</a></td>
<td class="num">(3,565)<span></span>
</td>
<td class="num">(3,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(22,930)<span></span>
</td>
<td class="num">(12,828)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember', window );">Reportable Segment | Anaphylm project expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total Research and Development Expenses</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">3,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember', window );">Reportable Segment | AQST-108 project expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total Research and Development Expenses</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember', window );">Reportable Segment | Libervant project expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total Research and Development Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember', window );">Reportable Segment | Personnel costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total Research and Development Expenses</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Total Selling expenses</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total General and Administrative Expenses</a></td>
<td class="nump">4,840<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember', window );">Reportable Segment | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total Research and Development Expenses</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Total Selling expenses</a></td>
<td class="nump">2,262<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total General and Administrative Expenses</a></td>
<td class="nump">$ 11,276<span></span>
</td>
<td class="nump">$ 4,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aqst_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_AnaphylmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_AnaphylmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_AQST108Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_AQST108Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_LibervantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_LibervantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_PersonnelCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_PersonnelCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Current and non-current contract assets</a></td>
<td class="nump">$ 718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">20,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract cost, net</a></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract and other receivables</a></td>
<td class="nump">$ 2,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aqst_IndiviorMember', window );">Indivior | Revenues | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aqst_IndiviorMember', window );">Indivior | Receivables | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk</a></td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aqst_HyperaMember', window );">Hypera | Revenues | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=aqst_HyperaMember', window );">Hypera | Receivables | Customer concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit loss</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_OtherReceivablesAndAccruedExpensesMember', window );">Other Receivables And Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit loss</a></td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember', window );">Doubtful Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ResearchAndDevelopmentProjectDuration', window );">Research and development, project duration</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ResearchAndDevelopmentProjectDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development, Project Duration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ResearchAndDevelopmentProjectDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aqst_IndiviorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aqst_IndiviorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aqst_HyperaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aqst_HyperaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_OtherReceivablesAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_OtherReceivablesAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net - Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aqst_ManufactureAndSupplyRevenueMember', window );">Manufacture and supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,193<span></span>
</td>
<td class="nump">10,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember', window );">License and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aqst_CoDevelopmentAndResearchFeesMember', window );">Co-development and research fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Proprietary product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_ManufactureAndSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_ManufactureAndSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_CoDevelopmentAndResearchFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_CoDevelopmentAndResearchFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Geographic Areas, Revenues from External Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Geographic Areas, Revenues from External Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">10,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Ex-United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Geographic Areas, Revenues from External Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,519<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net - Trade and Other Receivables, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Trade receivables</a></td>
<td class="nump">$ 8,308<span></span>
</td>
<td class="nump">$ 4,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract and other receivables</a></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">2,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_TradeAndOtherReceivablesNet', window );">Trade and other receivables, net</a></td>
<td class="nump">10,444<span></span>
</td>
<td class="nump">7,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember', window );">Doubtful Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableSalesRelatedMember', window );">Trade Accounts Receivable, Sales Related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">$ (77)<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_TradeAndOtherReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade and other receivables).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_TradeAndOtherReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableSalesRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableSalesRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net - Changes in Allowance for Bad Debt (Details) - Doubtful Accounts - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance reduction</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableDoubtfulAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and Trade Receivables, Net - Summary of Activity with Sales Related Allowances and Accruals (Details) - Trade Accounts Receivable, Sales Related - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance reduction</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Payments / credits</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at end of the period</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableSalesRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=aqst_TradeAccountsReceivableSalesRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">53 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
<th class="th"><div>Sep. 26, 2022</div></th>
<th class="th"><div>Nov. 03, 2020</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
<th class="th"><div>Apr. 01, 2016</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties related to the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aqst_AssertioHoldingsIncMember', window );">Assertio Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties related to the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aqst_ManufactureAndSupplyRevenueMember', window );">Manufacture and supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties related to the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,193<span></span>
</td>
<td class="nump">10,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember', window );">License and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties related to the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
<td class="nump">$ 1,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_CommercialExploitationAgreementWithIndiviorMember', window );">Commercial exploitation agreement with Indivior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LicenseAgreementTerm', window );">License agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_AutomaticRenewalPeriodOfAgreement', window );">Automatic renewal period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember', window );">License agreement with Sunovion Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Aggregate payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember', window );">License agreement with Sunovion Pharmaceuticals, Inc. upfront</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Aggregate payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember', window );">License agreement with Sunovion Pharmaceuticals, Inc milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Aggregate payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember', window );">License agreement with Sunovion Pharmaceuticals, Inc milestones | License and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties related to the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember', window );">MAM Pangolin Royalty , LLC | Monetization Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet', window );">Additional proceeds from sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ProceedsFromSaleOfFutureRevenuesNet', window );">Proceeds from sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ContingentMonetizationAgreementMilestonePayment', window );">Proceeds from debt, contingent on additional milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember', window );">MAM Pangolin Royalty , LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ProceedsFromSaleOfFutureRevenuesNet', window );">Proceeds from sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember', window );">Haisco Pharmaceutical Group Co., Ltd, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss', window );">Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseSupplyAgreementMember', window );">License &amp; Supply Agreement | Atnahs Pharma UK Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ProceedsFromSaleOfFutureRevenuesNet', window );">Proceeds from sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_AtnahsPharmaUKLimitedAmendedAgreementMember', window );">Atnahs Pharma UK Limited, Amended Agreement | License &amp; Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ProceedsFromSaleOfFutureRevenuesNet', window );">Proceeds from sale of future revenue</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds From Sale of Future Revenues, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_AutomaticRenewalPeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which the agreement is renewed automatically.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_AutomaticRenewalPeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ContingentMonetizationAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Monetization Agreement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ContingentMonetizationAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement term period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ProceedsFromSaleOfFutureRevenuesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of Future Revenues, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ProceedsFromSaleOfFutureRevenuesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aqst_AssertioHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aqst_AssertioHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_ManufactureAndSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_ManufactureAndSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_CommercialExploitationAgreementWithIndiviorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_CommercialExploitationAgreementWithIndiviorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=aqst_MonetizationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=aqst_MonetizationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_LicenseSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=aqst_AtnahsPharmaUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=aqst_AtnahsPharmaUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_AtnahsPharmaUKLimitedAmendedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_AtnahsPharmaUKLimitedAmendedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=aqst_LicenseSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=aqst_LicenseSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments &#8211; Fair Value Measurements (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Nov. 01, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Jul. 15, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_ExistingWarrantsMember', window );">Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_NewWarrantsMember', window );">New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants', window );">Shares of common stock (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants', window );">Shares of common stock in connection with securities purchase agreements (in shares)</a></td>
<td class="nump">8,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member', window );">Senior secured notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member', window );">Senior secured notes due 2025 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Of Common Stock Entitled To Purchasers By Pre-Funded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of Common Stock to be Purchased by Common Stock Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_ExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_ExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aqst_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aqst_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">$ 2,964<span></span>
</td>
<td class="nump">$ 3,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_InventoryPackingMaterialGross', window );">Packaging material</a></td>
<td class="nump">2,344<span></span>
</td>
<td class="nump">2,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 7,198<span></span>
</td>
<td class="nump">$ 6,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_InventoryPackingMaterialGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of packaging materials expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_InventoryPackingMaterialGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 47,435<span></span>
</td>
<td class="nump">$ 47,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(43,634)<span></span>
</td>
<td class="num">(43,501)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">3,801<span></span>
</td>
<td class="nump">3,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 20,348<span></span>
</td>
<td class="nump">20,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 769<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 21,419<span></span>
</td>
<td class="nump">21,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aqst_ComputerNetworkEquipmentAndSoftwareMember', window );">Computer, network equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,830<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aqst_ComputerNetworkEquipmentAndSoftwareMember', window );">Computer, network equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aqst_ComputerNetworkEquipmentAndSoftwareMember', window );">Computer, network equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,069<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aqst_ComputerNetworkEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aqst_ComputerNetworkEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Lease Obligations - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_NumberOfOperatingLeases', window );">Number of leases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated discount rate</a></td>
<td class="nump">14.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated discount rate</a></td>
<td class="nump">15.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right-of-Use Assets and Lease Obligations - Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">1,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter', window );">2029 and thereafter</a></td>
<td class="nump">3,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">8,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(3,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 5,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Components of Identifiable Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 4,367<span></span>
</td>
<td class="nump">$ 4,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(4,367)<span></span>
</td>
<td class="num">(4,367)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Purchased intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">3,858<span></span>
</td>
<td class="nump">3,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Purchased patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">$ 509<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-current Assets - Summary of Other Non-current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_CumulativeRoyaltyReceivable', window );">Royalty receivable</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other non-current assets</a></td>
<td class="nump">$ 4,215<span></span>
</td>
<td class="nump">$ 4,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_CumulativeRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative sum of the carrying amounts of royalty receivable as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_CumulativeRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-current Assets - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_NumberOfGuaranteedRoyaltyPayments', window );">Number of guaranteed royalty payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember', window );">License agreement with Sunovion Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_MinimumAnnualRoyaltyReceivable', window );">Minimum annual royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_NumberOfAnnualRoyaltyPaymentsReceivable', window );">Number of annual royalty payments receivable | payment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty | License agreement with Sunovion Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_MinimumAnnualRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty receivable by the entity for the use of its rights and property by another party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_MinimumAnnualRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_NumberOfAnnualRoyaltyPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of annual royalty payments receivable by the entity for the use of its rights and property by another party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_NumberOfAnnualRoyaltyPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_NumberOfGuaranteedRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Guaranteed Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_NumberOfGuaranteedRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 2,189<span></span>
</td>
<td class="nump">$ 4,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Real estate and personal property taxes</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 3,314<span></span>
</td>
<td class="nump">$ 5,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Narrative (Details) - 13.5% Senior Secured Notes due November 1, 2028<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Nov. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 15, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member', window );">Senior secured notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member', window );">Senior secured notes due 2025 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount (premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,254<span></span>
</td>
<td class="nump">$ 1,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 4,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Repurchase price percentage</a></td>
<td class="nump">108.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage', window );">Debt instrument, Interest rate, change in effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Royalty obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount, including exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028 | Senior notes | Redemption Scenario 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Repurchase price percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage of principal amount redeemed</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate', window );">Debt instrument, redemption price, basis points above treasury rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028 | Senior notes | Redemption Scenario 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Repurchase price percentage</a></td>
<td class="nump">108.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember', window );">Royalty Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm', window );">Royalty obligation, term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount (premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">$ 1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember', window );">Royalty Obligations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember', window );">Royalty Obligations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage', window );">Royalty obligation, percent of net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember', window );">Royalty Obligations | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 13,856<span></span>
</td>
<td class="nump">13,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Royalty obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount, including exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized discount (premium), net</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_DebtInstrumentExitFee', window );">Debt instrument, exit fee</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">3,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized deferred debt issuance cost and deferred debt discounts</a></td>
<td class="nump">20,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember', window );">Royalty Obligations | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Royalty obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount, including exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_ABLFacilityMember', window );">ABL Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold', window );">Line of credit facility, accordion feature, net revenue threshold</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit', window );">Line of credit facility, accordion feature, increase limit</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_DebtInstrumentCovenantTieredRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Tiered Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_DebtInstrumentCovenantTieredRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Tiered Royalty Percentage, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_DebtInstrumentInterestRateChangeInEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Change in Effective Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_DebtInstrumentInterestRateChangeInEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Basis Spread On Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Accordion Feature, Increase Limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Accordion Feature, Net Revenue Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_DebtCovenantRedemptionScenarioAxis=aqst_RedemptionScenario1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_DebtCovenantRedemptionScenarioAxis=aqst_RedemptionScenario1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_DebtCovenantRedemptionScenarioAxis=aqst_RedemptionScenario2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_DebtCovenantRedemptionScenarioAxis=aqst_RedemptionScenario2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_ABLFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_ABLFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule Of Royalty Right Agreements (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=aqst_MeasurementInputProbabilityOfSuccessMember', window );">Measurement Input, Probability Of Success</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=aqst_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=aqst_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Term Notes and Unamortized Debt Discount Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member', window );">13.5% Senior Secured Notes due November 1, 2028 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total outstanding notes</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount, including Exit Fee</a></td>
<td class="num">(11,392)<span></span>
</td>
<td class="num">(12,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, long-term</a></td>
<td class="nump">33,608<span></span>
</td>
<td class="nump">32,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease, long-term</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Notes payable, net</a></td>
<td class="nump">33,746<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Royalty obligations</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(11,392)<span></span>
</td>
<td class="num">(12,646)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember', window );">Royalty Obligations | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total outstanding notes</a></td>
<td class="nump">56,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount, including Exit Fee</a></td>
<td class="num">(13,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Royalty obligations</a></td>
<td class="nump">56,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(13,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember', window );">Royalty Obligations | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total outstanding notes</a></td>
<td class="nump">56,917<span></span>
</td>
<td class="nump">56,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount, including Exit Fee</a></td>
<td class="num">(35,269)<span></span>
</td>
<td class="num">(36,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, long-term</a></td>
<td class="nump">21,559<span></span>
</td>
<td class="nump">20,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Royalty obligations</a></td>
<td class="nump">56,917<span></span>
</td>
<td class="nump">56,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(35,269)<span></span>
</td>
<td class="num">(36,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of royalty obligation</a></td>
<td class="num">$ (89)<span></span>
</td>
<td class="num">$ (87)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_SeniorSecuredNotes13.5DueNovember12028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_RoyaltyObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Debt Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">9,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">14,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">20,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 15, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ClassOfWarrantOrRightWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_FirstAdditionalWarrantOfferingMember', window );">First Additional Warrant Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,683,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_InitialWarrantOfferingMember', window );">Initial Warrant Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod', window );">Warrants issued to purchase common stock (in shares)</a></td>
<td class="nump">3,689,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="nump">$ 3,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_ExistingWarrantsMember', window );">Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_NewWarrantsMember', window );">New Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants0.96ExercisePriceMember', window );">Warrants, $0.96 Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants4.25ExercisePriceMember', window );">Warrants, $4.25 Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants5.38ExercisePriceMember', window );">Warrants, $5.38 Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | First Additional Warrant Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member', window );">Senior secured notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of class of warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_FirstAdditionalWarrantOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_FirstAdditionalWarrantOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_InitialWarrantOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_InitialWarrantOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_ExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_ExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants0.96ExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants0.96ExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants4.25ExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants4.25ExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants5.38ExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aqst_Warrants5.38ExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">53 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments for loan acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,720<span></span>
</td>
<td class="nump">$ 12,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember', window );">MAM Pangolin Royalty , LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ProceedsFromSaleOfFutureRevenuesNet', window );">Proceeds from sale of future revenue</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember', window );">License agreement with Sunovion Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_MinimumAnnualRoyaltyReceivable', window );">Minimum annual royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember', window );">License agreement with Sunovion Pharmaceuticals, Inc. | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=aqst_MonetizationAgreementMember', window );">Monetization Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments for loan acquisition costs</a></td>
<td class="nump">$ 2,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective annual interest rate</a></td>
<td class="nump">24.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=aqst_MonetizationAgreementMember', window );">Monetization Agreement | MAM Pangolin Royalty , LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ProceedsFromSaleOfFutureRevenuesNet', window );">Proceeds from sale of future revenue</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ContingentMonetizationAgreementMilestonePayment', window );">Proceeds from debt, contingent on additional milestones</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet', window );">Additional proceeds from sale of future revenue</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds From Sale of Future Revenues, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ContingentMonetizationAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Monetization Agreement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ContingentMonetizationAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_MinimumAnnualRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty receivable by the entity for the use of its rights and property by another party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_MinimumAnnualRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ProceedsFromSaleOfFutureRevenuesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of Future Revenues, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ProceedsFromSaleOfFutureRevenuesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_MarathonPangolinRoyaltyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=aqst_MonetizationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=aqst_MonetizationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue - Royalty Obligation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfFutureRevenueRollForward', window );"><strong>Sale of Future Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LiabilitiesSaleOfFutureRoyalties', window );">Liability related to the sale of future revenue, net at beginning of the period</a></td>
<td class="nump">$ 63,718<span></span>
</td>
<td class="nump">$ 64,490<span></span>
</td>
<td class="nump">$ 64,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(8,720)<span></span>
</td>
<td class="num">$ (12,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of issuance costs</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LiabilitiesSaleOfFutureRoyalties', window );">Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively)</a></td>
<td class="nump">63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent', window );">Liability related to the sale of future revenue, current</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_SaleOfFutureRevenueRollForward', window );"><strong>Sale of Future Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,008)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LiabilitiesSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LiabilitiesSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Sale of Future Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_SaleOfFutureRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Future Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_SaleOfFutureRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,930)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares &#8211; basic (in shares)</a></td>
<td class="nump">95,497,056<span></span>
</td>
<td class="nump">73,614,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares &#8211; diluted (in shares)</a></td>
<td class="nump">95,497,056<span></span>
</td>
<td class="nump">73,614,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) Earnings per common share &#8211; basic (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">(Loss) Earnings per common share &#8211; diluted (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">6,977,367<span></span>
</td>
<td class="nump">6,169,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">5,167,351<span></span>
</td>
<td class="nump">3,918,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants on common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">4,594,332<span></span>
</td>
<td class="nump">4,624,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=aqst_ManufacturingAndSupplyMember', window );">Manufacture and supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 1,157<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=aqst_ManufacturingAndSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=aqst_ManufacturingAndSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Unit Awards (Details) - Restricted stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, at beginning of period (in shares) | shares</a></td>
<td class="nump">2,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, at end of period (in shares) | shares</a></td>
<td class="nump">3,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares', window );">Vested and expected to vest at end of period (in shares) | shares</a></td>
<td class="nump">3,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">3.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">3.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue', window );">Vested and expected to vest at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated fair value of nonvested equity-based awards on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan) as of grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date in shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>pricing_period </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs of RSU awards | $</a></td>
<td class="nump">$ 8,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">2 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Market Based</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs of RSU awards | $</a></td>
<td class="nump">$ 2,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">1 year 10 months 13 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod', window );">Average closing prices period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">50.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range Three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">99.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range Four</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range Five | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 2.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">100.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range Five | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">149.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2023 Market Based | Market Condition Range Six</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod', window );">Average closing prices period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods', window );">Number of pricing periods | pricing_period</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod', window );">Average closing price, number of days utilized in pricing period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Seven</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Eight</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Nine | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">50.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Nine | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">99.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Ten</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Eleven | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 7.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">100.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Eleven | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">149.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | 2025 Market Based | Vesting Condition Range Twelve</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare', window );">Performance price threshold (in dollars per share)</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">1 year 11 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to non-vested stock options | $</a></td>
<td class="nump">$ 3,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Closing Prices Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Days Utilized in Pricing Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Pricing Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation, Arrangement by Share-Based Payment, Market Condition, Performance Price Threshold, Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aqst_MarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aqst_MarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aqst_A2023MarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aqst_A2023MarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aqst_A2025MarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aqst_A2025MarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_VestingConditionAxis=aqst_VestingConditionRangeTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_VestingConditionAxis=aqst_VestingConditionRangeTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Performance Based (Details) - Performance Shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, at beginning of period (in shares) | shares</a></td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, at end of period (in shares) | shares</a></td>
<td class="nump">1,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares', window );">Vested and expected to vest at end of period (in shares) | shares</a></td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">2.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue', window );">Vested and expected to vest at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated fair value of nonvested equity-based awards on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan) as of grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date in shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - Stock options<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">6,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod', window );">Forfeited/expired (in shares) | shares</a></td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">6,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at end of period (in shares) | shares</a></td>
<td class="nump">6,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">5,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/expired (in dollars per share) | $ / shares</a></td>
<td class="nump">5.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">5.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">5.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were exercised, cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either exercised, forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Valuation Assumptions for Determination of Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (benefit) expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net (loss)/income before income taxes</a></td>
<td class="num">$ (22,930)<span></span>
</td>
<td class="num">$ (12,828)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 15, 2024 </div>
<div>pending_case</div>
</th>
<th class="th">
<div>Feb. 02, 2024 </div>
<div>pending_case</div>
</th>
<th class="th">
<div>Dec. 05, 2019 </div>
<div>pending_case</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=aqst_NeurelisIncVAquestiveTherapeuticsIncMember', window );">Neurelis, Inc. v. Aquestive Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Litigation settlement, amount awarded from other party | $</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aqst_LitigationSettlementAmountAwardPeriodDue', window );">Litigation settlement, period due</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=aqst_SuboxoneProduceLiabilityLitigationMember', window );">Suboxone Produce Liability Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=aqst_SuboxoneProduceLiabilityLitigationMember', window );">Suboxone Produce Liability Litigation | BRITISH COLUMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aqst_LitigationSettlementAmountAwardPeriodDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Award, Period Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aqst_LitigationSettlementAmountAwardPeriodDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aqst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=aqst_NeurelisIncVAquestiveTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=aqst_NeurelisIncVAquestiveTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=aqst_SuboxoneProduceLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=aqst_SuboxoneProduceLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .J K%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .J K%JR;P4*\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( .J K%I_A6V*T 4  ,H>   8
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MQ+./.M61^]D+Q8H7"(R,ON,$A\E(H<4J)L2S2XP[B?&1@05L5NJI&5"]BG8
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M,+(8O('1K[]@\=WG4/L7? T-O;,(_%3[-TK[&R5VS4N9.Z&4V#:7&\Y O3:
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MF> [)$RT9C,-NS86K=T09G9QJ82>)1JG\CEGI=X3*-$=II@5@):&2Z*+!1;
M5 6*%)A>HH_H _*1K/2HS'RE4QL"O^C2W+DTT0MIOF$Q0G%XA:(@2@?@\]?A
M]U#T\.08[FO#O>NH=QU9OO@%OJ7BQ6/%:0E"GI]=1^'DUNP]*8B:#IES;,DP
MFSEH4]G@ F:>/DD2Q!:\_/PL' >W0U;_$]F1\;@W'K_&KK>[KO7AD<;_%6JP
M0%M,6T 7A*&24XJ%1 T(M\^70TOA^">6WY2(;1Z,@B#,_.VAQ[>BCL0GO?CD
M!/'N5T2X5147Y(_^@XT)-SJHW)&G!YJB-'#/,_7OB3QRD/8.TM,=$"G;M]6G
M_VBZN8G#29C&S\0/!(9)&$^2:%C[N-<^/EV[OA>DPJPD;/.6@?%[#0P$#AOP
M#\J>N7)TD=D0)A&%M88&HXGF$*Z,NX[BC:V$*ZYT7;7-2M]\($R GE]SKO8=
M4US[NS3_"U!+ P04    " #J@*Q:N^U:YW4%  !3%@  &    'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;*U876^;2!3]*R-OM4JD-,!@#,XZEA)W5UMILXV:
M=OM0[<,8Q@85&'9F<))_OW<  X9AVDI^20#?>SCW8^X99O7,^#<14RK12Y;F
MXG862UG<6)8(8YH1<<T*FL,O.\8S(N&6[RU1<$JBRBE++6S;"RLC23Y;KZIG
MCWR]8J5,DYP^<B3*+"/\]9ZF[/EVYLR.#SXF^UBJ!]9Z59 ]?:+R<_'(X<YJ
M4:(DH[E(6(XXW=W.[IR;#5XHA\KBGX0^B]XU4J%L&?NF;MY'MS-;,:(I#:6"
M(/#O0#<T3142\/BO 9VU[U2._>LC^A]5\!#,E@BZ8>F7))+Q[2R8H8CN2)G*
MC^SY3]H$Y"F\D*6B^HN>&UM[AL)22)8USL @2_+Z/WEI$M%S<-T)!]PXX!]U
M<!L'MPJT9E:%]8Y(LEYQ]HRXL@8T=5'EIO*&:))<E?%)<O@U 3^YWK \@J+0
M"#U)(BD42 K$=NA#03E1B1:(Y!':L RZ)%;E.U#T%Q,"O46?G]ZABS>7Z U*
M<O0I9J4 4[&R)/!2Z%;8<+BO.> )#BYZ8+F,!?H=N$2G_A;$TP:%CT'=8R/@
M ^'7R'6N$+:QI^&S^7'WN8&.V^;8K?#<";SW><@RVB48?;W;"LFA@__5):L&
MF^O!U+*^$04)Z>T,*B(H/]#9^M=?G(7]FR[2,X&=Q#UOXYZ;T-<?Z8'F)=5V
M1.VYJ#S5J#FL Q_;*^O0)S\V<K#MN:W5"2NO9>49J[%A0M9-35\*U?KB1D?0
M.V<5S@1V$N^BC7=AK,(#R<L=]%K):16U*(LB?=6%O!BEVUUX>%"3L='<#9;Z
MDO@M1=](497D"CUR%I6AK$@^01*2D**OO[](-72V*87I4&;-4-*N&_,[ +W@
M"96@5:AHWL3K!KU".96ZLIT3\20Q09N8X#LK2%#"P[C*2038*2O4!-&%'XP*
MX[D+9U ]C='2Q?KJ+5N22R/))]#@)-]?H3W-H3YI199$(%:)FG)*IG5\:U"O
MO[B7MC]L-XV5O9CJ-\?N5,\V<O[$)! -1Z- *U[VB ,.[, ;,-69.;9C3U#M
M";1CI%J)[8ZS#+%6D[4TG='[WSI+6,%#GAJ[8.GY$SQQQQ,;Y^H'&5,..P&E
M==;%,:&7VN':0)UINIX+[33P3MT=HXB"O$L*N/+81-J W7'2L1\,NWW";#Y1
MFTZ(';,2#RG"G$IA,Q(AR1!GKR25KXAMTV1O:*^YIKWFKC^,0&?F>L%$!)UH
M.T:--$8 C8<$ 86 ?>NNK(2NF</:0+PQ0V\Y#$-G-!5$I\2.68K;(.I54DT>
MUELV4T)TW^#VZ?B..^0\-G+QU*3LI-DQJ]S?\"F9JA&TI?#12(_4)7F9F):^
MIH7QTAWN[71V#@[P5)([R73,FOF^1Q!=;$&3=HF\-"[.8$1EQ-9D<DJTDTW'
MK)O'S&HIC75/GT6-G2&+N!-(;!;(TP^^*9H-R.)[-'5V)IJ=.&+'*#J5.((L
M(A$3M;^5DB?;4A*U7X3) )V0L1S!5W3X+69I1+E^LX^-$ORS>G0NM-.<=$*,
MC7JWOB<B"=$%?)-'+$T)[R7H4AM\#1?TBV-?X_FPAEHS9V+?@#OYQ&;Y?)>D
MI1KD/T'8_3'"6K-)PIV8XKFQY[Y41T/ F!Q@/[:G;9<IP@*Q4@H)DQVVQ/I>
M,TKU3_?:F=!.<]'),C;+<M=K=?3Z>HW%=.G-E[[M+88E&UOZ\!$S]Z>VT;C3
M7FS6WGZ;F;B.172*JT:3]5RMWO$<?,'NJU-+ 6U3YK(^U&J?UB>C]\[-ICI
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M_&!0:/4E,M/57W17RT;1!"5[;61^6 P(<E'4G^S^X(BC!:#'O8 <%I#N@OG
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MF2D8-#7LB;>@,G@;036I^MV$^L;(LOIY?R.-D7EUN>,,/&(%X/];*<WCC7U
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M\8TLZTMLB6AW398IYZ@"FCCK![E86'F_G77<N@UE0YW'"'DF.-)A,AJ<"KF
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M? 7D*^,:&-<3+2[$4"Q+!=TL?6T4OY6 ;M',$&H""X$*N:%0.JN:/ 3.YBM
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MB N>@/>%,;Y]X VZKZ&W_P902P,$%     @ ZH"L6GE>31)B!   * H  !@
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MH)=%');TE$/' K2?6_*AF["!_G&X^@]02P,$%     @ ZH"L6LPL:!LD"
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M]X?*!M!^):79&_: \4/-_P%02P,$%     @ ZH"L6JA<&+5. P  60<  !D
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MM_&AVU0'=2P+%W'BU_ERZ>M^IB6NMB$?42&S!ELCF)I,)*O*J\(% QDD*._
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MCSMI>.1>G2Q/P/C,H E++[Q ^V^%R[\!4$L#!!0    ( .J K%HJ%^[KIP(
M  ,&   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;)54VV[;, S]%<(K
MB@T(:L=.VBQ- J3M+@76(6AW>1CVH-AT+%26/$FNNWW]*-EQ,S0-L(=8)'5X
MQ$O(6:/TO2D0+3R60IIY4%A;3</0I 66S)RH"B7=Y$J7S)*J-Z&I-++,.Y4B
MC*/H-"P9E\%BYFTKO9BIV@HN<:7!U&7)].\+%*J9!\-@:[CEF\(Z0[B856R#
M=VB_5BM-6MBS9+Q$:;B2H#&?!\OA]&+D\![PC6-C=F1PF:R5NG?*=38/(A<0
M"DRM8V!T/. E"N&(*(Q?'6?0/^D<=^4M^WN?.^6R9@8OE?C.,UO,@TD &>:L
M%O96-1^QRV?L^%(EC/]"TV+'20!I;:PJ.V>*H.2R/=EC5X<=ATGT@D/<.<0^
M[O8A'^45LVPQTZH![=#$Y@2?JO>FX+AT3;FSFFXY^=G%M;1,;OA:("R-06L&
M\!GM++3$[1!AVO%<M#SQ"SP)W"AI"P/O9(;9O_XAQ=0'%F\#NX@/$MXP?0+)
M< !Q%(\/\"5]HHGG2U[@^Z!4UG A@,D,GF4-5]RD0IE:(_Q8KHW5]'?YN:\,
M[2NC_:^X$9J:BJ4X#VA&#.H'#!;'KX:GT?F!'$9]#J-#[/_1K(,\^Z/<3PY?
M"H1<"1I>+C=@F;NOM'K@&1JP=)FJLE(2)151Y4!F:7G./8X_4;*.DE$'"-84
M/"V 4;5S+KE%$#2;V12HZV1W;;_"%,LU:J^L:C+3[&6[E$>0#";C27\^@2IF
M*0H81V_];S1(3L^Z[R<T9DJ[(*W+6A L U8J;?D?YI?$:X]ZTY_7SS.05)0C
M.'XUB8?Q^8ZTK[_ASF"6J#=^_1@J62UM.Z.]M=]PRW:PG^#M>J3*;+@T(# G
MU^CD;!R ;E=.JUA5^3%?*TM+PXL%;6G4#D#WN5)VJ[@'^KV_^ M02P,$%
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M/UG<7;14<ED([:31S(KEZY/;T<LW$UH?%OPFQ<;UKAEILC#F#[KYD+\^&9)
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M_0EN>E#.;BUW"Q>_&O&+O5+- LCLLQ]F8Q%6"N@UK31KH4Q03I5"FV#Y 4)
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M@.>5Q0R=?M !_>?!L_\#4$L#!!0    ( .J K%H4B1.F!P0  !<*   9
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;,59ZV_;.!+_5PAOLT@
MQ=;#SS0)D'1[=SULMT&R[7XXW =:HFU>)-$EJ3C>O_YFAI(B.[+C='L]((CU
MF!=G?C-#CLY72M^;A1"6/69I;BXZ"VN79[V>B1<BXZ:KEB*'-S.E,V[A5L][
M9JD%3X@I2WNA[P][&9=YY_*<GMWHRW-5V%3FXD8S4V09U^MKD:K512?H5 ]N
MY7QA\4'O\GS)Y^).V,_+&PUWO5I*(C.1&ZERIL7LHG,5G%WWD9X(ODBQ,HUK
MABN9*G6/-Q^2BXZ/!HE4Q!8E</AY$.]$FJ(@,.-K*;-3JT3&YG4E_6^T=EC+
ME!OQ3J5_R,0N+CKC#DO$C!>IO56K?XAR/0.4%ZO4T'^V<K3]J,/BPEB5E<Q@
M029S]\L?2S\T&,;^#H:P9 C);J>(K/R%6WYYKM6*::0&:7A!2R5N,$[F&)0[
MJ^&M!#Y[>;?@6IQ>P[H2]DYE$&O#T5WG/0O2D:87EY*NG:1PAZ2(?52Y71CV
M/D]$LLG? ZMJT\+*M.MPK\"/7'=9%'@L],/!'GE1O=2(Y$4'+/6&KP%9EEUI
MS?.YH.M_74V-U0"3?[<MWLGNM\O&U#DS2QZ+BP[DAA'Z070N?_XI&/IO]UC>
MKRWO[Y/^JB!]FR3V^T+0 YZO(==B-<_EGT!CB'Y*]'&37L*?-< "P<[Q[9WE
MEOQHF)JQ3TNAB= PGCM56BPPEQ\$^U49PY)"RWS.+.BU"RT$RQ ]#/BD2@P3
M""(&$(@7-09(%%ST&3=LIE(H*.8,+$?N)O8<,1%^Y'DQ@Y 66A"W*9;+=,W>
ML,#WX?_(9[<0+=*"KQ/Q &5J27"((I\%0' '%0,L]=A<Y+"HE AY KDH$2Y8
M5%C@!8,1_(_Z/OM=62#:Z3CQB-?"H W>8#PJ?T'/+HZ95MD9VFFUC"T&Q:KX
MGA4Y!@"Y S^$WTD401#PC5HZS_?' S;LC_ZB12U@>?^UD';-KE9<0Z@0.BX:
M%% ^34'64JL'F0C B6L<5(&GT!4HXB72?OYI' :CMP80U[(X%[#&BEP)1\U[
MP=.*G0T'.C=])@>V6N]:%&1 J[7<K1M@CHDNX\JK:"^PW4,KC2$OI(O" ^@%
MT25-ZTH1S?H[K*:*R/'MW6=SPDX!NPW[SMAO1385&@W_@[H5,!]#(MN%*@P8
M#RR?<S07UT+K^T7$@EA*Q7T6>L, ,R?J1F/V=RB>2!QX_6@ #\/N<,"^. ''
MHR Z(4)_Q*"!SH2DQU'@GDXFV\JVDCWR(C\@TB!B[P&CM%BKR*&[6/S(&1<$
M[*J%PF-OQEXTG. ;2UE1Y(UJUYX66J2\5%U4%F\&?D=0(7M(2F7X5#1+JWH
MOW)X@ELGQ-ZJB@F'-[ AJ@  MH;=H,_64*=,EP![D/IY&1W0++)EJM9".)M,
M,?T/&(4ON$/<*<I&AJ2@I9:89;@'3(K4U4YDS95MLH.%E-YY;4NL(<Q:<J8
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M1MB%U-B@<MBM: .GKTH2%0D0;<4).%[1,_%H<0.$E\]=)PV##FE<9K\)NB-
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M'V?=C55+^B Z5=:JC"X7@D-/1 )X/U/*5C>HH/Y"?OE?4$L#!!0    ( .J
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MM('XX1A") 7N,YW#<I+T5>4P:DV&<K6LO:GX,FH!.\$*"S)2 H$JC<#8D,=
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M1Q@W]0W5J3=9%XXI<10]0GVA)I971]Q MC6V6L*&*3D <L(=W%=]0;YQZ&V
M3&)*F_OL3LX?"MH_X 4F,:*4#I(Z]+.;=IZ!#:+[;F4 *DHK5?H)"LO9-8\^
M)Y"*(ACS6@2U/?IAJSVD(RA_W%;(&7=4L6?<JI!193ZO<*UDYZ7K#&_2R*0_
MYXGS'72J$W'36-<09ZP767L*>^*W5V+[^3>"BP"SI\\]HV<#N!,K8(:J1ZBD
MYTG4*8<]\ ;Z+[,N V*^+^7[C$^5W,/\W<;D*[S>JJH.Y<TG^N.=3HLP,@)]
MKLG65E4H"G.K5<8SEZ8B#!LG8P]MQJB[](SJZ"3#6 I,;\G<P_#/H^FC%O^
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M@Q[1QA34>>FE+&4J_Q=34L@V[N&L\A'YOZUQ?H.N$+=27M!G'F[90N2N;7V
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MK]M6N$G@ L5KVTQ;KG1KVF6AAR<(DZ#/=YRK8V *].,X_0U02P,$%     @
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MT9+4?/X?1+XRY<#T_??O\#VY;K%4M^*ZZA3?@-CTZB7O=Y@>K[I^>7:A[OS
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M(4.FBBN^$(@!ENR(9!\"\ '_XGL.>SK_P\LQ$J+'#6.9= LF/13D@][2 .@
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M@I\?)GS=" ].E_Z+PE0[5!9_FPEDHJ$->#_3VC4/=$#[B>GR7U!+ P04
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M+2H;0-\S*<W6L03=_D[^ E!+ P04    " #J@*Q:D@'+7[0"   +!@  &0
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MS3@ W8Z)UK"J]JVY498:W6]+FJRHG0/=%TK9@^$2]+,Z_0M02P,$%     @
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M[FYG\:P902_JS2"G"E,E# C,R30Z'0X"T,UP;!9657X@)<K2=?-B0>\):J=
MY[E2=K-P#K8OU/074$L#!!0    ( .J K%I5-6JK^P,  +()   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;*U6VX[;-A#]E8%2!&M :UD7WW9M WL+
M4J )C#AM'HH^T-+88I<B%9**X[_OD+(5M_7Z(<G#KDEJYO <SH6<[91^-B6B
MA:^5D&8>E-;6-U%D\A(K9OJJ1DE?-DI7S-)4;R-3:V2%=ZI$E P&HZAB7 :+
MF5];ZL5,-59PB4L-IJDJIO?W*-1N'L3!<>$#WY;6+42+6<VVN$+[>[W4-(LZ
ME()7* U7$C1NYL%=?'.?.7MO\ ?'G3D9@U.R5NK937XMYL' $4*!N74(C'Z^
MX ,*X8"(QN<#9M!MZ1Q/QT?T-UX[:5DS@P]*?.*%+>?!)( "-ZP1]H/:O<6#
MGJ'#RY4P_C_L6MMT'$#>&*NJ@S,QJ+AL?]G7PSF<.$P&+S@D!X?$\VXW\BP?
MF66+F58[T,Z:T-S 2_7>1(Y+%Y25U?25DY]=O*>X_Z:,@25J6)5,(UQ]9&N!
MIC>++&W@S*+\ ';?@B4O@*7P3DE;&GB2!1;_]H^(6,<N.;*[3RX"OF.Z#VD<
M0C)(AA?PTDYMZO'2%_">F)9<;D_5_GFW-E93<OQU3F\+EYV'<P5S8VJ6XSR@
MBC"HOV"P>/TJ'@UN+Y#-.K+9)?3%/3,\!R8+>.2BL5C _X-UCO-EU"/6TW(%
MW  K_J8DH_EZ#[9$P,V&Z@74!@IG2!4#!O-&<\O1A,!E+IJ"CA!4[:K*>'YL
MQW1AH*&H:X_RH*J:R?WK5Y,D'M\:P,\-MWO(:9GJF?EZK 63A$BNFDG; CVM
MELL^W-&$"MY083DBYP EG81P)T&$&JV)/_4G;VE+C0A5FX?H\A HB_*R2R._
M$0VR$)@04"N+TG(:[K])YI)RHJ'>0[RHDQE+/D[T3C6B@)*1"7'FUYU#>VQD
M3+I07QN?6CD3>2.\6M.'CR52PU$:0]=&#I$M#M'H]) WM-[NSPDRK,+O4 ?,
MN*;INI^+KNN^CH-S/RW2ULD[O"?!FEFE;WRB>3J_P%62A--TT'/#. DGR:0'
MCR@5]:+6]I-O?%A<TZEHZN,@FVI-*BAR%&^BVNHQX(,7WYY1/QV&V70<#H8C
M&*?A*,["<3QH,]V=QRG,!10B..@G6:\=Q.,>7+$>O/F.O#@-.77@_+G+=A(U
M"J?C<9B.QMYA%,:C:9A-IF 5U T!TA5Q5$S6#RWWE4,)75+7Z.\AL:?41_V?
M/.K#U?K'*=,N5G,?]Y9]([GU;(;$EK@/8^^9AM-X$F8T^TG<\Q_GWK4#VC\+
MA],L3-/$VV;AB(SI['\.VW,-.CJY1ZD6MOZU8"C_&FG;*[5;[1XD=^T]_,V\
M?<V0V"UU$1"X(==!?SP,0+<OA'9B5>UOY;6R=,?[84F/*M3.@+YO%#6FP\1M
MT#W3%O\ 4$L#!!0    ( .J K%IITATYVP4  /00   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0Q+GAM;+5866_;.!#^*X3;% G@V#ILR4X3 T[;/8#--LC1
M/BSV@9;&-A%)=$G*CO?7[PPI*TXJ:[.++A!8!^>>[QM2.=](]:"7 (8]YEFA
M+SI+8U9G_;Y.EI!SW9,K*'!E+E7.#3ZJ15^O%/#4*N59/_"\J)]S470FY_;=
MM9J<R])DHH!KQ729YUQM+R&3FXN.W]F]N!&+I:$7_<GYBB_@%LS]ZEKA4[^V
MDHH<"BUDP13,+SI3_^QR1/)6X(N C=Z[9Y3)3,H'>O@UO>AX%!!DD!BRP/&R
MA@^0960(P_A6V>S4+DEQ_WYG_2>;.^8RXQH^R.RK2,WRHC/JL!3FO,S,C=S\
M E4^0[*7R$S;7[9QLH.PPY)2&YE7RAA!+@IWY8]5'?841MX!A:!2"&S<SI&-
M\B,W?'*NY(8IDD9K=&-3M=H8G"BH*;=&X:I /3.Y77(%IY>85\H^R!Q[K;DM
MU_$=GV6@3\[[!MV0<#^I3%XZD\$!DR&[DH59:O:I2"%]KM_'\.H8@UV,ET&K
MP2NN>BSTNRSP@F&+O;#..;3VPE?D?,VW"#'#IDKQ8@'V_H_I3!N%>/FS*7EG
M>]!LFSATIE<\@8L.DD2#6D-G\NZ-'WGO6R(?U)$/VJQ7D<^^[]:G1[J'IGA;
M+3;'>[<$:YX76R1>(A>%^ L]ZCWOR;YW@7]&HPHVO*#56\.-K:5F<LX^KT!9
M0<UXX0)7L"1BKX'])K5F::E$L6 &_9JE F Y(8BAGI"I9D! 8@B#9%GCP)K"
MFP'CFLUEAM-%G[$[J[V//R=L!:]X4<ZQK:4"JZW+U2K;LK?,]SS\C3UV@Q6P
M7F@YA37.K)6%1!AZS$>!6QP?&&F7+:# I#(KR%,DIB#(T(1A?M<?QO@;#CQV
M)PT*'2P<N+9IBJ$[',75%?T<TI@KF9]1G$:)Q%!3C$P>6%E0 TC;]P*\CL,0
MFT K<N4J/Q@-632(_W-$+>@=UN@=MJ)W+VH7V[V->KKA*M5-T&TU=QBZ#@T6
M4':&L962:Y$"XM3M8G8[F.$691%7(?W=FU'@Q^\U(KZAN XP>Q5U^XDPVW;P
M-F+W60/W2]$8O=LOD8&-T7);/:(954 DNZY2O*CV@/MZ@KP4#@5K](NF*YG&
M3(E-Z@=D4_65'=_<WNL3=HK<V8OOC/U>YC-0%/A7NW6B\C$.$K.4I<;@4>6^
MH' I%YO?1TC JE2.!RSH1CXQ-^R%(_8S#G 2]KN#<(@O@UXT9%^<@>/8#T^L
MH!<SW,WG(.SKT'=OQ^.7SEX,F[ ;>KX5]4,[;&VR1MJ"'E+Q0A><[[>Q)ZK9
M$[6RYQJ416^1@!L/;%HAL(DZK;::J?.Z+EZU8^J']-7O>J/ MA!'Z*ZO\0@;
MWL/W54\M X+W]?6IK2]7VEOK=T=19)WAU'Y=:_UN-!XYE:BMM7'=VKA]6\>C
M=EIF0*Z^\*QT$VJJD?EN>C=UN-WD7<.HH#[A] .;$A%\SH5B:W0(NS<VO7\:
M&]7(X79\HH4%=8A)9\K%GEHW&T"4.AT:F'9?QK"XRB33(B^S:A07M GA<2!%
M^12MX*@IM;VZ"4@"YMEHY$^U:=ST7S2L;FLJ:"- <UL!6<J\HZ>EM:1P,IKH
M8[\W/&(W0C^<SLFTP+!I5C+<X8'&Q5'%D!7R!:@0K@24-7M+@Z<%%*,:%*-V
M4%@/G]UFTT;U?V/&=JZ1H],UGF<6\)*KGTNC#=ZZHC?3-:J&X[ 7/8WA&$>R
M'<&?'D$E0K<QMH]-$-3ZXR@X03/(JN_]OFAIU!W'L74:1J^D;=0=#<96!<=*
M%18!K%EZV U"(GG4\P9N8Z[9XK;;9\>K196VA?R.:"DK]>YH<)GQY.$4F2[=
MB40DM)++%+(GBOPO(*_*W0QU//KN+2#,<W:\Q3,PMC[J^0<Y,.@%1TT8[^]]
MB>:@%O9[6R.[R\*XC]+Z;?U)/W5?LD_B[O\!F-U"8&4SF*.JUXOQ-*C<-[9[
M,')EOVMGTN!7LKU= L<90@*X/I?2[![(0?V/CLG?4$L#!!0    ( .J K%I0
M*J\8%@H  ')R   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;+6=;6_;
MNAF&_PKA'0PMD,66Y-<L,9!$E$3@= V:=?LP[(-B,[%0O?B(<M(>[,>/>HDE
MRC)KI7?RH95E\2)MWZ(>/C=%7;XDZ3>QX3PCWZ,P%E>#399M+X9#L=KPR!?G
MR9;'\IW')(W\3+Y,GX9BFW)_712*PJ$Y&DV'D1_$@^5EL>\N75XFNRP,8GZ7
M$K&+(C_]<</#Y.5J8 Q>=WP)GC99OF.XO-SZ3_R>9U^W=ZE\-=Q3UD'$8Q$D
M,4GYX]7@VKA@XZ) <<2_ OXB&MLD_R@/2?(M?\'65X-1WB(>\E66(WSYWS._
MY6&8DV0[_JB@@WV=><'F]BO=*3Z\_# /ON"W2?CO8)UMK@;S 5GS1W\79E^2
M%X]7'VB2\U9)*(I_R4MU[&A 5CN1)5%56+8@"N+R?_][]44T"ICFD0)F5<!L
M%U@<*6!5!:Q3:QA7!<:M N-CGV%2%9B<6L.T*C!M%;!F1PK,J@*S4S_TO"HP
M/[7 HBJP*.10_G[%CV_[F;^\3),7DN9'2UJ^42BH*"U_\R#.Q7Z?I?+=0);+
MEK=)M/7C'^3S,T^?<VWZ\9K<^"(0)'DD=RD7/,[\0I<?;)[Y02@^DM_(D(B-
M+]\D04R^QD$FSN1.N?W/3;(3$B$NAYEL75['<%6UQ"U;8AYIB44^)7&V$83&
M:[[N*,_TY:<S#6 HOY;]=V.^?C<WII9XO4W/B6F=$7-DCLG7>YM\^.UC1\-N
M3\&8*J;Z_CIH]@FTT<\;1?683WY7HQH_[-'V.2>TSRC!IJ9][@GMLXP",]FW
M;YLFZ]TJ.]XX[W3J"3\%>TL;NVB*_*S]J6D5>.L(_G[W(()U("]!9^3>#WE^
M0MYGR>H;^<_O\E#",AZ)_W8T^Z;DCKNY^>7S0FS]%;\:;//S.WWF@^5?_V),
M1W_O$C<29B-A% ESD# 7"?.0, :"*8(>[P4]UM&7_]A%#SS-9;Q*HHBGJ\ /
M@S_Y^O6T%N1_KYM=JM;"^ZH:";.1,(J$.4B86\(F!2P/HI^7X\OA<U.JR.H8
M"*9(=;*7ZD0K5?K'+LA^D'4@LC1XV)5Q^5/*N8SS.\6IQ?45)Q)F(V$4"7.0
M,!<)\Y P!H(I.I[N=3Q]IQABBA0T$F8C810)<Y P%PGSD# &@BF"GNT%/3LQ
MAG@=@ JQDR&$''MFJ1\+O\RA?)"ORP,^RJ#B:(!_HZVLK\J1,!L)HTB8@X2Y
M2)B'A+'90;1CSBQC8HPG^Z!'4?!\K^"Y5L&W22R[9)Z62964KWCP+ 4LMT75
M08N\@^Y2JQ;<5ZU(F(V$423,0<)<),Q#PE@)FS;4.C?FYJ);JHN]5!=:J=[Y
M/_)X5Y#')"U5672W?KSB<@@GLLXN58OL*U(DS$;"*!+F(&$N$N8A86QQT*5:
M<V/<K5%C5&>P1V\?J\FK_R?_>Q#MHBZMZLE]Q0JEV5 :A=(<*,V%TCPHC:%H
MJK8;[HSQ3N.W"HR2-I)F0VD42G.@-!=*\Z TAJ*ITC9K:9O:;ON^&>V>R1Y;
M=ME/?I;O>^1I$#^1;1JL>*>VS8-HQQCE?VHZ\E;?@MZJ1=(HE.9 :2Z4YD%I
M#$5355M[<H;6(5E>RZ!B+8=K5=!A-X..:UV"6,_MW1]#73DHC4)I#I3F0FD>
ME,90-%79M3EGC-\KU( Z<U":#:51*,V!TEPHS8/2&(JF2KLV\PR]FP=.&NMK
MZZUWJ-L'I5$HS8'2W(K6S";,QI/9U)RU3.F. \>3R<PT6^$B0[5/56EMU1E:
MX^17$L-Z<F]%0NTZ*(U":0Z4YE:TYK#$-*S1M*W'P\,,<V28;36^A\UFU#Z;
MH3?:WI3[U3-[ZQ!JJ$%I%$ISH#37.+2NIHOV5)V.@ZR9U=8@J%VJ!FNGS-!;
M9:T4050F<I5KMA\ENR,#+JA;!J79QJ%=8TY:ER,*K=*!TEPHS8/2&(JFBK;V
MS R]:=82[2[>^L&ZF/$H^T\I65%,L4^RC8Q(FTH^WJE"'34HS8;2*)3F0&FN
M<6A>S1?M/A7JENEK5.]HJ,TR4V^6?>'Y'5!Y=M7?99LD+>;?'N]$];2^VH/2
M;"B-0FD.E.96M.;E8C8_2'=[T$K93RM5%5A;6J;65UC^'L2K)(S)G9]^T\^I
MU8-ZBP]J84%I%$ISH#072O.@-(:BJ5*N+2S3?*>4J8GT1&ZA-!M*HU": Z6Y
M4)H'I3$4395V[7.9>I\+G#+5U]9;[U#W"TJC4)H#I;D5K1E1'L004$L+15-%
M7%M:IM976!:W[I,L(8*'83$$RY.IY;CLV0]WG9,+],S>4H6Z65 :A=*<BM:,
M%\<M=;G0&CTHC:%HJE9KC\K4>U3[R0,DXVGG9$4]H+<PH;83E$:A-.<G7[PU
M)5&Q;D!GCPF]K0Q*8RB:*MC:KC+U=E7W.$X_WU:/["UAJ$\%I5$HS8'27"C-
M@](8BJ:*NG:]S-E[C>B@UA>49D-I%$ISH#072O.@-(:BJ=*NS33S)V;:7MHD
M20DOYR]&/-LD^:CNF8N,\S.RVD6[T,\7H");GJ[RQ7^>Y%GP$O-4;((M"8,H
MJ-8#\A]EI$)\&5DW1H3=HS^H%0>EV5 :A=*<BK9HCM?.1XO%HAU60]TX*(VA
M:*KJ:S?.U+MQ7^,U3U_2(,NX#%5V#V&P(I^K">:=4H6:;5":#:51*,V!TEPH
MS8/2&(JFK@E5&WC6Z)TB% OJY4%I-I1&H30'2G.A- ]*8RB:*NW:&;3TSB X
MYZROK;?>H?8AE$8K6C.O:TR+O]9<6 =:KPNE>5 :0]%4+=?6H*6_N^T7)O/J
MR;UU"_4&H31J'=['-QM-VO,:'&BE+I3F06D,15-%VUAP4F_ZO6G.KY[96Z[8
MY2:QZTUB%YS$KCB)77+2.C@QI_/6M82AJE3%6IM[EM[<N\OO#LZ3%&4(4(0%
MZR0,_534>_,(H5[4ME.^4+L/2K.A-%K1YDV#[GS2[FN15;I0F@>E,11-E6_M
M]UEZVVF?F,CG8JX#L<JG8'8K%.K[06DVE$8KFF(A=X0#T-O(H#0/2F,HFBK1
MVN&S] Y?OB;\WZ[#,,D*9^_S-H]E.Q4*M?6@-!M*HU": Z6Y4)H'I3$4355R
M;>M9[V7K65!;#TJSH30*I3E0F@NE>5 :0]%4:=>VGJ6W]=!),ZA55]&:B:G)
M9#$?&>HEW8;62J$T!TISH30/2F,HFJKDVJJS]%;=KZ3,H*Y=15/NSK2F\[9F
MH6X<E.9 :2Z4YD%I#$53'VA1NW%C_>UT;\J8Z9E]U5K1E(6*1ZU<C0VMDD)I
M#I3F0FD>E,90-%6LM;\VUOMKIZ<<]*#>"C4.^E-CT@X!H%52*,V!TEPHS8/2
M&(I6*G38>"Y=Q-.GXJ&&@A2Z*Q_#MM];/CC1-2Z\XOF"K?W7QL5U\1C!88TI
MG\;XR4^?@EB0D#]*Y.A\)OO!M'S 8?DB2[;%T^\>DBQ+HF)SPWUY(N0'R/<?
MDR1[?9%7L'_,Y/+_4$L#!!0    ( .J K%J[\A^VOP(  'H(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;*U676^;,!3]*Q;KIE7:0OA,VB5(;:)I
ME;:I:M;M8=J# S?!*MBI;9+NW^_:4)2T%*U27N :[CGW'/L:,]D)>:=R $T>
MRH*KJ9-KO3EW797F4%(U$!O@^&8E9$DU#N7:51L)-+.@LG#]X3!V2\JXDTSL
MLVN93$2E"\;A6A)5E265?R^A$+NIXSF/#V[8.M?F@9M,-G0-"]"WFVN)([=E
MR5@)7#'!B835U+GPSF<CDV\3?C+8J;V8&"=+(>[,X"J;.D,C" I(M6&@>-O"
M#(K"$*&,^X;3:4L:X'[\R/[9>D<O2ZI@)HI?+-/YU!D[)(,5K0I](W9?H/$3
M&;Y4%,I>R:[.C<X<DE9*B[(!HX*2\?I.'YIYV -XX0L OP'X_PL(&D!@C=;*
MK*TYU3292+$CTF0CFPGLW%@TNF'<K.)"2WS+$*>3&Z;N%*$\([<\!:EQW34#
M1=[/ >-"G9*/Y'8Q)^]/3LD)89S\R$6E,%]-7(WU#8N;-K4NZUK^"[6^43D@
M@?>!^$,_ZH#/^N%S2%MX> AWT75KW6^M^Y8O>(%O)M QUY+:?C(307Y_Q1QR
MI:%4?[K\U81A-Z'9<.=J0U.8.KBC%,@M.,F[-UX\_-3E]DAD!]Z#UGO0QY[,
MJ,KMJJ<F@/N*;6F!D]&YJC55;*G,5V&;Q.,X&DW<[;Z=YUDC+PKC-NM 9]CJ
M#'MU7J1I558%U9"9S<E2IKL4AL]J!^/8"\,G$CO2XL#WPFZ-4:LQZM7H!8/H
M+5D 9T+B+:TDBOTN-.ZBK *,ME N09*Z<\==^GL+O+:OCD1V,!=Q.Q?QL?=4
M?$SO1R([\#YJO8]Z^^"*:T!63= ]=#FMX6=[[3<<>$'TI$E[B[S6@KMW,IA3
M&3_!:\85*6"%],/!")M%UB==/=!B8P^+I=!X]-@PQY\#D"8!WZ\$-G8S,.=/
M^[N1_ -02P,$%     @ ZH"L6O"UA<8T!P   C   !D   !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&ULM5I;;]LV%/XKA%<4+=#6XDV6T\1 +MU6H-FRN-T>
MACTH-AUKE41/HI,4Z(\?=;%IB10CN_1+8MF'A]\YO'S?H7CZR+.O^9(Q 9Z2
M.,W/!DLA5B?#83Y;LB3,W_$52^4O"YXEH9"/V?TP7V4LG)>-DGB(/,\?)F&4
M#B:GY7<WV>24KT4<I>PF _DZ2<+LVP6+^>/9  XV7]Q&]TM1?#&<G*[">S9E
MXLOJ)I-/PZV7>92P-(]X"C*V.!N<PY-+ZA<-2HL_(_:8[WP&12AWG'\M'C[.
MSP9>@8C%;"8*%Z'\]\ N61P7GB2._VJG@VV?1</=SQOO/Y?!RV#NPIQ=\OBO
M:"Z69X-@ .9L$:YC<<L??V5U0+3P-^-Q7OX%CY4ME3W.UKG@2=U8/B=16OT/
MG^I$[#3 7D<#5#= K08(=33 =0-<!EHA*\.Z"D4X.<WX(\@*:^FM^%#FIFPM
MHXG28ABG(I._1K*=F$S9O1P4 6[9BF<B2N_!JRLFPBC.7X,7($K!YR5?YV$Z
MST^'0O97M!K.:M\7E6_4X1N#:YZ*90X^I',V;[8?2IQ;L&@#]@)9'5Z'V3N
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MS3!3#2QP':">SQB3FXG>H&Z)H[]02P,$%     @ ZH"L6B^$%+9E P  4 \
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M&!WQ*2O+;+'^<B;CJ<SK.U0_O\VR\NE&/<%#EO^^WNS+_P-02P,$%     @
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M#R/5=@/7 >K]DC&YG>C&KFKD_7]02P,$%     @ ZH"L6C-S/+O( @  / @
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MFRNY_@)-/B[ 5'+M?LFZMCT./))6VLBB 6,$!1/UE]XU.FP!D*<;$#: \+F
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M6J%M9%;6#=4TC:78$&F\D<U,;&XL&M6PRMSB7$O<98C3Z566R09R\GZ+=:%
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MH;%_VVF!+RQ(XX#[2X&5V1FFB?=O=OH;4$L#!!0    ( .J K%JYK.-*%@H
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MG:JC>#Q,"EDE1<+8:_MO1##=1S#]__M0\E_2O%X_WY>0E3XT(20L1,(H$L9
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M">8 G)EF8#8&ZLH/J95&&GE^N:%_#!CG0.>YUOADN+G7_K62GU!+ P04
M" #J@*Q:Z"1 CHX$  #'%0  &0   'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6RU6-MNXS80_15"W1:[0!*)E"7;J6V@L1MT@6X;Y-(^%'V@9=HF5B*]%!4G
MQ7[\DI(BR1;%V*GWQ=9EYO#,(3DSXFC+Q>=T38@$3TG,TK&SEG)SZ;IIM"8)
M3B_XAC#U9LE%@J6Z%2LWW0B"%[E3$KO(\T(WP90YDU'^[$9,1CR3,67D1H T
M2Q(LGJ](S+=C!SHO#V[I:BWU W<RVN 5N2/R87,CU)U;H2QH0EA*.0."+,?.
M+_!RBGK:(;?XBY)MVK@&.I0YYY_US<?%V/$T(Q*32&H(K/X>R93$L492/+Z4
MH$XUIG9L7K^@7^?!JV#F."53'O]-%W(]=@8.6) ESF)YR[>_D3*@0.-%/$[S
M7[ M;3T'1%DJ>5(Z*P8)9<4_?BJ%:#C 7H<#*AW0H0Y^Z>#G@1;,\K!F6.+)
M2/ M$-I:H>F+7)O<6T5#F9[&.RG46ZK\Y.1WSE;G]T0D8$;F$IR#.[50%EE,
M %^"_/D?7)(48+8 #PPG7$CZ'UD4UC.:1CQC$ESA&+-(F;V?$8EIG'Y02 ]W
M,_#^W0?P#E &[M<\2Q5(.G*EHJT'=Z.2XE5!$750_(3%!?#A&4 >"@SN4[O[
MC$25>V_7W55B58JA2C&4X_4Z\*!_$?P([@BC7*B_*!-*CD*D14;4U2-)YD2
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MB=!V1:@["3CX/IG5VJ$<+<*)T'9%J+L5:&]7CLFL[6Y$[538WU_:1C.$S+T
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M(KZ^;MFMS8XOX7PA\QWMT=62SMDCDU^7#T)MM;>4:1BS) UY0@2;7;=N[,O
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M=%X(H%A!BA1':@M(5CJO2YU%J?,U8OKHQ@JM8$,8(VQCUICU.0C"N[[W>>G
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M,_\#4-H!YOM2"+UOV #U/XO9OU!+ P04    " #J@*Q:MB]+$P<)  !;2P
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MF0OSE!<YH$$!?*X:^)P#5ESE1:AN9 3*N6-3SM5!.1<HY\HIIP*2.N0PD+C
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ML%YD7+!S4[ 2"H(>PRA#FS!>'W3+O;&_EP>?F5WWW!NM1QP8<NS]BV=&#ND
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M-);<I.995SQ^#\\4O>-,91*]9BFD3^5=[5OCH']R<.T/*GQ'Q 1-\>_(]_P
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M)[H%14[GH"DKU("<D>?'.3D]&9 3PCAYRD6E*$]5Y&H\U$#=I#E@6A_@OW)
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ZH"L6M"5X93N!0  U3,
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MB[.54[NNC-$HJ4R9K7*A#;@DLET:'UR[&V<^BPNIG;B7&)/2RI39*Y<&;G2
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M2P$"% ,4    " #J@*Q:1L=-2)4   #-    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .J K%JR;P4*\@   "L"   1
M              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M .J K%J97)PC$ 8  )PG   3              "  >0!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ ZH"L6G^%;8K0!0  RAX  !@
M     ("!)0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M .J K%J.9L3::P8  .,;   8              " @2L.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #J@*Q:V+Q>*I,"  !7!P  &
M            @(',%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ ZH"L6KOM6N=U!0  4Q8  !@              ("!E1<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .J K%JR9"%'5@@   Q4
M   8              " @4 =  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #J@*Q:=/PAQ3 '   M(@  &               @(',)0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ZH"L6NWJ @D]
M"P  /AT  !@              ("!,BT  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( .J K%I]RK71 @H  !D=   8              "
M@:4X  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #J@*Q:
M>5Y-$F($   H"@  &               @('=0@  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ ZH"L6LPL:!LD"   1!0  !D
M     ("!=4<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .J K%JH7!BU3@,  %D'   9              "
M@6"#  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ZH"L
M6K$%N+Q]!@  8A   !D              ("!Y88  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #J@*Q:*A?NZZ<"   #!@  &0
M        @(&9C0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( .J K%I+@+/P, 0  )D)   9              " @7>0  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ZH"L6I73; *% P  V@<
M !D              ("!WI0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #J@*Q:.X5;?!X,   D(0  &0              @(&:F
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .J K%J'H/&^
MJ@<  &T7   9              " @>^D  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ ZH"L6C,I>6\%"@  *AP  !D
M ("!T*P  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #J
M@*Q:%(D3I@<$   7"@  &0              @($,MP  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .J K%JH')R.4PD  "T?   9
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M970R."YX;6Q02P$"% ,4    " #J@*Q:SR.&2987  #/1P  &0
M    @($=W0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M .J K%J78Y?9P@0  &<+   9              " @>KT  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ ZH"L6LS4B4D)!P  ;A(  !D
M             ("!X_D  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #J@*Q:'C*Z$G8"  !<!0  &0              @($C 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .J K%K7KDK*%0,
M )\&   9              " @= # 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ ZH"L6N:K[S.R @  RP4  !D              ("!
M' <! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #J@*Q:
MD@'+7[0"   +!@  &0              @($%"@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( .J K%JB0T91D0(  +<%   9
M      " @? , 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ ZH"L6KM\3L&H @  T@4  !D              ("!N \! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #J@*Q::1^UT#X$  #Y"0
M&0              @(&7$@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( .J K%I0I[Y,Z@(  *T&   9              " @0P7 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ZH"L6E4U:JO[
M P  L@D  !D              ("!+1H! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #J@*Q::=(=.=L%  #T$   &0
M@(%?'@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .J
MK%I0*J\8%@H  ')R   9              " @7$D 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ ZH"L6KOR'[:_ @  >@@  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( .J K%HOA!2V90,  % /   9
M  " @8%& 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MZH"L6K7'<D;+ @  >P<  !D              ("!'4H! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " #J@*Q:J6+D? 4#  !."   &0
M            @($?30$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( .J K%JYK"ANR@L  .6P   9              " @5M0 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ZH"L6BD;:$RV!0
MJ3$  !D              ("!7%P! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " #J@*Q:OIO4'7\"  #%!@  &0              @(%)
M8@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .J K%K,
MIFCO1P4  (0E   9              " @?]D 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ ZH"L6LQN^U5C @  MP4  !D
M     ("!?6H! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .J K%I3W*[?C (  ),&   9              "
M@01Z 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ ZH"L
M6D8V"PA%!   #1D  !D              ("!QWP! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " #J@*Q:(:!&++L"  ":!P  &0
M        @(%#@0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( .J K%K(_.VN;P(  +\'   9              " @36$ 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ ZH"L6KFLXTH6"@  76D
M !D              ("!VX8! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " #J@*Q:#A"I_EX"  #!!@  &0              @($HD0$
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( .J K%KH)$".
MC@0  ,<5   9              " @;V3 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ ZH"L6GA:!AQ, @  Q04  !D
M ("!@I@! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #J
M@*Q:,B#V]]\)  #]?0  &0              @($%FP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( .J K%JGH+>Q5P8  %TY   9
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M970W,RYX;6Q02P$"% ,4    " #J@*Q:MB]+$P<)  !;2P  &0
M    @(&_NP$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M .J K%H!\L,[60,  $<,   9              " @?W$ 0!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ ZH"L6N:,GPJ; P  JPT  !D
M             ("!C<@! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    " #J@*Q:UI1!PH\#  #5#0  &0              @(%?S $ >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( .J K%H/-!0@H0(
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( .J K%K0E>&4[@4  -4S   /
M      "  3?; 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #J@*Q:NTG2
MWV("  "T+@  &@              @ %2X0$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #J@*Q:W2=K"Q@"  "%+0  $P
M    @ 'LXP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5P!7 -@7   U
%Y@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>251</ContextCount>
  <ElementCount>319</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Company Overview and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/CompanyOverviewandBasisofPresentation</Role>
      <ShortName>Company Overview and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RisksandUncertainties</Role>
      <ShortName>Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Revenues and Trade Receivables, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNet</Role>
      <ShortName>Revenues and Trade Receivables, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Material Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/MaterialAgreements</Role>
      <ShortName>Material Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Financial Instruments ??? Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/FinancialInstrumentsFairValueMeasurements</Role>
      <ShortName>Financial Instruments ??? Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Right-of-Use Assets and Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RightofUseAssetsandLeaseObligations</Role>
      <ShortName>Right-of-Use Assets and Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Other Non-current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/OtherNoncurrentAssets</Role>
      <ShortName>Other Non-current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Sale of Future Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SaleofFutureRevenue</Role>
      <ShortName>Sale of Future Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://aquestive.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/SegmentReporting</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Revenues and Trade Receivables, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNetTables</Role>
      <ShortName>Revenues and Trade Receivables, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/RevenuesandTradeReceivablesNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/Inventories</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Right-of-Use Assets and Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RightofUseAssetsandLeaseObligationsTables</Role>
      <ShortName>Right-of-Use Assets and Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/RightofUseAssetsandLeaseObligations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/IntangibleAssetsNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Other Non-current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/OtherNoncurrentAssetsTables</Role>
      <ShortName>Other Non-current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/OtherNoncurrentAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/AccruedExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/LongTermDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Sale of Future Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SaleofFutureRevenueTables</Role>
      <ShortName>Sale of Future Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/SaleofFutureRevenue</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/NetLossPerShare</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aquestive.com/role/ShareBasedCompensation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Company Overview and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails</Role>
      <ShortName>Company Overview and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/CompanyOverviewandBasisofPresentation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RisksandUncertaintiesDetails</Role>
      <ShortName>Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/RisksandUncertainties</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/SegmentReportingTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Revenues and Trade Receivables, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails</Role>
      <ShortName>Revenues and Trade Receivables, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Revenues and Trade Receivables, Net - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails</Role>
      <ShortName>Revenues and Trade Receivables, Net - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Revenues and Trade Receivables, Net - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails</Role>
      <ShortName>Revenues and Trade Receivables, Net - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Revenues and Trade Receivables, Net - Trade and Other Receivables, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails</Role>
      <ShortName>Revenues and Trade Receivables, Net - Trade and Other Receivables, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Revenues and Trade Receivables, Net - Changes in Allowance for Bad Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails</Role>
      <ShortName>Revenues and Trade Receivables, Net - Changes in Allowance for Bad Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Revenues and Trade Receivables, Net - Summary of Activity with Sales Related Allowances and Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails</Role>
      <ShortName>Revenues and Trade Receivables, Net - Summary of Activity with Sales Related Allowances and Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Material Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/MaterialAgreementsDetails</Role>
      <ShortName>Material Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/MaterialAgreements</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Financial Instruments ??? Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails</Role>
      <ShortName>Financial Instruments ??? Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/FinancialInstrumentsFairValueMeasurements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/InventoriesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Property and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/PropertyandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Right-of-Use Assets and Lease Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails</Role>
      <ShortName>Right-of-Use Assets and Lease Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Right-of-Use Assets and Lease Obligations - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails</Role>
      <ShortName>Right-of-Use Assets and Lease Obligations - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Intangible Assets, Net - Components of Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Components of Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Intangible Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/IntangibleAssetsNetNarrativeDetails</Role>
      <ShortName>Intangible Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Other Non-current Assets - Summary of Other Non-current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails</Role>
      <ShortName>Other Non-current Assets - Summary of Other Non-current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Other Non-current Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails</Role>
      <ShortName>Other Non-current Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Accrued Expenses - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/AccruedExpensesNarrativeDetails</Role>
      <ShortName>Accrued Expenses - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Long-Term Debt - Schedule Of Royalty Right Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails</Role>
      <ShortName>Long-Term Debt - Schedule Of Royalty Right Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Long-Term Debt - Schedule of Term Notes and Unamortized Debt Discount Balances (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Term Notes and Unamortized Debt Discount Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Long-Term Debt - Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails</Role>
      <ShortName>Long-Term Debt - Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/Warrants</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Sale of Future Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails</Role>
      <ShortName>Sale of Future Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Sale of Future Revenue - Royalty Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails</Role>
      <ShortName>Sale of Future Revenue - Royalty Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Share-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Share-Based Compensation - Restricted Stock Unit Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Unit Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Share-Based Compensation - Performance Based (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails</Role>
      <ShortName>Share-Based Compensation - Performance Based (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Share-Based Compensation - Valuation Assumptions for Determination of Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Valuation Assumptions for Determination of Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/IncomeTaxes</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="aqst-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aquestive.com/role/Contingencies</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="aqst-20250331.htm">aqst-20250331.htm</File>
    <File>aqst-20250331.xsd</File>
    <File>aqst-20250331_cal.xml</File>
    <File>aqst-20250331_def.xml</File>
    <File>aqst-20250331_lab.xml</File>
    <File>aqst-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="660">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aqst-20250331.htm": {
   "nsprefix": "aqst",
   "nsuri": "http://aquestive.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "aqst-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "aqst-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "aqst-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aqst-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aqst-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aqst-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 262,
   "keyCustom": 57,
   "axisStandard": 24,
   "axisCustom": 2,
   "memberStandard": 30,
   "memberCustom": 67,
   "hidden": {
    "total": 7,
    "http://fasb.org/us-gaap/2024": 2,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 251,
   "entityCount": 1,
   "segmentCount": 100,
   "elementCount": 656,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 660,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://aquestive.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aquestive.com/role/CondensedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Balance Sheets",
     "shortName": "Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://aquestive.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Balance Sheets (Parenthetical)",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseNonoperating",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit",
     "longName": "9952154 - Statement - Condensed Statements of Changes in Stockholders' Deficit",
     "shortName": "Condensed Statements of Changes in Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://aquestive.com/role/CondensedStatementsofCashFlows",
     "longName": "9952155 - Statement - Condensed Statements of Cash Flows",
     "shortName": "Condensed Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://aquestive.com/role/CompanyOverviewandBasisofPresentation",
     "longName": "9952156 - Disclosure - Company Overview and Basis of Presentation",
     "shortName": "Company Overview and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://aquestive.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aquestive.com/role/RisksandUncertainties",
     "longName": "9952158 - Disclosure - Risks and Uncertainties",
     "shortName": "Risks and Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aquestive.com/role/SegmentReporting",
     "longName": "9952159 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNet",
     "longName": "9952160 - Disclosure - Revenues and Trade Receivables, Net",
     "shortName": "Revenues and Trade Receivables, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aquestive.com/role/MaterialAgreements",
     "longName": "9952161 - Disclosure - Material Agreements",
     "shortName": "Material Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurements",
     "longName": "9952162 - Disclosure - Financial Instruments \u2013 Fair Value Measurements",
     "shortName": "Financial Instruments \u2013 Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aquestive.com/role/Inventories",
     "longName": "9952163 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aquestive.com/role/PropertyandEquipmentNet",
     "longName": "9952164 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aquestive.com/role/RightofUseAssetsandLeaseObligations",
     "longName": "9952165 - Disclosure - Right-of-Use Assets and Lease Obligations",
     "shortName": "Right-of-Use Assets and Lease Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aquestive.com/role/IntangibleAssetsNet",
     "longName": "9952166 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aquestive.com/role/OtherNoncurrentAssets",
     "longName": "9952167 - Disclosure - Other Non-current Assets",
     "shortName": "Other Non-current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aquestive.com/role/AccruedExpenses",
     "longName": "9952168 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://aquestive.com/role/LongTermDebt",
     "longName": "9952169 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aquestive.com/role/Warrants",
     "longName": "9952170 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "aqst:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "aqst:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aquestive.com/role/SaleofFutureRevenue",
     "longName": "9952171 - Disclosure - Sale of Future Revenue",
     "shortName": "Sale of Future Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "aqst:SaleOfFutureRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "aqst:SaleOfFutureRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aquestive.com/role/NetLossPerShare",
     "longName": "9952172 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aquestive.com/role/ShareBasedCompensation",
     "longName": "9952173 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aquestive.com/role/IncomeTaxes",
     "longName": "9952174 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aquestive.com/role/Contingencies",
     "longName": "9952175 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://aquestive.com/role/SegmentReportingTables",
     "longName": "9955512 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNetTables",
     "longName": "9955513 - Disclosure - Revenues and Trade Receivables, Net (Tables)",
     "shortName": "Revenues and Trade Receivables, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://aquestive.com/role/InventoriesTables",
     "longName": "9955514 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://aquestive.com/role/PropertyandEquipmentNetTables",
     "longName": "9955515 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsTables",
     "longName": "9955516 - Disclosure - Right-of-Use Assets and Lease Obligations (Tables)",
     "shortName": "Right-of-Use Assets and Lease Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://aquestive.com/role/IntangibleAssetsNetTables",
     "longName": "9955517 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aquestive.com/role/OtherNoncurrentAssetsTables",
     "longName": "9955518 - Disclosure - Other Non-current Assets (Tables)",
     "shortName": "Other Non-current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aquestive.com/role/AccruedExpensesTables",
     "longName": "9955519 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://aquestive.com/role/LongTermDebtTables",
     "longName": "9955520 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://aquestive.com/role/SaleofFutureRevenueTables",
     "longName": "9955521 - Disclosure - Sale of Future Revenue (Tables)",
     "shortName": "Sale of Future Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "aqst:RoyaltyObligationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "aqst:RoyaltyObligationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://aquestive.com/role/NetLossPerShareTables",
     "longName": "9955522 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aquestive.com/role/ShareBasedCompensationTables",
     "longName": "9955523 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails",
     "longName": "9955524 - Disclosure - Company Overview and Basis of Presentation (Details)",
     "shortName": "Company Overview and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "aqst:RevenueFromContractWithCustomerNumberOfCommercializedProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "aqst:RevenueFromContractWithCustomerNumberOfCommercializedProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://aquestive.com/role/RisksandUncertaintiesDetails",
     "longName": "9955525 - Disclosure - Risks and Uncertainties (Details)",
     "shortName": "Risks and Uncertainties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://aquestive.com/role/SegmentReportingDetails",
     "longName": "9955526 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
     "longName": "9955527 - Disclosure - Revenues and Trade Receivables, Net - Narrative (Details)",
     "shortName": "Revenues and Trade Receivables, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails",
     "longName": "9955528 - Disclosure - Revenues and Trade Receivables, Net - Revenue (Details)",
     "shortName": "Revenues and Trade Receivables, Net - Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-66",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails",
     "longName": "9955529 - Disclosure - Revenues and Trade Receivables, Net - Disaggregation of Revenue (Details)",
     "shortName": "Revenues and Trade Receivables, Net - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails",
     "longName": "9955530 - Disclosure - Revenues and Trade Receivables, Net - Trade and Other Receivables, Net (Details)",
     "shortName": "Revenues and Trade Receivables, Net - Trade and Other Receivables, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
     "longName": "9955531 - Disclosure - Revenues and Trade Receivables, Net - Changes in Allowance for Bad Debt (Details)",
     "shortName": "Revenues and Trade Receivables, Net - Changes in Allowance for Bad Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails",
     "longName": "9955532 - Disclosure - Revenues and Trade Receivables, Net - Summary of Activity with Sales Related Allowances and Accruals (Details)",
     "shortName": "Revenues and Trade Receivables, Net - Summary of Activity with Sales Related Allowances and Accruals (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://aquestive.com/role/MaterialAgreementsDetails",
     "longName": "9955533 - Disclosure - Material Agreements (Details)",
     "shortName": "Material Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-107",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
     "longName": "9955534 - Disclosure - Financial Instruments \u2013 Fair Value Measurements (Details)",
     "shortName": "Financial Instruments \u2013 Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "aqst:SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://aquestive.com/role/InventoriesDetails",
     "longName": "9955535 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
     "longName": "9955536 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://aquestive.com/role/PropertyandEquipmentNetNarrativeDetails",
     "longName": "9955537 - Disclosure - Property and Equipment, Net - Narrative (Details)",
     "shortName": "Property and Equipment, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails",
     "longName": "9955538 - Disclosure - Right-of-Use Assets and Lease Obligations - Narrative (Details)",
     "shortName": "Right-of-Use Assets and Lease Obligations - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "aqst:NumberOfOperatingLeases",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "aqst:NumberOfOperatingLeases",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails",
     "longName": "9955539 - Disclosure - Right-of-Use Assets and Lease Obligations - Maturities (Details)",
     "shortName": "Right-of-Use Assets and Lease Obligations - Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails",
     "longName": "9955540 - Disclosure - Intangible Assets, Net - Components of Identifiable Intangible Assets (Details)",
     "shortName": "Intangible Assets, Net - Components of Identifiable Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://aquestive.com/role/IntangibleAssetsNetNarrativeDetails",
     "longName": "9955541 - Disclosure - Intangible Assets, Net - Narrative (Details)",
     "shortName": "Intangible Assets, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails",
     "longName": "9955542 - Disclosure - Other Non-current Assets - Summary of Other Non-current Assets (Details)",
     "shortName": "Other Non-current Assets - Summary of Other Non-current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "aqst:CumulativeRoyaltyReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "aqst:CumulativeRoyaltyReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
     "longName": "9955543 - Disclosure - Other Non-current Assets - Narrative (Details)",
     "shortName": "Other Non-current Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "aqst:NumberOfGuaranteedRoyaltyPayments",
      "unitRef": "payment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails",
     "longName": "9955544 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
     "longName": "9955545 - Disclosure - Accrued Expenses - Narrative (Details)",
     "shortName": "Accrued Expenses - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://aquestive.com/role/LongTermDebtNarrativeDetails",
     "longName": "9955546 - Disclosure - Long-Term Debt - Narrative (Details)",
     "shortName": "Long-Term Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-156",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
     "longName": "9955547 - Disclosure - Long-Term Debt - Schedule Of Royalty Right Agreements (Details)",
     "shortName": "Long-Term Debt - Schedule Of Royalty Right Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-150",
      "name": "us-gaap:LongTermDebtMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "us-gaap:LongTermDebtMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails",
     "longName": "9955548 - Disclosure - Long-Term Debt - Schedule of Term Notes and Unamortized Debt Discount Balances (Details)",
     "shortName": "Long-Term Debt - Schedule of Term Notes and Unamortized Debt Discount Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails",
     "longName": "9955549 - Disclosure - Long-Term Debt - Debt Maturities (Details)",
     "shortName": "Long-Term Debt - Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://aquestive.com/role/WarrantsDetails",
     "longName": "9955550 - Disclosure - Warrants (Details)",
     "shortName": "Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "aqst:ClassOfWarrantOrRightWarrantsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "aqst:ClassOfWarrantOrRightWarrantsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
     "longName": "9955551 - Disclosure - Sale of Future Revenue - Narrative (Details)",
     "shortName": "Sale of Future Revenue - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-178",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails",
     "longName": "9955552 - Disclosure - Sale of Future Revenue - Royalty Obligation (Details)",
     "shortName": "Sale of Future Revenue - Royalty Obligation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "aqst:LiabilitiesSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "aqst:RoyaltyObligationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "aqst:RoyaltyObligationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
     "longName": "9955553 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://aquestive.com/role/ShareBasedCompensationExpenseDetails",
     "longName": "9955554 - Disclosure - Share-Based Compensation - Expense (Details)",
     "shortName": "Share-Based Compensation - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails",
     "longName": "9955555 - Disclosure - Share-Based Compensation - Restricted Stock Unit Awards (Details)",
     "shortName": "Share-Based Compensation - Restricted Stock Unit Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
     "longName": "9955556 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
     "longName": "9955557 - Disclosure - Share-Based Compensation - Performance Based (Details)",
     "shortName": "Share-Based Compensation - Performance Based (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-201",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-201",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "longName": "9955558 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-244",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-244",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
     "longName": "9955559 - Disclosure - Share-Based Compensation - Valuation Assumptions for Determination of Fair Value of Options (Details)",
     "shortName": "Share-Based Compensation - Valuation Assumptions for Determination of Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-202",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "aqst:ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://aquestive.com/role/IncomeTaxesDetails",
     "longName": "9955560 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://aquestive.com/role/ContingenciesDetails",
     "longName": "9955561 - Disclosure - Contingencies (Details)",
     "shortName": "Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-247",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "unitRef": "pending_case",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-247",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "unitRef": "pending_case",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aqst-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "aqst_A2023MarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "A2023MarketBasedMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Market Based",
        "label": "2023 Market Based [Member]",
        "documentation": "2023 Market Based"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_A2025MarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "A2025MarketBasedMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Market Based",
        "label": "2025 Market Based [Member]",
        "documentation": "2025 Market Based"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_ABLFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ABLFacilityMember",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABL Facility",
        "label": "ABL Facility [Member]",
        "documentation": "ABL Facility"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_AQST108Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AQST108Member",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AQST-108 project expenses",
        "label": "AQST-108 [Member]",
        "documentation": "AQST-108"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r819"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable Type [Axis]",
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r61"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r45",
      "r50",
      "r879"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r680"
     ]
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails": {
       "parentTag": "aqst_TradeAndOtherReceivablesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r217",
      "r218",
      "r904"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails",
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r123",
      "r506"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r629"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r680",
      "r936"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r808",
      "r809",
      "r810",
      "r811",
      "r880",
      "r937"
     ]
    },
    "aqst_AdditionalProceedsFromSaleOfFutureRevenuesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AdditionalProceedsFromSaleOfFutureRevenuesNet",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional proceeds from sale of future revenue",
        "label": "Additional Proceeds From Sale of Future Revenues, Net",
        "documentation": "Additional Proceeds From Sale of Future Revenues, Net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested restricted stock units, net",
        "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r344"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Costs of common stock issued under public equity offering",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r89"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of common stock issued under public equity offering",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used for operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r727",
      "r737",
      "r769"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "aqst_AgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AgreementTerm",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement term",
        "label": "Agreement Term",
        "documentation": "Agreement Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r765",
      "r773",
      "r777",
      "r785"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r378"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails": {
       "parentTag": "aqst_TradeAndOtherReceivablesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Allowance for credit loss",
        "negatedLabel": "Less: allowance for doubtful accounts",
        "periodStartLabel": "Balance at beginning of the period",
        "periodEndLabel": "Balance at end of the period",
        "terseLabel": "Accrued distribution expenses and sales returns provision",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r219",
      "r223",
      "r224",
      "r227",
      "r904"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments / credits",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_AmendedEquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AmendedEquityDistributionAgreementMember",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Equity Distribution Agreement",
        "label": "Amended Equity Distribution Agreement [Member]",
        "documentation": "Amended Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount (premium)",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r71",
      "r304",
      "r890"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r304",
      "r804",
      "r890"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs and discounts",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r658",
      "r659",
      "r804",
      "r890"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r241",
      "r247",
      "r653"
     ]
    },
    "aqst_AnaphylmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AnaphylmMember",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anaphylm project expenses",
        "label": "Anaphylm [Member]",
        "documentation": "Anaphylm"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "aqst_AssertioHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AssertioHoldingsIncMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assertio Holdings, Inc",
        "label": "Assertio Holdings, Inc [Member]",
        "documentation": "Assertio Holdings, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r105",
      "r126",
      "r150",
      "r181",
      "r187",
      "r205",
      "r209",
      "r220",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r406",
      "r408",
      "r434",
      "r500",
      "r575",
      "r646",
      "r647",
      "r680",
      "r708",
      "r846",
      "r847",
      "r894"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r132",
      "r150",
      "r220",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r406",
      "r408",
      "r434",
      "r680",
      "r846",
      "r847",
      "r894"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public Equity Offering - ATM",
        "terseLabel": "At-the-market offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_AtnahsPharmaUKLimitedAmendedAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AtnahsPharmaUKLimitedAmendedAgreementMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Atnahs Pharma UK Limited, Amended Agreement",
        "label": "Atnahs Pharma UK Limited, Amended Agreement [Member]",
        "documentation": "Atnahs Pharma UK Limited, Amended Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_AtnahsPharmaUKLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AtnahsPharmaUKLimitedMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Atnahs Pharma UK Limited",
        "label": "Atnahs Pharma UK Limited [Member]",
        "documentation": "Atnahs Pharma UK Limited"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_AutomaticRenewalPeriodOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "AutomaticRenewalPeriodOfAgreement",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Automatic renewal period of agreement",
        "label": "Automatic Renewal Period of Agreement",
        "documentation": "Period for which the agreement is renewed automatically."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails",
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA-BC": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA-BC",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BRITISH COLUMBIA",
        "label": "BRITISH COLUMBIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost, net",
        "label": "Capitalized Contract Cost, Net",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r121",
      "r634"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r75"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "aqst_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants (in shares)",
        "label": "Class of Warrant or Right, Warrants Exercised",
        "documentation": "The number of class of warrant or right exercised."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_ClassOfWarrantOrRightWarrantsIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ClassOfWarrantOrRightWarrantsIssuedDuringPeriod",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued to purchase common stock (in shares)",
        "label": "Class Of Warrant Or Right Warrants Issued During Period",
        "documentation": "The number of warrants issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_CoDevelopmentAndResearchFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "CoDevelopmentAndResearchFeesMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Co-development and research fees",
        "label": "Co-Development and Research Fees [Member]",
        "documentation": "The aggregate revenue generated from Co-development and research fees."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r115"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "aqst_CommercialExploitationAgreementWithIndiviorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "CommercialExploitationAgreementWithIndiviorMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial exploitation agreement with Indivior",
        "label": "Commercial Exploitation Agreement with Indivior [Member]",
        "documentation": "The commercial exploitation agreement with Indivior."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies (Note 20)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r97",
      "r502",
      "r562"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r263",
      "r264",
      "r617",
      "r834",
      "r839"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r702",
      "r703",
      "r704",
      "r705",
      "r808",
      "r809",
      "r811",
      "r880",
      "r935",
      "r937"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r563"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r563",
      "r581",
      "r937",
      "r938"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value. Authorized $250,000,000 shares; 99,317,153 and 91,413,742 shares issued and outstanding at March\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r503",
      "r680"
     ]
    },
    "aqst_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants",
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r134",
      "r136",
      "r141",
      "r495",
      "r511",
      "r512"
     ]
    },
    "aqst_ComputerNetworkEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ComputerNetworkEquipmentAndSoftwareMember",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer, network equipment and software",
        "label": "Computer, Network Equipment and Software [Member]",
        "documentation": "Assets which are related to computer, network equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r38",
      "r39",
      "r216",
      "r616"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r38",
      "r39",
      "r216",
      "r543",
      "r616"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r38",
      "r39",
      "r216",
      "r616",
      "r796"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/RisksandUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of risk",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r38",
      "r39",
      "r216"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r23",
      "r38",
      "r93",
      "r616"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r38",
      "r39",
      "r216",
      "r616"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_ContingentMonetizationAgreementMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ContingentMonetizationAgreementMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt, contingent on additional milestones",
        "label": "Contingent Monetization Agreement, Milestone Payment",
        "documentation": "Contingent Monetization Agreement, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and non-current contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r338"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails": {
       "parentTag": "aqst_TradeAndOtherReceivablesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract and other receivables",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r318",
      "r338"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r338"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r338"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, net of current portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r338"
     ]
    },
    "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable",
        "label": "Contract with Customer, Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r319",
      "r338",
      "r615"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacture and supply",
        "verboseLabel": "Total Manufacture and Supply Expenses",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r461"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSoldAbstract",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Cost of Goods and Services Sold [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "aqst_CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs associated with public equity offering-ATM in Accounts Payable",
        "label": "Costs Associated with At-the-Market Public Equity Offering in Accounts Payable",
        "documentation": "Costs Associated with At-the-Market Public Equity Offering in Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_CostsAssociatedWithPublicEquityOfferingInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "CostsAssociatedWithPublicEquityOfferingInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs associated with public equity offering in Accounts Payable",
        "label": "Costs Associated with Public Equity Offering in Accounts Payable",
        "documentation": "Costs Associated with Public Equity Offering in Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r286",
      "r313",
      "r456",
      "r459",
      "r499",
      "r636",
      "r638"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r844"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r844",
      "r845"
     ]
    },
    "aqst_CumulativeRoyaltyReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "CumulativeRoyaltyReceivable",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty receivable",
        "label": "Cumulative Royalty Receivable",
        "documentation": "Cumulative sum of the carrying amounts of royalty receivable as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer concentration risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r216"
     ]
    },
    "aqst_DebtCovenantRedemptionScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "DebtCovenantRedemptionScenarioAxis",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Covenant, Redemption Scenario [Axis]",
        "label": "Debt Covenant, Redemption Scenario [Axis]",
        "documentation": "Debt Covenant, Redemption Scenario"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_DebtCovenantRedemptionScenarioDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "DebtCovenantRedemptionScenarioDomain",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Covenant, Redemption Scenario [Domain]",
        "label": "Debt Covenant, Redemption Scenario [Domain]",
        "documentation": "Debt Covenant, Redemption Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r149",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r271",
      "r272",
      "r282",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r298",
      "r305",
      "r306",
      "r308",
      "r442"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails",
      "http://aquestive.com/role/RisksandUncertaintiesDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r44",
      "r45",
      "r95",
      "r96",
      "r154",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r677",
      "r805",
      "r835",
      "r836",
      "r837",
      "r889",
      "r891"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalty obligations",
        "terseLabel": "Total outstanding notes",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r96",
      "r309"
     ]
    },
    "aqst_DebtInstrumentCovenantTieredRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "DebtInstrumentCovenantTieredRoyaltyPercentage",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation, percent of net sales",
        "label": "Debt Instrument, Covenant, Tiered Royalty Percentage",
        "documentation": "Debt Instrument, Covenant, Tiered Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_DebtInstrumentCovenantTieredRoyaltyPercentageTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "DebtInstrumentCovenantTieredRoyaltyPercentageTerm",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation, term",
        "label": "Debt Instrument, Covenant, Tiered Royalty Percentage, Term",
        "documentation": "Debt Instrument, Covenant, Tiered Royalty Percentage, Term"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_DebtInstrumentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "DebtInstrumentExitFee",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, exit fee",
        "label": "Debt Instrument, Exit Fee",
        "documentation": "Debt Instrument, Exit Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r442",
      "r443",
      "r656",
      "r657",
      "r677"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee amount",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "aqst_DebtInstrumentInterestRateChangeInEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "DebtInstrumentInterestRateChangeInEffectivePercentage",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, Interest rate, change in effective percentage",
        "label": "Debt Instrument, Interest Rate, Change in Effective Percentage",
        "documentation": "Debt Instrument, Interest Rate, Change in Effective Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective annual interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r312",
      "r442",
      "r443",
      "r677"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/RisksandUncertaintiesDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r284"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r677",
      "r805",
      "r889",
      "r891"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails",
      "http://aquestive.com/role/RisksandUncertaintiesDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r154",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r677",
      "r805",
      "r835",
      "r836",
      "r837",
      "r889",
      "r891"
     ]
    },
    "aqst_DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, redemption price, basis points above treasury rate",
        "label": "Debt Instrument, Redemption Price, Basis Spread On Variable Rate",
        "documentation": "Debt Instrument, Redemption Price, Basis Spread On Variable Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase price percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, redemption price, percentage of principal amount redeemed",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r32",
      "r33",
      "r40",
      "r87",
      "r88",
      "r154",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r677",
      "r805",
      "r889",
      "r891"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized discount, including exit fee",
        "negatedLabel": "Unamortized discount, including Exit Fee",
        "negatedTerseLabel": "Unamortized discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r888",
      "r889",
      "r891"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized deferred debt issuance cost and deferred debt discounts",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r310",
      "r441",
      "r442",
      "r443",
      "r656",
      "r657",
      "r677"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized discount (premium), net",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r888",
      "r889",
      "r891"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, net",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r888",
      "r889",
      "r891"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r28"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation, amortization, and impairment",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r28"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r346",
      "r374",
      "r375",
      "r377",
      "r669"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share attributable to common stockholders:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "(Loss) Earnings per common share \u2013 basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r170",
      "r172",
      "r174",
      "r175",
      "r176",
      "r180",
      "r401",
      "r404",
      "r417",
      "r418",
      "r496",
      "r513",
      "r639"
     ]
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "(Loss) Earnings per common share \u2013 diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r172",
      "r174",
      "r175",
      "r176",
      "r180",
      "r401",
      "r404",
      "r417",
      "r418",
      "r496",
      "r513",
      "r639"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r177",
      "r178",
      "r179"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://aquestive.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r670"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost, recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs of RSU awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to non-vested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r116",
      "r137",
      "r138",
      "r139",
      "r155",
      "r156",
      "r157",
      "r159",
      "r164",
      "r166",
      "r168",
      "r182",
      "r221",
      "r222",
      "r251",
      "r315",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r444",
      "r446",
      "r455",
      "r510",
      "r537",
      "r538",
      "r539",
      "r548",
      "r601"
     ]
    },
    "aqst_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity distribution agreement",
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r727",
      "r737",
      "r769"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r724",
      "r734",
      "r766"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "aqst_ExistingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ExistingWarrantsMember",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existing Warrants",
        "label": "Existing Warrants [Member]",
        "documentation": "Existing Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r673"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments \u2013 Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r494",
      "r671",
      "r674"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, long-term",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r230",
      "r246",
      "r653"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r462",
      "r463",
      "r629"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r246",
      "r463",
      "r653"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r246",
      "r248",
      "r249",
      "r250",
      "r462",
      "r629",
      "r653"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r629"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r830"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_FirstAdditionalWarrantOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "FirstAdditionalWarrantOfferingMember",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Additional Warrant Offering",
        "label": "First Additional Warrant Offering [Member]",
        "documentation": "First Additional Warrant Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total General and Administrative Expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r585"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General &amp; Administrative expenses:",
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Areas, Revenues from External Customers [Abstract]",
        "label": "Geographic Areas, Revenues from External Customers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823"
     ]
    },
    "aqst_HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Haisco Pharmaceutical Group Co., Ltd, upfront payment",
        "label": "Haisco Pharmaceutical Group Co., Ltd, Upfront Payment [Member]",
        "documentation": "Haisco Pharmaceutical Group Co., Ltd, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_HyperaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "HyperaMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hypera",
        "label": "Hypera [Member]",
        "documentation": "Hypera"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets, finite-lived",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r804",
      "r833"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/IncomeTaxesDetails",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "terseLabel": "Net (loss)/income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r99",
      "r104",
      "r497",
      "r508",
      "r641",
      "r646",
      "r813",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r259",
      "r260",
      "r422",
      "r424",
      "r428",
      "r534",
      "r536",
      "r586",
      "r629",
      "r672",
      "r906"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r422",
      "r424",
      "r428",
      "r534",
      "r536",
      "r586",
      "r629",
      "r672",
      "r906"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r393",
      "r395",
      "r396",
      "r397",
      "r547",
      "r670"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes (benefit) expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r113",
      "r167",
      "r168",
      "r181",
      "r195",
      "r209",
      "r382",
      "r383",
      "r394",
      "r514",
      "r670"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments for interest",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r146",
      "r389",
      "r390"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade and other receivables, net",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r765",
      "r773",
      "r777",
      "r785"
     ]
    },
    "aqst_IndiviorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "IndiviorMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indivior",
        "label": "Indivior [Member]",
        "documentation": "Indivior"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_InitialWarrantOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "InitialWarrantOfferingMember",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Warrant Offering",
        "label": "Initial Warrant Offering [Member]",
        "documentation": "Initial Warrant Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r789"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r789"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r789"
     ]
    },
    "aqst_InterestAndOtherIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "InterestAndOtherIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income and other income, net",
        "label": "Interest And Other Income, Net",
        "documentation": "Interest And Other Income, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r801"
     ]
    },
    "aqst_InterestExpenseSaleOfFutureRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "InterestExpenseSaleOfFutureRevenues",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense related to the sale of future revenue",
        "label": "Interest Expense, Sale of Future Revenues",
        "documentation": "Interest Expense, Sale of Future Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aquestive.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r635",
      "r680"
     ]
    },
    "aqst_InventoryPackingMaterialGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "InventoryPackingMaterialGross",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Packaging material",
        "label": "Inventory Packing Material Gross",
        "documentation": "Amount of packaging materials expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw material",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r453"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r454"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r454"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "aqst_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Year Four And Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r892"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-Use Assets and Lease Obligations",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r44",
      "r45",
      "r46",
      "r49",
      "r50",
      "r51",
      "r52",
      "r150",
      "r220",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r407",
      "r408",
      "r409",
      "r434",
      "r561",
      "r640",
      "r708",
      "r846",
      "r894",
      "r895"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r98",
      "r505",
      "r680",
      "r806",
      "r820",
      "r887"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r120",
      "r150",
      "r220",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r407",
      "r408",
      "r409",
      "r434",
      "r680",
      "r846",
      "r894",
      "r895"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LiabilitiesSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LiabilitiesSaleOfFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Liability related to the sale of future revenue, net at beginning of the period",
        "periodEndLabel": "Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively)",
        "label": "Liabilities, Sale of Future Royalties",
        "documentation": "Liabilities, Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LiabilitiesSaleOfFutureRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LiabilitiesSaleOfFutureRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future revenue, current",
        "label": "Liabilities, Sale of Future Royalties, Current",
        "documentation": "Liabilities, Sale of Future Royalties, Current"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LibervantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LibervantMember",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Libervant project expenses",
        "label": "Libervant [Member]",
        "documentation": "Libervant"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LicenseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LicenseAgreementTerm",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement term",
        "label": "License Agreement Term",
        "documentation": "License agreement term period."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LicenseAgreementWithSunovionPharmaceuticalsIncMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement with Sunovion Pharmaceuticals, Inc.",
        "label": "License Agreement with Sunovion Pharmaceuticals, Inc. [Member]",
        "documentation": "The license agreement made with sunovion pharmaceuticals, inc."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement with Sunovion Pharmaceuticals, Inc milestones",
        "label": "License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member]",
        "documentation": "The license agreement made with sunovion pharmaceuticals, inc. milestones."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement with Sunovion Pharmaceuticals, Inc. upfront",
        "label": "License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member]",
        "documentation": "The license agreement made with sunovion pharmaceuticals, inc. advance payments."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LicenseAndRoyaltyRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LicenseAndRoyaltyRevenueMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and royalty revenue",
        "label": "License and Royalty Revenue [Member]",
        "documentation": "The aggregate revenue generated from licensing and royalties."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LicenseSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LicenseSupplyAgreementMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License &amp; Supply Agreement",
        "label": "License &amp; Supply Agreement [Member]",
        "documentation": "License &amp; Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LincolnParkAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LincolnParkAgreementMember",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lincoln Park agreement",
        "label": "Lincoln Park Agreement [Member]",
        "documentation": "Lincoln Park Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LineOfCreditFacilityAccordionFeatureIncreaseLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, accordion feature, increase limit",
        "label": "Line of Credit Facility, Accordion Feature, Increase Limit",
        "documentation": "Line of Credit Facility, Accordion Feature, Increase Limit"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LineOfCreditFacilityAccordionFeatureNetRevenueThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LineOfCreditFacilityAccordionFeatureNetRevenueThreshold",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, accordion feature, net revenue threshold",
        "label": "Line of Credit Facility, Accordion Feature, Net Revenue Threshold",
        "documentation": "Line of Credit Facility, Accordion Feature, Net Revenue Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r805",
      "r844"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r48",
      "r272",
      "r805",
      "r844"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_LitigationSettlementAmountAwardPeriodDue": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "LitigationSettlementAmountAwardPeriodDue",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, period due",
        "label": "Litigation Settlement, Amount Award, Period Due",
        "documentation": "Litigation Settlement, Amount Award, Period Due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, amount awarded from other party",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "documentation": "Amount awarded from other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans payable, current",
        "label": "Loans Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r96",
      "r295",
      "r311",
      "r656",
      "r657",
      "r677",
      "r903"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Notes payable, net",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r501"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current portion of royalty obligation",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r154",
      "r300"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r154",
      "r300"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r154",
      "r300"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_LongTermDebtMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMeasurementInput",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Long-Term Debt, Measurement Input",
        "documentation": "Value of input used to measure long-term debt."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, long-term",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r835",
      "r836",
      "r837"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r30",
      "r835",
      "r836",
      "r837"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r270",
      "r379",
      "r654",
      "r840",
      "r841"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r270",
      "r379",
      "r654",
      "r840",
      "r841"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of cases pending",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r841"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r663",
      "r690",
      "r695",
      "r850",
      "r905",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "aqst_ManufactureAndSupplyRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ManufactureAndSupplyRevenueMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacture and supply revenue",
        "label": "Manufacture and Supply Revenue [Member]",
        "documentation": "The aggregate revenue generated from manufacture and supply."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturedProductOtherMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proprietary product revenue, net",
        "label": "Manufactured Product, Other [Member]",
        "documentation": "Article or substance produced by labor or machinery, classified as other."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "aqst_ManufacturingAndSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ManufacturingAndSupplyMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Manufacture and supply",
        "label": "Manufacturing And Supply [Member]",
        "documentation": "Primary financial statement caption encompassing Manufacturing and supply expense."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_MarathonPangolinRoyaltyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "MarathonPangolinRoyaltyLLCMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MAM Pangolin Royalty , LLC",
        "label": "Marathon Pangolin Royalty LLC [Member]",
        "documentation": "Marathon Pangolin Royalty LLC"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_MarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "MarketBasedMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Based",
        "label": "Market Based [Member]",
        "documentation": "Market Based"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r341",
      "r379",
      "r421",
      "r460",
      "r533",
      "r535",
      "r542",
      "r553",
      "r554",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r627",
      "r628",
      "r651",
      "r660",
      "r668",
      "r673",
      "r674",
      "r675",
      "r676",
      "r691",
      "r848",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "aqst_MeasurementInputProbabilityOfSuccessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Probability Of Success",
        "label": "Measurement Input, Probability Of Success [Member]",
        "documentation": "Measurement Input, Probability Of Success"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r673"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r673"
     ]
    },
    "aqst_MinimumAnnualRoyaltyReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "MinimumAnnualRoyaltyReceivable",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum annual royalty receivable",
        "label": "Minimum Annual Royalty Receivable",
        "documentation": "Minimum annual royalty receivable by the entity for the use of its rights and property by another party."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r341",
      "r379",
      "r421",
      "r460",
      "r533",
      "r535",
      "r542",
      "r553",
      "r554",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r627",
      "r628",
      "r651",
      "r660",
      "r668",
      "r673",
      "r674",
      "r675",
      "r691",
      "r848",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "aqst_MonetizationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "MonetizationAgreementMember",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monetization Agreement",
        "label": "Monetization Agreement [Member]",
        "documentation": "Monetization Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r663",
      "r690",
      "r695",
      "r850",
      "r905",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r78"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit",
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
      "http://aquestive.com/role/SegmentReportingDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r78",
      "r100",
      "r118",
      "r133",
      "r135",
      "r139",
      "r150",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r173",
      "r220",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r401",
      "r404",
      "r418",
      "r434",
      "r509",
      "r583",
      "r599",
      "r600",
      "r706",
      "r846"
     ]
    },
    "aqst_NeurelisIncVAquestiveTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "NeurelisIncVAquestiveTherapeuticsIncMember",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neurelis, Inc. v. Aquestive Therapeutics, Inc.",
        "label": "Neurelis, Inc. v. Aquestive Therapeutics, Inc. [Member]",
        "documentation": "Neurelis, Inc. v. Aquestive Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Warrants",
        "label": "New Warrants [Member]",
        "documentation": "New Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r765",
      "r773"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ex-United States",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income/(expenses):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units Awards",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "aqst_NumberOfAnnualRoyaltyPaymentsReceivable": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "NumberOfAnnualRoyaltyPaymentsReceivable",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of annual royalty payments receivable",
        "label": "Number of Annual Royalty Payments Receivable",
        "documentation": "Number of annual royalty payments receivable by the entity for the use of its rights and property by another party."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_NumberOfGuaranteedRoyaltyPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "NumberOfGuaranteedRoyaltyPayments",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of guaranteed royalty payments",
        "label": "Number Of Guaranteed Royalty Payments",
        "documentation": "Number Of Guaranteed Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_NumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "NumberOfOperatingLeases",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leases",
        "label": "Number of Operating Leases",
        "documentation": "Number of operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r814"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r650",
      "r814"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r641",
      "r813",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r679"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Overview and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r79",
      "r80",
      "r92"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-current Assets",
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/OtherNoncurrentAssetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Total other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "aqst_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "OtherMember",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other [Member]",
        "documentation": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "aqst_OtherReceivablesAndAccruedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "OtherReceivablesAndAccruedExpensesMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables And Accrued Expenses",
        "label": "Other Receivables And Accrued Expenses [Member]",
        "documentation": "Other Receivables And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r729",
      "r739",
      "r771"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r732",
      "r742",
      "r774"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r732",
      "r742",
      "r774"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased patent",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_PaymentsForRoyaltyObligationsFinancingObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "PaymentsForRoyaltyObligationsFinancingObligations",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for royalty obligations",
        "label": "Payments for Royalty Obligations, Financing Obligations",
        "documentation": "Payments for Royalty Obligations, Financing Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of debt principal including lease liabilities",
        "terseLabel": "Payments for loan acquisition costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for taxes on share-based compensation",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capital expenditures",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_PersonnelCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "PersonnelCostsMember",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel costs",
        "label": "Personnel Costs [Member]",
        "documentation": "Personnel Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "aqst_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaborators",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r545"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from common stock issued under public equity offering",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "aqst_ProceedsFromSaleOfFutureRevenuesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ProceedsFromSaleOfFutureRevenuesNet",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of future revenue",
        "label": "Proceeds From Sale of Future Revenues, Net",
        "documentation": "Proceeds From Sale of Future Revenues, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options, net",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercises",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r461",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r632",
      "r661",
      "r689",
      "r691",
      "r692",
      "r696",
      "r697",
      "r842",
      "r843",
      "r850",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r461",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r632",
      "r661",
      "r689",
      "r691",
      "r692",
      "r696",
      "r697",
      "r842",
      "r843",
      "r850",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r453"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r122",
      "r507"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r453",
      "r498",
      "r507",
      "r680"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r453"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful Lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance reduction",
        "terseLabel": "Allowance reduction",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r225"
     ]
    },
    "aqst_PublicEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "PublicEquityOfferingMember",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Equity Offering",
        "label": "Public Equity Offering [Member]",
        "documentation": "Public Equity Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r340",
      "r341",
      "r369",
      "r370",
      "r371",
      "r379",
      "r421",
      "r457",
      "r458",
      "r460",
      "r533",
      "r535",
      "r542",
      "r553",
      "r554",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r627",
      "r628",
      "r651",
      "r660",
      "r668",
      "r673",
      "r674",
      "r675",
      "r676",
      "r691",
      "r700",
      "r838",
      "r848",
      "r884",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "verboseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r340",
      "r341",
      "r369",
      "r370",
      "r371",
      "r379",
      "r421",
      "r457",
      "r458",
      "r460",
      "r533",
      "r535",
      "r542",
      "r553",
      "r554",
      "r604",
      "r606",
      "r608",
      "r609",
      "r611",
      "r627",
      "r628",
      "r651",
      "r660",
      "r668",
      "r673",
      "r674",
      "r675",
      "r676",
      "r691",
      "r700",
      "r838",
      "r848",
      "r884",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable [Domain]",
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r61"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r724",
      "r734",
      "r766"
     ]
    },
    "aqst_RedemptionScenario1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RedemptionScenario1Member",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption Scenario 1",
        "label": "Redemption Scenario 1 [Member]",
        "documentation": "Redemption Scenario 1"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_RedemptionScenario2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RedemptionScenario2Member",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption Scenario 2",
        "label": "Redemption Scenario 2 [Member]",
        "documentation": "Redemption Scenario 2"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r286",
      "r313",
      "r456",
      "r459",
      "r499",
      "r637",
      "r638"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Total Research and Development Expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r629",
      "r646",
      "r902"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_ResearchAndDevelopmentProjectDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ResearchAndDevelopmentProjectDuration",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, project duration",
        "label": "Research and Development, Project Duration",
        "documentation": "Research and Development, Project Duration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r725",
      "r735",
      "r767"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r726",
      "r736",
      "r768"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents:",
        "label": "Restricted Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r89",
      "r504",
      "r540",
      "r541",
      "r546",
      "r564",
      "r680"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r155",
      "r156",
      "r157",
      "r159",
      "r164",
      "r166",
      "r168",
      "r221",
      "r222",
      "r251",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r410",
      "r412",
      "r413",
      "r415",
      "r416",
      "r444",
      "r446",
      "r537",
      "r539",
      "r548",
      "r937"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetRevenueDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "verboseLabel": "Royalties related to the sale of future revenue",
        "negatedTerseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r181",
      "r188",
      "r189",
      "r203",
      "r209",
      "r212",
      "r214",
      "r216",
      "r336",
      "r337",
      "r461"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r795"
     ]
    },
    "aqst_RevenueFromContractWithCustomerNumberOfCommercializedProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RevenueFromContractWithCustomerNumberOfCommercializedProducts",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of commercialized products",
        "label": "Revenue From Contract With Customer, Number Of Commercialized Products",
        "documentation": "Revenue From Contract With Customer, Number Of Commercialized Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://aquestive.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition and Performance Obligations",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r631"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues and Trade Receivables, Net",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r339"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate payment",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r140",
      "r150",
      "r181",
      "r188",
      "r189",
      "r203",
      "r209",
      "r212",
      "r214",
      "r216",
      "r220",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r434",
      "r497",
      "r646",
      "r846"
     ]
    },
    "aqst_RightToSellCommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RightToSellCommonStockValue",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right to sell common stock, value",
        "label": "Right to Sell Common Stock, Value",
        "documentation": "Right to Sell Common Stock, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties [Abstract]",
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense related to royalty obligations",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "aqst_RoyaltyObligationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RoyaltyObligationActivityTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/SaleofFutureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Obligation Activity",
        "label": "Royalty Obligation Activity [Table Text Block]",
        "documentation": "Royalty Obligation Activity"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_RoyaltyObligationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RoyaltyObligationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligations, net",
        "label": "Royalty Obligation, Liability, Noncurrent",
        "documentation": "Royalty Obligation, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_RoyaltyObligationsLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RoyaltyObligationsLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligations, current",
        "label": "Royalty Obligations, Liability, Current",
        "documentation": "Royalty Obligations, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_RoyaltyObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "RoyaltyObligationsMember",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Obligations",
        "label": "Royalty Obligations [Member]",
        "documentation": "Royalty Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "aqst_SaleOfFutureRevenueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SaleOfFutureRevenueRollForward",
     "presentation": [
      "http://aquestive.com/role/SaleofFutureRevenueRoyaltyObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Future Revenue [Roll Forward]",
        "label": "Sale of Future Revenue [Roll Forward]",
        "documentation": "Sale of Future Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SaleOfFutureRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SaleOfFutureRevenueTextBlock",
     "presentation": [
      "http://aquestive.com/role/SaleofFutureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Future Revenue",
        "label": "Sale of Future Revenue [Text Block]",
        "documentation": "Sale of Future Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SaleOfStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SaleOfStockAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, aggregate offering price",
        "label": "Sale of Stock, Aggregate Offering Price",
        "documentation": "Sale of Stock, Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on sale of stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts",
        "label": "Sale of Stock, Consideration Received on Transaction, Underwriting Discounts",
        "documentation": "Sale of Stock, Consideration Received on Transaction, Underwriting Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SaleOfStockMaximumTransactionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SaleOfStockMaximumTransactionAmount",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum transaction amount",
        "label": "Sale of Stock, Maximum Transaction Amount",
        "documentation": "Sale of Stock, Maximum Transaction Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails",
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SaleOfStockUnpaidCommissionsAndOtherTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SaleOfStockUnpaidCommissionsAndOtherTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, unpaid commissions and other transaction costs",
        "label": "Sale of Stock, Unpaid Commissions and Other Transaction Costs",
        "documentation": "Sale of Stock, Unpaid Commissions and Other Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts and Financing Receivables [Table]",
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r61",
      "r218",
      "r819"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Receivables, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r61"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r629"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Allowance for Bad Debt",
        "label": "Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss of financing receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r821"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r32",
      "r33",
      "r40",
      "r87",
      "r88",
      "r656",
      "r658",
      "r807",
      "r889"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r246",
      "r248",
      "r249",
      "r250",
      "r462",
      "r629",
      "r653"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Identifiable Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r829"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Net",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Maturity",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://aquestive.com/role/OtherNoncurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Non-current Assets",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://aquestive.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r453"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails",
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r90"
     ]
    },
    "aqst_ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Awards Other Than Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Schedule of Share-Based Payment Award, Awards Other Than Options, Valuation Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-Term Debt [Table]",
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "aqst_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities purchase agreement",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r181",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r216",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r250",
      "r261",
      "r262",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r643",
      "r646",
      "r647",
      "r652",
      "r694",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r550",
      "r551",
      "r552",
      "r605",
      "r607",
      "r610",
      "r612",
      "r614",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r633",
      "r662",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r693",
      "r700",
      "r850",
      "r905",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r199",
      "r201",
      "r202",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r642",
      "r644",
      "r645",
      "r646",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/SegmentReportingDetails": {
       "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Selling expenses",
        "label": "Selling Expense",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aquestive.com/role/SegmentReportingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Total Selling, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling expenses:",
        "label": "Selling, General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, net",
        "label": "Senior Notes, Noncurrent And Finance Lease, Liability, Noncurrent",
        "documentation": "Senior Notes, Noncurrent And Finance Lease, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SeniorSecuredNotes13.5DueNovember12028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SeniorSecuredNotes13.5DueNovember12028Member",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleOfRoyaltyRightAgreementsDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails",
      "http://aquestive.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "13.5% Senior Secured Notes due November 1, 2028",
        "label": "Senior Secured Notes, 13.5% due November 1, 2028 [Member]",
        "documentation": "Senior Secured Notes, 13.5% due November 1, 2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation expenses [Abstract]",
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at end of period (in dollars per share)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date Fair Value",
        "documentation": "The estimated fair value of nonvested equity-based awards on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan) as of grant date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at end of period (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, in Shares",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date in shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested, at beginning of period (in shares)",
        "periodEndLabel": "Unvested, at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested, at beginning of period (in dollars per share)",
        "periodEndLabel": "Unvested, at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average closing prices period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Closing Prices Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Average Closing Prices Period"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average closing price, number of days utilized in pricing period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Days Utilized in Pricing Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Days Utilized in Pricing Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails",
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pricing periods",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Pricing Periods",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Pricing Periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited/expired (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Forfeitures And Expirations In Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were exercised, cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/expired (in dollars per share)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either exercised, forfeited or expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested or expected to vest at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested or expected to vest at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "aqst_ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance price threshold (in dollars per share)",
        "label": "Share Based Compensation, Arrangement by Share-Based Payment, Market Condition, Performance Price Threshold, Per Share",
        "documentation": "Share Based Compensation, Arrangement by Share-Based Payment, Market Condition, Performance Price Threshold, Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
      "http://aquestive.com/role/ShareBasedCompensationExpenseDetails",
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationPerformanceBasedDetails",
      "http://aquestive.com/role/ShareBasedCompensationRestrictedStockUnitAwardsDetails",
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Share Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails",
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationValuationAssumptionsforDeterminationofFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "aqst_SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock (in shares)",
        "label": "Shares Of Common Stock Entitled To Purchasers By Pre-Funded Warrants",
        "documentation": "Shares Of Common Stock Entitled To Purchasers By Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SharesOfCommonStockToBePurchasedByCommonStockWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SharesOfCommonStockToBePurchasedByCommonStockWarrants",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock in connection with securities purchase agreements (in shares)",
        "label": "Shares Of Common Stock To Be Purchased By Common Stock Warrants",
        "documentation": "Shares of Common Stock to be Purchased by Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt [Line Items]",
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aquestive.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r148"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://aquestive.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r117",
      "r181",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r216",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r250",
      "r253",
      "r261",
      "r262",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r643",
      "r646",
      "r647",
      "r652",
      "r694",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r58",
      "r59",
      "r116",
      "r137",
      "r138",
      "r139",
      "r155",
      "r156",
      "r157",
      "r159",
      "r164",
      "r166",
      "r168",
      "r182",
      "r221",
      "r222",
      "r251",
      "r315",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r444",
      "r446",
      "r455",
      "r510",
      "r537",
      "r538",
      "r539",
      "r548",
      "r601"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r550",
      "r551",
      "r552",
      "r605",
      "r607",
      "r610",
      "r612",
      "r614",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r633",
      "r662",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r693",
      "r700",
      "r850",
      "r905",
      "r907",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r182",
      "r446",
      "r461",
      "r544",
      "r549",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r701"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r182",
      "r217",
      "r446",
      "r461",
      "r544",
      "r549",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r582",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r701"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r728",
      "r738",
      "r770"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock issued under public equity offering (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r89",
      "r545",
      "r601",
      "r613"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested restricted stock units, net (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r89"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit",
      "http://aquestive.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercises, net (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r89",
      "r355"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock issued under public equity offering",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r89",
      "r548",
      "r601",
      "r613",
      "r707"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised, net",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r58",
      "r59",
      "r89"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining authorized amount",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r58",
      "r59",
      "r82",
      "r565",
      "r581",
      "r602",
      "r603",
      "r680",
      "r708",
      "r806",
      "r820",
      "r887",
      "r937"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SuboxoneProduceLiabilityLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SuboxoneProduceLiabilityLitigationMember",
     "presentation": [
      "http://aquestive.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suboxone Produce Liability Litigation",
        "label": "Suboxone Produce Liability Litigation [Member]",
        "documentation": "Suboxone Produce Liability Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or equity method investee, cumulative percentage ownership limitation after all transactions",
        "label": "Subsidiary Or Equity Method Investee, Cumulative Percentage Ownership Limitation After All Transactions",
        "documentation": "Subsidiary Or Equity Method Investee, Cumulative Percentage Ownership Limitation After All Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails",
      "http://aquestive.com/role/CondensedStatementsofCashFlows",
      "http://aquestive.com/role/CondensedStatementsofChangesinStockholdersDeficit",
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/AccruedExpensesScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate and personal property taxes",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://aquestive.com/role/IntangibleAssetsNetComponentsofIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased intangible",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "aqst_TradeAccountsReceivableDoubtfulAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "TradeAccountsReceivableDoubtfulAccountsMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetChangesinAllowanceforBadDebtDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Doubtful Accounts",
        "label": "Trade Accounts Receivable, Doubtful Accounts [Member]",
        "documentation": "Trade Accounts Receivable, Doubtful Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAccountsReceivableMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable",
        "label": "Trade Accounts Receivable [Member]",
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_TradeAccountsReceivableSalesRelatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "TradeAccountsReceivableSalesRelatedMember",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetSummaryofActivitywithSalesRelatedAllowancesandAccrualsDetails",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable, Sales Related",
        "label": "Trade Accounts Receivable, Sales Related [Member]",
        "documentation": "Trade Accounts Receivable, Sales Related"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_TradeAndOtherReceivablesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "TradeAndOtherReceivablesNet",
     "crdr": "debit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets",
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetTradeandOtherReceivablesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other receivables, net",
        "totalLabel": "Trade and other receivables, net",
        "label": "Trade And Other Receivables, Net",
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade and other receivables)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "aqst_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aquestive.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aquestive.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future revenue, net",
        "label": "Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent",
        "documentation": "Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "aqst_TwelvePointFiveSeniorSecuredNotesDueJune302025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "TwelvePointFiveSeniorSecuredNotesDueJune302025Member",
     "presentation": [
      "http://aquestive.com/role/FinancialInstrumentsFairValueMeasurementsDetails",
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior secured notes due 2025",
        "label": "Twelve Point Five, Senior Secured Notes due June 30, 2025 [Member]",
        "documentation": "A debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aquestive.com/role/MaterialAgreementsDetails",
      "http://aquestive.com/role/OtherNoncurrentAssetsNarrativeDetails",
      "http://aquestive.com/role/SaleofFutureRevenueNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost, Product and Service [Extensible Enumeration]",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates type of cost from product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://aquestive.com/role/RevenuesandTradeReceivablesNetDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://aquestive.com/role/CompanyOverviewandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://aquestive.com/role/LongTermDebtNarrativeDetails",
      "http://aquestive.com/role/LongTermDebtScheduleofTermNotesandUnamortizedDebtDiscountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured Debt",
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://aquestive.com/role/RightofUseAssetsandLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r679"
     ]
    },
    "aqst_VestingConditionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionAxis",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition [Axis]",
        "label": "Vesting Condition [Axis]",
        "documentation": "Vesting Condition"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionDomain",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition [Domain]",
        "label": "Vesting Condition [Domain]",
        "documentation": "Market Conditions [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeEightMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition Range Eight",
        "label": "Vesting Condition Range Eight [Member]",
        "documentation": "Vesting Condition Range Eight"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeElevenMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition Range Eleven",
        "label": "Vesting Condition Range Eleven [Member]",
        "documentation": "Vesting Condition Range Eleven"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeFiveMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition Range Five",
        "label": "Vesting Condition Range Five [Member]",
        "documentation": "Vesting Condition Range Five"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeFourMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition Range Four",
        "label": "Vesting Condition Range Four [Member]",
        "documentation": "Vesting Condition Range Four"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeNineMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition Range Nine",
        "label": "Vesting Condition Range Nine [Member]",
        "documentation": "Vesting Condition Range Nine"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeOneMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition Range One",
        "label": "Vesting Condition Range One [Member]",
        "documentation": "Vesting Condition Range One"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeSevenMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition Range Seven",
        "label": "Vesting Condition Range Seven [Member]",
        "documentation": "Vesting Condition Range Seven"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeSixMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition Range Six",
        "label": "Vesting Condition Range Six [Member]",
        "documentation": "Vesting Condition Range Six"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeTenMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition Range Ten",
        "label": "Vesting Condition Range Ten [Member]",
        "documentation": "Vesting Condition Range Ten"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeThreeMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition Range Three",
        "label": "Vesting Condition Range Three [Member]",
        "documentation": "Vesting Condition Range Three"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeTwelveMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Condition Range Twelve",
        "label": "Vesting Condition Range Twelve [Member]",
        "documentation": "Vesting Condition Range Twelve"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_VestingConditionRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "VestingConditionRangeTwoMember",
     "presentation": [
      "http://aquestive.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition Range Two",
        "label": "Vesting Condition Range Two [Member]",
        "documentation": "Vesting Condition Range Two"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants on common shares outstanding",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705"
     ]
    },
    "aqst_Warrants0.96ExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "Warrants0.96ExercisePriceMember",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, $0.96 Exercise Price",
        "label": "Warrants, $0.96 Exercise Price [Member]",
        "documentation": "Warrants, $0.96 Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_Warrants4.25ExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "Warrants4.25ExercisePriceMember",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, $4.25 Exercise Price",
        "label": "Warrants, $4.25 Exercise Price [Member]",
        "documentation": "Warrants, $4.25 Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "aqst_Warrants5.38ExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "Warrants5.38ExercisePriceMember",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, $5.38 Exercise Price",
        "label": "Warrants, $5.38 Exercise Price [Member]",
        "documentation": "Warrants, $5.38 Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and Rights Note Disclosure [Abstract]",
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "aqst_WarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aquestive.com/20250331",
     "localname": "WarrantsDisclosureTextBlock",
     "presentation": [
      "http://aquestive.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants Disclosure [Text Block]",
        "documentation": "The entire disclosure for warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://aquestive.com/role/WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r886"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted-average number of common shares \u2013 diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aquestive.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://aquestive.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Weighted-average number of common shares \u2013 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r176"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "20A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-20A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001628280-25-024664-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-024664-xbrl.zip
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MBRLYAT(YMSZV0#D/%SDJW#K[)T8?&U_(]H9ON81MV,#P#]2@PQ$>#G1!&Q%
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MYY*[?6*670=+($5"N6T,3=OT?#>% Z*\F88/?R?#T>>KLTAP>J >90W,\0C
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M['OU='UV,>Y[EWJZ:XY8[@2+&3UA-N4U75>V[4RDC4M+LY?^SN2,GFU[TQW
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M8XG4G4@%+[J+$&LV%JP#7XZS-(1]NG?,@,%S\2AWD>!K<J&E\G)2*\S-(X8
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MQ4VT'CQBBEM2DL,+;#6E6$VMOAY?R6VK%<76<MHP7[(I@(M>#BR8VCJ6P/V
M63.2*G^<((,M;)=JJ5NA)V31I$+QS3,O;-/ZN>"[ 5UVVX9#T\?&;%[;-N:V
M-Z'%!KQRD0@S*0E[*"!54@!2<RV0TBBUS6MA9%%8>;-"Z:XODBT*+.]3 1V$
M;3QW-$4)QU_46%PEJS+:("L<?"L@O2C][3TQ=$_=[H"X]%VK8D6@#5_ B.J>
MN'=NU\?TDM^)%=#IA)$](<?BJ2&_+Q'7+44[P%*40DLNRRO:PBY]((V(*[W@
M=&6I'?@#Q\7S<VGM1CQ\H_<N..5W]L 6[$U?M)W--MV8^@Z,5R]-.];2,(Q:
MQ3BJO+(JPC+DP_5^3@KKA!NZ"WS/)S:R;M(=50X-[!O/"Y(#NEIH-9M%3:D7
ME>IR3ZUE.&,7A</2\QXPKB6&<<*U[09C\(V:2K&BX'V%Y0/_=;0LF>QE#.+.
M%"82\:7OQ-4'H5NE*44PZ-4J&W9%=3KL47?N4:4HP6PC"I._4&N\P?07YT8;
MSR(G-,$4Q[(OW&@@3W%R_B/.%(]ZIKB1-IHH"SBAC3,[&VS#JA':Q ([S31*
MIBWI9&3ZQ!('@SN77I_ ]!Y >F-?A@!-&#UL8N%UM5I41%_8DR2B3:77TR$B
M\-,T62TV:Z(N4%8-+8)A$%X>V=14[31-B0][258/U@^_+7+' _4)O,GH$-<&
M>'@S8+X*H9R44<#OUQJUHK(B\>VCL$]S351+DO9H1*4!4=6THKJB>\K1B>H,
M"Q#MTMGR#.O!'$1"SQZ8=/X,3'^<E'DJA59-+C:UY4CG]KR3%&,Y,(O/FOJV
M%>7[4U^549]27:ZEPA?UG7>:7=(&QELFV(2;O%AL%RVZR^\+&KY%T6$2%=NV
ML;\XPNQ%\.-5+>7LQ;W0F9%O(YA8,/&Q4S]386+,!Y658D7-.Q,SH^.3CV4!
MXT/3F3R>F7ET"N!VCT\)*LO9HE0BNNX,X=UC/"6V63W#J(8+4(*!/68-J1_7
M?X %@K//4@3+\T?",[N+7E%1P^#CR/%8G/:"E8@Q7^CG5]/P!S$QSGPQPI(\
M_0KI 4X"?_U7UD&R]:7G(AK6+)$7!%07SM5G?N)JD2O,GJ[4J5:E2J.J5GJR
M3JA"9=)L:#U%UAH&_;>*&3GAEP:3_,L1>::EGDO)CQ+IPP8OB/5*QA[2Y@P<
MAJ9=6D#7(J37 J;?/QA@0D8#,>&XK%#4!3 V=7$4K(EPLQ9IX**4_&DSBD"N
M/:(LP/O=F%B+#/3E$VFM0O][9!HNQD2^]"^TVA'2_Y82Q!G=MG][ZG0?;W[O
M2(^_=A[:]YVGQYO+;E&ZN;U<+Q=X8;K+B5SK3J09(B8JL.#8H=-T"6+1I0,8
M"3)+^N9X'O<[^W!C@^1V IC#\(H2?=,IJC5,#&);@@U&?QG$)Q)A17N\C_SO
MZ\DF@6'ZU%A>ZU;R?DC<9Q!UJ.C#G%FFF:=ZAYD!L!N+C#QZ$?_RV3"]D47&
M%Z;-UL2^]#F:*U)6*#(7K  &M?#Q5)J6Y5"B1H&(Z,W1XS(\^K3\>;U6KFK*
MRD=R>?7GZZ9JEANU2J*9UG]>U5:_(_F:JO7JIIE6N$(Q5L ZI-F,VA!2RE/:
M_FJS>K*IYC:;BG13-MM:?8/I$50SE;[#N($G=4#>&V'ZHZ0IQ2UN(PBR>)\L
M9N(2"4*WG-,,)L2FM>--MTU."FJ5@W'4$;DS]7L[6;#M0UA+:NER_<[79L\H
MY'<^03WE_:!>1$37KC-<5>ZH\Z9; 8(%BX'"_XU'\I8TSH<M&XMU]>"WOG,4
MC-_QN/J$V>^$.;":.0<V"RU%+<HK;F]Q6'CA9$R*'-[KOG0\/PR(T;<1ALV\
MT[K.?3*TE>\T\+F7PB1ZR7PK#4S#H/9%OP1C-@]1"JWOQ [Z(,>"*.#I!:/1
MS.7%^7_.([L\1<,01<%=_Q?',=AI+W5?3)UZ7<?:\F[K1/LH,B:3%VO5O0M9
MBWQR#LEH@W63(AEI6,):V[_[^T')*(>Z)-]7-A^H1UFP%U6  ;:TY8R&NS8;
M/X^[=AM# B%$@5^OIO#LA 9A8JZM%%K5HE;;^T*SN+7)(25M=&W3I*0J4E)3
MX[L?1@[E?[Y]B2ZUX,/GHO1,;>H2B^D!8@Q-V_1\E^6@"2=@5U40 ?>7$+3
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M[[/KU6G!8UE3F^"QS3RV;97.%'A,*;04N5:LK.BAQ1&/G7GSV-DC&,ED79Z
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MI>N%5J.YG%(A0M7<D:"0$%RC)Y&$6++E^140#4X$Q)G'J.]&"'9/HF_4U4U
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MK6'0?VM*(?[2P(UW,"+/M-1S*?E1(GW8X 6Q7LG80\*?@</0M$L+<%\$V5K
M]/L' TR8*6)0W7%9::T+U@8+1\&:"#=KD08N9O?\M!E%]4+K$04-MOFZQ,0@
MX(0OGTAK%?HS)=/Z2C)M__;4Z3[>_-Z1'G_M/+3O.T^/-Y?=HG1S>[F>GWGA
ML<N)/.I.I!## _$&TK7EO'K<;^'#C0VBU0E@#L/[R/]RGVP2&*9/C?5K'1+W
M&80/YHY563%FIHBG(IUEEL&"+3+RZ$7\R^=8B9LV>RW[TN=HKD@/5)>O1#+
MA(\C^=9LENMR'45<9(9%+XZD7QFV\6GY\WH%OE5;^4@N*RL_7S>5(I=KVNI'
MZZ9:_WE5T]);U/LOWV"ZYJGQXNK;#Y---;?95,AG&6UK25BS;3V"5J+2=Q@W
M\*0.R#[C2\_]U)I<QYW;\/F@<[JIM6FK*S)7.<>U*JO5M':\LH3!J4*MDG\N
M6+VWNQ%%.Q6<,LSY?@%_B'H71R*1-"EI,D>:);CJW" O6;VM)'L]M0LEJ[9X
M0A=#ENY_'J1 "E;%58M-;?G.=QX+[ AV.%EV.$J]H*9\FO6">%=O,[7U,5CL
M4L"];H+7;T=Z#S_%WW4,S00LA.RXDK.K2;-3E=<LOI]JF5&-<RJXHB/ O,F"
MJ46)#!U8VE_Q7[8AF<,1,5VDDC,K.[J7V3 O'F=AW+:-]@R05\E#!>3A_C5W
M^3$0!*%L6[(Y(:&HZ#POM\_.AE"X/T7/^P*3%2OD7>^LZSDN.KKLJF56]T%*
M;(UK8=O2O<6*:!G (0EM:AF0#@EQUB7[K.SY69L!S]4-VO,ET_,"5@A6=SSP
M]M"N!^6CPY[]<^LFD*+ G07U7?\Z3*^RGR\1QF"]7<403LP_5;#KBO7JWOPC
M7  .B6I3&_-#$146'BS6ZLN=#(6[(*SQ.W] 7=%1,9W#(0;,6\?&N&D8%N^\
MH3%%5[%EO="JU#@QE(2M?5!!GP:Y8#4YE1-R.:=<@,L!L9]A.M.>/0#Q/!J9
MTY9)>J:UQV'(-L93%M\_*S7XZ!*#,GPZR)1X)D;-%\QJ]<Y1.>Z7.C$OY4"R
MN91X](J&_][8;3VT9,&J92+P80KLQ,9M$\1B45&7#TT2U]@4.C2/.C0A=2T2
MD"IC#D*%EYAG2HIU:U$[<Q$@FJ*$XR\4E=T%R()(;NP7:ON."_ITX5;.>82I
M#BMZ9Z";4-2J,IY.%Y7J<ON"/.:N"2K:.C"U@8J6"44MM)JU?4K=<YC3Q;T%
M>^_2$3$-B88NI#=CS(;>RIF9L(>([RQS0@3U*]JGKDN-R'^/38\V _PJ%M$*
MK8JZ=T166*XG(4YW):)*H:56EXGHZ)[/>1VS1NZ%-")C="K$*6KZ@8'[$+2)
M+=0J6JBKNNR(X]/\4U-BL;HO-=60FM3&WNW:A#6[DY1U [K2FIT)N)^927N0
M"VTK^09A_VT*Y]@4F5QJG7F6F*WJ+,>EOGST*2*V^::XO4*VAZ2X!@KRQHH$
M&&$I'_:"4>C/2"Y]H79P;I;RD:1U#.6'$,BKZ!]O'=?VZ4(G[&$>:69W>;N9
M9A2YT-(:_-_+/9ELP?V/[!J9'=G=;G55>(_3O AD>W1RS3FK)ZA.@>7T[EWG
MQ32H\77\!!BYL2=65'N"C:1&E** $M&*L)?4NIEFWZ1X7XO^? DR07V(0Q&D
M"E:]7-16Q&<X(LAC)W0<EG!6E[K"TV OE;H0(A62 SEP24:F3ZPP]&:8?N"*
M0-L>IQSW9,PJK3PZ;?W/P'0IR$*0?O[XWB*VW[8-["X^PB&KA!S>R=7V2:40
MH3(>:6;#6<9^-(/'PASDPYZ>Y_9>,*[)N51?]M',%6I[GQ#=^1K#>WIG$_MI
MUAA>9NOJOJH@$9YR$-\[7X+;T_O:DN!J>^J1@]/;L4-O63A7DWO@HNC>*9R)
M 2O"Z@U/ZKO.$,L?#1U<@Z/_8*4Z0#6SMB;2*.A9IBY1L//\L>3T^_ Z^[G4
M?OR^^W6T_!Z+)%+&F_RQ" /7@(";J#K*7?_>-5^(3\&^UFEH5R>,1F%6@U+4
M:J)TQRD2E5K)A*@P<4$I-NLGEH*6Y^MI^PGP>>&]\T'8B7.;=@!NZYMOU"C]
M15UG%:,UL6U)0U74S^)*Q@D2E-K(0GRK<J%5EXN*RDN5E[Q'Y,0"CQ73/!T-
M3=^HJYL>Z_@8JFEGA"SH[:N*S\/P3>!,=1&Z=R%P.Q'4C01*6%524\+"A^*0
ME#:=>6TFI66240NM*C<%\\\J2^"!CL)#RDFIV1$X.+HY(I8$_UH!;DFR,-]4
MW-A)-9%@L3;H*K[0"BUQO^;4Z&/+I(%MZ*,"<C-[^LB[-2T6>/(+/+'3ITA$
ML/P/UQD3"V.3/5@8JSI];A7AT]#.Y$_/GXC>:\=]"*%Z-P7J1!K/?+9*)E?W
MD\G"Y\F/S[,KT6SO2]=X\Z7/RCF:D[,^>8.9\91(-#XZE$_T0"WB4^/1>21O
M?YC^8.!8"!9@K76-;999IH[1>@[NB NO*0NO*0T*:A1:C28'%'2>B<VC*,M1
MZHVE_HJL.9';G'[\?TV"Z<1ZV?UZGXI%"^1B;?\6&6>3]GP&Y+A!F!^.'#49
M9+M2K%>6RVBD3(XB,7I[N?_!B$I:?,0S!_8;]NE@Z@ +AK%?, 7K!="Y:\>[
M,[&3MKW$@@R&_W6F8'V@GN^:.IA/^*!M&_,?S(R\AXTXQG)!DNB\J/.FLVXK
M#V"*=?I]JB?.N=&P3$&QT>#@_INPXX\H^3FG2A5\2Z6HJ<L%=;C,!,M968)U
M]]C7: %1FR!ONGXM*B7B2SWZ;-HV^GI.7QHQ5CXS/9]$CFY(K=Y+CB86BQH3
MBU71!O$D24W=$#PX+JU56/VJ1OW$>BCF5VY3K.B\3F(?,"#''93^=J#-GXXD
MT7@2)-5"J]8HUJI[]XS+0V!2\*'@PQD^Y(H1:X56LUI45U2DY(T1(UT?KR"&
M?X7=D3ER_86976JP%<,)>A:=WV96I2&2+.T<S*=N,!I9[.HAL23#]'3+\; :
M'YI-S*+J6\ZK9-HAWP#AB\A&+B,;H]ET(1,$+N!XJ<3'WLXD=WO?7M^NVN+I
M:-7-;;*<(7W$++)[8AJW-'GXN8X-,*KJWGVQ^ FS"&XX56[8W.9K7VY@[6#D
M%:E^YQ$(8E>=,]%U>!L)F]$ZNHFY=M*KZ0_6%$K!8_Q)I\7[A4Z+<Y>U]\XP
MS[$D6+7%TY$$[]VX8+34GI 29FS>,T+J,#JZB\AH0Q/ =W/HM?2*PO!S-T-P
MRZERRWM737;GEB6NJ&!C(&5OW<G7K9+3TIU8)3(%_2DLZ9Q+A(3ZL^T_#NAW
MXOZ@_L["0<$;$)S8U<++%+R1EK9,SAM;FYD5E;?:@WF_L\_) C_Y2 FQNITI
ME#:#"9UBM/?X_**RXP5*):+C351BC]'GMAT?9O<=R1]0Y!<#6V\;\64J8L$"
M@2%8J+H\;TS,["YZ144MUZNPC)'CF>QHPL4+=N8+_?QJ&OX@9MF9+X8$>"%/
MOT)ZGF,%_OJO\ +)QH)I-?,35XN<;O9TI4ZU*E4:5;72DW5"%2J39D/K*;+6
M,.B_,4,I^M)@<E0X(L^TU',I^5$B?=C@!;%>R=A#(IN!P]"T2PMP7P396L#T
M^P<#3"AS0,XZ;G@\Q4KCXBA8$^%F+=+ 1:7PTV84U0NM1V1J/("[1'W"[I20
MUBKTOT>FX6),9##_0BVKU2,42UQJ+\ HM_W;4Z?[>/-[1WK\M?/0ON\\/=Y<
M=HO2S>WE>A;GA>UN8WEU.9%5UQ-9U9W(*N[W\>'))H%A@JU11+_-'S@!3&=X
M18F^Z113$? *,DND&U$W^FOFV/?CT@ZSV<>"N9)0_F%D81E'0^(^@W2+E$,-
MUA%]@ED"M7EK^S^!YYO]<4:LA-0H*>40",L_(^OT-AC"]/JRJS9_S''G/A/;
M_(NA%ZB;Y:*P/]JV<>]2#W,"\,])L2]B30G^:I(J *.[ !FS#X:>[4=&*JCZ
M>YA/-ZGW"$OX:CGZCZDYJH6FLFD'U&C[T6>X0 JFZPBYQ@TH!B28V2#=@1GY
M8@($D3J_$L]DV0FS2XRMVFCG"\(2GD6O8X.GR\!7KEB(6GB?/ Z'?#;C!;9&
M-/4MR.%#^Z.T"*2UDFB9RI?)>DYI: ?=ZKM<WOXSP.Y!+U0"G\@%D@C C0!9
M=6/K90G03Z01"*@AT=D#D,21A2D1XR6ZE#^D!I"?'0KOGAM^1/ .1S^P)'.(
M5_D9*>/S$1 &4C5SDNJ?)0M>#5\<@.OS/  Q:#LOS+ $UPK&Z:&<-"@.<\>2
M3_6!#9!Y!FHOXXHG2(&E&O2%6LX(W[^P9EB!$>@^6V T%]N'1=^DH6-1/;!F
M%D$L4!YVN IB@#5F>GYH9K )3/L%&.,E7)EI U6_4!OWA :U;1#7"#-Z0*K[
M#*2KUCJ%'HE7)XW,$44$A75F8+P/EJ(?5^7T8'>H-BR+ G7I$CS3H]+'TPJ=
MQ":CP=@B;R9\'+8NP(G:X<=# 'JEH7Z&B8E!F8PJAKL T+0-E]H$WN'1>!@%
M6-+1P,4UX2+=X'FZ2'"1?-19\UL;$$]:Z[E'&WTWLG5S>SWGOD=-[;&.+-IH
M.">Z\)? 10Y((!!#/>K>]>']0ZPL"SSV%P69&N)[SG$'#M'Q0/G5<0T09Q/G
M79Y*2[#9^T[@+GGN0*5Z:)'H<^^9$M;KP-2!<@!!0Q97" M7(%RCKP)],6.
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MS(1R9B7OX9AW'B+'9EXPR16U*"O+U1V.QKR; )"4><%LUNK+B99A'"/D!Q;
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MN&H5UMR\NM(H7_"X)M2,?V =D_!:4EK[78P_;-[LT\R"KN+U)(9 E?GA*P"
MX7,)D_#C4[ YEIX'@AOV'0E'L>2ID,SGI0/(S8 %CX%8^I0YKV"']#%'8.K"
MAFZK[^#!)KPC&6S7A-!W=%YK-2R2MH+=5P1N0#><A("?P7EQ*6R+9RAH.LZV
M(Y^C"K#>_A&U)B_.',BLU!4L8$6FKX-YDRJ$>G8* ;SY:K59;,C+K136F.E%
MEM\TL]O]Q&8]2[&)1T=%K;9<"+QX,+&Y9K^IB<WE3>)!4'49O3O+Q:3\<US1
MN8&>$HK.NHR-;Y9%YWY6<$8YT1\N/ZY+"EY( MX^-9K-=]=?2&8>AS^7$YKK
M*_*(Z\IR0G->U0[Z57.WN%@!,7.XX0*7](JYH2.7CD@80<3Q*,M8L!B]099U
M^$N[?<_XA'W4QAN#%I44&?'Y0)]9' +%=.E_I\7+X-W3-\(+P/^&=3'F9UZ.
MR8+4D<?I "^[F#%8E'3J8CAH]F8#>W7?<7R\FC97 L_&(98UCE)9PRT0VPZ0
MN5?M=W:K""_7F"YCNM4!P=0(2NT9\,&^G"&Z8F&^I;?I;AR&'#"@U$-#G\2P
M_4]@+[C:BY&'Z [(ZCD7KA@MIM0OI-&?_8V\YOH;>>)R7?XOUZVY-<+D^GMW
M2C;='LE"<ZXF8!1\L0T4WLN-<_S[)MH,TI@2-XJZ78&QAE;ZW E894XRKI(W
M[5!:/C )/4DM4^32/Z.$M(FDBI+$9H[9JE&$[P,^QAE5^3-[Z?I)V2CE\\>R
MU/:F:P/KBYH3DRT6JU^CD\SN@/[_[+UK<]M(DB[\5Q#:G;-V!,7FG90]H0BU
MV^[QK&WYM=P[L>?+&R!1%#$& 38NDMF__N2EJE @ )*0*/$B;)S3TTV10%56
MWNO)3'#U.6@LVR6BVT+*IO"U"=K#=9J4GT:W"@Y\2':)[IL6KH_< G^$TP/5
MP+=58&3 9T5FX)^_FJ"?')&[&O@>MEV1Q@C3.N!JTJ5L^H/7UD0ZUI3O080-
MPL(IHK&FMANB9=)^D?)K^3*"\V+2IG*C_,@P48J(G%S-. $;+!3(I(?)<65R
M0T%0?*H3XVL]HB6L[,X-D@C-+$5^Q4_#-#T[#_J^$%UN/\YL+5_V(>YL+R$.
MCY)Q)/Y,* =\IUNAIO9>5]K@P_'4B# */BAI5H$ IY%2OO*QO& *G,6X:Z*"
M+HJU%^!J34BCWB8N>SOT;5WB+Z$#,1<N&?X>DC_QM>*XNGE'CMC5S1](ZP]7
M-[\V\_Y(UO\H]DBVK 3M;E4)NL\ZS\Z.ZCPK5F<..P7!3"<?S-PD<RH^@=,R
MWF"EK[#4.QY4G<FO+%C(T51G8GYCA2!AX,._3XIJQBL=*:S9.,K,4S=$J@6E
MM\."TMMC55<?5E$-#0*\V^D9+#+4(D"YM#L2K8ZJAROAG& 1IY_KXK5(&0,$
MR +;9R#O;.[_\"':C#CQ<X^I)#0S211A];WYK+'P7'$G03+T%Q?^,"$H?$CL
MDYI%5<<IOXP+Q_OK)3@OZ>LU+($LN&TARBY$NZ2>Z\MZ&V6O5-B%$:CA$ 0+
MH8I+";E#M$ #>X3%59ODT+J2!UT*]'IS$J8<?- O6//,!54=6=U!["Y9#(TO
M_N6\-6SH;,!A'.*-N*7K^V\JUV.]^@[>],3JC%JOWU@?TWIN<CWX:^28J%_^
M9F1VGGAOZSTJ3>3#HO!PGT11J,$0^TSB"6%(I%I/@M!R^4I:4K[R)PXC;:P.
MO/6$3 C2Z4=\^@3ODY!$B_)_'/"0GN=P4L4^@4]8H'F 9=/"UM,PY),HQ^\2
M_@>X"=1CE)J(R<P56G?B50/8![P, #7\0U#) VR+:GY1UP9).)$W!! 7H;V
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MK\LOO>>,'B:T;=E4!T7%S&^G(7BGT\(0_,WJMX$S5M=@R0<;WM<>\^-X:ME
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MGTR0>M%)O(#@*!HX;F-!S)V0)3/JQ[K/M <2@/^*,C"Q?81UC.G2%86Z4;B
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M+1CA4-@_SNTI+/:-[=W;RPA#,5,Z0#16:+BZ_=)-3J=/MDD62$=, D:!O$E
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M(GP?,LI$9 R8YJ22+?$NHIA2J_!R6)(B7HB4X&UQ-D?N2Q]*;HU ((A+P/S
M*="5#R<M OH9D@9W1A$!;3T(?YRJ8OR<!FU,O 1,IPZR]JH?B2/:;]GL*S4
M_PK'!1;?X7IE'6=FHD]P+;P$;S]A*RAV$?@@P @34VI!^R%P^U:*GHNG#HH+
M&!L<["DLQ]$_4T(5)>-_HS<5( /"S^3?X9M_)C:EL"3V&]-CZ/;@SYK6E7J5
MMP1KS,[8(G"EZ@6:D7++/2,4?R9N*-G0AO/1>JVAR>$+4N4J'0PZ@W1Z9!')
M\+6@!4^4=3\9R8%O,CG ":!]LJW0?*N2%SIK@F>HO$)4CI25#MC#)OM#"0Q#
MUR*CJ*<@XRN+0)R/FIVSI64:D[S?N;U$QULZP5H3<N!(-H3?@/]FAR$ZY+B,
MIO5QFK5(:,\Q:B1'W@<)D>LP%XF6,4ABE,H[-T*CAW[&QH6"F<@88[PORVX=
M?R[@:W>NN&>_P#"0(.#3Q"=ILSWUJZP)C%' -.VC#(7U#F?XV D)';S"(D !
M;C=!6VVL!YV0]*\<C)E?:%H?"I<D3\0)+#^(E7C#]T):BIG$@I\SQ0+_-J"3
M@4?=@2\F5HG5R!V202+:BXHL2K=CRR""/2QM5/$9Y(T9W)NFTI1R07UF9[59
MJB=ER@]6("!<8].*9AS> =^/F$[1<C[&O&Q*)>(>4LWP('0]8Q>(>&=[H/!(
M]<*+X#'_E@1F?VR#*%#TR0]FOR1#PTV;#.XDKR #D>MATN\V%%)F;I*)6HGY
M]I+W9C*3G% MS*'"\3B.*WG)9!/MZ6A^@?C7Q;LL3*XSM^&.E-O#CKA)""?1
M_*&V@UML6E]E1A1I(,C<<L0NO4'.",!?;;R,6>H%W*-?*^P0]1NKNPPK:<=^
M+4')R<]SSOH3QK?-17PTQFZM$?F6S76C6"-^8$Y&?H64Y#MP0HJ4NG+A-%OF
MLNUIFIVHIK@<V&P<<0I]J5DFH3Y;6F19@CW, -ECOK4#*11AC']U,5_#2R=%
MI>R;SI;)]QJW S/[3@!#P@ZTK)&!<LFA ^DXD?,LB*GMT"6C2T8T?Q7!GNY"
MT-JM9!'(NPN*0)$%)FXX2>:H'E$#1!"](^9.27/^@4WK<_XEJ0\"-LD_YY,"
M,<*[M@B5&5O:5.?(N_3T\:_<)_:V*GJ%S;T&+4U*MWWY[<J:NH3J0+TU1NG
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M,Q&)E;=M=CJ4WZ)])Y4RX5H3T[7)?84#>A0>]/=^M3U:T\U,")3]*W(E/V.
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M=SW/\@-@E\DD"1L682@%+RZ!XP\1XA43KBF8N+0%B604)21F1!<HRCOA,%%
M^TT23T\XC@)-.2"-&XLY_N#/Q(5?F?@7H,3<_B$,;M$,Q.R/,)J&":YAYI6?
MI]!+$PGI20BCQ@4Q3>? QF,@%:R,@5#R?!CM(Q$V.03.0H7@$6\:\5V\0-N"
MKX:Q"+TE(WM6T"$E*IE[V!5TMNL<+VPC2N<R ^<F<U@[D1 9\ XA7L1/$FE,
MF-P2A.J;/,"FM#/G6LVN^V>6GT+G^9$@H^:H^Y!^><.+G8$N!OWUH(OM/^]>
M5/O%VD5=U$B0H\8_U$B0&@FR-1*D1H'4U]$'T6Q@V"UL-G" U]$UT*.6K">0
MK-&&25F[S^WUC@I?]1*Z@.A+YKI?7KF<;!C:6O6B'AM)]FM,QRERRH:"]JJ<
M,CB['+8/A%->0@NYKYQ(CZQ?9(51W3;N$7IQ._\!_BT $KBB4 *&9Y?M_"#A
MNH'<D7/.IN;H.^"<T=EE)]\GX]!:R1TA'.Y8L<YY.-R#4E%UQZQG(<UA:[N#
MZ*XZO"CLKGI<#;+JYG:UJ!Z.J#Y5KGG4VD6N^:!ZV>5NY_<!1SB-R;? 0F$"
M+"<G_ZX"M C?DD*]4IB7Q(1-L9^. C@Y;H@PBRS.:75^%7=),M]:BA<KAX!E
M8#<2,[:Z'M62QW.YWX^KN]G@R^$[8W;*(DN-5)7XJ!7P#:.MJ#79QFF*>F_P
M?=WZB5J<56J1,WHJLSUJ%YKMZOT'1T^FK3IGEX-6?M#-:K_ THYRC0=L9K<=
MB8S-%%_S/6"%NVU59*RP!^0>Y#/"Q>16&L]45*6FXKDT6'%_R:*E/M>*FM:-
M$!9.GK7:W48AU?8'9+Z2ZNF]5$][)50]#WO]/.S^"H'J>=@O9![VL99)P(Y1
M8D(-R/YL_QN[E:I^D"?A,^O=<%-0"5 'G3JGS1K-+Q'MCGZA0LR+GQ,AG,AJ
MM_Y&SC$VKM9_1%\XK9)%M'R0Q%$,S@+"UXQVGMIQY<>M/LUHR/M!/C(&]A76
M''8VBS #"3_*MAUL6!^IOR=\'YV3?RRQ,RDZ ;(O'KK4"_"*?Q):WEM:I=Z+
MGZ QSCDPF<8>G8)^U2G;?'.C'U]%B!^ 9FMKK^6\D[HM?7!;\G[LWVCQ59=V
ML=NE@>BV"Y;6R!UXUL=J6E?E+FW!X<C#QY[-<,#( GC($<127(VQB7>X0F5'
MQWO1VBT-08GV\U=O#SK>B_9NEU;<2,80P'A=D)@]\4WBN=HR7;/!AK-7&H7(
M=8@^^QK&VZ,[6I6S.KOEK(NSRU$!9QWD >:4F5)?)=W^]WFLSZ$]J[).=Z>L
M<X$IWCQ8YV'ZLK?;I;4+410/TI?;1(M;%C"/SK;R09_+RRXK["#^I43"H,D2
ME?]GM>[/[["V;!QP>_JK,,1&QX@[^LV-)EX0)6%!FV=4=*MU@Q<=?':V^?-G
M&]O'PY%>W8(]FW/DLUIVOD6E(C^[X(V;*A7W$ 85']F[8 [[G2 MWO]<> '\
MD#:H"<.%B4HQG414]!&VE]S"FD#CMT;9;OR41*$<NBQ!UBKYDSO!-)1!F5=$
MFB@91^+/!#\ _O4=XJ;73+9O8O+#C6/K5^'#O\!RK:\S.YS;$Y'0[5&$GM*D
MB1<+U)X>BSVI/%FI?.RECVN!-<%RQTN]'"ED7Y,P2FPN$UZ_VNPV;?S8X>)B
M/YF"KL-V_JKEOY>^AY#HP[>Z-IF1?VAX;I)Q\#/PQ9,8S$&SOTT:))];0P5X
MWFT6%)MBV31G:X!TP][;?1KZ!A4!CW$H!XZIF+K>G H$9'UXPP(YFL&Y8[C.
M!@>LO"LGXOP!9A'.C@9T1'+F!3@)7A+IB1D5IL8<L)S^00./*.P0X5RW2=B6
MQUW-M#E&5[R+TH5C2$*'0$\DL^HV[O<@P.!&_0C]JZ_D%$QH^H;OV*&C[PCA
M"53JS5*H)F\8$U/2&4R1H!% =+Z9?@Y_ BM@);BM;5*Y9LHH9?!H'9Z^87MX
M!;*&",$8.QE85U\_LOY0F1R3.$!F31^^* 5]0/TVTA=^7Z\9)0&HV!TGI,R3
M.5#!1UY/O=<_47'AALT74A^"E0T$("BW:NC3%%LUL%,KFR7H=<!?99%]Y@E$
M*UO/+\'7N?&*0H.78A^'(-&C8?!MQ,RPX""YG8$$TE-Q.-/&_>M:?Y[UQ(U'
M#.U-E?^^TL+) OM>)!!&VW2CBQP&KC_YO_"/V/6L?\+Y8,< 8_8&G7,H*)'>
M8+H!K4"K_%MV$) $-Z>PZ-81QMR(U770ZU'X?]*4&UNREN+ME74J!M('2/8#
MJ&?D '*"^$-8LJ>&%8'8>,AGM[#7A?;0]2BOA0*;QR[_&I.4W/@"!\,(ZY5M
MC$C#U4BI*C^=UUJ;2H7R1_.FV2B@W-S^R9RK>JL UWGNW#7&CWGN5#]&R?'"
MIE1Z\S1@%QLX'7U?&G_%N63D4=5RA*2=)B39LK.+@BHT)%8!5>9JWPL;)1S_
M@&<YMOT?8;*(L=T(CF(*%Q@/(+M$=#%&MI)&/@$SN([.Y>-QH-=$0Y1P'?!N
M8*X8(1HA92/P#8IG&[*-SWP.CY5/ +VE8@2\L)K,-EL?%'#A4F2(L^V6JVI9
M_Q+;K"C"B$T/=?FU'WZ[HCP[/=Y&$9M0G!^*6W0: J"[G<2S($2%"E&Q9X<B
M8S^T(S?/F#3PGPA-X@>6%X!*"+'A4)2X>N;36O-@N($HY>E#]!.X@Y'Q>X?&
M5^$X* $"/K-H1MY4T-0^G#TEH2]@-&)7,M 6I$?G>6UX>='/#&&53] /^ ZO
MR=1H@KA,WCA)> ^6/1)^&F%VSRXC3"3QE+[5J)'M)$WFP< *G KN.04'3?LR
M]/7:_<!9!MB99X*L Y3QJ:6.[%V$C@2Z>E4V?*4>^ V?97M?Z>KF>JI?N=WN
M>V>7<-;GN/?<UODVZ$1\S_?3J1Q!9\Z^ZI#Y[:[$4J \TGQW:?QXI8+#S;':
MBG^1_A+9//,&?1-'DTB7:)TA)B(AI6!4S:8S."N2K8FB-]8K]S6WV-+?,\4M
M_0W[(#)F;@^(" /:=^J"2".L-+=F8&9>*<E$RJTY>/ 4'-S?S,&P7_ O#,=2
M3D%%!1<;W<DD S30>_0$NI;QO?#N]/V(GJ_*K<P6;I@Q4#'>N:IH ZE#%V^Y
MP-NEFWGJ3D9S1F'S&6>%'FZ'X'.%&7-+.%4=-,EIJW*(;.9X&RI D<>G77 S
M!R3[HQ7H)3YN?YDY:*.;"7-',0D\(EK ?]&.E.SFIQPIBPJ8] #<]:+SEC;S
MR@7.)J]61678[&U*7.I.:%6X9>F8,V>R<F7G52]AFU<^3N$=3":PP*BB:W:3
M^, 8<&2%F:N3T/77$! #7W@<7:%^*XV[;?#XF4QVEDSOEKZ]B"!\1"-O+XA*
M$2?W7O&(U^WR>XK<K_%& 1A6QDQV)*,L>1@%J8^%D0KD-^IO<]1/S1[33%'#
M MWH.?<8"*E-O=)=#4E[4!^Z9'PN__R:)DW+P*W0O38=>QK+JD1-S@M5$LW2
M1WI-^K(QQP5<JX@_ H43A#(W%JDP@_ZR".80",Q@0]K\4<=+-<$ZF$XML7"C
MP.$ ]ZL=_H ()?"U2H7P05 (*Z<P-U-2)1'=M+E12?P %'# _?."!241S,4H
MG?'?__OE\_6O']5H7SQWNCF^0R3W,O7F?7 JEE:'0_H6VGQ7?9,NF]S;6V(\
MM3:]?)D/T9.G(2(%QE3:#"A0";%[L0&Q*UNN?@#'MFA8^_N?\L"O>.:O\]W^
M675B.UCZRUX#A+P W8O1@FQ\JJQ<, 77Q7[-K2G=$"?BVDNC#:QEW]FNIV;G
M4J_0!2NOI<H.9'*H;S$(>37FG#WE)'XJ$PX/Q;/2IY*U4.K,>/ O'C1?"3*L
M'P,EL8AEJ[,6'S.Q/G[31.LK:::TEIYAKCK=*A[/^!:,O5@=O]HZD:1#ZGVS
MWRU]SM:&NYH/Q S:768W>N7#A_O0Y<HWYU2G6M!@MO^&_W:".:>,8?D<RQ/T
M';,F[ AZFD7?_R$5"!L-Y$TGM.\CKF"9\[FK7Z>_H8QCNH/5(=41Z(UH:F>Z
M^^KAS4KIJ"]G%0U6N+#?ZH:.!:<.)HMRQ(DP_*1U)HK<LFS @9&Q=!%7C-9,
MVCQMB;(IDS6G0;-O Q_DQQ4T"Q=C\HRHU&CN]6CN08WF/HRU/"N:FW +16B&
M[E9]EY\IK%G+N0CA0EV1P0R/2/. ZID'#BQ-J1ZAC0RH:T'E>JR.I%IDUV+E
M^DJ99U1ZI%>T'LHF!<@#6KFV:>%WC$@#[1E'JW>K:RO,F[.W1X6#A9G=>QNS
M%/HZHK+>E$8$'8^8LP#2E26;B>'_1*-%J)<Z>+,K.Y0>T9J74"I!\9C,+.D5
M.F8(5'0Y6TH;G>@H] '6K$<M);)>4<=R:5'/Q\MS95SI2OVU6FLND8&ABI&1
ME\&2O@=2V:35'$TFH5&R)QGV")EH<_VF]0=>TIE?E_M>9W=QA3(=1!%G46!S
M&]J^O-@R65H%.^J&1)^^&?J<\[VBGL) 9TPM^>,5L3@1__3:MZXG<8#N!&:#
M\ZXI.8X2L[F&^3">]FQ8PM),TOW7:G+!N!Y3X7>F[G<C VA  F;MGLKMDOE@
MQ6D$6]$.9"X1&8I;.]1N(&PG$A.ZT*,?SFU*>Y+@RQ^N:KOR[&#Y&D^$_3[Z
M*\,F3)4?%8KR=@ZZR<)I*'M[BX<5"^,R'O&P>';5,@T;9N:JX2Z5TP?@^W0Z
MA?D#4F%T^58 94@68,']^.&9DPTS3A^\G]'99;\D'6*>$(HJO#I0 V,(R:'.
MJNIFP!U_HMU<8)E1\>FXQ,B^4%-8$$ZIX3?FU3:H!&F)Z*1T\!D5)G3H^^\3
M-&W6*_PK*HU.Z^U'>:G\6<>NJI<A?:']]C7;2J =:\69C8@Z(?Q4&C1#_4OY
M(Y_A0;'[URIN]I4CIF2ZQ[#L^]?9G -\\POH+0Y(I7/($27?5RC'"T[8$=$D
M=,><*9(:%.R#O9CQDW-XK_067B"^RN-%RPU0YD'+\58Z\S2N-[XJW!+R!L[(
M6KWH0.F9(O9$2@^$$'8\6QWU?*06XSK/;QMR:25<3:12I %OM!BB6?SC[!LC
MQ !RJ$8/4Y+GQE$&0I0ZKHJ%.09SI9RGB2C-UMMFI#1DR["4VK\H2.TWE%R2
M.1$_&46G$X@(2TO'(O&ZRVRJG[,^%$UJ8E17WR5]RNGN_"NB3X4381(?>?]Z
M^H$N9)1._R+BBFH=V.SLLM<J5NN<X=3V%L.,!YK8]=M*\55/L4&L!RK9H,2$
MTMG:DYD+;U';,S,'DC&S0]%FF6L"TV3+>X3J-"II,?MD1]\!_V0#90J*@PV1
M+-8/IW&;_,>&739,N>#LPZU(]0#IT&2!*FF'DO).O\=<E%Z3=HBD/U29([IG
ME\-BEU4.E5.H/U,;$MZX0(32>VF5;4MK[M(<A!7C/$;*-M"MG;V"W)Z&L'UU
M"3L)$@\]RBCQ.,]%!7V+ $-(E],@W.^@NO"5=.E],N'K@5KJ%-.:S-(_$S!8
MC%+3EL_V_0#G&#H2)QZ#%G*LN\ #?6.'( /Z>LG7KJ=&,B(\FD[@G>W;C@L2
M!>+X RC_EK-2"*S/FCG/_2'HF1(U9/J>:M;E>ADH415V&LBGC8L&A]:XZ$;Z
M 7S6ECSLO186HXLR34(2(4?$MNM%EA8^RG,JX-Y3J>>#"00RV;?O.KGU[M,5
M.[?_5]R%=@;&(XOT7J&@TBS+_Q9S0D.]/@F#]=%7Z-96N[,.^^2OYB695)D<
MH6T9=;LRF9?WNS//E9@8$T[+#W85+@L6UDYC#0AQS?RWG98&Y],CF4PFI1XG
M+B8.N?"%7X9Q!]>2D'+D=Z/5@M>AULI"NF7^6^;=0N,F?VY*#8C_?W\][[6I
M5(?^==3#!RRP^""R6-#<D-]!%\E1T[J"1]S*\"'S-&-6K1SQ.PLB888ON(QQ
M$L'A1A@^S<>2/)@@ 3U_A^+-.^-,OG%&6+RN[&Q*RZB1UAMD7D_D8*N:DBH4
M?"G =%04BT2ZY<8**$)A=:[^BL $+9^FN]N)EY&>B$9F_:"@@C=<@+R2<OB'
MC?U<R4*]_XG-5VV,U'NCSEOKU3?72_X*P.9>(V#P@^O-7],7KS[=6-\U,A D
M_AWXB?9)Z.SOZU(WDE:%%,3*8R0#RJ:J99MHMRV*TS'C-S/A_X40]9LXF/P
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M!^K-.^H23]O5I,FON5"+H'H25K$QJW&QZW&QPQH7>QAK>6Y<[/$@8,O]42!
MN:YH6JNMI$H45Z%;6M$I+1G)\&0I\\'99;?1+_8]S:PRJ$,#A-9(G;M@PN49
MC$93YDW7310T]2FAGD1&2A\NS8&7>*U@N:;@KT8S[.9 X<&]0 NUVL4!IY!D
MJH?H _.6,E][6V*Y3L)%6JT?Z@P+"_<-D&8A-61ILC*CX$XO^()?6UCE;RCG
M)R-CZ DA.%&:]4C?#],%5X.-;UHE1%UHZ(Z%HXY<O)A9HP(X%[@28WK; A&"
MJHE'),0/+IXL[!RBRML4 ISVC)21&W61^]@GE'5KUB?$*N$R0G@>Q,E3_%]:
M]U4$"_EJ$^ TKU8R\7;)CDI"7Y#<<U#[8 5H P_'%)1,47DR_8/XQ.+8ES*E
M)A4*$'%\(DHQK:/<R85XJW%=%&$R-K#^$7@H-Z=4A+[:<$3CRW5\MA:NI4F3
M45Y*+=TLX6=_V7Z=9'_ W>FKB1>,@7H0:NHDHU;\V%W-YW/+Q)PZJ+2C*)BX
M=$U#//Q)^'[P$V/AUNCM[W84VPD8^*7O@":@:RE5E(YQ*&C@^X [#5&ER:WL
M!NF!22A-8N99(<L[!CQ<?W538P")RRN.W*D;J.2PS%-+8F;]]^+2S0)L7'45
MOZ&HW=3RZ85E$%;/:X[.+B_*P1C*Q3,3R0]/YNZ]4K_7NCB[')3@?%9=6+,S
M+G*%(H#14A8(L8BYW9ILK</U5)QP3F]>OWZ_7E\&8K:18,#*#3=O^Q(TK?;@
ME_Z@W>@/NXU,WY>5B^>5-G[&,L0*A"\%@\.'&Q?.KW2=\J=C&EKK>W95.TWK
M ^,U&F;/G@VBG0DOTBPW+4?_M@"NJF]CUX<,^==GZ<+%""O]4@+_]IRD7W86
MMDML>D:+K,]%NH7)JU1KK8V!S>W2G8))LX*PJIAXFPD6)9-9;L^G[J%]!BN1
MC-UHYEK?(9(9*T<U#11.QF'#6QU9_ KRVE[M"9<!W.5O0,M2YY^_?[W23%8
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M/LN/LOC@8I4LGMQ'/X*/.'E([E'[K87OLNAEUF?@F"1\^+ +^?:"-6T:=G'
M2OR=% 6(TH3N\*RG,,M1S3C3F7$Q-CH*24C. 74%P.Y24Z0Q =^:3&\&P;E8
MNL<5@*EBXX(A;IU-EN&>@.EC(RJ0(1"MR*+VX:Z3:6%HZR4NK5=D1[!U-C[R
MM2X1A!4BT!%[J%ESD&@(1# E"0$DMCAG_'8:PZI7I<_EON T)!TKQE/\'RPU
MOL>"2/D,C:FDR@5^^SSE-%DKB1PHD8QB,O-=U/FRU5J@OF[0$10JUL]@^VV\
M_,5G)AR$!F-2^IC^<_U%$JL2,#_WS<3/?5?*;RHQ):<^L>&$\=C,LV78)74S
MGGCP0RXT(&@)BS$7:%)79%D%1!VA. #&J6D>WFYK>V@\>086#=/4RT9:>9J6
M$6$&8&5ZH[$S98JHDZ8;F=\R*?"F@LNUP* 5G'9/3.,WG>'>9)-J<@=[S/UD
M*=''1!6XOGB*5ILU;.>M=9V>Q9])0/W?41093<")(5DNP=WI4>.1!R:9SQ [
MG/M>G]-.SZE3=$[R@$C_HF3IJ0A2I2#.2IYED#O$<8(]8\(PH(P1>\%2%X*N
ML^L#W.T!=O4!_I%7Z.D18F# 5GJ,.-8X)D0HEL++LY&@F66#XW(:&L&=@.>!
M(["=+:IQ+(1!0"PB$:>@O-E@S$4\"QR@Q*VJ.8[ W'AV:%BSTXAI,=1#ZT=]
MJ-38"^T 2>?B78#K1)'YE8<,(E18Z;?OZV;D+>!1Z,T8Y7RR_34KPX8J1L)8
M:*GMFRT'P0LY"+XA^T'(]KAZAF@ZGE,65Z0VUAA]0JFO&>R(LU+P]2244VBX
M9*'8*SB= UZ]![BGJ@\NL5>A(:A ,:-KAJCH2A+O APQ1CBJ2J;RD=!'4W:P
M, )E7Z?B8,=V*],H)I?G_@U>DP8['V7WY&]P[A3S.^F@QX(YC[TVUG5WFOV"
M28\8YD7JUD)W:^VTVA>K\W"_4_V-IAP%Y<1H3LIH2H$9CBJQI9R\E/I_F/A0
M';2P!2G68_)8+V28A2"NL:CMYCE-%B%6M]V(+F'@!$+=<!:I3>?*+Z$V3^02
M1K'.T=T*'_Q-2E=,,"< /[[3_CGK.OVL/WR7&MG=Z(%7\(>O83 5-"D%)RCJ
MI:CI6)ROD D_W[H))JY@^9+?I7GDTF_57\,#=>.$>V]@6,8.]E><DC:QKE@O
MV+)52WOX5GVDD,!IB/%[ DY6P_B EHQ55G!TY_\0$&\I$7C_9X*B?X-!'?O^
M'Z,H86KB=T#=T"/,<M/^816;-JQ_22X\F )3U^=+):*]+[6JDI73T*-&4K&S
MVH"'& CD\AR1*BOZ54_/X@K_4L7(B*^\8LQTG&IE@"LW])/K*4[T#'PJVGDO
M2R6^!ZK[31C]NOP:B@^T,L4XVUT"ME(-VI'MNHLO GGMC+?$I<@"(H(TF1_\
M:V]T^1[\*A1%G%^7QE\>3)+NV>6H,2KKBE%"DA++:J@CW;4H'50KIQ2J/H#Z
M8)_,*-6@\/6@\%$-"C^,M3PG*/R!>>\]\6CM5^[*KZP]P=H3S T/DH/1BC#F
M.:#F)Q%CU]T5W 3^Y?U/O.LG5,4_*/1.$4ES.?NFT)6LZBRU6X7.DBX)QMN-
MZZGDI>OP&V[V&IP%%%581&77J">[F1:[1G*/Q1Y2'CZ^2KY&">E6K^C5S;R:
M;9;_!=_$"?Y<F-T(WZN[=>VQ$J2^V*=C<Z0;N>=_"PM8"_O[*D)R63><6V>K
M<Y/;%%\QY:W_&,F_1NVB\^J?7;::%X/\4>%,8MKUZJ;Y$%0N3Y.0KSGE ><(
M82)%\J?JEK0XSI^;2#\I?$]A>":Y*?\T'&BW)F!;;;%;6?;:U67O"R7)KJ=I
M6/ .F!,#E]7CK"R: RQ,&&Z.6C)4>3@#MY^'@;'<HCDHV)!FX#J!5SM:M:-U
M=(Z6;F&L7:V2<BG4\N;L@*H7$.W.4UY C,XNV]WR"XC\=&'\;Y*$?\@KF9Q7
M^4W6?9)6-)-%#J/-2>SSY&.L"8]^E>/"S?>4HT8R%[;=+1CGO#W:&^>DE_+[
MOMINMYLMNN>W+;#C='DI#T[!JBIS:K>04RGSF673=W#Z/JB#[_1BR3 ;.!5;
M]S?SAO1OQ)65E]I[PJ5V6FCTBY:*A1D\NRDM$,CT_+GR[<5LZ<UU:Q&Q@$-<
MS$+XYVN<;X^3+A*SPX@M)T4;'F )]K/=?_@VMYU)W^NTSRZ)XS;-I&= F:K[
M4/MF8.,M%KEYC&KD"_:'(ED.71V,#T<=M!CJ<AS:H-,ITP;K;FSVH@RZ#U8&
M1J,A+#PMZS-DS +30VFM5^W7Z\2,1KUU7A^$QN@]2&-HXIQ(FP@. I7O9%ZQ
M/44X2&.^J=F'[=NWLN$(T&-.(VMD[ROSA6; B-A"[O A!P"F#]&ED/].'-V[
M525C)/PM;57"NAU[=D_L*(ZXO,>5@W%,"+8!XI9>=*F3>4]C:KAHQ-Q !&=.
M8\?@&05X[-66L J!9R&PLJ%I0VU0QBD\FVOK)A# IGWRTN^F0Q3DS/&<G9<]
MB34KIW%F[] ZB7_"XDF4:@OUP,%$FWA0">4/=ED0U-NJ(&B?%4"C'54 ?<39
MQ-AY):T RA< =?KY8IM./U\ I!X&HK&QK&?[)=Y@A5^"[4_T8M^Q2J&+TX+E
M#E875G9S2IO8QF8<@H&0':Q](2=S:&H0[-B8^[V]082]Q*0%-?8!RVS.J2?W
M(A)OU+^\!3%;>/;RC>O3RNA';[./*^B=0:3C/Z?@@6:+ 01Q"/_?46^6?V["
MGW[)?SYL-2^&@\(_M9KMPL_+'M7N-'L7U1Y5_GF_6_R2!RUJM/91OQ"]F&9P
M+'C"Y*QFLR!O.HN?5COKZ:!_G^MJ0H?R_*S<8I _Z2G%I;'S@$TQSF9/V\KI
M9=J6'O3\]W'X"XY_[E?88@LW*,__Z"EA#KA7Q.AEB+&!F\?VY,=MB,WZS^6:
MP<D2T^G;8V+S;_:]I6J95SEATSZE(L928]@F-I5P'4LMV21"RSH&4OSGT^W?
MW#>-USBHC5=IJE,RO2GGJ0%??99L5;E'4(?ZOUT,>KF$1+%2WMDYX5\KG5>I
M*MRH&TQ56LM9+6>K<K9A#L%NY&R$?5X[@SQTY0#EK+(QGM+_'94Q_@J;L&^I
MR++$).N==ZKMO% S'+>$K)LCJ,4#*0HT4"+R>_B 41R="S1'W=ZCS5$Q1SZ9
MQ5EY7:'S7K-1B:+=/1MU\<:UT>[F<0S[8:.7$-U\<'TWPM9;MT'@1 ]2I@6[
M/D$IV-:M5P3]'>E960*PDK@QNLA?-#[,WS@ U[UFH<H>ZPH+Y;FD<W8YZ'4/
MA$>>V^U<5['VI$?]G28\N^J45NZIMK1),@*0R?8NT)OGB.DHX,6&LKLGT.EH
MCFV-SP-&"71QT'JC?3':D=.UN_/;D^=?2W MP?NS_0^1X!YU4-]9]+U?"29W
MXA>ZF2['@*RB$BI@0H8'CPFY:%J[ 85\E>,4OGJV'U_Y#O:F62"^:AU(I%L
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MA'C<R61A5O"*M(+7%W$=_>VM@T2Y/W?2R/]=DN:P%?9SQ,</Z"+1Q^OKQJA
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MM/-=SVA0Y7DP/?\#K.,5/%J.[:3G6M=CD'HZQ\V#\XIZH-$;C]=D&C/FR7T
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MEM3'FT.!0^&+>W#L@P7K"_$3W4EVV\<"_A,U2\3_#2L7<A@P1T.P3#=PX.A
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MI%R42XKF=YU\4XUBQ=QV?;1H6HH:6?DQ4\/4[-@3$_-\3:XY$='!Y%AZ";O
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MW!6Z1,]U9E:P'?#YW3#BC9O[QG2);=UZP1CV2-F#1IT&>-8TP)%H@T&9-GA
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M5[56>":V"ZA?EN; V4O^<IF#$ DOQ1QEK4)$2H%56%!D# 39NVEG6@75ZF:
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MA%V=,XOP=3GG3KM1R,+;,F%0NAJ^:L?9&0HGX##ELX+[O<YSF15,)8(T/)=
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M@M/GB,X',O)R&?O?A8:D%NX&=OE;UH^@R^'T\M/9Q86^S&2)[HLKL(#S-+=
MS6#"TIG\%/!^=>^DK*3HZ@^=__' % 7S1/HWFBI6K:\Z6BP  Z8-QVAF??4H
M$S:I7M3F&.,(5$[%*5721,,]2!TJ7-F?E>6:68><1P:@2LN88*/Z4V^Q !59
MC@&,TT!J3+2>H0[-6L[H<5Z(?YI(C?%:!*#:Q$ PP)=3TA9D 2H_9ZL]K:[2
M1_$L\L!H<,H-1)9ZTQKPLPT@8Y4?P(^YVF)=PC7$H*NR3PJ.'0OF>?CON2;
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ML3?7*@*;X[+93+([F<SF[GC;]'L&N'3X8@,T(,^0*18>T+VD:50]>5-@)6R
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M,(QN. <]H=E RJV#CV$NLK*%J-D%"H986Q1D!69WJ:U:JE"G-=C?(7XX\R@
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M7&@Q"S*JKTY3=B(3X0BS!@ZTG$L3;&SSAHWF24P0OP7]\,SJ0(\7RR,G@T[
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MQD";2HFC/ND$1.I3L]IMJ.(@=OBV3 [-@\;(F5YV6J>/>]7N#%/:[MHPI15
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MD#E3;^Q<@0R/,M;N<3O&B7<=Z=5.DGA& _S>N&C08MYYD3<.@%J!U+_[LN_
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M)N6$UE]R?1O.'], 639P2$]\^A0>\4=@:=.?AXL4QD[A#<-_\?5F#ZDWF@;
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M%PMCDEC./&5/29"*$N4ZRWBAP$Y&H*A-%B&9AQI:@] RE+J9=P\I=P685>2
M2F!KV=Q91/(W3@/Q1LH"5)%8*[XMQ1 Z B69?F(B(4O(U0!:F71&(]099ZZ$
MRU.K+H=BPV$.Q-P$/E4^F05 9V\5LQU7?.\$**AAFK6GB6H7SJ)HH6T;G#4P
M.'37'__CAJS4ITP3WM)?_(>/Y^:K0TW3>!1XRAGG9&#W3R8VF 4W#\)ZE"10
M 7F[DF_=,7-ZI3KFTM,38,B5PUZO_F]^6W_^RS!Y_7,E#NC6W@GJ\N"YI%L>
MC$ 8$"H!F&+LP;(\F_(U8\Q1?0?*:&^9KYDB ,79/$Y-L.GW"(4NBV(KW8$
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M@)G8O\](X%5$<QKRL_:0B8E&EUC(H);L<U1U_UQM3K:N[5?;?'(MDFS7PQG
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MFLZGRU5==A]Q@\U&]$9*#4A*D]1?S!"\B,",8A9]BCJV3HK9#=F8',NFLC(
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M-((S14!*VA4A!86\K<]/!R2GUS[8YB6;?9NS\6LX[XQ+S L.+*BZ+R <1/H
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MFI@; -VQ@OQ/(3#M.-0NX?TP+/!7PK(N)R'A/8LML@S6HPX@=#V2*ZXVOL
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MSS Y?RLVK1/K#YY,\]5O7/K-\PYD-]-":;*L[]&O7]+'V@WZ+;UDOY:"-6E
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ME29-)72Y7P7[E@<\0'I^?YEWC076,,!1;_^N+VR^GKVK37?3^2UPF3Q:P,#
MV=J4 \DB2CXSQ;T!C"G?*,78Z^+T;<\^]:.[B<P;MZW87-I],LUK1/,UT_N
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MR/5N?NW<*",+PF@)F?OD6L]8W0KFP>(,P^4KV@A^@"*+#; ;(1(RP'V=Z 3
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M=YR/,$9QB/4_N*H&V#?VBJMHK7+RF9E2FR2&X%B,NMYQ]CZJS+V[WB'RQPB
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M%ZM,5-;?L8!NJ+R]!M<GZ(AL,0*,CVU&BU1MVG0%4MD5=(GM[=[3<YZBYRA
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MC0FB%FT"816E))E%]T9]BW[/F I <^EHBGK'3ZN+VV?=!T]XL58=9)O^GI#
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M!YW3!9XQA>_*)Q;U^O("FSM]C\BDM-3%0L#"0@@V\E=:@O,NE!:UIV'3+4=
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M$)0Q+ANM=%*SM_SNQ-O;3GJ1G;0'P%XB4V]G/O^UT<=G/BL1*T-$"+8-_*7
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M3-HF':T=Y,&_M *W&)/]]3=&8)WU]D^6U*>K3S>$A)P24<T0J^$KH)('S(Z
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M[SI]%+2:7KH=0]_7M>-7:?7GZIP=CU6YRO3#*:9-%/*+0&Z(=#I+$DQ5%"Z
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M :T)92_HP=PKY:X4Y4NQ"JHA5FL U'- ^8!^U#HH_S8P\N>C]W!5]@SADHX
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MP@)EH9^" %/I!]$@ QG$$8B36/UO$(A4OV6;/1\3NS_R,T%-SDF]I6BPH%X
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M?W(8^R1%0BJL5K^W44H3F["6MB>)>X?4QW))#/$:5E2G*)@IJS4 VDJK+=Q
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M5D[[R0EG\\N'Q-EWO0>?,].CJJQWY65^X<5=B1_O<XI7;:UN'/D^SA!@Q.<
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M4^G-U/J<X#;7A@<1,,C/<X6$70*=\:=@EG>F(]Q@8MC@!/-E;NG(<9!:I37
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ML1T;<S<LO@BL$]V,+YO/SN)]6#])JD7Y?*J1%X.^H-*V M]721)Q)CW1+,I
MD*GFY9GTJP*MSBDZQ"9/X6I)YZ;77@8!TC,VKL0V,RA;JM/W*],1T)%Q&"0U
MJP'0$?JEDFN-L<C"5'4?I9&X+M;2?Y5&X8M:'-ZI),\^$Y.%(L8\!C 5%,"
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M![-/["+US>15829UE:*OSR1_L:FK&J^9=ANKT^#HJ;.UR&8*W#=E<I^_<%(
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MO&#M?:3FCUT?['??>4GSBK-E&F#L)QP"(E3NB"\C',P""!!A6,C%/\;,K-6
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MK>O6<'W)JW^H\[&WQ0/.UTOI<64!#Y0SAF, 6<9 EJ $X)1#'R40!\PHTV^
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M.68193B)DCQ/5<X#4EC?5AVC-K':?KC^@#:DT>9&XQ72Y 'W.$<1&U9;[S@
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MTND!4-JY'M, !#-A.VSV[F<;-MK\@TJ4B[)E85ORWV,N EA\7WD$]H3GS0$
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M'P*WX:!O$V9X0%LF_%D"F-">C(,ET5GM!0R(IR8$.-HAZ/F!-7^H59M3O&W
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M^=EP8JX.[7@Q?S+<8,,.:O'K8D[(L(1:GB8)/\'@\!Y<LB3_3*$C&#CG T/
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M7NJICU:?J=J6/0#61ZL^*FJU&R"Q6K/%XM%TW_AMV2:OMQ?$N@;C7U85.'8
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M!GKE+2U<%WBMEV1FR+G<W1[&RDY?+\?@PAY ?7_1+2*:-FJ)3] ):$A&W]V
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M^<D5L66FW4AJJM#2DT H;35U*H"@JMSR<85Z3MJ,@D->MC5J)SDG=,+!FT$
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MM*IO&W;_O137C6+++^I!56NU?*MY>O-#?]@56[Q:+U?UG?[&MU>" \6CA,H
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MHJC N>FE6"2!$#2(DI" RH$.DYO8.FQKB&&Q;IKVWD'+B4,9M?.(V?GG_G"
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MN6IGU^Z*2:C3SHFJ1*E.7E]*6)%%-,JQRI,"DSA4IDQ1C D5N:"%XI*!*CS
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MW!P\6V;]@+&S/!:9 !&@']YST-6!V +3<X%^;_E DUSNA KOZRS%ENR\9RM
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M;-AC;A!>&A5)RYU !V+7F?OC!L0-/^#C&L2-P?D\.H@6 :!1P70+\8P JET
MQQF3WA"-_:C3!6&<)=X+L[B/XN:D_:WIA#"_7O!K_E@L"IWHK*_??OA+QWC$
M#"<XH7$F89@F&")"0HAC+"'#-$ADP% :&E5!,:0WLL&^6]9D#CH>FLS4?2Y
MQX:E"S<$HID3YQ$:.PL\C(<_-\Y02$^.W!"U25TY0]$/G3G3UQS<N8]%6=77
M7)D:95S(_'>BH[GUC91"YTRM.Z]S0G-*"90B0!"A"$'",@ZIX'F" Q[EC!A[
M<"841[8!#0M@RP/HF !K+BS<"B, #=PQW[#8Z?\@(B[E1(R@L7"R?$/DF+SH
M_/'8N4\VTO9Z3$8#3><DV<BUYQ=9O3A5"^7ORUF8HS"D*(59I PC$I)!2D()
MLS1D09;*'%.CPDR7,#&RP50?539V^V2%I.DAU;CXV)YB];=._KY\S<;)6\E?
MK6VR8N&--TW>@G1YR^2=L5ZAJLGF:C/!04IYIBQ1) *((LH@3I,09AE.,4G3
M"*=6IVY>N!K92'DI8V%PT7K$:3,S@)-/AIU%G&H>IJT.,M+M>#\\_>O4\1BZ
M=^]W<#L3+!B?W97\NBR_Z:8[C:V_OK^_?B;%_/JQ-K&7 T.,; &O-UU.&X(Z
MU</,B@U)WF^7/ IM9VGN2M*TLMY)0;L"6Q[ "3S ]:.NTW*Y43$4^H29J 3[
MZ7[Y_)]JA,Y",+XU#$/C3J+JAL*ME=?T<7MU_/"_]<OU]Y)7U_S/=?MA0S4\
M\>K(ZM>U$&A2'M7'Q_]<575CE\R5\)2\P\IWH:AV2G=62H]Y/@-".2G5J?$F
M4Z8>87:5J.\QQ^W$D^YRK8SDY_:XJ&TX]S(+*!:I(!3F82(A2@+U4QS%,$^B
M",5(B(#3V;,HZ=)XBW":DLV'N$O/\D!GN:8.YMT1^Z:UGJ4C?P8P0]?\<A L
MG>V-W W%*["AZ=%O[A?*ER=\ALJTOFV_J$?>ZL#C;CJKHPW;!AD?A6A]EEG"
M6432/(!"G\8BE(60HES 5* TB6A,TS2UV=2?H3/VX8L0@/0[85:HF"FF!UGM
M%%,3W.DF= 6TW+Z<3T.I/&GF.2J3:N: J(>:.?2XFV9^$?4[4CW<ELOG@@O^
M\\NOE>"?%MU6='%_S>KBN5ET9E$6Y"1($BCC"&ME)9#*5,(XR=3/J3XYI;-:
MKUUFRFI.VDI_-PP8?]B*$< 4)^"I8T7?$Y-K-@#9\&&GWA;0FFG\.(#9&0&-
ME68"W.Y@]8-F!!2+'\&&%W ]C)JU<; 'P).]L" \J0FQ!^30JCB,X)"3\9MN
M?["X?[=<M&>=7W5PX^[[<MT()J)"YKKJ5T:UZQYB2#(<0$YSFK(X1$'"C+,Q
M^FF-[ K\0LI_: U9$P<-]=XS,VNT^HV%9PSLK$-']Y3\+ND6 T!8)%KX \0M
MQ:('&$_)%682]J95# PQ74*%F2Q[J12&K]C'ZYJHT*\+7LY?[G=B@>;!\[,#
MC&R*?M4%Q>8O^JO;DC6/VYV7>SAZYT5D.\O3D 0G9?8:(!\4S2F2=W[4R>)Y
M@X+M1O6&'W;;C=R*LBE]JKAM[MVO \8Y0412F<-8R@BB,$:0(BXA8RDF>1!C
MS(T<A $Z(VOD#M6V#(7EAN(<.F:[!P\RVZGDL;@CW)L=D,J3_W^.RJ3._H"H
MAY[]T.,.;GQ[4/)>9VOKA@;Z#'M=(G*MJ(PP*6D,113E2E$C!G.1YS#%."-9
M@N(H,<^K'B0WS>D7WV%@6Q/3PHT=ALW I?<*AITB=SCLT@8;XBY^_3 @%JZ]
M5V#<O/M>@#SY]\9B]KKXPZ-,Y^4;2[3GZ)N_Y>:"'-Q2^ZNH9HSE(D5!"!,D
M0HAPJ@M^X!0B*0@F61A@+&R\CV,2(QNR@PN3X ]-TS(=\ 0N9G['9=+:62I+
M0:V]C?.R>'(T3A"8U,<X+^"A>]'SI&,C&3%7O[W?W-%$- F(Q#!DDNOFT $D
M E,89F%"4:+T+[)J3;@__,@*UY[@=R1U06R'^Y<'>)@IF[N4=HJV%LW[5<K3
M OAJ4K(_^+2=14X*=M0.Y/13#KYZ=YFH"G["Z;H^MJY6)]8Q]YR$- LYE G/
M( K2#&*988C5YAHQ%$F:(V-/?8#8R-JVIGX%_ETSL.FDT)1Q-,P7-<+,P$WW
MB(2=1O:#X.*E#Z%AX:-[1,7-0W?\1.Q<=$,I>QWTH3&F<\\-I=ESSDW?L;-G
M7!2S:S7GO$E\F)/[6<XCQ)D4,**<0H1B#G,49S"EB8B59Y"H_Y@8KZ.11[94
M&UI $S/3Q6/I^\W013)9!MW-Q#'6HK.L]P35U3OMTJ]^V*[XQR--HCAG!5AK
MR?D'+K_>^Y$4Y6]DOA(S@N.,R#R$&0T3B**(0/5/#,91PF-*\BC/C*)PO51&
M5A5-!SQK0N[7=+>(F'G/%\MIISZ'%VT;D7_K%?FB"[9'(HUP@W9+X]6NR!Z)
MV7<']OAA^[7I0].Y[ZNX;\J8+.HOY%',(B0Y29B$A%$,D6X!DV.>P!!+@M*$
MIC0RNJ]ZCL#8L>^&)-C2!)JH^8IU$I/AA>M222T#VW9"6JUC?9(X+6<G!YQL
M5>L39W=QZWW.(?N"_WFW_+)<W(KE%['41=H_+K:M:$TS,/H&&=OCV]PFTHW3
M%!/P]L,-^*+^M]>DX.-R62^6M<7EQGYD^C7-*RB6+J,='N /KUUUC05WR^+H
M'7FZ3 X3 ?>R.8Q><(SJZC:!UT]/I6!%V]&VN'^HJV_77[^97WXT'FQD96[H
M@UT&0,L!^$'Q8-J+U1P:PYBO3U0LP\ #@(R0\&$LK:^8\2"]:</(IN(?19:-
M7W0(-E\OR-/#R_RQ^VY9D/(X2CGD)$XA$H)"$@FU"8V3A.8HR[%%/O?^V&,O
MUQTQ?17D3\%JR[.;4V 8!(W=1;1<?-?2.42##Z2R"/ZZ2^<6ZUW3\Q35/<U^
M;Q#WX)7I8K:G>=T+T9YYQ*6?']%MZQN[\@OYJWA</=XIC[_2UZ66B_4%3YGS
MF+(8RHS&$.6,09J$(8S#,$P%(2')$O,>?<,$QW8 % =-SV;-PQ5X;+D ]98-
MJXN@QC :V!#/X%CZ 1TNWUI<.@; #@=#2=ANN-@TM/.+CV.3NHMQLNPX9RYT
M?Q<Y@W$F[ QG+M5^MS>+]]QV.[\0]E L1/FBNT__[ZIXVDV-C7,LTC"&$682
M(IGF$*M!8,I#D? PBC)AU#3"@-;(5G!#V6Z_TP>.V4['D\AVMFU#M"GUMB$[
MPM;&0#Q/FYH^2I-N9PQ$/MS(F+SB>,WK;SIB^9[48GMP9'/)Z_CU*<[(&D*
M5'I=:3@ F@7+BUXG)#<((5XNM.7^I;GDM172ZXF9@43N=[M.C#GMS:[S0AW=
MZ^IYU#&ENFO ]D[SNF@J_>OP0_6/SOC'DDD<Y0CB/%&;!+U3("C)(<(93V42
MRS@V2D4SI#>R4F[:!;)=\J!4]"TSK@=@,ULS/8)AIZP;'/8H TUZA+734$Q?
M:=H#U*;-V383_2B!V_ UUXI/4I2E[JM<U=4[\E349%[\4^B*IT^DX&KMOJD?
M1'E=5:*NWA<5FR^K52DLZP9?2&6\CW_-&&@XNP([O%V!CKNKQJ%L& 0MAV#+
MXBCE@CW!Y:T(TV7<3%RLR0MTQT6=_ SKJR;+S6*=W2MP&H>9$)"$<0!1GL40
M4QS#+"(DSPD/&8LNJ\FRH37Z=O5D319%_M)2)%NT# )T_C"P,T7G2H\HTMYJ
MLFR!N+0FBQ,@?FNR]'T8'FJR'$EH7Y-E.\0KUV0YDF6X)LOQ*PZVZ^ORA<SK
MEQLZ+^Z;2=\4JORB1&E[P<_B/$0Y"U(H8XX@2FD*\Y3E,$B#)""<X3 TOXMN
M0G%D.]:Q )8;'I1CL1 V,74CW QLF6\T["S:&H@M^9TBL5=@RX)O9"R,FV^$
MW$S<Y4C9&3P;J7O-GM% TQD_&[GV3*#5BY?MM-J2?:+Q)+^(>A:@),$D#F&&
M=0)RGD<01R2"24*B,$_3D ?<KK;N23HC&[VFZ&Q15:NFC QK=U/&1F\(([M=
MY@62V^X>=:7=M=#=%O)+C]#..\$S(GG>X1U2>96=VQE1S^W(SCWNF :Y/7K\
MLM+>C_I+4Y1'S[(NN+ES$CFC*8VIH R&.>/*<>$4YDD0P9!'><)EQ/+$ZJ30
MAOC(ZMS2;U(HVHI01<,"*!9[210_J+^W#]CF5-K@;*;]8Z%G9Q(.,@>V.':5
MM3YM<-QAQV/6I0,(OA(P;4A/FXOI ,I16J;+&.Y%^+<AI.U= <0QB400P"Q'
M"42QQ! C97C",% [)\KBB%J5MSE#9V3+LG^9SKX0_RED3-V#B^5U< ]V0\5>
M[T@8BN6Q$O\I*I-7XN\1]50E_K['77(I5W3YUW(A;LLE7[%MWXW/1=UM'-99
M1%D@>$1RB%.,M6^00*J<><A((M(\)#+,C,KB6%$=6777;(".C^T6%6PYL<D<
M- 73(-(Q!D26*[\).BZ17&.8;+(L1X#+,=7RHH_*,LW24NK^7$O3P29,N+24
M;S_KTO9E._-9E8J$N-<?R-_$\KXD3P\%(_/WRT=2+&:1B),PR!(H\YQ"Q)@R
MG %&D/&$*,\FB=/,J)-Y+Y61S>,N0?!'2])0S_O!Z3=_WD2V,W=VTAKKJ9$T
M?3Z-&F#'GU%_V_HR_6-/HJ9&XJW5TNQA^QS*KX(MGT7Y<B,_E*6^1KIUDCX7
M"_&I%H]#12--AQGQ<*&CKO?6BKXR7,M5->^Z0S8)'3O7E'>=<,T;:)CS=%'9
M!@>GS$0C I.E*=J(NYNS:/6>E_9UA*T[M0F, XHC ;E@>GG)*,RS%$,J8Q'Q
M@(5A;E67_ARAD5>8V[)8L.))&5P/;>RVZ)AOGR^5V26\OMO(3A$=NY/=D5SC
MM++;DGG-7G9'P@XTLSM^WE%1BXIT';*;CNI?Q;-8K,2=[I.]#>ODF' BI80D
M(DSMH;&$.,\BJ'269)@A2;BTTEH3JF.?D^WQH!>OC@M+738"T%"Q?<-BJ>7G
M$ %_-"R <:)F-D+[,@%&-*>U!S8P'!D'JY<OJ$O2QMC?K]3R=W\KRF+)F^L.
M7\3WYC?5# M$2!XB&&4Y@8AS FE(!9292 .:\SC$F74!DR&J(UL*Y2(]*GUH
M2W=TQV\KW3<)/*WHO&! M-T,EE(*S:)#49-!7 U/WGRC91EX:Q#J#M9:!D#+
MP55[YTB?R7]O'_#8Y-)*:I]%3@9I3E_HQ!2&D\5.C%]VLR!W@CTLEO/E_<O/
MI.F96:N/IU FJDW6[F*G*$PS3$D&(\$01#1/(<TE@@'"%-.,11FV\C6,J(Z]
M75#__D#:EJ]K\G96P@P[,ROA'1$[*[$E#QOZ8,O ^E:'_]M.5C)[LA%F-">U
M$58P'-H(NY==JX)><ZX^GNIV6=5D_O\53^^67,Q8&LN4!02&* K5!B3A,,\C
MM0L)>880C1.)C3*3^\F,; 6ZXID=Y2O0T@:*.-#4;4N%G@2JWP+X$]].Y5TE
M=Z@?VB?8!55$3PX[<2W1/M&.*XKV/NVX@*O7;N2UKEA_W_2/:IH:D32-TU10
MB!*10A2E"&*6YA )$F*.PX21U&K!/D5E=!=_KEA8ZBN=SVH5VM)N;ASN_KV]
M?5@_D 78?\FE1=1I0 U7\4MALE/A\1&R7]/[$/"UAI^D,>V:W2?FT1K=^[!+
MGDV36W<CVTUPLTUH[,M<\+OEVJ\MJY]?;DOQ4>^*^;JEQ4QM]G,J8@H31JGN
M D=A'C("(\X3IAQ[FL?F%R+=^1@[%Z=-)UU*P-HX05/JS#XA]U*T^ZW&A!A:
MQ@Q:^&XDV NSK/D"=TNPY0S\_*+O@L.6.;#F;AJ ;9)Z)@':,<UG3, MLX N
MAJD_+\A]^ DSA2[&8#]WZ/+A7-(8E(]9-\N-KH+3.#&&9:!.O#JRO=ZA"-X+
M-<!CL>AR$]0__Y=Y&:A34O<;80\"VQG7?EF].60#<CFF6AR/-V%FQ5EA]A,I
MSC_FML/:<=RJZP7_LER0[;_L7&Q8!_PR9?3"5&8P#)(,(DD2B$620\+"6&!$
M=*J%S=[+DOZ_P*[,*OO/=1K,=FPC@CO]7LY;GN&%Z'C:Y]E2GW0'Z C-X=[0
M=1C[2.XWP59E4;^$$;W3OL>,AQG/<49AEI (HH0QB$/UDYH&EH2,J0VAT;'P
MJ<%'-D(-#;V]"Z,?Z(]@3=T\6GL$QG",]A(1+0]C+*6SBLB>$\,I#GLTV&31
MUW-B[,9<SS[C6 #RL,3<SR\ZLM/XF G)TY2A  :4I!"%-(($2;7PLX!21 3'
MS*B5IP&MT=?WHSJ'FK)3*+4/,;/EV1,.MDNQ$P3VU1Z'A?-5Z;&'TK15'H=%
M/JKP:/"*JT)O]N-ML6#=,3P+J(!YDH00,9)!RA&&&.=!V+3CM?/<#PE,DQ/5
MM77X]^"G( C!$^D:D/X$KE?UP[+4A?G OT=)<!4$S?^ZD.A_ XROXC"["I.X
M\3EQ>(7"^"I#T4&9 _W+Y:I6^ZP%U^E$I :_*/ ?_N/?PC3X[SB\ CKNTSSV
M7K#&;]G[%;H":K0GP;37.K>LOWXT:::&Q'TJ;*W'-H*W2;%JLWA\FH[3XGBS
M%P?#3VPD3@MW;!G./.><=MW=N&A"=9O[,5_%G-1=<<LFE$=UIL4M>6F=]G6M
MUYB@B B:P4#$ J(L0C"/<0:C*"(4,4PCRTI%%[$SQ0$+;"B#CO3>'M6@[NL8
M<V!F"Z9#UN'8I<N_<@35)=/; Q;^4L O86;JW' /P)U(&O<QJJ,_1*J'ZP77
M_]$M*937T Q>OR-E^:(6^G:]Q9BE 2$<(I1*B @-89X)!C-*14Y8&B:YG9-D
M0G5LSTD1;_P5IG\06S8L?1,C  T=%M^P6'HQ:T2:'W8XN-+NWIH)WWW>K83V
MY>L8T9S6 ;*!X<@KLGK9(?MDQ^U:GU-V(?< I;DR" C2C#7%&F.8YUFF3$,F
M@Y#GN<1&66?]9*;91;4G\ [9#.?AZ5=\?T*[[U<V\KI48CDON$66AA< W)(P
M[";>+JMB4*S>I(GS;T^7$S$HP5[*P_#3]AD-[QX6]Y\6'W4SGQMYLZHKOKA7
MAN[7Q7-5\P__6[]<?R]Y];=R4?-/B]NR_'NY_OX,\QZ<"8QLD?XN2 EU=0"H
M?P+O'IH"[\5BIW%44^>AO?'6E'BHVOY2;2W%V[)8ED"_6X&[![5\*_\1W.P&
M<-0ZKZ045=T3H_ X'_V&<+*IL+.3D\Z"Q]LV7N!T2A=QISI94LG%P.RFGEP^
MF*\&*!_F^K+QN@<*1_K_,&0R2"'BF$),> YQ'@=Y*J.(8?/NQ8/D1K:%Y]I=
MM"Q<V@%D#S<#=\TK&G;FJ!\(;SU1]A"YM"V**S)^.Z,,?"H>FJ.<DM.^/\K>
M**_<(N641,-=4DZ^Y6#CKC5B;0.D)CK:?8XT)5E.D8 X#AA$ >$09QG19_ R
M$I+*/#&J6]1#8V1KUIR3=9V=&JH6ZGH&% .K=;FH=J;J2$H7ZW1&7 N3=+G8
M;G;(?)+M3$^_/+WVYLRKTQF9?M[W+,O HVZA[H_%HJC%Y^+Y^,KTYTV1/Y0G
M&9/*OB 1$H@D91!'E$,6YS0@02:BG-I$NDV(CFQP6A9@P\.I._Z?#<K_N0-J
M%OGV#9.=L?*!D'7<VT9D3V%O(Y*31KUM0#@,>EN]ZUAK21^[-19H]V!NYWSV
MYY?M(]W)7!,%:","VSIQ59/ ??= %C=/36KOQV4I15&OU%?YNRCN']3^__I9
ME.1>G&AH3K)0!"'&RLMI&B+IMBHYCV&<IR'EB#)#I^=MB36VV6M941JMKX!R
MG35?5N!)E&UFDVU[EC<!F6GYJ3?![#1)$WM5;7<S)^@+.)E<H>6\6H?L=D3=
MO6/127L%=N2] FN)02=R&^EKKW!M X(>ZVF]J6GT5;#K;0@U;46PMR'SF77T
MC7'GME)_6CPK#I;ERU?R_1<U;EF0>36+$QHD:<ZAC'658XDII"PC,$]CRI(D
MCV6&;!;.DU1&7L<4*?#8T;);LTYC8K:$7"RIG47?D+L"6MX-Q2ME8Y>5QQJ%
MO7)Y,G&G:4QJ<7K%/#0 _0\[Q.YNRR43@E<?%5]MF["/*VT%NG*H30-+3D+*
M4(XA#1.UVPY%!&E*(RASS*-<X%Q&1OTM3 F.K*5K#H">"U!U/>]DPP4H;0H:
M&R-H$/7SC(N=3F\@T=3!N@U@R\"ZHO% =U#'3\L\/N@9(+=@H0>@[**(%E+W
MAA1-QIDNOF@AU5ZPT>8]-^=$C:!3\Q2AYX(+_O/+KTW9QK91:[&XO]:W8HJZ
M$#LW"S*:);K(>QJ0#**8ZXNZ60I1(@5"*4'<+@YIS\+X4<F6,B ;TH9%/RZ
MU<SY&1<L.RNJ>&GS<=?<Z(WM#[^V-6Q_!%L8MTR-<FG '1-/7I4# Y.Z7.X
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M:K!E^TK?IEWYW*A.BK"O6VB3\#SMK;8II^'HEMRDQ-V6H#9\-PN2)(P%SF'
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M>'WV(+-E<,->7*OE>D @IU7[W)B3+=X#0NVNX4./NBWE[;W^;VKCTX1E-WV
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MX/# VBLU[? 'ZOD^'QYIN+?+:HK %VUA^*=E6<^RF"5QH%/"<J$L,)4QS)'
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MNP6,)@NC24][""B12H3*4B YQ>;?KRB9CIS(%(<A=4F 1.*;>3$GY'#X!BB
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M#"*#3TPV$.T@(%*O<><OPQ(O9O.K43%!)VD*\)((X1XM^%6N)":7DC?)%=D
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M7V$9I_%RI*)DS-H"R.M^0&3@A.<0+4:>4G9N;ZO_4X#T-%7]IN0[PE1C90P
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M%3@ A-YM4*9%M*O9>=E28*VL,>!K-98117F7K0NY]:.TXQO \3_%S=WI@A\
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M^6^/P,Z*9"T:#87<;XK@?8!@> +$8$V(FNO8NAC[3)*;#,G>O3F"#"$EGX%
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M4=BO$>H.6P\?I7>FMT$:JL-ZG7;?MO79V[?VU<;58!U (!GYP1Y!&:/!$5@
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M@ZJM+OK.*:SW'/GZR_DX7JY4<S''U6GQ=_P2<3Y2UGG/&0(3-M2'39;VHA"
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ML$$/#/-M2&&"]BIY#1%](7E%3F=Y*6"B85HZYWSS"?:[J>FW"*^#XZN1X(<
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MHJ#_<6\/.F7N?K<_A3?2TJR-R/K6]G^_J@4@UVDOEF.PA0QB*+499>;@I;+
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M,+0=4R<=0N_CZK=\Q6#Z[=NU[WSGL*;%K3 *<G86E'&*-E<=%<BXC,Z%H.W
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M^JPA96E!25:;0F0'6J(U3G&6U#1ATL$DSNU:'AV"^ZCFJ2&/H)1/LDHEZ2Q
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M;_#LJI-CB+1S8Q6>1@M*,+)0K U@5%!>1\V<;WTPCB1Q7D1.!I7AD#Q8;QW
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MJRW.%ML3[I00%@.9&;NA!.06^4""-<D:8XHNB?-F(/MIZ4'P\K\4O/87_=S
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M8UY\W9FF')//TA3P(BA02)O-H8K ?&2VD)_#=1AT4SZ\3I?&>8.+L:%T.SC
M[N^.\:*4'&L9^+4&&4EG);(@7R8@7?)UC+-7V8$5T8OBC0ZY]=$UBL!Y7Q!.
M>FA-IZBYCZL?/;*'^#!&DGV)(8$(N=1W*)%VFDY@#/(LR43P9=CKKU'+SON*
M<+K#;#K9/Y6G.I<G^-MPNK@0;]LG._=^_"1/=X8Q<^0G/,9HATEQ\(X HP3W
M$(RQ4&RV=!:5Z'+KA@<]/.%1)F1DM%G";BR10D$.L4Q !D#)2&9D"*T=R:?_
MA&<,5D8]X1FCC3[2>3^GKJ() 7V= E#G :B"U?70#G*,(1LC,0V+OD^5\9WG
MV<XHK3Z6\1TCXCX@<D?^JO#(A8T.A""G0S&%$*)%<(:%&!U3$G,[G'2?\1VE
MTT$9WS$"[L"_NY&39(+E) WH4MT"EAP$ZVK;3B&S5\RYU#J'UWW&=Y1"'\[X
MCI!N!]!XU*NP*4>5#8.BD(/*4H&CV[G.U]-"VA1$\_<[33*^\SSEV><NFD05
M<_OS=WB/[U>GIR]7ZS]QG4ZLECK(VE4U6I(3#S549CQAP6-4IA1QL__9/0[\
MP^MT:;7LJ=#5--*=&RBO%QCJ2\I%WOS$U>Y0I3\\<<8')ZT"X^O1C,4 %KJ]
M?7U@&9..B'$05!Y;:1ZP--?G:BKA[HV4+[NF01^VN-[.EF]SOD@I6 +-DP*E
M?0 O61T36UA*@4?6O.'B5/FVYC?;5! \EK[& ]-? '-9CV9:K]U#UK/5^JI*
MXE96VY<B'2]TT ?,H(3.$'R2D##X8E!YSUNW<WF(GGD*"Z;&6C,-='\OVA!-
M"3G0T2W*Q0Y!9>GH#B5BX,3FP)[$3>[%YD4 \]Z+8X1[X+WX8IFF1\OS\W45
M=I48.L4R(&>LME0.X%+6$#FW"HEE<EJ;@.9RP2Y=M08&^!3R[C)9]B9O7Z\V
MFW=Y_>$SR?PWW"PB+M/OB]-SNCEO?/> K-E>ZQR>/CN<O49YM!>X7M(]]7VM
M'_W,O+2"V0+&,%_C280EF3R4E)S35NO8O$7S?;0<:AU]B)]S.J^[Y=ERNTA5
MQJ2,'X,M+@S!G"X,Q;,OY]O+?7N3H(M82^$IVN RL#H$5S%M 07MK<"U-CQF
M;7+KR25M.9@W.M$$<3?-KQE5W$$P]5FU2FKSE5W:P2C!M$8$H[P&%079*9@%
M%!.#2N@D-ZZUO7^=@'GA-2<2;OH$>ZNE TQ=W4LY52GEY>92@S^Z:/SV[<?/
M7)94[SC^P?8RO3O%Y1L\RY?I#IV5XSQZ<,&1W6-"N'@#&4/47DB9;&A]J4S!
MQ\S]<O:'U<U3<VX==X#S%V0EKK[EO!MO_O9+%<#5.WTIZ-XIC'RQ1)*MG:>#
M]04X6J=%J&Y\ZWK3>XF9^4R='2>K*936 ?K>DV.P7D2R^7>L_'.YV&[>?_CG
M)3/&>Z*:U_&66H#2K$#0VH'3D?OL&/>J]7'Y($'S>M7=H;"=\CI XH'6TF_?
M[OZ W1U5NY1J$Q&RK-$(5Q"\)'.*Q) M1F3"MDZ"3,C.S+N@(_NV$\ATNWNN
MG3-!*6:"$6!2;=P< P/'B#V4!9,61DO=W"E[A*:9K=A>P#,(U'MJL@-DWF\J
M&56DJT\V:K-H4"K4N>PE@T,KK(_,A_0WL6_;ZGRPK3I& 1T@Z6%S![W@03 #
M@@P;4$)ZNDBL!AY0I^)MM,;_?6S521'53A$=H.IR)-,E\=%%'7.4@#X@;0D?
MR# /"3A+HEB98Y&V,8I^(F#>K@>3HF9_07> D@.MA>N9UR"%KR][6"V4]5$
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M- PEK\8UW^;>O1WKFU[P[&JSV"/WXW Z()+RQ_E#8+:GV6*OVH^#[;!@JC"
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M 5LN\LB>EGNA)WK.-"KI5##9*ZR>YK;/<P=(]9M4C]S,,,^Q[NMTFV'\_=8
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ME<))%9CZ<&>@74;5J5J![$H,2\^XETIRXVK+R/<6MR-<I[(F 84_.[&/(%&
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M]X)8<]Y[G&8UH'H(\\*SKP:QT&^-_O+:E[VPA($_M6& +**]5(7SI48O2ZP
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M1\]CAQ4(P-&S>7=W.%(7=%MP A=(:8ZWW/+2WORNW_U/W?\;_@902P,$%
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MN>>NOOY?_7)PZGZQ^ =02P$"% ,4    " #J@*Q:"$)2>1VB 0 S#Q( $0
M            @ $     87%S="TR,#(U,#,S,2YH=&U02P$"% ,4    " #J
M@*Q:=+$..*H6   ["P$ $0              @ %,H@$ 87%S="TR,#(U,#,S
M,2YX<V102P$"% ,4    " #J@*Q:7 BHL-P:  #S_   %0
M@ $EN0$ 87%S="TR,#(U,#,S,5]C86PN>&UL4$L! A0#%     @ ZH"L6@C"
MP8:<@0  -N8% !4              ( !--0! &%Q<W0M,C R-3 S,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( .J K%HUA(G_5",! -]G"P 5              "
M 0-6 @!A<7-T+3(P,C4P,S,Q7VQA8BYX;6Q02P$"% ,4    " #J@*Q:YT_)
MQVV_  "T]0@ %0              @ &*>0, 87%S="TR,#(U,#,S,5]P<F4N
M>&UL4$L! A0#%     @ ZH"L6CTIPPL>$@  O3(  !P              ( !
M*CD$ &US8VAO8F5L<VEG;F5D8V]N<W5L=&EN9RYH=&U02P$"% ,4    " #J
M@*Q:2,_'8^X'   -*@  #P              @ &"2P0 <3$R,#(U97@S,3$N
M:'1M4$L! A0#%     @ ZH"L6M!._*P="   Y2H   \              ( !
MG5,$ '$Q,C R-65X,S$R+FAT;5!+ 0(4 Q0    ( .J K%I9_1D[C@4  '88
M   /              "  >=;! !Q,3(P,C5E>#,R,2YH=&U02P$"% ,4
M" #J@*Q:\:'X*K4%  "X&   #P              @ &B800 <3$R,#(U97@S
<,C(N:'1M4$L%!@     +  L R (  (1G!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>aqst-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aqst="http://aquestive.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aqst-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <instant>2025-05-08</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:AmendedEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-22</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AnaphylmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AnaphylmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AQST108Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:AQST108Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LibervantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LibervantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:PersonnelCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:PersonnelCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aqst:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:ManufactureAndSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:ManufactureAndSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LicenseAndRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LicenseAndRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:CoDevelopmentAndResearchFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:CoDevelopmentAndResearchFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableDoubtfulAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:TradeAccountsReceivableSalesRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:OtherReceivablesAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">aqst:OtherReceivablesAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:HyperaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:HyperaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:IndiviorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aqst:HyperaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:CommercialExploitationAgreementWithIndiviorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:CommercialExploitationAgreementWithIndiviorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aqst:LicenseAndRoyaltyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-01</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncUpfrontMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:MarathonPangolinRoyaltyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-03</startDate>
            <endDate>2020-11-03</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:MarathonPangolinRoyaltyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-03</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:MarathonPangolinRoyaltyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-03</startDate>
            <endDate>2020-11-03</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:HaiscoPharmaceuticalGroupCoLtdUpfrontPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:AtnahsPharmaUKLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-26</startDate>
            <endDate>2022-09-26</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:LicenseSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:AtnahsPharmaUKLimitedAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aqst:AssertioHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aqst:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aqst:ComputerNetworkEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aqst:LicenseAgreementWithSunovionPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:DebtCovenantRedemptionScenarioAxis">aqst:RedemptionScenario1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:DebtCovenantRedemptionScenarioAxis">aqst:RedemptionScenario2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:ABLFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:ABLFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aqst:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:SeniorSecuredNotes13.5DueNovember12028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:RoyaltyObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-15</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-15</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:InitialWarrantOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-15</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-15</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:FirstAdditionalWarrantOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-14</startDate>
            <endDate>2023-06-14</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:Warrants0.96ExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aqst:TwelvePointFiveSeniorSecuredNotesDueJune302025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:Warrants4.25ExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aqst:Warrants5.38ExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-03</startDate>
            <endDate>2020-11-03</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">aqst:MonetizationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-03</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">aqst:ManufacturingAndSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">aqst:ManufacturingAndSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2023MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="aqst:VestingConditionAxis">aqst:VestingConditionRangeTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aqst:A2025MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:NeurelisIncVAquestiveTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-05</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:NeurelisIncVAquestiveTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:SuboxoneProduceLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:SuboxoneProduceLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-15</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aqst:SuboxoneProduceLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-15</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>aqst:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>aqst:segment</measure>
    </unit>
    <unit id="lease">
        <measure>aqst:lease</measure>
    </unit>
    <unit id="payment">
        <measure>aqst:payment</measure>
    </unit>
    <unit id="pricing_period">
        <measure>aqst:pricing_period</measure>
    </unit>
    <unit id="pending_case">
        <measure>aqst:pending_case</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001398733</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-5" id="f-100">http://fasb.org/us-gaap/2024#ManufacturedProductOtherMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-1" id="f-101">http://fasb.org/us-gaap/2024#ManufacturedProductOtherMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38599</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Aquestive Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">30 Technology Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">07059</dei:EntityAddressPostalZipCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-12">82-3827296</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="c-1" id="f-13">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">941-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">AQST</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="0" id="f-24" unitRef="shares">99327928</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">68657000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">71546000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <aqst:TradeAndOtherReceivablesNet contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">10444000</aqst:TradeAndOtherReceivablesNet>
    <aqst:TradeAndOtherReceivablesNet contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">7344000</aqst:TradeAndOtherReceivablesNet>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">7198000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">6044000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">2870000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">3286000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">89169000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">88220000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">3801000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">3799000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">5049000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">5182000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">4215000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">4223000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">102234000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">101424000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">12280000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">10287000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">3314000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">5907000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">540000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">510000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">1048000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">1048000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">1000000</aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent>
    <aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">1000000</aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent>
    <aqst:RoyaltyObligationsLiabilityCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">89000</aqst:RoyaltyObligationsLiabilityCurrent>
    <aqst:RoyaltyObligationsLiabilityCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">87000</aqst:RoyaltyObligationsLiabilityCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">27000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">26000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">18298000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">18865000</us-gaap:LiabilitiesCurrent>
    <aqst:SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">33746000</aqst:SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent>
    <aqst:SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">32500000</aqst:SeniorNotesNoncurrentAndFinanceLeaseLiabilityNoncurrent>
    <aqst:RoyaltyObligationLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">21559000</aqst:RoyaltyObligationLiabilityNoncurrent>
    <aqst:RoyaltyObligationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">20129000</aqst:RoyaltyObligationLiabilityNoncurrent>
    <aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">62777000</aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent>
    <aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">62718000</aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">4822000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">4968000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">19744000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">20005000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">2218000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">2395000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">163164000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">161580000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-78" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-79" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="3"
      id="f-80"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="3"
      id="f-81"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="0" id="f-82" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="0" id="f-83" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-84" unitRef="shares">99317153</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="0" id="f-85" unitRef="shares">99317153</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="0" id="f-86" unitRef="shares">91413742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="0" id="f-87" unitRef="shares">91413742</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">99000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">91000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">325115000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">302967000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">-386144000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">-363214000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">-60930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">-60156000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">102234000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">101424000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">8720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">12053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">3652000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">4389000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">5361000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">5932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">19072000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">10689000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">28085000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">21010000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">-19365000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">-8957000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">2782000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">2784000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:RoyaltyExpense contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">1437000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">1358000</us-gaap:RoyaltyExpense>
    <aqst:InterestExpenseSaleOfFutureRevenues contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">59000</aqst:InterestExpenseSaleOfFutureRevenues>
    <aqst:InterestExpenseSaleOfFutureRevenues contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">58000</aqst:InterestExpenseSaleOfFutureRevenues>
    <aqst:InterestAndOtherIncomeNet contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">713000</aqst:InterestAndOtherIncomeNet>
    <aqst:InterestAndOtherIncomeNet contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">329000</aqst:InterestAndOtherIncomeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-22930000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">-12828000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-22930000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-22930000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">-12828000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-130" unitRef="shares">95497056</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-131" unitRef="shares">95497056</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-132" unitRef="shares">73614710</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-133" unitRef="shares">73614710</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c-6" decimals="0" id="f-134" unitRef="shares">91413742</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">91000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">302967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-137" unitRef="usd">-363214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-138" unitRef="usd">-60156000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-9" decimals="0" id="f-139" unitRef="shares">7457627</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-9" decimals="-3" id="f-140" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-10" decimals="-3" id="f-141" unitRef="usd">21992000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-11" decimals="-3" id="f-142" unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-10" decimals="-3" id="f-143" unitRef="usd">729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-11" decimals="-3" id="f-144" unitRef="usd">729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">1587000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">1587000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="0" id="f-147" unitRef="shares">445784</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c-12" decimals="-3" id="f-148" unitRef="usd">-702000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">-702000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-150" unitRef="usd">-22930000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">-22930000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c-15" decimals="0" id="f-152" unitRef="shares">99317153</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-153" unitRef="usd">99000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-154" unitRef="usd">325115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-155" unitRef="usd">-386144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-156" unitRef="usd">-60930000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-18" decimals="0" id="f-157" unitRef="shares">68533085</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-158" unitRef="usd">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-159" unitRef="usd">212521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-160" unitRef="usd">-319077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-161" unitRef="usd">-106487000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-22" decimals="0" id="f-162" unitRef="shares">4557220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-163" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-23" decimals="-3" id="f-164" unitRef="usd">12381000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-24" decimals="-3" id="f-165" unitRef="usd">12385000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-23" decimals="-3" id="f-166" unitRef="usd">410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-24" decimals="-3" id="f-167" unitRef="usd">410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-25" decimals="0" id="f-168" unitRef="shares">16666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-169" unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-26" decimals="-3" id="f-170" unitRef="usd">74983000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-171" unitRef="usd">75000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts contextRef="c-27" decimals="-3" id="f-172" unitRef="usd">-5187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts contextRef="c-28" decimals="-3" id="f-173" unitRef="usd">-5187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-174" unitRef="usd">1580000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-175" unitRef="usd">1580000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-25" decimals="0" id="f-176" unitRef="shares">490359</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c-26" decimals="-3" id="f-177" unitRef="usd">-893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">-893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-25" decimals="0" id="f-179" unitRef="shares">231400</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-26" decimals="-3" id="f-180" unitRef="usd">539000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">539000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-182" unitRef="usd">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c-30" decimals="0" id="f-184" unitRef="shares">90478731</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-185" unitRef="usd">90000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-186" unitRef="usd">295514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-187" unitRef="usd">-331905000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-188" unitRef="usd">-36301000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-22930000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">139000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">207000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">1587000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-194" unitRef="usd">1580000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">2750000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-5" decimals="-3" id="f-196" unitRef="usd">2673000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-46000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-5" decimals="-3" id="f-198" unitRef="usd">-32000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">3129000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c-5" decimals="-3" id="f-200" unitRef="usd">-147000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">1154000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-3" id="f-202" unitRef="usd">965000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-423000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">253000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">1905000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">1284000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-2776000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">-1873000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-261000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-5" decimals="-3" id="f-210" unitRef="usd">-388000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-23400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-212" unitRef="usd">-10384000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">135000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-214" unitRef="usd">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-135000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">-29000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-11" decimals="-3" id="f-217" unitRef="usd">21360000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-24" decimals="-3" id="f-218" unitRef="usd">11974000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-34" decimals="-3" id="f-219" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-28" decimals="-3" id="f-220" unitRef="usd">70126000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="-3" id="f-222" unitRef="usd">539000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">6000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-5" decimals="-3" id="f-224" unitRef="usd">5000</us-gaap:PaymentsOfFinancingCosts>
    <aqst:PaymentsForRoyaltyObligationsFinancingObligations contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">5000</aqst:PaymentsForRoyaltyObligationsFinancingObligations>
    <aqst:PaymentsForRoyaltyObligationsFinancingObligations contextRef="c-5" decimals="-3" id="f-226" unitRef="usd">0</aqst:PaymentsForRoyaltyObligationsFinancingObligations>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">703000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-228" unitRef="usd">893000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">20646000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-230" unitRef="usd">81741000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">-2889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-232" unitRef="usd">71328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-233" unitRef="usd">71546000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-21" decimals="-3" id="f-234" unitRef="usd">23872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-235" unitRef="usd">68657000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="-3" id="f-236" unitRef="usd">95200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">1525000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-5" decimals="-3" id="f-238" unitRef="usd">1003000</us-gaap:IncomeTaxesPaidNet>
    <aqst:CostsAssociatedWithPublicEquityOfferingInAccountsPayable contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">0</aqst:CostsAssociatedWithPublicEquityOfferingInAccountsPayable>
    <aqst:CostsAssociatedWithPublicEquityOfferingInAccountsPayable contextRef="c-5" decimals="-3" id="f-240" unitRef="usd">313000</aqst:CostsAssociatedWithPublicEquityOfferingInAccountsPayable>
    <aqst:CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">89000</aqst:CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable>
    <aqst:CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable contextRef="c-5" decimals="-3" id="f-242" unitRef="usd">0</aqst:CostsAssociatedWithAtTheMarketPublicEquityOfferingInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-243">Company Overview and Basis of Presentation&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(A) Company Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aquestive Therapeutics, Inc. is a pharmaceutical company advancing medicines to bring meaningful improvement to patients&#x2019; lives through innovative science and delivery technologies. The Company is developing pharmaceutical products to deliver complex molecules through alternative administrations to invasive and inconvenient standard of care therapies. The Company is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis, under the Anaphylm&#x2122; trade name, and its Adrenaverse&#x2122; epinephrine prodrug pipeline platform. The Company has four licensed commercialized products which are marketed by its licensees in the U.S. and around the world. The Company is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm&#xae;, and has proven drug development and commercialization capabilities. The Company&#x2019;s production facilities are located in Portage, Indiana, and its corporate headquarters and primary research laboratory facilities are based in Warren, New Jersey.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(B)&#160;Equity Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Offering of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company established its first ATM facility in September 2019, and since inception to March&#160;31, 2025, the Company has sold 27,315,145 shares of Common Stock under its ATM Facility which has generated net cash proceeds of approximately $81,829, net of commissions and other transactions costs of $3,814. On April 3, 2024, the Company filed a new shelf registration statement on Form S-3, the 2024 Registration Statement, which was declared effective by the SEC on April 23, 2024. Included as part of the 2024 Registration Statement are (i) a base prospectus registering the offer, issuance and sale of up to $250,000 worth of Common Stock, preferred stock, debt securities, warrants, rights and units and (ii) a $100,000 ATM facility prospectus. During the three months ended March 31, 2025, the Company sold 7,457,627 shares of Common Stock pursuant to the ATM prospectus and the Amended Equity Distribution Agreement with Piper Sandler &amp;amp; Co. (successor to Piper Jaffray &amp;amp; Co.), which provided net proceeds of approximately $21,306 after deducting commissions and other transaction costs of $694 of which $89 remains unpaid as of March 31, 2025. For the three months ended March 31, 2024, the Company sold 4,557,220 shares under the ATM facility which provided net proceeds of approximately $12,012 after deducting commissions and other transaction costs of $373. The remaining authorized balance of the ATM facility was $78,000 as of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 12, 2022, the Company entered into the Lincoln Park Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth in the Lincoln Park Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $40,000 worth of shares of Common Stock from time to time over the 36-month term of the Lincoln Park Purchase Agreement. The Lincoln Park Purchase Agreement contains an ownership limitation such that the Company will not issue, and Lincoln Park will not purchase, shares of Common Stock if it would result in Lincoln Park&#x2019;s beneficial ownership exceeding 9.99% of the Company&#x2019;s then outstanding Common Stock. Lincoln Park has covenanted under the Lincoln Park Purchase Agreement not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company&#x2019;s Common Stock. The Company did not sell shares in connection with the Lincoln Park Purchase Agreement during the three months ended March 31, 2025 or in 2024. The Lincoln Park Purchase agreement expired on May 1, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 22, 2024, the Company completed the underwritten public offering of 16,666,667 shares of its Common Stock at the public offering price of $4.50 per share. At closing, Aquestive received net proceeds of $70,500 after deducting underwriting discounts of $4,500. In addition to the underwriting discounts related to this offering, the Company incurred professional fees and other costs totaling $687 as of March 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, pursuant to the partial exercise of the underwriters' option, on April 22, 2024, the Company sold an additional 559,801 shares of Common Stock, for additional net proceeds of $2,368, after deducting underwriting discounts of $151. In addition to the underwriting discounts related to the partial exercise of the underwriters' option, the Company incurred professional fees and other costs totaling $207.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(C) Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed financial statements were prepared in conformity with U.S. GAAP and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and related notes for the fiscal year ended December&#160;31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March&#160;5, 2025 (the &#x201c;2024 Annual Report on Form 10-K&#x201d;). As included herein, the Condensed Balance Sheet as of December&#160;31, 2024 is derived from the audited financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of interim periods have been included. The accompanying condensed financial statements reflect certain reclassifications from previously issued financial statements to conform to the current presentation. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any reference in the Notes to applicable guidance refers to the authoritative U.S. GAAP as found in the ASC and ASU of FASB.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <aqst:RevenueFromContractWithCustomerNumberOfCommercializedProducts
      contextRef="c-1"
      decimals="INF"
      id="f-244"
      unitRef="product">4</aqst:RevenueFromContractWithCustomerNumberOfCommercializedProducts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-35" decimals="0" id="f-245" unitRef="shares">27315145</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-35" decimals="-3" id="f-246" unitRef="usd">81829000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-35" decimals="-3" id="f-247" unitRef="usd">3814000</us-gaap:PaymentsOfStockIssuanceCosts>
    <aqst:SaleOfStockMaximumTransactionAmount contextRef="c-36" decimals="-3" id="f-248" unitRef="usd">250000</aqst:SaleOfStockMaximumTransactionAmount>
    <aqst:SaleOfStockAggregateOfferingPrice contextRef="c-37" decimals="-6" id="f-249" unitRef="usd">100000000</aqst:SaleOfStockAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-38" decimals="0" id="f-250" unitRef="shares">7457627</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-38" decimals="-3" id="f-251" unitRef="usd">21306000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-38" decimals="-3" id="f-252" unitRef="usd">694000</us-gaap:PaymentsOfStockIssuanceCosts>
    <aqst:SaleOfStockUnpaidCommissionsAndOtherTransactionCosts contextRef="c-39" decimals="-3" id="f-253" unitRef="usd">89000</aqst:SaleOfStockUnpaidCommissionsAndOtherTransactionCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-40" decimals="0" id="f-254" unitRef="shares">4557220</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-40" decimals="-3" id="f-255" unitRef="usd">12012000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-40" decimals="-3" id="f-256" unitRef="usd">373000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-39" decimals="-3" id="f-257" unitRef="usd">78000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <aqst:RightToSellCommonStockValue contextRef="c-41" decimals="-3" id="f-258" unitRef="usd">40000</aqst:RightToSellCommonStockValue>
    <aqst:AgreementTerm contextRef="c-41" id="f-259">P36M</aqst:AgreementTerm>
    <aqst:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions contextRef="c-42" decimals="4" id="f-260" unitRef="number">0.0999</aqst:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipLimitationAfterAllTransactions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-43" decimals="0" id="f-261" unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-44" decimals="0" id="f-262" unitRef="shares">16666667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-45"
      decimals="2"
      id="f-263"
      unitRef="usdPerShare">4.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-44" decimals="-3" id="f-264" unitRef="usd">70500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <aqst:SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts contextRef="c-44" decimals="-3" id="f-265" unitRef="usd">4500000</aqst:SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-46" decimals="-3" id="f-266" unitRef="usd">687000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-47" decimals="0" id="f-267" unitRef="shares">559801</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-47" decimals="-3" id="f-268" unitRef="usd">2368000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <aqst:SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts contextRef="c-47" decimals="-3" id="f-269" unitRef="usd">151000</aqst:SaleOfStockConsiderationReceivedOnTransactionUnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-47" decimals="-3" id="f-270" unitRef="usd">207000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-271">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed financial statements were prepared in conformity with U.S. GAAP and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and related notes for the fiscal year ended December&#160;31, 2024 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March&#160;5, 2025 (the &#x201c;2024 Annual Report on Form 10-K&#x201d;). As included herein, the Condensed Balance Sheet as of December&#160;31, 2024 is derived from the audited financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of interim periods have been included. The accompanying condensed financial statements reflect certain reclassifications from previously issued financial statements to conform to the current presentation. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any reference in the Notes to applicable guidance refers to the authoritative U.S. GAAP as found in the ASC and ASU of FASB.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-272">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company adopted the new disclosure requirements as of December 31, 2024. Refer to Note 4,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the required disclosure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This Accounting Standards Update was issued to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Among other provisions, the amendments in this ASU significantly change the guidance on the issuer&#x2019;s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#x2019;s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. More specifically, the ASU reduces the number of models that may be used to account for convertible instruments from five to three, amends diluted EPS calculations for convertible instruments, modifies the requirements for a contract that may be settled in an entity&#x2019;s own shares to be classified in equity and requires expanded disclosures intended to increase transparency. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#x2019;s financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the FASB issued ASU 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This Accounting Standards Update was issued to clarify the guidance in Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, and to introduce new disclosure requirements for such equity securities. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Adopted as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the Statements of Operations, and Comprehensive Loss as well as qualitatively describe the remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company&#x2019;s definition of selling expenses. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact from the adoption of ASU 2024-03 on disclosures to its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&#x2014;Improvements to Income Tax Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This Accounting Standards Update was issued to enhance the transparency and decision usefulness of income tax &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;disclosures. The ASU requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). It further requires disclosure on an annual basis of the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). Additionally, it requires the following information disclosure: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The ASU eliminates certain current disclosure requirements. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2025, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2023-09 on disclosures to its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-273">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires all public entities, including public entities with a single reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024. The Company adopted the new disclosure requirements as of December 31, 2024. Refer to Note 4,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the required disclosure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This Accounting Standards Update was issued to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Among other provisions, the amendments in this ASU significantly change the guidance on the issuer&#x2019;s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#x2019;s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. More specifically, the ASU reduces the number of models that may be used to account for convertible instruments from five to three, amends diluted EPS calculations for convertible instruments, modifies the requirements for a contract that may be settled in an entity&#x2019;s own shares to be classified in equity and requires expanded disclosures intended to increase transparency. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#x2019;s financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the FASB issued ASU 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This Accounting Standards Update was issued to clarify the guidance in Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, and to introduce new disclosure requirements for such equity securities. The Company adopted the new guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Adopted as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the Statements of Operations, and Comprehensive Loss as well as qualitatively describe the remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company&#x2019;s definition of selling expenses. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact from the adoption of ASU 2024-03 on disclosures to its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)&#x2014;Improvements to Income Tax Disclosures. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This Accounting Standards Update was issued to enhance the transparency and decision usefulness of income tax &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;disclosures. The ASU requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). It further requires disclosure on an annual basis of the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). Additionally, it requires the following information disclosure: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. The ASU eliminates certain current disclosure requirements. These disclosure requirements will be effective for the Company for fiscal years beginning after December 15, 2025, with early adoption of the amendments permitted. The Company is currently evaluating the impact from the adoption of ASU 2023-09 on disclosures to its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c-1" id="f-274">Risks and Uncertainties&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company&#x2019;s cash requirements for the remainder of 2025 and beyond include expenses related to continuing development and clinical evaluation of its products, manufacture and supply costs, costs of regulatory filings, patent prosecution expenses and litigation expenses, expenses related to commercialization of its products, as well as costs to comply with the requirements of being a public company operating in a highly regulated industry. As of March&#160;31, 2025, the Company had $68,657 of cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has experienced a history of net losses. The Company&#x2019;s accumulated deficits totaled $386,144 as of March&#160;31, 2025. The net losses and accumulated deficits were partially offset by gross margins from sales of commercialized licensed and proprietary products, license fees, milestone and royalty payments from commercial licensees and co-development parties. The Company&#x2019;s funding requirements have been met by its cash and cash equivalents, as well as its equity and debt offerings, including the 13.5% Senior Secured Notes as further discussed in Note 14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the ATM facility and other equity offerings, including the underwritten public offering as discussed in Note 1, Part B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Transactions.&lt;/span&gt;&lt;/div&gt;While the Company&#x2019;s ability to execute its business objectives and achieve profitability over the longer term cannot be assured, the Company&#x2019;s on-going business, existing cash and cash equivalents, expense management activities, including, but not limited to the ceasing of R&amp;amp;D activities, as well as access to the equity capital markets through its ATM facility, provide near term liquidity for the Company to fund its operating needs for at least the next twelve months as it continues to execute its business strategy.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-275" unitRef="usd">68657000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-276" unitRef="usd">-386144000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-48" decimals="3" id="f-277" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-278">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is available for evaluation by the CODM in deciding how to allocate resources and in assessing performance. For the three months ended March 31, 2025 and 2024, the Company has identified one operating and reportable segment. The Company defines its operating segment based on internally reported financial information that is regularly reviewed by the CODM to analyze financial performance, make decisions, and allocate resources. The Company's Chief Executive Officer (&#x201c;CEO&#x201d;) is the CODM. The Company manages its operations as a single segment for purposes of assessing performance and making operating decisions. This segment encompasses the development and advancement of a product pipeline for the treatment of severe allergic reactions, including anaphylaxis, and the Adrenaverse epinephrine prodrug pipeline platform. Additionally, the Company serves as the exclusive manufacturer for its proprietary product, Libervant, and four licensed commercialized products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM reviews the segment's profit or loss based on net loss reported on the Condensed Statements of Operations and Comprehensive Loss. The CODM also considers forecast-to-actual variances on a monthly basis for expenses deemed significant. Furthermore, the CODM reviews the segment's assets based on total assets reported on the Condensed Balance Sheets. All long-lived assets are held in the United States. While the Company generated $8,720 and $12,053 in revenues for the three months ended March 31, 2025 and 2024, respectively, management expects the Company to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials, ultimately seeking regulatory approval. The CODM uses cash forecast models to guide investment decisions and assess entity-wide operating results and performance. Net loss is used to monitor budget and rolling forecasts versus actual results. The CODM views specific categories within research and development expenses, selling expenses, and general and administrative expenses as significant due to their direct correlation with cash burn and profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles reported revenues to net loss under the significant expense principle for the three months ended March 31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Manufacture and Supply Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;R&amp;amp;D Project expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anaphylm project expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AQST-108 project expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libervant project expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;R&amp;amp;D other expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Selling expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Selling expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General &amp;amp; Administrative expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 - R&amp;amp;D Personnel costs include payroll expenses,  share-based compensation expenses and severance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - Selling Personnel costs include payroll expenses and severance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - Other Selling expenses include commercialization and other related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - G&amp;amp;A Personnel costs include payroll expenses,  share-based compensation expenses and severance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-279"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-280"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-49" decimals="-3" id="f-281" unitRef="usd">8720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-50" decimals="-3" id="f-282" unitRef="usd">12053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-283">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles reported revenues to net loss under the significant expense principle for the three months ended March 31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Manufacture and Supply Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;R&amp;amp;D Project expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anaphylm project expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AQST-108 project expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libervant project expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;R&amp;amp;D other expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Selling expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Selling expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General &amp;amp; Administrative expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"&gt;6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 - R&amp;amp;D Personnel costs include payroll expenses,  share-based compensation expenses and severance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - Selling Personnel costs include payroll expenses and severance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - Other Selling expenses include commercialization and other related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - G&amp;amp;A Personnel costs include payroll expenses,  share-based compensation expenses and severance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-49" decimals="-3" id="f-284" unitRef="usd">8720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-50" decimals="-3" id="f-285" unitRef="usd">12053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-49" decimals="-3" id="f-286" unitRef="usd">3652000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-50" decimals="-3" id="f-287" unitRef="usd">4389000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-51" decimals="-3" id="f-288" unitRef="usd">2488000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-52" decimals="-3" id="f-289" unitRef="usd">3147000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-53" decimals="-3" id="f-290" unitRef="usd">195000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-54" decimals="-3" id="f-291" unitRef="usd">789000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-55" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-56" decimals="-3" id="f-293" unitRef="usd">17000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-57" decimals="-3" id="f-294" unitRef="usd">2132000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-58" decimals="-3" id="f-295" unitRef="usd">1704000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-59" decimals="-3" id="f-296" unitRef="usd">546000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-60" decimals="-3" id="f-297" unitRef="usd">275000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-49" decimals="-3" id="f-298" unitRef="usd">5361000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-50" decimals="-3" id="f-299" unitRef="usd">5932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingExpense contextRef="c-57" decimals="-3" id="f-300" unitRef="usd">694000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c-58" decimals="-3" id="f-301" unitRef="usd">932000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c-59" decimals="-3" id="f-302" unitRef="usd">2262000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c-60" decimals="-3" id="f-303" unitRef="usd">140000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c-49" decimals="-3" id="f-304" unitRef="usd">2956000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c-50" decimals="-3" id="f-305" unitRef="usd">1072000</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-57" decimals="-3" id="f-306" unitRef="usd">4840000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-58" decimals="-3" id="f-307" unitRef="usd">4661000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-59" decimals="-3" id="f-308" unitRef="usd">11276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-60" decimals="-3" id="f-309" unitRef="usd">4956000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-49" decimals="-3" id="f-310" unitRef="usd">16116000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-50" decimals="-3" id="f-311" unitRef="usd">9617000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-49" decimals="-3" id="f-312" unitRef="usd">19072000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-50" decimals="-3" id="f-313" unitRef="usd">10689000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-49" decimals="-3" id="f-314" unitRef="usd">28085000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-50" decimals="-3" id="f-315" unitRef="usd">21010000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-49" decimals="-3" id="f-316" unitRef="usd">-19365000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-50" decimals="-3" id="f-317" unitRef="usd">-8957000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-49" decimals="-3" id="f-318" unitRef="usd">-3565000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-50" decimals="-3" id="f-319" unitRef="usd">-3871000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-320" unitRef="usd">-22930000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-321" unitRef="usd">-12828000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-49" decimals="-3" id="f-322" unitRef="usd">-22930000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-50" decimals="-3" id="f-323" unitRef="usd">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-49" decimals="-3" id="f-324" unitRef="usd">-22930000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-50" decimals="-3" id="f-325" unitRef="usd">-12828000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-326">Revenues and Trade Receivables, Net&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues include (i) sales of manufactured products pursuant to contracts with commercialization licensees, (ii) license and royalty revenues, (iii) co-development and research fees generally in the form of milestone payments, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and (iv) sales of its proprietary CNS product, Libervant, for patients between two to five years of age while Libervant had U.S. market access. The Company recognizes revenue to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve this core principle, a five-step model is applied that includes (1) identifying the contract with a customer, (2) identifying the performance obligation in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the current revenue recognition standard.&#160;A contract&#x2019;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a distinct good.&#160;When identifying performance obligations, the Company considers all goods or services promised in a contract regardless of whether explicitly stated in the contract or implied by customary business practice. The Company&#x2019;s performance obligations consist mainly of transferring goods and services identified in the contracts, purchase orders, invoices or statements of work.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Manufacture and supply revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; this revenue is derived from products manufactured exclusively for specific customers according to their strictly-defined specifications, subject only to specified quality control inspections. Accordingly, at the point in time when quality control requirements are satisfied, revenue net of related discounts is recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Royalty Revenu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e &#x2013; license revenues are determined based on an assessment of whether the license is distinct from any other performance obligations that may be included in the underlying licensing arrangement. If the customer is able to benefit from the license without provision of any other performance obligations by the Company and the license is thereby viewed as a distinct or functional license, the Company then determines whether the customer has acquired a right to use the license or a right to access the license. For functional licenses that do not require further development or other ongoing activities by the Company, the customer is viewed as acquiring the right to use the license as, and when, transferred and revenues are generally recorded at a point in time, subject to contingencies or constraints. For symbolic licenses providing substantial value only in conjunction with other performance obligations to be provided by the Company, revenues are generally recorded over the term of the license agreement. Such other obligations provided by the Company generally include manufactured products, additional development services or other deliverables that are contracted to be provided during the license term. Payments received in excess of amounts ratably or otherwise earned are deferred and recognized over the term of the license or as contingencies or other performance obligations are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue is estimated and recognized when sales under supply agreements with commercial licensees are recorded, absent any contractual constraints or collectability uncertainties. Royalties based on sales of licensed products have been recorded in this manner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition arising from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.e&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., an NDA filing or obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales occur or the performance obligation to which the sales relate to has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-development and Research Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development defined within a contractual development or feasibility study agreement with a customer. The nature of these performance obligations, broadly referred to as milestones or deliverables, are usually dependent on the scope and structure of the project as contracted, as well as the complexity of the product and the specific regulatory approval path necessary for that product. Accordingly, the duration of the Company&#x2019;s research and development projects may range from several months to approximately three years. Although each contractual arrangement is unique, common milestones included in these arrangements include those for the performance of efficacy and other tests, reports of findings, formulation of initial prototypes, production of stability clinical and/or scale-up batches, and stability testing of those batches. Additional milestones may be established and linked to clinical results of the product submission and/or approval of the product by the FDA and the commercial launch of the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proprietary product revenue, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - this net revenue is recognized when product is shipped and title passes to the customer, typically at time of delivery. At the time of sale, estimates for various revenue allowances are recorded based on historical trends and judgmental estimates. For sales of Libervant for patients between two to five years of age, returns allowances and prompt pay discounts are estimated based on contract terms and historical return rates, if available, and these estimates are recorded as a reduction of receivables. Similarly determined estimates are recorded relating to wholesaler service fees, co-pay support redemptions, and other rebates, and these estimates are reflected as a component of accrued liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once all related variable considerations are resolved and uncertainties as to collectable amounts are eliminated, estimates are adjusted to actual allowance amounts. Provisions for these estimated amounts are reviewed and adjusted on no less than a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - in certain situations, customer contractual payment terms provide for invoicing in arrears. Accordingly, some, or all performance obligations may be completely satisfied before the customer may be invoiced under such agreements.&#160;In these situations, billing occurs after revenue recognition, which results in a contract asset supported by the estimated value of the completed portion of the performance obligation. These contract assets are reflected as a component of other receivables within Trade and other receivables within the Condensed Balance Sheets. As of March&#160;31, 2025, and December&#160;31, 2024, such contract assets were $718 and $578, respectively, consisting primarily of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - in certain situations, customer contractual payment terms are structured to permit invoicing in advance of delivery of a good or service. In such instances, the customer&#x2019;s cash payment may be received before satisfaction of some, or any, performance obligations that are specified. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. These contract liabilities are reflected as deferred revenue within the Condensed Balance Sheets. As remaining performance obligations are satisfied, an appropriate portion of the deferred revenue balance is credited to earnings. As of March&#160;31, 2025 and December&#160;31, 2024, such contract liabilities were $20,792 and $21,053, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs to Obtain Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - in certain situations, the Company may incur incremental costs of obtaining a contract with a customer. These costs, if expected to be recovered, are recognized as an asset and reflected as other assets within the Condensed Balance Sheets. The asset is amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. As of March&#160;31, 2025 and December&#160;31, 2024, such costs to obtain contracts were $472 and $480, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacture and supply revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License and royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Co-development and research fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides disaggregated net revenue by geographic area: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ex-United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2025, United States revenues were derived primarily from Indivior (manufacture and supply revenue, and co-development and research fees), and Assertio (manufacture and supply revenue, license and royalty revenue and co-development and research fees). Ex-United States revenues were derived primarily from Indivior (manufacture and supply revenue, license and royalty revenue and co-development and research fees), and Hypera (manufacture and supply revenue, and license and royalty revenue) for revenue markets outside of the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024, United States revenues were derived primarily from Indivior (manufacture and supply revenue, and co-development and research fees), and Assertio (manufacture and supply revenue, license and royalty revenue, and co-development and research fees). Ex-United States revenues were derived primarily from Indivior (manufacture and supply revenue, license and royalty revenue and co-development and research fees), Zambon (manufacture and supply revenue, license and royalty revenue and co-development and research fees), and Pharmanovia (co-development and research fees). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other receivables, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: sales-related allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract and other receivables totaled $2,213 and $2,473 as of March&#160;31, 2025 and December&#160;31, 2024, respectively, consisting primarily of contract assets and other receivables. Contract assets consist of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties. Other receivables include the current portion related to the Monetization royalty receivable and other receivables. Sales-related allowances as of March&#160;31, 2025 were estimated in relation to revenues recognized for sales of Libervant for patients between two to five years of age.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains an allowance for credit losses on accounts receivable, which is recorded as a reduction to accounts receivable. Changes in the allowance are classified as Selling, general and administrative expenses in the Statements of Operations and Comprehensive Loss. The Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when it identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status. It also considers customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. On an ongoing basis, management evaluates the adequacy of these reserves. The allowance for credit losses was $0 as of March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the allowance for credit losses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance reduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales-Related Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of products are recorded net of prompt payment discounts, wholesaler service fees, returns allowances, chargebacks, rebates and co-pay support redemptions. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provides a summary of activity with respect to sales-related allowances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for returns allowances and prompt pay discounts are reflected as a direct reduction of trade receivables and accruals for wholesaler service fees, co-pay support redemptions and other rebates are reflected as current liabilities. The accrued balances relative to these provisions included in Trade and other receivables, net and accrued expenses were $77 and $609, respectively, as of March&#160;31, 2025, and $48 and $665, respectively, as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers are considered major customers when net revenue exceeds 10% of total revenue for the period or outstanding receivable balances exceed 10% of total receivables. For the three months ended March 31, 2025, Indivior and Hypera, represented approximately 67% and 17%, of total revenue, respectively. As of March&#160;31, 2025, Indivior and Hypera exceeded the 10% threshold for outstanding receivable balances and represented approximately 56% and 14% of total trade and other receivables, respectively. For the three months ended March&#160;31, 2024, Indivior exceeded the 10% threshold for revenue and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;represented approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of total revenue. As of December&#160;31, 2024,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Indivior and Hypera exceeded the 10% threshold for outstanding receivable balances and represented 41% and 16% of total trade and other receivables, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-327">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues include (i) sales of manufactured products pursuant to contracts with commercialization licensees, (ii) license and royalty revenues, (iii) co-development and research fees generally in the form of milestone payments, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and (iv) sales of its proprietary CNS product, Libervant, for patients between two to five years of age while Libervant had U.S. market access. The Company recognizes revenue to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve this core principle, a five-step model is applied that includes (1) identifying the contract with a customer, (2) identifying the performance obligation in the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the current revenue recognition standard.&#160;A contract&#x2019;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a distinct good.&#160;When identifying performance obligations, the Company considers all goods or services promised in a contract regardless of whether explicitly stated in the contract or implied by customary business practice. The Company&#x2019;s performance obligations consist mainly of transferring goods and services identified in the contracts, purchase orders, invoices or statements of work.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Manufacture and supply revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; this revenue is derived from products manufactured exclusively for specific customers according to their strictly-defined specifications, subject only to specified quality control inspections. Accordingly, at the point in time when quality control requirements are satisfied, revenue net of related discounts is recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Royalty Revenu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e &#x2013; license revenues are determined based on an assessment of whether the license is distinct from any other performance obligations that may be included in the underlying licensing arrangement. If the customer is able to benefit from the license without provision of any other performance obligations by the Company and the license is thereby viewed as a distinct or functional license, the Company then determines whether the customer has acquired a right to use the license or a right to access the license. For functional licenses that do not require further development or other ongoing activities by the Company, the customer is viewed as acquiring the right to use the license as, and when, transferred and revenues are generally recorded at a point in time, subject to contingencies or constraints. For symbolic licenses providing substantial value only in conjunction with other performance obligations to be provided by the Company, revenues are generally recorded over the term of the license agreement. Such other obligations provided by the Company generally include manufactured products, additional development services or other deliverables that are contracted to be provided during the license term. Payments received in excess of amounts ratably or otherwise earned are deferred and recognized over the term of the license or as contingencies or other performance obligations are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue is estimated and recognized when sales under supply agreements with commercial licensees are recorded, absent any contractual constraints or collectability uncertainties. Royalties based on sales of licensed products have been recorded in this manner.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition arising from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.e&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., an NDA filing or obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales occur or the performance obligation to which the sales relate to has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-development and Research Fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development defined within a contractual development or feasibility study agreement with a customer. The nature of these performance obligations, broadly referred to as milestones or deliverables, are usually dependent on the scope and structure of the project as contracted, as well as the complexity of the product and the specific regulatory approval path necessary for that product. Accordingly, the duration of the Company&#x2019;s research and development projects may range from several months to approximately three years. Although each contractual arrangement is unique, common milestones included in these arrangements include those for the performance of efficacy and other tests, reports of findings, formulation of initial prototypes, production of stability clinical and/or scale-up batches, and stability testing of those batches. Additional milestones may be established and linked to clinical results of the product submission and/or approval of the product by the FDA and the commercial launch of the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proprietary product revenue, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - this net revenue is recognized when product is shipped and title passes to the customer, typically at time of delivery. At the time of sale, estimates for various revenue allowances are recorded based on historical trends and judgmental estimates. For sales of Libervant for patients between two to five years of age, returns allowances and prompt pay discounts are estimated based on contract terms and historical return rates, if available, and these estimates are recorded as a reduction of receivables. Similarly determined estimates are recorded relating to wholesaler service fees, co-pay support redemptions, and other rebates, and these estimates are reflected as a component of accrued liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once all related variable considerations are resolved and uncertainties as to collectable amounts are eliminated, estimates are adjusted to actual allowance amounts. Provisions for these estimated amounts are reviewed and adjusted on no less than a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - in certain situations, customer contractual payment terms provide for invoicing in arrears. Accordingly, some, or all performance obligations may be completely satisfied before the customer may be invoiced under such agreements.&#160;In these situations, billing occurs after revenue recognition, which results in a contract asset supported by the estimated value of the completed portion of the performance obligation. These contract assets are reflected as a component of other receivables within Trade and other receivables within the Condensed Balance Sheets. As of March&#160;31, 2025, and December&#160;31, 2024, such contract assets were $718 and $578, respectively, consisting primarily of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - in certain situations, customer contractual payment terms are structured to permit invoicing in advance of delivery of a good or service. In such instances, the customer&#x2019;s cash payment may be received before satisfaction of some, or any, performance obligations that are specified. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. These contract liabilities are reflected as deferred revenue within the Condensed Balance Sheets. As remaining performance obligations are satisfied, an appropriate portion of the deferred revenue balance is credited to earnings. As of March&#160;31, 2025 and December&#160;31, 2024, such contract liabilities were $20,792 and $21,053, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs to Obtain Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - in certain situations, the Company may incur incremental costs of obtaining a contract with a customer. These costs, if expected to be recovered, are recognized as an asset and reflected as other assets within the Condensed Balance Sheets. The asset is amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. As of March&#160;31, 2025 and December&#160;31, 2024, such costs to obtain contracts were $472 and $480, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <aqst:ResearchAndDevelopmentProjectDuration contextRef="c-61" id="f-328">P3Y</aqst:ResearchAndDevelopmentProjectDuration>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">718000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-4" decimals="-3" id="f-330" unitRef="usd">578000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">20792000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-332" unitRef="usd">21053000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CapitalizedContractCostNet contextRef="c-3" decimals="-3" id="f-333" unitRef="usd">472000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet contextRef="c-4" decimals="-3" id="f-334" unitRef="usd">480000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacture and supply revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License and royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Co-development and research fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-62" decimals="-3" id="f-336" unitRef="usd">7193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-63" decimals="-3" id="f-337" unitRef="usd">10518000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-64" decimals="-3" id="f-338" unitRef="usd">790000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-65" decimals="-3" id="f-339" unitRef="usd">1132000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-66" decimals="-3" id="f-340" unitRef="usd">418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-67" decimals="-3" id="f-341" unitRef="usd">403000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-68" decimals="-3" id="f-342" unitRef="usd">319000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">8720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-345" unitRef="usd">12053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-346">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides disaggregated net revenue by geographic area: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ex-United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="-3" id="f-347" unitRef="usd">5201000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-71" decimals="-3" id="f-348" unitRef="usd">10427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="-3" id="f-349" unitRef="usd">3519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-73" decimals="-3" id="f-350" unitRef="usd">1626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">8720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-352" unitRef="usd">12053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other receivables, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: sales-related allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract and other receivables totaled $2,213 and $2,473 as of March&#160;31, 2025 and December&#160;31, 2024, respectively, consisting primarily of contract assets and other receivables. Contract assets consist of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services, as well as estimated receivables from contracts with third parties. Other receivables include the current portion related to the Monetization royalty receivable and other receivables. Sales-related allowances as of March&#160;31, 2025 were estimated in relation to revenues recognized for sales of Libervant for patients between two to five years of age.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains an allowance for credit losses on accounts receivable, which is recorded as a reduction to accounts receivable. Changes in the allowance are classified as Selling, general and administrative expenses in the Statements of Operations and Comprehensive Loss. The Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when it identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status. It also considers customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. On an ongoing basis, management evaluates the adequacy of these reserves. The allowance for credit losses was $0 as of March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provides a summary of activity with respect to sales-related allowances:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross contextRef="c-3" decimals="-3" id="f-354" unitRef="usd">8308000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-4" decimals="-3" id="f-355" unitRef="usd">4919000</us-gaap:AccountsReceivableGross>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-3" decimals="-3" id="f-356" unitRef="usd">2213000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">2473000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-74" decimals="-3" id="f-358" unitRef="usd">77000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-75" decimals="-3" id="f-359" unitRef="usd">48000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <aqst:TradeAndOtherReceivablesNet contextRef="c-3" decimals="-3" id="f-360" unitRef="usd">10444000</aqst:TradeAndOtherReceivablesNet>
    <aqst:TradeAndOtherReceivablesNet contextRef="c-4" decimals="-3" id="f-361" unitRef="usd">7344000</aqst:TradeAndOtherReceivablesNet>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-3" decimals="-3" id="f-362" unitRef="usd">2213000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-4" decimals="-3" id="f-363" unitRef="usd">2473000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-76" decimals="-3" id="f-364" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-77" decimals="-3" id="f-365" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock contextRef="c-1" id="f-366">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the allowance for credit losses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance reduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-76" decimals="-3" id="f-367" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-78" decimals="-3" id="f-368" unitRef="usd">14000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-79" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-80" decimals="-3" id="f-370" unitRef="usd">14000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-77" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-76" decimals="-3" id="f-372" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-75" decimals="-3" id="f-373" unitRef="usd">48000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-81" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-82" decimals="-3" id="f-375" unitRef="usd">45000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-83" decimals="-3" id="f-376" unitRef="usd">71000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries contextRef="c-82" decimals="-3" id="f-377" unitRef="usd">16000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries contextRef="c-83" decimals="-3" id="f-378" unitRef="usd">23000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-74" decimals="-3" id="f-379" unitRef="usd">77000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-75" decimals="-3" id="f-380" unitRef="usd">48000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-84" decimals="-3" id="f-381" unitRef="usd">77000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-85" decimals="-3" id="f-382" unitRef="usd">609000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-86" decimals="-3" id="f-383" unitRef="usd">48000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-87" decimals="-3" id="f-384" unitRef="usd">665000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-88" decimals="2" id="f-385" unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-89" decimals="2" id="f-386" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="2" id="f-387" unitRef="number">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-91" decimals="2" id="f-388" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="2" id="f-389" unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-93" decimals="2" id="f-390" unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-94" decimals="2" id="f-391" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-392">Material Agreements&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial Exploitation Agreement with Indivior&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2008, the Company entered into the Indivior License Agreement (with subsequent amendments) with Reckitt Benckiser Pharmaceuticals, Inc. who was later succeeded to in interest by Indivior.&#160;Pursuant to the Indivior License Agreement, the Company agreed to manufacture and supply Indivior&#x2019;s requirements for Suboxone&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a sublingual film formulation, both inside and outside the United States on an exclusive basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Indivior License Agreement, the Company is required to manufacture Suboxone in accordance with current Good Manufacturing Practice standards and according to the specifications and processes set forth in the related quality agreements the Company entered into with Indivior. Additionally, the Company is required to obtain API&#160;for the manufacture of Suboxone directly from Indivior. The Indivior License Agreement specifies a minimum annual threshold quantity of Suboxone that the Company is obligated to fill and requires Indivior to provide the Company with a forecast of its requirements at various specified times throughout the year. The Indivior License Agreement provides for payment by Indivior of an agreed upon purchase price per unit until January 1, 2025 and, thereafter, that is subject to annual adjustments based on changes in an agreed upon price index. In addition to the purchase price for the Suboxone supplied, Indivior is required to make certain single digit percentage royalty payments tied to net sales value (as provided for in the Indivior License Agreement) outside of the U.S., subject to annual maximum amounts and limited to the life of the related patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Indivior License Agreement contains customary contractual termination provisions, including with respect to a filing for bankruptcy or corporate dissolution, an invalidation of the intellectual property surrounding Suboxone, and commission of a material breach of the Indivior License Agreement by either party. Additionally, Indivior may terminate the Indivior License Agreement if the FDA or other applicable regulatory authority declares the Company&#x2019;s manufacturing site to no longer be suitable for the manufacture of Suboxone or Suboxone is no longer suitable to be manufactured due to health or safety reasons. The initial term of the Indivior License Agreement was seven years from the commencement date. Thereafter, the Indivior License Agreement automatically renewed for successive one-year periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of March 2, 2023, the Company and Indivior entered into the Indivior Amendment to the Indivior License Agreement. The Indivior Amendment was entered into for the primary purpose of amending the Agreement as follows: (i) extending the term of the Agreement until August 16, 2026 and thereafter providing for automatic renewal terms of successive one-year periods unless Indivior delivers notice to the Company, at least twelve months prior to the expiration of the then current term, of Indivior&#x2019;s intent not to renew, subject to the earlier termination rights of the parties under the Agreement, and providing that the Agreement will not automatically renew for any renewal term beginning after the expiration of the last to expire of the product patents covered under the Indivior License Agreement; and (ii) agreeing to transfer pricing and payment terms for supplied product under the Indivior License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Sunovion Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2016, the Company entered into a license agreement with Cynapsus Therapeutics Inc. (which was later succeeded to in interest by Sunovion), referred to as the Sunovion License Agreement, pursuant to which Sunovion obtained an exclusive, worldwide license (with the right to sub-license) to certain intellectual property, including existing and future patents and patent applications, covering all oral films containing apomorphine for the treatment of off episodes in Parkinson&#x2019;s disease patients. Sunovion used this intellectual property to develop its apomorphine product KYNMOBI, which was approved by the FDA on May 21, 2020. This approval triggered Sunovion&#x2019;s obligation to remit a payment of $4,000, due on the earlier of: (a) the first day of product availability at a pharmacy in the United States; or (b) within six months of FDA approval of the product. This amount was received as of September 30, 2020 and was included in License and royalty revenues for the twelve months ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective March 16, 2020, the Company entered into the First Amendment. The First Amendment was entered into for the primary purpose of amending the Sunovion License Agreement as follows: (i) including the United Kingdom and any other country currently in the EU which later withdraws as a member country in the EU for purpose of determining the satisfaction of the condition triggering the obligation to pay the third milestone due under the Sunovion License Agreement, (ii) extending the date after which Sunovion has the right to terminate the Sunovion License Agreement for convenience from December 31, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024 to March 31, 2028, (iii) modifying the effective inception date of the first minimum annual royalty due from Sunovion to the Company form January 1, 2020 to April 1, 2020, and (iv) modifying the termination provision to reflect the Company&#x2019;s waiver of the right to terminate the Sunovion License Agreement in the event that KYNMOBI was not commercialized by January 1, 2020. This Sunovion License Agreement will continue until terminated by Sunovion in accordance with the termination provisions of the First Amendment. The Sunovion License Agreement continues (on a country-by-country basis) until the expiration of all applicable licensed patents unless earlier terminated under the termination provisions contained therein. Upon termination of the Sunovion License Agreement, all rights to intellectual property granted to Sunovion to develop and commercialize apomorphine-based products will revert to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2020, the Company amended the Sunovion License Agreement to clarify the parties' agreement with respect to certain provisions in the Sunovion License Agreement, specifically the date after which Sunovion has the right to terminate the Sunovion License Agreement and the rights and obligations of the parties regarding the prosecution and maintenance of the Company&#x2019;s patents covered under the Sunovion License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration of the rights granted to Sunovion under the Sunovion License Agreement, the Company received aggregate payments totaling $22,000 to date. In addition to the upfront payment of $5,000, the Company has also earned an aggregate of $17,000 in connection with specified regulatory and development milestones in the United States and Europe (the &#x201c;Initial Milestone Payments&#x201d;), all of which have been received to date. With the Monetization Agreement (defined below) entered into on November 3, 2020 relating to KYNMOBI as described in the paragraph below, the Company is no longer entitled to receive any payments under the Sunovion License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase and Sale Agreement with an affiliate of Marathon&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 3, 2020, the Company entered into the Monetization Agreement with Marathon. Under the terms of the Monetization Agreement, the Company sold to Marathon all of its contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#x2019;s apomorphine product, KYNMOBI. In exchange for the sale of these rights, the Company received an upfront payment from Marathon of $40,000 and an additional payment of $10,000 through the achievement of the first milestone. The Company has received an aggregate amount of $50,000 through March&#160;31, 2025 under the Monetization Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Monetization Agreement, additional contingent payments of up to $75,000 may be due to the Company upon the achievement of worldwide royalty and other commercial targets within a specified timeframe, which could result in total potential proceeds of $125,000. In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets; therefore, the Company likely will not receive any of the additional contingent payments under the Monetization agreement. See Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Future Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details on the accounting for the Monetization Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Agreement to Terminate CLA with Zevra Therapeutics, Inc. (formerly KemPharm)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2012, the Company entered into an agreement with Zevra to terminate a Collaboration and License Agreement entered into by the Company and Zevra in April 2011. Under this termination arrangement, the Company has the right to participate in any and all value that Zevra may derive from the commercialization or any other monetization of KP-415 and KP-484 compounds or their derivatives. Among these monetization transactions are those related to any business combinations involving Zevra and collaborations, royalty arrangements, or other transactions from which Zevra may realize value from these compounds, including the product Azstarys&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing and Supply Agreement with Haisco for Exservan&#x2122; (Riluzole Oral Film) for ALS Treatment in China&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into the Haisco Agreement with Haisco, a Chinese limited company listed on the Shenzhen Stock Exchange, effective as of March 3, 2022, pursuant to which Aquestive granted Haisco an exclusive license to develop and commercialize Exservan&#x2122; (riluzole oral film) for the treatment of ALS in China. Under the terms of the Haisco Agreement, Aquestive was the exclusive sole manufacturer and supplier for Exservan in China. Under the Haisco Agreement, as amended, the Company received a $7,000 upfront cash payment in September 2022 and was entitled to receive regulatory milestone payments and double-digit royalties on net sales of Exservan in China and earn manufacturing revenue upon the sale of Exservan in China. In June 2024, the Haisco Agreement was terminated, and the Company will not receive any contingent payments under the Haisco Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing and Supply Agreement with Atnahs Pharma UK Limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into the Pharmanovia Agreement, effective as of September 26, 2022, pursuant to which the Company granted Pharmanovia an exclusive license to certain of the Company&#x2019;s intellectual property to develop and commercialize Libervant&#x2122; (diazepam) Buccal Film for the treatment of prolonged or acute, convulsive seizures in all ages in the Territory during the term of the Pharmanovia Agreement. Under the Pharmanovia Agreement, Pharmanovia will lead the regulatory and commercialization activities for Libervant in the Territory and the Company will serve as the exclusive sole &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;manufacturer and supplier of Libervant in the Territory. Pursuant to the Pharmanovia Agreement, the Company received $3,500 upon agreement execution and, upon the occurrence of certain conditions set forth in the Pharmanovia Agreement, will receive additional milestone payments and profit shares, as well as manufacturing fees and royalty fees through the expiration of the Pharmanovia Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective March 27, 2023, the Company amended the Pharmanovia Agreement to expand the scope of territory for the license of Libervant to cover the rest of the world, excluding the U.S., Canada and China. Under the Pharmanovia Amendment, Pharmanovia will be responsible for seeking applicable regulatory approval in the expanded territories, which include Latin America, Africa and Asia Pacific. Pursuant to the terms of the Pharmanovia Amendment, the Company received a non-refundable payment of $2,000 from Pharmanovia in connection with the execution of the Pharmanovia Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreement with Assertio Holdings, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of October 26, 2022, the Company entered into the Assertio Agreement to license Sympazan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox&#x2010;Gastaut syndrome in patients aged two years of age and older. Under the terms of the Assertio Agreement, the Company granted to Assertio an exclusive, worldwide license of its intellectual property for Sympazan to Assertio during the term of the Assertio License Agreement for an upfront payment of $9,000. In addition, Aquestive received a $6,000 milestone payment subsequent to Aquestive&#x2019;s receipt of a notice of allowance from the PTO of the Company&#x2019;s patent application U.S. Serial No. 16/561,573, and payment by the Company of the related allowance fee. The Company received the notice of allowance from the PTO and paid the related allowance fee on October 27, 2022. Further, under the Assertio Agreement, the Company will receive royalties from Assertio for the sale of the product through the expiration of the Assertio Agreement. The Company also entered into a long-term supply agreement with Assertio for Sympazan pursuant to which the Company is the exclusive sole worldwide manufacturer and supplier of the product and will receive manufacturing fees from Assertio for the product through the expiration of such supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreement with Mitsubishi Tanabe Pharma America, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced that Aquestive granted an exclusive license to MTPA for the commercialization of Exservan in the United States. MTPA is a multinational pharmaceutical company with a focus on patients with ALS. The product was launched by MTPA in June 2021. Under the terms of the MTPA license agreement, Aquestive was the exclusive manufacturer and supplier of Exservan for MTPA in the United States. In June 2024, under the Second Amendment to the License and Supply Agreement, MTPA and the Company mutually agreed to terminate the agreement. As of June 30, 2024 and as part of the termination, the parties were released from any existing or ongoing obligations (except for certain limited non-material post-termination obligations).&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <aqst:LicenseAgreementTerm contextRef="c-95" id="f-393">P7Y</aqst:LicenseAgreementTerm>
    <aqst:AutomaticRenewalPeriodOfAgreement contextRef="c-95" id="f-394">P1Y</aqst:AutomaticRenewalPeriodOfAgreement>
    <aqst:AutomaticRenewalPeriodOfAgreement contextRef="c-96" id="f-395">P1Y</aqst:AutomaticRenewalPeriodOfAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-396" unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-98" decimals="-3" id="f-397" unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-99" decimals="-3" id="f-398" unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-100" decimals="-3" id="f-399" unitRef="usd">17000000</us-gaap:Revenues>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-101" decimals="-3" id="f-400" unitRef="usd">40000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet contextRef="c-101" decimals="-3" id="f-401" unitRef="usd">10000000</aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-102" decimals="-3" id="f-402" unitRef="usd">50000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <aqst:ContingentMonetizationAgreementMilestonePayment contextRef="c-101" decimals="-3" id="f-403" unitRef="usd">75000000</aqst:ContingentMonetizationAgreementMilestonePayment>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-103" decimals="-3" id="f-404" unitRef="usd">125000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss contextRef="c-104" decimals="-3" id="f-405" unitRef="usd">7000000</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-105" decimals="-3" id="f-406" unitRef="usd">3500000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-106" decimals="-3" id="f-407" unitRef="usd">2000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <us-gaap:ProceedsFromCollaborators contextRef="c-107" decimals="-3" id="f-408" unitRef="usd">9000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-409" unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-410">Financial Instruments &#x2013; Fair Value Measurements&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&#160;Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level 1 &#x2014; Observable quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level 2 &#x2014; Observable prices that are based on inputs not quoted on active markets but corroborated by market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity, such as pricing models, discounted cash flow&#160;methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the Condensed Balance Sheets for Trade and other receivables, prepaid and other current assets, accounts payable and accrued expenses, and deferred revenue approximate their fair values based on the short-term maturity of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted warrants to certain noteholders in connection with its debt repayment and debt refinancing of the 12.5% Notes during 2020 and 2019, respectively. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation. See Note 15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information on these warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company issued pre-funded warrants to purchase up to 4,000,000 shares of Common Stock and Common Stock Warrants to purchase up to 8,850,000 shares of Common Stock in connection with its Securities Purchase Agreements with certain purchasers. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide. See Note 15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information on these warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2023, the Company entered into the Letter Agreement with the Exercising Holder of the remaining warrants to purchase 5,000,000 of the shares of Common Stock. Pursuant to the Letter Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise all of its Existing Warrants for shares of Common Stock underlying the Existing Warrants at $0.96 per share of Common Stock, the current exercise price of the Existing Warrants. Under the Letter Agreement, in consideration of the Exercising Holder exercising the Existing Warrants, the Company issued to the Exercising Holder new warrants to purchase up to an aggregate of 2,750,000 shares of new warrants at $2.60 per share. Those warrants were valued based on Level 3 inputs and their&#160;fair value was based primarily on an independent third-party appraisal prepared as of the grant&#160;date consistent with generally accepted valuation methods of the Uniform Standards of Professional Appraisal Practice, the American Society of Appraisers and the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide. See Note 15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information on these warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2023, in connection with the issuance of the 13.5% Notes, the Company and the Note Holders entered into the Royalty Right Agreements dated as of November 1, 2023, which provides the Note Holders:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;a tiered royalty between 1.0% and 2.0% of annual worldwide net sales of Anaphylm&#x2122; (epinephrine) Sublingual Film for a period of eight years from the first sale of Anaphylm on a global basis, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;a tiered royalty between 1.0% to 2.0% of annual worldwide net sales of Libervant&#xae; (diazepam) Buccal Film until the earlier of (1) the first sale of Anaphylm and (2) eight years from the first sale of Libervant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Those Royalty Agreements were valued based on Level 3 inputs and their&#160;fair value was based primarily on internal management estimates developed based on third-party data and reflect management&#x2019;s judgements, current market conditions, and forecasts. The initial fair value measurement of the Royalty Right Agreements was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and the estimated amount of future sales of Anaphylm and Libervant. See Note 14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further discussion.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-108" decimals="3" id="f-411" unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aqst:SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants contextRef="c-109" decimals="0" id="f-412" unitRef="shares">4000000</aqst:SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants>
    <aqst:SharesOfCommonStockToBePurchasedByCommonStockWarrants contextRef="c-109" decimals="0" id="f-413" unitRef="shares">8850000</aqst:SharesOfCommonStockToBePurchasedByCommonStockWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-110" decimals="0" id="f-414" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-110"
      decimals="2"
      id="f-415"
      unitRef="usdPerShare">0.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-111" decimals="0" id="f-416" unitRef="shares">2750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="2"
      id="f-417"
      unitRef="usdPerShare">2.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-112" decimals="3" id="f-418" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-113" decimals="3" id="f-419" unitRef="number">0.010</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-114" decimals="3" id="f-420" unitRef="number">0.020</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm contextRef="c-115" id="f-421">P8Y</aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-113" decimals="3" id="f-422" unitRef="number">0.010</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-114" decimals="3" id="f-423" unitRef="number">0.020</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm contextRef="c-115" id="f-424">P8Y</aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-425">Inventories&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw material&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Packaging material&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Inventory are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw material&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Packaging material&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-3" decimals="-3" id="f-427" unitRef="usd">2964000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-3" id="f-428" unitRef="usd">3266000</us-gaap:InventoryRawMaterials>
    <aqst:InventoryPackingMaterialGross contextRef="c-3" decimals="-3" id="f-429" unitRef="usd">2344000</aqst:InventoryPackingMaterialGross>
    <aqst:InventoryPackingMaterialGross contextRef="c-4" decimals="-3" id="f-430" unitRef="usd">2135000</aqst:InventoryPackingMaterialGross>
    <us-gaap:InventoryFinishedGoods contextRef="c-3" decimals="-3" id="f-431" unitRef="usd">1890000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-432" unitRef="usd">643000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-433" unitRef="usd">7198000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-434" unitRef="usd">6044000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-435">Property and Equipment, Net&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful&lt;br/&gt;Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer, network equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total depreciation, amortization, and impairment related to property and equipment was $139 and $168 for the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-436">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful&lt;br/&gt;Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer, network equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Leasehold improvements are amortized over the shorter of the lease term or their estimated useful lives.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-116" id="f-437">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-117" id="f-438">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-118" decimals="-3" id="f-439" unitRef="usd">20348000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-119" decimals="-3" id="f-440" unitRef="usd">20317000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-120" id="f-441">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-121" id="f-442">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-122" decimals="-3" id="f-443" unitRef="usd">769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-123" decimals="-3" id="f-444" unitRef="usd">769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-124" decimals="-3" id="f-445" unitRef="usd">21419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-125" decimals="-3" id="f-446" unitRef="usd">21419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-126" id="f-447">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-127" id="f-448">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-128" decimals="-3" id="f-449" unitRef="usd">2830000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-129" decimals="-3" id="f-450" unitRef="usd">2685000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-130" decimals="-3" id="f-451" unitRef="usd">2069000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-131" decimals="-3" id="f-452" unitRef="usd">2110000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-453" unitRef="usd">47435000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">47300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-455" unitRef="usd">43634000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-456" unitRef="usd">43501000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-457" unitRef="usd">3801000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-458" unitRef="usd">3799000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-459" unitRef="usd">139000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-460" unitRef="usd">168000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-461">Right-of-Use Assets and Lease Obligations&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases all realty used at its production and warehouse facilities, corporate headquarters, commercialization operations center and research and laboratory facilities. None of these three leases include the characteristics specified in ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which require classification as financing leases and, accordingly, these leases are accounted for as operating leases. These leases, as amended, provide remaining terms between 3.0 years and 8.5 years, including renewal options expected to be exercised to extend the lease periods. Commitments under finance leases are not significant, and are included in Property and equipment, net, and Notes Payable, net on the Condensed Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not recognize a right-to-use asset and lease liability for short-term leases, which have terms of 12 months or less on its Condensed Balance Sheets. For longer-term lease arrangements that are recognized on the Company&#x2019;s Condensed Balance Sheets, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company&#x2019;s short-term leases, as well as variable costs relating to the Company&#x2019;s lease arrangements, are not material to the Company&#x2019;s financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The implicit interest rates of the Company&#x2019;s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. Measurement of the operating lease liability reflects a range of an estimated discount rate of 14.8% to 15.6% applied to minimum lease payments, including expected renewals, based on the incremental borrowing rate experienced in the Company&#x2019;s collateralized debt refinancing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease costs are recorded in manufacture and supply, research and development and selling, general and administrative expenses in its Condensed Statements of Operations and Comprehensive Loss. For the three months ended March&#160;31, 2025, total operating lease expenses totaled $427, including variable lease expenses such as common area maintenance and operating costs of $93. For the three months ended March&#160;31, 2024, total operating lease expenses totaled $444, including variable lease expenses such as common area maintenance and operating costs of $115.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s payments due under its operating leases are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <aqst:NumberOfOperatingLeases contextRef="c-3" decimals="INF" id="f-462" unitRef="lease">3</aqst:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-132" id="f-463">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-133" id="f-464">P8Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-132" decimals="3" id="f-465" unitRef="number">0.148</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-133" decimals="3" id="f-466" unitRef="number">0.156</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-467" unitRef="usd">427000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-468" unitRef="usd">93000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-3" id="f-469" unitRef="usd">444000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-3" id="f-470" unitRef="usd">115000</us-gaap:VariableLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-471">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s payments due under its operating leases are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-472" unitRef="usd">966000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-473" unitRef="usd">1318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-474" unitRef="usd">1346000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-475" unitRef="usd">1180000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <aqst:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter contextRef="c-3" decimals="-3" id="f-476" unitRef="usd">3915000</aqst:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-477" unitRef="usd">8725000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-478" unitRef="usd">3363000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-479" unitRef="usd">5362000</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-480">Intangible Assets, Net&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of identifiable intangible assets, all of which are finite lived:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased intangible&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased patent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;There was no amortization expense incurred during the three months ended March&#160;31, 2025. Amortization expense was $39 for the three months ended March&#160;31, 2024. In June 2024, in connection with a termination of an agreement, the Company recorded an adjustment to the remaining balance of $1,200 of the intangible asset</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of identifiable intangible assets, all of which are finite lived:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased intangible&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased patent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-134" decimals="-3" id="f-482" unitRef="usd">3858000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-135" decimals="-3" id="f-483" unitRef="usd">3858000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-136" decimals="-3" id="f-484" unitRef="usd">509000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-137" decimals="-3" id="f-485" unitRef="usd">509000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-3" decimals="-3" id="f-486" unitRef="usd">4367000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-487" unitRef="usd">4367000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-488" unitRef="usd">4367000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-489" unitRef="usd">4367000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-490" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-491" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-492" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-493" unitRef="usd">39000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-138" decimals="-3" id="f-494" unitRef="usd">1200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="c-1" id="f-495">Other Non-current Assets&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2020, under the Sunovion License Agreement, the Company recognized $8,000 of royalty revenue and corresponding royalty receivable, related to the eight $1,000 annual minimum guaranteed royalty payments that are due to the Company. In connection with the Monetization Agreement, the Company performed an assessment under ASC 860, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transfer and Servicing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to determine whether the existing receivable was transferred to Marathon and concluded it was not transferred. As of March&#160;31, 2025 and December&#160;31, 2024, Royalty receivable consists of four annual minimum payments due from Sunovion, the last of which is due in March 2028. The current portion of the royalty receivable is included in Trade and other receivables, net. See Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Future Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details on how this receivable relates to the Monetization Agreement transaction.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of costs to obtain contracts capitalized under ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs, &lt;/span&gt;is recorded within Other non-current assets on the  Condensed Balance Sheets as of March 31, 2025 and December 31, 2024.</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="c-1" id="f-496">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <aqst:CumulativeRoyaltyReceivable contextRef="c-3" decimals="-3" id="f-497" unitRef="usd">3000000</aqst:CumulativeRoyaltyReceivable>
    <aqst:CumulativeRoyaltyReceivable contextRef="c-4" decimals="-3" id="f-498" unitRef="usd">3000000</aqst:CumulativeRoyaltyReceivable>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="c-3" decimals="-3" id="f-499" unitRef="usd">1215000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="c-4" decimals="-3" id="f-500" unitRef="usd">1223000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-501" unitRef="usd">4215000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-502" unitRef="usd">4223000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-3" id="f-503" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <aqst:NumberOfGuaranteedRoyaltyPayments
      contextRef="c-140"
      decimals="INF"
      id="f-504"
      unitRef="payment">8</aqst:NumberOfGuaranteedRoyaltyPayments>
    <aqst:MinimumAnnualRoyaltyReceivable contextRef="c-141" decimals="-3" id="f-505" unitRef="usd">1000000</aqst:MinimumAnnualRoyaltyReceivable>
    <aqst:NumberOfAnnualRoyaltyPaymentsReceivable
      contextRef="c-142"
      decimals="INF"
      id="f-506"
      unitRef="payment">4</aqst:NumberOfAnnualRoyaltyPaymentsReceivable>
    <aqst:NumberOfAnnualRoyaltyPaymentsReceivable
      contextRef="c-143"
      decimals="INF"
      id="f-507"
      unitRef="payment">4</aqst:NumberOfAnnualRoyaltyPaymentsReceivable>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-508">Accrued Expenses&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate and personal property taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued distribution expenses and sales returns provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reduction in Accrued compensation is mostly related to payments of accrued bonuses during the three months ended March 31, 2025, partially offset by the current year accrual of bonuses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued distribution expenses and sales returns provision mostly represent estimated liabilities for wholesaler service fees, co-pay support redemptions and other rebates related to the proprietary product Libervant and returns and other expenses related to the proprietary product Sympazan (prior to outlicensing to Assertio in October 2022).&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-509">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate and personal property taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued distribution expenses and sales returns provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-510" unitRef="usd">2189000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-511" unitRef="usd">4732000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-3" decimals="-3" id="f-512" unitRef="usd">417000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-513" unitRef="usd">365000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-85" decimals="-3" id="f-514" unitRef="usd">609000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-87" decimals="-3" id="f-515" unitRef="usd">665000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InterestPayableCurrent contextRef="c-3" decimals="-3" id="f-516" unitRef="usd">17000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-517" unitRef="usd">17000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-518" unitRef="usd">82000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-519" unitRef="usd">128000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-520" unitRef="usd">3314000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-521" unitRef="usd">5907000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-522">Long-Term Debt&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;13.5% Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2023, the Company entered into an Indenture Agreement with certain institutional investors (the &#x201c;Note Holders&#x201d;) and issued $45,000 aggregate principal amount of its 13.5% Notes due 2028. The Company received net proceeds of approximately $4,326 from this transaction after the repayment of the 12.5% Notes and deduction of debt discount, and debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The 13.5% Notes are senior secured obligations of the Company and mature on November 1, 2028. The 13.5% Notes bear interest at a fixed rate of 13.5% per year, payable quarterly commencing on December 30, 2023. On each payment date commencing on June 30, 2026, the Company will pay an installment of principal of the 13.5% Notes pursuant to a fixed amortization schedule, along with the applicable Exit Fee. The Exit Fee totals $2,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may, at its option, redeem the 13.5% Notes in full or in part:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;if such redemption occurs prior to November 1, 2025, at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest, plus the applicable Exit Fee, plus an Applicable Premium which is the greater of &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-23.27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt"&gt;1.0% of the principal redeemed; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-26.04pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt"&gt;the amount, if any, by which the present value of the principal to be redeemed on November 1, 2025, plus all required interest due on such date, computed using a discount rate equal to the Treasury Rate, plus 100 basis points, exceeds the amount of principal to be redeemed; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;if such redemption occurs after November 1, 2025, the redemption price is equal to 108.5% of the principal amount plus accrued and unpaid interest, plus the applicable Exit Fee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a change of control, the Note Holders may require the Company to repurchase for cash all or any portion of the 13.5% Notes at a change of control repurchase price equal at 108.5% plus the Exit Fee of the remaining principal, plus accrued interest at the election of the Note Holders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Indenture permits the Company, upon the continuing satisfaction of certain conditions, including that the Company has at least $100,000 of net revenues for the most recently completed twelve calendar month period, to enter into an ABL facility not to exceed $10,000. The ABL Facility may be collateralized only by assets of the Company constituting inventory, accounts receivable, and the proceeds thereof. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of 13.5% Notes, the Company and the Note Holders entered into the Royalty Right Agreements dated as of November 1, 2023, which provides Note Holders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;a tiered royalty between 1.0% and 2.0% of annual worldwide net sales of Anaphylm&#x2122; (epinephrine) Sublingual Film for a period of eight years from the first sale of Anaphylm on a global basis, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;a tiered royalty between 1.0% to 2.0% of annual worldwide net sales of Libervant&#xae; (diazepam) Buccal Film until the earlier of (1) the first sale of Anaphylm and (2) eight years from the first sale of Libervant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Both the 13.5% Notes and Royalty Right Agreements, represent freestanding instruments which were issued in conjunction with each other. They are classified as debt within the scope of ASC 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and are subsequently measured on an amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial fair value measurement of the Royalty Right Agreements was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, and the estimated amount of future sales of Anaphylm and Libervant. These inputs are derived using internal management estimates developed based on third-party data and reflect management&#x2019;s judgements, current market conditions, and forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Royalty Right Agreements&#x2019; fair value is estimated by applying probability-weighted cash flows for future sales, which are then discounted to present value. Changes to fair value of the Royalty Rights Agreements can result from changes to one or a number of the aforementioned inputs. A significant change in unobservable inputs could result in a material increase or decrease to the effective interest rate of the Royalty Right Agreements liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant unobservable inputs used in the fair value measurement of the Royalty Right Agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Methodology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average (range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty Right Agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability weighted&lt;br/&gt;income approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of Success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Years of Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has updated the projected years of payments to 2034 and the effective interest rate by 0.56% as of December&#160;31, 2024. The Company periodically re-assesses the projections and, to the extent the future projections are greater or less than its previous estimates or the estimated timing of such payments is materially different than its previous estimates, the Company will adjust the effective interest calculation. As of March&#160;31, 2025, there were no material changes to the significant unobservable inputs used to recognize the Royalty Right Agreements liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Royalty Right Agreements were issued in connection with the 13.5% Notes, the Company allocated the proceeds to the two instruments based on their relative fair values. The Company allocated approximately $13,856 to the Royalty Right Agreements. The Company determined the allocated fair value by calculating the present value of estimated future royalties to be paid to Note Holders over the life of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of future estimated royalty payments of $56,926 over the $13,856 of allocated fair value is recognized as a discount related to the Royalty Right Agreements and is amortized as interest expense using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocated amounts of $13,856 when combined with the Exit Fee of $2,000, original issue discount of $1,125 and debt issuance costs of $3,517, resulted in a debt discount of $20,498. The debt discount is being amortized over the term of 13.5% Notes using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense arising from the discounts related to the 13.5% Notes for the three months ended March&#160;31, 2025 and 2024 was $1,254 and $1,257, respectively. Amortization expense arising from the discounts related to the Royalty Right Agreements for the three months ended March&#160;31, 2025 and 2024 was $1,437 and $1,358, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized discounts totaled $11,392 for the 13.5% Notes and $35,269 for the Royalty obligations as of March&#160;31, 2025. Unamortized discounts totaled $12,646 for the 13.5% Notes and $36,706 for the Royalty obligations as of December&#160;31, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term notes and unamortized debt discount balances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total outstanding notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount, including Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease, long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled principal payments on the 13.5% Notes as of March&#160;31, 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-523" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-112" decimals="-3" id="f-524" unitRef="usd">45000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-525" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-145" decimals="-3" id="f-526" unitRef="usd">4326000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-108" decimals="3" id="f-527" unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-528" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-529" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-530" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-531" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-144" decimals="-3" id="f-532" unitRef="usd">2000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-533" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-146" decimals="2" id="f-534" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="c-146" decimals="2" id="f-535" unitRef="number">0.010</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <aqst:DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate contextRef="c-146" decimals="2" id="f-536" unitRef="number">0.0100</aqst:DebtInstrumentRedemptionPriceBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-147" decimals="3" id="f-537" unitRef="number">1.085</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-538" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-145" decimals="3" id="f-539" unitRef="number">1.085</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <aqst:LineOfCreditFacilityAccordionFeatureNetRevenueThreshold contextRef="c-148" decimals="-3" id="f-540" unitRef="usd">100000</aqst:LineOfCreditFacilityAccordionFeatureNetRevenueThreshold>
    <aqst:LineOfCreditFacilityAccordionFeatureIncreaseLimit contextRef="c-149" decimals="-3" id="f-541" unitRef="usd">10000</aqst:LineOfCreditFacilityAccordionFeatureIncreaseLimit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-542" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-113" decimals="3" id="f-543" unitRef="number">0.010</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-114" decimals="3" id="f-544" unitRef="number">0.020</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm contextRef="c-115" id="f-545">P8Y</aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-113" decimals="3" id="f-546" unitRef="number">0.010</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentage contextRef="c-114" decimals="3" id="f-547" unitRef="number">0.020</aqst:DebtInstrumentCovenantTieredRoyaltyPercentage>
    <aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm contextRef="c-115" id="f-548">P8Y</aqst:DebtInstrumentCovenantTieredRoyaltyPercentageTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-549" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-550">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant unobservable inputs used in the fair value measurement of the Royalty Right Agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Methodology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average (range, if applicable)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty Right Agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability weighted&lt;br/&gt;income approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of Success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Years of Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:LongTermDebtMeasurementInput contextRef="c-150" decimals="2" id="f-551" unitRef="number">0.15</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:LongTermDebtMeasurementInput contextRef="c-151" decimals="2" id="f-552" unitRef="number">0.75</us-gaap:LongTermDebtMeasurementInput>
    <aqst:DebtInstrumentInterestRateChangeInEffectivePercentage contextRef="c-152" decimals="4" id="f-553" unitRef="number">0.0056</aqst:DebtInstrumentInterestRateChangeInEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-554" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue contextRef="c-153" decimals="-3" id="f-555" unitRef="usd">13856000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-153" decimals="-3" id="f-556" unitRef="usd">56926000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-153" decimals="-3" id="f-557" unitRef="usd">13856000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtFairValue contextRef="c-154" decimals="-3" id="f-558" unitRef="usd">13856000</us-gaap:LongTermDebtFairValue>
    <aqst:DebtInstrumentExitFee contextRef="c-155" decimals="-3" id="f-559" unitRef="usd">2000000</aqst:DebtInstrumentExitFee>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="c-154" decimals="-3" id="f-560" unitRef="usd">1125000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-154" decimals="-3" id="f-561" unitRef="usd">3517000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-154" decimals="-3" id="f-562" unitRef="usd">20498000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-563" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-564" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-156" decimals="-3" id="f-565" unitRef="usd">1254000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-157" decimals="-3" id="f-566" unitRef="usd">1257000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-158" decimals="-3" id="f-567" unitRef="usd">1437000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-159" decimals="-3" id="f-568" unitRef="usd">1358000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-144" decimals="-3" id="f-569" unitRef="usd">11392000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-570" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-160" decimals="-3" id="f-571" unitRef="usd">35269000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-161" decimals="-3" id="f-572" unitRef="usd">12646000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-573" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-162" decimals="-3" id="f-574" unitRef="usd">36706000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-575">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term notes and unamortized debt discount balances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total outstanding notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount, including Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease, long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-144" decimals="-3" id="f-576" unitRef="usd">45000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-161" decimals="-3" id="f-577" unitRef="usd">45000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-144" decimals="-3" id="f-578" unitRef="usd">11392000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-161" decimals="-3" id="f-579" unitRef="usd">12646000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-144" decimals="-3" id="f-580" unitRef="usd">33608000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-161" decimals="-3" id="f-581" unitRef="usd">32354000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-144" decimals="-3" id="f-582" unitRef="usd">138000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-161" decimals="-3" id="f-583" unitRef="usd">146000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-144" decimals="-3" id="f-584" unitRef="usd">33746000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-161" decimals="-3" id="f-585" unitRef="usd">32500000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-160" decimals="-3" id="f-586" unitRef="usd">56917000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-162" decimals="-3" id="f-587" unitRef="usd">56922000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-160" decimals="-3" id="f-588" unitRef="usd">35269000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-162" decimals="-3" id="f-589" unitRef="usd">36706000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtCurrent contextRef="c-160" decimals="-3" id="f-590" unitRef="usd">89000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-162" decimals="-3" id="f-591" unitRef="usd">87000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-160" decimals="-3" id="f-592" unitRef="usd">21559000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-162" decimals="-3" id="f-593" unitRef="usd">20129000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-594">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled principal payments on the 13.5% Notes as of March&#160;31, 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-595" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-596" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-3" decimals="-3" id="f-597" unitRef="usd">9540000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-3" decimals="-3" id="f-598" unitRef="usd">14535000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-3" decimals="-3" id="f-599" unitRef="usd">20925000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-3" id="f-600" unitRef="usd">45000000</us-gaap:LongTermDebt>
    <aqst:WarrantsDisclosureTextBlock contextRef="c-1" id="f-601">Warrants&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants Issued to 12.5% Senior Secured Noteholders &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants that were issued in conjunction with the Initial Notes (the &#x201c;Initial Warrants&#x201d;) and Additional Notes (the &#x201c;Additional Warrants&#x201d;) expire on June 30, 2025 and entitled the noteholders to purchase up to 2,143,000 shares of Common Stock and included specified registration rights. Management estimated the fair value of the Initial Warrants to be $6,800 and the Additional Warrants to be $735, each based on an assessment by an independent third-party appraiser. The fair value of the respective warrants was treated as a debt discount, amortizable over the term of the respective warrants, with the unamortized 12.5% Notes portion applied to reduce the aggregate principal amount of the 12.5% Notes. The 12.5% Notes were refinanced with the 13.5% Notes on November 1, 2023. Additionally, since the Initial Warrants and Additional Warrants issued do not provide warrant redemption or put rights within the control of the holders that could require the Company to make a payment of cash or other assets to satisfy the obligations under the warrants, except in the case of a &#x201c;cash change in control&#x201d;, the fair value attributed to the warrants is presented in Additional Paid-in Capital in the Company&#x2019;s Condensed Balance Sheets. There were no warrants exercised as it relates to the Initial Warrants and the Additional Warrants during the three months ended March&#160;31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to purchase a total of 1,683,784 shares of Common Stock with exercise prices of $4.25 and $5.38 for 1,571,429 warrants and 112,355 warrants, respectively, remain outstanding as of March&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants Issued Under Securities Purchase Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company issued pre-funded warrants and Common Stock warrants to certain purchasers in connection with the Securities Purchase Agreements. The pre-funded warrants entitled purchasers to purchase up to 4,000,000 shares of Common Stock and were exercised in full during the year ended December 31, 2022. The Common Stock warrants expire on June 8, 2027 and entitled the purchasers to purchase up to 8,850,000 shares of Common Stock at an exercise price of $0.96 per share. Management estimated the fair value of the pre-funded warrants and Common Stock warrants to be $5,874 based on an assessment by an independent third-party appraiser. The fair value of the pre-funded and Common Stock warrants is treated as equity and presented in Additional Paid-in Capital in the Company&#x2019;s Condensed Balance Sheets. On June 14, 2023, 3,689,452 Common Stock warrants issued pursuant to the Securities Purchase Agreements were exercised with proceeds of approximately $3,542.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2023, the Company entered into the Letter Agreement with the Exercising Holder of 5,000,000 of the remaining Common Stock Warrants. Pursuant to the Letter Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise all of its Existing Warrants for shares of Common Stock underlying the Existing Warrants at $0.96 per share of Common Stock, the current exercise price of the Existing Warrants. Under the Letter Agreement, in consideration of the Exercising Holder exercising the Existing Warrants, the Company issued to the Exercising Holder New Warrants to purchase up to an aggregate of 2,750,000 shares of Common Stock. The New Warrants became exercisable after February 2, 2024, expire on February 2, 2029 and are issuable only for cash, subject to exception if the shares of Common Stock underlying the New Warrants are not registered in accordance with the terms of the Letter Agreement, in which case the New Warrants may also be exercised, in whole or in part, at such time by means of a "cashless exercise". The New Warrants have an exercise price of $2.60 per share. Management estimated the fair value of the warrants to be $4,671 based on an assessment by an independent third-party appraiser. The fair value of the New Warrants is treated as equity and is presented in Additional Paid-in Capital in the Company&#x2019;s Condensed Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no warrants issued or exercised as it relates to the Warrants Issued Under Securities Purchase Agreements during the three months ended March&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the warrants to purchase 2,750,000 shares of Common Stock described above, there remain outstanding warrants to purchase 160,548 shares of Common Stock at an exercise price of $0.96 and warrants to purchase 1,683,784 shares of Common Stock outstanding related to the original issuance of the 12.5% Notes prior to the debt refinancing referenced in Note 14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with exercise prices of $4.25 and $5.38 for 1,571,429 warrants and 112,355 warrants, respectively.&lt;/span&gt;&lt;/div&gt;</aqst:WarrantsDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-163" decimals="3" id="f-602" unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-164" decimals="0" id="f-603" unitRef="shares">2143000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-165" decimals="-3" id="f-604" unitRef="usd">6800000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-166" decimals="-3" id="f-605" unitRef="usd">735000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-163" decimals="3" id="f-606" unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-163" decimals="3" id="f-607" unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-163" decimals="3" id="f-608" unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-144" decimals="3" id="f-609" unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aqst:ClassOfWarrantOrRightWarrantsExercised contextRef="c-1" decimals="0" id="f-610" unitRef="shares">0</aqst:ClassOfWarrantOrRightWarrantsExercised>
    <aqst:ClassOfWarrantOrRightWarrantsExercised contextRef="c-5" decimals="0" id="f-611" unitRef="shares">0</aqst:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-167" decimals="0" id="f-612" unitRef="shares">1683784</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-167"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">4.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-168"
      decimals="2"
      id="f-614"
      unitRef="usdPerShare">5.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-167" decimals="0" id="f-615" unitRef="shares">1571429</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-168" decimals="0" id="f-616" unitRef="shares">112355</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-169" decimals="0" id="f-617" unitRef="shares">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-170" decimals="0" id="f-618" unitRef="shares">8850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-171"
      decimals="2"
      id="f-619"
      unitRef="usdPerShare">0.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-172" decimals="-3" id="f-620" unitRef="usd">5874000</us-gaap:WarrantsAndRightsOutstanding>
    <aqst:ClassOfWarrantOrRightWarrantsIssuedDuringPeriod contextRef="c-173" decimals="0" id="f-621" unitRef="shares">3689452</aqst:ClassOfWarrantOrRightWarrantsIssuedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-173" decimals="-3" id="f-622" unitRef="usd">3542000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-110" decimals="0" id="f-623" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-110"
      decimals="2"
      id="f-624"
      unitRef="usdPerShare">0.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-111" decimals="0" id="f-625" unitRef="shares">2750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-111" decimals="0" id="f-626" unitRef="shares">2750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="2"
      id="f-627"
      unitRef="usdPerShare">2.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-111" decimals="-3" id="f-628" unitRef="usd">4671000</us-gaap:WarrantsAndRightsOutstanding>
    <aqst:ClassOfWarrantOrRightWarrantsExercised contextRef="c-1" decimals="0" id="f-629" unitRef="shares">0</aqst:ClassOfWarrantOrRightWarrantsExercised>
    <aqst:ClassOfWarrantOrRightWarrantsExercised contextRef="c-5" decimals="0" id="f-630" unitRef="shares">0</aqst:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-111" decimals="0" id="f-631" unitRef="shares">2750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-174" decimals="0" id="f-632" unitRef="shares">160548</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-174"
      decimals="2"
      id="f-633"
      unitRef="usdPerShare">0.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-167" decimals="0" id="f-634" unitRef="shares">1683784</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-175" decimals="3" id="f-635" unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-176"
      decimals="2"
      id="f-636"
      unitRef="usdPerShare">4.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-177"
      decimals="2"
      id="f-637"
      unitRef="usdPerShare">5.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-176" decimals="0" id="f-638" unitRef="shares">1571429</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-168" decimals="0" id="f-639" unitRef="shares">112355</us-gaap:ClassOfWarrantOrRightOutstanding>
    <aqst:SaleOfFutureRevenueTextBlock contextRef="c-1" id="f-640">Sale of Future Revenue&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 3, 2020, the Company entered into the Monetization Agreement with Marathon. Under the terms of the Monetization Agreement, the Company sold all of its contractual rights to receive royalties and milestone payments due under the Sunovion License Agreement related to Sunovion&#x2019;s apomorphine product, KYNMOBI, an apomorphine film therapy for the treatment of off episodes in Parkinson&#x2019;s disease patients, which received approval from the FDA on May 21, 2020. In exchange for the sale of these rights, the Company received an upfront payment of $40,000 and an additional payment of $10,000 through &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the achievement of the first milestone. The Company has received an aggregate amount of $50,000 through March&#160;31, 2025 under the Monetization Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Monetization Agreement, additional contingent payments of up to $75,000 may be due to the Company upon the achievement of worldwide royalty and other commercial targets within a specified timeframe, which could result in total potential proceeds of $125,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the upfront proceeds of $40,000 and subsequent first milestone of $10,000, reduced by $2,909 of transaction costs, as a liability related to the sale of future revenue that will be amortized using the effective interest method over the life of the Monetization Agreement. As future contingent payments are received, they will increase the balance of the liability related to the sale of future revenue. Although the Company sold all of its rights to receive royalties and milestones, as a result of ongoing obligations related to the generation of these royalties, the Company will account for these royalties as revenue. Its ongoing obligations include the maintenance and defense of the intellectual property and to provide assistance to Marathon in executing a new license agreement for KYNMOBI in the event Sunovion terminates the Sunovion License Agreement in one or more jurisdictions of the licensed territory under the Sunovion License Agreement. The accounting liabilities, as adjusted over time, resulting from this transaction and any non-cash interest expenses associated with those liabilities do not and will not represent any obligation to pay or any potential future use of cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2020, under the Sunovion License Agreement, the Company recognized $8,000 of royalty revenue and corresponding royalty receivable, related to the $1,000 annual minimum guaranteed royalty that is due. In connection with the Monetization Agreement, the Company performed an assessment under ASC 860, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transfer and Servicing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to determine whether the existing receivable was transferred to Marathon and concluded that the receivable was not transferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As royalties are remitted to Marathon from Sunovion, the collection of the royalty receivable and balance of the liability related to the sale of future revenue will be effectively repaid over the life of the agreement. In order to determine the amortization of the liability related to the sale of future revenue, the Company is required to estimate the total amount of future royalty and milestone payments to Marathon over the life of the Monetization Agreement and contingent milestone payments from Marathon to the Company. The sum of future royalty payments less the $50,000 in proceeds received and future contingent payments has been recorded as interest expense over the life of the Monetization Agreement. At execution, the estimate of this total interest expense resulted in an effective annual interest rate of approximately 24.9%. This estimate contained significant assumptions that impact both the amount recorded at execution and the interest expense that will be recognized over the life of the Monetization Agreement. The Company assesses the estimated royalty and milestone payments to Marathon from Sunovion and contingent milestone payments from Marathon to the Company. To the extent the amount or timing of such payments is materially different from the original estimates, an adjustment will be recorded prospectively to increase or decrease interest expense. There are a number of factors that could materially affect the amount and timing of royalty and milestone payments to Marathon from Sunovion and, correspondingly, the amount of interest expense recorded by the Company, most of which are not under the Company&#x2019;s control. Such factors include, but are not limited to, changing standards of care, the initiation of competing products, manufacturing or other delays, generic competition, intellectual property matters, adverse events that result in government health authority imposed restrictions on the use of products, significant changes in foreign exchange rates as the royalties remitted to Marathon are made in U.S. dollars (USD) while a portion of the underlying sales of KYNMOBI will be made in currencies other than USD, and other events or circumstances that are not currently foreseen. Changes to any of these factors could result in increases or decreases to both royalty revenue and interest expense related to the sale of future revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, Sunovion announced that it had voluntarily withdrawn KYNMOBI from the U.S. and Canadian markets. Therefore, the Company likely will not receive any of the additional contingent payments under the Monetization agreement. Further, the Company discontinued recording interest expense related to the sale of future revenue during the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity of the liability related to the sale of future revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future revenue, net at beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties related to the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aqst:SaleOfFutureRevenueTextBlock>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-101" decimals="-3" id="f-641" unitRef="usd">40000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet contextRef="c-101" decimals="-3" id="f-642" unitRef="usd">10000000</aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-102" decimals="-3" id="f-643" unitRef="usd">50000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <aqst:ContingentMonetizationAgreementMilestonePayment contextRef="c-101" decimals="-3" id="f-644" unitRef="usd">75000000</aqst:ContingentMonetizationAgreementMilestonePayment>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-103" decimals="-3" id="f-645" unitRef="usd">125000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-101" decimals="-3" id="f-646" unitRef="usd">40000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet contextRef="c-101" decimals="-3" id="f-647" unitRef="usd">10000000</aqst:AdditionalProceedsFromSaleOfFutureRevenuesNet>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-178" decimals="-3" id="f-648" unitRef="usd">2909000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-3" id="f-649" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <aqst:MinimumAnnualRoyaltyReceivable contextRef="c-141" decimals="-3" id="f-650" unitRef="usd">1000000</aqst:MinimumAnnualRoyaltyReceivable>
    <aqst:ProceedsFromSaleOfFutureRevenuesNet contextRef="c-102" decimals="-3" id="f-651" unitRef="usd">50000000</aqst:ProceedsFromSaleOfFutureRevenuesNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-179" decimals="3" id="f-652" unitRef="number">0.249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <aqst:RoyaltyObligationActivityTableTextBlock contextRef="c-1" id="f-653">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity of the liability related to the sale of future revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future revenue, net at beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties related to the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to the sale of future revenue, net at end of the period (includes current portion of $1,000 and $1,000, respectively)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aqst:RoyaltyObligationActivityTableTextBlock>
    <aqst:LiabilitiesSaleOfFutureRoyalties contextRef="c-4" decimals="-3" id="f-654" unitRef="usd">63718000</aqst:LiabilitiesSaleOfFutureRoyalties>
    <aqst:LiabilitiesSaleOfFutureRoyalties contextRef="c-21" decimals="-3" id="f-655" unitRef="usd">64490000</aqst:LiabilitiesSaleOfFutureRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-180" decimals="-3" id="f-656" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-181" decimals="-3" id="f-657" unitRef="usd">1008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-658" unitRef="usd">59000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-182" decimals="-3" id="f-659" unitRef="usd">236000</us-gaap:AmortizationOfFinancingCosts>
    <aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent contextRef="c-3" decimals="-3" id="f-660" unitRef="usd">1000000</aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent>
    <aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-661" unitRef="usd">1000000</aqst:LiabilitiesSaleOfFutureRoyaltiesCurrent>
    <aqst:LiabilitiesSaleOfFutureRoyalties contextRef="c-3" decimals="-3" id="f-662" unitRef="usd">63777000</aqst:LiabilitiesSaleOfFutureRoyalties>
    <aqst:LiabilitiesSaleOfFutureRoyalties contextRef="c-4" decimals="-3" id="f-663" unitRef="usd">63718000</aqst:LiabilitiesSaleOfFutureRoyalties>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-664">Net Loss Per Share&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted EPS is adjusted by the effect of dilutive securities, including options and awards under the Company&#x2019;s equity compensation plans, warrants and ESPP. As a result of the Company&#x2019;s net loss incurred for the three months ended March&#160;31, 2025 and 2024, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations.&#160;Therefore, basic and diluted net loss per share are the same for the three months ended March&#160;31, 2025 and 2024 as reflected below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares &#x2013; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,497,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,614,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per common share &#x2013; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt"&gt;For the three months ended March&#160;31, 2025 and 2024, outstanding stock options of 6,977,367 and 6,169,489 to purchase shares of Common Stock, respectively, were anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the three months ended March&#160;31, 2025 and 2024, outstanding restricted stock units of 5,167,351 and 3,918,451 to purchase shares of Common Stock, respectively, were anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt"&gt;For the three months ended March&#160;31, 2025 and 2024, outstanding warrants of 4,594,332 and 4,624,977 to purchase shares of Common Stock, respectively, were anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-665">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted EPS is adjusted by the effect of dilutive securities, including options and awards under the Company&#x2019;s equity compensation plans, warrants and ESPP. As a result of the Company&#x2019;s net loss incurred for the three months ended March&#160;31, 2025 and 2024, all potentially dilutive instruments outstanding would have anti-dilutive effects on per-share calculations.&#160;Therefore, basic and diluted net loss per share are the same for the three months ended March&#160;31, 2025 and 2024 as reflected below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares &#x2013; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,497,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,614,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per common share &#x2013; basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt"&gt;For the three months ended March&#160;31, 2025 and 2024, outstanding stock options of 6,977,367 and 6,169,489 to purchase shares of Common Stock, respectively, were anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the three months ended March&#160;31, 2025 and 2024, outstanding restricted stock units of 5,167,351 and 3,918,451 to purchase shares of Common Stock, respectively, were anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.03pt"&gt;For the three months ended March&#160;31, 2025 and 2024, outstanding warrants of 4,594,332 and 4,624,977 to purchase shares of Common Stock, respectively, were anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-666" unitRef="usd">-22930000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-667" unitRef="usd">-12828000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-668" unitRef="shares">95497056</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-669" unitRef="shares">95497056</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-670" unitRef="shares">73614710</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-671" unitRef="shares">73614710</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-672"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-673"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-674"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-675"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-183" decimals="0" id="f-676" unitRef="shares">6977367</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-184" decimals="0" id="f-677" unitRef="shares">6169489</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-185" decimals="0" id="f-678" unitRef="shares">5167351</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-186" decimals="0" id="f-679" unitRef="shares">3918451</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-187" decimals="0" id="f-680" unitRef="shares">4594332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-188" decimals="0" id="f-681" unitRef="shares">4624977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-682">Share-Based Compensation&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation in its Condensed Statements of Operations and Comprehensive Loss during the three month periods ended March&#160;31, 2025 and 2024 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacture and supply&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information about the Company&#x2019;s restricted stock unit and stock option activity during the three month period ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s awards of service-based and market conditions vesting-based restricted stock units for the three month period ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;Restricted Stock Unit Awards (RSUs) - Service-based:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, $8,369 of total unrecognized compensation expenses related to unvested service-based restricted stock units are expected to be recognized over a remaining weighted average period of 2.14 years. The service-based restricted stock units granted to employees are subject to a three-year graduated vesting schedule and are not subject to performance-based criteria other than continued employment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;Restricted Stock Unit Awards (RSUs) - Market conditions vesting-based:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, $2,798 of unrecognized compensation expense related to unvested market condition vesting- based restricted stock units are expected to be recognized over a remaining weighted average period of 1.87 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 market conditions vesting-based restricted stock units vest based on a Performance Price measured as the 30-day average of the closing prices of the Company&#x2019;s common stock as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the three-year performance period (which ends on the third anniversary of the grant date). To the extent the Performance Price is less than $1.75, the Vesting Percentage will be zero. To the extent the Performance Price is $1.75, the Vesting Percentage will be 50%. To the extent the Performance Price is $1.76 or greater, but less than $2.50, the Vesting Percentage will be a prorated amount between 50.01% and 99.99%, based on straight-line interpolation. To the extent the Performance Price is $2.50, the Vesting Percentage will be 100%. To the extent the Performance Price is $2.51 or greater, but less than $3.25, the Vesting Percentage will be a prorated amount between 100.01% and 149.99%, based on straight-line interpolation. To the extent the Performance Price is $3.25 or greater, the Vesting Percentage will be 150%. In no event will the Vesting Percentage exceed 150%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 market conditions vesting-based restricted stock units were measured over a three-year performance period. The performance period is split into two pricing periods. The first pricing period commences on the grant date and ends on the calendar day immediately proceeding the second anniversary of the grant date. The second pricing period commences on the second anniversary of the grant date and ends on the third anniversary of the grant date, The performance price for the first pricing period is calculated based on the 30-day average price observed for the last 30 days of the first pricing period. The performance price for the second pricing period is calculated based on the highest 30-day average for any 30-day period &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;throughout the second pricing period. To the extent the Performance Price is less than $6.00, the Vesting Percentage will be zero. To the extent the Performance Price is $6.00, the Vesting Percentage will be 50%. To the extent the Performance Price is $6.01 or greater, but less than $7.00, the Vesting Percentage will be a prorated amount between 50.01% and 99.99%, based on straight-line interpolation. To the extent the Performance Price is $7.00, the Vesting Percentage will be 100%. To the extent the Performance Price is $7.01 or greater, but less than $8.00, the Vesting Percentage will be a prorated amount between 100.01% and 149.99%, based on straight-line interpolation. To the extent the Performance Price is $8.00 or greater, the Vesting Percentage will be 150%. In no event will the Vesting Percentage exceed 150%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s estimates of the fair value of the 2025 market conditions vesting-based awards at their grant or valuation dates were based on a Monte Carlo simulation and considered various variables and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price at grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Nasdaq Listing Rule 5635(c)(4), the Company adopted the 2022 Equity Inducement Plan approved by the Compensation Committee of the Board of Directors of the Company effective as of July 29, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Stock Option Awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of stock options granted were estimated using the Black-Scholes pricing model based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.906%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of stock options granted during the three months ended March&#160;31, 2025 was $2.15. During the three months ended March&#160;31, 2025, stock options were granted with a weighted average exercise price of $2.65 and accordingly, given the Company&#x2019;s share price of $2.90 at March&#160;31, 2025, the intrinsic value provided by certain shares granted during this period was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, $3,849 of unrecognized compensation expense related to non-vested stock options is expected to be recognized over a remaining weighted average period of 1.97 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-683">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation in its Condensed Statements of Operations and Comprehensive Loss during the three month periods ended March&#160;31, 2025 and 2024 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.970%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacture and supply&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-189" decimals="-3" id="f-684" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-190" decimals="-3" id="f-685" unitRef="usd">70000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-686" unitRef="usd">330000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-687" unitRef="usd">170000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-193" decimals="-3" id="f-688" unitRef="usd">1157000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-194" decimals="-3" id="f-689" unitRef="usd">1340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-690" unitRef="usd">1587000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-691" unitRef="usd">1580000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-195" decimals="-3" id="f-692" unitRef="usd">1102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-196" decimals="-3" id="f-693" unitRef="usd">933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-197" decimals="-3" id="f-694" unitRef="usd">485000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-198" decimals="-3" id="f-695" unitRef="usd">647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-696" unitRef="usd">1587000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-697" unitRef="usd">1580000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-698">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information about the Company&#x2019;s restricted stock unit and stock option activity during the three month period ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s awards of service-based and market conditions vesting-based restricted stock units for the three month period ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;Restricted Stock Unit Awards (RSUs) - Service-based:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-199"
      decimals="-3"
      id="f-699"
      unitRef="shares">2610000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-199"
      decimals="2"
      id="f-700"
      unitRef="usdPerShare">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-195"
      decimals="-3"
      id="f-701"
      unitRef="shares">1435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-195"
      decimals="2"
      id="f-702"
      unitRef="usdPerShare">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-195"
      decimals="-3"
      id="f-703"
      unitRef="shares">713000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-195"
      decimals="2"
      id="f-704"
      unitRef="usdPerShare">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-195"
      decimals="-3"
      id="f-705"
      unitRef="shares">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-195"
      decimals="2"
      id="f-706"
      unitRef="usdPerShare">3.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-200"
      decimals="-3"
      id="f-707"
      unitRef="shares">3301000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-200"
      decimals="2"
      id="f-708"
      unitRef="usdPerShare">3.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares
      contextRef="c-200"
      decimals="-3"
      id="f-709"
      unitRef="shares">3030000</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue
      contextRef="c-200"
      decimals="2"
      id="f-710"
      unitRef="usdPerShare">3.11</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-200" decimals="-3" id="f-711" unitRef="usd">8369000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-195" id="f-712">P2Y1M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-195" id="f-713">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-714">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;Restricted Stock Unit Awards (RSUs) - Market conditions vesting-based:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-201"
      decimals="-3"
      id="f-715"
      unitRef="shares">1082000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-201"
      decimals="2"
      id="f-716"
      unitRef="usdPerShare">2.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-202"
      decimals="-3"
      id="f-717"
      unitRef="shares">784000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-202"
      decimals="2"
      id="f-718"
      unitRef="usdPerShare">2.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-202"
      decimals="-3"
      id="f-719"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-202"
      decimals="2"
      id="f-720"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-202"
      decimals="-3"
      id="f-721"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-202"
      decimals="2"
      id="f-722"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-203"
      decimals="-3"
      id="f-723"
      unitRef="shares">1866000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-203"
      decimals="2"
      id="f-724"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares
      contextRef="c-203"
      decimals="-3"
      id="f-725"
      unitRef="shares">1698000</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInShares>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue
      contextRef="c-203"
      decimals="2"
      id="f-726"
      unitRef="usdPerShare">2.56</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsEstimatedGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-204" decimals="-3" id="f-727" unitRef="usd">2798000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-205" id="f-728">P1Y10M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod contextRef="c-206" id="f-729">P30D</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-207" id="f-730">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-208"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">1.75</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-209" decimals="2" id="f-732" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-210"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">1.75</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-211" decimals="2" id="f-734" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-212"
      decimals="2"
      id="f-735"
      unitRef="usdPerShare">1.76</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-213"
      decimals="2"
      id="f-736"
      unitRef="usdPerShare">2.50</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-214" decimals="4" id="f-737" unitRef="number">0.5001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-215" decimals="4" id="f-738" unitRef="number">0.9999</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-216"
      decimals="2"
      id="f-739"
      unitRef="usdPerShare">2.50</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-217" decimals="2" id="f-740" unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-218"
      decimals="2"
      id="f-741"
      unitRef="usdPerShare">2.51</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-219"
      decimals="2"
      id="f-742"
      unitRef="usdPerShare">3.25</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-220" decimals="4" id="f-743" unitRef="number">1.0001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-221" decimals="4" id="f-744" unitRef="number">1.4999</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-222"
      decimals="2"
      id="f-745"
      unitRef="usdPerShare">3.25</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-223" decimals="2" id="f-746" unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-224" decimals="2" id="f-747" unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-225" id="f-748">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods
      contextRef="c-225"
      decimals="INF"
      id="f-749"
      unitRef="pricing_period">2</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPricingPeriods>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod contextRef="c-226" id="f-750">P30D</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod contextRef="c-226" id="f-751">P30D</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod contextRef="c-226" id="f-752">P30D</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageClosingPricesPeriod>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod contextRef="c-226" id="f-753">P30D</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDaysUtilizedInPricingPeriod>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-227"
      decimals="2"
      id="f-754"
      unitRef="usdPerShare">6.00</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-228" decimals="2" id="f-755" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-229"
      decimals="2"
      id="f-756"
      unitRef="usdPerShare">6.00</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-230" decimals="2" id="f-757" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-231"
      decimals="2"
      id="f-758"
      unitRef="usdPerShare">6.01</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-232"
      decimals="2"
      id="f-759"
      unitRef="usdPerShare">7.00</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-233" decimals="4" id="f-760" unitRef="number">0.5001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-234" decimals="4" id="f-761" unitRef="number">0.9999</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-235"
      decimals="2"
      id="f-762"
      unitRef="usdPerShare">7.00</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-236" decimals="2" id="f-763" unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-237"
      decimals="2"
      id="f-764"
      unitRef="usdPerShare">7.01</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-238"
      decimals="2"
      id="f-765"
      unitRef="usdPerShare">8.00</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-239" decimals="4" id="f-766" unitRef="number">1.0001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-240" decimals="4" id="f-767" unitRef="number">1.4999</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare
      contextRef="c-241"
      decimals="2"
      id="f-768"
      unitRef="usdPerShare">8.00</aqst:ShareBasedCompensationArrangementByShareBasedPaymentMarketConditionPerformancePriceThresholdPerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-242" decimals="2" id="f-769" unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-243" decimals="2" id="f-770" unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <aqst:ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-771">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s estimates of the fair value of the 2025 market conditions vesting-based awards at their grant or valuation dates were based on a Monte Carlo simulation and considered various variables and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price at grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aqst:ScheduleOfShareBasedPaymentAwardAwardsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-202" decimals="3" id="f-772" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-202" decimals="3" id="f-773" unitRef="number">0.915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-202" decimals="3" id="f-774" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c-203"
      decimals="2"
      id="f-775"
      unitRef="usdPerShare">2.65</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-776">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Stock Option Awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of stock options granted were estimated using the Black-Scholes pricing model based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.894%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.906%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-244"
      decimals="-3"
      id="f-777"
      unitRef="shares">6301000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-244"
      decimals="2"
      id="f-778"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-197"
      decimals="-3"
      id="f-779"
      unitRef="shares">738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-197"
      decimals="2"
      id="f-780"
      unitRef="usdPerShare">2.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-197"
      decimals="-3"
      id="f-781"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-197"
      decimals="2"
      id="f-782"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod
      contextRef="c-197"
      decimals="-3"
      id="f-783"
      unitRef="shares">62000</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriod>
    <aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-197"
      decimals="2"
      id="f-784"
      unitRef="usdPerShare">5.56</aqst:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-245"
      decimals="-3"
      id="f-785"
      unitRef="shares">6977000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-245"
      decimals="2"
      id="f-786"
      unitRef="usdPerShare">5.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-245"
      decimals="-3"
      id="f-787"
      unitRef="shares">6849000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-245"
      decimals="2"
      id="f-788"
      unitRef="usdPerShare">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-245"
      decimals="-3"
      id="f-789"
      unitRef="shares">5238000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-245"
      decimals="2"
      id="f-790"
      unitRef="usdPerShare">6.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-197" decimals="3" id="f-791" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-197" decimals="2" id="f-792" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-246" id="f-793">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-246" decimals="3" id="f-794" unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-197"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">2.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-197"
      decimals="2"
      id="f-796"
      unitRef="usdPerShare">2.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharePrice
      contextRef="c-3"
      decimals="2"
      id="f-797"
      unitRef="usdPerShare">2.90</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-245" decimals="-3" id="f-798" unitRef="usd">3849000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-197" id="f-799">P1Y11M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-800">Income Taxes&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as net operating loss carryforwards and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items. For the three months ended March&#160;31, 2025, the effective income tax rate was 0%, and the Company recorded no income tax expense from its pretax losses of $22,930. For the three months ended March&#160;31, 2024, the effective income tax rate was 0%, and the Company recorded no income tax expense from its pretax losses of $12,828.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary factors impacting the effective tax rate for three months ended March&#160;31, 2025 is the anticipated full year pre-tax book loss and a full valuation allowance against any associated net deferred tax assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="2" id="f-801" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-802" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-803" unitRef="usd">-22930000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="2" id="f-804" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-805" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-806" unitRef="usd">-12828000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-807">Contingencies&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has been and may again become involved in legal proceedings arising in the course of its business, including product liability, intellectual property, securities, civil tort, and commercial litigation, and environmental or other regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kentucky Litigation - Humana&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Humana Inc. v. Indivior Inc, Indivior Solutions Inc., Indivior PLC, Reckitt Benckiser Group plc, Reckitt Benckiser Healthcare (UK) Ltd., and Aquestive Therapeutics, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 20, 2021, Humana filed a complaint in state court in Kentucky, alleging conspiracy to violate the RICO Act, fraud under state law, unfair and deceptive trade practices under state law, insurance fraud, and unjust enrichment against the Company relating to Indivior&#x2019;s launch of Suboxone Sublingual Film in 2010. The Humana action was stayed pending related litigation, and the stay was lifted on October 30, 2023. The parties to this case reached a settlement in November 2024, the terms of which are confidential. Aquestive had no obligation, cost or liability in the settlement as all were assumed by Indivior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;California Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Neurelis, Inc. v. Aquestive Therapeutics, Inc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 5, 2019, Neurelis, Inc. ("Neurelis") filed a lawsuit against the Company in the Superior Court of California, County of San Diego alleging the following three causes of action: (1) Unfair Competition under California Business and Professional Code &#xa7; 17200 (&#x201c;UCL&#x201d;); (2) Defamation; and (3) Malicious Prosecution. Neurelis filed a First Amended Complaint on December 9, 2019, alleging the same three causes of action. The Company filed a Motion to Strike Neurelis&#x2019;s Complaint under California&#x2019;s anti-SLAPP (&#x201c;strategic lawsuit against public participation&#x201d;) statute on January 31, 2020, which Neurelis opposed. On August 6, 2020, the Court issued an order granting in part and denying in part the Company&#x2019;s anti-SLAPP motion. The parties cross-appealed the ruling to the California Court of Appeal. The appeals court held oral argument on the appeal on October 14, 2021, and issued its ruling on November 17, 2021. Under the ruling, the court struck the entirety of the malicious prosecution claim and struck portions of the UCL and defamation claims. On April 12, 2022, Neurelis filed a Second Amended Complaint in response to the Court of Appeal&#x2019;s decision. The Second Amended Complaint also added a cause of action for Trade Libel. On May 3, 2022, the Company filed a "demurrer" challenge to the sufficiency of the allegations of the Second Amended Complaint. Oral argument on the Company&#x2019;s motion for attorney fees related to the anti-SLAPP motion and on the Second Amended Complaint and demurer challenge was held on June 17, 2022. The Court entered an order granting the Company&#x2019;s motion for attorney fees, awarding $156 and ordering Neurelis to pay the fees within 60 days of June 17, 2022. The Court denied the Company&#x2019;s demurrer and the parties proceeded with discovery on the claims in the Second Amended Complaint. The plaintiff filed a motion to file a third amended complaint, which the Court granted on November 17, 2023. The Third Amended Complaint alleges additional facts but includes the same claims as the Second Amended Complaint. Hearings on motions for summary judgement are scheduled for May 16, 2025. The trial in this matter is scheduled for July 18, 2025. The Company is not able to determine or predict the ultimate outcome of this proceeding or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Neurelis FDA Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Neurelis v. Califf, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, U.S. District court for the District of Columbia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, Neurelis filed a complaint in the U.S. District Court for the District of Columbia against the U.S. Food and Drug Administration, the U.S. Department of Health and Human Services, and certain government officials. The complaint in this matter alleges that the defendants violated the Administrative Procedure Act by approving the Company's NDA for Libervant for ARS patients aged between two and five years, and asked the Court to vacate that approval and enjoin the defendants from approving Libervant for this pediatric patient population until January 10, 2027, the scheduled date for the expiration of the U.S. orphan drug market exclusivity granted by the FDA to the Valtoco nasal spray product of Neurelis. The Company intervened in this litigation to defend the approval of Libervant for this ARS pediatric patient population and, on June &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25, 2024, the Court entered a scheduling order governing further proceedings in the case. Pursuant to that order, Neurelis filed a motion for summary judgment on August 19, 2024; the Company and the federal defendants each filed their own cross-motions for summary judgment and opposed Neurelis&#x2019;s motion for summary judgment on September 18, 2024. Neurelis filed its combined reply brief in support of its motion for summary judgment and in opposition to the defendants&#x2019; cross-motions on October 9, 2024, and the Company and the federal defendants filed their closing briefs on October 30, 2024. Following the FDA's award of ODE to Libervant for ARS patients between two and five years of age, Neurelis filed a motion for preliminary injunction requesting an expedited order to vacate FDA's approval and enjoining the sale of Libervant. On February 14, 2025, the Court ruled in favor of Neurelis, granting its summary judgment motion, and against the FDA's and the Company's cross-motions for summary judgment. In an accompanying opinion, the Court directed the FDA to vacate the approval of Libervant. Because the Court entered a final appealable judgment in favor of Neurelis, Neurelis' motion for an expedited preliminary injunction was denied as moot by the Court. On February 18, 2025, the Company filed an appeal of the District Court's decision with the U.S. Circuit Court of Appeals for the District of Columbia (the "DC Appellate Court") and, on the same day, filed an emergency motion with the District Court to stay its order pending a decision on the appeal with the DC Appellate Court. The District Court denied the motion for a stay. On March 27, 2025, the DC Appellate Court denied the Company's emergency motion for stay. The FDA filed an appeal of the District Court's decision to the DC Appellate Court and the Company withdrew its appeal. As a result of the District Court's ruling, the FDA converted the approval of Libervant to a "tentative approval" and the Company has ceased marketing activities in the United States. The Company is communicating with the FDA on a path forward for approval of Libervant for ARS patients aged between two and five years but the Company has not yet received any decision from the FDA on market access for these Libervant pediatric patients. No dates have been set for arguments on the appeal proceedings at the DC Appellate Court. The Company is not able to determine or predict the ultimate outcome of these proceedings or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter or whether the FDA will grant U.S. market access to Libervant for ARS patients aged between two and five years in advance of the ODE expiration period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Suboxone Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was named as a defendant in a multitude of product liability lawsuits, along with Indivior and several other named defendants, in which the individual plaintiffs in those cases allege that their use of Suboxone&#xae; Sublingual Film, a prescription drug product for opioid use disorder, caused them dental injuries. On February 2, 2024, this litigation became a Multidistrict Litigation (&#x201c;MDL") consolidated in the U.S District Court for the Northern District of Ohio. One case alleging the same allegations as contained in the MDL has been filed in a state court in the State of New Jersey. The parties to the MDL have agreed to a tolling of unfiled claimants in several states. Indivior has agreed to defend the Company in these litigation matters. Discovery is underway and no trial date has been set in the MDL matter. The Company's motion to dismiss the MDL matter was granted as to all claims by plaintiffs except design defect claims. The Company is not able to determine or predict the ultimate outcome of this litigation or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was named as a defendant in three proposed class action lawsuits filed in Canada, along with Indivior and several other named defendants, in which the individual plaintiffs in those cases allege that their use of Suboxone&#xae; products caused them dental injuries. Two of these cases have been filed in British Columbia, and the plaintiffs in those cases are seeking assignment of a case management judge. The anticipated next step in British Columbia will involve applications by the plaintiffs to determine which of the two cases will proceed towards a certification hearing and which will be stayed. The third case has been filed in Quebec and is proceeding towards an authorization hearing, the date of which has not yet been set. The authorization and certification hearings will determine whether the Courts will allow the cases to proceed as class actions. Pre-discovery and case management proceedings are underway and no trial date has yet been set. Given the early stages of these proceedings, the Company is not able to determine or predict the ultimate outcome of this litigation or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this litigation.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-247"
      decimals="INF"
      id="f-808"
      unitRef="pending_case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-247"
      decimals="INF"
      id="f-809"
      unitRef="pending_case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-248" decimals="-3" id="f-810" unitRef="usd">156000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <aqst:LitigationSettlementAmountAwardPeriodDue contextRef="c-248" id="f-811">P60D</aqst:LitigationSettlementAmountAwardPeriodDue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-249"
      decimals="INF"
      id="f-812"
      unitRef="pending_case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-250"
      decimals="INF"
      id="f-813"
      unitRef="pending_case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-251"
      decimals="INF"
      id="f-814"
      unitRef="pending_case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-251"
      decimals="INF"
      id="f-815"
      unitRef="pending_case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-816">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-817">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-818">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-819">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
